PUBLIC_ID	MMTX_TYPE	MMTX_THERAPY	MMTX_ENTERCLINICAL	MMTX_REASONFORTREA	MMTX_UNITS	MMTX_ROUTE	VJ_INTERVAL	MMTX_ISTHISLINEOFT	MMTX_SPECIFY6	MMTX_ONGOING	MMTX_DOSE	MMTX_FREQUENCY	MMTX_SPECIFY3	MMTX_SPECIFY	MMTX_SPECIFY4	MMTX_SPECIFY2	MMTX_SPECIFY5	startday	stopday	enr
MMRF_1014	First line of therapy	Bortezomib		Completed regimen	mg	IV	Log Forms	Other	PLATEAUED		2.6	Q week	Q week					540	752	1
MMRF_1014	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	HIGH DOSE CHEMO PRE TRANSPLANT		200	Other	UNKNOW					814	815	1
MMRF_1014	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Other	PLATEAUED		500	Other	Q WEEK					540	752	1
MMRF_1014	First line of therapy	Thalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	100	Q day	Q day					977		1
MMRF_1014	First line of therapy	Carfilzomib		Investigator decision for other reasons	mg	IV	Log Forms	Induction	Induction		39	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					449	535	1
MMRF_1014	First line of therapy	Vincristine		Adverse Event or co-morbidity	mg	IV	Log Forms				2	Other	Q28 DAYS					381	407	1
MMRF_1014	First line of therapy	Liposomal doxorubicin		Adverse Event or co-morbidity	mg	IV	Log Forms				75	Other	Q28 DAYS					381	407	1
MMRF_1014	First line of therapy	Thalidomide		PLATEAUED RESPONSE	mg	PO	Log Forms				100	Q day	Q day					186	365	1
MMRF_1014	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	Other	DAILY ON DAYS 1-4 (ALL CYCLES) AND 9-12 (CYCLE 1 AND 2)					1	819	1
MMRF_1014	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg	INJECTION	Log Forms				2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	57	1
MMRF_1014	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					66	106	1
MMRF_1014	First line of therapy	Bortezomib		Lack of response	mg	IVB	Log Forms				2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	166	1
MMRF_1017	First line of therapy	Dexamethasone		DEATH	mg	PO	Log Forms				40	QWK	QWK					1	508	1
MMRF_1017	First line of therapy	Lenalidomide		DEATH	mg	PO	Log Forms				15	QD (D1-21)	QD (D1-21)					9	508	1
MMRF_1024	First line of therapy	Melphalan		Lack of response	mg	PO	Log Forms				6	Other	DAILY FOR 7 DAYS EACH MONTH; THEN DAILY FOR 5 DAYS EACH MONTH					1	149	1
MMRF_1024	First line of therapy	Prednisone		Lack of response	mg	PO	Log Forms				60	Other	DAILY FOR 7 DAYS EACH MONTH					1	149	1
MMRF_1024	First line of therapy	Thalidomide		Lack of response	mg	PO	Log Forms				100	Other	DAILY					1	149	1
MMRF_1024	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg	IV	Log Forms				2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					295	582	1
MMRF_1024	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms				40	Other	QD DAYS 1,2,4,5,8,9,11,12					295	582	1
MMRF_1024	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		15	QD (D1-21)	QD (D1-21)					162	240	1
MMRF_1024	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		40	Q week	Q week					162	240	1
MMRF_1024	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					659	1352	1
MMRF_1024	Second Line Therapy (after first relapse)	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	2.5	QD (D1-21)	QD (D1-21)					1353		1
MMRF_1038	First line of therapy	Dexamethasone		DEATH	mg	PO	Log Forms				40	QWK	QWK					1	1735	1
MMRF_1038	First line of therapy	Lenalidomide		DEATH	mg	PO	Log Forms				15	Other	DAILY					9	1738	1
MMRF_1033	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	123	1
MMRF_1033	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	QWK	QWK					1	123	1
MMRF_1033	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Unknown	Unknown		40	Other	D1, 8, & 15 OF EVERY 28-DAY CYCLE					2713	2825	1
MMRF_1033	Second Line Therapy (after first relapse)	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Unknown	Unknown		2.4	Q week	Q week					2713	2818	1
MMRF_1033	Second Line Therapy (after first relapse)	Pomalidomide		Completed regimen	mg	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					2713	2825	1
MMRF_1007	First line of therapy	Melphalan		Adverse Event or co-morbidity	mg	PO	Log Forms				8	QD (D1-7)	QD (D1-7)					1	85	1
MMRF_1007	First line of therapy	Prednisone		Adverse Event or co-morbidity	mg	PO	Log Forms				80	Other	QD (D1-28)					1	85	1
MMRF_1007	First line of therapy	Thalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms				50	QD (D1-7)	QD (D1-7)					1	85	1
MMRF_1007	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms				10	Other	ONCE A DAY, 3 WEEKS ON, 1 WEEK OFF					92	145	1
MMRF_1007	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms				20	Q week	Q week					92	145	1
MMRF_1007	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg	IV SubQ	Log Forms				2	Q week	Q week					155	208	1
MMRF_1007	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		10	Q week	Q week					155	208	1
MMRF_1052	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms				2.8	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					174	273	1
MMRF_1052	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms				40	Other	ODD CYCLES: D1-4, 9-12 AND 17-20; EVEN CYCLES: D1-4					119	162	1
MMRF_1052	First line of therapy	Thalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms				200	QD (D1-14)	QD (D1-14)					119	160	1
MMRF_1052	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms				20	QWK	QWK					1	51	1
MMRF_1052	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms				15	Other	1 TABLET DAILY FOR 28 DAYS					1	29	1
MMRF_1082	Second Line Therapy (after first relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Other	NEW LINE		4	QD (D1-21)	QD (D1-21)					588	680	1
MMRF_1082	Third Line Therapy (following 2nd relapse)	ETOPOSIDE		Completed regimen	mg	CIV	Log Forms	Consolidation	Consolidation		75	QD (D1-4)	QD (D1-4)					661	750	1
MMRF_1082	Third Line Therapy (following 2nd relapse)	CISPLATIN		Completed regimen	mg	CIV	Log Forms	Consolidation	Consolidation		75	QD (D1-4)	QD (D1-4)					661	750	1
MMRF_1082	Third Line Therapy (following 2nd relapse)	Dexamethasone		Completed regimen	mg	IV	Log Forms	Consolidation	Consolidation		4	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					661	750	1
MMRF_1082	Third Line Therapy (following 2nd relapse)	Cyclophosphamide		Completed regimen	mg	CIV	Log Forms	Other	SALVAGE		750	QD (D1-4)	QD (D1-4)					661	750	1
MMRF_1082	Second Line Therapy (after first relapse)	Lenalidomide		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					500	582	1
MMRF_1082	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Unknown	Unknown		100	BID	BID					371	372	1
MMRF_1082	Second Line Therapy (after first relapse)	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms				40	Other	D1, 8,15, 22					288	326	1
MMRF_1082	Second Line Therapy (after first relapse)	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					288	326	1
MMRF_1082	Second Line Therapy (after first relapse)	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					288	326	1
MMRF_1082	First line of therapy	Thalidomide		Investigator decision for other reasons	mg	PO	Log Forms				50	QD (D1-21)	QD (D1-21)					1	274	1
MMRF_1082	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	IVB	Log Forms				40	QWK	QWK					1	274	1
MMRF_1082	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	274	1
MMRF_1094	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	QWK	QWK					1	95	1
MMRF_1094	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms				154	Q day	Q day					142	143	1
MMRF_1094	Second Line Therapy (after first relapse)	ACP-196		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		100	BID	BID					1327	1454	1
MMRF_1094	Second Line Therapy (after first relapse)	PEMBROLIZUMAB		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Induction	Induction		2	Other	EVERY DAY 1					1327	1454	1
MMRF_1094	Third Line Therapy (following 2nd relapse)	Daratumumab		Investigator decision for other reasons	mg	IV	Log Forms	Induction	Induction		900	Other	C1-2D1,8,15,22; C3-6D1,15; C7+D1					1830	2033	1
MMRF_1094	Third Line Therapy (following 2nd relapse)	Dexamethasone		Investigator decision for other reasons	mg	IV	Log Forms	Induction	Induction		20	Other	D1,8,15,22					1830	2033	1
MMRF_1094	Third Line Therapy (following 2nd relapse)	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1829	2061	1
MMRF_1094	Fourth Line Therapy (following 3rd relapse)	Daratumumab		Disease progression/Relapse	mg	IV	Log Forms	Maintenance	Maintenance		900	QWK	QWK					2361	2521	1
MMRF_1094	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms				2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	95	1
MMRF_1094	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	95	1
MMRF_1094	Sixth Line Therapy (following 5th relapse)	STRO-001	NCT03424603	Disease progression/Relapse	mg/kg	IV	Log Forms	Unknown	Unknown		0.91	Other	D1 & D15 Q 28 DAYS					2683	2698	1
MMRF_1094	Fifth Line Therapy (following 4th relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Unknown	Unknown		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					2565	2573	1
MMRF_1093	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	154	1
MMRF_1093	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms				40	Q week	Q week					1	185	1
MMRF_1129	First line of therapy	Lenalidomide		DEATH	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					256	610	1
MMRF_1129	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	Other	DAILY ON DAYS 1, 8, 15, 22					1	249	1
MMRF_1129	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	248	1
MMRF_1130	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	351	1
MMRF_1130	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms				40	QWK	QWK					1	351	1
MMRF_1130	First line of therapy	Bortezomib		Investigator decision for other reasons	mg	IV SubQ	Log Forms				2.5	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	351	1
MMRF_1130	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		25	QD (D1-14)	QD (D1-14)					361	541	1
MMRF_1130	Second Line Therapy (after first relapse)	Lenalidomide		Lack of response	mg	PO	Log Forms	Other	PROGRESSION OF MYELOMA		25	QD (D1-21)	QD (D1-21)					879	1243	1
MMRF_1130	Second Line Therapy (after first relapse)	Dexamethasone		Lack of response	mg	PO	Log Forms	Other	PROGRESSIVE MULTIPLE MYELOMA		40	Other	QD ( D1, D8, D15 AND D22)					879	1243	1
MMRF_1130	Third Line Therapy (following 2nd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		4	Q day	Q day					1373	2004	1
MMRF_1130	Fourth Line Therapy (following 3rd relapse)	Daratumumab			mg/kg	IV	Log Forms	Maintenance	Maintenance	Checked	16	Q week	Q week					2087		1
MMRF_1137	Second Line Therapy (after first relapse)	Lenalidomide		Lack of response	mg	PO	Log Forms	Maintenance	Maintenance		5	Other	EVERY OTHER DAY					632	675	1
MMRF_1137	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					337	501	1
MMRF_1137	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		100	Q day	Q day					223	224	1
MMRF_1137	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	QWK	QWK					5	178	1
MMRF_1137	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	195	1
MMRF_1137	Third Line Therapy (following 2nd relapse)	Lenalidomide		Lack of response	mg	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					675	722	1
MMRF_1137	Third Line Therapy (following 2nd relapse)	Bortezomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Unknown	Unknown		1.3	Other	QD ( D1, D4, D8, D11, D21)					722	764	1
MMRF_1137	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		20	Other	QD ( D1, D4, D8, D11, D21)					722	764	1
MMRF_1137	Fourth Line Therapy (following 3rd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					785	1090	1
MMRF_1137	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		20	Other	QD ( D1, D2, D8, D9, D16, D22, D23)					785	1090	1
MMRF_1132	First line of therapy	Dexamethasone		DEATH	mg	PO	Log Forms				40	QD (D1-4)	QD (D1-4)					103	238	1
MMRF_1132	First line of therapy	Bortezomib		DEATH	mg	IV	Log Forms				2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					103	238	1
MMRF_1132	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms				40	Q week	Q week					5	85	1
MMRF_1132	First line of therapy	Lenalidomide		Lack of response	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	92	1
MMRF_1178	First line of therapy	Bortezomib		PROCEEDING WITH AUTOLOGOUS STEM CELL TRANSPLANT	mg	IV SubQ	Log Forms				2.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	150	1
MMRF_1178	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	Other	DAY 1-4, 9-12					1	150	1
MMRF_1178	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms				100	QD (D1-3)	QD (D1-3)					161	162	1
MMRF_1178	Second Line Therapy (after first relapse)	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Maintenance	Maintenance		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1870	1975	1
MMRF_1178	Second Line Therapy (after first relapse)	Lenalidomide		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		25	QD (D1-21)	QD (D1-21)					1870	1988	1
MMRF_1178	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		40	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1870	1988	1
MMRF_1178	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Unknown	Unknown		20	Other	D1 & D15					2712	2879	1
MMRF_1178	Third Line Therapy (following 2nd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					2712	2879	1
MMRF_1178	Third Line Therapy (following 2nd relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Unknown	Unknown		16	Other	D1 & D15					2712	2879	1
MMRF_1193	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		4	Other	DAY 1, 8, 15, 22 OF EACH 28 DAY CYCLE					1379	1437	1
MMRF_1193	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		8	Other	DAY 1, 8, 15, 22					1381	1437	1
MMRF_1193	Fourth Line Therapy (following 3rd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					1381	1437	1
MMRF_1193	Fourth Line Therapy (following 3rd relapse)	Elotuzumab		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		647	Other	DAY 1, 8, 15, 22  (28 DAY CYCLE)					1381	1437	1
MMRF_1193	Third Line Therapy (following 2nd relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	PROGRESSIVE DISEASE		40	Q week	Q week					896	1321	1
MMRF_1193	Third Line Therapy (following 2nd relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	PROGRESIVE DISEASE		25	QD (D1-21)	QD (D1-21)					896	1321	1
MMRF_1193	Second Line Therapy (after first relapse)	Bortezomib		PARTIAL RESPONSE.	mg	IV SubQ	Log Forms	Induction	Induction		1.3	Other	DAY 1, 8, 15					596	682	1
MMRF_1193	Second Line Therapy (after first relapse)	Lenalidomide		PARTIAL RESPONSE.	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					596	682	1
MMRF_1193	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	QWK	QWK					1	144	1
MMRF_1193	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms				2.6	QWK	QWK					1	144	1
MMRF_1229	First line of therapy	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	172	1
MMRF_1229	First line of therapy	Lenalidomide		Lack of response	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	173	1
MMRF_1229	First line of therapy	Dexamethasone		Lack of response	mg	PO	Log Forms				40	Q week	Q week					1	173	1
MMRF_1229	Second Line Therapy (after first relapse)	Liposomal doxorubicin		Lack of response	mg	IV	Log Forms	Induction	Induction		67	Other	EVERY 21 DAYS					183	270	1
MMRF_1229	Second Line Therapy (after first relapse)	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					311	395	1
MMRF_1229	Second Line Therapy (after first relapse)	Bortezomib		Lack of response	mg/m^2	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					183	277	1
MMRF_1229	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg	IV	Log Forms	Consolidation	Consolidation		200	Q day	Q day					426	427	1
MMRF_1229	Third Line Therapy (following 2nd relapse)	Carfilzomib		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1538	1602	1
MMRF_1229	Third Line Therapy (following 2nd relapse)	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		25	Q day	Q day					1538	1619	1
MMRF_1229	Third Line Therapy (following 2nd relapse)	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		10	Q day	Q day					1538	1619	1
MMRF_1229	Fourth Line Therapy (following 3rd relapse)	Daratumumab			mg/kg	IV	Log Forms	Unknown	Unknown	Checked	16	Other	Q 4 WEEKS					2202		1
MMRF_1256	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms				2.5	QWK	QWK					1	172	1
MMRF_1256	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	Other	DAYS 1-4, 9-12					1	172	1
MMRF_1256	First line of therapy	Bortezomib		Investigator decision for other reasons	mg	IV SubQ	Log Forms	Induction	Induction		2.5	Other	DAYS 1 AND 8					206	488	1
MMRF_1256	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					206	488	1
MMRF_1256	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		40	Other	DAYS 2 AND 9					206	488	1
MMRF_1256	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					506		1
MMRF_1277	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					46	77	1
MMRF_1277	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				10	QD (D1-14)	QD (D1-14)					1	77	1
MMRF_1277	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms				2.9	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	77	1
MMRF_1285	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.5	Q week	Q week					1	204	1
MMRF_1285	First line of therapy	Cyclophosphamide		Completed regimen	mg	PO	Log Forms				550	Other	DAYS 1, 8, 15, 22 OF EACH CYCLE					1	204	1
MMRF_1285	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	Q week	Q week					1	204	1
MMRF_1285	First line of therapy	Bortezomib		Disease progression/Relapse	mg	IV SubQ	Log Forms	Maintenance	Maintenance		2.5	Other	Q21DAYS					303	877	1
MMRF_1285	Second Line Therapy (after first relapse)	Bortezomib		Investigator decision for other reasons	mg	IV	Log Forms	Other	AFTER PROGRESSION		2.5	Other	WEEKLY ( Q D1, D8,D15) 1 WEEK OFF					898	1051	1
MMRF_1285	Second Line Therapy (after first relapse)	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Other	NEW LINE DUE TO PROGRESSION		15	QD (D1-21)	QD (D1-21)					898	1051	1
MMRF_1285	Second Line Therapy (after first relapse)	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Other	NEW LINE DUE TO PROGRESSION		20	QWK	QWK					898	1051	1
MMRF_1285	Second Line Therapy (after first relapse)	Lenalidomide		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					1093	1205	1
MMRF_1285	Second Line Therapy (after first relapse)	Lenalidomide		Completed regimen	mg	PO	Log Forms	Unknown	Unknown		15	QD (D1-21)	QD (D1-21)					1209	1823	1
MMRF_1285	Second Line Therapy (after first relapse)	Ixazomib		DEATH	mg	PO	Log Forms	Induction	Induction		4	QWK	QWK					1851	2018	1
MMRF_1285	Second Line Therapy (after first relapse)	Lenalidomide		DEATH	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					1851	2018	1
MMRF_1285	Second Line Therapy (after first relapse)	Dexamethasone		DEATH	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1851	2018	1
MMRF_1359	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		40	Q day	Q day					1123	1162	1
MMRF_1359	Third Line Therapy (following 2nd relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		25	Q day	Q day					1123	1162	1
MMRF_1359	Third Line Therapy (following 2nd relapse)	Carfilzomib		Disease progression/Relapse	mg	IVB	Log Forms	Induction	Induction		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1123	1162	1
MMRF_1359	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		25	QD (D1-21)	QD (D1-21)					882	1106	1
MMRF_1359	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	MOBILATION PRIOR TO HARVESTED AOUTOLOGOUS STEM CELL TRANPLANT		200	Q day	Q day					168	169	1
MMRF_1359	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QWK	QWK					694	876	1
MMRF_1359	Second Line Therapy (after first relapse)	Bortezomib		Completed regimen	mg	SUB - Q	Log Forms	Induction	Induction		3	Other	QD ( D1, D8,D15,D22)					694	862	1
MMRF_1359	Second Line Therapy (after first relapse)	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Induction	Induction		500	Other	QD ( D1, D8, D15, D22)					694	876	1
MMRF_1359	First line of therapy	Dexamethasone		TO PROCEED WITH TRANSPLANT	mg	PO	Log Forms				40	Other	D1-4, D 9-12					1	116	1
MMRF_1359	First line of therapy	Bortezomib		TO PROCEED WITH TRANSPLANT	mg	IV SubQ	Log Forms				2.5	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	116	1
MMRF_1395	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg	IV SubQ	Log Forms				2.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	108	1
MMRF_1395	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms				20	Other	Q 1, 2, 4, 5, 8, 9, 11, 12 OF EACH 21-DAY CYCLE					1	126	1
MMRF_1395	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	126	1
MMRF_1395	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		100	Q day	Q day					189	190	1
MMRF_1395	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					1156	1492	1
MMRF_1395	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	5	QD (D1-21)	QD (D1-21)					1493		1
MMRF_1401	Third Line Therapy (following 2nd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					430	500	1
MMRF_1401	Third Line Therapy (following 2nd relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					430	500	1
MMRF_1401	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		15	Other	QD					261	427	1
MMRF_1401	Second Line Therapy (after first relapse)	Lenalidomide		Lack of response	mg	PO	Log Forms	Consolidation	Consolidation		15	Other	QD					91	260	1
MMRF_1401	Second Line Therapy (after first relapse)	Carfilzomib		Lack of response	mg/m^2	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					91	247	1
MMRF_1401	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	QWK	QWK					1	542	1
MMRF_1401	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms				2.4	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	75	1
MMRF_1401	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	75	1
MMRF_1410	First line of therapy	RANDOMIZED MILS TRIAL, J1343 (NO MILS ARM)		Completed regimen	UNKNOWN	IV	Log Forms	Consolidation	Consolidation		200	Q day	Q day					187	187	1
MMRF_1410	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	5	QD (D1-21)	QD (D1-21)					245		1
MMRF_1410	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	Q week	Q week					1	164	1
MMRF_1410	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	164	1
MMRF_1410	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms				2.5	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	164	1
MMRF_1410	First line of therapy	Melphalan		Completed regimen	UNK	IV	Log Forms	Other	TRANSPLANT			Other	DAY -2 AND -1					175	176	1
MMRF_1598	First line of therapy	Dexamethasone		DEATH	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					1	45	1
MMRF_1598	First line of therapy	Thalidomide		DEATH	mg	PO	Log Forms	Induction	Induction		100	Q day	Q day					1	45	1
MMRF_1670	First line of therapy	Bortezomib		PLAN FOR STEM CELL RESCUE WHEN IN REMISSION	mg	IV SubQ	Log Forms	Induction	Induction		3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	81	1
MMRF_1670	First line of therapy	Lenalidomide		PLAN FOR STEM CELL RESCUE WHEN IN REMISSION.	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	74	1
MMRF_1670	First line of therapy	Dexamethasone		PLAN FOR STEM CELL RESCUE WHEN IN REMISSION.	mg	PO	Log Forms	Induction	Induction		40	Other	ONCE WEEKLY					1	74	1
MMRF_1670	Second Line Therapy (after first relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Other	DUE TO PROGRESSION		20	Other	D1,D8,D15					484	612	1
MMRF_1670	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Induction	Induction		210	Other	QD ON DAYS -2 AND -1 PRE TRANSPLANT					127	128	1
MMRF_1670	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	Other	QD					278	477	1
MMRF_1670	Third Line Therapy (following 2nd relapse)	ACP-196		Completed regimen	mg	PO	Log Forms	Induction	Induction		100	BID	BID					683	773	1
MMRF_1670	Third Line Therapy (following 2nd relapse)	PEMBROLIZUMAB		Completed regimen	mg/kg	IV	Log Forms	Induction	Induction		2	Other	DAY 1					683	773	1
MMRF_1670	Fourth Line Therapy (following 3rd relapse)	Cyclophosphamide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		600	Other	DAYS 1, 8, 15, 22					943	1111	1
MMRF_1670	Fourth Line Therapy (following 3rd relapse)	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Induction	Induction		1.5	Other	DAYS 1, 8, 15, 22					943	1111	1
MMRF_1670	Fifth Line Therapy (following 4th relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Unknown	Unknown		16	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1283	1416	1
MMRF_1670	Fifth Line Therapy (following 4th relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		25	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1283	1429	1
MMRF_1670	Fifth Line Therapy (following 4th relapse)	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Unknown	Unknown		20	Other	Q 2 WKS					1283	1416	1
MMRF_1670	Sixth Line Therapy (following 5th relapse)	Elotuzumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Maintenance	Maintenance		10	QWK	QWK					1443	1462	1
MMRF_1670	Sixth Line Therapy (following 5th relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					1436	1473	1
MMRF_1670	Seventh Line of Therapy (following 6th relapse)	Cyclophosphamide		Adverse Event or co-morbidity	mg	IV	Log Forms	Maintenance	Maintenance		750	QD (D1-4)	QD (D1-4)					1478	1502	1
MMRF_1670	Seventh Line of Therapy (following 6th relapse)	CISPLATIN		Adverse Event or co-morbidity	mg	IV	Log Forms	Maintenance	Maintenance		25	QD (D1-4)	QD (D1-4)					1478	1502	1
MMRF_1670	Seventh Line of Therapy (following 6th relapse)	ETOPOSIDE		Adverse Event or co-morbidity	mg	IV	Log Forms	Maintenance	Maintenance		75	QD (D1-4)	QD (D1-4)					1478	1502	1
MMRF_1670	Eighth Line of Therapy (following 7th relapse)	Daratumumab		Adverse Event or co-morbidity	mg/kg	IV	Log Forms	Maintenance	Maintenance		16	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1562	1646	1
MMRF_1670	Eighth Line of Therapy (following 7th relapse)	Bortezomib		Adverse Event or co-morbidity	mg	IV	Log Forms	Maintenance	Maintenance		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1562	1656	1
MMRF_1670	Ninth Line of Therapy (following 8th relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		40	Q week	Q week					1804	1877	1
MMRF_1670	Ninth Line of Therapy (following 8th relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		25	QD (D1-14)	QD (D1-14)					1804	1877	1
MMRF_1670	Ninth Line of Therapy (following 8th relapse)	Ixazomib		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		4	Other	D1, 8, & 15					1804	1877	1
MMRF_1670	Eighth Line of Therapy (following 7th relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	IV	Log Forms	Maintenance	Maintenance		20	Other	D1, 8, & 15					1562	1646	1
MMRF_1670	Seventh Line of Therapy (following 6th relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	IV	Log Forms	Maintenance	Maintenance		40	QD (D1-4)	QD (D1-4)					1478	1502	1
MMRF_1670	Seventh Line of Therapy (following 6th relapse)	MESNA		Adverse Event or co-morbidity	mg	CONTINUOUS IV INFUSION	Log Forms	Maintenance	Maintenance		750	QD (D1-4)	QD (D1-4)					1478	1502	1
MMRF_1695	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	5	QD (D1-21)	QD (D1-21)					471		1
MMRF_1695	First line of therapy	Melphalan		Completed regimen	mg/kg	IV	Log Forms	Other	MOBILIZATION		70	Q day	Q day					198	198	1
MMRF_1695	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					1	214	1
MMRF_1695	First line of therapy	Lenalidomide		DUE TO TRANSPLANT , MOBILIZATION	mg	PO	Log Forms	Induction	Induction		15	Other	EVERY OTHER DAY DAYS 1-14					1	144	1
MMRF_1695	First line of therapy	Bortezomib		DUE TO TRANSPLANT , MOBILIZATION	mg	IV	Log Forms	Induction	Induction		2.6	Other	QD (D1, D4, D8, D11)					1	144	1
MMRF_1838	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	DAYS 1-4, 9-12, 17-20					78	155	1
MMRF_1838	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.5	Other	DAYS 1, 8, 15, 22					78	155	1
MMRF_1838	First line of therapy	Cyclophosphamide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		50	Other	DAYS 1, 8, 15, 22					1	71	1
MMRF_1838	First line of therapy	Lenalidomide		AUTOLOGOUS TRANSPLANT	mg	PO	Log Forms	Other	NOT SUFFICIENT RESPONSE TO PREVIOUS TREATMENT.		25	QD (D1-14)	QD (D1-14)					78	155	1
MMRF_1838	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	PRE TRANSPLANT TREAMENT		70	Q day	Q day					209	210	1
MMRF_1838	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					316	615	1
MMRF_1838	Second Line Therapy (after first relapse)	Carfilzomib		DEATH	mg	IV	Log Forms	Induction	Induction		48	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					630	1005	1
MMRF_1838	Second Line Therapy (after first relapse)	Dexamethasone		DEATH	mg	IV	Log Forms	Induction	Induction		4	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					630	1005	1
MMRF_1866	First line of therapy	ETOPOSIDE		Completed regimen	mg/m^2	CONTINUOUS IV INFUSION	Log Forms	Other	PRE-TRANSPLANT		40	QD (D1-4)	QD (D1-4)					1173	1179	1
MMRF_1866	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	CONTINUOUS IV INFUSION	Log Forms	Other	PRE-TRANSPLANT		400	QD (D1-4)	QD (D1-4)					1173	1179	1
MMRF_1866	First line of therapy	Doxorubicin		Completed regimen	mg/m^2	CONTINUOUS IV INFUSION	Log Forms	Other	PRE-TRANSPLANT		10	QD (D1-4)	QD (D1-4)					1173	1179	1
MMRF_1866	First line of therapy	CISPLATIN		Completed regimen	mg/m^2	CONTINUOUS IV INFUSION	Log Forms	Other	PRE-TRANSPLANT		100	QD (D1-4)	QD (D1-4)					1173	1179	1
MMRF_1866	First line of therapy	Thalidomide		Completed regimen	mg	PO	Log Forms	Other	PRE-TRANSPLANT		100	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1173	1183	1
MMRF_1866	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Other	PRE-TRANSPLANT		20	Other	D1-4 & D7					1173	1183	1
MMRF_1866	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Other	PRE-TRANSPLANT		1.3	QD (D1-4)	QD (D1-4)					1173	1182	1
MMRF_1866	First line of therapy	Melphalan		Completed regimen		IV	Log Forms	Other	PRE-TRANSPLANT			Other	QD X 2					1216	1217	1
MMRF_1866	First line of therapy	Dexamethasone		COMPLETED CYCLE	mg	PO	Log Forms	Induction	Induction		20	Other	QD(D1, D2,D4,D5,D8,D9,D11) OF EACH 21-DAY CYCLE.					1	13	1
MMRF_1866	First line of therapy	Dexamethasone		COMPLETED CYCLE 2	mg	PO	Log Forms	Induction	Induction		20	Other	QD ( D1,D2,D4,D5,D8,D9,D11,12) OF 21-DAY CYCLE					22	33	1
MMRF_1866	First line of therapy	Dexamethasone		COMPLETED CYCLE 3	mg	PO	Log Forms	Induction	Induction		20	Other	QD ( D1,D2,D4,D5,D8,D9,D11,12) OF 21-DAY CYCLE					43	57	1
MMRF_1866	First line of therapy	Dexamethasone		COMPLETED CYCLE 4	mg	PO	Log Forms	Induction	Induction		20	Other	QD ( D1,D2,D4,D5,D8,D9,D11,12) OF 21-DAY CYCLE					65	78	1
MMRF_1866	First line of therapy	Dexamethasone		COMPLETED CYCLE 5	mg	PO	Log Forms	Induction	Induction		20	Other	QD ( D1,D2,D4,D5,D8,D9,D11,12) OF 21-DAY CYCLE					85	96	1
MMRF_1866	First line of therapy	Lenalidomide		Patient decision	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					107	192	1
MMRF_1866	First line of therapy	Dexamethasone		UNKNOWN	mg	PO	Log Forms	Maintenance	Maintenance		12	QWK	QWK					105	918	1
MMRF_1866	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IVB	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	95	1
MMRF_1866	Second Line Therapy (after first relapse)	Daratumumab			mg/kg	IV	Log Forms	Maintenance	Maintenance	Checked	16	QWK	QWK					1296		1
MMRF_1866	Second Line Therapy (after first relapse)	Pomalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	4	QD (D1-21)	QD (D1-21)					1348		1
MMRF_1866	Second Line Therapy (after first relapse)	Bortezomib			mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance	Checked	1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1597		1
MMRF_1866	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	192	1
MMRF_1950	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		3	Other	Q D1, 8, 15, 22					1	289	1
MMRF_1950	First line of therapy	Cyclophosphamide		Investigator decision for other reasons	mg/m^2	PO	Log Forms	Induction	Induction		300	Other	Q 1, 8, 15, 22					1	107	1
MMRF_1950	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	107	1
MMRF_1950	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		20	Other	QD (D1,D2) Q 2 WEEKS					114	289	1
MMRF_1950	Second Line Therapy (after first relapse)	Daratumumab		Investigator decision for other reasons	mg	IVB	Log Forms	Maintenance	Maintenance		1100	Q week	Q week					1152	1310	1
MMRF_1950	Second Line Therapy (after first relapse)	Dexamethasone		Investigator decision for other reasons	mg	IV	Log Forms	Maintenance	Maintenance		20	Other	D1, 2, 8, 15					1152	1310	1
MMRF_1950	Second Line Therapy (after first relapse)	Bortezomib		Investigator decision for other reasons	mg	IV SubQ	Log Forms	Maintenance	Maintenance		2.4	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1152	1236	1
MMRF_1997	Second Line Therapy (after first relapse)	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		20	Q week	Q week					1604	1660	1
MMRF_1997	Second Line Therapy (after first relapse)	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					1604	1660	1
MMRF_1997	Second Line Therapy (after first relapse)	Ixazomib		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		3	Other	D1, 8, & 15					1604	1660	1
MMRF_1997	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	QWK	QWK					7	93	1
MMRF_1997	First line of therapy	Lenalidomide		Patient decision	mg	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					1	787	1
MMRF_1997	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					94	241	1
MMRF_1997	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	DAYS 1, 8, 15, 22					473	557	1
MMRF_1997	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	DAY 1, 15					564	621	1
MMRF_2214	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		10	Other	Q3 WEEKS ON AND ONE WEEK OFF					44	433	1
MMRF_2214	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		4	QWK	QWK					1	433	1
MMRF_2214	First line of therapy	Cyclophosphamide		Investigator decision for other reasons	mg/m^2	PO	Log Forms	Induction	Induction		300	Other	DAY 1, 8, 15, 22					1	426	1
MMRF_2214	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		3.1	Q week	Q week					9	36	1
MMRF_2230	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	Other	DAY 1-4. 9-12, 17-20					1	124	1
MMRF_2230	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg	IV	Log Forms	Induction	Induction		2.7	Other	DAY 1. 8, 15 AND 22					1	64	1
MMRF_2230	First line of therapy	Cyclophosphamide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		500	Other	DAYS 1, 8, 15 AND 22					1	64	1
MMRF_2258	First line of therapy	Bortezomib		Completed regimen	mg	IV	Log Forms	Induction	Induction		2.2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	112	1
MMRF_2258	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					1	112	1
MMRF_2442	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		20	Other	D1, 8, & 15					1106	1254	1
MMRF_2442	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					779	1040	1
MMRF_2442	Second Line Therapy (after first relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Induction	Induction		16	Other	D1, 8, & 15					1106	1254	1
MMRF_2442	Third Line Therapy (following 2nd relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		25	QD (D1-21)	QD (D1-21)					1274	1543	1
MMRF_2442	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	190	1
MMRF_2442	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		2.4	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	190	1
MMRF_2442	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		20	Other	DAY 1-2, 4-5, 8-9, 11-12					1	36	1
MMRF_2442	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	DAY 1-2, 4-5, 8-9, 11-12					36	190	1
MMRF_2442	Fourth Line Therapy (following 3rd relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Maintenance	Maintenance		27	Other	D1-2, D15-16					1555	1717	1
MMRF_2442	Fourth Line Therapy (following 3rd relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Maintenance	Maintenance		16	Other	Q 4 WKS					1555	1702	1
MMRF_2442	Fourth Line Therapy (following 3rd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		3	QD (D1-21)	QD (D1-21)					1555	1732	1
MMRF_2442	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Maintenance	Maintenance		20	Other	Q 4 WKS					1274	1543	1
MMRF_2442	Third Line Therapy (following 2nd relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Maintenance	Maintenance		16	Other	Q 4WKS					1274	1543	1
MMRF_2442	Second Line Therapy (after first relapse)	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1106	1263	1
MMRF_2442	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Maintenance	Maintenance		20	Other	Q 4 WKS					1555	1702	1
MMRF_2442	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Unknown	Unknown		177	Q day	Q day					224	225	1
MMRF_2442	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					406	767	1
MMRF_2456	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					918	1803	1
MMRF_2456	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					596	918	1
MMRF_2456	Second Line Therapy (after first relapse)	Pomalidomide			mg	PO	Log Forms	Consolidation	Consolidation	Checked	2	QD (D1-21)	QD (D1-21)					2003		1
MMRF_2456	Second Line Therapy (after first relapse)	Carfilzomib				IV	Log Forms	Consolidation	Consolidation	Checked		Other	D1, D8, D15					1804		1
MMRF_2456	Second Line Therapy (after first relapse)	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Consolidation	Consolidation		10	Q day	Q day					1804	2002	1
MMRF_2456	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Consolidation	Consolidation	Checked	20	Q week	Q week					1804		1
MMRF_2456	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	D1, 8, 15, 22					153	469	1
MMRF_2456	First line of therapy	Melphalan		Completed regimen	UNK	IV	Log Forms	Induction	Induction			Other	DAY -2 & DAY -1					509	510	1
MMRF_2456	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					153	472	1
MMRF_2456	First line of therapy	Carfilzomib		Completed regimen	mg	IV	Log Forms	Induction	Induction		54	Other	Q WEEKLY D1,D8,D15					153	469	1
MMRF_2456	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		40	BID	BID					1	110	1
MMRF_2456	First line of therapy	Bortezomib		Investigator decision for other reasons	mg	IV SubQ	Log Forms	Induction	Induction		3	Other	DAY 1, 8, 15, 22					5	124	1
MMRF_2456	First line of therapy	Cyclophosphamide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		600	Other	DAY 1, 8, 15, 22					5	110	1
MMRF_2471	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	231	1
MMRF_2471	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	DAYS 1, 8, 15, 22					4	597	1
MMRF_2471	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					154	231	1
MMRF_2471	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		5	BID	BID					232	597	1
MMRF_2471	Second Line Therapy (after first relapse)	Carfilzomib		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Induction	Induction		56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1136	1184	1
MMRF_2471	Second Line Therapy (after first relapse)	Carfilzomib		Investigator decision for other reasons	mg	IVB	Log Forms	Induction	Induction		50	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1148	1184	1
MMRF_2471	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					1148	1988	1
MMRF_2471	Second Line Therapy (after first relapse)	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1148	1207	1
MMRF_2471	Third Line Therapy (following 2nd relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Induction	Induction		16	Q week	Q week					2011	2109	1
MMRF_2471	Third Line Therapy (following 2nd relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					2011	2109	1
MMRF_2471	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		20	Q week	Q week					2011	2109	1
MMRF_2471	Fourth Line Therapy (following 3rd relapse)	Carfilzomib			mg	IV	Log Forms	Maintenance	Maintenance	Checked	36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					2151		1
MMRF_2471	Fourth Line Therapy (following 3rd relapse)	POMALIDOMIDE			mg	PO	Log Forms	Maintenance	Maintenance	Checked	2	Other	1 TAB DAILY FOR 21 DAYS ON 28 DAYS CYCLE					2151		1
MMRF_2471	Fourth Line Therapy (following 3rd relapse)	Dexamethasone			mg	PO	Log Forms	Maintenance	Maintenance	Checked	20	Other	ON DAYS 18, 15, 22 OF EACH CYCLE					2151		1
MMRF_2475	Third Line Therapy (following 2nd relapse)	Elotuzumab			mg/kg	IV	Log Forms	Induction	Induction	Checked	10	Other	Q 4 WEEKS					1730		1
MMRF_2475	Third Line Therapy (following 2nd relapse)	Lenalidomide			mg	PO	Log Forms	Induction	Induction	Checked	20	QD (D1-21)	QD (D1-21)					1730		1
MMRF_2475	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	131	1
MMRF_2475	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	222	1
MMRF_2475	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	DAYS 1,2,4,5,8,9,11,12 OF EACH 21 DAY CYCLE					1	222	1
MMRF_2475	Second Line Therapy (after first relapse)	Lenalidomide		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		20	Q day	Q day					423	1729	1
MMRF_2546	First line of therapy	Bortezomib		Disease progression/Relapse	mg	IV	Log Forms	Unknown	Unknown		2.8	Other	Q 28 D ( D1,8,15)					197	366	1
MMRF_2546	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					1	136	1
MMRF_2546	First line of therapy	Lenalidomide		Lack of response	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	117	1
MMRF_2579	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	101	1
MMRF_2579	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		2.5	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	73	1
MMRF_2579	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	QD (D1-2, D4-5, D8-9, D11-12)					1	105	1
MMRF_2579	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	INDUCTION		100	Q day	Q day					140	141	1
MMRF_1021	First line of therapy	Bortezomib		TOXICITY	mg	IV	Log Forms				2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	29	1
MMRF_1021	Third Line Therapy (following 2nd relapse)	Daratumumab			mg/kg	IV	Log Forms	Other	SALVAGE	Checked	16	Other	MONTHLY					2363		1
MMRF_1021	Third Line Therapy (following 2nd relapse)	Pomalidomide			mg	PO	Log Forms	Other	SALVAGE	Checked	4	QD (D1-21)	QD (D1-21)					2363		1
MMRF_1021	Third Line Therapy (following 2nd relapse)	Dexamethasone			mg	PO	Log Forms	Other	SALVAGE	Checked	20	Other	DAYS 1, 8, 15					2363		1
MMRF_1021	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					84	84	1
MMRF_1021	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	29	1
MMRF_1021	First line of therapy	Dexamethasone		TOXICITY	mg	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	29	1
MMRF_1021	Second Line Therapy (after first relapse)	Lenalidomide		Completed regimen	mg	PO	Log Forms	Other	EVIDENCE OF DISEASE PROGRESION		25	QD (D1-21)	QD (D1-21)					630	825	1
MMRF_1021	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Other	EVIDENCE OF DISEASE PROGRESSION		40	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					630	825	1
MMRF_1021	Second Line Therapy (after first relapse)	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Other	CONDITIONING		1.6	QD (D1-4)	QD (D1-4)					845	848	1
MMRF_1021	Second Line Therapy (after first relapse)	FLUDARABINE		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		30	Q day	Q day					844	847	1
MMRF_1021	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONSOLIDATION		140	Q day	Q day					847	847	1
MMRF_1030	Sixth Line Therapy (following 5th relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		20	Q week	Q week					2760	2816	1
MMRF_1030	Sixth Line Therapy (following 5th relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		4	QD (D1-21)	QD (D1-21)					2760	2816	1
MMRF_1030	Sixth Line Therapy (following 5th relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Other	SALVAGE		16	QWK	QWK					2760	2816	1
MMRF_1030	First line of therapy	Bortezomib		PATIENT WENT TO TRANSPLANT	mg	IV	Log Forms				1	QWK	QWK					1	106	1
MMRF_1030	First line of therapy	Lenalidomide		PATIENT WENT TO TRANSPLANT	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	106	1
MMRF_1030	First line of therapy	Dexamethasone		PATIENT WENT TO TRANSPLANT	mg	IV	Log Forms				20	QWK	QWK					1	106	1
MMRF_1030	First line of therapy	Cyclophosphamide		PATIENT GOING TO TRANSPLANT	GRAMS	IV	Log Forms				3	Q day	Q day					116	116	1
MMRF_1030	First line of therapy	ETOPOSIDE		PATIENT GOING TO TRANSPLANT	mg	IV	Log Forms				300	Q day	Q day					116	116	1
MMRF_1030	First line of therapy	Dexamethasone		PATIENT GOING TO TRANSPLANT	mg	IV	Log Forms				40	Q day	Q day					116	116	1
MMRF_1030	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms				200	Q day	Q day					140	140	1
MMRF_1030	First line of therapy	Thalidomide		Completed regimen	mg	PO	Log Forms				1000	Q day	Q day					280	283	1
MMRF_1030	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms				1.6	Q day	Q day					281	283	1
MMRF_1030	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms				200	Q day	Q day					282	282	1
MMRF_1030	Second Line Therapy (after first relapse)	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Unknown	Unknown		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1984	2205	1
MMRF_1030	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		25	QD (D1-21)	QD (D1-21)					1984	2205	1
MMRF_1030	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	IV	Log Forms	Unknown	Unknown		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1984	2205	1
MMRF_1030	Third Line Therapy (following 2nd relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		25	QD (D1-21)	QD (D1-21)					2373	2459	1
MMRF_1030	Third Line Therapy (following 2nd relapse)	Ixazomib		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		4	Other	DAYS 1, 8, AND 15					2373	2459	1
MMRF_1030	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		20	Q week	Q week					2373	2459	1
MMRF_1030	Fourth Line Therapy (following 3rd relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Other	SALVAGE		27	Other	DAYS 1, 2, 8, 9, 15, 16					2465	2493	1
MMRF_1030	Fourth Line Therapy (following 3rd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		4	QD (D1-21)	QD (D1-21)					2465	2493	1
MMRF_1030	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Other	SALVAGE		20	Other	DAYS 1, 2, 8, 9, 15, 16					2465	2493	1
MMRF_1030	Fifth Line Therapy (following 4th relapse)	Cyclophosphamide		Disease progression/Relapse	mg/m^2	IV	Log Forms	Other	SALVAGE		300	Other	DAYS 1, 8, 15					2493	2760	1
MMRF_1030	Fifth Line Therapy (following 4th relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Other	SALVAGE		27	Other	DAYS 1, 2, 8, 9, 15, 16					2493	2760	1
MMRF_1030	Fifth Line Therapy (following 4th relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		4	QD (D1-21)	QD (D1-21)					2493	2760	1
MMRF_1030	Fifth Line Therapy (following 4th relapse)	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Other	SALVAGE		20	Other	DAYS 1, 2, 8, 9, 15, 16					2493	2760	1
MMRF_1032	Second Line Therapy (after first relapse)	Dexamethasone		DIED	mg	PO	Log Forms	Unknown	Unknown		12	Q week	Q week					726	934	1
MMRF_1032	Second Line Therapy (after first relapse)	Lenalidomide		DIED	mg	PO	Log Forms	Unknown	Unknown		15	QD (D1-21)	QD (D1-21)					612	934	1
MMRF_1032	Second Line Therapy (after first relapse)	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Unknown	Unknown		20	Q week	Q week					439	725	1
MMRF_1032	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		25	QD (D1-21)	QD (D1-21)					439	578	1
MMRF_1032	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	IV	Log Forms				10	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	42	1
MMRF_1032	First line of therapy	Cyclophosphamide		Investigator decision for other reasons	mg	IV	Log Forms				1050	Q week	Q week					1	39	1
MMRF_1032	First line of therapy	Bortezomib		Investigator decision for other reasons	mg	IV SubQ	Log Forms				2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					2	52	1
MMRF_1072	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	14	1
MMRF_1072	First line of therapy	Bortezomib		PT GOING TO TRANSPLANT	mg	IV SubQ	Log Forms				2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	32	1
MMRF_1072	First line of therapy	Dexamethasone		GOING TO TRANSPLANT	mg	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	32	1
MMRF_1072	First line of therapy	Cyclophosphamide		Completed regimen	G	PO	Log Forms	Other	MOBILIZATION		3.1	Q day	Q day					60	60	1
MMRF_1072	First line of therapy	ETOPOSIDE		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		310	Q day	Q day					60	60	1
MMRF_1072	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		10	Q day	Q day					60	60	1
MMRF_1072	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONIG		312	Q day	Q day					86	86	1
MMRF_1072	Second Line Therapy (after first relapse)	Dexamethasone		Investigator decision for other reasons	mg	IV	Log Forms				20	Other	QD (D1-2, D15-16)					2305	2445	1
MMRF_1072	Second Line Therapy (after first relapse)	Dexamethasone		Investigator decision for other reasons	mg	IV	Log Forms				20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					2117	2292	1
MMRF_1072	Second Line Therapy (after first relapse)	Carfilzomib		Investigator decision for other reasons	mg/m^2	IV	Log Forms				56	Other	QD (D1-2, D15-16)					2305	2445	1
MMRF_1072	Second Line Therapy (after first relapse)	Carfilzomib		Investigator decision for other reasons	mg/m^2	IV	Log Forms				56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					2117	2292	1
MMRF_1079	Fifth Line Therapy (following 4th relapse)	Bortezomib		Disease progression/Relapse	mg	IV SubQ	Log Forms	Unknown	Unknown		2.4	Other	QD(D1,D5,D15,D19)					1999	2074	1
MMRF_1079	Fifth Line Therapy (following 4th relapse)	Panobinostat		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		20	Other	QD (D1, D3, D5, D15, D17, D19)					1999	2074	1
MMRF_1079	Fifth Line Therapy (following 4th relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		20	Other	ON DAYS OF VELCADE					1999	2074	1
MMRF_1079	Sixth Line Therapy (following 5th relapse)	Bortezomib		Disease progression/Relapse	mg	IV SubQ	Log Forms	Unknown	Unknown		2.5	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					2081	2126	1
MMRF_1079	Sixth Line Therapy (following 5th relapse)	NELFINAVIR (VIRACEPT)		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		625	Q day	Q day					2081	2126	1
MMRF_1079	Sixth Line Therapy (following 5th relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					2081	2126	1
MMRF_1079	Fourth Line Therapy (following 3rd relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Unknown	Unknown		16	Other	DAYS 1,8,15 & 22 OF A 28 DAYS FOR C1&2/DAYS A AND 15 C3TO C6/DAYS 1 CYCLE 7					1887	1971	1
MMRF_1079	Fourth Line Therapy (following 3rd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					1887	1971	1
MMRF_1079	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Unknown	Unknown		40	Other	WITH EACH DARATUMUMAB INFUSION					1887	1971	1
MMRF_1079	Second Line Therapy (after first relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Other	SECOND LINE		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1331	1752	1
MMRF_1079	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Other	SECOND LINE		25	QD (D1-21)	QD (D1-21)					1331	1752	1
MMRF_1079	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Other	SECOND LINE		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1331	1752	1
MMRF_1079	Third Line Therapy (following 2nd relapse)	Cyclophosphamide		Disease progression/Relapse	mg/m^2	IV	Log Forms	Other	THIRD LINE		500	Other	D1, 8					1597	1752	1
MMRF_1079	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Q day	Q day					226	226	1
MMRF_1079	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Q day	Q day					99	99	1
MMRF_1079	First line of therapy	ETOPOSIDE		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Q day	Q day					75	75	1
MMRF_1079	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Induction	Induction		10	Q day	Q day					75	75	1
MMRF_1079	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		2000	Q day	Q day					75	75	1
MMRF_1079	First line of therapy	Lenalidomide		PROCEED TO TRANSPLANT	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	43	1
MMRF_1079	First line of therapy	Dexamethasone		PROCEED TO TRANSPLANT	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	40	1
MMRF_1079	First line of therapy	Bortezomib		MOVE TO TRANSPLANT	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	40	1
MMRF_1098	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	89	1
MMRF_1098	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	89	1
MMRF_1098	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	92	1
MMRF_1098	First line of therapy	Dexamethasone		Patient decision	mg	PO	Log Forms				40	Q week	Q week					105	329	1
MMRF_1099	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		25	Other	EVERY OTHER DAY					144	285	1
MMRF_1099	Second Line Therapy (after first relapse)	Dexamethasone		Patient decision	mg	PO	Log Forms	Unknown	Unknown		40	Q week	Q week					333	588	1
MMRF_1099	Second Line Therapy (after first relapse)	Pomalidomide		Patient decision	mg	PO	Log Forms				4	QD (D1-21)	QD (D1-21)					333	588	1
MMRF_1099	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	285	1
MMRF_1099	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	136	1
MMRF_1099	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	4	1
MMRF_1139	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_1139	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	35	1
MMRF_1139	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_1139	First line of therapy	Cyclophosphamide		Completed regimen	G/M^2	IV	Log Forms				2	Q day	Q day					74	74	1
MMRF_1139	First line of therapy	ETOPOSIDE		Completed regimen	mg/m^2	IV	Log Forms				200	Q day	Q day					74	74	1
MMRF_1139	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms				10	Q day	Q day					74	74	1
MMRF_1139	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					99	99	1
MMRF_1139	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		1.3	QD (D1-4)	QD (D1-4)					274	277	1
MMRF_1139	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					276	276	1
MMRF_1159	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms				3.1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	92	1
MMRF_1159	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	92	1
MMRF_1159	First line of therapy	Cyclophosphamide		Completed regimen	G	IV	Log Forms				4.7	Other	ONCE					122	122	1
MMRF_1159	First line of therapy	ETOPOSIDE		Completed regimen	mg/m^2	IV	Log Forms				200	Other	ONCE					122	122	1
MMRF_1159	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms				10	Other	ONCE					122	122	1
MMRF_1159	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms				200	Other	ONCE					170	170	1
MMRF_1177	Second Line Therapy (after first relapse)	Cyclophosphamide		DEATH	mg	IV	Log Forms	Other	SALVAGE		890	Other	QD (D1, D8)					711	819	1
MMRF_1177	Second Line Therapy (after first relapse)	Bortezomib		DEATH	mg/m^2	IV SubQ	Log Forms	Other	SALVAGE		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					711	819	1
MMRF_1177	Second Line Therapy (after first relapse)	Dexamethasone		DEATH	mg	PO	Log Forms	Other	SALVAGE		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					711	819	1
MMRF_1177	First line of therapy	Dexamethasone		INTOLERANCE TO THERAPY	mg	PO	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	71	1
MMRF_1177	First line of therapy	Cyclophosphamide		INTOLERANCE TO THERAPY	mg/m^2	IV	Log Forms				500	Other	QD (D1, D8)					1	71	1
MMRF_1177	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	71	1
MMRF_1208	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms				500	Other	QD 1-8					1	63	1
MMRF_1208	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	63	1
MMRF_1208	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					170	170	1
MMRF_1208	Second Line Therapy (after first relapse)	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Other	SECOND LINE THERAPY		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					711	722	1
MMRF_1208	Second Line Therapy (after first relapse)	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Other	SECOND LINE THERAPY		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					711	742	1
MMRF_1208	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Other	SECOND LINE		15	QD (D1-21)	QD (D1-21)					732	905	1
MMRF_1208	Third Line Therapy (following 2nd relapse)	Carfilzomib		Adverse Event or co-morbidity	mg	IV	Log Forms	Consolidation	Consolidation		32	Other	QD (DAY1-DAY2; DAY15-DAY16)					1137	1320	1
MMRF_1208	Third Line Therapy (following 2nd relapse)	Thalidomide		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		100	QD (D1-21)	QD (D1-21)					1074	1114	1
MMRF_1208	Third Line Therapy (following 2nd relapse)	Cyclophosphamide		Disease progression/Relapse	mg/m^2	IV	Log Forms	Consolidation	Consolidation		300	Other	DAYS 1 & 15					1074	1102	1
MMRF_1208	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Consolidation	Consolidation		40	Other	DAYS 1, 8, 15					1074	1114	1
MMRF_1208	Third Line Therapy (following 2nd relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	IV	Log Forms	Unknown	Unknown		40	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1137	1320	1
MMRF_1208	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					8	66	1
MMRF_1194	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					181	181	1
MMRF_1194	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		10	QID	QID					142	142	1
MMRF_1194	First line of therapy	ETOPOSIDE		Completed regimen	mg/m^2	IV	Log Forms	Other	MOBILIZATION		200	QID	QID					142	142	1
MMRF_1194	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Other	MOBILIZATION		2000	QID	QID					142	142	1
MMRF_1194	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					91	136	1
MMRF_1194	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					91	136	1
MMRF_1194	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					91	100	1
MMRF_1194	First line of therapy	Dexamethasone		Lack of response	mg	PO	Log Forms				40	Q week	Q week					1	90	1
MMRF_1194	First line of therapy	Lenalidomide		Lack of response	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	90	1
MMRF_1205	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	N/A		12	Q week	Q week					667	685	1
MMRF_1205	Second Line Therapy (after first relapse)	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	N/A		4	Other	QOD (D1-21)					667	685	1
MMRF_1205	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		20	Q week	Q week					618	666	1
MMRF_1205	Second Line Therapy (after first relapse)	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					618	666	1
MMRF_1205	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		140	Q day	Q day					187	187	1
MMRF_1205	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		500	QWK	QWK					135	135	1
MMRF_1205	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					114	127	1
MMRF_1205	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	142	1
MMRF_1205	First line of therapy	Cyclophosphamide		Lack of response	mg/m^2	IV	Log Forms				300	Other	QD (D1, D8)					1	85	1
MMRF_1205	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	142	1
MMRF_1211	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					127	127	1
MMRF_1211	First line of therapy	ETOPOSIDE		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Q day	Q day					101	101	1
MMRF_1211	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Induction	Induction		40	Q day	Q day					101	101	1
MMRF_1211	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		40	Other	QD1, 8, 15					64	78	1
MMRF_1211	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.6	Other	QD1, 8, 15					64	78	1
MMRF_1211	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		2000	Q day	Q day					101	101	1
MMRF_1211	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_1211	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_1211	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	SALVAGE		200	Other	ONCE					2649	2649	1
MMRF_1221	Fifth Line Therapy (following 4th relapse)	Dexamethasone		ADMITTED	mg	PO	Log Forms	Maintenance	Maintenance		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1093	1164	1
MMRF_1221	Fifth Line Therapy (following 4th relapse)	Pomalidomide		ADMISSION	mg	PO	Log Forms	Unknown	Unknown		4	QD (D1-14)	QD (D1-14)					1093	1164	1
MMRF_1221	Fifth Line Therapy (following 4th relapse)	Bortezomib		ADMITTED	mg/m^2	IV SubQ	Log Forms	Unknown	Unknown		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1093	1164	1
MMRF_1221	Fifth Line Therapy (following 4th relapse)	PANOBINOSTAT		ADMITTED	mg	PO	Log Forms	Unknown	Unknown		20	Other	THREE TIMES WEEKLY (MONDAY-WEDNESDAY-FRIDAY)					1093	1164	1
MMRF_1221	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		40	Q week	Q week					947	1080	1
MMRF_1221	Fourth Line Therapy (following 3rd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					947	1079	1
MMRF_1221	Fourth Line Therapy (following 3rd relapse)	Carfilzomib		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Unknown	Unknown		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					947	1067	1
MMRF_1221	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Unknown	Unknown		40	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					852	922	1
MMRF_1221	Third Line Therapy (following 2nd relapse)	Cyclophosphamide		Disease progression/Relapse	mg/m^2	IV	Log Forms	Unknown	Unknown		500	Other	D1 AND D8					851	914	1
MMRF_1221	Third Line Therapy (following 2nd relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Unknown	Unknown		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					851	922	1
MMRF_1221	Second Line Therapy (after first relapse)	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Other	REINDUCTION		40	QWK	QWK					711	760	1
MMRF_1221	Second Line Therapy (after first relapse)	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Other	REINDUCTION		25	QD (D1-21)	QD (D1-21)					711	760	1
MMRF_1221	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					128	128	1
MMRF_1221	First line of therapy	TH1 CELL INFUSION		Completed regimen	N/A. INFUSION	IV	Log Forms	Induction	Induction		0	Other	ONCE					352	352	1
MMRF_1221	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					297	297	1
MMRF_1221	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		20	Other	DAY 1 AND 4					295	298	1
MMRF_1221	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Other	MOBILIZATION		1.6	Other	DAY 1 AND 4					295	298	1
MMRF_1221	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		10	Q day	Q day					96	96	1
MMRF_1221	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Other	MOBLOZATION		2000	Q day	Q day					96	96	1
MMRF_1221	First line of therapy	ETOPOSIDE		Completed regimen	mg/m^2	IV	Log Forms	Other	MOBILIZATION		200	Q day	Q day					96	96	1
MMRF_1221	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	64	1
MMRF_1221	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	64	1
MMRF_1221	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	64	1
MMRF_1230	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms				200	Q day	Q day					168	168	1
MMRF_1230	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				8	Q day	Q day					169	169	1
MMRF_1230	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				8	BID	BID					170	170	1
MMRF_1230	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				12	Q day	Q day					168	168	1
MMRF_1230	First line of therapy	ETOPOSIDE		Completed regimen	mg/m^2	IV	Log Forms				200	Q day	Q day					136	136	1
MMRF_1230	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms				10	Q day	Q day					136	136	1
MMRF_1230	First line of therapy	Cyclophosphamide		Completed regimen	G/M^2	IV	Log Forms				2	Q day	Q day					136	136	1
MMRF_1230	First line of therapy	Cyclophosphamide		Investigator decision for other reasons	mg/m^2	IV	Log Forms				500	Other	QD D1 AND D8					22	102	1
MMRF_1230	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	106	1
MMRF_1230	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	107	1
MMRF_1230	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	106	1
MMRF_1257	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		20	Q week	Q week					1248	1418	1
MMRF_1257	Third Line Therapy (following 2nd relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		25	QD (D1-21)	QD (D1-21)					1248	1418	1
MMRF_1257	Third Line Therapy (following 2nd relapse)	Ixazomib		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		4	Other	QD (D1, D8 & D15)					1248	1418	1
MMRF_1257	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					905	1214	1
MMRF_1257	Second Line Therapy (after first relapse)	Cyclophosphamide		Disease progression/Relapse	mg/m^2	IV	Log Forms	Unknown	Unknown		500	QD (D1-4)	QD (D1-4)					905	1207	1
MMRF_1257	Second Line Therapy (after first relapse)	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms	Unknown	Unknown		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					905	1214	1
MMRF_1257	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					99	99	1
MMRF_1257	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	52	1
MMRF_1257	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms				500	Other	QD DAY 1-8					1	29	1
MMRF_1257	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	52	1
MMRF_1257	Fourth Line Therapy (following 3rd relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Unknown	Unknown		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1428	1443	1
MMRF_1257	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Unknown	Unknown		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1428	1443	1
MMRF_1257	Fourth Line Therapy (following 3rd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					1428	1448	1
MMRF_1257	Fifth Line Therapy (following 4th relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Unknown	Unknown		16	Other	WEEKLY FOR WEEKS 1-8, EVERY OTHER WEEK 9-24, MONTHLY WEEK 25 ONWARDS					1449	1578	1
MMRF_1257	Fifth Line Therapy (following 4th relapse)	Thalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Unknown	Unknown		200	Q day	Q day					1449	1554	1
MMRF_1257	Fifth Line Therapy (following 4th relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		4	Q week	Q week					1449	1578	1
MMRF_1257	Fifth Line Therapy (following 4th relapse)	Prednisone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		25	Other	DAYS 1 AND 2 FOLLOWING DARA DOSING					1452	1578	1
MMRF_1257	Fifth Line Therapy (following 4th relapse)	Cyclophosphamide		Disease progression/Relapse	mg/m^2	IV	Log Forms	Other	ANTI CANCER REGIMEN		300	Other	D 1,8 &15					1536	1578	1
MMRF_1257	Fifth Line Therapy (following 4th relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		3	QD (D1-21)	QD (D1-21)					1564	1578	1
MMRF_1257	Sixth Line Therapy (following 5th relapse)	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Unknown	Unknown		56	Q day	Q day					1589	1590	1
MMRF_1257	Sixth Line Therapy (following 5th relapse)	Bendamustine		Completed regimen	mg/m^2	IV	Log Forms	Unknown	Unknown		110	Q day	Q day					1589	1590	1
MMRF_1257	Sixth Line Therapy (following 5th relapse)	Dexamethasone		Completed regimen	mg	IV	Log Forms	Unknown	Unknown		40	Q day	Q day					1589	1590	1
MMRF_1257	Seventh Line of Therapy (following 6th relapse)	PEMBROLIZUMAB		DEATH	mg	IV	Log Forms	Unknown	Unknown		100	Other	EVERY TWO WEEKS					1617	1666	1
MMRF_1257	Seventh Line of Therapy (following 6th relapse)	Pomalidomide		DEATH	mg	PO	Log Forms	Unknown	Unknown		4	QD (D1-4)	QD (D1-4)					1610	1666	1
MMRF_1257	Seventh Line of Therapy (following 6th relapse)	Dexamethasone		DEATH	mg	PO	Log Forms	Unknown	Unknown		20	Q week	Q week					1617	1666	1
MMRF_1257	Third Line Therapy (following 2nd relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		25	QD (D1-21)	QD (D1-21)					1248	1418	1
MMRF_1274	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	54	1
MMRF_1274	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms				500	QD (D1-7)	QD (D1-7)					1	50	1
MMRF_1274	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	54	1
MMRF_1274	First line of therapy	FLUDARABINE		Completed regimen	mg/m^2	IV	Log Forms				30	Q day	Q day					288	291	1
MMRF_1274	First line of therapy	Cyclophosphamide		Completed regimen	G/M^2	IV	Log Forms	Other	MOBILIZATION		2	Other	ONCE					92	92	1
MMRF_1274	First line of therapy	ETOPOSIDE		Completed regimen	mg/m^2	IV	Log Forms	Other	MOBILIZATION		200	Other	ONCE					92	92	1
MMRF_1274	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		10	Other	ONCE					92	92	1
MMRF_1274	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Other	ONCE					117	117	1
MMRF_1274	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		140	Q day	Q day					291	291	1
MMRF_1274	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Other	MOBILIZATION		1.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					289	292	1
MMRF_1286	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms				2.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	40	1
MMRF_1286	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	47	1
MMRF_1286	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	40	1
MMRF_1286	First line of therapy	Cyclophosphamide		Completed regimen	G/M^2	IV	Log Forms				2	Other	ONCE					74	74	1
MMRF_1286	First line of therapy	ETOPOSIDE		Completed regimen	mg/m^2	IV	Log Forms				200	Other	ONCE					74	74	1
MMRF_1286	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		10	Q day	Q day					74	74	1
MMRF_1286	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		140	Q day	Q day					100	100	1
MMRF_1286	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					268	920	1
MMRF_1286	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		20	Q week	Q week					268	1018	1
MMRF_1286	Third Line Therapy (following 2nd relapse)	Pomalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Other	THIRD LINE		4	QD (D1-21)	QD (D1-21)					941	1107	1
MMRF_1286	Fourth Line Therapy (following 3rd relapse)	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms	Other	FOURTH LINE (VELCADE POMALIDOMIDE DEXAMETHASONE)		1.3	Other	QD (D1, 8, 15)					1032	1101	1
MMRF_1286	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Other	FOURTH LINE (VELCADE POMALIDOMIDE DEXAMETHASONE)		20	Other	QD (D1, 8, 15)					1032	1101	1
MMRF_1286	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	FOURTH LINE (IXAZOMIB, POMALIDOMIDE, DEXAMETHASONE)		20	Q week	Q week					1129	1206	1
MMRF_1286	Fourth Line Therapy (following 3rd relapse)	Ixazomib		Disease progression/Relapse	mg	PO	Log Forms	Other	FOURTH LINE (IXAZOMIB, POMALIDOMIDE, DEXAMETHASONE)		4	Other	QWK (D1, 8, 15)					1129	1199	1
MMRF_1286	Fourth Line Therapy (following 3rd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Other	FOURTH LINE (IXAZOMIB, POM, DEX)		4	QD (D1-21)	QD (D1-21)					1129	1205	1
MMRF_1286	Fifth Line Therapy (following 4th relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Other	FIFTH LINE		16	Q week	Q week					1227	2017	1
MMRF_1286	Fifth Line Therapy (following 4th relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Other	FIFTH LINE		4	QD (D1-21)	QD (D1-21)					1227	2017	1
MMRF_1286	Fifth Line Therapy (following 4th relapse)	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Other	FIFTH LINE		40	Q week	Q week					1227	2017	1
MMRF_1286	Sixth Line Therapy (following 5th relapse)	Prednisone		Disease progression/Relapse	mg	PO	Log Forms	Other	FIFTH LINE		25	Other	EVERY FRIDAY AND SATURDAY AFTER DARATUMUMAB ADMINISTRATION					1229	2017	1
MMRF_1286	Seventh Line of Therapy (following 6th relapse)	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms	Other	SALVAGE		1.6	Other	QD (1,8,15)					2083	2139	1
MMRF_1286	Seventh Line of Therapy (following 6th relapse)	VENETOCLAX		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		400	Other	DAYS 1-8					2083	2139	1
MMRF_1286	Seventh Line of Therapy (following 6th relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		20	Q week	Q week					2083	2139	1
MMRF_1286	Eighth Line of Therapy (following 7th relapse)	Panobinostat		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	SALVAGE		20	Other	DAYS 1,3,5; 15,17,19					2146	2153	1
MMRF_1286	Eighth Line of Therapy (following 7th relapse)	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Other	SALVAGE		1.6	Other	DAYS 1,8,15					2146	2153	1
MMRF_1286	Eighth Line of Therapy (following 7th relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	SALVAGE		20	Other	DAYS 1,8,15					2146	2153	1
MMRF_1325	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				15	Q day	Q day					1	80	1
MMRF_1325	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	QWK	QWK					1	78	1
MMRF_1325	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					39	78	1
MMRF_1325	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Other	MOBILIZATION		2000	QID	QID					123	123	1
MMRF_1325	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		10	QID	QID					123	123	1
MMRF_1325	First line of therapy	ETOPOSIDE		Completed regimen	mg/m^2	IV	Log Forms	Other	MOBILIZATION		200	QID	QID					123	123	1
MMRF_1325	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					148	148	1
MMRF_1394	Fifth Line Therapy (following 4th relapse)	Dexamethasone			mg	PO	Log Forms	Other	SALVAGE	Checked	20	Q week	Q week					2683		1
MMRF_1394	Fifth Line Therapy (following 4th relapse)	Pomalidomide			mg	PO	Log Forms	Other	SALVAGE	Checked	3	Other	QOD					2683		1
MMRF_1394	Fifth Line Therapy (following 4th relapse)	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Other	SALVAGE		56	Other	ONCE					2683	2761	1
MMRF_1394	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	74	1
MMRF_1394	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)					1	74	1
MMRF_1394	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	77	1
MMRF_1394	First line of therapy	Cyclophosphamide		Completed regimen	G/M^2	IV	Log Forms	Other	MOBILIZATION		2	Other	ONCE					87	87	1
MMRF_1394	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		10	Other	ONCE					87	87	1
MMRF_1394	First line of therapy	ETOPOSIDE		Completed regimen	mg/m^2	IV	Log Forms	Other	MOBILIZATION		200	Other	ONCE					87	87	1
MMRF_1394	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					112	112	1
MMRF_1394	Second Line Therapy (after first relapse)	Ixazomib		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		4	Other	QD (D1,8,15)					1366	1400	1
MMRF_1394	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		25	QD (D1-21)	QD (D1-21)					1366	1414	1
MMRF_1394	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		40	Q week	Q week					1366	1400	1
MMRF_1394	Third Line Therapy (following 2nd relapse)	Daratumumab			mg/kg	IV	Log Forms	Other	SALVAGE	Checked	16	Other	WEEKLY FOR WEEKS 1-8, QOW 9-24, MONTHLY 25 ONWARD					1821		1
MMRF_1394	Third Line Therapy (following 2nd relapse)	Bortezomib		PATIENT HAS DEBILITATING NEUROPATHY	mg/m^2	IV	Log Forms	Other	SALVAGE		1.3	Other	D1, D8, D15					1821	1961	1
MMRF_1394	Third Line Therapy (following 2nd relapse)	Dexamethasone			mg	PO	Log Forms	Other	SALVAGE	Checked	40	Other	DAY OF AND DAY AFTER DARA					1821		1
MMRF_1394	Fourth Line Therapy (following 3rd relapse)	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms				300	Other	D1, D8, D15					2192	2206	1
MMRF_1394	Third Line Therapy (following 2nd relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Other	SALVAGE		33	Q week	Q week					2136	2216	1
MMRF_1408	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	96	1
MMRF_1408	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	101	1
MMRF_1408	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	96	1
MMRF_1408	First line of therapy	Cyclophosphamide		Completed regimen	GM	IV	Log Forms	Other	MOBILIZATION		2.9	Q day	Q day					121	121	1
MMRF_1408	First line of therapy	ETOPOSIDE		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		290	Q day	Q day					121	121	1
MMRF_1408	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Other	MOILIZATION		10	Q day	Q day					121	121	1
MMRF_1408	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		296	Q day	Q day					272	272	1
MMRF_1408	Second Line Therapy (after first relapse)	Ixazomib		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		4	Other	QD (D1, D8, D15, D22)					1624	1722	1
MMRF_1408	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		25	QD (D1-21)	QD (D1-21)					1624	1722	1
MMRF_1408	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		40	QWK	QWK					1624	1722	1
MMRF_1408	Third Line Therapy (following 2nd relapse)	Elotuzumab			mg/kg	IV	Log Forms	Unknown	Unknown	Checked	10	Other	WEEKLY 1-8, QOW 9 ONWARD					1748		1
MMRF_1408	Third Line Therapy (following 2nd relapse)	Dexamethasone			mg	IV	Log Forms	Unknown	Unknown	Checked	28	Other	3-24 HOURS PRIOR TO ELO					1748		1
MMRF_1408	Third Line Therapy (following 2nd relapse)	Lenalidomide			mg	PO	Log Forms	Unknown	Unknown	Checked	25	QD (D1-21)	QD (D1-21)					1748		1
MMRF_1413	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	81	1
MMRF_1413	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		500	Other	QD (D1, D8)					1	78	1
MMRF_1413	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	81	1
MMRF_1413	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					127	127	1
MMRF_1413	First line of therapy	Cyclophosphamide		Completed regimen	G/M^2	IV	Log Forms	Other	MOBILIZATION		2	Q day	Q day					101	101	1
MMRF_1413	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Other	MOBILIZATION		10	Q day	Q day					101	101	1
MMRF_1413	First line of therapy	ETOPOSIDE		Completed regimen	mg/m^2	IV	Log Forms	Other	MOBILIZATION		200	Q day	Q day					101	101	1
MMRF_1413	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		20	QD (D1-21)	QD (D1-21)					1571	1612	1
MMRF_1413	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		8	Q week	Q week					1570	1612	1
MMRF_1413	Second Line Therapy (after first relapse)	Elotuzumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Unknown	Unknown		10	Other	WEEKLY FOR WEEKS 1-8, QOW WEEKS 9 ONWARD					1591	1612	1
MMRF_1413	Third Line Therapy (following 2nd relapse)	Carfilzomib			mg/m^2	IV	Log Forms	Other	SALVAGE	Checked	70	Other	DAYS 1, 8, 15					1661		1
MMRF_1413	Third Line Therapy (following 2nd relapse)	Dexamethasone			mg	PO	Log Forms	Other	SALVAGE	Checked	16	Other	DAYS 1, 8, 15					1661		1
MMRF_1418	First line of therapy	Lenalidomide		NEUROPATHY	mg	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					1864	2179	1
MMRF_1418	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		20	Other	D1-7 AND 15-21					2235	2543	1
MMRF_1418	Second Line Therapy (after first relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Other	SALVAGE		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					2544	2910	1
MMRF_1418	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		20	QD (D1-21)	QD (D1-21)					2544	2910	1
MMRF_1418	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Other	SALVAGE		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					2544	2910	1
MMRF_1418	Third Line Therapy (following 2nd relapse)	Daratumumab			MG	SC	Log Forms	Other	SALVAGE	Checked	1800	Other	DAYS 1,8,15,22 FOR 9 WEEKS, DAYS 1,15 CYCLES 3-6, DAY 1 CYCLE 7 ONWARDS					2928		1
MMRF_1418	Third Line Therapy (following 2nd relapse)	Pomalidomide			mg	PO	Log Forms	Other	SALVAGE	Checked	4	QD (D1-21)	QD (D1-21)					2928		1
MMRF_1418	Third Line Therapy (following 2nd relapse)	Dexamethasone			mg	IV	Log Forms	Other	SALVAGE	Checked	20	Other	DAYS 1,8,15,22 FOR 9 WEEKS, DAYS 1,15 CYCLES 3-6, DAY 1 CYCLE 7 ONWARDS					2928		1
MMRF_1418	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_1418	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_1418	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	57	1
MMRF_1418	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Other	MOBILIZATION		2000	QID	QID					80	80	1
MMRF_1418	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		10	QID	QID					80	80	1
MMRF_1418	First line of therapy	ETOPOSIDE		Completed regimen	mg/m^2	IV	Log Forms	Other	MOBILIZATION		200	QID	QID					80	80	1
MMRF_1418	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		200	QID	QID					108	108	1
MMRF_1418	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.6	Other	QOD					284	286	1
MMRF_1418	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Q day	Q day					286	286	1
MMRF_1418	First line of therapy	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Maintenance	Maintenance		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1185	2543	1
MMRF_1418	First line of therapy	Lenalidomide		REDUCED DUE TO NEUROPATHY	mg	PO	Log Forms	Maintenance	Maintenance		25	QD (D1-21)	QD (D1-21)					1185	1843	1
MMRF_1418	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Maintenance	Maintenance		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1185	2543	1
MMRF_1423	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	28	1
MMRF_1423	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	28	1
MMRF_1423	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	28	1
MMRF_1423	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Q day	Q day					99	99	1
MMRF_1426	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Other	ONCE					2725	2725	1
MMRF_1426	Second Line Therapy (after first relapse)	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		1.6	Other	D-4 AND D-1					2723	2726	1
MMRF_1426	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	59	1
MMRF_1426	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	62	1
MMRF_1426	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	59	1
MMRF_1426	First line of therapy	Cyclophosphamide		Completed regimen	G/M^2	IV	Log Forms	Other	MOBILIZATION		2	Q day	Q day					122	122	1
MMRF_1426	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Other	MOBILIZATION		10	Q day	Q day					122	122	1
MMRF_1426	First line of therapy	ETOPOSIDE		Completed regimen	mg/m^2	IV	Log Forms	Other	MOBILIZATION		200	Q day	Q day					122	122	1
MMRF_1426	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					71	91	1
MMRF_1426	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					71	92	1
MMRF_1426	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					147	147	1
MMRF_1433	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	65	1
MMRF_1433	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	68	1
MMRF_1433	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	QD (D1-14)	QD (D1-14)					1	68	1
MMRF_1433	First line of therapy	Cyclophosphamide		Completed regimen	G/M2	IV	Log Forms	Other	MOBILIZATION		2	Q day	Q day					95	95	1
MMRF_1433	First line of therapy	ETOPOSIDE		Completed regimen	mg/m^2	IV	Log Forms	Other	MOBILIZATION		200	Q day	Q day					95	95	1
MMRF_1433	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		10	Q day	Q day					95	95	1
MMRF_1433	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Q day	Q day					120	120	1
MMRF_1433	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.6	Q day	Q day					256	256	1
MMRF_1433	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Q day	Q day					255	257	1
MMRF_1433	Second Line Therapy (after first relapse)	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Unknown	Unknown		70	Q week	Q week					883	1082	1
MMRF_1433	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		40	Q week	Q week					883	1082	1
MMRF_1433	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		25	QD (D1-21)	QD (D1-21)					883	1082	1
MMRF_1433	Third Line Therapy (following 2nd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		4	Other	QD (D1-21)					1100	1332	1
MMRF_1433	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Unknown	Unknown		40	Q week	Q week					1100	1332	1
MMRF_1433	Fourth Line Therapy (following 3rd relapse)	PEMBROLIZUMAB		Disease progression/Relapse	mg	IV	Log Forms	Unknown	Unknown		200	Other	Q2W					1359	1472	1
MMRF_1433	Fourth Line Therapy (following 3rd relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		25	Other	QD 91-21)					1359	1472	1
MMRF_1433	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		40	Q week	Q week					1359	1472	1
MMRF_1433	Fifth Line Therapy (following 4th relapse)	IDASANUTLIN		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		200	Other	QD (D1-5) OF A 28 DAYS CYCLE					1523	1607	1
MMRF_1433	Fifth Line Therapy (following 4th relapse)	Ixazomib		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		4	Other	QD (D1,8,15) OF A28 DAYS CYCLE					1523	1607	1
MMRF_1433	Fifth Line Therapy (following 4th relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		40	Other	QD (D1,D8,D15,D22) OF A 28 DAYS CYCLE					1523	1607	1
MMRF_1433	Sixth Line Therapy (following 5th relapse)	Daratumumab		PATIENT EXPIRED	mg	IV	Log Forms	Unknown	Unknown		1778	Other	WEEKLY FOR CYCLES 1-3, Q3 WEEKS 4-8, MONTHLY 9 ONWARD					1646	2158	1
MMRF_1433	Sixth Line Therapy (following 5th relapse)	Bortezomib		PATIENT EXPIRED	mg/m^2	IV SubQ	Log Forms	Unknown	Unknown		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1646	2158	1
MMRF_1433	Sixth Line Therapy (following 5th relapse)	Dexamethasone		PATIENT EXPIRED	mg	IV	Log Forms	Unknown	Unknown		20	Other	DAYS 1,2,4,5,8,9,11,12					1646	2158	1
MMRF_1434	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_1434	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	56	1
MMRF_1434	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_1434	First line of therapy	Cyclophosphamide		Completed regimen	G/M^2	IV	Log Forms	Other	MOBILIZATION		2	Q day	Q day					88	88	1
MMRF_1434	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		10	Q day	Q day					88	88	1
MMRF_1434	First line of therapy	ETOPOSIDE		Completed regimen	mg/m^2	IV	Log Forms	Other	MOBILIZATION		200	Q day	Q day					88	88	1
MMRF_1434	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					113	113	1
MMRF_1434	Second Line Therapy (after first relapse)	Lenalidomide			mg	PO	Log Forms	Unknown	Unknown	Checked	25	QD (D1-21)	QD (D1-21)					1677		1
MMRF_1434	Second Line Therapy (after first relapse)	Dexamethasone		DIARRHEA AND WORSENING FATIGUE	mg	PO	Log Forms	Unknown	Unknown		40	Q week	Q week					1677	2271	1
MMRF_1452	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	86	1
MMRF_1452	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms				500	Other	D1 & D8					1	83	1
MMRF_1452	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					2	86	1
MMRF_1452	First line of therapy	Cyclophosphamide		Completed regimen	G/M^2	IV	Log Forms	Other	MOBILIZATION		2	Q day	Q day					107	107	1
MMRF_1452	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		10	Q day	Q day					107	107	1
MMRF_1452	First line of therapy	ETOPOSIDE		Completed regimen	mg/m^2	IV	Log Forms	Other	MOBILIZATION		200	Q day	Q day					107	107	1
MMRF_1452	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					133	133	1
MMRF_1452	Second Line Therapy (after first relapse)	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					177	272	1
MMRF_1452	Second Line Therapy (after first relapse)	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					177	272	1
MMRF_1452	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					177	272	1
MMRF_1452	Second Line Therapy (after first relapse)	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Other	CONDITIONING		1.6	Q day	Q day					289	292	1
MMRF_1452	Second Line Therapy (after first relapse)	FLUDARABINE		Completed regimen	mg	IV	Log Forms	Other	CONSOLIDATION		49	Q day	Q day					288	291	1
MMRF_1452	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	MAINTENANCE		140	Q day	Q day					291	291	1
MMRF_1461	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_1461	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	56	1
MMRF_1461	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_1461	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		200	QID	QID					107	107	1
MMRF_1461	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		25	QD (D1-21)	QD (D1-21)					508	815	1
MMRF_1461	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		40	Q week	Q week					508	815	1
MMRF_1461	Third Line Therapy (following 2nd relapse)	Pomalidomide		Patient decision	mg	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					823	831	1
MMRF_1461	Third Line Therapy (following 2nd relapse)	Dexamethasone		Patient decision	mg	PO	Log Forms	Unknown	Unknown		40	Q week	Q week					823	831	1
MMRF_1461	Fourth Line Therapy (following 3rd relapse)	Carfilzomib		Disease progression/Relapse	mg	IV	Log Forms	Unknown	Unknown		44	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					850	865	1
MMRF_1461	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					850	865	1
MMRF_1461	Fourth Line Therapy (following 3rd relapse)	Cyclophosphamide		Disease progression/Relapse	mg/m^2	IV	Log Forms	Unknown	Unknown		500	Other	QD (D1 AND D8)					850	865	1
MMRF_1461	Fifth Line Therapy (following 4th relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Unknown	Unknown		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					878	962	1
MMRF_1461	Fifth Line Therapy (following 4th relapse)	Panobinostat		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		20	Other	D1 ,3,5,15,17,19					878	962	1
MMRF_1461	Fifth Line Therapy (following 4th relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					878	962	1
MMRF_1461	Sixth Line Therapy (following 5th relapse)	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Unknown	Unknown		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					969	1003	1
MMRF_1461	Sixth Line Therapy (following 5th relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		15	QD (D1-21)	QD (D1-21)					969	1003	1
MMRF_1461	Sixth Line Therapy (following 5th relapse)	Panobinostat		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		20	Other	D1, 3,5,15,17,19					969	1003	1
MMRF_1461	Sixth Line Therapy (following 5th relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					969	1003	1
MMRF_1466	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	54	1
MMRF_1466	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	54	1
MMRF_1466	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					3	57	1
MMRF_1466	First line of therapy	Cyclophosphamide		Completed regimen	G/M^2	IV	Log Forms	Other	MOBILIZATION		2	Q day	Q day					88	88	1
MMRF_1466	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		10	Q day	Q day					88	88	1
MMRF_1466	First line of therapy	ETOPOSIDE		Completed regimen	mg/m^2	IV	Log Forms	Other	MOBILIZATION		200	Q day	Q day					88	88	1
MMRF_1466	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					115	115	1
MMRF_1466	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		1.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					113	116	1
MMRF_1466	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		10	Q day	Q day					113	113	1
MMRF_1466	Second Line Therapy (after first relapse)	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Other	NOT APPLICABLE		25	QD (D1-21)	QD (D1-21)					745	942	1
MMRF_1466	Second Line Therapy (after first relapse)	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Other	NOT APPLICABLE		20	Q week	Q week					745	943	1
MMRF_1466	Third Line Therapy (following 2nd relapse)	Carfilzomib			mg/m^2	IV	Log Forms	Other	THIRD LINE	Checked	36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1327		1
MMRF_1466	Third Line Therapy (following 2nd relapse)	Dexamethasone			mg	IV	Log Forms	Other	THIRD LINE	Checked	20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1327		1
MMRF_1466	Third Line Therapy (following 2nd relapse)	Lenalidomide			mg	PO	Log Forms	Other	THIRD LINE	Checked	15	QD (D1-21)	QD (D1-21)					1327		1
MMRF_1478	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	73	1
MMRF_1478	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	73	1
MMRF_1478	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		500	Q day	Q day					7	7	1
MMRF_1478	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					21	76	1
MMRF_1478	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Other	MOBILIZATION		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					91	94	1
MMRF_1478	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Other	MOBILIZATION		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					91	94	1
MMRF_1478	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Other	MOBILIZATION		25	QD (D1-4)	QD (D1-4)					91	94	1
MMRF_1478	First line of therapy	ETOPOSIDE		Completed regimen	mg/m^2	IV	Log Forms	Other	MOBILIZATION		40	QD (D1-4)	QD (D1-4)					91	94	1
MMRF_1478	First line of therapy	Doxorubicin		Completed regimen	mg/m^2	IV	Log Forms	Other	MOBILIZATION		10	QD (D1-4)	QD (D1-4)					91	94	1
MMRF_1478	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Other	MOBILIZATION		500	QD (D1-4)	QD (D1-4)					91	94	1
MMRF_1478	First line of therapy	CISPLATIN		Completed regimen	mg/m^2	IV	Log Forms	Other	MOBILIZATION		15	QD (D1-4)	QD (D1-4)					91	94	1
MMRF_1478	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					118	118	1
MMRF_1478	First line of therapy	FLUDARABINE		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		30	Q day	Q day					305	308	1
MMRF_1478	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		140	Q day	Q day					675	675	1
MMRF_1485	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	15	1
MMRF_1485	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	15	1
MMRF_1497	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	21	1
MMRF_1497	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					35	119	1
MMRF_1497	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	22	1
MMRF_1497	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					35	119	1
MMRF_1497	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					35	119	1
MMRF_1497	First line of therapy	Cyclophosphamide		Completed regimen	G/M^2	IV	Log Forms	Other	DEBULKING/MOBILIZATION		2	Q day	Q day					172	172	1
MMRF_1497	First line of therapy	ETOPOSIDE		Completed regimen	mg/m^2	IV	Log Forms	Other	DEBULKING/MOBOLIZATION		200	Q day	Q day					182	182	1
MMRF_1497	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Other	DEBULKING/MOBILIZATION		10	Q day	Q day					182	182	1
MMRF_1497	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		360	Q day	Q day					208	208	1
MMRF_1489	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Other	ONCE					357	357	1
MMRF_1489	First line of therapy	PLERIXAFOR		Completed regimen	mg	IV SubQ	Log Forms	Other	MOBILIZATION		18	Other	QD FIRST 3 DAYS; QOD WEEK 2					334	343	1
MMRF_1489	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	107	1
MMRF_1489	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	107	1
MMRF_1489	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	107	1
MMRF_1491	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	QD (D1, 8, 15, 22)					1	179	1
MMRF_1491	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	179	1
MMRF_1491	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Other	MOBILIZATION		200	Q day	Q day					193	193	1
MMRF_1491	First line of therapy	ETOPOSIDE		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		360	Q day	Q day					193	193	1
MMRF_1491	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		10	Q day	Q day					193	193	1
MMRF_1491	Second Line Therapy (after first relapse)	Bortezomib		PATIENT DECEASED	mg/m^2	IV SubQ	Log Forms	Other	SALVAGE REGIMEN		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					390	397	1
MMRF_1491	Second Line Therapy (after first relapse)	Cyclophosphamide		PATIENT DECEASED	mg	IV	Log Forms	Other	SALVAGE REGIMEN		500	Other	DAY 1 AND  8					390	397	1
MMRF_1491	Second Line Therapy (after first relapse)	Dexamethasone		PATIENT DECEASED	mg	IV	Log Forms	Other	SALVAGE REGIMEN		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					390	397	1
MMRF_1491	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Other	ONCE					234	234	1
MMRF_1494	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	34	1
MMRF_1494	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	34	1
MMRF_1494	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	35	1
MMRF_1494	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Other	MOBILIZATION		2000	Q day	Q day					65	65	1
MMRF_1494	First line of therapy	ETOPOSIDE		Completed regimen	mg/m^2	IV	Log Forms	Other	MOBILIZATION		200	Q day	Q day					65	65	1
MMRF_1494	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		10	Q day	Q day					65	65	1
MMRF_1494	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					90	90	1
MMRF_1494	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Other	CONDITIONING		1.6	Other	DAYS -4 AND -1					264	272	1
MMRF_1494	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONSOLIDATION		200	Q day	Q day					266	266	1
MMRF_1500	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	65	1
MMRF_1500	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	65	1
MMRF_1500	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	46	1
MMRF_1500	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					122	122	1
MMRF_1500	First line of therapy	Cyclophosphamide		Completed regimen	G/M^2	IV	Log Forms	Other	MOBILIZATION		2	Q day	Q day					102	102	1
MMRF_1500	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Other	MOBILIZATION		10	Q day	Q day					102	102	1
MMRF_1500	First line of therapy	ETOPOSIDE		Completed regimen	mg/m^2	IV	Log Forms	Other	MOBILIZATION		200	Q day	Q day					102	102	1
MMRF_1500	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Other	CONDITIONING		1.6	Other	DAYS -4 AND -1					260	263	1
MMRF_1500	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONSOLIDATION		200	Q day	Q day					262	262	1
MMRF_1500	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Other	CONSOLIDATION		10	Q day	Q day					260	263	1
MMRF_1500	Second Line Therapy (after first relapse)	Carfilzomib		PATIENT GOIN OT ASTC	mg/m^2	IV	Log Forms	Unknown	Unknown		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					947	1198	1
MMRF_1500	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		25	QD (D1-21)	QD (D1-21)					947	974	1
MMRF_1500	Second Line Therapy (after first relapse)	Dexamethasone		PATIENT GOING TO ASCT	mg	IV	Log Forms	Unknown	Unknown		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					947	1198	1
MMRF_1500							Log Forms													1
MMRF_1500	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					1214	1214	1
MMRF_1500	Second Line Therapy (after first relapse)	NIVOLUMAB		Completed regimen	mg/kg	IV	Log Forms	Maintenance	Maintenance		3	Other	WEEKS 1,4,7,10,12,14,16,18,22,24,& 26					1243	1419	1
MMRF_1500	Second Line Therapy (after first relapse)	IPILIMUMAB		Completed regimen	mg/kg	IV	Log Forms	Maintenance	Maintenance		1	Other	WEEKS 1,4,7,10,16 & 22					1243	1419	1
MMRF_1500	Second Line Therapy (after first relapse)	Prednisone		REDUCE DOSAGE PER SUB-INVESTIGATOR	mg	PO	Log Forms	Other	SALVAGE		5	Q day	Q day					1636	1670	1
MMRF_1500	Second Line Therapy (after first relapse)	Prednisone		Completed regimen	mg	PO	Log Forms	Other	SALVAGE		2.5	Q day	Q day					1670	1670	1
MMRF_1500	Third Line Therapy (following 2nd relapse)	Daratumumab		Completed regimen	mg/kg	IV	Log Forms	Unknown	Unknown		16	Other	QD (D1, D15)					2108	2206	1
MMRF_1500	Third Line Therapy (following 2nd relapse)	Daratumumab			mg/kg	IV	Log Forms	Unknown	Unknown	Checked	16	Other	QD (D1)					2220		1
MMRF_1500	Third Line Therapy (following 2nd relapse)	Pomalidomide			mg	PO	Log Forms	Unknown	Unknown	Checked	4	QD (D1-21)	QD (D1-21)					2053		1
MMRF_1500	Third Line Therapy (following 2nd relapse)	Dexamethasone			mg	PO	Log Forms	Unknown	Unknown	Checked	20	Other	QD (D8, D15)					2053		1
MMRF_1500	Third Line Therapy (following 2nd relapse)	Dexamethasone			mg	IV	Log Forms	Unknown	Unknown	Checked	20	Other	QD (D1)					2053		1
MMRF_1500	Third Line Therapy (following 2nd relapse)	Daratumumab		Completed regimen	mg/kg	IV	Log Forms	Unknown	Unknown		16	Q week	Q week					2053	2101	1
MMRF_1523	Second Line Therapy (after first relapse)	Lenalidomide			mg	PO	Log Forms	Other	SALVAGE	Checked	25	QD (D1-21)	QD (D1-21)					2344		1
MMRF_1523	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	41	1
MMRF_1523	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	44	1
MMRF_1523	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	41	1
MMRF_1523	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Other	MOBILIZATION		2000	QID	QID					79	79	1
MMRF_1523	First line of therapy	ETOPOSIDE		Completed regimen	mg	IV	Log Forms	Other	MOBOLIZATION		200	QID	QID					79	79	1
MMRF_1523	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Other	MOBOLIZATION		10	QID	QID					79	79	1
MMRF_1523	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITINING		200	Q day	Q day					103	103	1
MMRF_1523	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Other	CONDITIONING		1.6	Other	DAYS -7 AND -1 PRE-PBSCT					250	259	1
MMRF_1523	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Other	DAY -2 OF PBSCT					258	258	1
MMRF_1537	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	52	1
MMRF_1537	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	52	1
MMRF_1537	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	52	1
MMRF_1565	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	104	1
MMRF_1565	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	104	1
MMRF_1565	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					20	104	1
MMRF_1565	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Other	MOBOLIZATION		200	Q day	Q day					129	129	1
MMRF_1565	First line of therapy	ETOPOSIDE		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		315	Q day	Q day					129	129	1
MMRF_1565	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		10	Q day	Q day					129	129	1
MMRF_1565	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		314	Q day	Q day					162	162	1
MMRF_1565	Second Line Therapy (after first relapse)	Carfilzomib			mg/m^2	IV	Log Forms	Unknown	Unknown	Checked	27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1183		1
MMRF_1565	Second Line Therapy (after first relapse)	Lenalidomide			mg	PO	Log Forms	Unknown	Unknown	Checked	25	QD (D1-21)	QD (D1-21)					1183		1
MMRF_1565	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Unknown	Unknown	Checked	20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1183		1
MMRF_1573	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	88	1
MMRF_1573	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	111	1
MMRF_1573	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	88	1
MMRF_1573	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Other	CONDITIONING		1.6	Other	DAYS -4 AND -1 PRE-SCT					193	196	1
MMRF_1573	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		140	Q day	Q day					195	195	1
MMRF_1583	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_1583	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		500	Other	QD1, 8					1	29	1
MMRF_1583	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_1583	First line of therapy	ETOPOSIDE		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		370	Q day	Q day					67	67	1
MMRF_1583	First line of therapy	Cyclophosphamide		Completed regimen	G	IV	Log Forms	Other	MOBILIZATION		3.7	Q day	Q day					67	67	1
MMRF_1583	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Other	MOBOLIZATION		10	Q day	Q day					67	67	1
MMRF_1583	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		364	Q day	Q day					119	119	1
MMRF_1583	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		370	Q day	Q day					261	261	1
MMRF_1583	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Other	CONDITIONING		1.6	Other	DAYS -7 TO -1					259	262	1
MMRF_1583							Log Forms													1
MMRF_1583	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					2481	2481	1
MMRF_1625	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		500	Other	D1 & D8					1	12	1
MMRF_1625	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	12	1
MMRF_1625	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	12	1
MMRF_1625	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Other	MOBILIZATION		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					29	32	1
MMRF_1625	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Other	MOBILIZATION		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					29	32	1
MMRF_1625	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Other	MOBILIZATION		25	Q day	Q day					30	34	1
MMRF_1625	First line of therapy	ETOPOSIDE		Completed regimen	mg/m^2	IV	Log Forms	Other	MOBILIZATION		40	Q day	Q day					30	34	1
MMRF_1625	First line of therapy	Doxorubicin		Completed regimen	mg/m^2	IV	Log Forms	Other	MOBILIZATION		10	Q day	Q day					30	34	1
MMRF_1625	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Other	MOBILIZATION		500	Q day	Q day					30	34	1
MMRF_1625	First line of therapy	CISPLATIN		Completed regimen	mg/m^2	IV	Log Forms	Other	MOBILIZATION		15	Q day	Q day					30	34	1
MMRF_1625	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					111	111	1
MMRF_1625	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Other	ONCE					245	245	1
MMRF_1625	Second Line Therapy (after first relapse)	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Other	CONDITIONING		1.6	Other	QD D-4, D-1					243	246	1
MMRF_1640	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Other	SALVAGE	Checked	20	Other	DAY 8, 15					2780		1
MMRF_1640	Second Line Therapy (after first relapse)	Lenalidomide			mg	PO	Log Forms	Other	SALVAGE	Checked	25	QD (D1-21)	QD (D1-21)					2780		1
MMRF_1640	Second Line Therapy (after first relapse)	Daratumumab			mg	IV	Log Forms	Other	SALVAGE	Checked	1800	QWK	QWK					2780		1
MMRF_1640	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	32	1
MMRF_1640	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	34	1
MMRF_1640	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	32	1
MMRF_1640	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					136	136	1
MMRF_1683	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	85	1
MMRF_1683	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	84	1
MMRF_1683	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	84	1
MMRF_1683	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONSOLIDATION		200	Q day	Q day					135	135	1
MMRF_1683	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		25	QD (D1-21)	QD (D1-21)					1363	1640	1
MMRF_1683	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Other	SALVAGE		20	Q week	Q week					1363	1640	1
MMRF_1683	Second Line Therapy (after first relapse)	SOLUMEDROL		Disease progression/Relapse	mg	IV	Log Forms	Unknown	Unknown		100	Other	PRIOR TO EACH DOSE OF DARATUMUMAB					1220	1640	1
MMRF_1683	Second Line Therapy (after first relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Other	SALVAGE		16	Q week	Q week					1363	1640	1
MMRF_1683	Third Line Therapy (following 2nd relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Other	SALVAGE		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1653	2178	1
MMRF_1683	Third Line Therapy (following 2nd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		4	QD (D1-21)	QD (D1-21)					1653	2178	1
MMRF_1683	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1653	2178	1
MMRF_1683	Fourth Line Therapy (following 3rd relapse)	Carfilzomib		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Other	SALVAGE		70	Other	QD (1,8,15)					2186	2291	1
MMRF_1683	Fourth Line Therapy (following 3rd relapse)	Dexamethasone			mg	PO	Log Forms	Other	SALVAGE	Checked	20	Other	QD (1,8,15)					2186		1
MMRF_1714	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	50	1
MMRF_1714	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	53	1
MMRF_1714	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	50	1
MMRF_1714	First line of therapy	Cyclophosphamide		Completed regimen	G	IV	Log Forms	Other	MOBILIZATION		4.4	Q day	Q day					74	74	1
MMRF_1714	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		10	Q day	Q day					74	74	1
MMRF_1714	First line of therapy	ETOPOSIDE		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		440	Q day	Q day					74	74	1
MMRF_1714	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					100	100	1
MMRF_1731	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	35	1
MMRF_1731	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		500	Other	QD (D1, 8)					1	9	1
MMRF_1731	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	35	1
MMRF_1731	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	Q day	Q day					24	37	1
MMRF_1731	First line of therapy	Cyclophosphamide		Completed regimen	G	IV	Log Forms	Other	MOBILIZATION		3.1	Q day	Q day					59	59	1
MMRF_1731	First line of therapy	ETOPOSIDE		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		310	Q day	Q day					69	69	1
MMRF_1731	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		10	Q day	Q day					59	59	1
MMRF_1731	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONSOLIDATION		200	Q day	Q day					84	84	1
MMRF_1731	Second Line Therapy (after first relapse)	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Induction	Induction		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					755	1616	1
MMRF_1731	Second Line Therapy (after first relapse)	Pomalidomide			mg	PO	Log Forms	Induction	Induction	Checked	4	QD (D1-21)	QD (D1-21)					755		1
MMRF_1731	Second Line Therapy (after first relapse)	Dexamethasone			mg	IV	Log Forms	Induction	Induction	Checked	40	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					755		1
MMRF_1731	Second Line Therapy (after first relapse)	Daratumumab			mg/kg	IV	Log Forms	Induction	Induction	Checked	16	Other	D1, D8, D15					2148		1
MMRF_1730	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Unknown	Unknown	Checked	20	QWK	QWK					1824		1
MMRF_1730	Second Line Therapy (after first relapse)	Pomalidomide			mg	PO	Log Forms	Unknown	Unknown	Checked	4	QD (D1-21)	QD (D1-21)					1824		1
MMRF_1730	Third Line Therapy (following 2nd relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	SALVAGE		20	Q week	Q week					1824	1943	1
MMRF_1730	Third Line Therapy (following 2nd relapse)	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	SALVAGE		4	QD (D1-21)	QD (D1-21)					1824	2015	1
MMRF_1730	Second Line Therapy (after first relapse)	FLUDARABINE		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		30	Other	DAYS -6 THRU -3					848	851	1
MMRF_1730	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		140	Other	ONCE					852	852	1
MMRF_1730	Fourth Line Therapy (following 3rd relapse)	Daratumumab			mg	IV SubQ	Log Forms	Other	SALVAGE	Checked	1800	Other	DAYS 1,8,15 AND 22					2546		1
MMRF_1730	Fourth Line Therapy (following 3rd relapse)	Pomalidomide			mg	PO	Log Forms	Other	SALVAGE	Checked	3	Other	DAYS 1-21					2546		1
MMRF_1730	Fourth Line Therapy (following 3rd relapse)	Dexamethasone			mg	IV	Log Forms	Other	SALVAGE	Checked	20	Other	DAYS 1,8 AND 15					2546		1
MMRF_1730	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	33	1
MMRF_1730	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	36	1
MMRF_1730	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	33	1
MMRF_1730	First line of therapy	Cyclophosphamide		Completed regimen	G	IV	Log Forms	Other	MOBOLIZATION		4.2	Q day	Q day					92	92	1
MMRF_1730	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		10	Q day	Q day					92	92	1
MMRF_1730	First line of therapy	ETOPOSIDE		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		420	Q day	Q day					92	92	1
MMRF_1730	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		428	Q day	Q day					117	117	1
MMRF_1730	Second Line Therapy (after first relapse)	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Unknown	Unknown		25	QD (D1-4)	QD (D1-4)					706	802	1
MMRF_1730	Second Line Therapy (after first relapse)	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Unknown	Unknown		40	QWK	QWK					705	802	1
MMRF_1759	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	507	1
MMRF_1759	First line of therapy	Cyclophosphamide		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Induction	Induction		500	Other	QD (D1, 8)					1	507	1
MMRF_1759	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	507	1
MMRF_1759	First line of therapy	Bortezomib		Disease progression/Relapse	mg	IV SubQ	Log Forms	Maintenance	Maintenance		2.4	Other	EVERY TWO TO THREE WEEKS					507	714	1
MMRF_1759	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		5	Other	EVERY TWO TO THREE WEEKS WITH BORTEZOMIB DOSING					507	714	1
MMRF_1759	Second Line Therapy (after first relapse)	Carfilzomib			mg	IV	Log Forms	Unknown	Unknown	Checked	37	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					741		1
MMRF_1759	Second Line Therapy (after first relapse)	Lenalidomide			MG (DOSE UNKNOWN)	PO	Log Forms	Unknown	Unknown	Checked	0	QD (D1-21)	QD (D1-21)					741		1
MMRF_1759	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Unknown	Unknown	Checked	5	QWK	QWK					741		1
MMRF_1758	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	65	1
MMRF_1758	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		500	Other	QD (D1, 8)					1	62	1
MMRF_1758	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	65	1
MMRF_1758	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					111	111	1
MMRF_1758	Second Line Therapy (after first relapse)	Carfilzomib		Adverse Event or co-morbidity	mg	IV	Log Forms	Unknown	Unknown		44	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1300	1589	1
MMRF_1758	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	IV	Log Forms	Unknown	Unknown		12	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1300	1589	1
MMRF_1781	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	57	1
MMRF_1781	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	57	1
MMRF_1781	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	60	1
MMRF_1781	First line of therapy	MOZOBIL		Completed regimen	mg	IV SubQ	Log Forms	Other	MOBILIZATION		12	Q day	Q day					85	87	1
MMRF_1781	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					106	106	1
MMRF_1781	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Other	PRE-TRANSPLANT		1.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					295	298	1
MMRF_1781	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	PRE-TRANSPLANT		200	Q day	Q day					297	297	1
MMRF_1781	Second Line Therapy (after first relapse)	Daratumumab			mg/kg	IV	Log Forms	Other	SALVAGE	Checked	16	Other	DAYS 1,8,15,22 CYCLE 1-2. DAYS 1-5 CYCLES 3-6 DAY 1 C7 AND BEYOND					1990		1
MMRF_1781	Second Line Therapy (after first relapse)	Pomalidomide			mg	PO	Log Forms	Other	SALVAGE	Checked	4	QD (D1-21)	QD (D1-21)					1990		1
MMRF_1781	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Other	SALVAGE	Checked	20	Other	D 1,8,15					1990		1
MMRF_1787	Second Line Therapy (after first relapse)	CLINICAL TRIAL	NCT02332850		mg	IV	Log Forms	Other	SALVAGE	Checked	934	Other	DAY 1					2510		1
MMRF_1787	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_1787	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_1787	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	56	1
MMRF_1787	First line of therapy	Cyclophosphamide		Completed regimen	G	IV	Log Forms	Other	MOBILIZATION		4.3	Q day	Q day					82	82	1
MMRF_1787	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		10	Q day	Q day					82	82	1
MMRF_1787	First line of therapy	ETOPOSIDE		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		430	Q day	Q day					82	82	1
MMRF_1787	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		412	Q day	Q day					106	106	1
MMRF_1802	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		344	Q day	Q day					2443	2443	1
MMRF_1802	Second Line Therapy (after first relapse)	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Other	CONDITIONING		2.8	Q day	Q day					2444	2444	1
MMRF_1802	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	54	1
MMRF_1802	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	54	1
MMRF_1802	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	57	1
MMRF_1802	First line of therapy	ETOPOSIDE		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		360	Q day	Q day					85	85	1
MMRF_1802	First line of therapy	Cyclophosphamide		Completed regimen	G	IV	Log Forms	Other	MOBILIZATION		3.6	Q day	Q day					85	85	1
MMRF_1802	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		10	Q day	Q day					85	85	1
MMRF_1802	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		352	Q day	Q day					112	112	1
MMRF_1802	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		1.6	Other	ONCE					232	232	1
MMRF_1802	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		1.6	Other	ONCE					235	235	1
MMRF_1802	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Other	ONCE					234	234	1
MMRF_1801	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	84	1
MMRF_1801	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	87	1
MMRF_1801	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	84	1
MMRF_1801	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		2000	Q day	Q day					102	102	1
MMRF_1801	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Induction	Induction		10	Q day	Q day					102	102	1
MMRF_1801	First line of therapy	ETOPOSIDE		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Q day	Q day					102	102	1
MMRF_1801	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Q day	Q day					127	127	1
MMRF_1801	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Other	PRE-TRANSPLANT		1.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					295	298	1
MMRF_1801	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	PRE-TRANSPLANT		200	Q day	Q day					297	297	1
MMRF_1807	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	82	1
MMRF_1807	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	76	1
MMRF_1807	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	82	1
MMRF_1807	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					122	122	1
MMRF_1819	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	35	1
MMRF_1819	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	35	1
MMRF_1819	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	35	1
MMRF_1850	First line of therapy	Bortezomib		MOVE TO TRANSPLANT	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					9	68	1
MMRF_1850	First line of therapy	Lenalidomide		MOVE TO TRANSPLANT	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	71	1
MMRF_1850	First line of therapy	Dexamethasone		MOVE TO TRANSPLANT	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					9	68	1
MMRF_1850	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		2000	Q day	Q day					95	95	1
MMRF_1850	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Induction	Induction		10	Q day	Q day					95	95	1
MMRF_1850	First line of therapy	ETOPOSIDE		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Q day	Q day					95	95	1
MMRF_1850	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Q day	Q day					121	121	1
MMRF_1850	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Other	MOBILIZATION		1.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					274	277	1
MMRF_1850	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					276	276	1
MMRF_1850	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					529		1
MMRF_1860	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	75	1
MMRF_1860	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	75	1
MMRF_1860	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	75	1
MMRF_1860	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Induction	Induction		1090	Q day	Q day					95	98	1
MMRF_1860	First line of therapy	CISPLATIN		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		25	Q day	Q day					95	98	1
MMRF_1860	First line of therapy	ETOPOSIDE		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		75	Q day	Q day					95	98	1
MMRF_1860	First line of therapy	Doxorubicin		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		22	Q day	Q day					95	98	1
MMRF_1860	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Other	MOBILIZATION		1.3	Q day	Q day					95	95	1
MMRF_1860	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		428	Q day	Q day					123	123	1
MMRF_1860	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		438	Q day	Q day					256	256	1
MMRF_1860	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Other	CONDITIONING		3.5	Other	D1 TO D4					254	257	1
MMRF_1865	First line of therapy	Bortezomib		Lack of response	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	30	1
MMRF_1865	First line of therapy	Lenalidomide		Lack of response	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	33	1
MMRF_1865	First line of therapy	Dexamethasone		Lack of response	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	30	1
MMRF_1865	First line of therapy	Carfilzomib		MOVE TO TRANSPLANT	mg/m^2	IV	Log Forms	Induction	Induction		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					47	118	1
MMRF_1865	First line of therapy	Cyclophosphamide		MOVE TO TRANSPLANT	mg/m^2	IV	Log Forms	Induction	Induction		300	Other	QD1, 8, 15					47	117	1
MMRF_1865	First line of therapy	Dexamethasone		MOVE TO TRANSPLANT	mg	PO	Log Forms	Induction	Induction		40	Other	QWEEK D1, 8, 15, 22					47	124	1
MMRF_1865	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		2000	Q day	Q day					141	141	1
MMRF_1865	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Induction	Induction		10	Q day	Q day					141	141	1
MMRF_1865	First line of therapy	ETOPOSIDE		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Q day	Q day					141	141	1
MMRF_1865	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Q day	Q day					167	167	1
MMRF_1865	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		465	Other	ONCE					141	141	1
MMRF_1865	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		40	Other	ONCE					141	141	1
MMRF_1865	First line of therapy	ETOPOSIDE		Completed regimen	mg/m^2	IV	Log Forms	Other	MOBILIZATION		200	Other	ONCE					141	141	1
MMRF_1865	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Induction	Induction		10	Other	ONCE					167	167	1
MMRF_1865	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		1.6	Other	D-4 AND -1 TRANSPLANT					325	328	1
MMRF_1865	First line of therapy	FLUDARABINE		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		30	QD (D1-3)	QD (D1-3)					324	326	1
MMRF_1865	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Induction	Induction		214	Other	ONCE					327	327	1
MMRF_1895	First line of therapy	Bortezomib		MOVING TO TRANSPLANT	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	95	1
MMRF_1895	First line of therapy	Lenalidomide		MOVING TO TRANSPLANT	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	98	1
MMRF_1895	First line of therapy	Dexamethasone		MOVING TO TRANSPLANT	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	95	1
MMRF_1895	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		2000	Q day	Q day					122	122	1
MMRF_1895	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Induction	Induction		10	Q day	Q day					122	122	1
MMRF_1895	First line of therapy	ETOPOSIDE		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Q day	Q day					122	122	1
MMRF_1895	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Q day	Q day					148	148	1
MMRF_1895	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Other	MOBILIZATION		1.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					287	290	1
MMRF_1895	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					289	289	1
MMRF_1936	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	57	1
MMRF_1936	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	57	1
MMRF_1936	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	57	1
MMRF_1936	First line of therapy	CISPLATIN		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		25	Q day	Q day					97	99	1
MMRF_1936	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Other	MOBOLIZATION		1065	Q day	Q day					97	99	1
MMRF_1936	First line of therapy	ETOPOSIDE		Completed regimen	mg	IV	Log Forms	Induction	Induction		75	Q day	Q day					97	99	1
MMRF_1936	First line of therapy	Doxorubicin		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		20	Q day	Q day					97	99	1
MMRF_1936	Second Line Therapy (after first relapse)	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Other	FIRST RELAPSE		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					155	242	1
MMRF_1936	Second Line Therapy (after first relapse)	Pomalidomide		Completed regimen	mg	PO	Log Forms	Other	FISRT RELAPSE		4	Other	QD FROM DAY 1 - 14, OFF FOR 7 DAYS IN A 21 DAY CYCLE					155	256	1
MMRF_1936	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Other	FIRST RELAPSE		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					155	242	1
MMRF_1936	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		426	Q day	Q day					294	294	1
MMRF_1936	Second Line Therapy (after first relapse)	Cyclophosphamide		Completed regimen	G	IV	Log Forms	Other	MOBILIZATION		4.2	Q day	Q day					270	270	1
MMRF_1936	Second Line Therapy (after first relapse)	ETOPOSIDE		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		420	Q day	Q day					270	270	1
MMRF_1936	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		10	Q day	Q day					270	270	1
MMRF_1936	Third Line Therapy (following 2nd relapse)	Carfilzomib		Investigator decision for other reasons	mg	IV	Log Forms	Other	FIRST RELAPSE		41	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					457	457	1
MMRF_1936	Third Line Therapy (following 2nd relapse)	Dexamethasone		Investigator decision for other reasons	mg	IV	Log Forms	Other	RELAPSE		4	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					457	457	1
MMRF_1936	Third Line Therapy (following 2nd relapse)	Cyclophosphamide		Investigator decision for other reasons	mg	IV	Log Forms	Other	RELAPSE		1020	Other	DAYS 1 AND 8 OF 21 DAYS CYCLE					457	526	1
MMRF_1936	Third Line Therapy (following 2nd relapse)	Bortezomib		Lack of response	mg	IV	Log Forms	Unknown	Unknown		2.7	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					465	529	1
MMRF_1936	Third Line Therapy (following 2nd relapse)	Dexamethasone		Lack of response	mg	PO	Log Forms	Unknown	Unknown		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					465	529	1
MMRF_1936	Third Line Therapy (following 2nd relapse)	Pomalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Unknown	Unknown		4	QD (D1-4)	QD (D1-4)					465	524	1
MMRF_1936	Third Line Therapy (following 2nd relapse)	PANIBINOSTAT		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		20	Other	QD (D1,3,5,8,10 &12)					550	556	1
MMRF_1936	Fourth Line Therapy (following 3rd relapse)	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms	Unknown	Unknown		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					557	568	1
MMRF_1936	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Unknown	Unknown		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					557	568	1
MMRF_1936	Fourth Line Therapy (following 3rd relapse)	PANOBINOSTAT		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		20	Other	QD (D1,D3,D5,D8,D10,D12)					557	568	1
MMRF_1936	Fifth Line Therapy (following 4th relapse)	CARMUSTINE		Completed regimen	mg	IV	Log Forms	Induction	Induction		120	Q day	Q day					578	578	1
MMRF_1936	Fifth Line Therapy (following 4th relapse)	Dexamethasone		Completed regimen	mg	IV	Log Forms	Induction	Induction		40	Q day	Q day					578	578	1
MMRF_1936	Fifth Line Therapy (following 4th relapse)	Melphalan		Completed regimen	mg	IV	Log Forms	Unknown	Unknown		120	Q day	Q day					578	578	1
MMRF_1936	Sixth Line Therapy (following 5th relapse)	Daratumumab		Disease progression/Relapse	mg	IV	Log Forms	Unknown	Unknown		1345	QD (D1-14)	QD (D1-14)					604	625	1
MMRF_1936	Sixth Line Therapy (following 5th relapse)	Prednisone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		20	Other	TWO DAYS AFTER DARATUMUMAB					604	625	1
MMRF_1936	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Q day	Q day					97	97	1
MMRF_1941	First line of therapy	Bortezomib		MOVE TO TRANSPLANT	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	95	1
MMRF_1941	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	84	1
MMRF_1941	First line of therapy	Lenalidomide		MOVE TO TRANSPLANT	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	98	1
MMRF_1941	First line of therapy	Dexamethasone		MOVE TO TRANSPLANT	mg	PO	Log Forms	Induction	Induction		12	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					85	95	1
MMRF_1941	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		2000	Q day	Q day					130	130	1
MMRF_1941	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Induction	Induction		10	Q day	Q day					130	130	1
MMRF_1941	First line of therapy	ETOPOSIDE		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Q day	Q day					130	130	1
MMRF_1941	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Other	OTHER					191	191	1
MMRF_1947	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_1947	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	56	1
MMRF_1947	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_1947	First line of therapy	Cyclophosphamide		Completed regimen	G/M^2	IV	Log Forms	Induction	Induction		2	Q day	Q day					80	80	1
MMRF_1947	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		10	Q day	Q day					80	80	1
MMRF_1947	First line of therapy	ETOPOSIDE		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Q day	Q day					80	80	1
MMRF_1947	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Q day	Q day					105	105	1
MMRF_1947	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Other	MOBILIZATION		1.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					287	290	1
MMRF_1947	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					289	289	1
MMRF_1947	Second Line Therapy (after first relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Unknown	Unknown		16	Other	16 MG/K (WEEKLY 1-8, QOW 9-24, MONTHLY 25 ONWARD)					1218	2136	1
MMRF_1947	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		20	Other	EACH DARATUMUMAB DOSE					1218	2136	1
MMRF_1947	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		25	QD (D1-21)	QD (D1-21)					1218	2136	1
MMRF_1947	Third Line Therapy (following 2nd relapse)	Carfilzomib			mg/m^2	IV	Log Forms	Other	SALVAGE	Checked	56	Other	20 MG/M2 ON DAYS 1, AND THEN 56MG/M2 ON ALL SUBSEQUENT DAYS					2178		1
MMRF_1947	Third Line Therapy (following 2nd relapse)	Pomalidomide			mg	PO	Log Forms	Other	SALVAGE	Checked	4	QD (D1-21)	QD (D1-21)					2178		1
MMRF_1947	Third Line Therapy (following 2nd relapse)	Dexamethasone			mg	IV ON DAY 1 AND 20 MG ORALLY ON DAYS 8 AND 15.	Log Forms	Other	SALVAGE	Checked	20	Other	QD 1, 8, 15					2178		1
MMRF_1951	Eighth Line of Therapy (following 7th relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		20	Other	DAYS 1, 8 AND 15					1579	2027	1
MMRF_1951	Eighth Line of Therapy (following 7th relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Other	SALVAGE		56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1579	2027	1
MMRF_1951	Seventh Line of Therapy (following 6th relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		4	Other	ONCE WEEKLY ON THE WEEKS OFF OF DARA					1475	1538	1
MMRF_1951	Seventh Line of Therapy (following 6th relapse)	SOLUMEDROL		Disease progression/Relapse	mg	IV	Log Forms	Other	SALVAGE		100	Other	QOW					1475	1538	1
MMRF_1951	Seventh Line of Therapy (following 6th relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		4	QD (D1-21)	QD (D1-21)					1475	1538	1
MMRF_1951	Seventh Line of Therapy (following 6th relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Other	SALVAGE		16	Other	QOW					1475	1538	1
MMRF_1951	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	607	1
MMRF_1951	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	QWK	QWK					1	607	1
MMRF_1951	Second Line Therapy (after first relapse)	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Unknown	Unknown		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					614	617	1
MMRF_1951	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					614	617	1
MMRF_1951	Third Line Therapy (following 2nd relapse)	Ixazomib		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		4	Other	QD (D1, D8, D15, D20)					656	918	1
MMRF_1951	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		20	Q week	Q week					656	918	1
MMRF_1951	Fourth Line Therapy (following 3rd relapse)	Elotuzumab		Disease progression/Relapse	mg	IV	Log Forms	Unknown	Unknown		695	Q week	Q week					930	972	1
MMRF_1951	Fourth Line Therapy (following 3rd relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		15	QD (D1-21)	QD (D1-21)					930	972	1
MMRF_1951	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		28	Other	3-24H PRIOR ELOTUZUMAB DOSING					930	972	1
MMRF_1951	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		8	Other	PRIOR TO ELO					899	972	1
MMRF_1951	Fifth Line Therapy (following 4th relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					986	1097	1
MMRF_1951	Fifth Line Therapy (following 4th relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		20	Q week	Q week					986	1097	1
MMRF_1951	Sixth Line Therapy (following 5th relapse)	Daratumumab		Disease progression/Relapse	mg	IV	Log Forms	Unknown	Unknown		1131	Other	WEEKLY FOR WEEKS 1-8, QOW WEEKS 9-25, MONTHLY WEEK 25 ONWARD					1104	1468	1
MMRF_1951	Sixth Line Therapy (following 5th relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					1104	1468	1
MMRF_1951	Sixth Line Therapy (following 5th relapse)	Prednisone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		25	Other	DAYS 1,2 FOLLOWING EACH DARA DOSE					1107	1468	1
MMRF_1951	Sixth Line Therapy (following 5th relapse)	SOLUMEDROL		Disease progression/Relapse	mg	IV	Log Forms	Unknown	Unknown		100	Other	PRIOR TO EACH DOSE OF DARA					1077	1468	1
MMRF_1967	First line of therapy	Lenalidomide			mg	PO	Log Forms	Induction	Induction	Checked	25	QD (D1-14)	QD (D1-14)					1		1
MMRF_1967	First line of therapy	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_1967	First line of therapy	Bortezomib			mg/m^2	IV SubQ	Log Forms	Induction	Induction	Checked	1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_1967	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Other	ONCE					166	166	1
MMRF_1965	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	57	1
MMRF_1965	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					6	60	1
MMRF_1965	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	57	1
MMRF_1965	First line of therapy	CISPLATIN		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		15	QD (D1-4)	QD (D1-4)					81	84	1
MMRF_1965	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		500	QD (D1-4)	QD (D1-4)					81	84	1
MMRF_1965	First line of therapy	ETOPOSIDE		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		40	QD (D1-4)	QD (D1-4)					81	84	1
MMRF_1965	First line of therapy	Doxorubicin		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		10	QD (D1-4)	QD (D1-4)					81	84	1
MMRF_1965	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-4)	QD (D1-4)					81	84	1
MMRF_1965	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Other	QD1 & 4					81	84	1
MMRF_1965	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Induction	Induction		40	QD (D1-4)	QD (D1-4)					81	84	1
MMRF_1965	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Q day	Q day					111	111	1
MMRF_1965	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Other	PRE-TRANSPLANT		1.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					262	265	1
MMRF_1965	First line of therapy	FLUDARABINE		Completed regimen	mg/m^2	IV	Log Forms	Other	PRE-TRANSPLANT		30	Other	D -5, D -2					261	264	1
MMRF_1965	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	PRE-TRANSPLANT		140	Q day	Q day					264	264	1
MMRF_1965	Second Line Therapy (after first relapse)	Pomalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Other	SECOND LINE		4	QD (D1-21)	QD (D1-21)					855	938	1
MMRF_1965	Second Line Therapy (after first relapse)	Prednisone		Investigator decision for other reasons	mg	PO	Log Forms	Other	SECOND LINE		16	Other	48MG IN QAM, 32MG QHS					855	903	1
MMRF_1965	Second Line Therapy (after first relapse)	Prednisone		Investigator decision for other reasons	mg	PO	Log Forms	Other	SECOND LINE		32	Q day	Q day					904	910	1
MMRF_1965	Second Line Therapy (after first relapse)	Prednisone		Investigator decision for other reasons	mg	PO	Log Forms	Other	SECOND LINE		16	Q day	Q day					911	924	1
MMRF_1965	Second Line Therapy (after first relapse)	Prednisone		Investigator decision for other reasons	mg	PO	Log Forms	Other	SECOND LINE		8	Q day	Q day					925	945	1
MMRF_1965	Second Line Therapy (after first relapse)	Prednisone		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	SECOND LINE		4	Other	8MG QOD, 4MG QOD					946	1086	1
MMRF_1965	Second Line Therapy (after first relapse)	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	SECOND LINE		3	QD (D1-21)	QD (D1-21)					946	1086	1
MMRF_1981	First line of therapy	Bortezomib		TOXICITY (NEUROPATHY)	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	39	1
MMRF_1981	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		15	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	76	1
MMRF_1981	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	76	1
MMRF_1981	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					126	126	1
MMRF_1981	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		4100	Q day	Q day					101	101	1
MMRF_1981	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		10	Q day	Q day					101	101	1
MMRF_1981	First line of therapy	ETOPOSIDE		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		410	Q day	Q day					101	101	1
MMRF_1981	Second Line Therapy (after first relapse)	Ixazomib		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		4	Other	QD (D 1, 8, 15)					1022	1418	1
MMRF_1981	Second Line Therapy (after first relapse)	Cyclophosphamide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		650	Other	QD (D 1, 8, 15)					1022	1418	1
MMRF_1981	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		40	Q week	Q week					1022	1418	1
MMRF_1981	Third Line Therapy (following 2nd relapse)	Daratumumab			mg/kg	IV	Log Forms	Other	SALVAGE	Checked	16	Other	WEEKS 1-8, QOW 9-24, MONTHLY 25 ONWARD					1429		1
MMRF_1981	Third Line Therapy (following 2nd relapse)	Ixazomib		DOSE REDUCED	mg	PO	Log Forms	Other	SALVAGE		4	Other	DAYS 1,8,15					1429	1483	1
MMRF_1981	Third Line Therapy (following 2nd relapse)	Dexamethasone			mg	PO	Log Forms	Other	SALVAGE	Checked	20	Other	THE DAY OF AND DAY AFTER DARA					1429		1
MMRF_1981	Third Line Therapy (following 2nd relapse)	Ixazomib			mg	PO	Log Forms	Other	SALVAGE	Checked	3	Other	QD (D1,8,15)					1484		1
MMRF_1988	Second Line Therapy (after first relapse)	Lenalidomide			mg	PO	Log Forms	Other	SALVAGE	Checked	25	Other	EVERY OTHER DAY (D1-D21)					1573		1
MMRF_1988	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Other	SALVAGE	Checked	20	Other	QD (D1, D8, D15)					1573		1
MMRF_1988	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	82	1
MMRF_1988	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	85	1
MMRF_1988	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	82	1
MMRF_1988	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					115	115	1
MMRF_2059	Third Line Therapy (following 2nd relapse)	Dexamethasone			mg	PO	Log Forms	Other	SALVAGE	Checked	20	Other	DAYS 8 AND 22 ON 28 DAY CYCLE					2282		1
MMRF_2059	Third Line Therapy (following 2nd relapse)	Pomalidomide			mg	PO	Log Forms	Other	SALVAGE	Checked	4	Other	DAYS 1-7 AND DAYS 15-21 OF 28 DAY CYCLE					2282		1
MMRF_2059	Third Line Therapy (following 2nd relapse)	Daratumumab			mg	IV	Log Forms	Other	SALVAGE	Checked	1800	QWK	QWK					2282		1
MMRF_2059	First line of therapy	Bortezomib		MOVE TO TRANSPLANT	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	43	1
MMRF_2059	First line of therapy	Dexamethasone		MOVE TO TRANSPLANT	mg	IV	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	43	1
MMRF_2059	First line of therapy	Cyclophosphamide		MOVE TO TRANSPLANT	mg/m^2	IV	Log Forms	Induction	Induction		500	Other	DAY 1 AND 8 OF 21-DAY CYCLE					1	43	1
MMRF_2059	First line of therapy	Lenalidomide		MOVE TO TRANSPLANT	mg	PO	Log Forms	Induction	Induction		5	QD (D1-14)	QD (D1-14)					1	46	1
MMRF_2059	First line of therapy	MOZOBIL		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		18.6	Q day	Q day					74	76	1
MMRF_2059	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		140	Q day	Q day					105	105	1
MMRF_2059	Second Line Therapy (after first relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Other	SECOND LINE		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					839	2282	1
MMRF_2059	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Other	SECOND LINE		40	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					839	2282	1
MMRF_2059	Second Line Therapy (after first relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Other	SECOND LINE		4	QD (D1-21)	QD (D1-21)					839	2282	1
MMRF_2061	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	44	1
MMRF_2061	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		500	Other	DAY 1 & 8 OF 28 DAYS CYCLE					1	44	1
MMRF_2061	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	47	1
MMRF_2061	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	44	1
MMRF_2061	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		402	Q day	Q day					85	85	1
MMRF_2076	First line of therapy	Bortezomib		TOXICITY; PERIPHERAL NEUROPATHY	mg	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	42	1
MMRF_2076	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	42	1
MMRF_2076	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	42	1
MMRF_2076	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Other	ONCE					124	124	1
MMRF_2076	Second Line Therapy (after first relapse)	Daratumumab		Adverse Event or co-morbidity	mg/kg	IV	Log Forms	Unknown	Unknown		16	Other	D A,8,15 AND 22 OF A 28D CYCLE FOR C1-C2/D 1 & 15 FOR CYCLE 3-6/ D1 C7 AND					943	1363	1
MMRF_2076	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		15	QD (D1-21)	QD (D1-21)					943	1363	1
MMRF_2076	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	IV	Log Forms	Unknown	Unknown		20	Other	WITH EACH DARATUMUMAB INFUSION					943	1363	1
MMRF_2076	Third Line Therapy (following 2nd relapse)	Pomalidomide			mg	PO	Log Forms	Other	SALVAGE	Checked	4	QD (D1-21)	QD (D1-21)					1846		1
MMRF_2076	Third Line Therapy (following 2nd relapse)	Prednisone			mg	PO	Log Forms	Other	SALVAGE	Checked	60	Other	DAYS 1, 8, 15					1846		1
MMRF_2129	First line of therapy	Bortezomib		MOVE TO TRANSPLANT	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	123	1
MMRF_2129	First line of therapy	Lenalidomide		MOVE TO TRANSPLANT	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	125	1
MMRF_2129	First line of therapy	Dexamethasone		MOVE TO TRANSPLANT	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	123	1
MMRF_2129	First line of therapy	Cyclophosphamide		MOVE TO TRANSPLANT	mg/m^2	IV	Log Forms	Induction	Induction		500	Other	QD1, 8 OF EACH CYCLE					49	119	1
MMRF_2129	First line of therapy	Cyclophosphamide		Completed regimen	G	IV	Log Forms	Other	MOBILIZATION		3.3	Q day	Q day					151	151	1
MMRF_2129	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		10	Q day	Q day					151	151	1
MMRF_2129	First line of therapy	ETOPOSIDE		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		330	Q day	Q day					151	151	1
MMRF_2129	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					175	175	1
MMRF_1755	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	105	1
MMRF_1755	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	105	1
MMRF_1755	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	21	1
MMRF_1755	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					205	205	1
MMRF_2152	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_2152	First line of therapy	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_2152	First line of therapy	Cyclophosphamide			mg/m^2	IV	Log Forms	Induction	Induction	Checked	500	Other	DAY 1 AND 8					1		1
MMRF_2172	First line of therapy	Bortezomib		MOVE TO TRANSPLANT	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	71	1
MMRF_2172	First line of therapy	Dexamethasone		MOVE TO TRANSPLANT	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	71	1
MMRF_2172	First line of therapy	Lenalidomide		MOVE TO TRANSPLANT	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	74	1
MMRF_2172	First line of therapy	MOBOZIL		Completed regimen	mg	IV SubQ	Log Forms	Other	MOBILIZATION		22	Other	TWICE (5/JAN/15 AND 13/JAN/15)					103	111	1
MMRF_2172	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					126	126	1
MMRF_2172	Second Line Therapy (after first relapse)	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Other	SECOND LINE		25	QD (D1-21)	QD (D1-21)					345	431	1
MMRF_2172	Second Line Therapy (after first relapse)	Dexamethasone		SWITCH ROUTE WITH CARFILZOMIB ADDITION	mg	PO	Log Forms	Other	SECOND LINE		40	QWK	QWK					349	364	1
MMRF_2172	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	IV	Log Forms	Other	SECOND LINE		40	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					365	555	1
MMRF_2172	Second Line Therapy (after first relapse)	Carfilzomib		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Other	SECOND LINE		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					365	461	1
MMRF_2172	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Other	SECOND LINE		40	Other	PULSE D1-4 THEN QWK					345	348	1
MMRF_2172	Second Line Therapy (after first relapse)	Pomalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Other	SECOND LINE		4	QD (D1-21)	QD (D1-21)					446	522	1
MMRF_2172	Second Line Therapy (after first relapse)	Carfilzomib		Investigator decision for other reasons	mg	IV	Log Forms	Other	SECOND LINE		60	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					474	513	1
MMRF_2172	Second Line Therapy (after first relapse)	Cyclophosphamide		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Other	SECOND LINE		300	Other	DAYS 1, 8, 15					474	554	1
MMRF_2172	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	SECOND LINE		25	QD (D1-21)	QD (D1-21)					540	560	1
MMRF_2172	Second Line Therapy (after first relapse)	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Other	SECOND LINE		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					540	555	1
MMRF_2231	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	64	1
MMRF_2231	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	64	1
MMRF_2231	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	64	1
MMRF_2231	First line of therapy	ETOPOSIDE		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		325	Q day	Q day					130	130	1
MMRF_2231	First line of therapy	Cyclophosphamide		Completed regimen	G	IV	Log Forms	Other	MOBILIZATION		3.2	Q day	Q day					130	130	1
MMRF_2231	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		10	Q day	Q day					130	130	1
MMRF_2231	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					232	232	1
MMRF_2231	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms			Checked	20	Other	QD (D1, D8, D15)					1781		1
MMRF_2231	Second Line Therapy (after first relapse)	Lenalidomide			mg	PO	Log Forms	Unknown	Unknown	Checked	25	QD (D1-21)	QD (D1-21)					1781		1
MMRF_2231	Second Line Therapy (after first relapse)	Ixazomib			mg	PO	Log Forms	Unknown	Unknown	Checked	4	Other	QD (D1, D8, D15)					1781		1
MMRF_2267	Second Line Therapy (after first relapse)	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	SALVAGE		4	QD (D1-21)	QD (D1-21)					1300	1331	1
MMRF_2267	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	SALVAGE		20	Q week	Q week					1300	1331	1
MMRF_2267	Third Line Therapy (following 2nd relapse)	Carfilzomib			mg/m^2	IV	Log Forms	Other	SALVAGE	Checked		QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1419		1
MMRF_2267	Third Line Therapy (following 2nd relapse)	Dexamethasone			mg	IV	Log Forms	Other	SALVAGE	Checked	10	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1419		1
MMRF_2267	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	58	1
MMRF_2267	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	23	1
MMRF_2267	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	142	1
MMRF_2267	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		20	Other	QD(1-2,8-9 & 15-16)					62	142	1
MMRF_2267	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		4	Other	QD(1-2,8-9 & 15-16)					72	142	1
MMRF_2267	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					154	154	1
MMRF_2291	First line of therapy	Bortezomib			mg/m^2	IV SubQ	Log Forms	Induction	Induction	Checked	1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_2291	First line of therapy	Lenalidomide			mg	PO	Log Forms	Induction	Induction	Checked	25	QD (D1-14)	QD (D1-14)					1		1
MMRF_2291	First line of therapy	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_2310	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_2310	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		500	Other	QD1, D8					1	8	1
MMRF_2310	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_2310	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					119	119	1
MMRF_2310	First line of therapy	Cyclophosphamide		Completed regimen	G/M2	IV	Log Forms	Other	MOBILIZATION		2	Q day	Q day					95	95	1
MMRF_2310	First line of therapy	ETOPOSIDE		Completed regimen	mg/m^2	IV	Log Forms	Other	MOBILIZATION		200	Q day	Q day					95	95	1
MMRF_2310	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		10	Q day	Q day					95	95	1
MMRF_2310	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					22	43	1
MMRF_2310	Fourth Line Therapy (following 3rd relapse)	Daratumumab		Adverse Event or co-morbidity	mg	IV	Log Forms	Unknown	Unknown		1384	QID	QID					815	815	1
MMRF_2310	Second Line Therapy (after first relapse)	Elotuzumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Unknown	Unknown		10	Other	QD (1,8,15,22)					605	648	1
MMRF_2310	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Unknown	Unknown		8	Other	QD (1,8,15,22)					605	648	1
MMRF_2310	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		25	QD (D1-21)	QD (D1-21)					605	655	1
MMRF_2310	Third Line Therapy (following 2nd relapse)	Carfilzomib		Adverse Event or co-morbidity	mg	IV	Log Forms	Unknown	Unknown		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					666	759	1
MMRF_2310	Third Line Therapy (following 2nd relapse)	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					666	815	1
MMRF_2310	Third Line Therapy (following 2nd relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	IV	Log Forms	Unknown	Unknown		40	Other	QD (1,8,15,22)					666	815	1
MMRF_2316	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		311	Other	ONCE					142	142	1
MMRF_2316	Second Line Therapy (after first relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Unknown	Unknown	Checked	16	Other	D 1, 8, 15, 22					1849		1
MMRF_2316	Second Line Therapy (after first relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown	Checked	4	QD (D1-21)	QD (D1-21)					1849		1
MMRF_2316	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Unknown	Unknown	Checked	20	Other	D 1, 8, 15, 22					1849		1
MMRF_2316	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Induction	Induction		1080	QD (D1-7)	QD (D1-7)					1	102	1
MMRF_2316	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	71	1
MMRF_2316	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	102	1
MMRF_2330	First line of therapy	Bortezomib		PROCEED TO TRANSPLANT	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	74	1
MMRF_2330	First line of therapy	Dexamethasone		PROCEED TO TRANSPLANT	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	74	1
MMRF_2330	First line of therapy	Lenalidomide		PROCEED TO TRANSPLANT	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	77	1
MMRF_2330	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		2000	Q day	Q day					88	88	1
MMRF_2330	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Induction	Induction		10	Q day	Q day					88	88	1
MMRF_2330	First line of therapy	ETOPOSIDE		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Q day	Q day					88	88	1
MMRF_2330	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Q day	Q day					122	122	1
MMRF_2330	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		1.3	Q day	Q day					235	235	1
MMRF_2330	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Q day	Q day					234	234	1
MMRF_2330	Second Line Therapy (after first relapse)	Elotuzumab		Lack of response	mg/kg	IV	Log Forms	Unknown	Unknown		10	Other	D1, 8, 15, 22					607	677	1
MMRF_2330	Second Line Therapy (after first relapse)	Lenalidomide		Lack of response	mg	PO	Log Forms	Unknown	Unknown		25	QD (D1-21)	QD (D1-21)					607	683	1
MMRF_2330	Second Line Therapy (after first relapse)	Dexamethasone		Lack of response	mg	IV	Log Forms	Unknown	Unknown		40	Other	QWK 1 DAY BEFORE ELOTUZUMAB					607	684	1
MMRF_2330	Second Line Therapy (after first relapse)	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Other	SECOND LINE		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					694	857	1
MMRF_2330	Second Line Therapy (after first relapse)	Lenalidomide		TOOK LENALIDOMIDE UNTIL POMALIDOMIDE DELIVERED	mg	PO	Log Forms	Other	SECOND LINE		25	QD (D1-21)	QD (D1-21)					694	695	1
MMRF_2330	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	IV	Log Forms	Other	SECOND LINE		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					694	857	1
MMRF_2330	Second Line Therapy (after first relapse)	Pomalidomide		Completed regimen	mg	PO	Log Forms	Other	SECOND LINE		4	QD (D1-21)	QD (D1-21)					696	857	1
MMRF_2330	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		100	Q day	Q day					874	874	1
MMRF_2330	Second Line Therapy (after first relapse)	FLUDARABINE		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		77	Q day	Q day					875	875	1
MMRF_2330	Third Line Therapy (following 2nd relapse)	Daratumumab			mg/kg	IV	Log Forms	Other	SALVAGE	Checked	16	Q week	Q week					1186		1
MMRF_2330	Third Line Therapy (following 2nd relapse)	Pomalidomide			mg	PO	Log Forms	Other	SALVAGE	Checked	4	QD (D1-21)	QD (D1-21)					1186		1
MMRF_2330	Third Line Therapy (following 2nd relapse)	METHYLPREDNISONE			mg	IV	Log Forms	Other	SALVAGE	Checked	125	Other	WITH DARA ADMINISTRATION					1186		1
MMRF_2331	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	64	1
MMRF_2331	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	64	1
MMRF_2331	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	64	1
MMRF_2331	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONSOLIDATION		200	Q day	Q day					122	122	1
MMRF_2331	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Other	SALVAGE	Checked	20	Q week	Q week					1510		1
MMRF_2331	Second Line Therapy (after first relapse)	Lenalidomide			mg	PO	Log Forms	Other	SALVAGE	Checked	25	QD (D1-21)	QD (D1-21)					1510		1
MMRF_2331	Second Line Therapy (after first relapse)	Elotuzumab			mg/kg	IV	Log Forms	Other	SALVAGE	Checked	10	Q week	Q week					1510		1
MMRF_2378	First line of therapy	Bortezomib		Investigator decision for other reasons	mg	IV SubQ	Log Forms	Induction	Induction		2.7	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	32	1
MMRF_2378	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	44	1
MMRF_2378	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	25	1
MMRF_2378	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					85	85	1
MMRF_2407	First line of therapy	Bortezomib		PROCEED TO TRANSPLANT	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	33	1
MMRF_2407	First line of therapy	Cyclophosphamide		SWITCHED TO LENALIDOMIDE AFTER ONE CYCLE	mg/m^2	IV	Log Forms	Induction	Induction		500	Other	D1 AND D8					1	8	1
MMRF_2407	First line of therapy	Dexamethasone		PROCEED TO TRANSPLANT	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	33	1
MMRF_2407	First line of therapy	Lenalidomide		PROCEED TO TRANSPLANT	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					22	36	1
MMRF_2407	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		2000	Q day	Q day					64	64	1
MMRF_2407	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Induction	Induction		10	Q day	Q day					64	64	1
MMRF_2407	First line of therapy	ETOPOSIDE		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Q day	Q day					64	64	1
MMRF_2407	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Q day	Q day					89	89	1
MMRF_2407	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		1.6	Other	D-4 AND D-1					207	210	1
MMRF_2407	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					209	209	1
MMRF_2407	Second Line Therapy (after first relapse)	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Other	SALVAGE		20	Other	DAY OF AND AFTER DARA FOR FIRST WEEK, THEN 40 MG ON DAY OF DARA THEREAFTER					1800	1999	1
MMRF_2407	Second Line Therapy (after first relapse)	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Other	SALVAGE		25	QD (D1-21)	QD (D1-21)					1800	1998	1
MMRF_2407	Second Line Therapy (after first relapse)	Daratumumab		Investigator decision for other reasons	mg/kg	IV	Log Forms	Other	SALVAGE		16	Other	DAYS 1,8,15,22; THEN DAYS 1 AND 15 FOR CYCLES 3-6; THEN DAY 1 FOR CYCLE 7 AND BEYOND					1800	1992	1
MMRF_2422	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	85	1
MMRF_2422	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	85	1
MMRF_2422	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Induction	Induction		4200	Q day	Q day					237	237	1
MMRF_2422	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		424	Q day	Q day					254	254	1
MMRF_2437	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Other	SALVAGE	Checked	20	Other	DAYS 1, 8, 15					1499		1
MMRF_2437	Second Line Therapy (after first relapse)	Lenalidomide			mg	PO	Log Forms	Other	SALVAGE	Checked	20	QD (D1-21)	QD (D1-21)					1499		1
MMRF_2437	Second Line Therapy (after first relapse)	Daratumumab			mg/kg	IV	Log Forms	Other	SALVAGE	Checked	16	Other	DAY 1					1499		1
MMRF_2437	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_2437	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		500	Other	QD (D1 AND D8)					1	8	1
MMRF_2437	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_2437	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	57	1
MMRF_2437	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		278	Q day	Q day					106	106	1
MMRF_2437	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Other	CONDITIONING		12	Q day	Q day					106	106	1
MMRF_2489	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Other	SALVAGE	Checked	20	Other	ON DAYS OF AND AFTER DARATUMUMAB					1383		1
MMRF_2489	Second Line Therapy (after first relapse)	Lenalidomide			mg	PO	Log Forms	Other	SALVAGE	Checked	25	QD (D1-21)	QD (D1-21)					1383		1
MMRF_2489	Second Line Therapy (after first relapse)	Daratumumab			mg/kg	IV	Log Forms	Other	SALVAGE	Checked	16	Other	CYLE 1 DAYS 1,8,15,22. C2 DAYS 1,15,					1383		1
MMRF_2489	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_2489	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_2489	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	56	1
MMRF_2489	First line of therapy	ETOPOSIDE		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		400	Q day	Q day					73	73	1
MMRF_2489	First line of therapy	Cyclophosphamide		Completed regimen	G	IV	Log Forms	Other	MOBILIZATION		4	Q day	Q day					73	73	1
MMRF_2489	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		10	Q day	Q day					73	73	1
MMRF_2489	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		390	Q day	Q day					98	98	1
MMRF_2489	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		1.6	Other	DAYS -4 AND -1					273	276	1
MMRF_2489	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					275	275	1
MMRF_2499	Second Line Therapy (after first relapse)	Dexamethasone			mg	IV	Log Forms	Other	SALVAGE	Checked	20	Other	DAY1,8,15 AND 22					1899		1
MMRF_2499	Second Line Therapy (after first relapse)	Pomalidomide			mg	PO	Log Forms	Other	SALVAGE	Checked	4	QD (D1-21)	QD (D1-21)					1899		1
MMRF_2499	Second Line Therapy (after first relapse)	Daratumumab			mg/kg	IV	Log Forms	Other	SALVAGE	Checked	16	Other	DAY 1,8,15 AND 22					1899		1
MMRF_2499	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					28	86	1
MMRF_2499	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	58	1
MMRF_2499	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					28	115	1
MMRF_2499	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Induction	Induction		1045	Other	QD (D1, D8)					58	115	1
MMRF_2499	First line of therapy	ETOPOSIDE		Completed regimen	mg	IV	Log Forms	Consolidation	Consolidation		420	Other	ONCE					115	115	1
MMRF_2499	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Consolidation	Consolidation		412	Other	ONCE					141	141	1
MMRF_2499	Second Line Therapy (after first relapse)	Ixazomib		WORSENING MARKERS, AND CYTOPENIAS+HYPERCALCEMIA AND INTOLERANCE.	mg	PO	Log Forms	Other	SALVAGE		4	Other	QD (1,8,15)					1561	1892	1
MMRF_2499	Second Line Therapy (after first relapse)	Cyclophosphamide		WORSENING MARKERS, AND CYTOPENIAS+HYPERCALCEMIA AND INTOLERANCE.	mg/m^2	PO	Log Forms	Other	SALVAGE		300	Other	QD (1,8,15)					1561	1892	1
MMRF_2499	Second Line Therapy (after first relapse)	Dexamethasone		WORSENING MARKERS, AND CYTOPENIAS+HYPERCALCEMIA AND INTOLERANCE.	mg	PO	Log Forms	Other	SALVAGE		20	Other	QD (1,8,15)					1561	1892	1
MMRF_2506	First line of therapy	Lenalidomide		MD TEMPORARILY GIVING PATIENT BREAK FROM TREATMENT	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	371	1
MMRF_2506	First line of therapy	Dexamethasone		MD TEMPORARILY GIVING PATIENT BREAK FROM TREATMENT	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					1	371	1
MMRF_2548	First line of therapy	Cyclophosphamide		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Induction	Induction		500	Other	QD (D1, D8)					1	1	1
MMRF_2548	First line of therapy	Bortezomib		PROCEED TO TRANSPLANT	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	54	1
MMRF_2548	First line of therapy	Dexamethasone		PROCEED TO TRANSPLANT	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	54	1
MMRF_2548	First line of therapy	Lenalidomide		PROCEED TO TRANSPLANT	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					8	57	1
MMRF_2548	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		2000	Q day	Q day					79	79	1
MMRF_2548	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Induction	Induction		10	Q day	Q day					79	79	1
MMRF_2548	First line of therapy	ETOPOSIDE		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Q day	Q day					79	79	1
MMRF_2548	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Q day	Q day					103	103	1
MMRF_2548	First line of therapy	FLUDARABINE		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		30	Q day	Q day					247	249	1
MMRF_2548	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		140	Q day	Q day					250	250	1
MMRF_2548	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		1.6	Other	QD-4, D-1					248	251	1
MMRF_2554	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	102	1
MMRF_2554	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	102	1
MMRF_2554	First line of therapy	Cyclophosphamide		Completed regimen	G	IV	Log Forms	Other	MOBOLIZATION		3.3	Q day	Q day					126	126	1
MMRF_2554	First line of therapy	ETOPOSIDE		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		330	Q day	Q day					126	126	1
MMRF_2554	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		10	Q day	Q day					126	126	1
MMRF_2554	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		320	Q day	Q day					161	161	1
MMRF_2554	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	102	1
MMRF_2574	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	54	1
MMRF_2574	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	54	1
MMRF_2574	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	54	1
MMRF_2574	Second Line Therapy (after first relapse)	Carfilzomib		Adverse Event or co-morbidity	mg	IV	Log Forms	Unknown	Unknown		40	Other	DAYS 1,2,8,9,15,16					445	446	1
MMRF_2574	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	IV	Log Forms	Unknown	Unknown		40	Other	1,2,8,9,15,16					445	446	1
MMRF_2574	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Other	ONCE					89	89	1
MMRF_2593	First line of therapy	Bortezomib		PROCEED TO TRANSPLANT	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	50	1
MMRF_2593	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	15	1
MMRF_2593	First line of therapy	Dexamethasone		PROCEED TO TRANSPLANT	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	50	1
MMRF_2593	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		2000	Q day	Q day					64	64	1
MMRF_2593	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Induction	Induction		10	Q day	Q day					64	64	1
MMRF_2593	First line of therapy	ETOPOSIDE		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Q day	Q day					64	64	1
MMRF_2593	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Q day	Q day					90	90	1
MMRF_2593	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Unknown	Unknown	Checked	40	Q week	Q week					1079		1
MMRF_2593	Second Line Therapy (after first relapse)	Ixazomib			mg	PO	Log Forms	Unknown	Unknown	Checked	4	Other	QD (D1, D8, D15)					1079		1
MMRF_2593	Second Line Therapy (after first relapse)	Lenalidomide			mg	PO	Log Forms	Unknown	Unknown	Checked	25	QD (D1-21)	QD (D1-21)					1079		1
MMRF_2596	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	32	1
MMRF_2596	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	11	1
MMRF_2596	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	32	1
MMRF_2596	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		392	Q day	Q day					78	78	1
MMRF_2605	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	37	1
MMRF_2605	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	37	1
MMRF_2605	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	37	1
MMRF_2605	First line of therapy	ETOPOSIDE		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		310	Q day	Q day					65	65	1
MMRF_2605	First line of therapy	Cyclophosphamide		Completed regimen	G	IV	Log Forms	Other	MOBIIZATION		3.1	Q day	Q day					65	65	1
MMRF_2605	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		10	Q day	Q day					65	65	1
MMRF_2605	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		302	Q day	Q day					90	90	1
MMRF_2605	Third Line Therapy (following 2nd relapse)	Daratumumab		Disease progression/Relapse	mg	IV	Log Forms	Unknown	Unknown		850	Other	DAYS 1,8,15,22					901	971	1
MMRF_2605	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		40	Other	DAYS OF AND AFTER DARATUMMUMAB					901	971	1
MMRF_2605	Third Line Therapy (following 2nd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					901	971	1
MMRF_2605	Fourth Line Therapy (following 3rd relapse)	IDASANUTLIN		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		200	Other	QD (D 1-5)					1016	1020	1
MMRF_2605	Fourth Line Therapy (following 3rd relapse)	Ixazomib		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		4	Other	QD (D 1, 8, 15 OUT OF 28 DAYS CYCLE)					1016	1030	1
MMRF_2605	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		40	QWK	QWK					1016	1030	1
MMRF_2605	Fifth Line Therapy (following 4th relapse)	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Other	SALVAGE		459	Q day	Q day					1113	1115	1
MMRF_2605	Fifth Line Therapy (following 4th relapse)	FLUDARABINE		Completed regimen	mg	IV	Log Forms	Other	SALVAGE		28	Q day	Q day					1113	1115	1
MMRF_2605	Fifth Line Therapy (following 4th relapse)	CAR T CELLS	NCT03361748	Completed regimen	X10^6 CAR T CELLS.	IV	Log Forms	Other	SALVAGE		150	Other	ONCE					1118	1118	1
MMRF_2605	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		25	QD (D1-21)	QD (D1-21)					603	884	1
MMRF_2605	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		40	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					603	884	1
MMRF_2605	First line of therapy	Bortezomib		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		2.5	Q day	Q day					257	260	1
MMRF_2605	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		310	Q day	Q day					259	259	1
MMRF_2605	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		10	Q day	Q day					257	260	1
MMRF_2605	Second Line Therapy (after first relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Unknown	Unknown		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					603	884	1
MMRF_2619	Second Line Therapy (after first relapse)	Daratumumab			mg	IV	Log Forms	Other	SALVAGE	Checked	1800	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					2290		1
MMRF_2619	Second Line Therapy (after first relapse)	Pomalidomide			mg	PO	Log Forms	Other	SALVAGE	Checked	3	QD (D1-21)	QD (D1-21)					2290		1
MMRF_2619	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Other	SALVAGE	Checked	20	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					2290		1
MMRF_2619	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					444	457	1
MMRF_2619	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					444	457	1
MMRF_2619	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					444	457	1
MMRF_2619	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Induction	Induction		1.5	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					28	35	1
MMRF_2619	First line of therapy	Cyclophosphamide		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Induction	Induction		300	Other	PHYSICIAN DISCRETION					1	35	1
MMRF_2619	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					472	500	1
MMRF_2619	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					472	500	1
MMRF_2619	First line of therapy	Cyclophosphamide		Completed regimen	G	IV	Log Forms	Other	MOBILIZATION		4.6	Q day	Q day					510	510	1
MMRF_2619	First line of therapy	ETOPOSIDE		Completed regimen	G	IV	Log Forms	Other	MOBILIZATION		4.6	Q day	Q day					510	510	1
MMRF_2619	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		10	Q day	Q day					510	510	1
MMRF_2619	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					536	536	1
MMRF_2619	First line of therapy	Daratumumab		Adverse Event or co-morbidity	mg/kg	IV	Log Forms	Other	SALVAGE		16	QWK	QWK					1500	1662	1
MMRF_2619	First line of therapy	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	SALVAGE		3	Other	QD 1-21					1500	1662	1
MMRF_2619	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	SALVAGE		40	Other	QWEEK FOR 9 DOSES					1500	1662	1
MMRF_1222	Second Line Therapy (after first relapse)	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms				27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					170	354	1
MMRF_1222	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	IV	Log Forms				40	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					170	354	1
MMRF_1222	Second Line Therapy (after first relapse)	Pomalidomide		Completed regimen	mg	PO	Log Forms				4	QD (D1-21)	QD (D1-21)					170	359	1
MMRF_1222	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		200	Q day	Q day					407	407	1
MMRF_1222	Third Line Therapy (following 2nd relapse)	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		140	Q day	Q day					532	532	1
MMRF_1222	Third Line Therapy (following 2nd relapse)	Bendamustine		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Induction	Induction		120	Other	UNKNOWN					513	513	1
MMRF_1222	Third Line Therapy (following 2nd relapse)	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QWK	QWK					513	520	1
MMRF_1222	Third Line Therapy (following 2nd relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	IV	Log Forms	Induction	Induction		20	Q week	Q week					513	520	1
MMRF_1222	Fourth Line Therapy (following 3rd relapse)	Bortezomib		Lack of response	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					597	611	1
MMRF_1222	Fourth Line Therapy (following 3rd relapse)	Carfilzomib		DOSE TO BE ESCALATED PER STANDARD TREATMENT REGIMEN	mg/m^2	IV	Log Forms	Induction	Induction		20	Other	QD1, D2					618	619	1
MMRF_1222	Fourth Line Therapy (following 3rd relapse)	Carfilzomib		DOSE TO BE ESCALATED PER STANDARD TREATMENT REGIMEN	mg/m^2	IV	Log Forms	Induction	Induction		27	Other	QD (D8-9, D15-16)					625	633	1
MMRF_1222	Fourth Line Therapy (following 3rd relapse)	Carfilzomib		STOPPED SO PATIENT COULD RECEIVE XRT TO ORBITAL PLASMACYTOMA	mg/m^2	IV	Log Forms	Consolidation	Consolidation		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					646	660	1
MMRF_1222	First line of therapy	Lenalidomide		NO LONGER INDICATED	mg	PO	Log Forms	Induction	Induction	Checked	25	Q day	Q day					742		1
MMRF_1222	First line of therapy	Bortezomib		Lack of response	mg/m^2	SUBQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	160	1
MMRF_1222	First line of therapy	Dexamethasone		Lack of response	mg	PO	Log Forms				20	Q week	Q week					1	160	1
MMRF_1264	First line of therapy	Bortezomib		Lack of response	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1	372	1
MMRF_1264	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms				20	Q week	Q week					1	15	1
MMRF_1264	First line of therapy	Melphalan		Investigator decision for other reasons	mg	PO	Log Forms				2	Other	6 TABS DAILY FOR 5 DAYS Q6 WEEKS					86	302	1
MMRF_1264	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		5	QD (D1-14)	QD (D1-14)					45	58	1
MMRF_1264	Second Line Therapy (after first relapse)	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		3	QD (D1-21)	QD (D1-21)					388	1210	1
MMRF_1264	Second Line Therapy (after first relapse)	Pomalidomide		DOSE DECREASED	mg	PO	Log Forms	Induction	Induction		3	QD (D1-21)	QD (D1-21)					1239	1550	1
MMRF_1264	Second Line Therapy (after first relapse)	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		2	Q day	Q day					1551	1610	1
MMRF_1547	First line of therapy	Bortezomib		SUBJECT TO BE WORKED UP FOR TRANSPLANT	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QWK	QWK					1	148	1
MMRF_1547	First line of therapy	Dexamethasone		SUBJECT TO BE WORKED UP FOR TRANSPLANT	mg	PO	Log Forms	Induction	Induction		10	Other	QD (D1-2)					1	148	1
MMRF_1547	First line of therapy	Cyclophosphamide		SUBJECT TO BE WORKED UP FOR TRANSPLANT	mg	PO	Log Forms	Induction	Induction		300	QWK	QWK					1	148	1
MMRF_1547	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	2 DAYS HIGH DOSE MELPHALAN PRIOR TO TRANSPLANT		200	Other	QD -1,-2					192	193	1
MMRF_1547	First line of therapy	Bortezomib		PATIENT STARTED TO HAVE DIFFICULTIES TOLERATING THERAPY	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	Q (D1, D8)					642	865	1
MMRF_1547	First line of therapy	Ixazomib		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		4	Q week	Q week					892	1222	1
MMRF_1570	First line of therapy	Bortezomib		Patient decision	mg	SUBQ INJECTION	Log Forms	Induction	Induction		2.3	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1	29	1
MMRF_1570	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		10	Other	DAY 1 AND DAY 2					1	110	1
MMRF_1570	First line of therapy	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Induction	Induction		150	Other	DAY 1 AND DAY 2					1	110	1
MMRF_1570	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		2.3	QD (D1-3)	QD (D1-3)					29	110	1
MMRF_1570	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	HIGH DOSE MELPHALAN GIVEN 1 DAY PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANT		200	Q day	Q day					154	155	1
MMRF_1570	First line of therapy	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	Q2W					386	546	1
MMRF_1570	Second Line Therapy (after first relapse)	Dexamethasone		Patient decision	mg	PO	Log Forms	Unknown	Unknown		10	Other	MONDAY & TUESDAY FOR 3 WEEKS THEN 1 WEEK OFF					546	546	1
MMRF_1570	Second Line Therapy (after first relapse)	Lenalidomide		Patient decision	mg	PO	Log Forms	Unknown	Unknown		15	QD (D1-21)	QD (D1-21)					546	546	1
MMRF_1586	First line of therapy	Bortezomib		CHANGED FREQUENCY	mg	SUBQ	Log Forms	Induction	Induction		2.04	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1	128	1
MMRF_1586	First line of therapy	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	10	Other	QD 1-2, 8-9, 22-23, 29-30					1		1
MMRF_1586	First line of therapy	Bortezomib			mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance	Checked	1.3	Other	Q EVERY 2 WEEKS					128		1
MMRF_2038	First line of therapy	Bortezomib		Lack of response	mg	IV SubQ	Log Forms	Induction	Induction		2	Q week	Q week					1	92	1
MMRF_2038	First line of therapy	Dexamethasone		Lack of response	mg	PO	Log Forms	Induction	Induction		10	Other	QD (D1-D2)					1	94	1
MMRF_2038	First line of therapy	Cyclophosphamide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		300	QWK	QWK					1	34	1
MMRF_2038	First line of therapy	Lenalidomide		Lack of response	mg	PO	Log Forms	Induction	Induction		5	Q day	Q day					35	94	1
MMRF_2038	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Other	DAYS 1,4,8					121	128	1
MMRF_2038	First line of therapy	Thalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		200	BID	BID					124	127	1
MMRF_2038	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	DAYS 1-4 AND DAY 8					121	128	1
MMRF_2038	First line of therapy	ADRIAMYCIN		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		10	QD (D1-4)	QD (D1-4)					121	124	1
MMRF_2038	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		300	QD (D1-4)	QD (D1-4)					121	124	1
MMRF_2038	First line of therapy	ETOPOSIDE		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		40	QD (D1-4)	QD (D1-4)					121	124	1
MMRF_2038	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Unknown	Unknown		50	Q day	Q day					158	158	1
MMRF_2038	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Unknown	Unknown		50	Q day	Q day					164	164	1
MMRF_2038	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Unknown	Unknown		75	Q day	Q day					168	168	1
MMRF_2038	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Unknown	Unknown		20	Q day	Q day					158	158	1
MMRF_2038	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Unknown	Unknown		20	Q day	Q day					164	164	1
MMRF_2038	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Unknown	Unknown		20	Q day	Q day					168	168	1
MMRF_2038	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					275	666	1
MMRF_2038	First line of therapy	Thalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		50	Q day	Q day					275	409	1
MMRF_2038	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		12	Q week	Q week					539	632	1
MMRF_2038	First line of therapy	Pomalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		1	QD (D1-21)	QD (D1-21)					698	719	1
MMRF_2038	First line of therapy	Pomalidomide		OUTSIDE PROVIDER DECIDED PATIENT DOING WELL OFF TREATMENT AND IN SCR	mg	PO	Log Forms	Maintenance	Maintenance		1	Other	EVERY OTHER DAY FOR 28 DAY CYCLES WITH NO BREAK					732	1675	1
MMRF_2168	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1	281	1
MMRF_2168	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		10	Other	QD (D1-2, D8-9, D22-23, D29-30)					1	322	1
MMRF_2168	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		15	QD (D1-14)	QD (D1-14)					135	276	1
MMRF_2168	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING FOR BONE MARROW TRANSPLANT		200	Q day	Q day					308	308	1
MMRF_2168	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Other	HIGH-DOSE PRIMING PRIOR TO STEM CELL COLLECTION		3000	Q day	Q day					288	288	1
MMRF_2168	First line of therapy	Ixazomib		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		4	Q week	Q week					430	542	1
MMRF_2168	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		20	Q week	Q week					430	542	1
MMRF_2168	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					430	542	1
MMRF_2168	First line of therapy	Daratumumab		Completed regimen	mg/kg	IV	Log Forms	Induction	Induction		16	Other	Q2 WEEKS					626	891	1
MMRF_2168	First line of therapy	Daratumumab		MOVED TO MAINTENANCE REGIMEN	mg/kg	IV	Log Forms	Induction	Induction		16	Other	Q4 WEEKS					919	1521	1
MMRF_2168	First line of therapy	Daratumumab			mg/kg	IV	Log Forms	Maintenance	Maintenance	Checked	16	Other	Q4 WEEKS					1577		1
MMRF_2168	First line of therapy	Dexamethasone			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					2046		1
MMRF_2168	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	15	QD (D1-21)	QD (D1-21)					2046		1
MMRF_2215	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	93	1
MMRF_2215	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		10	Other	QD (D1-2, D4-5, D8-9, D11-12)					1	94	1
MMRF_2215	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		140	Q day	Q day					128	128	1
MMRF_2215	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					242	423	1
MMRF_2215	First line of therapy	Lenalidomide		CHANGED DOSING FREQUENCY	mg	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					428	1090	1
MMRF_2215	First line of therapy	Lenalidomide		PATIENT TOLERATES THE 21/28 DAY REGIMEN BETTER	mg	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					1098	1388	1
MMRF_2215	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	5	QD (D1-21)	QD (D1-21)					1388		1
MMRF_1011	First line of therapy	Bortezomib		GRADE 2 NEUROPATHY	mg	IV	Log Forms				2.7	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	74	1
MMRF_1011	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	Other	D1, D2, D3, D4,D9,D10, D11, D12					1	67	1
MMRF_1011	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	Other	DAY 1 AND DAY 8					67	156	1
MMRF_1011	First line of therapy	Lenalidomide		DOSE CHANGE	mg	PO	Log Forms				10	QD (D1-21)	QD (D1-21)					253	451	1
MMRF_1011	First line of therapy	Lenalidomide		PATIENT DIAGNOSED WITH COLON CANCER	mg	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					452	925	1
MMRF_1011	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION FOR BONE MARROW TRANSPLANT		3720	Other	ONCE					131	131	1
MMRF_1011	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		370	Other	ONCE					153	153	1
MMRF_1011	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		3720	Other	ONCE					131	131	1
MMRF_1011	Second Line Therapy (after first relapse)	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1726	1908	1
MMRF_1011	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1726	1909	1
MMRF_1011	Second Line Therapy (after first relapse)	Pomalidomide			mg/dL	PO	Log Forms	Maintenance	Maintenance	Checked	1	Q day	Q day					1933		1
MMRF_1034	First line of therapy	Bortezomib		DOSEAGE AND ROUTE CHANGED DUE TO NEUROPATHY	mg	IV	Log Forms				2	QWK	QWK					5	60	1
MMRF_1034	First line of therapy	Dexamethasone		DOSEAGE CHANGED	mg	PO	Log Forms				10	QD (D1-4)	QD (D1-4)					1	60	1
MMRF_1034	First line of therapy	Bortezomib		PATIENT DEVELOPED HYPERCALCEMIA	mg/dL	IV SubQ	Log Forms				1	QWK	QWK					60	115	1
MMRF_1034	First line of therapy	Dexamethasone		DOSEAGE AND FREQUENCY CHANGED	mg	PO	Log Forms				20	QWK	QWK					60	110	1
MMRF_1034	First line of therapy	Lenalidomide		BEGINNING STEM CELL MOBILIZATION FOR AUTOLOGOUS STEM CELL TRANSPLANT	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					115	249	1
MMRF_1034	First line of therapy	Dexamethasone		BEGINNING STEM CELL MOBLIZATION FOR AUTOLOGOUS STEM CELL TRANSPLANT	mg	PO	Log Forms				40	Other	DAYS 1, 8, 15, 22					115	249	1
MMRF_1034	First line of therapy	PLERIXAFOR		Completed regimen	mg	SUBQ	Log Forms	Other	STEM CELL MOBILIZATION		24	Q day	Q day					254	255	1
MMRF_1034	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Consolidation	Consolidation		300	Q day	Q day					258	258	1
MMRF_1029	First line of therapy	Bortezomib		GRADE 2 PERIPHERAL NEUROPATHY AND GOOD RESPONSE	mg	IV	Log Forms				3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	74	1
MMRF_1029	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					22	560	1
MMRF_1029	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms				20	Other	DAYS 1, 2, 8, 9, 15, 16, 22, 23					1	84	1
MMRF_1029	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms				20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					85	530	1
MMRF_1029	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms				15	Q day	Q day					561	883	1
MMRF_1029	First line of therapy	Dexamethasone			mg	PO	Log Forms			Checked	20	Q week	Q week					561		1
MMRF_1029	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	15	QD (D1-21)	QD (D1-21)					913		1
MMRF_1042	First line of therapy	Bortezomib		PATIENT'S RESPONSE REACHED A PLATEAU	mg	IV SubQ	Log Forms				2.4	QWK	QWK					1	148	1
MMRF_1042	First line of therapy	Dexamethasone		DOSEAGE REDUCED	mg	PO	Log Forms				40	QWK	QWK					1	148	1
MMRF_1042	Second Line Therapy (after first relapse)	Lenalidomide		LOWERED DOSAGE	mg	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					581	882	1
MMRF_1042	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					581	644	1
MMRF_1042	Second Line Therapy (after first relapse)	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					644	700	1
MMRF_1042	Second Line Therapy (after first relapse)	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	5	QD (D1-21)	QD (D1-21)					882		1
MMRF_1042	Second Line Therapy (after first relapse)	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		8	QWK	QWK					1429	1764	1
MMRF_1039	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms				2.6	QWK	QWK					1	105	1
MMRF_1039	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	Other	DAYS 1-4, 9-12					1	246	1
MMRF_1039	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					102	210	1
MMRF_1039	Second Line Therapy (after first relapse)	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					998	1149	1
MMRF_1039	Second Line Therapy (after first relapse)	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					1150	1358	1
MMRF_1039	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					1038	1358	1
MMRF_1039	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Consolidation	Consolidation		385	Other	ONCE					243	243	1
MMRF_1039	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		2.5	Q week	Q week					105	210	1
MMRF_1039	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		2	Q week	Q week					210	221	1
MMRF_1039	Second Line Therapy (after first relapse)	Pomalidomide			mg	PO	Log Forms	Induction	Induction	Checked	2	QD (D1-21)	QD (D1-21)					1403		1
MMRF_1039	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	20	Q week	Q week					1373		1
MMRF_1055	First line of therapy	Bortezomib		Completed regimen	MG	IV SubQ	Log Forms				2.5	Q week	Q week					1	142	1
MMRF_1055	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	QWK	QWK					1	142	1
MMRF_1055	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					296	392	1
MMRF_1055	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms				10	QD (D1-21)	QD (D1-21)					414	444	1
MMRF_1055	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Consolidation	Consolidation		385	Other	ONCE					165	165	1
MMRF_1124	First line of therapy	Dexamethasone		DISCHARGED FROM HOSPITAL TO FOLLOW-UP CARE IN OKLAHOMA	mg	PO	Log Forms				20	Other	ONE TIME DOSING					1	1	1
MMRF_1124	First line of therapy	Bortezomib		Patient decision	mg	IV	Log Forms				2.1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					18	379	1
MMRF_1124	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms				20	Other	DAY 1-4 AND DAY 9-12					15	60	1
MMRF_1124	First line of therapy	Dexamethasone		Patient decision	mg	PO	Log Forms				20	Q week	Q week					60	379	1
MMRF_1166	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	106	1
MMRF_1166	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms				20	Other	D1-2, D4-5, D8-9, D11-12					1	106	1
MMRF_1166	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	106	1
MMRF_1209	First line of therapy	Bortezomib		DEATH	mg	IV SubQ	Log Forms				2.1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	320	1
MMRF_1209	First line of therapy	Cyclophosphamide		DEATH	mg	PO	Log Forms				750	Other	D1, D8, D11					1	320	1
MMRF_1209	First line of therapy	Dexamethasone		DEATH	mg	PO	Log Forms				20	Other	D1, D8, D15					1	320	1
MMRF_1333	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms				1.3	Q week	Q week					1	176	1
MMRF_1333	First line of therapy	Cyclophosphamide		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms				750	Other	Q28D (D1)					1	176	1
MMRF_1333	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	IV	Log Forms				40	Q week	Q week					1	176	1
MMRF_1342	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms				2.4	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	747	1
MMRF_1342	First line of therapy	Lenalidomide		Patient decision	mg	PO	Log Forms				15	QD (D1-14)	QD (D1-14)					1	747	1
MMRF_1342	First line of therapy	Dexamethasone		PATIENT WAS EXPERIENCING ANXIETY	mg	PO	Log Forms				20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	498	1
MMRF_1342	First line of therapy	Dexamethasone		Patient decision	mg	PO	Log Forms	Induction	Induction		12	Other	TWICE A WEEK					498	672	1
MMRF_1342	First line of therapy	Dexamethasone		DEATH	mg	PO	Log Forms	Induction	Induction		16	Q week	Q week					672	778	1
MMRF_1383	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.3	Q week	Q week					1	135	1
MMRF_1383	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO	Log Forms				300	Q week	Q week					1	135	1
MMRF_1383	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms				20	Other	DAYS 1-4, 9-12, 17-20					1	56	1
MMRF_1383	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					57	135	1
MMRF_1383	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		2.3	Other	Q2WEEKS					276	1009	1
MMRF_1383	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Consolidation	Consolidation		240	Other	ONCE					167	167	1
MMRF_1550	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					1	23	1
MMRF_1550	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	204	1
MMRF_1550	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO	Log Forms	Induction	Induction		500	Q week	Q week					1	142	1
MMRF_1550	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1	Q week	Q week					30	51	1
MMRF_1550	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		0.7	Q week	Q week					58	142	1
MMRF_1550	Second Line Therapy (after first relapse)	Carfilzomib		Lack of response	mg/m^2	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					709	827	1
MMRF_1550	First line of therapy	Lenalidomide		Disease progression/Relapse	mg/dL	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					310	708	1
MMRF_1550	Second Line Therapy (after first relapse)	Daratumumab		Lack of response	mg/kg	IV	Log Forms	Induction	Induction		16	Other	Q2WK					838	1232	1
MMRF_1550	Second Line Therapy (after first relapse)	Pomalidomide			mg	PO	Log Forms	Unknown	Unknown	Checked	3	QD (D1-21)	QD (D1-21)					1332		1
MMRF_1550	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Unknown	Unknown	Checked	4	Other	10 Q.W.					1328		1
MMRF_1568	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					1	22	1
MMRF_1568	First line of therapy	Cyclophosphamide		Adverse Event or co-morbidity	mg/m^2	PO	Log Forms	Induction	Induction		500	Q week	Q week					1	50	1
MMRF_1568	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1	22	1
MMRF_1568	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1	Q week	Q week					29	113	1
MMRF_1568	First line of therapy	Cyclophosphamide		Investigator decision for other reasons	mg/m^2	PO	Log Forms	Induction	Induction		100	Q week	Q week					55	113	1
MMRF_1568	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					29	113	1
MMRF_1568	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					285	441	1
MMRF_1568	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Induction	Induction		300	Other	ONCE					171	171	1
MMRF_1568	Second Line Therapy (after first relapse)	Daratumumab			mg/kg	IV	Log Forms	Induction	Induction	Checked	8	Other	CYCLE 1 - D1, D2, D8, D15, D22, CYCLE 2 AND BEYOND - D1, D8, D15, D22					1275		1
MMRF_1568	Second Line Therapy (after first relapse)	Bortezomib			mg/m^2	INJECTION	Log Forms	Induction	Induction	Checked	2.4	Other	D1, D8					1275		1
MMRF_1568	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	40	QWK	QWK					1275		1
MMRF_1721	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					1	120	1
MMRF_1721	First line of therapy	Cyclophosphamide		Investigator decision for other reasons	mg/m^2	PO	Log Forms	Induction	Induction		300	Q week	Q week					1	120	1
MMRF_1721	First line of therapy	Dexamethasone		TROUBLE SLEEPING	mg	PO	Log Forms	Induction	Induction		40	Other	D1-4. D9-12, D17-20					1	120	1
MMRF_1721	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					57	120	1
MMRF_1834	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	69	1
MMRF_1834	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	69	1
MMRF_1834	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	D1-2, 4-5, 8-9, 11-12					1	69	1
MMRF_1834	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Induction	Induction		300	Other	ONCE					145	145	1
MMRF_1834	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		4	Other	D1, D8D, D15					222	940	1
MMRF_1834	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					222	940	1
MMRF_1970	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg	IV SubQ	Log Forms	Induction	Induction		3.5	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	176	1
MMRF_1970	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	Other	DAYS 1,8,15,22					1	148	1
MMRF_2057	First line of therapy	Lenalidomide			mg	PO	Log Forms	Induction	Induction	Checked	10	QD (D1-21)	QD (D1-21)					1		1
MMRF_2057	First line of therapy	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	20	Other	DAYS. 1,8,15,22					1		1
MMRF_2454	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	BID	BID					1	74	1
MMRF_2454	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	IV	Log Forms	Induction	Induction		40	Q week	Q week					1	74	1
MMRF_2480	First line of therapy	Lenalidomide		DEATH	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	141	1
MMRF_2480	First line of therapy	Dexamethasone		DEATH	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					14	141	1
MMRF_2560	First line of therapy	Lenalidomide			mg	PO	Log Forms	Induction	Induction	Checked	10	QD (D1-21)	QD (D1-21)					1		1
MMRF_2560	First line of therapy	Bortezomib		DOSE ADJUSTMENT	mg	IV SubQ	Log Forms	Induction	Induction		2.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	11	1
MMRF_2560	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	20 MG DAILY ON D1, D2, D4, D5, D8, D9, D11, D12 AND D21.					1	74	1
MMRF_2560	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					22	74	1
MMRF_1031	First line of therapy	Bortezomib		Completed regimen	mg	IV	Log Forms				1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	61	1
MMRF_1031	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	61	1
MMRF_1031	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				20	Other	D1, D4, D11, D18					1	61	1
MMRF_1031	First line of therapy	MAGE VACCINE		Disease progression/Relapse	MCG	IV	Log Forms				300	Other	Q3 WEEKS APPROXIMATELY					185	1339	1
MMRF_1031	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		25	Q day	Q day					1339	1581	1
MMRF_1031	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		40	Q week	Q week					1339	1581	1
MMRF_1031	Third Line Therapy (following 2nd relapse)	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Consolidation	Consolidation		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1581	1670	1
MMRF_1031	Third Line Therapy (following 2nd relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Consolidation	Consolidation		10	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1581	1670	1
MMRF_1018	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				15	QD (D1-21)	QD (D1-21)					1	160	1
MMRF_1018	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				20	QWK	QWK					1	160	1
MMRF_1018	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms				1.3	Other	D1,8,15					44	105	1
MMRF_1018	First line of therapy	Lenalidomide			mg	PO	Log Forms			Checked	10	QD (D1-21)	QD (D1-21)					218		1
MMRF_1018	First line of therapy	Dexamethasone			mg	PO	Log Forms			Checked	20	Q week	Q week					218		1
MMRF_1041	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	IV	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	18	1
MMRF_1041	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IVB	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	18	1
MMRF_1041	First line of therapy	Cyclophosphamide		Investigator decision for other reasons	mg/m^2	IV	Log Forms				250	Other	DAYS 4, 11					1	18	1
MMRF_1041	First line of therapy	Thalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms				50	Other	DAYS 1 - 28					18	260	1
MMRF_1041	First line of therapy	Dexamethasone		Lack of response	mg	IV	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					18	432	1
MMRF_1041	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					18	211	1
MMRF_1041	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms				250	Other	DAYS 1, 8					18	159	1
MMRF_1041	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		15	Other	EVERY OTHER DAY FOR 21 DAYS					260	406	1
MMRF_1041	Second Line Therapy (after first relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Consolidation	Consolidation		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					432	953	1
MMRF_1041	Second Line Therapy (after first relapse)	Cyclophosphamide		Disease progression/Relapse	mg/m^2	IV	Log Forms	Consolidation	Consolidation		300	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					432	953	1
MMRF_1041	Third Line Therapy (following 2nd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		2	QD (D1-21)	QD (D1-21)					981	1084	1
MMRF_1041	Third Line Therapy (following 2nd relapse)	Cyclophosphamide		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Consolidation	Consolidation		300	Other	QD D1 AND D15					1061	1095	1
MMRF_1041	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		40	Q day	Q day					953	1226	1
MMRF_1016	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms				40	Other	DAYS 1, 4, 11, 18					1	43	1
MMRF_1016	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IVP ON DAYS 1, 4 AND SUBQ ON 11 AND 18	Log Forms				1.3	Other	DAYS 1, 4, 11, 18					1	43	1
MMRF_1016	First line of therapy	Cyclophosphamide		Investigator decision for other reasons	mg/m^2	IVB	Log Forms				250	Other	DAYS 1, 11					1	43	1
MMRF_1016	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					43	113	1
MMRF_1016	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms				1.3	Other	DAYS 1, 4, 11, 18					43	113	1
MMRF_1016	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms				40	Other	DAYS 1, 4, 11, 18					43	113	1
MMRF_1016	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms				1.3	Other	DAYS 1, 4, 11, 18					113	158	1
MMRF_1016	First line of therapy	Cyclophosphamide		Investigator decision for other reasons	mg/m^2	IV	Log Forms				250	Other	DAYS 1, 11					113	158	1
MMRF_1016	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms				40	Other	DAYS 1, 4, 11, 18					113	158	1
MMRF_1016	First line of therapy	Bortezomib		Lack of response	mg/m^2	IV SubQ	Log Forms				1.3	Other	DAYS 1, 8, 15					234	535	1
MMRF_1016	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms				40	Other	DAYS 1, 8, 15					234	673	1
MMRF_1016	First line of therapy	Lenalidomide		Lack of response	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					234	458	1
MMRF_1016	First line of therapy	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Consolidation	Consolidation		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					547	673	1
MMRF_1016	First line of therapy	Cyclophosphamide		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Consolidation	Consolidation		300	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					547	673	1
MMRF_1054	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms				20	QWK	QWK					1	21	1
MMRF_1054	First line of therapy	Prednisone		Investigator decision for other reasons	mg	PO	Log Forms				50	Other	3 X PER WEEK: M, W, F					29	112	1
MMRF_1054	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms				15	QD (D1-21)	QD (D1-21)					1	112	1
MMRF_1054	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms				1.3	Other	DAYS 1, 4, 11, 18					112	568	1
MMRF_1054	First line of therapy	Cyclophosphamide		Investigator decision for other reasons	mg/m^2	IV	Log Forms				300	Other	DAYS 1, 8					112	162	1
MMRF_1054	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms				40	Other	DAYS 1, 4, 11, 18					112	169	1
MMRF_1054	First line of therapy	Prednisone		Investigator decision for other reasons	mg	PO	Log Forms				50	Other	3 X PER WEEK: M, W, F					169	568	1
MMRF_1054	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				15	QD (D1-21)	QD (D1-21)					167	568	1
MMRF_1054	First line of therapy	Prednisone		Completed regimen	mg	PO	Log Forms	Induction	Induction		30	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					568	757	1
MMRF_1054	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					568		1
MMRF_1049	Sixth Line Therapy (following 5th relapse)	Melphalan		Completed regimen	mg	IV	Log Forms	Consolidation	Consolidation		234	Other	ONCE					2206	2206	1
MMRF_1049	Third Line Therapy (following 2nd relapse)	Panobinostat		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		20	Other	ON DAYS 1,3,5,15,17, AND 19 AS DIRECTED PER STUDY PROTOCOL.					1084	1224	1
MMRF_1049	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		40	QD (D1, D4, D8, D11, D28, D35, D38)	QD (D1, D4, D8, D11, D28, D35, D38)					218	1079	1
MMRF_1049	Second Line Therapy (after first relapse)	Lenalidomide		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		15	Other	ONCE						1079	1
MMRF_1049	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		15	Other	ONCE						189	1
MMRF_1049	Second Line Therapy (after first relapse)	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					218	711	1
MMRF_1049	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		300	Other	ONCE					22	183	1
MMRF_1049	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	64	1
MMRF_1049	Twelfth Line of Therapy (following 11th relapse)	Daratumumab		DEATH	mg	IV	Log Forms	Maintenance	Maintenance		920	QWK	QWK					3030	3037	1
MMRF_1049	Twelfth Line of Therapy (following 11th relapse)	METRO28					Log Forms	Maintenance	Maintenance	Checked								3019		1
MMRF_1049	Eleventh Line of Therapy (following 10th relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		12	QWK	QWK					2991	3021	1
MMRF_1049	Eleventh Line of Therapy (following 10th relapse)	Bortezomib		Disease progression/Relapse	mg	IV SubQ	Log Forms	Maintenance	Maintenance		1.55	QWK	QWK					2991	3019	1
MMRF_1049	Eleventh Line of Therapy (following 10th relapse)	VENETOCLAX		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		100	QID	QID					2978	3012	1
MMRF_1049	Eleventh Line of Therapy (following 10th relapse)	Daratumumab		Disease progression/Relapse	mg	IV	Log Forms	Maintenance	Maintenance		900	QWK	QWK					2991	3012	1
MMRF_1049	Tenth Line of Therapy (following 9th relapse)	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Maintenance	Maintenance		8	QWK	QWK					2873	2939	1
MMRF_1049	Tenth Line of Therapy (following 9th relapse)	SELINEXOR		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		80	QWK	QWK					2870	2922	1
MMRF_1049	Tenth Line of Therapy (following 9th relapse)	Carfilzomib		Disease progression/Relapse	mg	IV	Log Forms	Maintenance	Maintenance		89.6	QWK	QWK					2873	2887	1
MMRF_1049	Ninth Line of Therapy (following 8th relapse)	CC-220		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		0.2	QID	QID					2731	2807	1
MMRF_1049	Eighth Line of Therapy (following 7th relapse)	GSK2857916		Disease progression/Relapse	mg	IV	Log Forms	Maintenance	Maintenance		219	QWK	QWK					2452	2493	1
MMRF_1049	Seventh Line of Therapy (following 6th relapse)	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Maintenance	Maintenance		20	QWK	QWK					2395	2416	1
MMRF_1049	Seventh Line of Therapy (following 6th relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		3	QD (D1-21)	QD (D1-21)					2415	2431	1
MMRF_1049	Seventh Line of Therapy (following 6th relapse)	Elotuzumab		Disease progression/Relapse	mg	IV	Log Forms	Maintenance	Maintenance		655	QWK	QWK					2395	2416	1
MMRF_1049	Sixth Line Therapy (following 5th relapse)	CISPLATIN		Completed regimen	mg	IV	Log Forms	Induction	Induction		13	QD (D1-4)	QD (D1-4)					2144	2177	1
MMRF_1049	Sixth Line Therapy (following 5th relapse)	ETOPOSIDE		Completed regimen	mg	IV	Log Forms	Induction	Induction		52	QD (D1-4)	QD (D1-4)					2144	2177	1
MMRF_1049	Sixth Line Therapy (following 5th relapse)	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Induction	Induction		510	QD (D1-4)	QD (D1-4)					2144	2177	1
MMRF_1049	Sixth Line Therapy (following 5th relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	QD (D1-4)	QD (D1-4)					2144	2207	1
MMRF_1049	Fifth Line Therapy (following 4th relapse)	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Maintenance	Maintenance		20	QWK	QWK					1392	2085	1
MMRF_1049	Fifth Line Therapy (following 4th relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		2	QID	QID					1414	2078	1
MMRF_1049	Fifth Line Therapy (following 4th relapse)	Daratumumab		Disease progression/Relapse	mg	IV	Log Forms	Maintenance	Maintenance		1016	QWK	QWK					1392	2113	1
MMRF_1049	Fourth Line Therapy (following 3rd relapse)	ATEZOLIZUMAB		Disease progression/Relapse	mg	IV	Log Forms	Maintenance	Maintenance		1200	QWK	QWK					1291	2818	1
MMRF_1049	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		4	Q week	Q week					1084	1224	1
MMRF_1049	Third Line Therapy (following 2nd relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		25	QID	QID					1084	1224	1
MMRF_1049	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	22	1
MMRF_1064	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	692	1
MMRF_1064	Second Line Therapy (after first relapse)	Daratumumab		Completed regimen	mg/kg	IV	Log Forms	Unknown	Unknown		16	Other	EVERY OTHER WEEK					2740	3016	1
MMRF_1064	Second Line Therapy (after first relapse)	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Unknown	Unknown		70	QWK	QWK					2740	3016	1
MMRF_1064	Second Line Therapy (after first relapse)	Pomalidomide		Completed regimen	mg	PO	Log Forms	Unknown	Unknown		2	QD (D1-4)	QD (D1-4)					2740	3016	1
MMRF_1064	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	IV	Log Forms	Unknown	Unknown		40	QWK	QWK					2740	3025	1
MMRF_1064	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	92	1
MMRF_1064	First line of therapy	Dexamethasone		REORDER	mg	PO	Log Forms				20	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1	373	1
MMRF_1064	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		20	QWK	QWK					374	762	1
MMRF_1064	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		40	Other	DAY 1, 8, 15					1511	1543	1
MMRF_1064	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		25	Q day	Q day					1511	1543	1
MMRF_1064	Second Line Therapy (after first relapse)	Ixazomib		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		4	Other	DAYS 1, 8, 15					1511	1543	1
MMRF_1064	Third Line Therapy (following 2nd relapse)	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		20	Other	DAYS 1 AND 2					1543	1602	1
MMRF_1064	Third Line Therapy (following 2nd relapse)	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		36	Other	DAYS 8, 9, 15, 16					1543	1592	1
MMRF_1064	Third Line Therapy (following 2nd relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1543	1568	1
MMRF_1064	Third Line Therapy (following 2nd relapse)	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					1616	1616	1
MMRF_1064	Third Line Therapy (following 2nd relapse)	Elotuzumab		Completed regimen	mg/kg	IV	Log Forms	Maintenance	Maintenance		10	Q week	Q week					1769	2806	1
MMRF_1064	Third Line Therapy (following 2nd relapse)	Lenalidomide		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					1769	2806	1
MMRF_1064	Third Line Therapy (following 2nd relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		40	Q week	Q week					1769	2740	1
MMRF_1071	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	7	1
MMRF_1071	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	65	1
MMRF_1071	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	65	1
MMRF_1071	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms				300	Other	DAYS 1, 8					102	137	1
MMRF_1071	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	Other	DAYS 1, 8, 15					102	137	1
MMRF_1071	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.3	Other	DAYS 1, 8, 15					102	137	1
MMRF_1071	First line of therapy	MAGE- A3 VACCINE		Completed regimen	MCG	IM	Log Forms	Induction	Induction		300	Other	GIVEN Q3WKS THEN 3 MONTH INTERVALS.					158	197	1
MMRF_1071	Second Line Therapy (after first relapse)	Pomalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		4	QD (D1-21)	QD (D1-21)					973	1757	1
MMRF_1071	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		40	QWK	QWK					973	1904	1
MMRF_1071	Second Line Therapy (after first relapse)	Pomalidomide		Completed regimen	mg	PO	Log Forms	Other	SALVAGE		2	QD (D1-21)	QD (D1-21)					1757	2219	1
MMRF_1084	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.3	QWK	QWK					1	93	1
MMRF_1084	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				15	QD (D1-21)	QD (D1-21)					1	93	1
MMRF_1084	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms				20	QWK	QWK					1	93	1
MMRF_1084	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				12	QWK	QWK					200	313	1
MMRF_1084	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms				15	QD (D1-21)	QD (D1-21)					200	313	1
MMRF_1084	Second Line Therapy (after first relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Consolidation	Consolidation		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					631	996	1
MMRF_1084	Second Line Therapy (after first relapse)	Cyclophosphamide		Disease progression/Relapse	mg/m^2	IV	Log Forms	Consolidation	Consolidation		300	Other	D1,D8					631	996	1
MMRF_1084	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		10	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					631	984	1
MMRF_1084	Third Line Therapy (following 2nd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		2	Other	QD  (D1-28)					996	1142	1
MMRF_1084	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		10	QWK	QWK					996	1142	1
MMRF_1084	Third Line Therapy (following 2nd relapse)	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms	Consolidation	Consolidation		1.3	QWK	QWK					1102	1142	1
MMRF_1084	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		40	Q day	Q day					1166	1338	1
MMRF_1084	Fourth Line Therapy (following 3rd relapse)	Doxorubicin		Disease progression/Relapse	mg/m^2	IV	Log Forms	Consolidation	Consolidation		20	QD (D1-21)	QD (D1-21)					1166	1338	1
MMRF_1084	Fourth Line Therapy (following 3rd relapse)	Cyclophosphamide		Disease progression/Relapse	mg/m^2	IV	Log Forms	Consolidation	Consolidation		400	QD (D1-21)	QD (D1-21)					1166	1338	1
MMRF_1084	Fourth Line Therapy (following 3rd relapse)	CISPLATIN		Disease progression/Relapse	mg/m^2	IV	Log Forms	Consolidation	Consolidation		15	QD (D1-21)	QD (D1-21)					1166	1338	1
MMRF_1084	Fourth Line Therapy (following 3rd relapse)	ETOPOSIDE		Disease progression/Relapse	mg/m^2	IV	Log Forms	Consolidation	Consolidation		40	QD (D1-21)	QD (D1-21)					1166	1338	1
MMRF_1084	Fifth Line Therapy (following 4th relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Consolidation	Consolidation		16	Q week	Q week					1363	1648	1
MMRF_1084	Fifth Line Therapy (following 4th relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		20	Other	TWICE WEEKLY					1363	1648	1
MMRF_1100	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms				1.3	Other	D1,4,11,18					1	128	1
MMRF_1100	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	Other	D1-28					1	128	1
MMRF_1100	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				20	Other	D1,4,11,18					1	128	1
MMRF_1100	First line of therapy	Bortezomib		Completed regimen	mg	IV	Log Forms				2.5	Other	DAY 1 AND DAY 4					128	155	1
MMRF_1100	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				20	Q week	Q week					128	155	1
MMRF_1100	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms				580	Other	DAY 1 AND DAY 4					128	155	1
MMRF_1100	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		1.3	Other	D1,4,11,18					190	606	1
MMRF_1100	First line of therapy	Lenalidomide		Lack of response	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					190	974	1
MMRF_1100	First line of therapy	Dexamethasone		Lack of response	mg	PO	Log Forms	Consolidation	Consolidation		20	Other	D1,4,11,18					190	974	1
MMRF_1100	Second Line Therapy (after first relapse)	Bortezomib		Lack of response	mg/m^2	IV SubQ	Log Forms	Consolidation	Consolidation		1.3	Q week	Q week					859	947	1
MMRF_1100	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		160	Other	ONCE					975	975	1
MMRF_1100	Third Line Therapy (following 2nd relapse)	Daratumumab		Completed regimen	mg/kg	IV	Log Forms	Consolidation	Consolidation		16	Other	ONCE WKLY					1187	1927	1
MMRF_1100	Third Line Therapy (following 2nd relapse)	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Consolidation	Consolidation		4	QD (D1-21)	QD (D1-21)					1384	1800	1
MMRF_1101	First line of therapy	Cyclophosphamide		Investigator decision for other reasons	mg/m^2	PO	Log Forms				250	BID	BID					1	29	1
MMRF_1101	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms				20	Other	DAYS 1, 8, 15					1	422	1
MMRF_1101	First line of therapy	Lenalidomide		PET CT NEGATIVE	mg	PO	Log Forms				15	QD (D1-21)	QD (D1-21)					50	534	1
MMRF_1101	First line of therapy	Lenalidomide		CR	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					534	562	1
MMRF_1101	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms				1.3	Other	DAYS 1, 8, 15					1	99	1
MMRF_1111	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms				1.3	Other	DAYS 1, 5, 8, 12					1	26	1
MMRF_1111	First line of therapy	Cyclophosphamide		Investigator decision for other reasons	mg/m^2	IV	Log Forms				300	Other	DAYS 1, 5, 8, 12					1	26	1
MMRF_1111	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms				40	Other	DAYS 1, 5, 8, 12					1	26	1
MMRF_1111	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.3	Other	DAYS 1, 4, 8, 15					26	285	1
MMRF_1111	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	Other	DAYS 1, 4, 8, 15					26	553	1
MMRF_1111	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					26	340	1
MMRF_1111	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				15	QD (D1-21)	QD (D1-21)					340	2223	1
MMRF_1111	First line of therapy	Cyclophosphamide		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Consolidation	Consolidation		300	Other	DAYS 1, 5, 8, 12					109	124	1
MMRF_1111	Second Line Therapy (after first relapse)	Pomalidomide			mg	PO	Log Forms	Induction	Induction	Checked	2	QD (D1-21)	QD (D1-21)					2349		1
MMRF_1111	Second Line Therapy (after first relapse)	Daratumumab			mg	IV SubQ	Log Forms	Induction	Induction	Checked	1800	Other	Q28 DAYS					2349		1
MMRF_1127	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV	Log Forms				1.3	Other	DAYS 1, 8, 15					1	82	1
MMRF_1127	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	82	1
MMRF_1127	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms				40	Other	DAYS 1, 8, 15					2	82	1
MMRF_1127	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					264	264	1
MMRF_1127	Second Line Therapy (after first relapse)	Bortezomib			mg/m^2	IV SubQ	Log Forms	Unknown	Unknown	Checked	1.3	Q week	Q week					2018		1
MMRF_1127	Second Line Therapy (after first relapse)	Dexamethasone			mg	IV	Log Forms	Unknown	Unknown	Checked	12	Q week	Q week					2018		1
MMRF_1127	Second Line Therapy (after first relapse)	Lenalidomide			mg	PO	Log Forms	Unknown	Unknown	Checked	25	QD (D1-21)	QD (D1-21)					2046		1
MMRF_1151	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	37	1
MMRF_1151	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	37	1
MMRF_1151	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms				300	Other	DAYS 1, 8					1	37	1
MMRF_1151	First line of therapy	Bortezomib		DEATH	MG/MSQ	IV SubQ	Log Forms				1.3	QWK	QWK					70	250	1
MMRF_1151	First line of therapy	Dexamethasone		DEATH	mg	IV	Log Forms				40	QWK	QWK					71	250	1
MMRF_1156	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	84	1
MMRF_1156	First line of therapy	Bortezomib		INDUCTION	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	204	1
MMRF_1156	First line of therapy	Dexamethasone		INDUCTION	mg	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	204	1
MMRF_1156	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					315	1358	1
MMRF_1156	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		40	QWK	QWK					315	1368	1
MMRF_1156	First line of therapy	Cyclophosphamide		INDUCTION	mg	PO	Log Forms	Induction	Induction		300	Other	DAYS 1 , 8,  15					87	204	1
MMRF_1156	First line of therapy	ETOPOSIDE		INDUCTION	mg/m^2	IV	Log Forms	Induction	Induction		30	QD (D1-4)	QD (D1-4)					143	204	1
MMRF_1156	First line of therapy	CISPLATIN		INDUCTION	mg/m^2	IV	Log Forms	Induction	Induction		15	QD (D1-4)	QD (D1-4)					143	204	1
MMRF_1156	First line of therapy	Melphalan		Lack of response	mg/m^2	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					211	211	1
MMRF_1156	Third Line Therapy (following 2nd relapse)	ATEZOLIZUMAB		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		1200	QWK	QWK					1746	1893	1
MMRF_1156	Third Line Therapy (following 2nd relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1746	1991	1
MMRF_1156	Fourth Line Therapy (following 3rd relapse)	Pomalidomide			mg	PO	Log Forms	Unknown	Unknown	Checked	3	QD (D1-21)	QD (D1-21)					1982		1
MMRF_1156	Fourth Line Therapy (following 3rd relapse)	Daratumumab			mg/kg	IV	Log Forms	Unknown	Unknown	Checked	16	Other	EVERY 4 WEEKS					1924		1
MMRF_1157	Twelfth Line of Therapy (following 11th relapse)	VENETOCLAX			mg	PO	Log Forms	Maintenance	Maintenance	Checked	100	QID	QID					2739		1
MMRF_1157	Twelfth Line of Therapy (following 11th relapse)	Dexamethasone			mg	IV	Log Forms	Maintenance	Maintenance	Checked	20	QWK	QWK					2746		1
MMRF_1157	Twelfth Line of Therapy (following 11th relapse)	Bortezomib			mg	IV SubQ	Log Forms	Maintenance	Maintenance	Checked	2	QWK	QWK					2746		1
MMRF_1157	Twelfth Line of Therapy (following 11th relapse)	Daratumumab			mg	IV	Log Forms	Maintenance	Maintenance	Checked	900	QWK	QWK					2746		1
MMRF_1157	Eleventh Line of Therapy (following 10th relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		4	Other	ON DAYS 1, 8, 15 OF A 28 DAY CYCLE					2634	2739	1
MMRF_1157	Eleventh Line of Therapy (following 10th relapse)	ONC 201		Disease progression/Relapse			Log Forms	Maintenance	Maintenance									2634	2746	1
MMRF_1157	Eleventh Line of Therapy (following 10th relapse)	Ixazomib		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		3	Other	ONCE A WEEK ON DAYS 1, 8 AND 15 OF A 28-DAY CYCLE					2634	2739	1
MMRF_1157	Tenth Line of Therapy (following 9th relapse)	Daratumumab		Completed regimen	mg/kg	IV	Log Forms	Induction	Induction		16	QWK	QWK					2508	2634	1
MMRF_1157	Tenth Line of Therapy (following 9th relapse)	Lenalidomide		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		10	QID	QID					2511	2619	1
MMRF_1157	Tenth Line of Therapy (following 9th relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		20	QWK	QWK					2508	2634	1
MMRF_1157	Ninth Line of Therapy (following 8th relapse)	ONC 201		Disease progression/Relapse			Log Forms	Maintenance	Maintenance									2445	2466	1
MMRF_1157	Eighth Line of Therapy (following 7th relapse)	GSK2857916		Disease progression/Relapse	mg	IV	Log Forms	Maintenance	Maintenance		107.4	QWK	QWK					2271	2397	1
MMRF_1157	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	240	1
MMRF_1157	First line of therapy	Cyclophosphamide		FURTHER THERAPY	mg/m^2	IV	Log Forms				300	Other	DAYS 1, 8					1	43	1
MMRF_1157	First line of therapy	Bortezomib		SCH	mg	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	156	1
MMRF_1157	First line of therapy	Lenalidomide		INCREASED DOSE	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					43	71	1
MMRF_1157	First line of therapy	Lenalidomide		INDUCTION	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					71	222	1
MMRF_1157	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					326	442	1
MMRF_1157	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					415	556	1
MMRF_1157	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					415	527	1
MMRF_1157	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		140	Other	ONCE					239	239	1
MMRF_1157	Second Line Therapy (after first relapse)	Carfilzomib		Disease progression/Relapse	mg	IV	Log Forms	Consolidation	Consolidation		33	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					591	682	1
MMRF_1157	Second Line Therapy (after first relapse)	IBRUTINIB		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		140	Q day	Q day					598	682	1
MMRF_1157	Second Line Therapy (after first relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Consolidation	Consolidation		56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					682	921	1
MMRF_1157	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		8	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					682	921	1
MMRF_1157	Third Line Therapy (following 2nd relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Consolidation	Consolidation		16	Other	D1, 18,15, 22					960	1578	1
MMRF_1157	Third Line Therapy (following 2nd relapse)	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Consolidation	Consolidation		4	QD (D1-21)	QD (D1-21)					960	969	1
MMRF_1157	Third Line Therapy (following 2nd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		3	QD (D1-21)	QD (D1-21)					990	1578	1
MMRF_1157	Fourth Line Therapy (following 3rd relapse)	SELINEXOR		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		80	Other	DAYS 1, 3, 8, 10, 15, 17, 22 AND 24					1626	1836	1
MMRF_1157	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		20	Other	D1,3,8,10,15,17,22,24					1626	1836	1
MMRF_1157	Fifth Line Therapy (following 4th relapse)	TAS4464		Disease progression/Relapse	mg/m^2	IV	Log Forms	Unknown	Unknown		40	Other	TWICE WEEKLY					1870	1927	1
MMRF_1157	Sixth Line Therapy (following 5th relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Unknown	Unknown		16	Other	ONCE WEEKLY					1944	2097	1
MMRF_1157	Sixth Line Therapy (following 5th relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Unknown	Unknown		27	Other	ONCE WEEKLY					1944	2097	1
MMRF_1157	Sixth Line Therapy (following 5th relapse)	Dexamethasone			mg	IV	Log Forms	Unknown	Unknown	Checked	20	Other	ONCE WEEKLY					1944		1
MMRF_1157	Seventh Line of Therapy (following 6th relapse)	JNJ-64407564			UG/KG	IV	Log Forms	Unknown	Unknown	Checked	1.5	Other	DAY 1 AND DAY 15 ON 28 DAY CYCLE					2130		1
MMRF_1179	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.3	Q week	Q week					1	269	1
MMRF_1179	First line of therapy	Dexamethasone		Lack of response	mg	PO	Log Forms				20	Q week	Q week					1	20	1
MMRF_1179	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms				10	QD (D1-21)	QD (D1-21)					1	715	1
MMRF_1179	First line of therapy	Cyclophosphamide		Investigator decision for other reasons	mg	PO	Log Forms	Consolidation	Consolidation		400	Other	QWK (DAY 1, 8, 15)					687	715	1
MMRF_1179	Second Line Therapy (after first relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Consolidation	Consolidation		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					715	1024	1
MMRF_1179	Second Line Therapy (after first relapse)	Thalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		50	QD (D1-21)	QD (D1-21)					843	1024	1
MMRF_1179	Third Line Therapy (following 2nd relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Consolidation	Consolidation		16	Q week	Q week					1087	1709	1
MMRF_1179	Fourth Line Therapy (following 3rd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		2	QD (D1-21)	QD (D1-21)					1356	1693	1
MMRF_1179	Fifth Line Therapy (following 4th relapse)	VENETOCLAX		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		100	Q day	Q day					1732	1773	1
MMRF_1179	Fifth Line Therapy (following 4th relapse)	Ixazomib		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		3	Q week	Q week					1767	1773	1
MMRF_1212	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	233	1
MMRF_1212	First line of therapy	Cyclophosphamide		Investigator decision for other reasons	mg/m^2	IV	Log Forms				300	Other	D1,D8					1	148	1
MMRF_1212	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms				20	Other	QD (1-28)					1	176	1
MMRF_1212	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms				15	QD (D1-21)	QD (D1-21)					120	127	1
MMRF_1212	First line of therapy	Thalidomide			mg	PO	Log Forms			Checked	50	QD (D1-21)	QD (D1-21)					176		1
MMRF_1212	First line of therapy	Prednisone			mg	PO	Log Forms	Consolidation	Consolidation	Checked	50	Other	3 X WEEK					176		1
MMRF_1212	First line of therapy	Cyclophosphamide		LOST TO FOLLOW UP	mg	PO	Log Forms	Consolidation	Consolidation		50	BID	BID					148	947	1
MMRF_1212	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Consolidation	Consolidation		1.3	Other	EVERY OTHER WEEK					233	657	1
MMRF_1223	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					7	334	1
MMRF_1223	First line of therapy	Cyclophosphamide		FURTHER THERAPY	mg/m^2	IV SubQ	Log Forms				300	Other	DAYS 1, 8					7	95	1
MMRF_1223	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms				4	QD (D1-4)	QD (D1-4)					1	508	1
MMRF_1223	First line of therapy	Thalidomide		FURTHER THERAPY	mg	PO	Log Forms				200	Q day	Q day					7	95	1
MMRF_1223	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		15	QD (D1-21)	QD (D1-21)					95	606	1
MMRF_1223	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Other	ONE TIME ONLY					606	606	1
MMRF_1223	Second Line Therapy (after first relapse)	Carfilzomib		Lack of response	mg/m^2	IV	Log Forms	Consolidation	Consolidation		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					742	839	1
MMRF_1223	Third Line Therapy (following 2nd relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Consolidation	Consolidation		16	QWK	QWK					942	1453	1
MMRF_1223	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Consolidation	Consolidation		20	Other	DAYS 1, 2, 4, 5, 8, 9, 15					942	1453	1
MMRF_1223	Fourth Line Therapy (following 3rd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		4	QD (D1-21)	QD (D1-21)					1476	2010	1
MMRF_1223	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		8	Q week	Q week					1481	2020	1
MMRF_1223	Fourth Line Therapy (following 3rd relapse)	Daratumumab		Disease progression/Relapse	MG/KG	IV	Log Forms	Consolidation	Consolidation		16	Other	TWICE MONTHLY					1509	2020	1
MMRF_1223	Fourth Line Therapy (following 3rd relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Consolidation	Consolidation		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1593	2020	1
MMRF_1223	Fifth Line Therapy (following 4th relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Other	SALVAGE		20	Q week	Q week					2042	2042	1
MMRF_1223	Fifth Line Therapy (following 4th relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE	Checked	20	Other	DAYS 1,2,8,9,15,16,22,23					2042		1
MMRF_1223	Fifth Line Therapy (following 4th relapse)	SELINEXOR		TREATMENT FAILURE WITH FORMULARY ALTERNATIVE	mg	PO	Log Forms	Other	SALVAGE		100	Q week	Q week					2042	2204	1
MMRF_1223	Ninth Line of Therapy (following 8th relapse)	SELINEXOR		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		60	QWK	QWK					2597	2941	1
MMRF_1223	Eighth Line of Therapy (following 7th relapse)	Melphalan		Disease progression/Relapse	mg/m^2	IV	Log Forms	Induction	Induction		100	Other	ONCE					2498	2498	1
MMRF_1223	Eighth Line of Therapy (following 7th relapse)	BCNU		Disease progression/Relapse	mg/m^2	IV	Log Forms	Induction	Induction		100	Other	ONCE					2497	2497	1
MMRF_1223	Seventh Line of Therapy (following 6th relapse)	IBRANCE		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		75	QID	QID					2364	2464	1
MMRF_1223	Seventh Line of Therapy (following 6th relapse)	Panobinostat		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	Other	EVERY MON, WED, & FRI					2364	2464	1
MMRF_1223	Seventh Line of Therapy (following 6th relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		2	Other	5 TIMES A WEEK					2365	2465	1
MMRF_1223	Seventh Line of Therapy (following 6th relapse)	Elotuzumab		Disease progression/Relapse	mg	IV	Log Forms	Maintenance	Maintenance		735	QWK	QWK					2380	2471	1
MMRF_1223	Sixth Line Therapy (following 5th relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		4	QWK	QWK					2303	2359	1
MMRF_1223	Sixth Line Therapy (following 5th relapse)	VENETOCLAX		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		100	QID	QID					2297	2316	1
MMRF_1223	Sixth Line Therapy (following 5th relapse)	Carfilzomib		Disease progression/Relapse	mg	IV	Log Forms	Maintenance	Maintenance		60	QWK	QWK					2303	2373	1
MMRF_1224	Seventh Line of Therapy (following 6th relapse)	METRO28		Adverse Event or co-morbidity	mg	IV	Log Forms	Unknown	Unknown		500	Other	EVERY 8 HOURS					2206	2331	1
MMRF_1224	Sixth Line Therapy (following 5th relapse)	Bendamustine		Disease progression/Relapse	mg	IV	Log Forms	Unknown	Unknown		135	QWK	QWK					2234	2237	1
MMRF_1224	First line of therapy	Cyclophosphamide		SCH	mg/m^2	PO	Log Forms				300	Other	DAYS 1, 8, 15					1	203	1
MMRF_1224	First line of therapy	Dexamethasone		SCH	mg	PO	Log Forms				20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	203	1
MMRF_1224	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		15	QD (D1-21)	QD (D1-21)					226	780	1
MMRF_1224	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		20	Q week	Q week					226	666	1
MMRF_1224	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Other	ONCE					1056	1057	1
MMRF_1224	First line of therapy	Elotuzumab		Adverse Event or co-morbidity	mg/kg	IV	Log Forms	Consolidation	Consolidation		10	Q week	Q week					1178	1492	1
MMRF_1224	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					1178	1492	1
MMRF_1224	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		20	Q week	Q week					1178	1492	1
MMRF_1224	Third Line Therapy (following 2nd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		4	QD (D1-21)	QD (D1-21)					1526	1890	1
MMRF_1224	Third Line Therapy (following 2nd relapse)	Cyclophosphamide		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		50	BID	BID					1525	1890	1
MMRF_1224	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		40	Q week	Q week					1525	1890	1
MMRF_1224	Fourth Line Therapy (following 3rd relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Other	SALVAGE		8	Q week	Q week					1967	2002	1
MMRF_1224	Fourth Line Therapy (following 3rd relapse)	Bortezomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Other	SALVAGE		1.3	Q week	Q week					1967	2002	1
MMRF_1224	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		20	Q week	Q week					1967	2002	1
MMRF_1224	Fifth Line Therapy (following 4th relapse)	Doxorubicin		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Other	SALVAGE		0.5	Other	DAY 1-28					2002	2020	1
MMRF_1224	Fifth Line Therapy (following 4th relapse)	Vincristine		Adverse Event or co-morbidity	mg	IV	Log Forms	Other	SALVAGE		0.07	Other	DAY 1-28					2002	2020	1
MMRF_1224	Fifth Line Therapy (following 4th relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	IV	Log Forms	Other	SALVAGE		12	Other	Q24H					2002	2020	1
MMRF_1224	Fifth Line Therapy (following 4th relapse)	CISPLATIN		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Other	SALVAGE		1	Other	DAY 1-28					2002	2020	1
MMRF_1224	Fifth Line Therapy (following 4th relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Other	SALVAGE		16	Q week	Q week					2002	2193	1
MMRF_1224	Fifth Line Therapy (following 4th relapse)	Bortezomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Unknown	Unknown		1.3	Q week	Q week					2002	2172	1
MMRF_1224	Fifth Line Therapy (following 4th relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		12	Q day	Q day					2026	2027	1
MMRF_1224	First line of therapy	Bortezomib		SCH	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)					1	203	1
MMRF_1231	First line of therapy	Cyclophosphamide		DEATH	mg/m^2	IV	Log Forms				300	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					8	85	1
MMRF_1231	First line of therapy	Bortezomib		DEATH	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	85	1
MMRF_1231	First line of therapy	Dexamethasone		DEATH	mg	PO	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	85	1
MMRF_1232	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	86	1
MMRF_1232	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	86	1
MMRF_1232	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		300	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					33	101	1
MMRF_1232	First line of therapy	RECMAGE VACCINE		Completed regimen	MCG	IM	Log Forms	Induction	Induction		300	Other	21, 10, 31,52,73, 94, 180, 194, 270, 284, 360, 374 DAYS POST TRANSPLANT					109	417	1
MMRF_1232	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					522	560	1
MMRF_1232	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Unknown	Unknown		40	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					560	707	1
MMRF_1232	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					560	655	1
MMRF_1232	Second Line Therapy (after first relapse)	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					655	707	1
MMRF_1232	Fourth Line Therapy (following 3rd relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Consolidation	Consolidation		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					852	951	1
MMRF_1232	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					852	951	1
MMRF_1232	Fourth Line Therapy (following 3rd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		3	QD (D1-21)	QD (D1-21)					847	951	1
MMRF_1232	Third Line Therapy (following 2nd relapse)	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Consolidation	Consolidation		1.3	QD (D1-3)	QD (D1-3)					783	847	1
MMRF_1232	Third Line Therapy (following 2nd relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		40	Q day	Q day					783	847	1
MMRF_1232	Third Line Therapy (following 2nd relapse)	CISPLATIN		Completed regimen	mg	IV	Log Forms	Consolidation	Consolidation		17	QD (D1-4)	QD (D1-4)					783	847	1
MMRF_1232	Third Line Therapy (following 2nd relapse)	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Consolidation	Consolidation		336	QD (D1-4)	QD (D1-4)					783	847	1
MMRF_1232	Third Line Therapy (following 2nd relapse)	ETOPOSIDE		Completed regimen	mg	IV	Log Forms	Consolidation	Consolidation		34	QD (D1-4)	QD (D1-4)					783	847	1
MMRF_1244	First line of therapy	Bortezomib		UNKNOWN	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	158	1
MMRF_1244	First line of therapy	Dexamethasone		UNKNOWN	mg	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	158	1
MMRF_1244	First line of therapy	Cyclophosphamide		UNKNOWN	mg/m^2	IV SubQ	Log Forms				300	Other	DAYS 1, 8					1	158	1
MMRF_1252	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	45	1
MMRF_1252	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	45	1
MMRF_1252	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms				300	Other	DAYS 1, 8					1	45	1
MMRF_1252	First line of therapy	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					45	333	1
MMRF_1252	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					45	333	1
MMRF_1252	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					45	333	1
MMRF_1252	Second Line Therapy (after first relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		4	QD (D1-21)	QD (D1-21)					338	366	1
MMRF_1252	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		20	QWK	QWK					338	366	1
MMRF_1266	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	1632	1
MMRF_1266	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.3	Other	QD (D1, D4, D11, D18)					1	1314	1
MMRF_1266	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				20	Other	QD (D1, D4, D11, D18)					1	408	1
MMRF_1266	First line of therapy	Ixazomib		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		4	Q week	Q week					1314	1437	1
MMRF_1266	Second Line Therapy (after first relapse)	Pomalidomide			mg	PO	Log Forms	Induction	Induction	Checked	2	QD (D1-21)	QD (D1-21)					2269		1
MMRF_1266		Daratumumab			mg	IV SubQ	Log Forms	Induction	Induction	Checked	1800	Other	Q28 DAYS					2269		1
MMRF_1267	First line of therapy	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	183	1
MMRF_1267	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					2	183	1
MMRF_1267	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	183	1
MMRF_1267	Second Line Therapy (after first relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Consolidation	Consolidation		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					191	224	1
MMRF_1267	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		4	QD (D1-21)	QD (D1-21)					191	224	1
MMRF_1267	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					191	224	1
MMRF_1267	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg	IV	Log Forms	Consolidation	Consolidation		540	Other	ONCE					234	234	1
MMRF_1267	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg	IV	Log Forms	Consolidation	Consolidation		272	Other	ONCE					368	368	1
MMRF_1267	Second Line Therapy (after first relapse)	Bortezomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Maintenance	Maintenance		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					472	665	1
MMRF_1267	Second Line Therapy (after first relapse)	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		15	QD (D1-21)	QD (D1-21)					472	563	1
MMRF_1267	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					472	1066	1
MMRF_1267	Third Line Therapy (following 2nd relapse)	Bendamustine		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		90	Other	ONCE					901	901	1
MMRF_1267	Third Line Therapy (following 2nd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		2	QD (D1-21)	QD (D1-21)					901	924	1
MMRF_1267	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		40	Q day	Q day					901	945	1
MMRF_1267	Fourth Line Therapy (following 3rd relapse)	BCNU		Disease progression/Relapse	mg/m^2	IV	Log Forms	Consolidation	Consolidation		300	Other	ONCE					945	963	1
MMRF_1267	Fourth Line Therapy (following 3rd relapse)	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		100	Other	ONCE					960	960	1
MMRF_1267	Fifth Line Therapy (following 4th relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		2	QD (D1-21)	QD (D1-21)					985	1016	1
MMRF_1267	Fifth Line Therapy (following 4th relapse)	NIVOLUMAB		Disease progression/Relapse	mg/kg	IV	Log Forms	Consolidation	Consolidation		6	Q week	Q week					1010	1016	1
MMRF_1267	Sixth Line Therapy (following 5th relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Consolidation	Consolidation		16	Other	D1, D8, D15, D22					1036	1066	1
MMRF_1267	Seventh Line of Therapy (following 6th relapse)	Bortezomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Consolidation	Consolidation		1	Other	D1,4,7,10,13,16,19,22,25,28					1066	1094	1
MMRF_1267	Seventh Line of Therapy (following 6th relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		12	Other	D1-4, 7-10, 13-16, 19-22, 25-28					1066	1094	1
MMRF_1267	Seventh Line of Therapy (following 6th relapse)	Thalidomide		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		100	Q day	Q day					1066	1094	1
MMRF_1267	Seventh Line of Therapy (following 6th relapse)	Doxorubicin		Disease progression/Relapse	mg/m^2	IV	Log Forms	Consolidation	Consolidation		1	Q day	Q day					1066	1094	1
MMRF_1267	Seventh Line of Therapy (following 6th relapse)	CISPLATIN		Disease progression/Relapse	mg/m^2	IV	Log Forms	Consolidation	Consolidation		1	Q day	Q day					1066	1094	1
MMRF_1267	Seventh Line of Therapy (following 6th relapse)	Bortezomib		Disease progression/Relapse	mg	IV	Log Forms	Consolidation	Consolidation		0.07	Q day	Q day					1066	1094	1
MMRF_1275	First line of therapy	Bortezomib		Lack of response	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	11	1
MMRF_1275	First line of therapy	Dexamethasone		Lack of response	mg	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	11	1
MMRF_1275	First line of therapy	Cyclophosphamide		Lack of response	mg/m^2	IV	Log Forms				300	Other	DAYS 1, 8					1	8	1
MMRF_1275	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms				20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					19	391	1
MMRF_1275	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				8	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					19	380	1
MMRF_1275	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					19	380	1
MMRF_1275	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Other	ONCE					401	401	1
MMRF_1275	Second Line Therapy (after first relapse)	Bortezomib		Disease progression/Relapse	mg	IV SubQ	Log Forms	Consolidation	Consolidation		3	Q week	Q week					557	620	1
MMRF_1275	Second Line Therapy (after first relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		4	QD (D1-21)	QD (D1-21)					557	663	1
MMRF_1275	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		20	QWK	QWK					557	610	1
MMRF_1275	Second Line Therapy (after first relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Consolidation	Consolidation		56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					638	663	1
MMRF_1275	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		20	QWK	QWK					610	663	1
MMRF_1275	Third Line Therapy (following 2nd relapse)	Bortezomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Consolidation	Consolidation		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					663	695	1
MMRF_1275	Fourth Line Therapy (following 3rd relapse)	CISPLATIN		Completed regimen	mg	IV	Log Forms	Consolidation	Consolidation		67	QD (D1-4)	QD (D1-4)					663	666	1
MMRF_1275	Third Line Therapy (following 2nd relapse)	ETOPOSIDE		Completed regimen	mg	IV	Log Forms	Consolidation	Consolidation		270	QD (D1-4)	QD (D1-4)					663	667	1
MMRF_1275	Third Line Therapy (following 2nd relapse)	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Consolidation	Consolidation		2688	QD (D1-4)	QD (D1-4)					663	667	1
MMRF_1275	Third Line Therapy (following 2nd relapse)	Doxorubicin		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		30	Other	ONCE					663	663	1
MMRF_1275	Third Line Therapy (following 2nd relapse)	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms	Consolidation	Consolidation		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					695	733	1
MMRF_1275	Third Line Therapy (following 2nd relapse)	Bendamustine		Disease progression/Relapse	mg/m^2	IV	Log Forms	Induction	Induction		90	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					695	733	1
MMRF_1275	Third Line Therapy (following 2nd relapse)	Melphalan		Disease progression/Relapse	mg/m^2	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					792	848	1
MMRF_1280	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	351	1
MMRF_1280	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				4	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	351	1
MMRF_1280	First line of therapy	Cyclophosphamide		Investigator decision for other reasons	mg	IV	Log Forms				580	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					4	37	1
MMRF_1280	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				15	QD (D1-21)	QD (D1-21)					37	351	1
MMRF_1280	First line of therapy	Prednisone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		60	Q day	Q day					401	429	1
MMRF_1280	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Other	ONCE					350	350	1
MMRF_1280	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Maintenance	Maintenance		1.3	Q week	Q week					589	645	1
MMRF_1280	Second Line Therapy (after first relapse)	Cyclophosphamide		Lack of response	mg/m^2	IV	Log Forms	Consolidation	Consolidation		300	Other	3 OF 4 WEEKS					997	1193	1
MMRF_1280	Second Line Therapy (after first relapse)	Dexamethasone		Lack of response	mg	PO	Log Forms	Consolidation	Consolidation		20	Other	3 OF 4 WEEKS					997	1193	1
MMRF_1280	Second Line Therapy (after first relapse)	Bortezomib		Lack of response	mg/m^2	IV SubQ	Log Forms	Consolidation	Consolidation		1.3	Q week	Q week					1024	1193	1
MMRF_1280	Second Line Therapy (after first relapse)	Thalidomide		Patient decision	mg	PO	Log Forms	Consolidation	Consolidation		50	Q day	Q day					1130	1130	1
MMRF_1280	Third Line Therapy (following 2nd relapse)	Daratumumab		Completed regimen	mg/kg	IV	Log Forms	Induction	Induction		16	QWK	QWK					1235	1900	1
MMRF_1280	Fourth Line Therapy (following 3rd relapse)	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Consolidation	Consolidation		1.3	Other	EVERY 2 WEEKS					1522	1935	1
MMRF_1280	Fifth Line Therapy (following 4th relapse)	CISPLATIN		Completed regimen	mg/m^2	IV	Log Forms	Other	SALVAGE		10	QD (D1-4)	QD (D1-4)					2089	2093	1
MMRF_1280	Fifth Line Therapy (following 4th relapse)	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Other	SALVAGE		300	QD (D1-4)	QD (D1-4)					2089	2093	1
MMRF_1280	Fifth Line Therapy (following 4th relapse)	ETOPOSIDE		Completed regimen	mg/m^2	IV	Log Forms	Other	SALVAGE		30	QD (D1-4)	QD (D1-4)					2089	2093	1
MMRF_1280	Fifth Line Therapy (following 4th relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Other	SALVAGE		20	QD (D1-4)	QD (D1-4)					2089	2093	1
MMRF_1280	Sixth Line Therapy (following 5th relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Induction	Induction		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					2256	2608	1
MMRF_1280	Sixth Line Therapy (following 5th relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		10	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					2256	2608	1
MMRF_1280	Seventh Line of Therapy (following 6th relapse)	REGN5458 (BCMA X CD3)	NCT03761108		mg	IV	Log Forms	Induction	Induction	Checked	50	Q week	Q week					2773		1
MMRF_1308	First line of therapy	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	232	1
MMRF_1308	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	232	1
MMRF_1308	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms				300	Other	DAYS 1, 8, 15					1	138	1
MMRF_1308	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					26	102	1
MMRF_1308	Second Line Therapy (after first relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		4	QD (D1-21)	QD (D1-21)					283	563	1
MMRF_1308	Second Line Therapy (after first relapse)	Cyclophosphamide		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		50	QD (D1-21)	QD (D1-21)					354	563	1
MMRF_1308	Third Line Therapy (following 2nd relapse)	Panobinostat		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		20	QWK	QWK					563	1670	1
MMRF_1308	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		40	Other	D1, D8, D15					283	563	1
MMRF_1308	Third Line Therapy (following 2nd relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					563	1670	1
MMRF_1308	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		40	Q week	Q week					563	1670	1
MMRF_1308	Fourth Line Therapy (following 3rd relapse)	Carfilzomib			mg/m^2	IV	Log Forms	Other	SALVAGE	Checked	27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1328		1
MMRF_1308	Fourth Line Therapy (following 3rd relapse)	ISATUXIMAB			mg/kg	IV	Log Forms	Other	SALVAGE	Checked	10	Other	EVERY OTHER WEEK					1693		1
MMRF_1308	Fourth Line Therapy (following 3rd relapse)	Dexamethasone			mg	IV	Log Forms	Other	SALVAGE	Checked	10	Other	EVERY OTHER WEEK					1693		1
MMRF_1307	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	1142	1
MMRF_1307	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms				10	QD (D1-21)	QD (D1-21)					11	1724	1
MMRF_1307	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms				40	Other	D1,8,15,22					11	1724	1
MMRF_1307	First line of therapy	Ixazomib		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		4	Other	EVERY OTHER WEEK					1142	1724	1
MMRF_1314	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	1430	1
MMRF_1314	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms				300	Other	D1, D8					1	15	1
MMRF_1314	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	1430	1
MMRF_1314	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					15	1430	1
MMRF_1314	First line of therapy	Bortezomib			mg/m^2	IV	Log Forms	Induction	Induction	Checked	1.3	QWK	QWK					2712		1
MMRF_1314	Second Line Therapy (after first relapse)	Dexamethasone			UNKNOWN	PO	Log Forms	Induction	Induction	Checked		QWK	QWK					2712		1
MMRF_1314	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		15	QWK	QWK					2712	2859	1
MMRF_1311	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1010	1251	1
MMRF_1311	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1010	1261	1
MMRF_1311	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1010	1251	1
MMRF_1311	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		450	Q day	Q day					1290	1290	1
MMRF_1311	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Other	CONDITIONING		3.6	Q day	Q day					1450	1450	1
MMRF_1311	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		446	Q day	Q day					1452	1452	1
MMRF_1311	Second Line Therapy (after first relapse)	FLUDARABINE		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		30	Other	DAYS -5 TO -2					2554	2557	1
MMRF_1311	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		140	Other	DAY -1					1	1	1
MMRF_1311	Second Line Therapy (after first relapse)	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		1.6	Other	DAY -4					2555	2555	1
MMRF_1324	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms				15	QD (D1-21)	QD (D1-21)					4	424	1
MMRF_1324	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms			Checked	40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_1324	First line of therapy	Cyclophosphamide		INDUCTION	mg/m^2	PO	Log Forms				300	Other	ONCE					1	3	1
MMRF_1324	First line of therapy	Cyclophosphamide		SCH	mg/m^2	IV	Log Forms				300	Q week	Q week					92	124	1
MMRF_1324	First line of therapy	Prednisone		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		50	Other	ONCE					323	607	1
MMRF_1324	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					774	774	1
MMRF_1324	Second Line Therapy (after first relapse)	Carfilzomib		Adverse Event or co-morbidity	mg	IV	Log Forms	Consolidation	Consolidation		34.2	Q week	Q week					623	680	1
MMRF_1324	Second Line Therapy (after first relapse)	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		50	Q week	Q week					623	730	1
MMRF_1324	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		10	Q week	Q week					623	1310	1
MMRF_1324	Second Line Therapy (after first relapse)	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Consolidation	Consolidation		1.3	Q week	Q week					680	730	1
MMRF_1324	Second Line Therapy (after first relapse)	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					880	1446	1
MMRF_1324	Second Line Therapy (after first relapse)	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Maintenance	Maintenance		27	Other	QOW					953	1310	1
MMRF_1324	Second Line Therapy (after first relapse)	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Unknown	Unknown		56	Other	QOW					1310	2427	1
MMRF_1324	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	IV	Log Forms	Unknown	Unknown		8	Q week	Q week					1310	2199	1
MMRF_1324	First line of therapy	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	607	1
MMRF_1345	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	218	1
MMRF_1345	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					9	73	1
MMRF_1345	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms				40	QWK	QWK					1	218	1
MMRF_1345	First line of therapy	Cyclophosphamide		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Induction	Induction		300	Other	D1,8					95	218	1
MMRF_1345	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					219	219	1
MMRF_1345	Second Line Therapy (after first relapse)	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		250	Q week	Q week					911	1086	1
MMRF_1345	Second Line Therapy (after first relapse)	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		1.3	Q week	Q week					911	1086	1
MMRF_1345	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		20	Q week	Q week					911	1598	1
MMRF_1345	Second Line Therapy (after first relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		4	QD (D1-21)	QD (D1-21)					1086	1598	1
MMRF_1345	Third Line Therapy (following 2nd relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Other	SALVAGE		16	Q week	Q week					1674	1751	1
MMRF_1345	Third Line Therapy (following 2nd relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		10	QD (D1-21)	QD (D1-21)					1674	1751	1
MMRF_1345	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		20	Q week	Q week					1674	1751	1
MMRF_1345	Fourth Line Therapy (following 3rd relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Unknown	Unknown		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1774	1810	1
MMRF_1345	Fourth Line Therapy (following 3rd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		3	QD (D1-21)	QD (D1-21)					1774	1810	1
MMRF_1345	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1774	1810	1
MMRF_1345	Fifth Line Therapy (following 4th relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		40	QD (D1-4)	QD (D1-4)					1819	1823	1
MMRF_1345	Fifth Line Therapy (following 4th relapse)	Cyclophosphamide		Disease progression/Relapse	mg/m^2	IV	Log Forms	Other	SALVAGE		300	QD (D1-4)	QD (D1-4)					1819	1823	1
MMRF_1345	Fifth Line Therapy (following 4th relapse)	ETOPOSIDE		Disease progression/Relapse	mg/m^2	IV	Log Forms	Other	SALVAGE		30	QD (D1-4)	QD (D1-4)					1819	1823	1
MMRF_1345	Fifth Line Therapy (following 4th relapse)	CISPLATIN		Disease progression/Relapse	mg/m^2	IV	Log Forms	Other	SALVAGE		15	QD (D1-4)	QD (D1-4)					1819	1823	1
MMRF_1345	Sixth Line Therapy (following 5th relapse)	Daratumumab			mg/kg	IV	Log Forms	Other	SALVAGE	Checked	16	Q week	Q week					1926		1
MMRF_1345	Sixth Line Therapy (following 5th relapse)	NIVOLUMAB		Investigator decision for other reasons	mg	IV	Log Forms	Other	SALVAGE		240	Other	EVERY OTHER WEEK					1828	2304	1
MMRF_1345	Sixth Line Therapy (following 5th relapse)	Pomalidomide			mg	PO	Log Forms	Other	SALVAGE	Checked	3	QD (D1-21)	QD (D1-21)					1828		1
MMRF_1352	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.3	Other	WEEKLY X 4 WEEKS					1	218	1
MMRF_1352	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	190	1
MMRF_1352	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	Other	WEEKLY X 4 WEEKS					1	233	1
MMRF_1352	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Other	ONCE					267	267	1
MMRF_1352	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		300	Other	D1 AND 8					190	218	1
MMRF_1352	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		25	QD (D1-21)	QD (D1-21)					374	1102	1
MMRF_1352	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		20	Other	3 WEEKS ON AND 1 WEEK OFF					374	1102	1
MMRF_1352	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		8	QD (D1-21)	QD (D1-21)					1102	1515	1
MMRF_1352	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					1102	1515	1
MMRF_1354	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	67	1
MMRF_1354	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	142	1
MMRF_1354	First line of therapy	Cyclophosphamide		FURTHER THERAPY	mg	IV	Log Forms				520	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	22	1
MMRF_1354	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					22	389	1
MMRF_1354	Second Line Therapy (after first relapse)	Prednisone		Lack of response	mg	PO	Log Forms	Induction	Induction		10	Other	3 TIMES A WEEK					391	1175	1
MMRF_1354	Second Line Therapy (after first relapse)	Elotuzumab			mg/kg	IV	Log Forms	Induction	Induction	Checked	10	Other	DAY 1 AND 15 OF 21 DAY CYCLE					1089		1
MMRF_1354	Second Line Therapy (after first relapse)	Prednisone			mg	PO	Log Forms	Consolidation	Consolidation	Checked	100	Other	DAY 1, 8, 15					1175		1
MMRF_1354	Second Line Therapy (after first relapse)	Lenalidomide			mg	PO	Log Forms	Consolidation	Consolidation	Checked	15	QD (D1-21)	QD (D1-21)					1175		1
MMRF_1089	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	547	1
MMRF_1089	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	Other	DAYS 1, 8, 15					1	547	1
MMRF_1089	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					547		1
MMRF_1387	First line of therapy	Bortezomib			mg	IV SubQ	Log Forms			Checked	1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_1387	First line of therapy	Cyclophosphamide			mg/m^2	IV	Log Forms			Checked	300	Other	D1, D8					1		1
MMRF_1387	First line of therapy	Dexamethasone			mg	PO	Log Forms			Checked	40	Other	DAYS 1, 8, 15					1		1
MMRF_1389	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	78	1
MMRF_1389	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms				1.3	QWK	QWK					1	78	1
MMRF_1389	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	Other	DAYS 1, 8, 15					1	78	1
MMRF_1389	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					183	183	1
MMRF_1391	First line of therapy	Bortezomib		PT MOVING TO FLORIDA.	mg/m^2	IVP	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	148	1
MMRF_1391	First line of therapy	Lenalidomide		PATIENT MOVING TO FLORIDA	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	148	1
MMRF_1391	First line of therapy	Dexamethasone		PATIENT MOVING TO FLORIDA	mg	PO	Log Forms				20	Other	DAYS 1,2,4,5,8,9,11,12					1	148	1
MMRF_1391	First line of therapy	Melphalan		Completed regimen	mg/dL	IV	Log Forms	Induction	Induction		320	Other	ONCE					161	161	1
MMRF_1391	First line of therapy	Lenalidomide			mg/dL	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					1026		1
MMRF_1446	First line of therapy	Bortezomib		Lack of response	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	99	1
MMRF_1446	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms				300	Other	D4,11					1	11	1
MMRF_1446	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	346	1
MMRF_1446	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					106	346	1
MMRF_1446	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		300	Other	D1,D8					163	190	1
MMRF_1446	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Other	ONCE					345	345	1
MMRF_1446	First line of therapy	Thalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		50	Q week	Q week					190	239	1
MMRF_1446	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					239	346	1
MMRF_1446	Second Line Therapy (after first relapse)	Pomalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					805	1682	1
MMRF_1446	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					106	162	1
MMRF_1446	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Consolidation	Consolidation		40	Q week	Q week					805	1682	1
MMRF_1446	Second Line Therapy (after first relapse)	ACY-1215		Adverse Event or co-morbidity	mg	PO	Log Forms	Consolidation	Consolidation		160	QD (D1-21)	QD (D1-21)					805	1682	1
MMRF_1450	First line of therapy	Bortezomib		DEATH	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	16	1
MMRF_1450	First line of therapy	Dexamethasone		DEATH	mg	PO	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	16	1
MMRF_1455	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					1	140	1
MMRF_1455	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		10	Q week	Q week					1	140	1
MMRF_1455	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	140	1
MMRF_1455	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Other	ONCE					146	146	1
MMRF_1455	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					252		1
MMRF_1455	First line of therapy	Dexamethasone			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	Other	D1,8,15					247		1
MMRF_1454	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	159	1
MMRF_1454	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	Q week	Q week					1	159	1
MMRF_1454	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.3	Q week	Q week					1	159	1
MMRF_1454	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					160	160	1
MMRF_1454	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1	Q week	Q week					337	524	1
MMRF_1474	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	8	1
MMRF_1474	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	947	1
MMRF_1474	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					389	1030	1
MMRF_1474	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Induction	Induction		300	Other	ONCE					205	205	1
MMRF_1474	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					389	1030	1
MMRF_1474	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		40	Q week	Q week					526	942	1
MMRF_1474	Second Line Therapy (after first relapse)	ATEZOLIZUMAB		Patient decision	mg	IV	Log Forms	Consolidation	Consolidation		840	Other	D12,D16 OF CYCLE 1 AND D1,D15 OF CYCLES THEREAFTER					1188	1457	1
MMRF_1474	Second Line Therapy (after first relapse)	Daratumumab		Patient decision	mg/kg	IV	Log Forms	Consolidation	Consolidation		16	Other	D1,8,15,22					1187	1457	1
MMRF_1474	Third Line Therapy (following 2nd relapse)	Carfilzomib			mg/m^2	IV	Log Forms	Unknown	Unknown	Checked	20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1697		1
MMRF_1474	Third Line Therapy (following 2nd relapse)	Pomalidomide			mg	PO	Log Forms	Unknown	Unknown	Checked	3	QD (D1-21)	QD (D1-21)					1691		1
MMRF_1474	Third Line Therapy (following 2nd relapse)	Dexamethasone			mg	IV	Log Forms	Unknown	Unknown	Checked	20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1697		1
MMRF_1479	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					1	190	1
MMRF_1479	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	TWICE WEEKLY					1	151	1
MMRF_1479	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					5	190	1
MMRF_1479	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Other	ONCE					204	204	1
MMRF_1479	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					314	363	1
MMRF_1479	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					314	647	1
MMRF_1479	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					314	1166	1
MMRF_1479	Second Line Therapy (after first relapse)	Ixazomib		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		4	Q week	Q week					1185	1254	1
MMRF_1479	Second Line Therapy (after first relapse)	Lenalidomide		Patient decision	mg	PO	Log Forms	Consolidation	Consolidation		15	QD (D1-21)	QD (D1-21)					1185	1254	1
MMRF_1479	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		8	Q week	Q week					1185	1254	1
MMRF_1479	Third Line Therapy (following 2nd relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Consolidation	Consolidation		16	Q week	Q week					1275	1697	1
MMRF_1479	Third Line Therapy (following 2nd relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Consolidation	Consolidation		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1275	1697	1
MMRF_1479	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Consolidation	Consolidation		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1275	1697	1
MMRF_1479	Third Line Therapy (following 2nd relapse)	TRAMETINIB		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		2	TID	TID					1272	1612	1
MMRF_1479	Third Line Therapy (following 2nd relapse)	Pomalidomide		Completed regimen	mg	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					1275	1613	1
MMRF_1479	Third Line Therapy (following 2nd relapse)	Pomalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Unknown	Unknown		2	QD (D1-21)	QD (D1-21)					1613	1713	1
MMRF_1479	Third Line Therapy (following 2nd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		4	QD (D1-21)	QD (D1-21)					1713	1912	1
MMRF_1479	Third Line Therapy (following 2nd relapse)	MEKINIST		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		2	Other	THREE TIMES PER WEEK					1713	1912	1
MMRF_1502	Fourth Line Therapy (following 3rd relapse)	Daratumumab		Disease progression/Relapse		IV	Log Forms	Consolidation	Consolidation	Checked		Q week	Q week					1346	1403	1
MMRF_1502	Fourth Line Therapy (following 3rd relapse)	Pomalidomide		Patient decision	mg	PO	Log Forms	Consolidation	Consolidation		4	QD (D1-21)	QD (D1-21)					1346	1403	1
MMRF_1502	Fourth Line Therapy (following 3rd relapse)	Dexamethasone			mg	PO	Log Forms	Consolidation	Consolidation	Checked	16	Q week	Q week					1346		1
MMRF_1502	Fourth Line Therapy (following 3rd relapse)	TRAMETINIB		Patient decision	mg	PO	Log Forms	Consolidation	Consolidation		2	QD (D1-21)	QD (D1-21)					1403	1403	1
MMRF_1502	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	47	1
MMRF_1502	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		300	Other	D1,8					1	47	1
MMRF_1502	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	47	1
MMRF_1502	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					812	1182	1
MMRF_1502	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		28	Other	D1, D8, D15, D22					812	1143	1
MMRF_1502	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					218	218	1
MMRF_1502	First line of therapy	Bortezomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Maintenance	Maintenance		1.3	QWK	QWK					368	764	1
MMRF_1502	Second Line Therapy (after first relapse)	Elotuzumab		Completed regimen	mg	IV	Log Forms	Consolidation	Consolidation		631	Other	D1, D8, D15, D22					829	898	1
MMRF_1502	Third Line Therapy (following 2nd relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Consolidation	Consolidation		16	Q week	Q week					1198	1283	1
MMRF_1502	Third Line Therapy (following 2nd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		4	QD (D1-21)	QD (D1-21)					1130	1311	1
MMRF_1502	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		20	Q week	Q week					1130	1311	1
MMRF_1502	Fourth Line Therapy (following 3rd relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Consolidation	Consolidation		20	Other	UNK					1346	1394	1
MMRF_1510	Fourth Line Therapy (following 3rd relapse)	Daratumumab			mg	IV SubQ	Log Forms	Other	TREATMENT AFTER PD	Checked	1800	QWK	QWK					2556		1
MMRF_1510	Fourth Line Therapy (following 3rd relapse)	Carfilzomib			mg/m^2	IV	Log Forms	Other	TREATMENT AFTER PD	Checked	20	Q week	Q week					2556		1
MMRF_1510	Fourth Line Therapy (following 3rd relapse)	Pomalidomide		Completed regimen	mg	PO	Log Forms	Other	TREATMENT AFTER PD		2	QD (D1-7)	QD (D1-7)					2551	2557	1
MMRF_1510	Third Line Therapy (following 2nd relapse)	VENETOCLAX		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		100	QID	QID					2283	2436	1
MMRF_1510	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1	240	1
MMRF_1510	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1	281	1
MMRF_1510	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	726	1
MMRF_1510	First line of therapy	Lenalidomide		Patient decision	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					726	1447	1
MMRF_1510	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		12	Q week	Q week					245	281	1
MMRF_1510	Second Line Therapy (after first relapse)	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1470	1671	1
MMRF_1510	Second Line Therapy (after first relapse)	Cyclophosphamide		Disease progression/Relapse	mg/m^2	IV	Log Forms	Consolidation	Consolidation		300	Other	DAY 1,8					1481	1516	1
MMRF_1510	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		10	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1470	1671	1
MMRF_1510	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Other	ONCE					1744	1744	1
MMRF_1513	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	889	1
MMRF_1513	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		20	Other	DAYS 1, 2, 4, 5, 8, 9, 11 AND 12 EVERY 21 DAY CYCLE					1	889	1
MMRF_1513	First line of therapy	Bortezomib		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		2.73	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	889	1
MMRF_1513	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					904	905	1
MMRF_1513	Second Line Therapy (after first relapse)	Ixazomib		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		3	Other	ONCE A WEEK					1022	1639	1
MMRF_1513	Third Line Therapy (following 2nd relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Consolidation	Consolidation		16	QWK	QWK					1646	1717	1
MMRF_1513	Third Line Therapy (following 2nd relapse)	ATEZOLIZUMAB		Disease progression/Relapse	mg	IV	Log Forms	Consolidation	Consolidation		840	QWK	QWK					1646	1717	1
MMRF_1513	Fourth Line Therapy (following 3rd relapse)	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		1200	QD (D1-4)	QD (D1-4)					1722	1722	1
MMRF_1513	Fourth Line Therapy (following 3rd relapse)	ETOPOSIDE		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		120	QD (D1-4)	QD (D1-4)					1722	1722	1
MMRF_1513	Fourth Line Therapy (following 3rd relapse)	CISPLATIN		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		30	QD (D1-4)	QD (D1-4)					1722	1722	1
MMRF_1513	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		4	Other	TAKE 5 TABLETS BY MOUTH ONCE A WEEK. FOR 3 WEEKS, ONE WEEK BREAK					1722	1722	1
MMRF_1513	Fourth Line Therapy (following 3rd relapse)	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	SALVAGE		4	QD (D1-21)	QD (D1-21)					1757	1780	1
MMRF_1513	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	SALVAGE		20	Q week	Q week					1757	1780	1
MMRF_1513	Fourth Line Therapy (following 3rd relapse)	Pomalidomide		Completed regimen	mg	PO	Log Forms	Other	SALVAGE		2	QD (D1-21)	QD (D1-21)					1780	1816	1
MMRF_1513	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		20	Q week	Q week					1780	1816	1
MMRF_1516	First line of therapy	Lenalidomide			mg	PO	Log Forms	Induction	Induction	Checked	10	QD (D1-21)	QD (D1-21)					1		1
MMRF_1516	First line of therapy	Prednisone			mg	PO	Log Forms	Induction	Induction	Checked	30	Other	TIW (MON,WED,FRI)					1		1
MMRF_1622	First line of therapy	Bortezomib		Lack of response	mg/m^2	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	638	1
MMRF_1622	First line of therapy	Dexamethasone		Lack of response	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	638	1
MMRF_1622	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		10	Other	D1,8					1	18	1
MMRF_1622	First line of therapy	Lenalidomide		Lack of response	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					18	638	1
MMRF_1622	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					306	306	1
MMRF_1622	First line of therapy	Pomalidomide			mg	PO	Log Forms	Induction	Induction	Checked	4	QD (D1-21)	QD (D1-21)					638		1
MMRF_1622	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					638	990	1
MMRF_1628	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	404	1
MMRF_1628	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	404	1
MMRF_1628	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					430	1027	1
MMRF_1628	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					430	1027	1
MMRF_1628	First line of therapy	Prednisone		Completed regimen	mg	PO	Log Forms	Induction	Induction		50	Other	BIW					430	500	1
MMRF_1628	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Other	ONCE					1158	1158	1
MMRF_1628	Second Line Therapy (after first relapse)	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Unknown	Unknown		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					474	1061	1
MMRF_1628	Third Line Therapy (following 2nd relapse)	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		3	QD (D1-21)	QD (D1-21)					1560	1715	1
MMRF_1628	Third Line Therapy (following 2nd relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Unknown	Unknown		16	Q week	Q week					1560	1714	1
MMRF_1628	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		4	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1560	1714	1
MMRF_1628	Third Line Therapy (following 2nd relapse)	MEKINIST		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		2	Other	DAYS MONDAY/THURSDAY X 4/4 WEEKS					1560	1715	1
MMRF_1628	Third Line Therapy (following 2nd relapse)	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Other	SALVAGE		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1560	1665	1
MMRF_1628	Fourth Line Therapy (following 3rd relapse)	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Other	SALVAGE		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1748	1762	1
MMRF_1628	Fourth Line Therapy (following 3rd relapse)	Lenalidomide		Completed regimen	mg	PO	Log Forms	Other	SALVAGE		25	QD (D1-21)	QD (D1-21)					1748	1762	1
MMRF_1628	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Other	SALVAGE		10	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1748	1762	1
MMRF_1634	First line of therapy	Bortezomib		DEATH	mg/m^2	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	16	1
MMRF_1634	First line of therapy	Lenalidomide		DEATH	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	16	1
MMRF_1634	First line of therapy	Dexamethasone		DEATH	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	16	1
MMRF_1637	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		1.3	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1	206	1
MMRF_1637	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	209	1
MMRF_1637	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1	209	1
MMRF_1637	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	TRANSPLANT		422	Other	ONCE					206	206	1
MMRF_1637	First line of therapy	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms	Consolidation	Consolidation		1.3	Other	D1, 8, 15					337	460	1
MMRF_1637	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					337	596	1
MMRF_1637	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		40	Other	D1, D8, D15					337	596	1
MMRF_1637	Second Line Therapy (after first relapse)	Pomalidomide		Patient decision	mg	PO	Log Forms	Consolidation	Consolidation		4	QD (D1-21)	QD (D1-21)					597	621	1
MMRF_1637	Second Line Therapy (after first relapse)	Dexamethasone		Patient decision	mg	PO	Log Forms	Consolidation	Consolidation		40	Q week	Q week					597	621	1
MMRF_1637	Second Line Therapy (after first relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		2	QD (D1-21)	QD (D1-21)					662	719	1
MMRF_1637	Second Line Therapy (after first relapse)	Cyclophosphamide		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		300	Other	WEEKLY X 3 WEEKS ON/1 WEEK OFF					662	719	1
MMRF_1637	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		20	Other	WEEKLY X 3 WEEKS ON/1 WEEK OFF					662	719	1
MMRF_1637	Third Line Therapy (following 2nd relapse)	Carfilzomib		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Consolidation	Consolidation		20	Q week	Q week					721	838	1
MMRF_1637	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		20	Other	WEEKLY X 3 WEEKS ON/1 WEEK OFF					721	1073	1
MMRF_1637	Third Line Therapy (following 2nd relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Consolidation	Consolidation		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					838	901	1
MMRF_1637	Third Line Therapy (following 2nd relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Consolidation	Consolidation		70	Q week	Q week					906	1073	1
MMRF_1637	Third Line Therapy (following 2nd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		2	QD (D1-21)	QD (D1-21)					964	1073	1
MMRF_1637	Fourth Line Therapy (following 3rd relapse)	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		300	Other	4 DAYS					662	1090	1
MMRF_1637	Fourth Line Therapy (following 3rd relapse)	ETOPOSIDE		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		30	Other	4 DAYS					1073	1073	1
MMRF_1637	Fourth Line Therapy (following 3rd relapse)	CISPLATIN		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		10	Other	4 DAYS					1073	1073	1
MMRF_1637	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		20	Other	4 DAYS					1073	1073	1
MMRF_1637	Fifth Line Therapy (following 4th relapse)	Pomalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		2	QD (D1-21)	QD (D1-21)					1272	1510	1
MMRF_1637	Fifth Line Therapy (following 4th relapse)	Panobinostat		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		20	Other	DAYS 1, 3, 5, 8, 10, 12 OF 21 DAY CYCLE					1272	1510	1
MMRF_1637	Fifth Line Therapy (following 4th relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Consolidation	Consolidation		16	Q week	Q week					1272	1510	1
MMRF_1637	Fifth Line Therapy (following 4th relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Consolidation	Consolidation		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1433	1510	1
MMRF_1637	Fifth Line Therapy (following 4th relapse)	VENETOCLAX		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		400	Other	DAY 1-28					1433	1510	1
MMRF_1637	First line of therapy	Panobinostat		Adverse Event or co-morbidity	mg	PO	Log Forms	Consolidation	Consolidation		20	Other	DAYS 1, 3, 5, 8, 10, 12					1289	1346	1
MMRF_1637	Sixth Line Therapy (following 5th relapse)	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Other	SALVAGE		300	QD (D1-4)	QD (D1-4)					1510	1513	1
MMRF_1637	Sixth Line Therapy (following 5th relapse)	ETOPOSIDE		Completed regimen	mg/m^2	IV	Log Forms	Other	SALVAGE		30	QD (D1-4)	QD (D1-4)					1510	1513	1
MMRF_1637	Sixth Line Therapy (following 5th relapse)	CISPLATIN		Completed regimen	mg/m^2	IV	Log Forms	Other	SALVAGE		7.5	QD (D1-4)	QD (D1-4)					1510	1513	1
MMRF_1637	Sixth Line Therapy (following 5th relapse)	ADRIAMYCIN		Completed regimen	mg/m^2	IV	Log Forms	Other	SALVAGE		10	QD (D1-4)	QD (D1-4)					1510	1513	1
MMRF_1637	Sixth Line Therapy (following 5th relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Other	SALVAGE		40	QD (D1-4)	QD (D1-4)					1510	1513	1
MMRF_1637	Seventh Line of Therapy (following 6th relapse)	Dexamethasone		Completed regimen	mg	IV	Log Forms	Other	SALVAGE		40	QD (D1-4)	QD (D1-4)					1517	1517	1
MMRF_1637	Seventh Line of Therapy (following 6th relapse)	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Other	SALVAGE		300	QD (D1-4)	QD (D1-4)					1517	1517	1
MMRF_1637	Seventh Line of Therapy (following 6th relapse)	ETOPOSIDE		Completed regimen	mg/m^2	IV	Log Forms	Other	SALVAGE		30	QD (D1-4)	QD (D1-4)					1517	1517	1
MMRF_1637	Seventh Line of Therapy (following 6th relapse)	CISPLATIN		Completed regimen	mg/m^2	IV	Log Forms	Other	SALVAGE		7.5	QD (D1-4)	QD (D1-4)					1517	1517	1
MMRF_1637	Seventh Line of Therapy (following 6th relapse)	ADRIAMYCIN		Completed regimen	mg/m^2	IV	Log Forms	Other	SALVAGE		10	QD (D1-4)	QD (D1-4)					1517	1517	1
MMRF_1637	Eighth Line of Therapy (following 7th relapse)	CARMUSTINE		Completed regimen	mg/m^2	IV	Log Forms	Other	SALVAGE		100	Other	ONCE					1566	1566	1
MMRF_1637	Eighth Line of Therapy (following 7th relapse)	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	SALVAGE		100	Other	ONCE					1567	1567	1
MMRF_1637	Eighth Line of Therapy (following 7th relapse)	CISPLATIN		Completed regimen	mg/m^2	IV	Log Forms	Other	SALVAGE		30	QD (D1-4)	QD (D1-4)					1702	1705	1
MMRF_1637	Eighth Line of Therapy (following 7th relapse)	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Other	SALVAGE		1200	QD (D1-4)	QD (D1-4)					1702	1706	1
MMRF_1637	Eighth Line of Therapy (following 7th relapse)	ETOPOSIDE		Completed regimen	mg/m^2	IV	Log Forms	Other	SALVAGE		120	QD (D1-4)	QD (D1-4)					1702	1706	1
MMRF_1643	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	632	1
MMRF_1643	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	359	1
MMRF_1643	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	479	1
MMRF_1648	First line of therapy	Bortezomib			mg/m^2	IV	Log Forms	Induction	Induction	Checked	1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_1648	First line of therapy	Lenalidomide			mg	PO	Log Forms	Induction	Induction	Checked	25	QD (D1-14)	QD (D1-14)					1		1
MMRF_1648	First line of therapy	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	20	Other	DAYS 1,2,4,5,8,9,11 AND 12					1		1
MMRF_1665	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	309	1
MMRF_1665	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	309	1
MMRF_1665	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					22	121	1
MMRF_1665	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO	Log Forms	Induction	Induction		300	Other	D1 AND D8					1	22	1
MMRF_1665	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Other	ONCE					309	309	1
MMRF_1665	First line of therapy	Lenalidomide		DECREASING RENAL FUNCTION	mg	PO	Log Forms	Induction	Induction		5	Other	MWF 3 WKS ON 1 WK OFF					432	831	1
MMRF_1665	First line of therapy	Prednisone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		50	Other	MWF QW					432	831	1
MMRF_1665	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Other	EVERY OTHER WEEK					436	932	1
MMRF_1665	First line of therapy	Ixazomib		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		3	Other	ONCE A WEEK					936	1016	1
MMRF_1665	First line of therapy	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Maintenance	Maintenance		70	QWK	QWK					1648	1674	1
MMRF_1665	Second Line Therapy (after first relapse)	Carfilzomib		POOR TOLERANCE	mg/m^2	IV	Log Forms	Other	SALVAGE		56	QWK	QWK					1678	1774	1
MMRF_1677	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	218	1
MMRF_1677	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QWK	QWK					2	218	1
MMRF_1677	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					7	26	1
MMRF_1677	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					38	218	1
MMRF_1677	First line of therapy	Liposomal doxorubicin		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Other	ONCE					300	300	1
MMRF_1677	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Consolidation	Consolidation		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					218	273	1
MMRF_1677	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					218	273	1
MMRF_1677	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		10	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					57	273	1
MMRF_1677	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					300	300	1
MMRF_1677	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		300	Other	X3/4 WEEKS					148	175	1
MMRF_1677	First line of therapy	Elotuzumab		Completed regimen			Log Forms	Consolidation	Consolidation									1121	1282	1
MMRF_1677	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		20	Other	X3/4 WEEKS					577	1135	1
MMRF_1677	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Q week	Q week					1375	1674	1
MMRF_1677	First line of therapy	VENETOCLAX			mg	PO	Log Forms	Maintenance	Maintenance	Checked	400	Q day	Q day					1375		1
MMRF_1677	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		20	Q week	Q week					1375	1674	1
MMRF_1677	First line of therapy	Dexamethasone			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	Q week	Q week					1674		1
MMRF_1686	First line of therapy	Bortezomib		PATIENT HAD TRANSPLANT.	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	214	1
MMRF_1686	First line of therapy	Dexamethasone		PATIENT HAD TRANSPLANT.	mg	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	214	1
MMRF_1686	First line of therapy	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Induction	Induction		300	QWK	QWK					1	214	1
MMRF_1686	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					224	224	1
MMRF_1686	First line of therapy	Lenalidomide		ADMITTED FOR C2 FRACTURE, TREATMENT PUT ON HOLD.	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					85	172	1
MMRF_1686	First line of therapy	Carfilzomib		9/10 MATCHED UNRELATED DONOR IDENTIFIED.	mg/m^2	IV	Log Forms	Consolidation	Consolidation		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					275	380	1
MMRF_1686	First line of therapy	Lenalidomide		9/10 MATCHED UNRELATED DONOR IDENTIFIED.	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					275	380	1
MMRF_1710	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	235	1
MMRF_1710	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	235	1
MMRF_1710	First line of therapy	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Induction	Induction		300	QWK	QWK					1	235	1
MMRF_1710	First line of therapy	Bortezomib			mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance	Checked	1.3	QWK	QWK					253		1
MMRF_1710	First line of therapy	Dexamethasone			mg	PO	Log Forms	Maintenance	Maintenance	Checked	20	QWK	QWK					618		1
MMRF_1710	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	25	QD (D1-21)	QD (D1-21)					580		1
MMRF_1698	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	60	1
MMRF_1698	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	54	1
MMRF_1698	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	DAYS 1,2,4,5,8,9,11,12					1	54	1
MMRF_1698	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					127	127	1
MMRF_1698	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					204	270	1
MMRF_1698	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					204	270	1
MMRF_1698	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		10	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					204	270	1
MMRF_1698	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					268	900	1
MMRF_1746	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	153	1
MMRF_1746	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	153	1
MMRF_1746	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	153	1
MMRF_1746	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					274	1007	1
MMRF_1746	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Other	ONCE					160	160	1
MMRF_1744	First line of therapy	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	874	1
MMRF_1744	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		300	Other	DAY 1 AND DAY 4					1	321	1
MMRF_1744	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	854	1
MMRF_1744	First line of therapy	Doxorubicin		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		30	Other	DAY 4					43	64	1
MMRF_1744	First line of therapy	Thalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		100	Other	D1-28					30	37	1
MMRF_1744	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		10	Other	MWF					120	854	1
MMRF_1744	First line of therapy	Elotuzumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Induction	Induction		10	QWK	QWK					727	867	1
MMRF_1744	Second Line Therapy (after first relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Consolidation	Consolidation		16	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					884	1128	1
MMRF_1744	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		8	Q week	Q week					885	947	1
MMRF_1744	Second Line Therapy (after first relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		2	QD (D1-21)	QD (D1-21)					875	1156	1
MMRF_1744	Third Line Therapy (following 2nd relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Consolidation	Consolidation		16	Other	MONTHLY					1161	1525	1
MMRF_1744	Second Line Therapy (after first relapse)	NELFINAVIR		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		625	Other	BID FOR 14 DAYS					1075	1155	1
MMRF_1744	Second Line Therapy (after first relapse)	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		1.3	Q week	Q week					1075	1155	1
MMRF_1744	Third Line Therapy (following 2nd relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Consolidation	Consolidation		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1161	1532	1
MMRF_1744	Third Line Therapy (following 2nd relapse)	VENETOCLAX		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		400	Other	QD					1155	1433	1
MMRF_1744	Fourth Line Therapy (following 3rd relapse)	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Unknown	Unknown		100	Other	QD					1550	1550	1
MMRF_1744	Fourth Line Therapy (following 3rd relapse)	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Unknown	Unknown		100	Other	QD					1551	1551	1
MMRF_1744	Seventh Line of Therapy (following 6th relapse)	Ixazomib		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		3	QWK	QWK					2241	2326	1
MMRF_1744	Seventh Line of Therapy (following 6th relapse)	Bortezomib		Disease progression/Relapse	mg	IV SubQ	Log Forms	Unknown	Unknown		2.4	QWK	QWK					2232	2239	1
MMRF_1744	Seventh Line of Therapy (following 6th relapse)	SELINEXOR		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		80	QWK	QWK					2226	2305	1
MMRF_1744	Sixth Line Therapy (following 5th relapse)	GPRC5D		Disease progression/Relapse	MCG/KG	IV	Log Forms	Unknown	Unknown		20	QWK	QWK					1980	2219	1
MMRF_1744	Fifth Line Therapy (following 4th relapse)	GSK2857916		Disease progression/Relapse	mg	IV	Log Forms	Maintenance	Maintenance		222.2	QWK	QWK					1724	1870	1
MMRF_1744	Fifth Line Therapy (following 4th relapse)	CISPLATIN		Completed regimen	mg	IV	Log Forms	Maintenance	Maintenance		14.5	QD (D1-4)	QD (D1-4)					1696	1700	1
MMRF_1744	Fifth Line Therapy (following 4th relapse)	ETOPOSIDE		Completed regimen	mg	IV	Log Forms	Maintenance	Maintenance		48	QD (D1-4)	QD (D1-4)					1696	1700	1
MMRF_1744	Fifth Line Therapy (following 4th relapse)	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Maintenance	Maintenance		477.5	QD (D1-4)	QD (D1-4)					1696	1700	1
MMRF_1744	Fifth Line Therapy (following 4th relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		20	QWK	QWK					1696	1699	1
MMRF_1768	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	148	1
MMRF_1768	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	148	1
MMRF_1768	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	148	1
MMRF_1768	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Other	ONCE					148	148	1
MMRF_1808	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	65	1
MMRF_1808	First line of therapy	Cyclophosphamide		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Induction	Induction		300	Other	DAY 1 AND DAY 8					1	15	1
MMRF_1808	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	122	1
MMRF_1808	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		27	Q week	Q week					79	122	1
MMRF_1808	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					33	71	1
MMRF_1808	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		300	QWK	QWK					79	121	1
MMRF_1808	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Other	ONCE					174	174	1
MMRF_1808	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					267	396	1
MMRF_1808	First line of therapy	Prednisone		Completed regimen	mg	PO	Log Forms	Induction	Induction		30	Other	TIW					267	367	1
MMRF_1808	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		56	QWK	QWK					367	501	1
MMRF_1808	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		20	QWK	QWK					367	501	1
MMRF_1830	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	862	1
MMRF_1830	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		300	Other	DAY 1 AND DAY 8					1	79	1
MMRF_1830	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	1317	1
MMRF_1830	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					123	1317	1
MMRF_1830	First line of therapy	Ixazomib		Completed regimen	mg	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					863	1317	1
MMRF_1830	First line of therapy	Ixazomib		NONE	mg	PO	Log Forms	Maintenance	Maintenance		3	Other	QOW					1317	1467	1
MMRF_1830	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					1317		1
MMRF_1830	First line of therapy	Dexamethasone		NONE	mg	PO	Log Forms	Maintenance	Maintenance		8	Other	QOW					1317	1467	1
MMRF_1859	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					1	161	1
MMRF_1859	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					1	161	1
MMRF_1859	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	161	1
MMRF_1859	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					234	547	1
MMRF_1859	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		300	Other	QW 3WK ON 1WK OFF					234	262	1
MMRF_1859	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					262	945	1
MMRF_1871	First line of therapy	Bortezomib			mg/m^2	IV SubQ	Log Forms	Induction	Induction	Checked	1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_1871	First line of therapy	Cyclophosphamide			mg/m^2	IV	Log Forms	Induction	Induction	Checked	300	Other	DAY 1, 8, 15					1		1
MMRF_1871	First line of therapy	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	4	Q day	Q day					3		1
MMRF_1871	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					166	166	1
MMRF_1921	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	419	1
MMRF_1921	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	Q day	Q day					1	34	1
MMRF_1921	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	720	1
MMRF_1921	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		300	Other	QD (D1 AND D8)					34	207	1
MMRF_1921	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					221	221	1
MMRF_1921	First line of therapy	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	D1, D15					419	720	1
MMRF_1921	First line of therapy	Ixazomib		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		3	Q week	Q week					724	1307	1
MMRF_1921	Second Line Therapy (after first relapse)	Carfilzomib			mg/m^2	IV	Log Forms	Unknown	Unknown	Checked	20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1342		1
MMRF_1921	Second Line Therapy (after first relapse)	ISATUXIMAB			mg/kg	IV	Log Forms	Unknown	Unknown	Checked	5	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1342		1
MMRF_1921	Second Line Therapy (after first relapse)	Dexamethasone			mg	IV	Log Forms	Unknown	Unknown	Checked	20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1342		1
MMRF_1963	First line of therapy	Bortezomib			mg/m^2	IV SubQ	Log Forms	Induction	Induction	Checked	1.3	Q week	Q week					1		1
MMRF_1963	First line of therapy	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	40	Q week	Q week					1		1
MMRF_1963	First line of therapy	Lenalidomide			mg	PO	Log Forms	Induction	Induction	Checked	25	QD (D1-21)	QD (D1-21)					1		1
MMRF_1992	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					2	113	1
MMRF_1992	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Induction	Induction		430	Other	D 1, 8, 15					2	19	1
MMRF_1992	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	D1,2,3,5,6					1	111	1
MMRF_1992	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					19	113	1
MMRF_1992	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					166	166	1
MMRF_1992	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					467	659	1
MMRF_1992	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		40	Other	D1,8,15					467	653	1
MMRF_1992	Second Line Therapy (after first relapse)	Panobinostat		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		20	Other	DAYS 1, 3, 5, 15, 17, 19.					467	655	1
MMRF_1992	Third Line Therapy (following 2nd relapse)	Elotuzumab		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Consolidation	Consolidation		10	Other	D1,8,15,22					701	786	1
MMRF_1992	Third Line Therapy (following 2nd relapse)	Pomalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Consolidation	Consolidation		4	QD (D1-21)	QD (D1-21)					701	786	1
MMRF_1992	Fourth Line Therapy (following 3rd relapse)	Daratumumab		Disease progression/Relapse	mg	IV SubQ	Log Forms	Consolidation	Consolidation		1800	Other	D1,8,15,22					811	961	1
MMRF_1992	Third Line Therapy (following 2nd relapse)	Dexamethasone		Investigator decision for other reasons	mg	IV	Log Forms	Consolidation	Consolidation		8	Other	D1,8,15,22					701	786	1
MMRF_1992	Fourth Line Therapy (following 3rd relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Consolidation	Consolidation		16	Q week	Q week					975	1051	1
MMRF_1992	Fourth Line Therapy (following 3rd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		4	QD (D1-21)	QD (D1-21)					975	1051	1
MMRF_1992	Fifth Line Therapy (following 4th relapse)	IBRUTINIB		Disease progression/Relapse	mg/dL	PO	Log Forms	Other	SALVAGE		840	Q day	Q day					1205	1498	1
MMRF_1992	Fifth Line Therapy (following 4th relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Other	SALVAGE		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1198	1493	1
MMRF_1992	Fifth Line Therapy (following 4th relapse)	Dexamethasone		Completed regimen	mg	IV	Log Forms	Other	SALVAGE		4	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1198	1493	1
MMRF_1992	Fifth Line Therapy (following 4th relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Other	SALVAGE		56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1506	1569	1
MMRF_1992	Fifth Line Therapy (following 4th relapse)	Cyclophosphamide		Disease progression/Relapse	mg/m^2	IV	Log Forms	Other	SALVAGE		300	Q week	Q week					1506	1562	1
MMRF_1992	Fifth Line Therapy (following 4th relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		20	Q week	Q week					1506	1569	1
MMRF_1992	Ninth Line of Therapy (following 8th relapse)	REGN5458			mg	IV	Log Forms	Unknown	Unknown	Checked	5	QWK	QWK					2217		1
MMRF_1992	Eighth Line of Therapy (following 7th relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		8	QWK	QWK					1849	2002	1
MMRF_1992	Eighth Line of Therapy (following 7th relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		3	QD (D1-7)	QD (D1-7)					1849	2002	1
MMRF_1992	Eighth Line of Therapy (following 7th relapse)	Carfilzomib		Disease progression/Relapse	mg	IV	Log Forms	Unknown	Unknown		73.08	QWK	QWK					1849	2002	1
MMRF_1992	Eighth Line of Therapy (following 7th relapse)	Daratumumab		Disease progression/Relapse	mg	IV	Log Forms	Unknown	Unknown		1500	QWK	QWK					1848	2001	1
MMRF_1992	Seventh Line of Therapy (following 6th relapse)	SELINEXOR		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		100	Other	WEEKLY ON DAYS 1, 8, 15 & 22 OF CYCLE					1717	1843	1
MMRF_1992	Seventh Line of Therapy (following 6th relapse)	Carfilzomib		Disease progression/Relapse	mg	IV	Log Forms	Unknown	Unknown		110.88	QWK	QWK					1717	1849	1
MMRF_1992	Sixth Line Therapy (following 5th relapse)	JNJ-64407564		Disease progression/Relapse	MCG/KG	IV	Log Forms	Unknown	Unknown		2.25	QWK	QWK					1596	1694	1
MMRF_1998	First line of therapy	Bortezomib		DEATH	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	292	1
MMRF_1998	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	121	1
MMRF_1998	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		300	Other	QD D1 AND D8					1	85	1
MMRF_1998	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		25	Q day	Q day					162	252	1
MMRF_1998	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		8	Q week	Q week					162	252	1
MMRF_2000	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	93	1
MMRF_2000	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		300	Other	D1, D8					1	8	1
MMRF_2000	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	93	1
MMRF_2000	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					18	93	1
MMRF_2000	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Other	ONCE					126	126	1
MMRF_2000	First line of therapy	Lenalidomide			mg	PO	Log Forms	Induction	Induction	Checked	10	QD (D1-21)	QD (D1-21)					287		1
MMRF_2000	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					287	638	1
MMRF_2000	First line of therapy	Dexamethasone			mg	PO	Log Forms	Maintenance	Maintenance	Checked	12	Q week	Q week					638		1
MMRF_2000	First line of therapy	Elotuzumab			mg/kg	IV	Log Forms	Consolidation	Consolidation	Checked	10	Q week	Q week					1178		1
MMRF_2002	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	450	1
MMRF_2002	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		300	Other	D1, D8					1	80	1
MMRF_2002	First line of therapy	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_2002	First line of therapy	Lenalidomide			mg	PO	Log Forms	Induction	Induction	Checked	15	Other	WD (D1, 4, 11, AND 18)					80		1
MMRF_2018	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	29	1
MMRF_2018	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	29	1
MMRF_2018	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	29	1
MMRF_2018	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Other	ONCE A WEEK. X 3  OUT OF 4 WEEKS,					29	126	1
MMRF_2018	First line of therapy	Thalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		100	Q day	Q day					29	211	1
MMRF_2018	First line of therapy	Cyclophosphamide		Lack of response	mg/m^2	IV	Log Forms	Induction	Induction		300	Other	D1 AND D8					29	126	1
MMRF_2018	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	WEEKLY X 3 WEEKS					80	1113	1
MMRF_2018	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					126	127	1
MMRF_2018	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					133	316	1
MMRF_2018	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					329	728	1
MMRF_2018	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		70	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					742	1113	1
MMRF_2018	First line of therapy	Ixazomib			mg	PO	Log Forms	Induction	Induction	Checked	4	Q week	Q week					1120		1
MMRF_2081	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	100	1
MMRF_2081	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	100	1
MMRF_2081	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					8	100	1
MMRF_2081	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Maintenance	Maintenance		1.3	Other	EVERY OTHER WEEK					373	736	1
MMRF_2081	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		180	Other	ONCE					179	179	1
MMRF_2081	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					373	736	1
MMRF_2081	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		20	Q week	Q week					373	736	1
MMRF_2081	First line of therapy	Elotuzumab		Completed regimen	mg/kg	IV	Log Forms	Maintenance	Maintenance		10	Other	EVERY OTHER WEEK					736	1814	1
MMRF_2081	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					736	1186	1
MMRF_2081	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		10	Q week	Q week					736	1186	1
MMRF_2081	Second Line Therapy (after first relapse)	Pomalidomide			mg	PO	Log Forms	Unknown	Unknown	Checked	2	Q day	Q day					1717		1
MMRF_2081	Second Line Therapy (after first relapse)	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Unknown	Unknown		36	Other	TWICE WEEKLY					1731	2024	1
MMRF_2081	Second Line Therapy (after first relapse)	Daratumumab			mg/kg	IV	Log Forms	Unknown	Unknown	Checked	20	QWK	QWK					1731		1
MMRF_2082							Log Forms			Checked	0									1
MMRF_2082	Third Line Therapy (following 2nd relapse)	Daratumumab			mg/kg	IVPB	Log Forms	Maintenance	Maintenance	Checked	16	Other	EVERY OTHER WEEK					1307		1
MMRF_2082	Third Line Therapy (following 2nd relapse)	Dexamethasone			mg	IVPB	Log Forms	Maintenance	Maintenance	Checked	20	Other	EVERY OTHER WEEK					1307		1
MMRF_2082	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					1	284	1
MMRF_2082	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	284	1
MMRF_2082	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	284	1
MMRF_2082	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					508	508	1
MMRF_2082	Second Line Therapy (after first relapse)	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Consolidation	Consolidation		1.3	Q week	Q week					437	498	1
MMRF_2082	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		40	Q week	Q week					437	498	1
MMRF_2082	Second Line Therapy (after first relapse)	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					437	498	1
MMRF_2107	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					1	295	1
MMRF_2107	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	1161	1
MMRF_2107	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	1100	1
MMRF_2107	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Other	QOW					295	375	1
MMRF_2107	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	5	QD (D1-21)	QD (D1-21)					1161		1
MMRF_2144	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	68	1
MMRF_2144	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	68	1
MMRF_2144	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		300	Other	DAYS 1 AND 8 OF EVERY 21 DAY CYCLE					1	68	1
MMRF_2144	First line of therapy	Lenalidomide			mg	PO	Log Forms	Induction	Induction	Checked	10	QD (D1-21)	QD (D1-21)					253		1
MMRF_2176	First line of therapy	Bortezomib			mg/m^2	IV SubQ	Log Forms	Induction	Induction	Checked	1.3	Q week	Q week					1		1
MMRF_2176	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	1348	1
MMRF_2176	First line of therapy	Lenalidomide			mg	PO	Log Forms	Induction	Induction	Checked	25	QD (D1-21)	QD (D1-21)					1		1
MMRF_2180	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					1	102	1
MMRF_2180	First line of therapy	Dexamethasone		Lack of response	mg	PO	Log Forms	Induction	Induction		10	Q week	Q week					1	176	1
MMRF_2180	First line of therapy	Bortezomib		Lack of response	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					1	176	1
MMRF_2180	First line of therapy	Cyclophosphamide		Lack of response	mg	PO	Log Forms	Induction	Induction		50	Q week	Q week					102	176	1
MMRF_2180	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					176	380	1
MMRF_2180	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		5	Other	TIW					176	380	1
MMRF_2180	First line of therapy	Prednisone		Completed regimen	mg	PO	Log Forms	Induction	Induction		30	Other	TIW					176	380	1
MMRF_2180	Second Line Therapy (after first relapse)	Daratumumab			mg/kg	IV	Log Forms	Consolidation	Consolidation	Checked	16	Other	QOW					1033		1
MMRF_2180	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Consolidation	Consolidation	Checked	4	Other	2 DAYS POST DARA INFUSION					1033		1
MMRF_2180	Second Line Therapy (after first relapse)	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		3	QD (D1-21)	QD (D1-21)					1312	1314	1
MMRF_2180	Second Line Therapy (after first relapse)	Pomalidomide			mg	PO	Log Forms	Induction	Induction	Checked	1	QD (D1-21)	QD (D1-21)					1340		1
MMRF_2199	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					1	237	1
MMRF_2199	First line of therapy	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	20	Q week	Q week					1		1
MMRF_2199	First line of therapy	Lenalidomide			mg	PO	Log Forms	Induction	Induction	Checked	15	QD (D1-21)	QD (D1-21)					13		1
MMRF_2199	First line of therapy	Prednisone		Completed regimen	mg	PO	Log Forms	Induction	Induction		30	Other	MWF					237	461	1
MMRF_2207	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					1	122	1
MMRF_2207	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	122	1
MMRF_2207	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	122	1
MMRF_2207	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					172	172	1
MMRF_2207	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		36	Q week	Q week					323	802	1
MMRF_2207	First line of therapy	Dexamethasone			mg	PO	Log Forms	Consolidation	Consolidation	Checked	20	Q week	Q week					323		1
MMRF_2207	First line of therapy	Lenalidomide			mg	PO	Log Forms	Consolidation	Consolidation	Checked	15	QD (D1-21)	QD (D1-21)					323		1
MMRF_2207	First line of therapy	Ixazomib			mg	PO	Log Forms	Consolidation	Consolidation	Checked	3	Q week	Q week					802		1
MMRF_2240	First line of therapy	Bortezomib		Lack of response	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Other	D1, D8, D15					1	90	1
MMRF_2240	First line of therapy	Cyclophosphamide		Lack of response	mg/m^2	PO	Log Forms	Induction	Induction		300	Other	D1 AND D8					1	68	1
MMRF_2240	First line of therapy	Dexamethasone		Lack of response	mg	PO	Log Forms	Induction	Induction		20	QWK	QWK					1	91	1
MMRF_2240	First line of therapy	Bortezomib		Lack of response	mg/m^2	IV SubQ	Log Forms	Consolidation	Consolidation		1.3	Other	WEEKLY X 3 WEEKS ON/1 WEEK OFF					91	202	1
MMRF_2240	First line of therapy	Lenalidomide		Lack of response	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					91	202	1
MMRF_2240	First line of therapy	Dexamethasone		Lack of response	mg	PO	Log Forms	Consolidation	Consolidation		20	Other	WEEKLY X 3 WEEKS ON/1 WEEK OFF					91	202	1
MMRF_2240	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					202	672	1
MMRF_2240	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					202	672	1
MMRF_2240	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		10	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					202	672	1
MMRF_2240	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Other	ONCE					733	733	1
MMRF_2240	Second Line Therapy (after first relapse)	Daratumumab		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		16	Other	ONCE WEEKLY					849	1083	1
MMRF_2240	Second Line Therapy (after first relapse)	Pomalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		2	QD (D1-21)	QD (D1-21)					846	1141	1
MMRF_2240	Second Line Therapy (after first relapse)	VENETOCLAX		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		400	Q day	Q day					1015	1128	1
MMRF_2240	Second Line Therapy (after first relapse)	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		20	Other	ONCE					1070	1070	1
MMRF_2240	Second Line Therapy (after first relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Induction	Induction		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1071	1128	1
MMRF_2240	Fourth Line Therapy (following 3rd relapse)	CYTOXAN		Disease progression/Relapse	mg/m^2	IV	Log Forms	Other	SALVAGE		300	QD (D1-4)	QD (D1-4)					1136	1140	1
MMRF_2240	Third Line Therapy (following 2nd relapse)	ETOPOSIDE		Disease progression/Relapse	mg/m^2	IV	Log Forms	Other	SALVAGE		30	QD (D1-4)	QD (D1-4)					1136	1140	1
MMRF_2240	Third Line Therapy (following 2nd relapse)	CISPLATIN		Disease progression/Relapse	mg/m^2	IV	Log Forms	Other	SALVAGE		10	QD (D1-4)	QD (D1-4)					1136	1140	1
MMRF_2240	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		40	QD (D1-4)	QD (D1-4)					1136	1140	1
MMRF_2240	Second Line Therapy (after first relapse)	MEKINIST		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		2	Other	TIW					825	1141	1
MMRF_2240							Log Forms													1
MMRF_2240	Fourth Line Therapy (following 3rd relapse)	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Induction	Induction		1.3	Other	X3/4 WEEKS					1176	1544	1
MMRF_2240	Fourth Line Therapy (following 3rd relapse)	VENETOCLAX		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		100	Other	M-F UNTIL MARCH 2018, THEN MWF					1176	1544	1
MMRF_2289	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	239	1
MMRF_2289	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	Other	D1-D14					1	239	1
MMRF_2289	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	D1, D2, D4, D5, D8, D9, D10, D11					1	239	1
MMRF_2289	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					239	358	1
MMRF_2289	Second Line Therapy (after first relapse)	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Consolidation	Consolidation		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					359	431	1
MMRF_2289	Second Line Therapy (after first relapse)	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		300	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					359	431	1
MMRF_2289	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		40	QD (D1-21)	QD (D1-21)					359	431	1
MMRF_2289	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					442	442	1
MMRF_2289	Second Line Therapy (after first relapse)	Ixazomib		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		4	Q week	Q week					550	1033	1
MMRF_2289	Third Line Therapy (following 2nd relapse)	SAR650984 ISATUXIMAB			mg/kg	IV	Log Forms	Induction	Induction	Checked	10	Other	D1, 15					1047		1
MMRF_2289	Third Line Therapy (following 2nd relapse)	Carfilzomib			mg/m^2	IV	Log Forms	Induction	Induction	Checked	27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1047		1
MMRF_2289	Third Line Therapy (following 2nd relapse)	Dexamethasone			mg	IV	Log Forms	Induction	Induction	Checked	20	Other	D1, 15					1047		1
MMRF_2289	Third Line Therapy (following 2nd relapse)	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	4	Other	D2, 8, 9, 16					1047		1
MMRF_2341	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					1	85	1
MMRF_2341	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	85	1
MMRF_2341	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	85	1
MMRF_2344	First line of therapy	Bortezomib		Lack of response	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	85	1
MMRF_2344	First line of therapy	Cyclophosphamide		Lack of response	mg	IV	Log Forms	Induction	Induction		300	Other	D1, D8					1	22	1
MMRF_2344	First line of therapy	Dexamethasone		Patient decision	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	596	1
MMRF_2344	Second Line Therapy (after first relapse)	Bortezomib		Lack of response	mg/m^2	IV SubQ	Log Forms	Consolidation	Consolidation		1.3	Q week	Q week					219	328	1
MMRF_2344	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					22	175	1
MMRF_2344	First line of therapy	Cyclophosphamide		Lack of response	mg/m^2	IV	Log Forms	Consolidation	Consolidation		300	Q week	Q week					106	267	1
MMRF_2344	Second Line Therapy (after first relapse)	Cyclophosphamide		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms	Consolidation	Consolidation		250	Q week	Q week					279	328	1
MMRF_2344	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		15	Q day	Q day					279	328	1
MMRF_2344	Second Line Therapy (after first relapse)	Daratumumab		Completed regimen	mg/kg	IV	Log Forms	Unknown	Unknown		16	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					338	568	1
MMRF_2344	Second Line Therapy (after first relapse)	Pomalidomide		Completed regimen	mg	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					338	568	1
MMRF_2344	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Other	ONCE					572	572	1
MMRF_2344	Third Line Therapy (following 2nd relapse)	Elotuzumab			mg/kg	IV	Log Forms	Maintenance	Maintenance	Checked	10	Other	UNKNOWN					1241		1
MMRF_2344	Third Line Therapy (following 2nd relapse)	Pomalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	2	QD (D1-21)	QD (D1-21)					1241		1
MMRF_2344	Third Line Therapy (following 2nd relapse)	Dexamethasone			mg	PO	Log Forms	Maintenance	Maintenance	Checked	4	Other	WEEKLY ON POM WEEKS THAT PATIENT DOES NOT RECEIVE ELOTUZUMAB					1241		1
MMRF_2353	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Other	DAY 1, 8 , 15					1	127	1
MMRF_2353	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	DAY 1, 8, 15					1	127	1
MMRF_2353	First line of therapy	Lenalidomide		Lack of response	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	288	1
MMRF_2353	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					443	443	1
MMRF_2353	First line of therapy	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Induction	Induction		500	Other	WEEKLY					176	394	1
MMRF_2353	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					176	394	1
MMRF_2353	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	WEEKLY					176	394	1
MMRF_2366	First line of therapy	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Other	D 1, 8, 15					1	42	1
MMRF_2366	First line of therapy	Cyclophosphamide		Disease progression/Relapse	mg/m^2	IV	Log Forms	Induction	Induction		250	Other	D 1, 8 15					1	42	1
MMRF_2366	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		20	Other	D 1, 8, 15					1	42	1
MMRF_2366	Second Line Therapy (after first relapse)	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms	Consolidation	Consolidation		1.32	Other	D 1,8,15					80	261	1
MMRF_2366	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Consolidation	Consolidation		15	QD (D1-21)	QD (D1-21)					80	164	1
MMRF_2366	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		20	Other	DAY 1,8,15					80	261	1
MMRF_2366	Third Line Therapy (following 2nd relapse)	Bendamustine		Disease progression/Relapse	mg/m^2	IV	Log Forms	Unknown	Unknown		70	Other	DAYS 1, 4					261	287	1
MMRF_2366	Third Line Therapy (following 2nd relapse)	Bortezomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Consolidation	Consolidation		1.3	Other	DAY 1, 4					261	287	1
MMRF_2366	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		20	Other	DAY 1, 4					261	287	1
MMRF_2366	Fourth Line Therapy (following 3rd relapse)	Carfilzomib			mg/m^2	IV	Log Forms	Consolidation	Consolidation	Checked	20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					324		1
MMRF_2366	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		20	Other	D1, 8, 15					324	387	1
MMRF_2366	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		4	Other	D2, 9, 16					324	387	1
MMRF_2366	Fourth Line Therapy (following 3rd relapse)	Dexamethasone			mg	PO	Log Forms	Consolidation	Consolidation	Checked	4	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					387		1
MMRF_2373	First line of therapy	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Other	D 1, 4 , 11, 18					1	146	1
MMRF_2373	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	146	1
MMRF_2373	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		40	Other	D 1, 4, 11 , 18					1	146	1
MMRF_2373	Second Line Therapy (after first relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Consolidation	Consolidation		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					274	351	1
MMRF_2373	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		15	QD (D1-21)	QD (D1-21)					64	415	1
MMRF_2373	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					175	536	1
MMRF_2373	Third Line Therapy (following 2nd relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Consolidation	Consolidation		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					361	515	1
MMRF_2373	Fifth Line Therapy (following 4th relapse)	Pomalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	2	QD (D1-21)	QD (D1-21)					508		1
MMRF_2373	Fifth Line Therapy (following 4th relapse)	Dexamethasone		Completed regimen	mg	IV	Log Forms	Maintenance	Maintenance		40	Q week	Q week					507	536	1
MMRF_2373	Fifth Line Therapy (following 4th relapse)	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Maintenance	Maintenance		2.2	Q week	Q week					507	526	1
MMRF_2373	Fifth Line Therapy (following 4th relapse)	Daratumumab		Completed regimen	mg/kg	IV	Log Forms	Maintenance	Maintenance		16	Q week	Q week					500	526	1
MMRF_2373	Fourth Line Therapy (following 3rd relapse)	BCNU		Completed regimen	mg	IV	Log Forms	Maintenance	Maintenance		520	Other	ONCE					455	455	1
MMRF_2373	Fourth Line Therapy (following 3rd relapse)	Melphalan		Completed regimen	mg	IV	Log Forms	Maintenance	Maintenance		173	Other	ONCE					456	456	1
MMRF_2373	Fourth Line Therapy (following 3rd relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Maintenance	Maintenance		16	Q week	Q week					445	493	1
MMRF_2373	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					175	175	1
MMRF_2404	First line of therapy	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Other	WEEKLY X 3 WEEKS ON / 1 WEEK OFF					1	29	1
MMRF_2404	First line of therapy	Cyclophosphamide		Disease progression/Relapse	mg/m^2	IV	Log Forms	Induction	Induction		300	Other	DAYS 1 ,8					1	29	1
MMRF_2404	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		40	Other	WEEKLY X 3 WEEKS ON / 1 WEEK OFF					1	29	1
MMRF_2404	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					103	103	1
MMRF_2404	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Consolidation	Consolidation		40	Q day	Q day					33	202	1
MMRF_2404	First line of therapy	Cyclophosphamide		Disease progression/Relapse	mg/m^2	PO	Log Forms	Consolidation	Consolidation		400	QD (D1-4)	QD (D1-4)					33	202	1
MMRF_2404	First line of therapy	CISPLATIN		Disease progression/Relapse	mg/m^2	IV	Log Forms	Consolidation	Consolidation		15	QD (D1-4)	QD (D1-4)					33	202	1
MMRF_2404	First line of therapy	ETOPOSIDE		Disease progression/Relapse	mg/m^2	IV	Log Forms	Consolidation	Consolidation		40	Q day	Q day					33	202	1
MMRF_2404	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		25	Q day	Q day					207	245	1
MMRF_2404	Second Line Therapy (after first relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Consolidation	Consolidation		27	Q day	Q day					207	245	1
MMRF_2404	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		10	Q day	Q day					207	245	1
MMRF_2410	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	64	1
MMRF_2410	First line of therapy	Lenalidomide			mg	PO	Log Forms	Induction	Induction	Checked	25	QD (D1-21)	QD (D1-21)					1		1
MMRF_2410	First line of therapy	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					75		1
MMRF_2410	First line of therapy	Bortezomib			mg/m^2	IV SubQ	Log Forms	Induction	Induction	Checked	1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_2445	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Consolidation	Consolidation		2.75	Other	2X A WEEK					1	361	1
MMRF_2445	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	479	1
MMRF_2445	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					116	479	1
MMRF_2445	Second Line Therapy (after first relapse)	Elotuzumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Consolidation	Consolidation		10	Q week	Q week					585	704	1
MMRF_2445	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		20	QD (D1-21)	QD (D1-21)					592	691	1
MMRF_2445	Third Line Therapy (following 2nd relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		20	QD (D1-4)	QD (D1-4)					779	782	1
MMRF_2445	Third Line Therapy (following 2nd relapse)	CISPLATIN		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		7.5	QD (D1-4)	QD (D1-4)					779	782	1
MMRF_2445	Third Line Therapy (following 2nd relapse)	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		250	QD (D1-4)	QD (D1-4)					779	782	1
MMRF_2445	Third Line Therapy (following 2nd relapse)	ETOPOSIDE		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		20	QD (D1-4)	QD (D1-4)					779	782	1
MMRF_2445	Third Line Therapy (following 2nd relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Consolidation	Consolidation		16	Other	QOW					802	1110	1
MMRF_2445	Fourth Line Therapy (following 3rd relapse)	TRAMETINIB			mg	PO	Log Forms	Other	SALVAGE	Checked	2	QD (D1-21)	QD (D1-21)					1120		1
MMRF_2445	Fourth Line Therapy (following 3rd relapse)	DABRAFENIB			mg	PO	Log Forms	Other	SALVAGE	Checked	75	BID	BID					1120		1
MMRF_2445	Fourth Line Therapy (following 3rd relapse)	Daratumumab			mg/kg	IV	Log Forms	Maintenance	Maintenance	Checked	16	QWK	QWK					1501		1
MMRF_2445	Fourth Line Therapy (following 3rd relapse)	VENCLEXTA		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		300	Q day	Q day					1135	1192	1
MMRF_2457	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Other	WEEKLY X3, 3 WEEKD ON 1/WEEK OFF					1	9	1
MMRF_2457	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	331	1
MMRF_2457	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	Other	WEEKLY X 3, 3 WEEKS ON/1 WEEK OFF					1	40	1
MMRF_2457	First line of therapy	Cyclophosphamide		Disease progression/Relapse	mg/kg	PO	Log Forms	Induction	Induction		1.5	Q week	Q week					85	331	1
MMRF_2457	First line of therapy	Prednisone		Completed regimen	mg	PO	Log Forms	Induction	Induction		10	Other	THREE TIMES WEEK					17	211	1
MMRF_2457	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		20	Q week	Q week					1	198	1
MMRF_2457	First line of therapy	Prednisone		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		10	Other	THREE TIMES WEEK					264	331	1
MMRF_2457	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					369	369	1
MMRF_2457	Third Line Therapy (following 2nd relapse)	Elotuzumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Consolidation	Consolidation		10	Other	DAYS 1, 8, 15, 22					587	699	1
MMRF_2457	Third Line Therapy (following 2nd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		4	QD (D1-21)	QD (D1-21)					587	699	1
MMRF_2457	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		28	Other	DAYS 1, 8, 15, 22					587	699	1
MMRF_2457	Third Line Therapy (following 2nd relapse)	Daratumumab		Disease progression/Relapse	mg	IV SubQ	Log Forms	Consolidation	Consolidation		1800	Q week	Q week					734	805	1
MMRF_2457	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		40	Other	Q24H					825	828	1
MMRF_2457	Fourth Line Therapy (following 3rd relapse)	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		10	Other	Q24H					825	828	1
MMRF_2457	Fourth Line Therapy (following 3rd relapse)	CISPLATIN		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		10	Other	Q24H					825	828	1
MMRF_2457	Fourth Line Therapy (following 3rd relapse)	ETOPOSIDE		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		30	Other	Q24H					825	828	1
MMRF_2457	Fourth Line Therapy (following 3rd relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Consolidation	Consolidation		16	Q week	Q week					881	916	1
MMRF_2457	Fourth Line Therapy (following 3rd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		4	QD (D1-21)	QD (D1-21)					881	909	1
MMRF_2457	Fourth Line Therapy (following 3rd relapse)	Panobinostat		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		15	Other	EVERY OTHER DAY.					905	929	1
MMRF_2457	Fifth Line Therapy (following 4th relapse)	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Unknown	Unknown		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1051	1058	1
MMRF_2457	Fifth Line Therapy (following 4th relapse)	Pomalidomide		Completed regimen	mg	PO	Log Forms	Unknown	Unknown		2	QD (D1-21)	QD (D1-21)					1051	1058	1
MMRF_2457	Fifth Line Therapy (following 4th relapse)	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Unknown	Unknown		8	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1051	1058	1
MMRF_2469	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					8	235	1
MMRF_2469	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	235	1
MMRF_2469	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	235	1
MMRF_2469	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Other	ONCE					396	396	1
MMRF_2469	First line of therapy	Elotuzumab		Completed regimen	mg/kg	IV	Log Forms	Consolidation	Consolidation		20	Other	DAY 1 OF EVERY 28 DAY CYCLE					401	708	1
MMRF_2469	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					736		1
MMRF_2472	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QWK	QWK					1	1086	1
MMRF_2472	First line of therapy	Cyclophosphamide		Lack of response	mg	PO	Log Forms	Induction	Induction		500	Q week	Q week					1	1	1
MMRF_2472	First line of therapy	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	40	QWK	QWK					1		1
MMRF_2472	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					36	283	1
MMRF_2472	First line of therapy	Lenalidomide			mg	PO	Log Forms	Induction	Induction	Checked	15	QD (D1-21)	QD (D1-21)					283		1
MMRF_2498	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1	106	1
MMRF_2498	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1	111	1
MMRF_2498	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	111	1
MMRF_2498	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					173	173	1
MMRF_2498	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	TWICE MONTHLY					288	343	1
MMRF_2498	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		40	Other	TWICE MONTHLY					288	343	1
MMRF_2498	First line of therapy	Ixazomib		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		4	QD (D1-21)	QD (D1-21)					334	664	1
MMRF_2498	Second Line Therapy (after first relapse)	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	QWK	QWK					1410	1878	1
MMRF_2498	Second Line Therapy (after first relapse)	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		2	Q day	Q day					1349	1377	1
MMRF_2498	Second Line Therapy (after first relapse)	Daratumumab		Adverse Event or co-morbidity	mg/kg	IV	Log Forms	Maintenance	Maintenance		20	QWK	QWK					1347	1377	1
MMRF_2538	Fourth Line Therapy (following 3rd relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Unknown	Unknown		16	QWK	QWK					1326	1404	1
MMRF_2538	Fourth Line Therapy (following 3rd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		2	QWK	QWK					1326	1404	1
MMRF_2538	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Other	D1,8,15,22					1	727	1
MMRF_2538	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	77	1
MMRF_2538	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1	99	1
MMRF_2538	First line of therapy	Prednisone		Completed regimen	mg	PO	Log Forms	Induction	Induction		30	Other	Q MONDAY, WED, FRIDAY					162	727	1
MMRF_2538	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		300	Other	Q 3 WEEKS ON, 1 WEEK OFF					92	99	1
MMRF_2538	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					162	727	1
MMRF_2538	First line of therapy	Elotuzumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Induction	Induction		10	Q week	Q week					727	977	1
MMRF_2538	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					727	977	1
MMRF_2538	First line of therapy	Prednisone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		10	Other	MWF					727	977	1
MMRF_2538	Second Line Therapy (after first relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Unknown	Unknown		16	Other	D1,8,15,22					1075	1326	1
MMRF_2538	Second Line Therapy (after first relapse)	Bortezomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Maintenance	Maintenance		1.3	Other	D1,8, 15, 22					1075	1326	1
MMRF_2550	First line of therapy	Bortezomib			mg/m^2	IV SubQ	Log Forms	Induction	Induction	Checked	1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_2550	First line of therapy	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_2550	First line of therapy	Lenalidomide			mg	PO	Log Forms	Induction	Induction	Checked	25	QD (D1-21)	QD (D1-21)					1		1
MMRF_2564	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					1	71	1
MMRF_2564	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	Q week	Q week					1	414	1
MMRF_2564	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	71	1
MMRF_2564	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Other	ONCE					118	118	1
MMRF_2564	Second Line Therapy (after first relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Maintenance	Maintenance		16	QWK	QWK					1114	1367	1
MMRF_2564	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	Other	QD FOR THREE WEEKS, THEN ONE WEEK OFF.					1110	1367	1
MMRF_2564	Third Line Therapy (following 2nd relapse)	Daratumumab			mg/kg	IV	Log Forms			Checked	16	QWK	QWK					1367		1
MMRF_2564	Third Line Therapy (following 2nd relapse)	Bortezomib			mg/m^2	IV SubQ	Log Forms			Checked	1.3	Q week	Q week					1514		1
MMRF_2564	Third Line Therapy (following 2nd relapse)	Pomalidomide			mg	PO	Log Forms			Checked	3	QD (D1-21)	QD (D1-21)					1367		1
MMRF_2577	Second Line Therapy (after first relapse)	Daratumumab		Completed regimen	mg/kg	IV	Log Forms	Unknown	Unknown		16	Other	Q ALT WK					1396	1737	1
MMRF_2577	Third Line Therapy (following 2nd relapse)	Cyclophosphamide			mg	IV	Log Forms	Unknown	Unknown	Checked	747	QWK	QWK					1737		1
MMRF_2577	Third Line Therapy (following 2nd relapse)	Dexamethasone			mg	PO	Log Forms	Unknown	Unknown	Checked	4	QWK	QWK					1737		1
MMRF_2577	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					1	191	1
MMRF_2577	First line of therapy	Cyclophosphamide		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Induction	Induction		200	Q week	Q week					1	171	1
MMRF_2577	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	792	1
MMRF_2577	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					141	792	1
MMRF_2577	First line of therapy	Ixazomib		Completed regimen	mg	PO	Log Forms	Induction	Induction		4	Other	D1,8,15					185	792	1
MMRF_2577	First line of therapy	Daratumumab		Completed regimen	mg/kg	IV	Log Forms	Induction	Induction		16	Q week	Q week					470	703	1
MMRF_2577	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Other	ONCE					779	779	1
MMRF_2577	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					1151	1375	1
MMRF_2577	First line of therapy	Ixazomib		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		3	Other	D1,8,15					948	1123	1
MMRF_2614	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					1	180	1
MMRF_2614	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	113	1
MMRF_2614	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	155	1
MMRF_2614	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Other	ONCE					181	181	1
MMRF_2614	First line of therapy	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Induction	Induction		50	QD (D1-21)	QD (D1-21)					142	171	1
MMRF_2614	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		5	Other	M/W/F X 3/4 WEEKS					300	507	1
MMRF_2614	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		10	Other	M/W/F X 3/4 WEEKS					510	1252	1
MMRF_2614	First line of therapy	Prednisone		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		30	Other	TIW					35	741	1
MMRF_2614	First line of therapy	Prednisone		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		1	Other	TIW					741	1252	1
MMRF_2614	Third Line Therapy (following 2nd relapse)	Pomalidomide			mg	PO	Log Forms			Checked	2	QD (D1-21)	QD (D1-21)					1486		1
MMRF_2614	Third Line Therapy (following 2nd relapse)	Daratumumab			mg/kg	IV	Log Forms			Checked	16	Other	QOW X 8 DOSES; C7 MONTHLY					1486		1
MMRF_2614	Second Line Therapy (after first relapse)	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Other	RELAPSED		20	Q week	Q week					1267	1483	1
MMRF_2614	Second Line Therapy (after first relapse)	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Other	RELAPSED		25	QD (D1-21)	QD (D1-21)					1267	1483	1
MMRF_2614	Second Line Therapy (after first relapse)	Elotuzumab		Investigator decision for other reasons	mg/kg	IV	Log Forms				10	Q week	Q week					1267	1483	1
MMRF_1037	First line of therapy	Dexamethasone		Patient decision	mg	PO	Log Forms				40	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1	88	1
MMRF_1037	First line of therapy	Lenalidomide		Patient decision	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					15	88	1
MMRF_1088	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg	IVB	Log Forms				2.7	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					3	87	1
MMRF_1088	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms				40	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1	13	1
MMRF_1088	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					124	126	1
MMRF_1088	First line of therapy	Bortezomib		Completed regimen	mg	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					109	118	1
MMRF_1102	First line of therapy	Thalidomide		Patient decision	mg	PO	Log Forms				200	Q day	Q day					28	34	1
MMRF_1102	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms				20	Q week	Q week					1	13	1
MMRF_1128	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IVB	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	116	1
MMRF_1128	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms				300	Other	DAY 1 & 8					1	40	1
MMRF_1128	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				4	Other	DAY 1-2, 4-5, 8-9, 11-12					1	117	1
MMRF_1128	First line of therapy	Thalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		100	Q day	Q day					62	147	1
MMRF_1128	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					313	537	1
MMRF_1128	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					537	634	1
MMRF_1128	First line of therapy	Lenalidomide		Patient decision	mg	PO	Log Forms	Maintenance	Maintenance		5	Other	QOD D1-21					634	1118	1
MMRF_1128	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		200	Q day	Q day					214	214	1
MMRF_1475	First line of therapy	Lenalidomide			mg	PO	Log Forms	Induction	Induction	Checked	25	QD (D1-21)	QD (D1-21)					1		1
MMRF_1735	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	74	1
MMRF_1735	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	85	1
MMRF_1735	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1	85	1
MMRF_1735	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					176	241	1
MMRF_1735	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					241	507	1
MMRF_1735	Second Line Therapy (after first relapse)	Pomalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					516	1011	1
MMRF_1735	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		40	Q week	Q week					516	718	1
MMRF_1735	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		200	Q day	Q day					106	107	1
MMRF_1735	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	QWK	QWK					718	764	1
MMRF_1735	Third Line Therapy (following 2nd relapse)	Bortezomib		Adverse Event or co-morbidity	mg	IV SubQ	Log Forms	Other	SALVAGE		3.3	Other	EVERY 2 WEEKS					2082	2140	1
MMRF_1735	Third Line Therapy (following 2nd relapse)	Daratumumab			mg	IV	Log Forms	Other	SALVAGE	Checked	1800	Other	W 3 WEEKS					2032		1
MMRF_1735	Third Line Therapy (following 2nd relapse)	Daratumumab		SWITCHED FREQUENCY TO Q 3 WEEKS	mg	IV	Log Forms	Other	SALVAGE		1800	QWK	QWK					1968	2032	1
MMRF_1735	Third Line Therapy (following 2nd relapse)	Bortezomib		Adverse Event or co-morbidity	mg	IV SubQ	Log Forms	Other	SALVAGE		3.2	Q week	Q week					1955	2074	1
MMRF_1735	Third Line Therapy (following 2nd relapse)	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	SALVAGE		4	QD (D1-21)	QD (D1-21)					1940	1953	1
MMRF_1735	Third Line Therapy (following 2nd relapse)	Dexamethasone			mg	PO	Log Forms	Other	SALVAGE	Checked	40	Q week	Q week					1937		1
MMRF_1061	First line of therapy	Bortezomib		AUTOLOGOUS BONE MARROW TRANSPLANT	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	74	1
MMRF_1061	First line of therapy	Dexamethasone		AUTOLOGOUS BONE MARROW TRANSPLANT	mg	PO	Log Forms				20	Other	DAYS 1,2, 4,5, 8, 9, 11, 12					1	74	1
MMRF_1061	First line of therapy	Lenalidomide		AUTOLOGOUS BONE MARROW TRANSPLANT	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					15	74	1
MMRF_1061	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Induction	Induction		240	Q day	Q day					118	118	1
MMRF_1061	Second Line Therapy (after first relapse)	Carfilzomib			mg	IV	Log Forms	Induction	Induction	Checked	43	Other	EVERY OTHER WEEK					2061		1
MMRF_1068	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms				2.7	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	78	1
MMRF_1068	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	64	1
MMRF_1068	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.3	QWK	QWK					239	407	1
MMRF_1068	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				15	QD (D1-21)	QD (D1-21)					239	407	1
MMRF_1068	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				4	QD (D1-7)	QD (D1-7)					239	407	1
MMRF_1068	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		4	Other	DAYS 1 - 7					1	78	1
MMRF_1068	Second Line Therapy (after first relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Induction	Induction		20	QWK	QWK					477	535	1
MMRF_1068	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	MELPHALAN		200	Q day	Q day					127	127	1
MMRF_1065	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					230	2391	1
MMRF_1065	Second Line Therapy (after first relapse)	Daratumumab		PATIENT EXPIRED	mg	IV	Log Forms	Unknown	Unknown		888	Other	CYCLE 1 DAYS 1, 8, AND 15; CYCLE 2 DAYS 1, 8, 15, 22; CYCLE 3-6 DAYS 1, 15; CYCLES 7+ DAY 1					2465	2850	1
MMRF_1065	Second Line Therapy (after first relapse)	Lenalidomide		PATIENT EXPIRED	mg	PO	Log Forms	Unknown	Unknown		25	Other	1QM					2465	2850	1
MMRF_1065	Second Line Therapy (after first relapse)	Dexamethasone		PATIENT EXPIRED	mg	PO	Log Forms	Unknown	Unknown		20	Other	CYCLE 1 DAYS 1, 8, AND 15; CYCLE 2 DAYS 1, 8, 15, 22; CYCLE 3-6 DAYS 1, 15; CYCLES 7+ DAY 1					2465	2850	1
MMRF_1065	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms				2.1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	81	1
MMRF_1065	First line of therapy	Lenalidomide		STEM CELL TRANSPLANT	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	115	1
MMRF_1065	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		4	Other	DAYS 1,2,3,4,5					1	123	1
MMRF_1065	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	MALPHALAN		100	Q day	Q day					124	125	1
MMRF_1368	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms				2.7	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	116	1
MMRF_1368	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	115	1
MMRF_1368	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		4	Other	DAYS 1,2,3,4,5					1	115	1
MMRF_1368	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	Other	DAYS 1 - 28					299		1
MMRF_1368	First line of therapy	MOZOBIL		Completed regimen	mg	IV SubQ	Log Forms	Other	TRANSPLANT		26	Q day	Q day					148	150	1
MMRF_1180	First line of therapy	Bortezomib		Completed regimen	mg	IV	Log Forms				2.3	Other	D1, D8, D22					7	112	1
MMRF_1180	First line of therapy	Cyclophosphamide		Completed regimen	mg	PO	Log Forms				50	Q day	Q day					7	539	1
MMRF_1180	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	Q day	Q day					1	125	1
MMRF_1180	First line of therapy	ALKERAN		Completed regimen	mg	IV	Log Forms	Other	TRANSPLANT		215	Q day	Q day					194	194	1
MMRF_1180	First line of therapy	MELPHALAN		Completed regimen	mg	IV	Log Forms	Other	TRANSPLANT		50	Q day	Q day					194	194	1
MMRF_1188	First line of therapy	Bortezomib		Completed regimen	mg	IV	Log Forms				2.54	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	800	1
MMRF_1188	First line of therapy	Dexamethasone		SUBJECT IS DECEASED.	mg	PO	Log Forms				20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	1777	1
MMRF_1188	First line of therapy	Bendamustine		Completed regimen	mg	IV	Log Forms				156	Other	D1, D2					1	234	1
MMRF_1188	First line of therapy	Elotuzumab		Adverse Event or co-morbidity	mg	IV	Log Forms	Induction	Induction		778	Other	UNKNOWN					1198	1331	1
MMRF_1188	Second Line Therapy (after first relapse)	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		5	QD (D1-21)	QD (D1-21)					1303	1352	1
MMRF_1188	Second Line Therapy (after first relapse)	Ixazomib		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		3	Other	DAYS 1, 8, 15, AND 28/CYCLE					1479	1647	1
MMRF_1213	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms				15	QD (D1-21)	QD (D1-21)					1	1638	1
MMRF_1213	First line of therapy	Bortezomib		Disease progression/Relapse	mg	SUBCUTANEOUS	Log Forms				2.9	Other	DAYS 1, 4, 8, 22					34	217	1
MMRF_1213	First line of therapy	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		2	QD (D1-21)	QD (D1-21)					210	1251	1
MMRF_1213	First line of therapy	Dexamethasone		DEATH	mg	PO	Log Forms	Unknown	Unknown		4	Other	DAYS 1,2,3,4,5					224	1694	1
MMRF_1213	Second Line Therapy (after first relapse)	Carfilzomib		Adverse Event or co-morbidity	mg	IV	Log Forms	Induction	Induction		85	Q day	Q day					1055	1384	1
MMRF_1213	Second Line Therapy (after first relapse)	Elotuzumab		LACK OF INSURANCE	mg	IV	Log Forms	Induction	Induction		993	QWK	QWK					1271	1450	1
MMRF_1213	Third Line Therapy (following 2nd relapse)	Daratumumab		DEATH	mg	IV	Log Forms	Induction	Induction		1364	QWK	QWK					1462	1694	1
MMRF_1268	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg	IV	Log Forms				2.7	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1	100	1
MMRF_1268	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	IV	Log Forms				12	Other	DAYS 1, 2, 8, 15					1	100	1
MMRF_1268	First line of therapy	BENDAMUSTINE		Adverse Event or co-morbidity	mg	IV	Log Forms				167	Other	DAYS 1 & 2					1	87	1
MMRF_1331	First line of therapy	Bortezomib		Lack of response	mg	SUBCUTANEOUS	Log Forms				2.8	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	99	1
MMRF_1331	First line of therapy	Dexamethasone		Lack of response	mg	PO	Log Forms				20	Other	DAYS 1, 2, 4, 5, 8, 9, 11, AND 12					1	99	1
MMRF_1331	First line of therapy	Lenalidomide		Lack of response	mg	PO	Log Forms				10	QD (D1-14)	QD (D1-14)					1	99	1
MMRF_1331	First line of therapy	Lenalidomide			mg	PO	Log Forms	Other	SECOND LINE OF TREATMENT, PRIOR TO RELAPSE	Checked	10	QD (D1-21)	QD (D1-21)					102		1
MMRF_1331	First line of therapy	Dexamethasone			mg	PO	Log Forms	Other	SECOND LINE OF TREATMENT, PRIOR TO RELAPSE	Checked	4	Other	DAILY 1-10					102		1
MMRF_1487	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		2.4	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	970	1
MMRF_1487	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		15	QD (D1-14)	QD (D1-14)					1	60	1
MMRF_1487	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	TRANSPLANT		170	Q day	Q day					184	185	1
MMRF_1487	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		4	Other	DAYS 1,2,4,5, 8,9,11,12					1	136	1
MMRF_1541	First line of therapy	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Induction	Induction		36	Other	C1-C8: D1, D2, D8, D9, D15, D16, D22					1	204	1
MMRF_1541							Log Forms													1
MMRF_1541	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	204	1
MMRF_1541	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		40	Other	DAY 1, 8, 15, & 22					1	204	1
MMRF_1541	Second Line Therapy (after first relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		3	QD (D1-21)	QD (D1-21)					379	561	1
MMRF_1541	Third Line Therapy (following 2nd relapse)	KPT-330		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		40	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					561	645	1
MMRF_1541	Fifth Line Therapy (following 4th relapse)	Dexamethasone		SUBJECT IS DECEASED	mg	PO	Log Forms	Maintenance	Maintenance		40	QWK	QWK					902	1788	1
MMRF_1541	Fourth Line Therapy (following 3rd relapse)	Carfilzomib		Completed regimen	mg	IV	Log Forms	Maintenance	Maintenance		61	Q day	Q day					676	860	1
MMRF_1541	Fifth Line Therapy (following 4th relapse)	Daratumumab		Disease progression/Relapse	mg	IV	Log Forms	Maintenance	Maintenance		1700	Q day	Q day					902	1308	1
MMRF_1541	Sixth Line Therapy (following 5th relapse)	Lenalidomide		SUBJECT IS DECEASED.	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1309	1788	1
MMRF_1541	Sixth Line Therapy (following 5th relapse)	Daratumumab		Completed regimen	MG/ML	IV	Log Forms	Induction	Induction		20	QWK	QWK					1295	1469	1
MMRF_1603	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	280	1
MMRF_1603	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Induction	Induction		400	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1	280	1
MMRF_1603	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Induction	Induction		40	Other	D1, D8, D15					1	280	1
MMRF_1603	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					280	403	1
MMRF_1603	First line of therapy	Bortezomib		Investigator decision for other reasons	mg	IV SubQ	Log Forms	Maintenance	Maintenance		2.4	Q day	Q day					731	819	1
MMRF_1603	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Maintenance	Maintenance	Checked	4	Q week	Q week					731		1
MMRF_1664	First line of therapy	Lenalidomide		STEM CELL TRANSPLANT	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	116	1
MMRF_1664	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	DAYS 1, 8, 15, 22					17	676	1
MMRF_1664	First line of therapy	Carfilzomib		Completed regimen	mg	IV	Log Forms	Induction	Induction		76	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					17	676	1
MMRF_1664	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	TRANSPLANT		100	Q day	Q day					174	175	1
MMRF_1664	First line of therapy	Lenalidomide		SUBJECT IS DECEASED.	mg	PO	Log Forms	Induction	Induction		5	QD (D1-21)	QD (D1-21)					941	2169	1
MMRF_1664	First line of therapy	Carfilzomib		Completed regimen	mg	IV	Log Forms	Consolidation	Consolidation		76	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					283	676	1
MMRF_1664	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Consolidation	Consolidation		40	QWK	QWK					283	676	1
MMRF_1664	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					283	940	1
MMRF_1719	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg	IV SubQ	Log Forms	Induction	Induction		2.4	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					10	51	1
MMRF_1719	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		4	Other	DAYS 1,2,4,5, 8,9,11,12					1	197	1
MMRF_1719	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	QD (D1-4)	QD (D1-4)					199	203	1
MMRF_1719	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		4	Q week	Q week					218	310	1
MMRF_1719	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		25	QD (D1-21)	QD (D1-21)					218	310	1
MMRF_1719	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					310	419	1
MMRF_1719	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					10	197	1
MMRF_1815	First line of therapy	Dexamethasone		Patient decision	mg	PO	Log Forms	Induction	Induction		4	Other	DAYS 1-5					1	117	1
MMRF_1815	First line of therapy	Lenalidomide		Patient decision	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	117	1
MMRF_1880	First line of therapy	Bortezomib		Completed regimen	mg	IV	Log Forms	Induction	Induction		2.5	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	142	1
MMRF_1880	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	142	1
MMRF_1880	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		4	Other	DAYS 1,2,3,4,5					1	142	1
MMRF_1880	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	TRANSPLANT		170	Q day	Q day					188	189	1
MMRF_1949	First line of therapy	Carfilzomib		Investigator decision for other reasons	mg	IV	Log Forms	Induction	Induction		68	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	667	1
MMRF_1949	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		5	QD (D1-21)	QD (D1-21)					1	400	1
MMRF_1949	First line of therapy	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	4	Other	DAYS 1-5					1		1
MMRF_1949	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	TRANSPLANT		140	Q day	Q day					184	184	1
MMRF_1949	Second Line Therapy (after first relapse)	Elotuzumab		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		814	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					708	1369	1
MMRF_1949	Second Line Therapy (after first relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					708	1369	1
MMRF_1949	Third Line Therapy (following 2nd relapse)	Daratumumab			mg	IV	Log Forms	Maintenance	Maintenance	Checked	1357	Other	C1-C2 (D1, D8, D15, D22), C3-ONGOING (D1, D15)					1374		1
MMRF_2216	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		4	Other	DAYS 1, 8, 15, 22					1	77	1
MMRF_2216	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					12	385	1
MMRF_2429	First line of therapy	Carfilzomib		Completed regimen	mg	IV	Log Forms	Induction	Induction		43	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	253	1
MMRF_2429	First line of therapy	Lenalidomide			mg	PO	Log Forms	Induction	Induction	Checked	40	Other	DAYS 1,8,15					1		1
MMRF_2429	First line of therapy	Dexamethasone			mg	IV SubQ	Log Forms	Induction	Induction	Checked	40	Other	D 1,8,15, 22					1		1
MMRF_2429	First line of therapy	Carfilzomib		Investigator decision for other reasons	mg	IV SubQ	Log Forms	Induction	Induction		77	Other	D 8-9, 15-16					1	625	1
MMRF_2429	Second Line Therapy (after first relapse)	Melphalan		Completed regimen		IV	Log Forms	Other	CONDITIONING			Other	ONCE DAY-3 AND DAY-2					147	148	1
MMRF_2539	First line of therapy	Bortezomib			mg	IV SubQ	Log Forms	Induction	Induction	Checked	2.4	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_2539	First line of therapy	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	4	Other	DAYS 1-10					1		1
MMRF_2539	First line of therapy	Lenalidomide			mg	PO	Log Forms	Induction	Induction	Checked	25	QD (D1-14)	QD (D1-14)					1		1
MMRF_2539	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	KG	IV	Log Forms	Other	CONDITIONING		4.57	Other	ON DAY -3 AND DAY -2					113	114	1
MMRF_2562	First line of therapy	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	137	1
MMRF_2562	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		4	Other	DAYS 1-10					1	137	1
MMRF_2562	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	137	1
MMRF_2562	Second Line Therapy (after first relapse)	Carfilzomib		PATIENT RECEIVED ASCT	mg/m^2	IV	Log Forms	Induction	Induction		56	Q week	Q week					199	396	1
MMRF_2562	Second Line Therapy (after first relapse)	Dexamethasone		PATIENT RECEIVED ASCT	mg	IV	Log Forms	Induction	Induction		20	QWK	QWK					298	396	1
MMRF_2562	Second Line Therapy (after first relapse)	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Unknown	Unknown		25	QD (D1-21)	QD (D1-21)					199	255	1
MMRF_2562	Second Line Therapy (after first relapse)	Dexamethasone		PATIENT UNDERWENT ASCT	mg	PO	Log Forms	Unknown	Unknown		40	QWK	QWK					199	297	1
MMRF_2562	Second Line Therapy (after first relapse)	Ixazomib		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		3	Other	QD (D1, D8, D15)					585	661	1
MMRF_2562	Third Line Therapy (following 2nd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					704	1004	1
MMRF_2562	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		40	Other	Q28D					704	1004	1
MMRF_2562	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		20	Q week	Q week					1038	1117	1
MMRF_2562	Fourth Line Therapy (following 3rd relapse)	Daratumumab		Disease progression/Relapse	mg	IV	Log Forms	Unknown	Unknown		1432	Q week	Q week					1039	1117	1
MMRF_2562	Fourth Line Therapy (following 3rd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		3	QD (D1-21)	QD (D1-21)					1038	1117	1
MMRF_2562	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg	IV	Log Forms	Other	ASCT PREP		200	Q day	Q day					437	439	1
MMRF_2562	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	X10^6 CD34+/KG	IV	Log Forms	Other	CONDITIONING		5.26	Other	ONCE					439	439	1
MMRF_1020	Third Line Therapy (following 2nd relapse)	Cyclophosphamide		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Induction	Induction		300	Other	D1, D8, D15					1370	1623	1
MMRF_1020	Third Line Therapy (following 2nd relapse)	Dexamethasone		PT DEATH	mg	PO	Log Forms	Induction	Induction		40	QWK	QWK					1370	2150	1
MMRF_1020	Fourth Line Therapy (following 3rd relapse)	Daratumumab		PT DEATH	mg/kg	IV	Log Forms	Induction	Induction		16	QWK	QWK					1638	2142	1
MMRF_1020	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	61	1
MMRF_1020	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	Other	QD (D1-4, D9-11)					1	61	1
MMRF_1020	Second Line Therapy (after first relapse)	Bortezomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					827	1360	1
MMRF_1020	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					827	1360	1
MMRF_1020	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		40	Other	QD (D1-4, D9-11)					827	1360	1
MMRF_1020	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Induction	Induction		200	Q day	Q day					132	133	1
MMRF_1020	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg	IV	Log Forms	Induction	Induction		200	Q day	Q day					987	988	1
MMRF_1020	Third Line Therapy (following 2nd relapse)	Carfilzomib		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Induction	Induction		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1370	1623	1
MMRF_1020	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms				2.5	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					6	91	1
MMRF_1045	First line of therapy	Lenalidomide		CONTINUE AT A REDUCED DOSE DUE TO BAD TASTE/DECREASED APPETITE	mg	PO	Log Forms				15	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1	127	1
MMRF_1045	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms				20	Q week	Q week					1	229	1
MMRF_1045	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms				10	QD (D1-21)	QD (D1-21)					130	322	1
MMRF_1044	First line of therapy	Bortezomib			mg	IV SubQ	Log Forms	Maintenance	Maintenance	Checked	1.525	Other	D1, 8, 15					2878		1
MMRF_1044	First line of therapy	Dexamethasone			mg	PO	Log Forms	Maintenance	Maintenance	Checked	20	Q week	Q week					2878		1
MMRF_1044	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	155	1
MMRF_1044	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms				40	Q week	Q week					1	29	1
MMRF_1044	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	78	1
MMRF_1044	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1	Other	DAY 1, 8, 15					183	1688	1
MMRF_1044	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms				24	Q week	Q week					29	541	1
MMRF_1044	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms				15	QD (D1-14)	QD (D1-14)					78	127	1
MMRF_1044	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms				10	QD (D1-14)	QD (D1-14)					127	183	1
MMRF_1044	First line of therapy	Lenalidomide			mg	PO	Log Forms			Checked	5	Other	QD (D1-12)					183		1
MMRF_1044	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms				1.3	Other	DAY 1, 8, 15					155	183	1
MMRF_1044	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		12	QWK	QWK					568	1688	1
MMRF_1046	First line of therapy	Bortezomib		ROUTE SWITCHED FROM IV TO SUBQ	mg	IV	Log Forms				2.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	32	1
MMRF_1046	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms				2.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					43	102	1
MMRF_1046	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	Other	QD (D1-14)					5	105	1
MMRF_1046	First line of therapy	Dexamethasone		DECREASED DOSE	mg	PO	Log Forms				20	Other	QD (D1-2, 4-5, 8-9, 11-12)					1	82	1
MMRF_1046	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				10	Other	QD (D1-2, 4-5, 8-9, 11-12)					92	103	1
MMRF_1046	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					218	267	1
MMRF_1046	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					218	267	1
MMRF_1046	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				20	Other	QD (D1, 2, 4, 5, 8, 9, 11, 12)					218	306	1
MMRF_1046	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					267	305	1
MMRF_1046	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				15	QD (D1-14)	QD (D1-14)					267	308	1
MMRF_1046	First line of therapy	Lenalidomide			mg	PO	Log Forms			Checked	10	QD (D1-21)	QD (D1-21)					323		1
MMRF_1046	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Induction	Induction		170	Q day	Q day					134	135	1
MMRF_1059	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	175	1
MMRF_1059	First line of therapy	Dexamethasone		DOSE REDUCED	mg	PO	Log Forms				20	Other	QD (D1-2, 4-5, 8-9. 11-12)					1	115	1
MMRF_1059	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				10	Other	QD (D1-2, 4-5, 8-9, 11-12)					116	176	1
MMRF_1059	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					74	181	1
MMRF_1059	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					287	390	1
MMRF_1059	First line of therapy	Lenalidomide		Lack of response	mg	PO	Log Forms				15	QD (D1-21)	QD (D1-21)					390	1236	1
MMRF_1059	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Induction	Induction		160	Q day	Q day					204	205	1
MMRF_1059	First line of therapy	Lenalidomide		PT STARTED NEW DRUG	mg	PO	Log Forms	Maintenance	Maintenance		25	QD (D1-21)	QD (D1-21)					1243	2430	1
MMRF_1059	Second Line Therapy (after first relapse)	Dexamethasone		DUE TO CONCERN FOR LIVER TOXICITY	mg	PO	Log Forms	Maintenance	Maintenance		20	QWK	QWK					1827	2265	1
MMRF_1059	Third Line Therapy (following 2nd relapse)	Daratumumab			mg/kg	IV	Log Forms	Other	SALVAGE	Checked	8	Other	MONTHLY					2483		1
MMRF_1059	Third Line Therapy (following 2nd relapse)	Carfilzomib			mg/m^2	IV	Log Forms	Other	SALVAGE	Checked	20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					2485		1
MMRF_1059	Third Line Therapy (following 2nd relapse)	Dexamethasone			mg	PO	Log Forms	Other	SALVAGE	Checked	20	Other	D1-2, 8-9, 15-16, 22					2485		1
MMRF_1059	Third Line Therapy (following 2nd relapse)	Pomalidomide			mg	PO	Log Forms	Other	SALVAGE	Checked	3	QD (D1-21)	QD (D1-21)					2611		1
MMRF_1074	First line of therapy	Bortezomib		DOSE MODIFIED	mg/m^2	IV	Log Forms				1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	8	1
MMRF_1074	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	98	1
MMRF_1074	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms				20	Other	QD (1-2, 4-5, 8-9, 11-12)					1	54	1
MMRF_1074	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				10	Other	QD (D 1-2, 4-5, 8-9, 11-12)					64	96	1
MMRF_1074	First line of therapy	Bortezomib		DOSE MODIFIED	mg/m^2	IV SubQ	Log Forms				0.7	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					8	11	1
MMRF_1074	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					22	95	1
MMRF_1074	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					204	319	1
MMRF_1074	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					204	225	1
MMRF_1074	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				20	Other	QD (D1, D2, D4, D5, D8, D9, D11, D12)					204	294	1
MMRF_1074	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					225	294	1
MMRF_1074	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms				10	Other	QD (D1, D2, D4, D5, D8, D9, D11, D12)					294	319	1
MMRF_1074	First line of therapy	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms				1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					294	319	1
MMRF_1074	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					294	319	1
MMRF_1074	Second Line Therapy (after first relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms				27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					330	415	1
MMRF_1074	Second Line Therapy (after first relapse)	Cyclophosphamide		Disease progression/Relapse	mg/m^2	IV	Log Forms				300	Other	ONCE					330	386	1
MMRF_1074	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms				40	Q week	Q week					319	414	1
MMRF_1074	Second Line Therapy (after first relapse)	Carfilzomib		Lack of response	mg/m^2	IV	Log Forms				27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					414	415	1
MMRF_1074	Second Line Therapy (after first relapse)	Dexamethasone		Lack of response	mg	PO	Log Forms				40	Q week	Q week					414	414	1
MMRF_1074	Second Line Therapy (after first relapse)	METHOTREXATE		Patient decision	mg	INTRATHECAL	Log Forms	Unknown	Unknown		15	Other	X2					414	417	1
MMRF_1074	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Induction	Induction		150	Q day	Q day					126	127	1
MMRF_1150	First line of therapy	Bortezomib			mg	IV SubQ	Log Forms			Checked	2.6	Q week	Q week					8		1
MMRF_1150	First line of therapy	Lenalidomide			mg	PO	Log Forms			Checked	25	QD (D1-14)	QD (D1-14)					1		1
MMRF_1150	First line of therapy	Dexamethasone			mg	PO	Log Forms			Checked	20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1		1
MMRF_1181	First line of therapy	Bortezomib		PATIENT DIED	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	39	1
MMRF_1181	First line of therapy	Dexamethasone		PATIENT DIED	mg	PO	Log Forms				40	Other	DAYS 1, 2,3,4,8,9, 10, 11					1	39	1
MMRF_1181	First line of therapy	Lenalidomide		DEATH	mg	PO	Log Forms				15	QD (D1-21)	QD (D1-21)					22	39	1
MMRF_1242	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO	Log Forms				300	QWK	QWK					1	72	1
MMRF_1242	First line of therapy	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms				1.3	QWK	QWK					1	190	1
MMRF_1242	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	QWK	QWK					1	190	1
MMRF_1242	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				15	QD (D1-21)	QD (D1-21)					141	190	1
MMRF_1242	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		40	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					386	540	1
MMRF_1242	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					386	540	1
MMRF_1242	First line of therapy	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms	Consolidation	Consolidation		1.3	Other	QD (D1, D8, D15)					386	540	1
MMRF_1242	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Induction	Induction		100	Q day	Q day					232	233	1
MMRF_1242	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Induction	Induction		150	Q day	Q day					302	303	1
MMRF_1258	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms				15	QD (D1-21)	QD (D1-21)					1	246	1
MMRF_1258	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms				40	Q week	Q week					11	268	1
MMRF_1281	First line of therapy	Bortezomib		Disease progression/Relapse	mg	IV	Log Forms				1.9	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	153	1
MMRF_1281	First line of therapy	Cyclophosphamide		Disease progression/Relapse	mg	IV	Log Forms				560	QWK	QWK					1	153	1
MMRF_1281	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms				20	Other	QD (D1, D2, D4, D5, D8, D9, D11)					1	153	1
MMRF_1318	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	204	1
MMRF_1318	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms				20	Q week	Q week					1	29	1
MMRF_1318	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms				40	Q week	Q week					29	85	1
MMRF_1318	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms				20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					85	155	1
MMRF_1318	First line of therapy	Bortezomib		Lack of response	mg/m^2	IV SubQ	Log Forms				1.3	Q week	Q week					29	113	1
MMRF_1318	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					113	368	1
MMRF_1318	First line of therapy	Bortezomib			mg/m^2	IV	Log Forms	Consolidation	Consolidation	Checked	1.3	Other	D1, D8, D15					379		1
MMRF_1318	First line of therapy	Lenalidomide			mg	PO	Log Forms	Consolidation	Consolidation	Checked	10	QD (D1-21)	QD (D1-21)					211		1
MMRF_1318	First line of therapy	Dexamethasone			mg	PO	Log Forms	Consolidation	Consolidation	Checked	20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					162		1
MMRF_1355	First line of therapy	Elotuzumab		Investigator decision for other reasons	mg/kg	IV	Log Forms				20	Q week	Q week					1	1282	1
MMRF_1355	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	1282	1
MMRF_1355	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms				8	Q week	Q week					1	1282	1
MMRF_1355	Second Line Therapy (after first relapse)	Daratumumab			mg	IV SubQ	Log Forms			Checked	1800	QWK	QWK					1824		1
MMRF_1355	Second Line Therapy (after first relapse)	Lenalidomide			mg	PO	Log Forms			Checked	25	Q day	Q day					2920		1
MMRF_1355	Second Line Therapy (after first relapse)				mg	PO	Log Forms			Checked	20	QWK	QWK					2920		1
MMRF_1358	First line of therapy	Lenalidomide		Patient decision	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	121	1
MMRF_1358	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms				20	Q week	Q week					1	194	1
MMRF_1358	First line of therapy	Bortezomib		Lack of response	mg/m^2	IV	Log Forms	Induction	Induction		1.6	Other	QD (D1, D8, D15, D22)					194	313	1
MMRF_1358	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					194	327	1
MMRF_1358	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					327		1
MMRF_1361	First line of therapy	Bortezomib		SWITCHED FROM IV TO SUBQ	mg/m^2	IV	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	47	1
MMRF_1361	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					47	68	1
MMRF_1361	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms				20	Other	QD (D1, D2, D4, D5, D8, D9, D11, D12)					1	68	1
MMRF_1361	First line of therapy	Cyclophosphamide		Investigator decision for other reasons	mg/m^2	IV	Log Forms				300	Q week	Q week					22	68	1
MMRF_1361	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms				27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					68	154	1
MMRF_1361	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms				15	QD (D1-21)	QD (D1-21)					68	138	1
MMRF_1361	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	Q week	Q week					68	160	1
MMRF_1361	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		300	Q week	Q week					117	153	1
MMRF_1392	First line of therapy	Carfilzomib		STEM CELL COLLECTION	mg/m^2	IV	Log Forms				27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	139	1
MMRF_1392	First line of therapy	Lenalidomide		STEM CELL COLLECTION	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	139	1
MMRF_1392	First line of therapy	Dexamethasone		STEM CELL COLLECTION	mg	PO	Log Forms				40	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	139	1
MMRF_1392	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					168	463	1
MMRF_1392	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					168	463	1
MMRF_1392	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	QD (1, 8, 15, 22)					168	463	1
MMRF_1392	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Induction	Induction		240	Q day	Q day					504	505	1
MMRF_1392	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					595	769	1
MMRF_1392	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Consolidation	Consolidation		20	QWK	QWK					595	763	1
MMRF_1392	First line of therapy	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Consolidation	Consolidation		27	Other	QD D1-2, D15-16)					595	764	1
MMRF_1393	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms				36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	323	1
MMRF_1393	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	1209	1
MMRF_1393	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms				20	Other	QD (1,2, 8,9, 15,16, 22,23)					1	490	1
MMRF_1393	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Induction	Induction		200	Q day	Q day					131	132	1
MMRF_1393	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Maintenance	Maintenance		36	Other	QD (D1-2, D15-16)					323	590	1
MMRF_1393	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		20	Other	QD (1, 8, 15, 22)					490	590	1
MMRF_1393	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	15	QD (D1-21)	QD (D1-21)					1210		1
MMRF_1420	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	67	1
MMRF_1420	First line of therapy	Cyclophosphamide		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms				300	Q week	Q week					1	64	1
MMRF_1420	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms				20	Other	QD (D1, D2, D4, D5, D8, D9, D11, D12)					1	1205	1
MMRF_1420	First line of therapy	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					99	134	1
MMRF_1420	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		5	QD (D1-21)	QD (D1-21)					274	1205	1
MMRF_1520	First line of therapy	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Induction	Induction		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	71	1
MMRF_1520	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	106	1
MMRF_1520	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	57	1
MMRF_1520	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Induction	Induction		200	Q day	Q day					148	149	1
MMRF_1520	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					71	106	1
MMRF_1520	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					225	442	1
MMRF_1520	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Maintenance	Maintenance		27	Other	QD (D1-2, D15-16)					442	607	1
MMRF_1520	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					225	414	1
MMRF_1520	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		20	QD (D1-21)	QD (D1-21)					414	442	1
MMRF_1520	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		20	QD (D1-21)	QD (D1-21)					442	980	1
MMRF_1520	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	QD (1, 8, 15, 22)					57	106	1
MMRF_1520	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Consolidation	Consolidation		20	Other	QD (1, 8, 15, 22)					225	281	1
MMRF_1520	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		12	Other	QD (1, 8, 15, 22)					281	442	1
MMRF_1520	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		12	Other	QD (1, 8, 15, 22)					442	607	1
MMRF_1520	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	15	QD (D1-21)	QD (D1-21)					1204		1
MMRF_1540	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	518	1
MMRF_1540	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Induction	Induction		1.3	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1	518	1
MMRF_1540	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	518	1
MMRF_1576	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	21	1
MMRF_1576	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	21	1
MMRF_1621	First line of therapy	Lenalidomide			mg	PO	Log Forms	Induction	Induction	Checked	10	QD (D1-21)	QD (D1-21)					1		1
MMRF_1621	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	106	1
MMRF_1621	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	Other	QD (1, 8, 15, 22)					1	225	1
MMRF_1621	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Induction	Induction		230	Q day	Q day					137	138	1
MMRF_1621	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					225	365	1
MMRF_1621	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Maintenance	Maintenance		36	Other	QD (D1-2, D15-16)					365	645	1
MMRF_1621	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		20	Other	QD (1, 8, 15, 22)					225	645	1
MMRF_1630	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	QD(D1, D8, D15, D22)					1	133	1
MMRF_1630	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					21	133	1
MMRF_1630	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					21	867	1
MMRF_1630	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Induction	Induction		200	Q day	Q day					171	172	1
MMRF_1630	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					252	371	1
MMRF_1630	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Maintenance	Maintenance		36	Other	QD (D1-2, D15-16)					371	658	1
MMRF_1630	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		20	Other	QD (1, 8, 15, 22)					252	658	1
MMRF_1630	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					867		1
MMRF_1652	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	100	1
MMRF_1652	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	QD(D1, D8, D15, D22)					1	100	1
MMRF_1652	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	100	1
MMRF_1652	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Induction	Induction		200	Q day	Q day					139	140	1
MMRF_1652	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					246	632	1
MMRF_1652	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		20	QWK	QWK					246	632	1
MMRF_1652	First line of therapy	Lenalidomide			mg	PO	Log Forms	Consolidation	Consolidation	Checked	15	QD (D1-21)	QD (D1-21)					246		1
MMRF_1690	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	107	1
MMRF_1690	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	107	1
MMRF_1690	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	QD (D1, D8, D15, D22)					1	107	1
MMRF_1690	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Induction	Induction		180	Q day	Q day					138	139	1
MMRF_1690	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					226	345	1
MMRF_1690	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Maintenance	Maintenance		27	Other	QD (D1-2, D15-16)					345	625	1
MMRF_1690	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Consolidation	Consolidation		15	QD (D1-21)	QD (D1-21)					226	254	1
MMRF_1690	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					254	345	1
MMRF_1690	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		25	QD (D1-21)	QD (D1-21)					345	653	1
MMRF_1690	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		25	Other	QD (1-21: 2D ON, 1D OFF)					653	734	1
MMRF_1690	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	15	QD (D1-21)	QD (D1-21)					734		1
MMRF_1690	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		10	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					226	345	1
MMRF_1690	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		20	Other	QD (D22)					226	345	1
MMRF_1690	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					345	401	1
MMRF_1690	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		20	Other	QD (D22)					345	401	1
MMRF_1690	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	Other	QD (D1, D15)					401	569	1
MMRF_1690	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		6	Other	QD (D2, D16)					401	457	1
MMRF_1690	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		16	Other	QD (D8, D22)					401	457	1
MMRF_1690	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		4	Other	QD (D2, D16)					457	569	1
MMRF_1690	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		14	Other	QD (D8, D22)					457	569	1
MMRF_1690	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		8	Other	QD (D1, D15)					569	625	1
MMRF_1690	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		4	Other	QD (D2, D16)					569	625	1
MMRF_1690	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		12	Other	QD (D8, D22)					569	625	1
MMRF_1749	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	106	1
MMRF_1749	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	106	1
MMRF_1749	First line of therapy	Dexamethasone		Completed regimen	mg	IV OR PO	Log Forms	Induction	Induction		40	QWK	QWK					1	106	1
MMRF_1749	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Induction	Induction		195	Q day	Q day					144	145	1
MMRF_1749	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					231	953	1
MMRF_1749	First line of therapy	Lenalidomide		DOSE ESCALATION	mg	PO	Log Forms	Consolidation	Consolidation		15	QD (D1-21)	QD (D1-21)					596	617	1
MMRF_1749	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Consolidation	Consolidation		12	Q week	Q week					231	1274	1
MMRF_1749	First line of therapy	Lenalidomide			mg	PO	Log Forms	Consolidation	Consolidation	Checked	25	QD (D1-21)	QD (D1-21)					259		1
MMRF_1773	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	191	1
MMRF_1773	First line of therapy	Lenalidomide			mg	PO	Log Forms	Induction	Induction	Checked	10	QD (D1-21)	QD (D1-21)					1		1
MMRF_1773	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	QD (1,2, 4,5, 8,9, 11,12)					1	722	1
MMRF_1773	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Induction	Induction		225	Q day	Q day					116	117	1
MMRF_1773	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Induction	Induction		230	Q day	Q day					217	218	1
MMRF_1773	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					303	710	1
MMRF_1797	First line of therapy	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Induction	Induction		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	567	1
MMRF_1797	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	567	1
MMRF_1797	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	567	1
MMRF_1797	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Induction	Induction		200	Q day	Q day					225	226	1
MMRF_1822	First line of therapy	Lenalidomide		Patient decision	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					185	284	1
MMRF_1822	First line of therapy	Dexamethasone		Patient decision	mg	PO	Log Forms	Induction	Induction		40	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					185	284	1
MMRF_1822	Second Line Therapy (after first relapse)	Ixazomib		INSURANCE REASONS	mg	PO	Log Forms	Induction	Induction		4	Other	ONCE WEEK FOR 3WKS 4TH WK OFF					746	962	1
MMRF_1822	Third Line Therapy (following 2nd relapse)	Dexamethasone		LOST TO FOLLOW-UP, NONCOMPLIANCE (UNKNOWN ACTUAL STOP-DATE)	mg	PO	Log Forms	Induction	Induction		4	Other	QD (D1, D8, D15, D22)					962	1021	1
MMRF_1822	Fourth Line Therapy (following 3rd relapse)	Bortezomib		Completed regimen	mg	INJECTION	Log Forms	Induction	Induction		2.3	Other	EVERY 72 HOURS					1591	1606	1
MMRF_1822	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Other	SALVAGE		40	Q day	Q day					1591	1606	1
MMRF_1822	Fourth Line Therapy (following 3rd relapse)	Pomalidomide		Completed regimen	mg	PO	Log Forms	Other	SALVAGE		2	Q day	Q day					1591	1606	1
MMRF_1822	Fourth Line Therapy (following 3rd relapse)	Doxorubicin		Completed regimen	mg	IV	Log Forms	Other	SALVAGE		12	Q day	Q day					1591	1606	1
MMRF_1822	Fourth Line Therapy (following 3rd relapse)	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Other	SALVAGE		70	Q day	Q day					1591	1606	1
MMRF_1822	Fourth Line Therapy (following 3rd relapse)	ETOPOSIDE		Completed regimen	mg/m^2	IV	Log Forms	Other	SALVAGE		30	QD (D1-4)	QD (D1-4)					1561	1606	1
MMRF_1822	Fourth Line Therapy (following 3rd relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Other	SALVAGE		16	Q week	Q week					1613	1688	1
MMRF_1822	Fourth Line Therapy (following 3rd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		4	QD (D1-21)	QD (D1-21)					1614	1688	1
MMRF_1822	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		20	Other	TWICE WEEKLY					1614	1688	1
MMRF_1822	First line of therapy	Carfilzomib		Patient decision	mg/m^2	IV	Log Forms	Induction	Induction		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	130	1
MMRF_1822	First line of therapy	Lenalidomide		Patient decision	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	135	1
MMRF_1822	First line of therapy	Dexamethasone		Patient decision	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	136	1
MMRF_1822	First line of therapy	Bortezomib		Patient decision	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Other	QD (D1, D18, D15, D22)					185	284	1
MMRF_1822	Fifth Line Therapy (following 4th relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms				20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1690	1795	1
MMRF_1822	Fifth Line Therapy (following 4th relapse)	Cyclophosphamide		Disease progression/Relapse	mg/m^2	IV	Log Forms				300	Other	QD (D1, D8, D15)					1690	1795	1
MMRF_1822	Fifth Line Therapy (following 4th relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms				20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1690	1795	1
MMRF_2005	First line of therapy	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Induction	Induction		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	29	1
MMRF_2005	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	112	1
MMRF_2005	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	112	1
MMRF_2005	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Induction	Induction		200	Q day	Q day					148	149	1
MMRF_2005	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					239	626	1
MMRF_2005	First line of therapy	Lenalidomide		DOSE ESCALATION	mg	PO	Log Forms	Consolidation	Consolidation		15	QD (D1-21)	QD (D1-21)					239	260	1
MMRF_2005	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		20	Q week	Q week					239	639	1
MMRF_2005	First line of therapy	Lenalidomide			mg	PO	Log Forms	Consolidation	Consolidation	Checked	25	QD (D1-21)	QD (D1-21)					267		1
MMRF_2005	First line of therapy	Carfilzomib		Investigator decision for other reasons	mg	IV	Log Forms	Induction	Induction		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					29	64	1
MMRF_2005	First line of therapy	Carfilzomib		Completed regimen	mg	IV	Log Forms	Induction	Induction		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					64	113	1
MMRF_2021	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		21	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	105	1
MMRF_2021	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	QD (D1, D8, D22, D22)					1	105	1
MMRF_2021	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	105	1
MMRF_2021	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Induction	Induction		220	Q day	Q day					144	145	1
MMRF_2021	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					224	336	1
MMRF_2021	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Consolidation	Consolidation		15	QD (D1-21)	QD (D1-21)					224	252	1
MMRF_2021	First line of therapy	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Maintenance	Maintenance		36	Other	QD (D1-2, D15-16)					336	449	1
MMRF_2021	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					252	336	1
MMRF_2021	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		25	QD (D1-21)	QD (D1-21)					336	354	1
MMRF_2021	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		20	QD (D1-21)	QD (D1-21)					364	434	1
MMRF_2021	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		20	Other	QD (1-21: 3D ON, 1D OFF)					434	450	1
MMRF_2021	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					462	504	1
MMRF_2021	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					504	505	1
MMRF_2021	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	15	QD (D1-21)	QD (D1-21)					529		1
MMRF_2021	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		20	Other	QD (1, 8, 15, 22)					224	336	1
MMRF_2021	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		20	Other	QD (1, 8, 15, 22)					336	687	1
MMRF_2056	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	106	1
MMRF_2056	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	QD (D1, D8, D15, D22)					1	106	1
MMRF_2056	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	1247	1
MMRF_2056	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Induction	Induction		175	Q day	Q day					141	142	1
MMRF_2056	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					232	359	1
MMRF_2056	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Maintenance	Maintenance		36	Other	QD (D1-2, D15-16)					359	1247	1
MMRF_2056	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		20	Other	QD (1, 8, 15, 22)					232	1247	1
MMRF_2056	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	20	Other	QD (D1-2, D8-9, D15-16, D22-23)					1715		1
MMRF_2056	Second Line Therapy (after first relapse)	Carfilzomib			mg/m^2	IV	Log Forms	Induction	Induction	Checked	27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1715		1
MMRF_2056	Second Line Therapy (after first relapse)	Pomalidomide			mg	PO	Log Forms	Induction	Induction	Checked	4	QD (D1-21)	QD (D1-21)					1715		1
MMRF_2056	Second Line Therapy (after first relapse)	Daratumumab			mg/kg	IV	Log Forms	Induction	Induction	Checked	16	Other	QWK FOR 8 WEEKS, THEN Q2WK FOR 16 WEEKS, THEN QMONTH					1715		1
MMRF_2056	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		25	QD (D1-21)	QD (D1-21)					1247	1687	1
MMRF_2091	Fourth Line Therapy (following 3rd relapse)	CAR-T		Completed regimen		IV	Log Forms	Other	CAR-T			Other	ONCE					1752	1752	1
MMRF_2091	Third Line Therapy (following 2nd relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Induction	Induction		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1585	1619	1
MMRF_2091	Third Line Therapy (following 2nd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					1585	1619	1
MMRF_2091	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1585	1619	1
MMRF_2091	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	617	1
MMRF_2091	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	QD (D1, D8, D15, D22)					1	617	1
MMRF_2091	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					1	1080	1
MMRF_2091	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Induction	Induction		230	Q day	Q day					141	142	1
MMRF_2091	Second Line Therapy (after first relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Induction	Induction		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1149	1562	1
MMRF_2091	Second Line Therapy (after first relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					1149	1562	1
MMRF_2091	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1149	1562	1
MMRF_2091	Second Line Therapy (after first relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Induction	Induction		16	Other	SPLIT 1+2, 8, 15, 22					1149	1562	1
MMRF_2098	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		20	QD (D1-21)	QD (D1-21)					1	216	1
MMRF_2098	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	Other	QD (D1-5; D8-12; D15-19)					1	216	1
MMRF_2122	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	264	1
MMRF_2122	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	264	1
MMRF_2122	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	QD (D1-2, D4-5, D8-9, D11-12)					1	264	1
MMRF_2122	Second Line Therapy (after first relapse)	Ixazomib			mg	PO	Log Forms	Induction	Induction	Checked	4	Other	QD (D1, D8, D15)					602		1
MMRF_2122	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	4	Q week	Q week					615		1
MMRF_2122	Second Line Therapy (after first relapse)	Lenalidomide			mg	PO	Log Forms	Induction	Induction	Checked	25	QD (D1-21)	QD (D1-21)					609		1
MMRF_2238	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		1.3	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					27	118	1
MMRF_2238	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	118	1
MMRF_2238	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		300	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					27	118	1
MMRF_2238	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Induction	Induction		245	Q day	Q day					140	141	1
MMRF_2238	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					230	1722	1
MMRF_2238	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Other	SALVAGE	Checked	10	Q week	Q week					1777		1
MMRF_2238	Second Line Therapy (after first relapse)	Pomalidomide			mg	PO	Log Forms	Other	SALVAGE	Checked	4	QD (D1-21)	QD (D1-21)					1777		1
MMRF_2238	Second Line Therapy (after first relapse)	Daratumumab			mg/kg	IV	Log Forms	Other	SALVAGE	Checked	16	Other	Q MONTH (D1)					1777		1
MMRF_2238	Third Line Therapy (following 2nd relapse)	CAR-T		Disease progression/Relapse		IV	Log Forms	Other	SALVAGE	Checked								2723		1
MMRF_2570	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	101	1
MMRF_2570	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	106	1
MMRF_2570	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	107	1
MMRF_2570	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Induction	Induction		150	Q day	Q day					145	146	1
MMRF_2570	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Consolidation	Consolidation		40	Other	QD (1, 8, 15, 22)					225	253	1
MMRF_2570	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		20	Other	QD (1, 8, 15, 22)					253	625	1
MMRF_2570	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		20	QD (D1-21)	QD (D1-21)					225	623	1
MMRF_2570	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		27	Other	QD (D1-2, D15-16)					225	618	1
MMRF_2570	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	20	QD (D1-21)	QD (D1-21)					631		1
MMRF_1085	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	211	1
MMRF_1085	Third Line Therapy (following 2nd relapse)	Bortezomib		Disease progression/Relapse	mg	IV	Log Forms	Consolidation	Consolidation		1.4	Other	DAYS 1 & 8					1105	1162	1
MMRF_1085	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		DIFFICULTY TOLERATING THERAPY	mg	PO	Log Forms	Consolidation	Consolidation		20	Other	TWICE PER WEEK					1182	1217	1
MMRF_1085	Fourth Line Therapy (following 3rd relapse)	SELINEXOR		Adverse Event or co-morbidity	mg	PO	Log Forms	Consolidation	Consolidation		80	Other	TWICE PER WEEK					1182	1217	1
MMRF_1085	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	217	1
MMRF_1085	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				20	Other	D1, D2, D4, D5, D8, D9, D11, AND D12					1	212	1
MMRF_1085	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms				10	Q day	Q day					225	308	1
MMRF_1085	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		5	QD (D1-21)	QD (D1-21)					316	413	1
MMRF_1085	Second Line Therapy (after first relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					449	841	1
MMRF_1085	Second Line Therapy (after first relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					449	841	1
MMRF_1085	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		40	QWK	QWK					449	841	1
MMRF_1085	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Unknown	Unknown		140	Other	SINGLE DOSE IN PREPARATION FOR STEM CELL TRANSPLANT					870	870	1
MMRF_1085	Third Line Therapy (following 2nd relapse)	Bendamustine		Disease progression/Relapse	mg	IV	Log Forms	Consolidation	Consolidation		201	Other	DAYS 1 & 2					1105	1162	1
MMRF_1233	Third Line Therapy (following 2nd relapse)	Daratumumab			mg/kg	IV	Log Forms	Induction	Induction	Checked	16	QWK	QWK					2723		1
MMRF_1233	First line of therapy	Cyclophosphamide		PATIENT NON-COMPLIANT	mg/m^2	IV	Log Forms				500	Q week	Q week					2	128	1
MMRF_1233	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms				1.5	Q week	Q week					1	319	1
MMRF_1233	First line of therapy	Dexamethasone		Patient decision	mg	PO	Log Forms				40	Q week	Q week					1	266	1
MMRF_1233	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		15	Other	EVERY OTHER DAY					477	589	1
MMRF_1233	Second Line Therapy (after first relapse)	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Consolidation	Consolidation		2	QD (D1-21)	QD (D1-21)					589	2684	1
MMRF_1233	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	QWK	QWK					477	575	1
MMRF_1327	First line of therapy	Cyclophosphamide			mg/m^2	PO	Log Forms			Checked	300	Q week	Q week					1		1
MMRF_1327	First line of therapy	Bortezomib			mg/m^2	IV	Log Forms			Checked	1.5	Q week	Q week					1		1
MMRF_1327	First line of therapy	Dexamethasone			mg	PO	Log Forms			Checked	40	Q week	Q week					1		1
MMRF_1700	First line of therapy	Lenalidomide		TOXICITY - BONE AND JOINT ARTHRALGIA	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					1	14	1
MMRF_1700	First line of therapy	Dexamethasone		Lack of response	mg	PO	Log Forms	Induction	Induction		20	QWK	QWK					1	481	1
MMRF_1700	First line of therapy	Bortezomib		Disease progression/Relapse	mg	IV SubQ	Log Forms	Induction	Induction		2.6	Q week	Q week					19	432	1
MMRF_1700	First line of therapy	Cyclophosphamide		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Induction	Induction		300	Q week	Q week					47	194	1
MMRF_1700	First line of therapy	Lenalidomide		Disease progression/Relapse	mg/dL	PO	Log Forms	Induction	Induction		5	QD (D1-21)	QD (D1-21)					194	432	1
MMRF_1700	Second Line Therapy (after first relapse)	Carfilzomib		Lack of response	mg/m^2	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					439	481	1
MMRF_1700	Third Line Therapy (following 2nd relapse)	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		2	Q day	Q day					481	559	1
MMRF_1739	First line of therapy	Bortezomib		Completed regimen	mg/m^2	SQ	Log Forms	Induction	Induction		1.5	QWK	QWK					1	253	1
MMRF_1739	First line of therapy	Cyclophosphamide		Lack of response	mg/m^2	IV	Log Forms	Induction	Induction		350	QWK	QWK					1	155	1
MMRF_1739	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	QWK	QWK					1	253	1
MMRF_1739	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					171	256	1
MMRF_1739	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					525	1878	1
MMRF_1739	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		25	QD (D1-21)	QD (D1-21)					734	1100	1
MMRF_1739	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		40	Q week	Q week					734	1100	1
MMRF_1739	Second Line Therapy (after first relapse)	Daratumumab		Disease progression/Relapse	mg	IV	Log Forms	Other	SALVAGE		848	Q week	Q week					1101	1195	1
MMRF_1739	Third Line Therapy (following 2nd relapse)	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	SALVAGE		4	QD (D1-21)	QD (D1-21)					1193	1878	1
MMRF_1739	Third Line Therapy (following 2nd relapse)	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Other	SALVAGE		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1193	1878	1
MMRF_1739	Third Line Therapy (following 2nd relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	SALVAGE		20	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1193	1878	1
MMRF_1774	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	214	1
MMRF_1774	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	211	1
MMRF_1774	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	D1, 2, 4, 5, 8, 9, 11, AND 12					1	212	1
MMRF_1774	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					213	305	1
MMRF_1774	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					306	954	1
MMRF_1774	Second Line Therapy (after first relapse)	Bortezomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Other	SALVAGE		1.3	Q week	Q week					986	1435	1
MMRF_1774	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		20	Q week	Q week					986	1435	1
MMRF_1774	Second Line Therapy (after first relapse)	Melphalan		GIVEN IN PREOARATION FOR TRANSPLANT	mg/m^2	IVB	Log Forms	Other	SALVAGE		140	Other	ONE TIME					1013	1013	1
MMRF_1774	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		20	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1461	1591	1
MMRF_1774	Third Line Therapy (following 2nd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		4	QD (D1-21)	QD (D1-21)					1461	1591	1
MMRF_1774	Fifth Line Therapy (following 4th relapse)	Carfilzomib		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		154	QWK	QWK					1660	1958	1
MMRF_1774	Fourth Line Therapy (following 3rd relapse)	Daratumumab		Adverse Event or co-morbidity	mg	IV	Log Forms	Induction	Induction		1523	QWK	QWK					1628	1660	1
MMRF_1814	First line of therapy	Cyclophosphamide		Patient decision	mg	IV	Log Forms	Induction	Induction		552	QWK	QWK					1	113	1
MMRF_1814	First line of therapy	Bortezomib		Patient decision	mg/m^2	SQ	Log Forms	Induction	Induction		1.5	QWK	QWK					1	113	1
MMRF_1814	First line of therapy	Dexamethasone		Patient decision	mg	PO	Log Forms	Induction	Induction		20	QWK	QWK					1	113	1
MMRF_1823	First line of therapy	Bortezomib		PROCEEDING TO AUTOLOGOUS STEM CELL TRANSPLANT	mg/m^2	SQ	Log Forms	Induction	Induction		1.3	QWK	QWK					1	141	1
MMRF_1823	First line of therapy	Lenalidomide		PROCEEDING TO AUTOLOGOUS STEM CELL TRANSPLANT	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	141	1
MMRF_1823	First line of therapy	Dexamethasone		PROCEEDING TO AUTOLOGOUS STEM CELL TRANSPLANT	mg	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	141	1
MMRF_1823	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					293	743	1
MMRF_1823	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		25	QD (D1-21)	QD (D1-21)					714	887	1
MMRF_1823	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		40	Q week	Q week					714	887	1
MMRF_1823	Third Line Therapy (following 2nd relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IVB	Log Forms	Other	SALVAGE		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					888	1280	1
MMRF_1823	Third Line Therapy (following 2nd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		4	QD (D1-21)	QD (D1-21)					888	1345	1
MMRF_1823	Third Line Therapy (following 2nd relapse)	Dexamethasone		DOSE REDUCTION PER PROTOCOL REQUIREMENT	mg	PO	Log Forms	Other	SALVAGE		40	QWK	QWK					888	994	1
MMRF_1823	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		20	QWK	QWK					1001	1280	1
MMRF_1823	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Other	ONCE					196	196	1
MMRF_1832	First line of therapy	Dexamethasone		Lack of response	mg	PO	Log Forms	Maintenance	Maintenance		40	Other	EVERY OTHER WEEK					141	210	1
MMRF_1832	First line of therapy	Bortezomib		DEATH	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Q week	Q week					211	1188	1
MMRF_1832	First line of therapy	Dexamethasone		DEATH	mg	PO	Log Forms	Maintenance	Maintenance		40	Q week	Q week					211	1188	1
MMRF_1832	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	SUBQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	117	1
MMRF_1832	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	117	1
MMRF_1832	First line of therapy	Bortezomib		Lack of response	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	EVERY OTHER WEEK					141	210	1
MMRF_1841	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	162	1
MMRF_1841	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	113	1
MMRF_1841	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	D1, 2, 4, 5, 8, 9, 11, 12					1	162	1
MMRF_1841	First line of therapy	Lenalidomide		DOSE REDUCED	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					288	1211	1
MMRF_1841	First line of therapy	Bortezomib			mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance	Checked	2.2	Q week	Q week					439		1
MMRF_1841	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	5	Q day	Q day					1211		1
MMRF_2080	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	5	Q day	Q day					428		1
MMRF_2080	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	212	1
MMRF_2080	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	212	1
MMRF_2080	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	D 1, 2, 4, 5, 8, 9, 11, 12					1	212	1
MMRF_2080	First line of therapy	Lenalidomide		DOSE REDUCED DUE TO AE	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					212	428	1
MMRF_2104	First line of therapy	Carfilzomib		Completed regimen	mg	IV	Log Forms	Induction	Induction		43	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	269	1
MMRF_2104	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	269	1
MMRF_2104	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		20	Other	D 1, 2, 4, 5, 8, 9, 11, 12					1	1983	1
MMRF_2104	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					302	1983	1
MMRF_2104	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg	IV	Log Forms	Other	TRANSPLANT		430	Other	ONCE					2143	2143	1
MMRF_2104	Third Line Therapy (following 2nd relapse)	Dexamethasone			mg	PO	Log Forms	Other	SALVAGE	Checked	20	QWK	QWK					2500		1
MMRF_2104	Third Line Therapy (following 2nd relapse)	Carfilzomib			mg	IVB	Log Forms	Other	SALVAGE	Checked	148	QWK	QWK					2500		1
MMRF_2104	Third Line Therapy (following 2nd relapse)	Daratumumab			mg	IV SubQ	Log Forms	Other	SALVAGE	Checked	1800	QWK	QWK					2500		1
MMRF_2104	Second Line Therapy (after first relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		2	QD (D1-21)	QD (D1-21)					2234	2500	1
MMRF_2190	First line of therapy	Bortezomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	1295	1
MMRF_2190	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	1295	1
MMRF_2190	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		20	Other	DAYS 1, 2, 4, 5, 8, 9, 11, AND 12					1	1295	1
MMRF_2190	Second Line Therapy (after first relapse)	Daratumumab		Adverse Event or co-morbidity	mg	IV	Log Forms	Consolidation	Consolidation		1042	Q week	Q week					1305	1764	1
MMRF_2190	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					1305	1764	1
MMRF_2190	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Consolidation	Consolidation		20	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1305	1764	1
MMRF_2250	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	106	1
MMRF_2250	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	106	1
MMRF_2250	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	Other	D 1, 2, 4, 5, 8, 9, 11, 12					1	106	1
MMRF_2250	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					106	1066	1
MMRF_2250	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		10	QD (D1-21)	QD (D1-21)					1072	1278	1
MMRF_2250	Second Line Therapy (after first relapse)	Daratumumab		Disease progression/Relapse	mg	IV	Log Forms	Consolidation	Consolidation		923	Q week	Q week					1072	1278	1
MMRF_2250	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		20	Q week	Q week					1072	1278	1
MMRF_2250	Third Line Therapy (following 2nd relapse)	Carfilzomib		CONSIDERATION FOR TRANSPLANT	mg	IV	Log Forms	Induction	Induction		40	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1291	1362	1
MMRF_2250	Third Line Therapy (following 2nd relapse)	Dexamethasone		CONSIDERATION FOR TRANSPLANT	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					1291	1362	1
MMRF_2250	Second Line Therapy (after first relapse)	Bortezomib		Disease progression/Relapse	mg	IV SubQ	Log Forms	Maintenance	Maintenance			Other	Q2WEEKS					1545	1765	1
MMRF_2250	Third Line Therapy (following 2nd relapse)	REGN5458	NCT03761108		mg	IV	Log Forms	Induction	Induction	Checked		QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1807		1
MMRF_2333	First line of therapy	Bortezomib		Completed regimen	mg	SUBCUTANEOUS	Log Forms	Maintenance	Maintenance		2.2	QWK	QWK					1	176	1
MMRF_2333	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					1		1
MMRF_2333	First line of therapy	Dexamethasone			mg	PO	Log Forms	Maintenance	Maintenance	Checked	20	QWK	QWK					1		1
MMRF_2333	First line of therapy	Bortezomib			mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance	Checked	1.3	Other	EVERY OTHER WEEK					176		1
MMRF_2511	First line of therapy	Bortezomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	200	1
MMRF_2511	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		10	QD (D1-14)	QD (D1-14)					1	308	1
MMRF_2511	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	Other	DAYS 1, 2, 4, 5, 8, 9, 11, AND 12					1	308	1
MMRF_2511	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		140	Other	ONE TIME DOSE					391	391	1
MMRF_2511	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		5	Other	Q OTHER DAY					484	1566	1
MMRF_2511	Second Line Therapy (after first relapse)	Pomalidomide			mg	PO	Log Forms	Induction	Induction	Checked	4	QD (D1-21)	QD (D1-21)					1639		1
MMRF_2511	Second Line Therapy (after first relapse)	Ixazomib			mg	PO	Log Forms	Induction	Induction	Checked	4	Other	QD1,8,15					1639		1
MMRF_2511	Second Line Therapy (after first relapse)	Daratumumab			mg/kg	IV	Log Forms	Induction	Induction	Checked	16	Q week	Q week					1639		1
MMRF_2511	First line of therapy	Carfilzomib		Adverse Event or co-morbidity	mg	IV	Log Forms	Induction	Induction		53	Other	TWICE EVERY TWO WEEKS					217	308	1
MMRF_1056	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		170	Other	DAYS -2, -1					106	107	1
MMRF_1056	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				20	Other	DAY OF AND DAY AFTER BORTEZOMIB					1	69	1
MMRF_1056	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	69	1
MMRF_1056	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms				10	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					215	446	1
MMRF_1056	First line of therapy	Bortezomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Maintenance	Maintenance		1.3	Other	TWICE MONTHLY					446	635	1
MMRF_1056	Second Line Therapy (after first relapse)	Bortezomib		Adverse Event or co-morbidity	mg	IV SubQ	Log Forms	Induction	Induction		2.5	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					635	691	1
MMRF_1056	Second Line Therapy (after first relapse)	Dexamethasone		Lack of response	mg	PO	Log Forms	Induction	Induction		20	Other	DAY OF AND DAY AFTER BORTEZOMIB					653	1396	1
MMRF_1056	Second Line Therapy (after first relapse)	Bortezomib		Disease progression/Relapse	mg	IV SubQ	Log Forms	Induction	Induction		1.9	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					698	1142	1
MMRF_1056	Third Line Therapy (following 2nd relapse)	Cyclophosphamide		Disease progression/Relapse	mg/kg	PO	Log Forms	Consolidation	Consolidation		10	Q week	Q week					1063	1142	1
MMRF_1056	Fourth Line Therapy (following 3rd relapse)	OPROZOMIB		Lack of response	mg	PO	Log Forms	Consolidation	Consolidation		180	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1170	1237	1
MMRF_1056	Fourth Line Therapy (following 3rd relapse)	Lenalidomide		Lack of response	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					1269	1396	1
MMRF_1056	Fourth Line Therapy (following 3rd relapse)	SAR650984		Lack of response	mg/kg	IV	Log Forms	Consolidation	Consolidation		10	Q week	Q week					1269	1396	1
MMRF_1056	Fifth Line Therapy (following 4th relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		2	QD (D1-21)	QD (D1-21)					1397	1766	1
MMRF_1056	Fifth Line Therapy (following 4th relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		40	QWK	QWK					1397	1766	1
MMRF_1056	Fifth Line Therapy (following 4th relapse)	BIAXIN		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		500	Q day	Q day					1397	1766	1
MMRF_1056	Sixth Line Therapy (following 5th relapse)	Carfilzomib		Lack of response	mg/m^2	IV	Log Forms	Other	SALVAGE		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1780	1912	1
MMRF_1056	Sixth Line Therapy (following 5th relapse)	Cyclophosphamide		DOSE REDUCTION TO IMPROVE BLOOD COUNTS	mg/m^2	IV	Log Forms	Other	SALVAGE		300	Other	QD (D1, D8, D15)					1780	1842	1
MMRF_1056	Sixth Line Therapy (following 5th relapse)	Dexamethasone		Lack of response	mg	PO	Log Forms	Other	SALVAGE		20	Q week	Q week					1780	1912	1
MMRF_1056	Sixth Line Therapy (following 5th relapse)	Cyclophosphamide		Lack of response	mg/m^2	PO	Log Forms	Other	SALVAGE		150	Other	QD (D1, D8, D15)					1843	1912	1
MMRF_1056	Sixth Line Therapy (following 5th relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Other	SALVAGE		16	Other	QW(C1-2), Q2W(C3-6), Q4W(C7+)					1929	2312	1
MMRF_1056	Sixth Line Therapy (following 5th relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		2	QD (D1-21)	QD (D1-21)					1929	2312	1
MMRF_1056	Sixth Line Therapy (following 5th relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		20	QWK	QWK					1929	2312	1
MMRF_1056	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	69	1
MMRF_1048	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms				2.2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	81	1
MMRF_1048	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	81	1
MMRF_1048	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	81	1
MMRF_1048	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					192	953	1
MMRF_1048	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		1	QWK	QWK					192	953	1
MMRF_1048	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		200	Other	DAYS -3 -2					81	82	1
MMRF_1048	Second Line Therapy (after first relapse)	Elotuzumab			mg/kg	IV	Log Forms	Other	SALVAGE	Checked	10	Other	WEEKLY(C1-2), Q 2 WEEKS(C3+)					1832		1
MMRF_1048	Second Line Therapy (after first relapse)	Lenalidomide			mg	PO	Log Forms	Other	SALVAGE	Checked	25	QD (D1-21)	QD (D1-21)					1832		1
MMRF_1048	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Other	SALVAGE	Checked	40	Q week	Q week					1832		1
MMRF_1057	First line of therapy	Bortezomib		MOVED TO SCT	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	103	1
MMRF_1057	First line of therapy	Dexamethasone		MOVED TO AUTO SCT	mg	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	103	1
MMRF_1057	First line of therapy	Lenalidomide		MOVED TO AUTO SCT	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					22	103	1
MMRF_1057	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					233	954	1
MMRF_1057	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		200	Other	DAYS -3 -2					132	133	1
MMRF_1060	First line of therapy	Vincristine		Lack of response	mg/dL	IV	Log Forms				0.1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	54	1
MMRF_1060	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1	138	1
MMRF_1060	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms				1000	Other	ONCE MONTHLY					1	138	1
MMRF_1060	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					54	138	1
MMRF_1060	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-14)	QD (D1-14)					285	425	1
MMRF_1060	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					285	716	1
MMRF_1060	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		40	QWK	QWK					285	716	1
MMRF_1060	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					534	898	1
MMRF_1060	Second Line Therapy (after first relapse)	Ixazomib		PERIPHERAL NEUROPATHY	mg	PO	Log Forms	Other	SALVAGE		4	Other	QD (DAYS 1, 8, 15)					1990	2088	1
MMRF_1060	Second Line Therapy (after first relapse)	Dexamethasone		PERIPHERAL NEUROPATHY	mg	PO	Log Forms	Other	SALVAGE		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1990	2088	1
MMRF_1060	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		161	Other	DAYS -2, -1					162	163	1
MMRF_1070	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	93	1
MMRF_1070	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	93	1
MMRF_1070	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	93	1
MMRF_1070	First line of therapy	Bortezomib			mg/m^2	IV	Log Forms			Checked	1.3	Other	EVERY 2 WEEKS---MAINTENANCE THERAPY					208		1
MMRF_1086	First line of therapy	Bortezomib		MOVED TO AUTO SCT	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	142	1
MMRF_1086	First line of therapy	Lenalidomide		MOVED TO AUTO SCT	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	142	1
MMRF_1086	First line of therapy	Dexamethasone		MOVED TO AUTO SCT	mg	PO	Log Forms				40	Q week	Q week					1	142	1
MMRF_1086	First line of therapy	Lenalidomide		TRAUMATIC RIGHT LEG FRACTURE- NON-MM	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					257	358	1
MMRF_1086	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					388	479	1
MMRF_1086	Second Line Therapy (after first relapse)	Ixazomib		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	SALVAGE		4	Other	QD (D1, D8, D15)					1900	1942	1
MMRF_1086	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	SALVAGE		40	Q week	Q week					1900	2203	1
MMRF_1086	Second Line Therapy (after first relapse)	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Other	SALVAGE		1.3	Other	Q 2 WEEKS					1956	2203	1
MMRF_1086	Second Line Therapy (after first relapse)	Carfilzomib		SCHEDULE/DOSE CHANGE DUE TO TRAVELLING COMPLICATION	mg/m^2	IV	Log Forms	Other	SALVAGE		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					2206	2251	1
MMRF_1086	Second Line Therapy (after first relapse)	Dexamethasone		SCHEDULE/DOSE CHANGE DUE TO TRAVELLING COMPLICATION	mg	PO	Log Forms	Other	SALVAGE		10	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					2206	2251	1
MMRF_1086	Second Line Therapy (after first relapse)	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Other	SALVAGE		45	Other	DAYS 1,8,15					2251	2507	1
MMRF_1086	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	SALVAGE		10	Other	DAYS 1,8,15					2251	2507	1
MMRF_1086	Third Line Therapy (following 2nd relapse)	Daratumumab			mg/kg	IV	Log Forms	Other	SALVAGE	Checked	16	Other	QW(C1-2), Q2W(C3-6), Q4W(C7+)					2648		1
MMRF_1086	Third Line Therapy (following 2nd relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	SALVAGE		10	Q day	Q day					2648	2655	1
MMRF_1086	Third Line Therapy (following 2nd relapse)	Dexamethasone			mg	PO	Log Forms	Other	SALVAGE	Checked	40	Q week	Q week					2648		1
MMRF_1086	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		148	Q day	Q day					174	175	1
MMRF_1097	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	85	1
MMRF_1097	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms				40	Q week	Q week					1	85	1
MMRF_1097	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	85	1
MMRF_1097	Second Line Therapy (after first relapse)	Bortezomib		DOCTOR DECISION	mg/m^2	IV	Log Forms	Other	SALVAGE		1.3	Q week	Q week					1196	1492	1
MMRF_1097	Second Line Therapy (after first relapse)	Dexamethasone		DOCTOR DECISION	mg	PO	Log Forms	Other	SALVAGE		20	Other	QD (D1-2, D4-5, D8-9, D11-12)					1196	1492	1
MMRF_1110	Third Line Therapy (following 2nd relapse)	Ixazomib		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		4	Other	DAYS 1, 8, 15 OF 28D CYCLE					1846	1895	1
MMRF_1110	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		40	QWK	QWK					1846	1895	1
MMRF_1110	Fourth Line Therapy (following 3rd relapse)	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	SALVAGE		2	QD (D1-21)	QD (D1-21)					1909	2142	1
MMRF_1110	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	SALVAGE		40	QWK	QWK					1909	2142	1
MMRF_1110	Fourth Line Therapy (following 3rd relapse)	Daratumumab		Adverse Event or co-morbidity	mg/kg	IV	Log Forms	Other	SALVAGE		16	Other	WEEKLY(C1-C2); Q 2 WEEKS(C3-C6); MONTHLY(C7+)					1909	2142	1
MMRF_1110	Fifth Line Therapy (following 4th relapse)	Daratumumab		Adverse Event or co-morbidity	mg/kg	IV	Log Forms	Other	SALVAGE		16	Other	WEEKLY(C1-2); Q2W(C3-6); Q4W(C7+)					2304	2350	1
MMRF_1110	Fifth Line Therapy (following 4th relapse)	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	SALVAGE		2	QD (D1-21)	QD (D1-21)					2304	2350	1
MMRF_1110	Fifth Line Therapy (following 4th relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	SALVAGE		40	QWK	QWK					2304	2350	1
MMRF_1110	First line of therapy	Bortezomib		MOVED TO AUTO SCT	mg	IV	Log Forms				3.5	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	71	1
MMRF_1110	First line of therapy	Dexamethasone		MOVED TO AUTO SCT	mg	PO	Log Forms				40	Q week	Q week					1	71	1
MMRF_1110	First line of therapy	Lenalidomide		MOVED TO AUTO SCT	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	71	1
MMRF_1110	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					204	344	1
MMRF_1110	First line of therapy	Lenalidomide		HOSPITALIZATION FOR PNEUMONIA	mg	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					371	671	1
MMRF_1110	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					712	876	1
MMRF_1110	Second Line Therapy (after first relapse)	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Other	SALVAGE		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1331	1496	1
MMRF_1110	Second Line Therapy (after first relapse)	Cyclophosphamide		POOR TOLERANCE	mg/m^2	PO	Log Forms	Other	SALVAGE		300	Other	QD: D1, D8, D15					1331	1387	1
MMRF_1110	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Other	SALVAGE		40	Q week	Q week					1331	1496	1
MMRF_1110	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg	IV	Log Forms	Other	TRANSPLANT		250	Other	DAY -2					1501	1501	1
MMRF_1110	Second Line Therapy (after first relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		2	Q day	Q day					1635	1822	1
MMRF_1110	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		185	Other	DAYS -3, -2					93	94	1
MMRF_1119	First line of therapy	Bortezomib		MOVED TO AUTO SCT	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	67	1
MMRF_1119	First line of therapy	Dexamethasone		MOVED TO AUTO SCT	mg	PO	Log Forms				20	Other	DAY OF AND DAY AFTER BORTEZOMIB					1	68	1
MMRF_1119	First line of therapy	Lenalidomide		MOVED TO AUTO SCT	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					22	70	1
MMRF_1119	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					207	225	1
MMRF_1119	First line of therapy	Lenalidomide		DOSE INCREASED	mg	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					225	379	1
MMRF_1119	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					379	683	1
MMRF_1119	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					683	960	1
MMRF_1119	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	5	Q day	Q day					960		1
MMRF_1119	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		190	Q day	Q day					106	107	1
MMRF_1138	First line of therapy	Bortezomib		MOVED TO SCT	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	60	1
MMRF_1138	First line of therapy	Dexamethasone		MOVED TO SCT	mg	PO	Log Forms				40	QWK	QWK					1	60	1
MMRF_1138	First line of therapy	Thalidomide		MOVED TO SCT	DOSE UNKNOWN	PO	Log Forms				0	Other	UNKNOWN					1	60	1
MMRF_1138	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	5	Q day	Q day					258		1
MMRF_1141	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	175	1
MMRF_1141	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	175	1
MMRF_1141	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms				25	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	48	1
MMRF_1142	First line of therapy	Lenalidomide		MOVED TO SCT	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	63	1
MMRF_1142	First line of therapy	Dexamethasone		MOVED TO SCT	mg	PO	Log Forms				20	Other	DAY OF AND DAY AFTER BORTEZOMIB					1	63	1
MMRF_1142	First line of therapy	Bortezomib		MOVED TO SCT	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	63	1
MMRF_1142	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					216	948	1
MMRF_1142	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	TRANSPLANT		185	Other	DAYS -3, -2					103	104	1
MMRF_1142	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Other	TRANSPLANT		10	Other	DAYS -3, -2, -1					103	105	1
MMRF_1143	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		245	Other	ONCE					1098	1098	1
MMRF_1143	Fourth Line Therapy (following 3rd relapse)	Pomalidomide			mg	PO	Log Forms	Other	SALVAGE	Checked	1							2887		1
MMRF_1143	Fourth Line Therapy (following 3rd relapse)	Dexamethasone			mg	PO	Log Forms	Other	SALVAGE	Checked	20							2887		1
MMRF_1143	Fourth Line Therapy (following 3rd relapse)	Daratumumab			mg/kg	IV	Log Forms	Other	SALVAGE	Checked	16	Other	QW(C1-2); Q2W(C3-6); QM(C7+)					2887		1
MMRF_1143	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	Q week	Q week					1	187	1
MMRF_1143	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				15	QD (D1-21)	QD (D1-21)					1	187	1
MMRF_1143	Second Line Therapy (after first relapse)	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Consolidation	Consolidation		1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					997	1090	1
MMRF_1143	Second Line Therapy (after first relapse)	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		15	QD (D1-14)	QD (D1-14)					997	1090	1
MMRF_1143	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		20	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					997	1090	1
MMRF_1143	Third Line Therapy (following 2nd relapse)	Lenalidomide		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					1202	1652	1
MMRF_1155	First line of therapy	Bortezomib		MOVED TO SCT	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	67	1
MMRF_1155	First line of therapy	Dexamethasone		MOVED TO SCT	mg	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	67	1
MMRF_1155	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	67	1
MMRF_1155	Second Line Therapy (after first relapse)	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Other	SALVAGE		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1473	1586	1
MMRF_1155	Second Line Therapy (after first relapse)	Cyclophosphamide		Completed regimen	mg/m^2	PO	Log Forms	Other	SALVAGE		300	Other	QD: (D1, D8, D15)					1473	1586	1
MMRF_1155	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Other	SALVAGE		40	Q week	Q week					1473	1586	1
MMRF_1155	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg	IV	Log Forms	Other	TRANSPLANT		375	Other	DAY -2					1591	1591	1
MMRF_1155	Second Line Therapy (after first relapse)	Ixazomib		DOSE REDUCTION DUE TO FATIGUE	mg	PO	Log Forms	Maintenance	Maintenance		4	Other	DAYS 1, 8, 15 OF 28D CYCLE					1771	1829	1
MMRF_1155	Second Line Therapy (after first relapse)	Ixazomib		DOSE REDUCTION DUE TO FATIGUE	mg	PO	Log Forms	Maintenance	Maintenance		3	Other	DAYS 1, 8, 15 OF 28D CYCLE					1830	1872	1
MMRF_1155	Second Line Therapy (after first relapse)	Ixazomib		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		2.3	Other	DAYS 1, 8, 15 OF 28D CYCLE					1873	2468	1
MMRF_1155	Fourth Line Therapy (following 3rd relapse)	Carfilzomib		FREQUENCY CHANGE TO REDUCE CLINIC VISITS BECAUSE OF COVID-19	mg/m^2	IV	Log Forms	Other	SALVAGE		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					2748	2799	1
MMRF_1155	Fourth Line Therapy (following 3rd relapse)	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Other	SALVAGE		56	QWK	QWK					2811	2846	1
MMRF_1155	Fourth Line Therapy (following 3rd relapse)	Carfilzomib			mg/m^2	IV	Log Forms	Other	SALVAGE	Checked	27	QWK	QWK					2867		1
MMRF_1155	Fourth Line Therapy (following 3rd relapse)	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	SALVAGE		2	QD (D1-21)	QD (D1-21)					2748	2867	1
MMRF_1155	Fourth Line Therapy (following 3rd relapse)	Dexamethasone			mg	PO	Log Forms	Other	SALVAGE	Checked	20	Other	DAYS 1,2,8,9,15,16,22,23					2748		1
MMRF_1155	Third Line Therapy (following 2nd relapse)	TAK-079		Disease progression/Relapse	mg	IV SubQ	Log Forms	Other	SALVAGE		600	Other	QW(C1-2); Q2W(C3-6); Q4W(C7+)					2482	2713	1
MMRF_1155	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		20	Other	BEFORE TAK-079 INJECTION					2482	2713	1
MMRF_1155	Third Line Therapy (following 2nd relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	SALVAGE		4	Other	TAKE FOR 2 DAYS FOLLOWING TAK-079 INJECTION					2482	2545	1
MMRF_1155	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		185	Q day	Q day					102	103	1
MMRF_1155	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					238	596	1
MMRF_1160	First line of therapy	Bortezomib			mg/m^2	IV	Log Forms			Checked	1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_1173	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	126	1
MMRF_1173	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	126	1
MMRF_1173	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	126	1
MMRF_1173	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					248	2155	1
MMRF_1173	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	5	QD (D1-21)	QD (D1-21)					2188		1
MMRF_1173	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		190	Q day	Q day					130	131	1
MMRF_1195	First line of therapy	Bortezomib			mg/m^2	IV SubQ	Log Forms			Checked	1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_1195	First line of therapy	Dexamethasone			mg	PO	Log Forms			Checked	20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_1195	First line of therapy	Lenalidomide			mg	PO	Log Forms			Checked	25	Other	QD 1-14					1		1
MMRF_1195	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Other	TRANSPLANT		10	Other	DAYS -3, -2, -1					106	108	1
MMRF_1195	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	TRANSPLANT		185	Other	DAYS -3, -2					106	107	1
MMRF_1219	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	95	1
MMRF_1219	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				25	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	95	1
MMRF_1219	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	95	1
MMRF_1219	Second Line Therapy (after first relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Induction	Induction		72	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					278	1307	1
MMRF_1219	Second Line Therapy (after first relapse)	Doxorubicin		Disease progression/Relapse	mg/m^2	IV	Log Forms	Induction	Induction		30	Other	DAY 8					278	1307	1
MMRF_1219	Third Line Therapy (following 2nd relapse)	Elotuzumab		Completed regimen	mg/kg	IV	Log Forms	Induction	Induction		10	Q week	Q week					1377	1433	1
MMRF_1219	Third Line Therapy (following 2nd relapse)	Pomalidomide		DOSE REDUCTION DUE TO DIZZINESS	mg	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					1377	1433	1
MMRF_1219	Third Line Therapy (following 2nd relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1377	1797	1
MMRF_1219	Third Line Therapy (following 2nd relapse)	Pomalidomide			mg	PO	Log Forms	Induction	Induction	Checked	3	QD (D1-21)	QD (D1-21)					1433		1
MMRF_1219	Third Line Therapy (following 2nd relapse)	Elotuzumab		Completed regimen	mg/kg	IV	Log Forms	Induction	Induction		10	Other	D1, D15					1433	1545	1
MMRF_1219	Third Line Therapy (following 2nd relapse)	Elotuzumab			mg/kg	IV	Log Forms	Induction	Induction	Checked	20	Other	D1					1545		1
MMRF_1219	Third Line Therapy (following 2nd relapse)	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	20	Q week	Q week					1797		1
MMRF_1219	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		110	Q day	Q day					124	125	1
MMRF_1225	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		186	Q day	Q day					156	157	1
MMRF_1225	Fourth Line Therapy (following 3rd relapse)	TAK-079			mg	IV SubQ	Log Forms	Other	SALVAGE	Checked	1200	Other	QW(C1-2); Q2W(C3-6); Q4W(C7+)					2507		1
MMRF_1225	Fourth Line Therapy (following 3rd relapse)	Dexamethasone			mg	PO	Log Forms	Other	SALVAGE	Checked	20	Other	BEFORE TAK-079 INJECTION					2507		1
MMRF_1225	Fourth Line Therapy (following 3rd relapse)	Dexamethasone			mg	PO	Log Forms	Other	SALVAGE	Checked	4	Other	FOR 2 DAYS FOLLOWING TAK-079 INJECTION					2507		1
MMRF_1225	First line of therapy	Bortezomib		MOVED TO SCT	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	132	1
MMRF_1225	First line of therapy	Dexamethasone		MOVED TO SCT	mg	PO	Log Forms				40	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	132	1
MMRF_1225	First line of therapy	Lenalidomide		MOVED TO SCT	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	132	1
MMRF_1225	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					267	341	1
MMRF_1225	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		15	QD (D1-14)	QD (D1-14)					267	344	1
MMRF_1225	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		40	Other	DAYS 1, 8, AND 15					267	344	1
MMRF_1225	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					358	394	1
MMRF_1225	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		5	Q day	Q day					410	431	1
MMRF_1225	First line of therapy	Bortezomib		Patient decision	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	TWICE A MONTH					431	960	1
MMRF_1225	Second Line Therapy (after first relapse)	Dexamethasone		DOSE REDUCTION	mg	PO	Log Forms	Other	SALVAGE		40	Q week	Q week					1373	1422	1
MMRF_1225	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Other	SALVAGE		20	Q week	Q week					1422	1513	1
MMRF_1225	Third Line Therapy (following 2nd relapse)	Ixazomib		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		4	Other	DAYS 1, 8, 15					1669	2489	1
MMRF_1225	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1669	2489	1
MMRF_1226	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	68	1
MMRF_1226	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	68	1
MMRF_1226	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					4	68	1
MMRF_1226	First line of therapy	Bortezomib		DOCTOR DECISION	mg	IV SubQ	Log Forms	Maintenance	Maintenance		2.2	Other	Q2W					218	1212	1
MMRF_1226	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	5	QD (D1-21)	QD (D1-21)					736		1
MMRF_1226	First line of therapy	Ixazomib			mg	PO	Log Forms	Maintenance	Maintenance	Checked	4	Other	QD: DAYS 1, 8, 15					1219		1
MMRF_1226	First line of therapy	Dexamethasone		Patient decision	mg	PO	Log Forms	Maintenance	Maintenance		40	Q week	Q week					1219	1377	1
MMRF_1226	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	TRANSPLANT		160	Other	DAYS -3, -2					96	97	1
MMRF_1234	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Other	TRANSPLANT		10	Other	DAYS -3, -2, -1					204	206	1
MMRF_1234	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	TRANSPLANT		210	Other	DAYS -3, -2					204	205	1
MMRF_1234	First line of therapy	Bortezomib			mg/m^2	IV SubQ	Log Forms			Checked	1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_1234	First line of therapy	Dexamethasone			mg	PO	Log Forms			Checked	40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_1234	First line of therapy	Lenalidomide			mg	PO	Log Forms			Checked	25	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_1234	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Other	TRANSPLANT		10	Other	DAYS -3, -2, -1					80	82	1
MMRF_1234	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	TRANSPLANT		215	Other	DAYS -3, -2					80	81	1
MMRF_1269	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	103	1
MMRF_1269	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	103	1
MMRF_1269	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	103	1
MMRF_1269	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					236	1462	1
MMRF_1269	Second Line Therapy (after first relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Other	SALVAGE		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1475	1538	1
MMRF_1269	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	IV WEEKS WITH CARFILZOMIB, PO OFF-WEEK	Log Forms	Other	SALVAGE		40	Q week	Q week					1475	1538	1
MMRF_1269	Third Line Therapy (following 2nd relapse)	Daratumumab		DEATH	mg/kg	IV	Log Forms	Other	SALVAGE		16	Q week	Q week					1544	1590	1
MMRF_1269	Third Line Therapy (following 2nd relapse)	Pomalidomide		DEATH	mg	PO	Log Forms	Other	SALVAGE		2	QD (D1-21)	QD (D1-21)					1544	1590	1
MMRF_1269	Third Line Therapy (following 2nd relapse)	Dexamethasone		DEATH	mg	PO	Log Forms	Other	SALVAGE		4	Other	DAYS 1, 2 AFTER DARATUMUMAB					1544	1590	1
MMRF_1269	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	PRE-TRANSPLANT		205	Other	DAYS -3, -2					135	136	1
MMRF_1270	First line of therapy	Bortezomib			mg/m^2	IV SubQ	Log Forms			Checked	1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_1270	First line of therapy	Dexamethasone			mg	PO	Log Forms			Checked	40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_1270	First line of therapy	Lenalidomide			mg	PO	Log Forms			Checked	25	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_1289	First line of therapy	Bortezomib		MOVED TO AUTO SCT	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	49	1
MMRF_1289	First line of therapy	Lenalidomide		MOVED TO AUTO SCT	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	49	1
MMRF_1289	First line of therapy	Dexamethasone		MOVED TO AUTO SCT	mg	PO	Log Forms				20	Other	DAY OF AND DAY AFTER BORTEZOMIB					1	49	1
MMRF_1289	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					219	295	1
MMRF_1289	First line of therapy	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	TWICE A MONTH					219	295	1
MMRF_1289	First line of therapy	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Induction	Induction		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					330	393	1
MMRF_1289	First line of therapy	Cyclophosphamide		Disease progression/Relapse	mg/m^2	PO	Log Forms	Induction	Induction		300	Q week	Q week					330	393	1
MMRF_1289	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		20	QWK	QWK					330	393	1
MMRF_1289	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		40	Other	DAILY DAYS 1-4					393	417	1
MMRF_1289	Second Line Therapy (after first relapse)	Cyclophosphamide		Disease progression/Relapse	mg/m^2	IV	Log Forms	Induction	Induction		400	Other	DAILY DAYS 1-4					393	417	1
MMRF_1289	Second Line Therapy (after first relapse)	ETOPOSIDE		Patient decision	mg/m^2	IV	Log Forms	Induction	Induction		40	Other	DAILY DAYS 1-4					393	417	1
MMRF_1289	Second Line Therapy (after first relapse)	CISPLATIN		Disease progression/Relapse	mg/m^2	IV	Log Forms	Induction	Induction		10	Other	DAILY DAYS 1-4					393	417	1
MMRF_1289	Third Line Therapy (following 2nd relapse)	Vincristine		PATIENT WENT ON HOSPICE	mg/m^2	IV	Log Forms	Unknown	Unknown		1.2	QID	QID					465	477	1
MMRF_1289	Third Line Therapy (following 2nd relapse)	BCNU		PATIENT WENT ON HOSPICE	mg/m^2	IV	Log Forms	Unknown	Unknown		20	QID	QID					465	477	1
MMRF_1289	Third Line Therapy (following 2nd relapse)	Melphalan		PATIENT WENT ON HOSPICE	mg/m^2	PO	Log Forms	Unknown	Unknown		8	QD (D1-4)	QD (D1-4)					465	477	1
MMRF_1289	Third Line Therapy (following 2nd relapse)	Cyclophosphamide		PATIENT WENT ON HOSPICE	mg/m^2	IV	Log Forms	Unknown	Unknown		400	QD (D1-4)	QD (D1-4)					465	477	1
MMRF_1289	Third Line Therapy (following 2nd relapse)	Prednisone		PATIENT WENT ON HOSPICE	mg/m^2	PO	Log Forms	Unknown	Unknown		40	QD (D1-7)	QD (D1-7)					465	477	1
MMRF_1289	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	TRANSPLANT		190	Other	DAYS -3, -2					88	89	1
MMRF_1356	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	260	1
MMRF_1356	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1	260	1
MMRF_1356	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1	260	1
MMRF_1356	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					260	464	1
MMRF_1356	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	SALVAGE		25	QD (D1-21)	QD (D1-21)					1018	1298	1
MMRF_1356	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	SALVAGE		40	Q week	Q week					1018	1298	1
MMRF_1356	Second Line Therapy (after first relapse)	Elotuzumab		Adverse Event or co-morbidity	mg/kg	IV	Log Forms	Other	SALVAGE		10	Q week	Q week					1018	1298	1
MMRF_1356	Third Line Therapy (following 2nd relapse)	Carfilzomib		Adverse Event or co-morbidity	mg	IV	Log Forms	Other	SALVAGE		57	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1424	1501	1
MMRF_1356	Third Line Therapy (following 2nd relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	SALVAGE		25	Q week	Q week					1424	1501	1
MMRF_1356	Third Line Therapy (following 2nd relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	10 MG IV; 40 MG PO	Log Forms	Other	SALVAGE		50	Q week	Q week					1424	1501	1
MMRF_1356	Third Line Therapy (following 2nd relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Other	SALVAGE		16	Other	WEEKLY(C1-2); Q 2 WEEKS(C3-6); MONTHLY(C7+)					1515	1675	1
MMRF_1356	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Other	SALVAGE		20	Q week	Q week					1515	1675	1
MMRF_1356	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg	IV	Log Forms	Other	TRANSPLANT		125	Other	DAYS -3, -2					548	549	1
MMRF_1356	Second Line Therapy (after first relapse)	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	EVERY 2 WEEKS					659	1002	1
MMRF_1373	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	5	Q day	Q day					328		1
MMRF_1373	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IVB	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	71	1
MMRF_1373	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				20	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1	71	1
MMRF_1373	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms				25	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	18	1
MMRF_1373	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	TRANSPLANT		155	Other	DAYS -3, -2					124	125	1
MMRF_1373	First line of therapy	Lenalidomide		DOSE REDUCTION DUE TO NEUTROPENIA	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					227	328	1
MMRF_1390	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms				40	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1	26	1
MMRF_1390	First line of therapy	Bortezomib		Lack of response	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	47	1
MMRF_1441	First line of therapy	Bortezomib			mg	IV	Log Forms			Checked	2.16	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_1441	First line of therapy	Dexamethasone			mg	PO	Log Forms			Checked	10	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_1441	First line of therapy	Lenalidomide			mg	PO	Log Forms			Checked	15	QD (D1-21)	QD (D1-21)					1		1
MMRF_1445	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	37	1
MMRF_1445	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg	IV SubQ	Log Forms				2.08	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	86	1
MMRF_1445	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms				40	Q week	Q week					1	86	1
MMRF_1445	First line of therapy	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	4	Q week	Q week					133		1
MMRF_1445	First line of therapy	Bortezomib			mg	IV	Log Forms	Induction	Induction	Checked	2.08	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					133		1
MMRF_1496	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					1	121	1
MMRF_1496	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		2.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					5	60	1
MMRF_1496	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					47	121	1
MMRF_1496	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					226	293	1
MMRF_1496	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms	Consolidation	Consolidation		1.3	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					320	342	1
MMRF_1496	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		4	Q day	Q day					289	453	1
MMRF_1496	First line of therapy	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		50	QWK	QWK					320	370	1
MMRF_1496	Second Line Therapy (after first relapse)	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					342	423	1
MMRF_1496	Second Line Therapy (after first relapse)	Pomalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		4	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					383	423	1
MMRF_1496	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	TRANSPLANT		180	Other	DAYS -3, -2					121	122	1
MMRF_1496	Second Line Therapy (after first relapse)	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Other	TRANSPLANT		4200	Other	DAYS -3, -2					423	424	1
MMRF_1511	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		1	Other	EVERY OTHER DAY					2791	2847	1
MMRF_1511	Fourth Line Therapy (following 3rd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		4	QD (D1-21)	QD (D1-21)					2791	2847	1
MMRF_1511	Fourth Line Therapy (following 3rd relapse)	ISATUXIMAB		Disease progression/Relapse	UNK	UNK	Log Forms	Other	SALVAGE			Other	UNK					2791	2847	1
MMRF_1511	First line of therapy	Bortezomib		MOVED TO SCT	mg	IV SubQ	Log Forms	Induction	Induction		2.4	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	63	1
MMRF_1511	First line of therapy	Dexamethasone		MOVED TO SCT	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	63	1
MMRF_1511	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	8	1
MMRF_1511	First line of therapy	Bortezomib		INCREASING NEUROPATHY	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		1	Other	TWICE A MONTH					192	777	1
MMRF_1511	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Maintenance	Maintenance		36	Other	QD: DAYS 1, 2, 15, 16					777	973	1
MMRF_1511	Second Line Therapy (after first relapse)	Ixazomib		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		4	Q week	Q week					1215	1496	1
MMRF_1511	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		2	Q week	Q week					1215	1496	1
MMRF_1511	Third Line Therapy (following 2nd relapse)	Daratumumab		Patient decision	mg/kg	IV	Log Forms	Other	SALVAGE		16	QWK	QWK					1518	1600	1
MMRF_1511	Third Line Therapy (following 2nd relapse)	Dexamethasone		DOSE REDUCTION	mg	PO	Log Forms	Other	SALVAGE		2	QWK	QWK					1518	1748	1
MMRF_1511	Third Line Therapy (following 2nd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		2	Other	Q 2 DAYS (DAYS 1-21 OF 28D)					1518	2241	1
MMRF_1511	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		1	Q week	Q week					1749	2241	1
MMRF_1511	Fourth Line Therapy (following 3rd relapse)	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Other	SALVAGE		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					2252	2367	1
MMRF_1511	Fourth Line Therapy (following 3rd relapse)	Elotuzumab		Adverse Event or co-morbidity	mg/kg	IV	Log Forms	Other	SALVAGE		10	Q week	Q week					2252	2367	1
MMRF_1511	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	SALVAGE		20	Other	DAYS 2,4,5,9,11,12 Q 21D					2252	2367	1
MMRF_1511	Fourth Line Therapy (following 3rd relapse)	Carfilzomib		Adverse Event or co-morbidity	UNKNOWN	IV	Log Forms	Other	SALVAGE			Other	UNKNOWN					2477	2791	1
MMRF_1511	Fourth Line Therapy (following 3rd relapse)	Cyclophosphamide		Adverse Event or co-morbidity	UNKNOWN	PO	Log Forms	Other	SALVAGE			Other	UNKNOWN					2477	2791	1
MMRF_1511	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	SALVAGE		12	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					2477	2791	1
MMRF_1511	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		120	Q day	Q day					75	76	1
MMRF_1584	First line of therapy	Lenalidomide			mg	PO	Log Forms	Induction	Induction	Checked	25	QD (D1-14)	QD (D1-14)					32		1
MMRF_1584	First line of therapy	Bortezomib			mg	IV	Log Forms	Induction	Induction	Checked	2.2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					32		1
MMRF_1584	First line of therapy	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	40	Q week	Q week					32		1
MMRF_1584	First line of therapy	Dexamethasone		CHANGED DOSE	mg	PO	Log Forms	Induction	Induction		16	Q day	Q day					1	11	1
MMRF_1584	First line of therapy	Dexamethasone		CHNAGED DOSE	mg	PO	Log Forms	Induction	Induction		4	Q day	Q day					11	32	1
MMRF_1624	First line of therapy	Bortezomib		Completed regimen	mg	IV	Log Forms	Induction	Induction		2.9	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	142	1
MMRF_1624	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	142	1
MMRF_1624	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	142	1
MMRF_1624	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					292	1440	1
MMRF_1624	Second Line Therapy (after first relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Other	SALVAGE		16	Other	QW(C1-2); Q2W(C3-6)					1449	1582	1
MMRF_1624	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	SALVAGE		40	Q week	Q week					1449	1469	1
MMRF_1624	Second Line Therapy (after first relapse)	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	SALVAGE		4	Q day	Q day					1449	1469	1
MMRF_1624	Third Line Therapy (following 2nd relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Other	SALVAGE		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1616	1861	1
MMRF_1624	Third Line Therapy (following 2nd relapse)	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	SALVAGE		4	QD (D1-21)	QD (D1-21)					1616	1840	1
MMRF_1624	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		40	Q week	Q week					1616	1861	1
MMRF_1624	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	TRANSPLANT		140	Q day	Q day					181	182	1
MMRF_1624	Third Line Therapy (following 2nd relapse)	Cyclophosphamide		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		300	QWK	QWK					1840	1861	1
MMRF_1624	Fourth Line Therapy (following 3rd relapse)	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	TRANSPLANT		140	Other	ONCE					1922	1922	1
MMRF_1667	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		165	Q day	Q day					147	148	1
MMRF_1667	First line of therapy	Dexamethasone		MOVED TO SCT	mg	PO	Log Forms	Induction	Induction		20	Other	DAY OF AND DAY AFTER VELCADE					1	107	1
MMRF_1667	First line of therapy	Cyclophosphamide		MOVED TO SCT	mg/m^2	PO	Log Forms	Induction	Induction		300	Q week	Q week					1	106	1
MMRF_1667	First line of therapy	Bortezomib		MOVED TO SCT	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					1	106	1
MMRF_1667	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					259	474	1
MMRF_1667	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					475	536	1
MMRF_1668	First line of therapy	Cyclophosphamide		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		650	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					8	142	1
MMRF_1668	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					2	142	1
MMRF_1668	First line of therapy	Bortezomib		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		3.2	Q week	Q week					1	142	1
MMRF_1668	Second Line Therapy (after first relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					142	202	1
MMRF_1668	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		40	QWK	QWK					143	202	1
MMRF_1668	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					142	202	1
MMRF_1668	Third Line Therapy (following 2nd relapse)	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					209	251	1
MMRF_1668	Third Line Therapy (following 2nd relapse)	Pomalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		4	QD (D1-21)	QD (D1-21)					209	251	1
MMRF_1668	Third Line Therapy (following 2nd relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		20	QWK	QWK					209	251	1
MMRF_1668	Third Line Therapy (following 2nd relapse)	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		4300	Q day	Q day					230	230	1
MMRF_1760	First line of therapy	Prednisone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		100	QD (D1-4)	QD (D1-4)					135	197	1
MMRF_1760	Second Line Therapy (after first relapse)	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Other	SALVAGE		1	Q week	Q week					211	848	1
MMRF_1760	Second Line Therapy (after first relapse)	Dexamethasone		DOCTOR DECISION	mg	PO	Log Forms	Other	SALVAGE		20	Q week	Q week					211	673	1
MMRF_1760	Third Line Therapy (following 2nd relapse)	Pomalidomide		FREQUENCY CHANGE DUE TO PERIPHERAL NEUROPATHY	mg	PO	Log Forms	Other	SALVAGE		2	QD (D1-21)	QD (D1-21)					953	1057	1
MMRF_1760	Third Line Therapy (following 2nd relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	SALVAGE		20	Q week	Q week					953	1113	1
MMRF_1760	Third Line Therapy (following 2nd relapse)	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	SALVAGE		2	Other	Q 2 DAYS (DAYS 1-21)					1058	1113	1
MMRF_1760	Fourth Line Therapy (following 3rd relapse)	Daratumumab		Adverse Event or co-morbidity	mg/kg	IV	Log Forms	Other	SALVAGE		16	Other	WEEKLY(C1-2); Q 2 WEEKS(C3-6); MONTHY (C7+)					1211	2052	1
MMRF_1760	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	SALVAGE		8	Other	WEEKLY(C1-2); Q 2 WEEKS(C3-6); MONTHY (C7+)					1211	2052	1
MMRF_1760	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					22	134	1
MMRF_1760	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					1	134	1
MMRF_1760	First line of therapy	Melphalan		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		16	QD (D1-4)	QD (D1-4)					135	197	1
MMRF_1783	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	156	1
MMRF_1783	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg	IV	Log Forms	Induction	Induction		3.71	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	11	1
MMRF_1783	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	156	1
MMRF_1783	First line of therapy	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					192	380	1
MMRF_1783	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		10	Q day	Q day					192	380	1
MMRF_1783	Second Line Therapy (after first relapse)	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Unknown	Unknown		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					380	481	1
MMRF_1783	Second Line Therapy (after first relapse)	Cyclophosphamide		Completed regimen	mg/m^2	PO	Log Forms	Unknown	Unknown		300	QWK	QWK					380	481	1
MMRF_1783	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Unknown	Unknown		40	QWK	QWK					380	481	1
MMRF_1783	Second Line Therapy (after first relapse)	Pomalidomide		DEATH	mg	PO	Log Forms	Maintenance	Maintenance		2	QD (D1-21)	QD (D1-21)					632	718	1
MMRF_1783	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg	IV	Log Forms	Other	TRANSPLANT		470	Other	DAY -2					493	493	1
MMRF_1784	Fifth Line Therapy (following 4th relapse)	BELANTAMAB		Adverse Event or co-morbidity	mg/kg	IV	Log Forms	Other	SALVAGE		2.5	Other	EVERY 3 WEEKS					2419	2440	1
MMRF_1784	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		40	Q week	Q week					2333	2402	1
MMRF_1784	Fourth Line Therapy (following 3rd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		4	QD (D1-21)	QD (D1-21)					2333	2402	1
MMRF_1784	Fourth Line Therapy (following 3rd relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Other	SALVAGE		16	Q week	Q week					2333	2402	1
MMRF_1784	First line of therapy	Dexamethasone		MOVED TO SCT	mg	PO	Log Forms	Induction	Induction		40	Other	DAY OF AND AFTER BORTEZOIB					1	75	1
MMRF_1784	First line of therapy	Bortezomib		MOVED TO AUTO SCT	mg	IV SubQ	Log Forms	Induction	Induction		2.7	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	74	1
MMRF_1784	First line of therapy	Lenalidomide		MOVED TO SCT	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					22	77	1
MMRF_1784	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					204	1688	1
MMRF_1784	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		180	Q day	Q day					120	121	1
MMRF_1784	Third Line Therapy (following 2nd relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Other	SALVAGE		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					2110	2332	1
MMRF_1784	Third Line Therapy (following 2nd relapse)	Cyclophosphamide		Disease progression/Relapse	mg/m^2	IV	Log Forms	Other	SALVAGE		300	Other	QD (D1, D8, D15)					2110	2332	1
MMRF_1784	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					2110	2332	1
MMRF_1784	Second Line Therapy (after first relapse)	Elotuzumab		Completed regimen	mg/kg	IV	Log Forms	Other	SALVAGE		10	Q week	Q week					1702	1814	1
MMRF_1784	Second Line Therapy (after first relapse)	Pomalidomide		Completed regimen	mg	PO	Log Forms	Other	SALVAGE		4	QD (D1-21)	QD (D1-21)					1702	1814	1
MMRF_1784	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	28MG(PO); 8MG(IV)	Log Forms	Other	SALVAGE		36	Q week	Q week					1702	1814	1
MMRF_1784	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg	IV	Log Forms	Other	TRANSPLANT		350	Other	ONCE					1820	1820	1
MMRF_1784	Second Line Therapy (after first relapse)	Elotuzumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Consolidation	Consolidation		10	Other	Q 2 WEEKS					1929	2108	1
MMRF_1784	Second Line Therapy (after first relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		2	QD (D1-21)	QD (D1-21)					1929	2108	1
MMRF_1784	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		8	Other	Q 2 WEEKS					1929	2108	1
MMRF_1839	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	TRANSPLANT		170	Q day	Q day					113	114	1
MMRF_1839	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					7	102	1
MMRF_1839	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	102	1
MMRF_1839	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	102	1
MMRF_1839	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					240	1123	1
MMRF_1839	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Maintenance	Maintenance		1.3	Other	TWICE A MONTH					240	898	1
MMRF_1851	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q day	Q day					1	4	1
MMRF_1851	First line of therapy	Lenalidomide		PATIENT WENT ON HOSPICE	mg	PO	Log Forms	Induction	Induction		20	QD (D1-14)	QD (D1-14)					13	25	1
MMRF_1851	First line of therapy	Bortezomib		PATIENT WENT ON HOSPICE	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					12	25	1
MMRF_1851	First line of therapy	Dexamethasone		PATIENT WENT ON HOSPICE	mg	PO	Log Forms	Induction	Induction		20	Other	DAY OF AND DAY AFTER BORTEZOMIB					12	25	1
MMRF_1876	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	85	1
MMRF_1876	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO	Log Forms	Induction	Induction		300	QWK	QWK					1	85	1
MMRF_1876	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	QD 1-4, 9-12, 17-20 OF 28					1	85	1
MMRF_1876	Second Line Therapy (after first relapse)	Bortezomib		Lack of response	mg/m^2	IV	Log Forms	Other	SALVAGE		1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					490	564	1
MMRF_1876	Second Line Therapy (after first relapse)	Dexamethasone		Lack of response	mg	PO	Log Forms	Other	SALVAGE		20	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					490	564	1
MMRF_1876	Second Line Therapy (after first relapse)	Cyclophosphamide		Lack of response	mg/m^2	PO	Log Forms	Other	SALVAGE		150	Other	BID (D1-5)					490	564	1
MMRF_1876	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					239	490	1
MMRF_1876	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		100	Q day	Q day					146	147	1
MMRF_1889	Fourth Line Therapy (following 3rd relapse)	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	SALVAGE		2	QD (D1-21)	QD (D1-21)					687	800	1
MMRF_1889	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		40	Q week	Q week					519	638	1
MMRF_1889	Third Line Therapy (following 2nd relapse)	Bendamustine		Disease progression/Relapse	mg/m^2	IVB	Log Forms	Other	SALVAGE		80	Other	D1, D2					557	638	1
MMRF_1889	Fourth Line Therapy (following 3rd relapse)	Pomalidomide		DOSE REDUCTION DUE TO ADVERSE EVENT	mg	PO	Log Forms	Other	SALVAGE		4	QD (D1-21)	QD (D1-21)					659	687	1
MMRF_1889	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	SALVAGE		20	Q week	Q week					659	800	1
MMRF_1889	Fourth Line Therapy (following 3rd relapse)	Daratumumab		Adverse Event or co-morbidity	mg/kg	IV	Log Forms	Other	SALVAGE		16	Q week	Q week					659	800	1
MMRF_1889	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	TRANSPLANT		160	Other	DAYS -3, -2					139	140	1
MMRF_1889	First line of therapy	Carfilzomib		Completed regimen	mg	IV	Log Forms	Induction	Induction		38	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	106	1
MMRF_1889	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	106	1
MMRF_1889	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	106	1
MMRF_1889	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		25	Q day	Q day					266	421	1
MMRF_1889	Second Line Therapy (after first relapse)	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms	Other	SALVAGE		1.5	QWK	QWK					421	519	1
MMRF_1889	Second Line Therapy (after first relapse)	Cyclophosphamide		Disease progression/Relapse	mg/m^2	PO	Log Forms	Other	SALVAGE		300	QWK	QWK					421	519	1
MMRF_1889	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		40	Q day	Q day					421	519	1
MMRF_1889	Third Line Therapy (following 2nd relapse)	Carfilzomib		Lack of response	mg/m^2	IV	Log Forms	Other	SALVAGE		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					519	554	1
MMRF_1889	Third Line Therapy (following 2nd relapse)	Thalidomide		Lack of response	mg	PO	Log Forms	Other	SALVAGE		200	Q day	Q day					519	554	1
MMRF_1891	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	103	1
MMRF_1891	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	103	1
MMRF_1891	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	DAY OF AND DAY AFTER BORTEZOMIB					1	103	1
MMRF_1891	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					204	599	1
MMRF_1891	Second Line Therapy (after first relapse)	ABBV-838		NEUROPATHY	mg/kg	IV	Log Forms	Other	SALVAGE		0.6	Other	Q 21 DAYS					645	1037	1
MMRF_1891	Second Line Therapy (after first relapse)	Elotuzumab			mg/kg	IV	Log Forms	Other	SALVAGE	Checked	10	Other	WEEKLY(C1-2); Q 2 WEEKS(C3+)					1058		1
MMRF_1891	Second Line Therapy (after first relapse)	Lenalidomide			mg	PO	Log Forms	Other	SALVAGE	Checked	25	QD (D1-21)	QD (D1-21)					1058		1
MMRF_1891	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Other	SALVAGE	Checked	28	Q week	Q week					1058		1
MMRF_1891	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					103	104	1
MMRF_1893	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	TRANSPLANT		180	Q day	Q day					117	118	1
MMRF_1893	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					4	73	1
MMRF_1893	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					4	73	1
MMRF_1893	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	DAY OF AND DAY AFTER BORTEZOMIB					4	73	1
MMRF_1893	First line of therapy	Dexamethasone		SWITCHED REGIMEN	mg	PO	Log Forms	Induction	Induction		40	Q day	Q day					1	3	1
MMRF_1893	First line of therapy	Lenalidomide		PATIENT FORGETFULLNESS AND INABILITY/RELUCTANCE TO MEET DEDUCTIBLE	mg	PO	Log Forms	Maintenance	Maintenance		20	Q day	Q day					232	802	1
MMRF_1900	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Other	DAY 1, DAY 8 & DAY 15, OF 28					1	253	1
MMRF_1900	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					1	253	1
MMRF_1900	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	DAY 1, DAY 8 & DAY 15, OF 28					1	253	1
MMRF_1900	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					253	344	1
MMRF_1900	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-14)	QD (D1-14)					405	539	1
MMRF_1900	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		20	Other	TWICE WEEKLY					405	539	1
MMRF_1900	Second Line Therapy (after first relapse)	Lenalidomide		DOCTOR DECISION	mg	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-14)	QD (D1-14)					614	708	1
MMRF_1900	Second Line Therapy (after first relapse)	Dexamethasone		DOCTOR DECISION	mg	PO	Log Forms	Maintenance	Maintenance		20	Other	B.I. WEEKLY					614	708	1
MMRF_1900	Third Line Therapy (following 2nd relapse)	Lenalidomide		DEATH	mg	PO	Log Forms	Other	SALVAGE		5	QD (D1-14)	QD (D1-14)					925	1282	1
MMRF_1900	Third Line Therapy (following 2nd relapse)	Dexamethasone		DEATH	mg	PO	Log Forms	Other	SALVAGE		4	Other	3X WEEKLY					925	1282	1
MMRF_1911	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		185	Q day	Q day					116	117	1
MMRF_1911	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	91	1
MMRF_1911	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	91	1
MMRF_1911	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	91	1
MMRF_1911	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					213	317	1
MMRF_1911	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					213	317	1
MMRF_1911	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		40	Q week	Q week					213	317	1
MMRF_1911	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					360	2698	1
MMRF_1953	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	65	1
MMRF_1953	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	65	1
MMRF_1953	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	65	1
MMRF_1953	First line of therapy	Lenalidomide		DOCTOR DECISION	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					248	640	1
MMRF_1953	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					752		1
MMRF_1953	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	TRANSPLANT		175	Q day	Q day					124	125	1
MMRF_1955	First line of therapy	Dexamethasone		SWITCHED TO WEEKLY DEX	mg	IV	Log Forms	Induction	Induction		40	Q day	Q day					1	4	1
MMRF_1955	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					3	162	1
MMRF_1955	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		20	Other	DAY OF AND DAY AFTER BORTEZOMIB					10	162	1
MMRF_1974	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	96	1
MMRF_1974	First line of therapy	Dexamethasone		CHANGED FREQUENCY	mg	PO	Log Forms	Induction	Induction		40	Other	DAYS 1-4, 9-12, 17-20					1	22	1
MMRF_1974	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		300	Other	DAYS 1 AND 8					4	96	1
MMRF_1974	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	DAY OF AND DAY AFTER BORTEZOMIB					23	96	1
MMRF_1974	First line of therapy	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Maintenance	Maintenance		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					188	363	1
MMRF_1974	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		25	QD (D1-21)	QD (D1-21)					188	363	1
MMRF_1974	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					188	363	1
MMRF_1974	Second Line Therapy (after first relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		4	QD (D1-21)	QD (D1-21)					371	398	1
MMRF_1974	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		40	Other	DAYS 1,8,15,22					371	398	1
MMRF_1974	Second Line Therapy (after first relapse)	CLARITHROMYCIN (BIAXIN)		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		250	BID	BID					371	398	1
MMRF_1974	Second Line Therapy (after first relapse)	Bendamustine		Disease progression/Relapse	mg/m^2	IV	Log Forms	Other	SALVAGE		75	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					408	419	1
MMRF_1974	Second Line Therapy (after first relapse)	Prednisone		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		50	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					408	419	1
MMRF_1974	Second Line Therapy (after first relapse)	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Other	SALVAGE		40	QD (D1-4)	QD (D1-4)					429	545	1
MMRF_1974	Second Line Therapy (after first relapse)	Cyclophosphamide		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Other	SALVAGE		400	Other	CONTINUOUS INFUSION DAYS 1-4					429	545	1
MMRF_1974	Second Line Therapy (after first relapse)	ETOPOSIDE (VEPESID)		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Other	SALVAGE		40	Other	CONTINUOUS INFUSION DAYS 1-4					429	545	1
MMRF_1974	Second Line Therapy (after first relapse)	CISPLATIN (PLATINOL)		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Other	SALVAGE		15	Other	CONTINUOUS INFUSION DAYS 1-4					429	545	1
MMRF_1974	Second Line Therapy (after first relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Other	SALVAGE		16	Q week	Q week					573	713	1
MMRF_1974	Second Line Therapy (after first relapse)	Pomalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Other	SALVAGE		2.5	Q day	Q day					573	636	1
MMRF_1974	Second Line Therapy (after first relapse)	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Other	SALVAGE		40	Q week	Q week					573	636	1
MMRF_1974	Second Line Therapy (after first relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		2	QD (D1-21)	QD (D1-21)					671	713	1
MMRF_1974	Third Line Therapy (following 2nd relapse)	Cyclophosphamide		Disease progression/Relapse	mg/m^2	IV	Log Forms	Other	SALVAGE		400	Other	CONTINUOUS INFUSION DAYS 1-4					721	842	1
MMRF_1974	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		40	QD (D1-4)	QD (D1-4)					721	842	1
MMRF_1974	Third Line Therapy (following 2nd relapse)	ETOPOSIDE (VEPESID)		Disease progression/Relapse	mg/m^2	IV	Log Forms	Other	SALVAGE		40	Other	CONTINUOUS INFUSION DAYS 1-4					721	842	1
MMRF_1974	Third Line Therapy (following 2nd relapse)	CISPLATIN (PLATINOL)		Disease progression/Relapse	mg/m^2	IV	Log Forms	Other	SALVAGE		15	Other	CONTINUOUS INFUSION DAYS 1-4					721	842	1
MMRF_1974	Fourth Line Therapy (following 3rd relapse)	NIVOLUMAB		DEATH	mg/kg	IV	Log Forms	Other	SALVAGE		3	Other	QD (D1, D15)					863	892	1
MMRF_1974	Fourth Line Therapy (following 3rd relapse)	Pomalidomide		DEATH	mg	PO	Log Forms	Other	SALVAGE		2	QD (D1-21)	QD (D1-21)					863	892	1
MMRF_1974	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		DEATH	mg	PO	Log Forms	Other	SALVAGE		40	Other	QD (D8, D22)					863	892	1
MMRF_1974	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	TRANSPLANT		185	Other	DAYS -3, -2					103	104	1
MMRF_1982	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	91	1
MMRF_1982	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	91	1
MMRF_1982	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	DAY OF AND DAY AFTER VELCADE					1	91	1
MMRF_1982	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		4	Q day	Q day					91	165	1
MMRF_1986	First line of therapy	Dexamethasone		SWITCHED TO PO DEX	mg	IV	Log Forms	Induction	Induction		40	Q day	Q day					1	2	1
MMRF_1986	First line of therapy	Dexamethasone		SWITCHED TO WEEKLY DEX	mg	PO	Log Forms	Induction	Induction		40	Q day	Q day					3	4	1
MMRF_1986	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					6	125	1
MMRF_1986	First line of therapy	Dexamethasone		DISCONTINUED DUE TO GRADE 2 TRANSAMINITIS	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					6	398	1
MMRF_1986	First line of therapy	Lenalidomide		DISCONTINUED DUE TO GRADE 2 TRANSAMINITIS	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					13	398	1
MMRF_1999	First line of therapy	Dexamethasone		SWITCHED TO WEEKLY	mg	PO	Log Forms	Induction	Induction		40	Q day	Q day					1	4	1
MMRF_1999	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		1.9	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					14	56	1
MMRF_1999	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					10	56	1
MMRF_1999	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					10	56	1
MMRF_1999	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	TRANSPLANT		145	Other	DAYS -3, -2					118	119	1
MMRF_2014	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	93	1
MMRF_2014	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	93	1
MMRF_2014	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	93	1
MMRF_2014	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					212	1010	1
MMRF_2014	First line of therapy	Prednisone		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		40	Q day	Q day					458	711	1
MMRF_2014	Second Line Therapy (after first relapse)	Elotuzumab		Adverse Event or co-morbidity	mg/kg	IV	Log Forms	Other	SALVAGE		10	Q week	Q week					1066	1320	1
MMRF_2014	Second Line Therapy (after first relapse)	Lenalidomide		SHOULDER SURGERY	mg	PO	Log Forms	Other	SALVAGE		15	QD (D1-21)	QD (D1-21)					1066	1320	1
MMRF_2014	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	SALVAGE		28	Q week	Q week					1066	1320	1
MMRF_2014	Third Line Therapy (following 2nd relapse)	Lenalidomide		PATIENT DECEASED	mg	PO	Log Forms	Other	SALVAGE		10	QD (D1-21)	QD (D1-21)					2042	2094	1
MMRF_2014	Third Line Therapy (following 2nd relapse)	Dexamethasone		PATIENT DECEASED	mg	PO	Log Forms	Other	SALVAGE		40	Q week	Q week					2042	2094	1
MMRF_2014	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		430	Other	ONCE					107	107	1
MMRF_2043	Second Line Therapy (after first relapse)	Bortezomib			mg	IV SubQ	Log Forms	Other	SALVAGE	Checked	2.9	Q week	Q week					2755		1
MMRF_2043	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Other	SALVAGE	Checked	40	Q week	Q week					2755		1
MMRF_2043	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	81	1
MMRF_2043	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	81	1
MMRF_2043	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	81	1
MMRF_2043	First line of therapy	Lenalidomide		Patient decision	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					202	254	1
MMRF_2063	First line of therapy	Bortezomib		PATIENT EXPIRED	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	46	1
MMRF_2063	First line of therapy	Cyclophosphamide		PATIENT EXPIRED	mg	PO	Log Forms	Induction	Induction		450	Q week	Q week					1	46	1
MMRF_2101	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Other	SALVAGE	Checked	20	Q week	Q week					2507		1
MMRF_2101	Second Line Therapy (after first relapse)	Pomalidomide			mg	PO	Log Forms	Other	SALVAGE	Checked	4	QD (D1-21)	QD (D1-21)					2507		1
MMRF_2101	Second Line Therapy (after first relapse)	Daratumumab			mg	IV SubQ	Log Forms	Other	SALVAGE	Checked	1800	Q week	Q week					2507		1
MMRF_2101	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		4	QWK	QWK					1	89	1
MMRF_2101	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	89	1
MMRF_2101	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		10	QD (D1-14)	QD (D1-14)					20	62	1
MMRF_2101	First line of therapy	Lenalidomide		DOSE REDUCTION	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					224	567	1
MMRF_2101	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					567	2478	1
MMRF_2101	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		300	Other	ONCE					110	110	1
MMRF_2124	Fourth Line Therapy (following 3rd relapse)	Daratumumab			mg	SUBCUTANEOUS	Log Forms	Other	SALVAGE	Checked	1800	Other	QW(C1-2); Q2W(C3-6); Q4W(C7+)					2598		1
MMRF_2124	Fourth Line Therapy (following 3rd relapse)	Pomalidomide			mg	PO	Log Forms	Other	SALVAGE	Checked	4	QD (D1-21)	QD (D1-21)					2597		1
MMRF_2124	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	SALVAGE		20	Q week	Q week					2598	2640	1
MMRF_2124	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	SALVAGE		10	Other	Q 2 WEEKS					2654	2672	1
MMRF_2124	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	20	1
MMRF_2124	First line of therapy	Bortezomib		Completed regimen	mg	IV	Log Forms	Induction	Induction		2.2	Q week	Q week					1	20	1
MMRF_2124	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					21	159	1
MMRF_2124	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					21	159	1
MMRF_2124	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		10	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					21	159	1
MMRF_2124	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					280	679	1
MMRF_2124	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					280	679	1
MMRF_2124	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		10	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					280	679	1
MMRF_2124	First line of therapy	Lenalidomide		DOSE REDUCTION DUE TO GRADE 2 NEUTROPENIA	mg	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					679	762	1
MMRF_2124	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		2.5	Q day	Q day					763	1218	1
MMRF_2124	Second Line Therapy (after first relapse)	Elotuzumab		Completed regimen	mg/kg	IV	Log Forms	Induction	Induction		10	Q week	Q week					1258	1370	1
MMRF_2124	Second Line Therapy (after first relapse)	Pomalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					1258	1370	1
MMRF_2124	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1258	1370	1
MMRF_2124	Third Line Therapy (following 2nd relapse)	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1386	1475	1
MMRF_2124	Third Line Therapy (following 2nd relapse)	Daratumumab		Completed regimen	mg/kg	IV	Log Forms	Induction	Induction		16	Q week	Q week					1386	1475	1
MMRF_2124	Third Line Therapy (following 2nd relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1386	1475	1
MMRF_2124	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		310	Q day	Q day					165	165	1
MMRF_2124	Third Line Therapy (following 2nd relapse)	Ixazomib		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		2.3	Q week	Q week					2086	2587	1
MMRF_2124	Third Line Therapy (following 2nd relapse)	Melphalan		Completed regimen	mg	IV	Log Forms	Other	TRANSPLANT CONDITIONING		300	Other	ONCE					1497	1497	1
MMRF_2124	Third Line Therapy (following 2nd relapse)	Dexamethasone		Completed regimen	mg	IV	Log Forms	Other	TRANSPLANT CONDITIONING		10	Q day	Q day					1497	1499	1
MMRF_2124	Third Line Therapy (following 2nd relapse)	Ixazomib		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		3	Q week	Q week					1624	2086	1
MMRF_2198	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	29	1
MMRF_2198	First line of therapy	Dexamethasone		TOXICITY	mg	PO	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	99	1
MMRF_2198	First line of therapy	Bortezomib		TOXICITY	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	99	1
MMRF_2198	First line of therapy	Cyclophosphamide		TOXICITY	mg	PO	Log Forms	Induction	Induction		50	Q day	Q day					29	99	1
MMRF_2198	Second Line Therapy (after first relapse)	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					141	225	1
MMRF_2198	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		10	Q day	Q day					141	225	1
MMRF_2198	Second Line Therapy (after first relapse)	Bortezomib		FATIGUE	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	EVERY OTHER WEEK					365	743	1
MMRF_2198	Second Line Therapy (after first relapse)	Ixazomib		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		4	Other	QD (D1, D8, D15)					743	897	1
MMRF_2198	Third Line Therapy (following 2nd relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Other	SALVAGE		16	Other	WEEKLY(C1-2), Q 2WEEKS(C3-6), MONTHLY(C7+)					943	1170	1
MMRF_2198	Third Line Therapy (following 2nd relapse)	DURVALUMAB		Disease progression/Relapse	mg	IV	Log Forms	Other	SALVAGE		1500	Other	DAY 1 (28D CYCLE)					943	1170	1
MMRF_2198	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		20	QWK	QWK					943	1170	1
MMRF_2198	Fourth Line Therapy (following 3rd relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Other	SALVAGE		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1188	1527	1
MMRF_2198	Fourth Line Therapy (following 3rd relapse)	Pomalidomide		DOSE REDUCTION	mg	PO	Log Forms	Other	SALVAGE		4	QD (D1-21)	QD (D1-21)					1188	1274	1
MMRF_2198	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1188	1527	1
MMRF_2198	Fourth Line Therapy (following 3rd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		2	QD (D1-21)	QD (D1-21)					1275	1527	1
MMRF_2198	Seventh Line of Therapy (following 6th relapse)	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Other	SALVAGE		2000	Other	DAY 1 Q 28D					1940	1940	1
MMRF_2198	Seventh Line of Therapy (following 6th relapse)	Cyclophosphamide		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Other	SALVAGE		1500	Other	DAY 1 Q 28D					1981	2078	1
MMRF_2198	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		410	Q week	Q week					250	250	1
MMRF_2198	Eighth Line of Therapy (following 7th relapse)	BELANTAMAB		Adverse Event or co-morbidity	mg/kg	IV	Log Forms	Other	SALVAGE		2.5	Other	DAY 1 EVERY 28D					2192	2255	1
MMRF_2198	Seventh Line of Therapy (following 6th relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	IV	Log Forms	Other	SALVAGE		10	Other	DAY 1 Q 28D					1940	2078	1
MMRF_2198	Seventh Line of Therapy (following 6th relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	SALVAGE		8	Other	DAY 1,2, POST CYCLOPHOSPHAMIDE ADMINSTRATION					1941	2078	1
MMRF_2198	Fifth Line Therapy (following 4th relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Other	SALVAGE		16	Q week	Q week					1558	1611	1
MMRF_2198	Fifth Line Therapy (following 4th relapse)	Lenalidomide		DOSE REDUCTION	mg	PO	Log Forms	Other	SALVAGE		25	QD (D1-21)	QD (D1-21)					1558	1582	1
MMRF_2198	Fifth Line Therapy (following 4th relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		15	QD (D1-21)	QD (D1-21)					1583	1611	1
MMRF_2198	Fifth Line Therapy (following 4th relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		40	Q week	Q week					1558	1611	1
MMRF_2198	Sixth Line Therapy (following 5th relapse)	Cyclophosphamide		DOSE REDUCTION	mg/m^2	IV	Log Forms	Other	SALVAGE		400	QD (D1-4)	QD (D1-4)					1635	1639	1
MMRF_2198	Sixth Line Therapy (following 5th relapse)	CISPLATIN		DOSE REDUCTION	mg/m^2	IV	Log Forms	Other	SALVAGE		10	QD (D1-4)	QD (D1-4)					1635	1639	1
MMRF_2198	Sixth Line Therapy (following 5th relapse)	ETOPOSIDE		DOSE REDUCTION	mg/m^2	IV	Log Forms	Other	SALVAGE		40	QD (D1-4)	QD (D1-4)					1635	1639	1
MMRF_2198	Sixth Line Therapy (following 5th relapse)	Dexamethasone		DOSE REDUCTION	mg	PO	Log Forms	Other	SALVAGE		40	QD (D1-4)	QD (D1-4)					1635	1639	1
MMRF_2198	Sixth Line Therapy (following 5th relapse)	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Other	SALVAGE		300	QD (D1-4)	QD (D1-4)					1671	1711	1
MMRF_2198	Sixth Line Therapy (following 5th relapse)	CISPLATIN		Completed regimen	mg/m^2	IV	Log Forms	Other	SALVAGE		7.5	QD (D1-4)	QD (D1-4)					1671	1711	1
MMRF_2198	Sixth Line Therapy (following 5th relapse)	ETOPOSIDE		Completed regimen	mg/m^2	IV	Log Forms	Other	SALVAGE		30	QD (D1-4)	QD (D1-4)					1671	1711	1
MMRF_2198	Sixth Line Therapy (following 5th relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Other	SALVAGE		20	QD (D1-4)	QD (D1-4)					1671	1711	1
MMRF_2226	First line of therapy	Bortezomib			mg	IV SubQ	Log Forms	Induction	Induction	Checked	1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_2226	First line of therapy	Lenalidomide			mg	PO	Log Forms	Induction	Induction	Checked	15	QD (D1-14)	QD (D1-14)					1		1
MMRF_2226	First line of therapy	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1		1
MMRF_2270	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		2.9	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	99	1
MMRF_2270	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	99	1
MMRF_2270	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	99	1
MMRF_2270	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Other	DAYS -3, -2					110	111	1
MMRF_2270	First line of therapy	Lenalidomide		DOSE REDUCTION	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					226	957	1
MMRF_2270	Second Line Therapy (after first relapse)	Elotuzumab			mg/kg	IV	Log Forms	Maintenance	Maintenance	Checked	10	Other	DAYS 1, 15 Q 28D					2227		1
MMRF_2270	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	28MG PO; 8MG IV	Log Forms	Maintenance	Maintenance		36	Other	DAY 1					2227	2570	1
MMRF_2270	Second Line Therapy (after first relapse)	Pomalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	2	QD (D1-21)	QD (D1-21)					2227		1
MMRF_2270	Second Line Therapy (after first relapse)	Carfilzomib		Completed regimen	mg	IV	Log Forms	Other	SALVAGE		60	Other	UNKNOWN					2037	2087	1
MMRF_2270	Second Line Therapy (after first relapse)	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Other	SALVAGE		650	Other	DAYS 1, 8, 15 Q 28D					2037	2087	1
MMRF_2270	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Other	SALVAGE		40	Q week	Q week					2037	2087	1
MMRF_2270	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Other	ONCE					2115	2115	1
MMRF_2270	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					957	1991	1
MMRF_2270	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	8MG PO; 8MG IV	Log Forms	Maintenance	Maintenance		16	Other	DAY 1 Q 28D					2570	2598	1
MMRF_2270	Second Line Therapy (after first relapse)	Dexamethasone			mg	IV	Log Forms	Maintenance	Maintenance	Checked	8	Other	DAY 1 Q 28D					2598		1
MMRF_2271	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	154	1
MMRF_2271	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		12	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	154	1
MMRF_2272	First line of therapy	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	17	1
MMRF_2272	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		40	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	17	1
MMRF_2449	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	74	1
MMRF_2449	First line of therapy	Cyclophosphamide		Completed regimen	mg/kg	PO	Log Forms	Induction	Induction		10	Q week	Q week					1	74	1
MMRF_2449	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Q day	Q day					1	74	1
MMRF_2449	First line of therapy	Melphalan		Completed regimen	mg	IVB	Log Forms	Other	PRE-ASCT		315	Q day	Q day					114	114	1
MMRF_2449	First line of therapy	Bortezomib			mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance	Checked	1.3	Other	EVERY 2 WEEKS					215		1
MMRF_2449	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	5	Q day	Q day					215		1
MMRF_2446	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.5	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	93	1
MMRF_2446	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO	Log Forms	Induction	Induction		300	Q week	Q week					1	93	1
MMRF_2446	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1-4)	QD (D1-4)					1	93	1
MMRF_2446	First line of therapy	Bortezomib			mg/m^2	IV	Log Forms	Maintenance	Maintenance	Checked	1.6	Other	TWICE A MONTH					232		1
MMRF_2446	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					260		1
MMRF_2446	First line of therapy	Melphalan		Completed regimen	mg	PO	Log Forms	Other	CONDITIONING		304	Other	DAYS -2					118	118	1
MMRF_2514	First line of therapy	Bortezomib		Investigator decision for other reasons	mg	IV SubQ	Log Forms	Induction	Induction		1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	23	1
MMRF_2514	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		15	QD (D1-14)	QD (D1-14)					1	23	1
MMRF_2514	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	24	1
MMRF_2514	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		10	QD (D1-14)	QD (D1-14)					105	196	1
MMRF_2514	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					105	210	1
MMRF_2514	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					105	210	1
MMRF_2514	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	D1, D8, D15					287	389	1
MMRF_2514	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		20	Q week	Q week					287	389	1
MMRF_2514	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	TRANSPLANT		330	Other	DAY -2					418	418	1
MMRF_2514	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	Q day	Q day					555		1
MMRF_2531	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	85	1
MMRF_2531	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		10	QD (D1-14)	QD (D1-14)					1	85	1
MMRF_2531	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		4	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	85	1
MMRF_2531	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					239	413	1
MMRF_2531	Second Line Therapy (after first relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Other	SALVAGE		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					423	480	1
MMRF_2531	Second Line Therapy (after first relapse)	Cyclophosphamide		Disease progression/Relapse	mg/m^2	IV	Log Forms	Other	SALVAGE		300	Other	QD (D1, D8, D15)					423	480	1
MMRF_2531	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					423	480	1
MMRF_2531	Third Line Therapy (following 2nd relapse)	Daratumumab		DEATH	mg/kg	IV	Log Forms	Other	SALVAGE		16	Q week	Q week					484	546	1
MMRF_2531	Third Line Therapy (following 2nd relapse)	Dexamethasone		DEATH	mg	PO	Log Forms	Other	SALVAGE		4	Other	QD: D1, D2 AFTER DARATUMUMAB INFUSION					484	546	1
MMRF_2531	Third Line Therapy (following 2nd relapse)	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	SALVAGE		2	QD (D1-21)	QD (D1-21)					484	505	1
MMRF_2531	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	TRANSPLANT		298	Other	DAY -2					119	119	1
MMRF_2541	First line of therapy	Bortezomib		Lack of response	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	93	1
MMRF_2541	First line of therapy	Cyclophosphamide		Lack of response	mg/m^2	IV	Log Forms	Induction	Induction		500	QWK	QWK					1	93	1
MMRF_2541	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	158	1
MMRF_2541	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Other	SALVAGE		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					106	158	1
MMRF_2541	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Other	SALVAGE		25	QD (D1-21)	QD (D1-21)					106	158	1
MMRF_2541	Sixth Line Therapy (following 5th relapse)	Melphalan		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		2	QD (D1-4)	QD (D1-4)					968	1029	1
MMRF_2541	Sixth Line Therapy (following 5th relapse)	Prednisone		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		10	Other	5 TIMES A DAY FOR DAYS 1-7, TAPER BY 10 MG FOR DAYS 8-11					968	1029	1
MMRF_2541	Sixth Line Therapy (following 5th relapse)	Vincristine		Disease progression/Relapse	mg	IV	Log Forms	Other	SALVAGE		1.28	Other	DAY 1					968	1029	1
MMRF_2541	Sixth Line Therapy (following 5th relapse)	Cyclophosphamide		Disease progression/Relapse	mg	IV	Log Forms	Other	SALVAGE		425	Other	DAY 1					968	1029	1
MMRF_2541	Sixth Line Therapy (following 5th relapse)	BCNU		Disease progression/Relapse	mg	IV	Log Forms	Other	SALVAGE		16	Other	DAY 1					968	1029	1
MMRF_2541	Seventh Line of Therapy (following 6th relapse)	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms	Other	SALVAGE		1.3	Other	DAYS 1,4,15,18					1043	1064	1
MMRF_2541	Seventh Line of Therapy (following 6th relapse)	Panobinostat		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		20	Other	M, W, F: Q 2 WEEKS					1043	1064	1
MMRF_2541	Seventh Line of Therapy (following 6th relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		20	Other	DAYS 1,2,4,5,15,16,18,19					1043	1064	1
MMRF_2541	Eighth Line of Therapy (following 7th relapse)	Cyclophosphamide		DEATH	mg	IV	Log Forms	Other	SALVAGE		2100	Other	DAY 1					1068	1079	1
MMRF_2541	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	TRANSPLANT		278	Other	DAY -2					161	161	1
MMRF_2541	First line of therapy	Ixazomib		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		3	Other	QD: D1, D8, D15					329	385	1
MMRF_2541	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					329	561	1
MMRF_2541	First line of therapy	Ixazomib		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		4	Other	QD: D1, D8, D15					273	328	1
MMRF_2541	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					273	328	1
MMRF_2541	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		40	Other	QD: D1, D8, D15					273	385	1
MMRF_2541	Second Line Therapy (after first relapse)	Daratumumab		Lack of response	mg/kg	IV	Log Forms	Other	SALVAGE		16	Q week	Q week					571	662	1
MMRF_2541	Second Line Therapy (after first relapse)	Pomalidomide		DOSE/FREQUENCY CHANGE	mg	PO	Log Forms	Other	SALVAGE		4	Other	Q 2 DAYS					571	620	1
MMRF_2541	Second Line Therapy (after first relapse)	Dexamethasone		Lack of response	mg	PO	Log Forms	Other	SALVAGE		4	Other	DAY 1, 2 AFTER DARATUMUMAB INFUSION					571	662	1
MMRF_2541	Second Line Therapy (after first relapse)	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	SALVAGE		2	QD (D1-21)	QD (D1-21)					621	701	1
MMRF_2541	Second Line Therapy (after first relapse)	Carfilzomib		FREQUENCY CHANGE DUE TO SHORTNESS OF BREATH	mg	IV	Log Forms	Other	SALVAGE		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					666	701	1
MMRF_2541	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Other	SALVAGE		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					666	760	1
MMRF_2541	Second Line Therapy (after first relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Other	SALVAGE		36	Other	QD (D1, D8, D15)					701	760	1
MMRF_2541	Third Line Therapy (following 2nd relapse)	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Other	SALVAGE		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					792	803	1
MMRF_2541	Third Line Therapy (following 2nd relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	SALVAGE		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					792	803	1
MMRF_2541	Third Line Therapy (following 2nd relapse)	VIRACEPT		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	SALVAGE		2500	Other	BID (D1-14)					792	803	1
MMRF_2541	Third Line Therapy (following 2nd relapse)	Bendamustine		Disease progression/Relapse	mg/m^2	IV	Log Forms	Other	SALVAGE		70	Other	QD (D 1-2)					819	834	1
MMRF_2541	Third Line Therapy (following 2nd relapse)	Prednisone		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		50	QD (D1-4)	QD (D1-4)					819	834	1
MMRF_2541	Fourth Line Therapy (following 3rd relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Other	SALVAGE		16	QWK	QWK					847	903	1
MMRF_2541	Fourth Line Therapy (following 3rd relapse)	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms	Other	SALVAGE		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					847	903	1
MMRF_2541	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		20	QWK	QWK					847	903	1
MMRF_2541	Fifth Line Therapy (following 4th relapse)	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Other	SALVAGE		40	QD (D1-4)	QD (D1-4)					926	953	1
MMRF_2541	Fifth Line Therapy (following 4th relapse)	Cyclophosphamide		Disease progression/Relapse	mg/m^2	IV	Log Forms	Other	SALVAGE		400	QD (D1-4)	QD (D1-4)					926	953	1
MMRF_2541	Fifth Line Therapy (following 4th relapse)	ETOPOSIDE		Disease progression/Relapse	mg/m^2	IV	Log Forms	Other	SALVAGE		40	QD (D1-4)	QD (D1-4)					926	953	1
MMRF_2541	Fifth Line Therapy (following 4th relapse)	CISPLATIN		Disease progression/Relapse	mg/m^2	IV	Log Forms	Other	SALVAGE		10	QD (D1-4)	QD (D1-4)					926	953	1
MMRF_2592	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QWK	QWK					1	125	1
MMRF_2592	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		300	QWK	QWK					1	125	1
MMRF_2592	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1	125	1
MMRF_2592	First line of therapy	Ixazomib		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		4	Other	QD: D1, D8, D15					282	394	1
MMRF_2592	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		15	QD (D1-21)	QD (D1-21)					282	394	1
MMRF_2592	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		40	Other	QD: D1, D8, D15					282	394	1
MMRF_2592	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					415	468	1
MMRF_2592	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					482	2336	1
MMRF_2592	Second Line Therapy (after first relapse)	Pomalidomide			mg	PO	Log Forms	Other	SALVAGE	Checked	2	QD (D1-21)	QD (D1-21)					2463		1
MMRF_2592	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	28 MG(PO); 8 MG(IV)	Log Forms	Other	SALVAGE		36	Q week	Q week					2337	2386	1
MMRF_2592	Second Line Therapy (after first relapse)	Dexamethasone			mg	28 MG(PO); 8 MG(IV)	Log Forms	Other	SALVAGE	Checked	36	Other	DAY 1 Q 28D					2393		1
MMRF_2592	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Other	SALVAGE	Checked	40	Other	DAYS 8, 15, 22 Q 28D					2393		1
MMRF_2592	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		300	Other	ONCE					166	166	1
MMRF_2592	Second Line Therapy (after first relapse)	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	SALVAGE		4	QD (D1-21)	QD (D1-21)					2337	2463	1
MMRF_2592	Second Line Therapy (after first relapse)	Elotuzumab			mg/kg	IV	Log Forms	Other	SALVAGE	Checked	20	Other	Q 28D					2393		1
MMRF_2592	Second Line Therapy (after first relapse)	Elotuzumab		Completed regimen	mg/kg	IV	Log Forms	Other	SALVAGE		10	Q week	Q week					2337	2386	1
MMRF_2611	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		328	Other	ONCE					134	134	1
MMRF_2611	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	105	1
MMRF_2611	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	105	1
MMRF_2611	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	105	1
MMRF_2611	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					246	358	1
MMRF_2611	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		40	Q week	Q week					246	358	1
MMRF_2611	First line of therapy	Ixazomib		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		4	Q week	Q week					246	358	1
MMRF_2611	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					379	1502	1
MMRF_2611	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Other	SALVAGE	Checked	28	Q week	Q week					1597		1
MMRF_2611	Second Line Therapy (after first relapse)	Pomalidomide			mg	PO	Log Forms	Other	SALVAGE	Checked	4	QD (D1-21)	QD (D1-21)					1597		1
MMRF_2611	Second Line Therapy (after first relapse)	Elotuzumab			mg/kg	IV	Log Forms	Other	SALVAGE	Checked	10	Q week	Q week					1597		1
MMRF_2621	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	133	1
MMRF_2621	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	133	1
MMRF_2621	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	133	1
MMRF_1013	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg/m^2	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	47	1
MMRF_1013	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	96	1
MMRF_1013	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	96	1
MMRF_1013	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms				200	Q day	Q day					135	136	1
MMRF_1013	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms				5	QD (D1-21)	QD (D1-21)					212	1865	1
MMRF_1013	Second Line Therapy (after first relapse)	Ixazomib		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		3	Other	QD(D1,D8,D15)					1655	1865	1
MMRF_1013	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		20	QWK	QWK					1657	1865	1
MMRF_1013	Third Line Therapy (following 2nd relapse)	Elotuzumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Unknown	Unknown		10	Other	QD(D1,D8,D15,D22)					1896	1957	1
MMRF_1013	Third Line Therapy (following 2nd relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		15	QD (D1-21)	QD (D1-21)					1896	1957	1
MMRF_1013	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		28	Other	QD(D1,D8,D15,D22)					1896	1957	1
MMRF_1013	Fourth Line Therapy (following 3rd relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Unknown	Unknown		16	Q week	Q week					2038	2088	1
MMRF_1013	Fifth Line Therapy (following 4th relapse)	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Unknown	Unknown		50	Q day	Q day					2126	2126	1
MMRF_1013	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		20	Q week	Q week					2038	2079	1
MMRF_1013	Fourth Line Therapy (following 3rd relapse)	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Unknown	Unknown		2	Other	QD(D1,D4)					1986	1989	1
MMRF_1013	Fourth Line Therapy (following 3rd relapse)	Cyclophosphamide		Completed regimen	mg	IVB	Log Forms	Unknown	Unknown		620	QD (D1-4)	QD (D1-4)					1986	1989	1
MMRF_1013	Fourth Line Therapy (following 3rd relapse)	CISPLATIN		Completed regimen	mg	IVB	Log Forms	Unknown	Unknown		8	QD (D1-4)	QD (D1-4)					1986	1989	1
MMRF_1013	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Unknown	Unknown		40	QD (D1-4)	QD (D1-4)					1986	1989	1
MMRF_1013	Fourth Line Therapy (following 3rd relapse)	ETOPOSIDE		Completed regimen	mg	IVB	Log Forms	Unknown	Unknown		46	QD (D1-4)	QD (D1-4)					1986	1989	1
MMRF_1013	Fifth Line Therapy (following 4th relapse)	Bortezomib		Adverse Event or co-morbidity	mg	SUBCUTAN INJECTION	Log Forms	Unknown	Unknown		2	Q day	Q day					2098	2098	1
MMRF_1013	Fifth Line Therapy (following 4th relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		40	Q day	Q day					2098	2100	1
MMRF_1013	Fifth Line Therapy (following 4th relapse)	ETOPOSIDE		Adverse Event or co-morbidity	mg	IVB	Log Forms	Unknown	Unknown		30	Q day	Q day					2098	2100	1
MMRF_1013	Fifth Line Therapy (following 4th relapse)	Cyclophosphamide		Adverse Event or co-morbidity	mg	IVB	Log Forms	Unknown	Unknown		460	Q day	Q day					2098	2100	1
MMRF_1013	Fifth Line Therapy (following 4th relapse)	CISPLATIN		Adverse Event or co-morbidity	mg	IVB	Log Forms	Unknown	Unknown		8	Q day	Q day					2098	2100	1
MMRF_1073	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	92	1
MMRF_1073	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.9	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	92	1
MMRF_1073	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	92	1
MMRF_1073	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms				200	Other	1X					139	139	1
MMRF_1073	First line of therapy	Lenalidomide			mg	PO	Log Forms			Checked	10	QD (D1-21)	QD (D1-21)					265		1
MMRF_1076	First line of therapy	Lenalidomide		Completed regimen	mg/m^2	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	77	1
MMRF_1076	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				2.1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	75	1
MMRF_1076	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				12	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	77	1
MMRF_1076	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		25	QD (D1-21)	QD (D1-21)					77	108	1
MMRF_1076	Third Line Therapy (following 2nd relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		8	Other	EVERY OTHER DAY					927	1022	1
MMRF_1076	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		8	Other	Q TWICE A WEEK					479	884	1
MMRF_1076	Third Line Therapy (following 2nd relapse)	Cyclophosphamide		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		500	Q week	Q week					927	1030	1
MMRF_1076	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					434	884	1
MMRF_1095	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	85	1
MMRF_1095	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	85	1
MMRF_1095	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	85	1
MMRF_1095	First line of therapy	Lenalidomide		PLANNED FOR 2 CYCLES, STEM CELL MOBILIZATION, THEN CONTINUE 2 MORE CYCLES	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					113	142	1
MMRF_1095	First line of therapy	Dexamethasone		PLANNED FOR 2 CYCLES, STEM CELL MOBILIZATION, THEN CONTINUE 2 MORE CYCLES	mg	PO	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					113	142	1
MMRF_1095	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms				140	Other	1X					286	286	1
MMRF_1095	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					449	478	1
MMRF_1095	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					479	899	1
MMRF_1092	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	83	1
MMRF_1092	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	83	1
MMRF_1092	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	Q week	Q week					1	83	1
MMRF_1092	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				15	QD (D1-14)	QD (D1-14)					96	161	1
MMRF_1092	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1	Other	1, 8					96	161	1
MMRF_1092	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				20	Other	1, 8					96	161	1
MMRF_1092	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					191	1539	1
MMRF_1092	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		20	Q week	Q week					191	1539	1
MMRF_1092	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Unknown	Unknown		140	Other	ONCE					1549	1549	1
MMRF_1092	Second Line Therapy (after first relapse)	Ixazomib			mg	PO	Log Forms	Maintenance	Maintenance	Checked	3	Other	QD(D1,D8,D15)					1683		1
MMRF_1092	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Maintenance	Maintenance	Checked	20	Q week	Q week					1683		1
MMRF_1115	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				2.5	Other	D1, D8, D15					1	85	1
MMRF_1115	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	Other	D1, D8, D15 OF 21 DAY CYCLE					1	85	1
MMRF_1115	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms				200	Other	1X					119	119	1
MMRF_1115	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	85	1
MMRF_1134	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms				2.5	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	56	1
MMRF_1134	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	56	1
MMRF_1134	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	56	1
MMRF_1134	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms				200	Other	1X					134	134	1
MMRF_1134	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					531	757	1
MMRF_1134	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					972	1047	1
MMRF_1134	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	5	QD (D1-21)	QD (D1-21)					1047		1
MMRF_1153	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	102	1
MMRF_1153	First line of therapy	Bortezomib		Investigator decision for other reasons	mg	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	102	1
MMRF_1153	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	102	1
MMRF_1153	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms				200	Other	1X					183	183	1
MMRF_1153	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					339	875	1
MMRF_1153	First line of therapy	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	QD(Q1,Q15,Q29,Q430					974	1240	1
MMRF_1153	Second Line Therapy (after first relapse)	Ixazomib		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		4	Q week	Q week					1317	1380	1
MMRF_1153	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		10	QD (D1-21)	QD (D1-21)					1317	1362	1
MMRF_1153	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		20	Q week	Q week					1317	1362	1
MMRF_1153	Third Line Therapy (following 2nd relapse)	Daratumumab			mg/kg	IV	Log Forms	Unknown	Unknown	Checked	16	Other	QD(D1,D8,D15,D22)					1389		1
MMRF_1153	Third Line Therapy (following 2nd relapse)	Lenalidomide			mg	PO	Log Forms	Unknown	Unknown	Checked	15	QD (D1-21)	QD (D1-21)					1389		1
MMRF_1153	Third Line Therapy (following 2nd relapse)	Prednisone			mg	PO	Log Forms	Unknown	Unknown	Checked	20	Other	TWO DOSES POST DARA INFUSION					1389		1
MMRF_1168	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	156	1
MMRF_1168	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				2.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	156	1
MMRF_1168	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				20	Q week	Q week					1	156	1
MMRF_1168	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					187		1
MMRF_1171	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	89	1
MMRF_1171	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	89	1
MMRF_1171	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					1	89	1
MMRF_1171	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Other	1X					155	155	1
MMRF_1171	First line of therapy	Lenalidomide			mg	PO	Log Forms	Induction	Induction	Checked	10	Q day	Q day					278		1
MMRF_1185	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				10	QD (D1-14)	QD (D1-14)					1	81	1
MMRF_1185	First line of therapy	Bortezomib		Completed regimen	mg	IV	Log Forms				1.3	Q week	Q week					1	81	1
MMRF_1185	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				20	Q week	Q week					1	81	1
MMRF_1185	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms				200	Other	1X					117	117	1
MMRF_1185	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms				5	QD (D1-21)	QD (D1-21)					256	1211	1
MMRF_1196	Third Line Therapy (following 2nd relapse)	ETOPOSIDE		Completed regimen	mg	IVB	Log Forms	Other	SALVAGE CYCLE 1		40	QD (D1-4)	QD (D1-4)					702	705	1
MMRF_1196	Third Line Therapy (following 2nd relapse)	CISPLATIN		Completed regimen	mg	IVB	Log Forms	Other	SALVAGE CYCLE 1		10	QD (D1-4)	QD (D1-4)					702	705	1
MMRF_1196	Third Line Therapy (following 2nd relapse)	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Other	SALVAGE CYCLE 2		2.6	Other	QD(D1,D4)					740	745	1
MMRF_1196	Third Line Therapy (following 2nd relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Other	SALVAGE CYCLE 2		40	Other	QD(D4,D5)					740	745	1
MMRF_1196	Third Line Therapy (following 2nd relapse)	Cyclophosphamide		Completed regimen	mg	IVB	Log Forms	Other	SALVAGE CYCLE 2		800	Other	QD(D4,D5)					740	745	1
MMRF_1196	Third Line Therapy (following 2nd relapse)	ETOPOSIDE		Completed regimen	mg	IVB	Log Forms	Other	SALGAVE CYCLE2		40	Other	QD(D4,D5)					740	745	1
MMRF_1196	Third Line Therapy (following 2nd relapse)	CISPLATIN		Completed regimen	mg	IVB	Log Forms	Other	SALVAGE CYCLE 2		10	Other	QD(D4,D5)					740	745	1
MMRF_1196	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	259	1
MMRF_1196	First line of therapy	Bortezomib		Completed regimen	mg	IV	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	259	1
MMRF_1196	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				4	Other	1,2,4,5,8,9,11,12					1	259	1
MMRF_1196	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		200	Q day	Q day					327	327	1
MMRF_1196	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					370	616	1
MMRF_1196	Third Line Therapy (following 2nd relapse)	Carfilzomib		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		40	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					617	660	1
MMRF_1196	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		40	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					617	660	1
MMRF_1196	Third Line Therapy (following 2nd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		2	QD (D1-21)	QD (D1-21)					617	660	1
MMRF_1196	Third Line Therapy (following 2nd relapse)	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Other	SALVAGE CYCLE 1		2.7	Other	QD(D1,D4)					702	706	1
MMRF_1196	Third Line Therapy (following 2nd relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Other	SALVAGE		40	QD (D1-4)	QD (D1-4)					702	705	1
MMRF_1196	Third Line Therapy (following 2nd relapse)	Cyclophosphamide		Completed regimen	mg	IVB	Log Forms	Other	SALVAGE CYCLE 1		820	QD (D1-4)	QD (D1-4)					702	705	1
MMRF_1235	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	72	1
MMRF_1235	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	72	1
MMRF_1235	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				20	Other	1-2, 4-5, 8-9, 11-12					1	72	1
MMRF_1235	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms				200	Other	1X					105	105	1
MMRF_1235	First line of therapy	Lenalidomide		Patient decision	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					254	2303	1
MMRF_1235	Second Line Therapy (after first relapse)	FLUDARABINE	N/A	Completed regimen	UNKNOWN	IV	Log Forms	Other	CONDITIONING			Other	QD (1-6)					2426	2431	1
MMRF_1235	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	UNKNOWN	IV	Log Forms	Other	CONDITIONING			Other	ONCE					2430	2430	1
MMRF_1251	Fifth Line Therapy (following 4th relapse)	Cyclophosphamide	CRB-402	Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		300	QD (D1-4)	QD (D1-4)					2781	2786	1
MMRF_1251	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown			Other	QD (D1, D8, & D15					2488	2739	1
MMRF_1251	Fourth Line Therapy (following 3rd relapse)	Cyclophosphamide		Disease progression/Relapse	mg/m^2	PO	Log Forms	Unknown	Unknown		300	Other	QD (D1, D8, & D15					2488	2739	1
MMRF_1251	Fourth Line Therapy (following 3rd relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Unknown	Unknown		56	Other	QD (D1, D8, & D15					2488	2739	1
MMRF_1251	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		20	Other	QD (D1, D8, D15, & D22)					2165	2486	1
MMRF_1251	Third Line Therapy (following 2nd relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Unknown	Unknown		16	Other	QD (DAYS 1,8,15,&22)					2165	2486	1
MMRF_1251	Third Line Therapy (following 2nd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					2165	2486	1
MMRF_1251	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	85	1
MMRF_1251	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	85	1
MMRF_1251	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	85	1
MMRF_1251	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms				200	Other	1X					112	112	1
MMRF_1251	First line of therapy	Bortezomib		Completed regimen	mg	IV	Log Forms	Consolidation	Consolidation		2.9	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					183	213	1
MMRF_1251	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		5	QD (D1-14)	QD (D1-14)					183	213	1
MMRF_1251	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		10	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					183	213	1
MMRF_1251	First line of therapy	Bortezomib		Disease progression/Relapse	mg	IV SubQ	Log Forms	Maintenance	Maintenance		2.9	Other	Q WEEK FOR 3 WEEKS ON A 28 DAY CYCLE					232	1142	1
MMRF_1251	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					834	2165	1
MMRF_1251	First line of therapy	Bortezomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Maintenance	Maintenance		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					288	1142	1
MMRF_1251	Second Line Therapy (after first relapse)	Ixazomib		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		4	Other	QD(D1,D8D15)					1156	2165	1
MMRF_1290	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	Other	2X A WK (SATURDAYS AND SUNDAYS)					1	86	1
MMRF_1290	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				10	QD (D1-21)	QD (D1-21)					3	86	1
MMRF_1290	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					7	86	1
MMRF_1290	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms				200	Other	1X					130	130	1
MMRF_1290	First line of therapy	Lenalidomide			mg	PO (MONTH AND YEAR FOR START DATE ARE CORRECT, THE EXACT DAY IS UNKNOWN)	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					206		1
MMRF_1284	First line of therapy	Bortezomib		PLANNED FOR 3 CYCLES, VDCEP, THEN STEM CELL MOBILIZATION	mg	IV SubQ	Log Forms				2.4	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	43	1
MMRF_1284	First line of therapy	Lenalidomide		PLANNED FOR 3 CYCLES, VDCEP, THEN STEM CELL MOBILIZATION	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	43	1
MMRF_1284	First line of therapy	Dexamethasone		PLANNED FOR 3 CYCLES, VDCEP, THEN STEM CELL MOBILIZATION	mg	PO	Log Forms				20	Other	1,2,4,5,8,9,11,12					1	43	1
MMRF_1284	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms				2.5	Other	Q72H, 2 DOSES					71	74	1
MMRF_1284	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	QD (D1-4)	QD (D1-4)					71	74	1
MMRF_1284	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms				760	QD (D1-4)	QD (D1-4)					71	74	1
MMRF_1284	First line of therapy	ETOPOSIDE		Completed regimen	mg	IV	Log Forms				76	QD (D1-4)	QD (D1-4)					71	74	1
MMRF_1284	First line of therapy	CISPLATIN		Completed regimen	mg	IV	Log Forms				19	QD (D1-4)	QD (D1-4)					71	74	1
MMRF_1284	Second Line Therapy (after first relapse)	Pomalidomide			mg	PO	Log Forms	Consolidation	Consolidation	Checked	2	QD (D1-21)	QD (D1-21)					240		1
MMRF_1284	First line of therapy	Melphalan		Completed regimen	mg	IVB	Log Forms	Induction	Induction		200	Q day	Q day					107	107	1
MMRF_1304	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	78	1
MMRF_1304	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms				2.7	Q week	Q week					1	78	1
MMRF_1304	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				20	Other	1,2,4,5,8,9,11,12					1	78	1
MMRF_1304	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms				200	Other	1X					122	122	1
MMRF_1304	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					288	401	1
MMRF_1304	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-14)	QD (D1-14)					429	1038	1
MMRF_1304	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	5	QD (D1-21)	QD (D1-21)					1038		1
MMRF_1323	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		2.5	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	77	1
MMRF_1323	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					20	77	1
MMRF_1323	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	77	1
MMRF_1323	First line of therapy	Melphalan		GIVEN FOR ASCT	mg/m^2	IV	Log Forms	Induction	Induction		150	Other	FOR ASCT COLLECTION					117	117	1
MMRF_1323	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					230		1
MMRF_1328	First line of therapy	Lenalidomide		Completed regimen	mg/dL	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	215	1
MMRF_1328	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	215	1
MMRF_1328	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				20	Other	1,2,4,5,8,9,11,12					1	215	1
MMRF_1328	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	Other	UNKNOWN					216	544	1
MMRF_1328	Second Line Therapy (after first relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		2	QD (D1-21)	QD (D1-21)					684	838	1
MMRF_1328	Second Line Therapy (after first relapse)	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Maintenance	Maintenance		56	Other	QD(D1,D7,D14)					741	837	1
MMRF_1328	Second Line Therapy (after first relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Maintenance	Maintenance		56	Other	QD(D1,D8,D15)					768	838	1
MMRF_1328	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		20	Other	QD(D1,D8,D15)					741	838	1
MMRF_1328	Third Line Therapy (following 2nd relapse)	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Other	CYCLE 1		2	Other	Q72HR					856	859	1
MMRF_1328	Third Line Therapy (following 2nd relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Other	CYCLE 1		40	QD (D1-4)	QD (D1-4)					856	859	1
MMRF_1328	Third Line Therapy (following 2nd relapse)	Cyclophosphamide		Completed regimen	mg	IVB	Log Forms	Other	CYCLE 1		800	QD (D1-4)	QD (D1-4)					856	859	1
MMRF_1328	Third Line Therapy (following 2nd relapse)	CISPLATIN		Completed regimen	mg	IVB	Log Forms	Other	CYCLE 1		20	QD (D1-4)	QD (D1-4)					856	859	1
MMRF_1328	Third Line Therapy (following 2nd relapse)	ETOPOSIDE		Completed regimen	mg	IVB	Log Forms	Other	CYCLE 1		80	QD (D1-4)	QD (D1-4)					856	859	1
MMRF_1328	Third Line Therapy (following 2nd relapse)	Thalidomide		Completed regimen	mg	PO	Log Forms	Unknown	Unknown		100	Q day	Q day					862	897	1
MMRF_1328	Third Line Therapy (following 2nd relapse)	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Other	CYCLE 2		2.7	Other	QD(EVERY 72 HRS)					881	885	1
MMRF_1328	Third Line Therapy (following 2nd relapse)	CISPLATIN		Completed regimen	mg	IVB	Log Forms	Other	CYCLE 2		21	QD (D1-4)	QD (D1-4)					881	885	1
MMRF_1328	Third Line Therapy (following 2nd relapse)	Cyclophosphamide		Completed regimen	mg	IVB	Log Forms	Other	CYCLE 2 VDCEP		830	QD (D1-4)	QD (D1-4)					881	885	1
MMRF_1328	Third Line Therapy (following 2nd relapse)	ETOPOSIDE		Completed regimen	mg	IVB	Log Forms	Other	CYCLE 2 VDCEP		83	QD (D1-4)	QD (D1-4)					881	885	1
MMRF_1328	Third Line Therapy (following 2nd relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Other	CYCLE 2 VDCEP		40	QD (D1-4)	QD (D1-4)					880	885	1
MMRF_1328	Third Line Therapy (following 2nd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		4	QD (D1-21)	QD (D1-21)					916	974	1
MMRF_1328	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		4	Other	ONCE A WEEK ON MONDAY					916	974	1
MMRF_1328	Fourth Line Therapy (following 3rd relapse)	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Unknown	Unknown		2.7	Other	Q(D1,D5)					996	1001	1
MMRF_1328	Fourth Line Therapy (following 3rd relapse)	Cyclophosphamide		Completed regimen	mg	IVPB	Log Forms	Unknown	Unknown		824	Other	QD(D1,D3,D4,D5)					996	1001	1
MMRF_1328	Fourth Line Therapy (following 3rd relapse)	ETOPOSIDE		Completed regimen	mg	IVPB	Log Forms	Unknown	Unknown		82	Other	QD(D1,D3,D4,D5)					996	1001	1
MMRF_1328	Fourth Line Therapy (following 3rd relapse)	CISPLATIN		Completed regimen	mg	IVPB	Log Forms	Unknown	Unknown		21	Other	QD(D1,D3,D4,D5)					996	1001	1
MMRF_1328	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Unknown	Unknown		40	Other	QD(D1,D2,D3,D5)					996	1001	1
MMRF_1328	Fourth Line Therapy (following 3rd relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Unknown	Unknown		16	Other	QD(D1,D8,D15,D22)					1038	1252	1
MMRF_1328	Fourth Line Therapy (following 3rd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					1038	1252	1
MMRF_1328	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		4	Q week	Q week					1038	1252	1
MMRF_1328	Fifth Line Therapy (following 4th relapse)	NIVOLUMAB		Disease progression/Relapse	mg/kg	IV	Log Forms	Unknown	Unknown		3	Other	QD(D1,D15))					1182	1252	1
MMRF_1328	Sixth Line Therapy (following 5th relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Unknown	Unknown		40	QD (D1-4)	QD (D1-4)					1268	1271	1
MMRF_1328	Sixth Line Therapy (following 5th relapse)	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Unknown	Unknown		2.7	Other	QD(D1,D5)					1268	1272	1
MMRF_1328	Sixth Line Therapy (following 5th relapse)	CISPLATIN		Completed regimen	mg	IV	Log Forms	Unknown	Unknown		21	Other	QD(D1,D2,D3,D5)					1268	1272	1
MMRF_1328	Sixth Line Therapy (following 5th relapse)	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Unknown	Unknown		830	Other	QD(D1,D2,D3,D5)					1268	1272	1
MMRF_1328	Sixth Line Therapy (following 5th relapse)	ETOPOSIDE		Completed regimen	mg	IV	Log Forms	Unknown	Unknown		83	Other	QD(D1,D2,D3,D5)					1268	1272	1
MMRF_1328	Sixth Line Therapy (following 5th relapse)	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Unknown	Unknown		2.7	Other	D1 & D4					1293	1296	1
MMRF_1328	Sixth Line Therapy (following 5th relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Unknown	Unknown		40	QD (D1-4)	QD (D1-4)					1293	1296	1
MMRF_1328	Sixth Line Therapy (following 5th relapse)	CISPLATIN		Completed regimen	mg	IVB	Log Forms	Unknown	Unknown		21	QD (D1-4)	QD (D1-4)					1293	1296	1
MMRF_1328	Sixth Line Therapy (following 5th relapse)	ETOPOSIDE		Completed regimen	mg	IVB	Log Forms	Unknown	Unknown		82	QD (D1-4)	QD (D1-4)					1293	1296	1
MMRF_1328	Sixth Line Therapy (following 5th relapse)	Cyclophosphamide		Completed regimen	mg	IVB	Log Forms	Unknown	Unknown		825	QD (D1-4)	QD (D1-4)					1293	1296	1
MMRF_1328	Sixth Line Therapy (following 5th relapse)	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Unknown	Unknown		41	Other	D1					1334	1334	1
MMRF_1328	Sixth Line Therapy (following 5th relapse)	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Unknown	Unknown		56	Other	QD(D8,D15)					1336	1343	1
MMRF_1328	Sixth Line Therapy (following 5th relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		20	Other	QD(D1,D8,D15)					1334	1371	1
MMRF_1328	Sixth Line Therapy (following 5th relapse)	Cyclophosphamide		Disease progression/Relapse	mg	IV	Log Forms	Unknown	Unknown		300	Other	QD(D1,D8,D15)					1334	1371	1
MMRF_1328	Sixth Line Therapy (following 5th relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		2	QD (D1-21)	QD (D1-21)					1334	1371	1
MMRF_1328	Sixth Line Therapy (following 5th relapse)	Carfilzomib		Lack of response	mg/m^2	IV	Log Forms	Unknown	Unknown		56	Other	QD(D1,D8,D15)					1357	1371	1
MMRF_1328	Sixth Line Therapy (following 5th relapse)	Panobinostat		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		20	Other	QD(TUES/THURS/SAT WEEKS 1 AND 3)					1357	1367	1
MMRF_1328	Sixth Line Therapy (following 5th relapse)	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Unknown	Unknown		2.7	Other	Q72HR					1385	1389	1
MMRF_1328	Sixth Line Therapy (following 5th relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Unknown	Unknown		40	QD (D1-4)	QD (D1-4)					1385	1389	1
MMRF_1328	Sixth Line Therapy (following 5th relapse)	Cyclophosphamide		Completed regimen	mg	IVB	Log Forms	Unknown	Unknown		820	QD (D1-4)	QD (D1-4)					1385	1389	1
MMRF_1328	Sixth Line Therapy (following 5th relapse)	CISPLATIN		Completed regimen	mg	IVB	Log Forms	Unknown	Unknown		20	QD (D1-4)	QD (D1-4)					1385	1389	1
MMRF_1328	Sixth Line Therapy (following 5th relapse)	ETOPOSIDE		Completed regimen	mg	IVB	Log Forms	Unknown	Unknown		82	QD (D1-4)	QD (D1-4)					1385	1389	1
MMRF_1328	Sixth Line Therapy (following 5th relapse)	NIVOLUMAB		Disease progression/Relapse	mg/kg	IV	Log Forms	Unknown	Unknown		3	Other	QD(D1,D15)					1406	1448	1
MMRF_1328	Sixth Line Therapy (following 5th relapse)	Elotuzumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Unknown	Unknown		10	Other	QD(D1,D8,D15,D22)					1406	1455	1
MMRF_1328	Sixth Line Therapy (following 5th relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		2	QD (D1-21)	QD (D1-21)					1406	1449	1
MMRF_1328	Sixth Line Therapy (following 5th relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		28	Other	QD(D1,D8,D15,D22) DURING C1&C2, QD(D1,D15) DURING C3 AND BEYOND					1406	1449	1
MMRF_1328	Sixth Line Therapy (following 5th relapse)	Cyclophosphamide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		300	QWK	QWK					1441	1455	1
MMRF_1328	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		40	Other	QD(D1,D8,D15)					684	699	1
MMRF_1328	Second Line Therapy (after first relapse)	Carfilzomib		Completed regimen	mg	IV	Log Forms	Maintenance	Maintenance		40	Other	QD, DAY 1 AND 2 OF CYCLE 1					684	685	1
MMRF_1328	Second Line Therapy (after first relapse)	Carfilzomib		Completed regimen	mg	IV	Log Forms	Maintenance	Maintenance		54	Other	QD DAYS 8,9,15,16 OF CYCLE 1					691	699	1
MMRF_1328	Second Line Therapy (after first relapse)	Carfilzomib		Completed regimen	mg	IV	Log Forms	Consolidation	Consolidation		53	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					713	728	1
MMRF_1328	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg	IVB	Log Forms	Induction	Induction		400	Q day	Q day					593	593	1
MMRF_1328	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		20	Other	QD(D1,D8,D15)					713	728	1
MMRF_1374	First line of therapy	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		1.6	Other	QD 1,8,15					319	340	1
MMRF_1374	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					319	340	1
MMRF_1374	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		40	Other	QD 1,8,15					319	340	1
MMRF_1374	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Q day	Q day					58	58	1
MMRF_1374	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		1.6	Other	QD: DAY 1, 8, 15					144	183	1
MMRF_1374	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					144	183	1
MMRF_1374	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		40	Other	QD: DAY 1, 8, 15					144	183	1
MMRF_1374	First line of therapy	Bortezomib		Completed regimen	mg	IV	Log Forms				2.7	Other	UNK					1	23	1
MMRF_1374	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	Other	UNK					1	23	1
MMRF_1374	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms				825	Other	UNK					1	23	1
MMRF_1374	First line of therapy	ETOPOSIDE		Completed regimen	mg	IV	Log Forms				82	Other	UNK					1	23	1
MMRF_1374	First line of therapy	CISPLATIN		Completed regimen	mg	IV	Log Forms				21	Other	UNK					1	23	1
MMRF_1415	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				15	QD (D1-14)	QD (D1-14)					1	84	1
MMRF_1415	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	84	1
MMRF_1415	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	84	1
MMRF_1415	First line of therapy	Lenalidomide		Lack of response	mg	PO	Log Forms	Maintenance	Maintenance		10	Other	QD ON A 28 DAY CYCLE					220	310	1
MMRF_1415	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Other	QD					115	115	1
MMRF_1415	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		25	Other	QD ON 28 DAY CYCLE					310	371	1
MMRF_1415	First line of therapy	Bortezomib		Disease progression/Relapse	mg	IV SubQ	Log Forms	Maintenance	Maintenance		3	Other	UNKNOWN					310	371	1
MMRF_1415	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		40	Q week	Q week					320	371	1
MMRF_1415	Second Line Therapy (after first relapse)	Cyclophosphamide		Completed regimen	UNKNOWN	UNKNOWN	Log Forms	Other	SALVAGE THERAPY		0	Other	UNKNOWN					378	381	1
MMRF_1415	Second Line Therapy (after first relapse)	ETOPOSIDE		Completed regimen	UNKNOWN	UNKNOWN	Log Forms	Other	SALVAGE THERAPY		0	Other	UNKNOWN					378	381	1
MMRF_1415	Second Line Therapy (after first relapse)	CISPLATIN		Completed regimen	UNKNOWN	UNKNOWN	Log Forms	Other	SALVAGE		0	Other	UNKNOWN					378	381	1
MMRF_1415	Second Line Therapy (after first relapse)	PREDNISONE		Completed regimen	UNKNOWN	UNKNOWN	Log Forms	Other	SALVAGE THERAPY		0	Other	UNKNOWN					378	381	1
MMRF_1415	Second Line Therapy (after first relapse)	Bortezomib		Completed regimen	UNKNOWN	UNKNOWN	Log Forms	Other	SALVAGE THERAPY		0	Other	UNKNOWN					378	381	1
MMRF_1415	Second Line Therapy (after first relapse)	Carfilzomib		Lack of response	mg	IV	Log Forms	Induction	Induction		58	Other	UNKNOWN					402	463	1
MMRF_1415	Second Line Therapy (after first relapse)	Pomalidomide		Lack of response	mg	PO	Log Forms	Unknown	Unknown		4	Other	UNKNOWN					402	463	1
MMRF_1415	Second Line Therapy (after first relapse)	Dexamethasone		Lack of response	mg	PO	Log Forms	Unknown	Unknown		20	Other	UNKNOWN					402	463	1
MMRF_1430	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms				2.8	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	119	1
MMRF_1430	First line of therapy	Dexamethasone		DOSE REDUCTION	mg	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	3	1
MMRF_1430	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					4	119	1
MMRF_1430	First line of therapy	Thalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		100	Other	UNKNOWN					42	119	1
MMRF_1430	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		140	Q day	Q day					192	192	1
MMRF_1430	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					316	665	1
MMRF_1430	Second Line Therapy (after first relapse)	Daratumumab		DEATH	mg/kg	IV	Log Forms	Unknown	Unknown		16	Other	QD(D1,D8,D15,D22)					1453	1574	1
MMRF_1430	Second Line Therapy (after first relapse)	Bortezomib		DEATH	mg/m^2	IV SubQ	Log Forms	Unknown	Unknown		1.6	Other	QD(D1,D8,D15)					1453	1574	1
MMRF_1430	Second Line Therapy (after first relapse)	Dexamethasone		DEATH	mg	PO	Log Forms	Unknown	Unknown		20	Other	QD(D2,D9,D16)					1453	1574	1
MMRF_1430	Third Line Therapy (following 2nd relapse)	Pomalidomide		DEATH	mg	PO	Log Forms	Unknown	Unknown		3	QD (D1-21)	QD (D1-21)					1533	1574	1
MMRF_1447	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	81	1
MMRF_1447	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				20	Other	1,2,4,5,8,9,11,12					1	81	1
MMRF_1447	First line of therapy	Melphalan		Completed regimen	mg/m^2	UNKNOWN	Log Forms	Induction	Induction		200	Other	UNKNOWN					125	125	1
MMRF_1447	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					259		1
MMRF_1447	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	81	1
MMRF_1447	Second Line Therapy (after first relapse)	REVLIMID		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					1081	2421	1
MMRF_1447	Third Line Therapy (following 2nd relapse)	Pomalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	2	QD (D1-21)	QD (D1-21)					2452		1
MMRF_1447	Third Line Therapy (following 2nd relapse)	DARZALEX				IV SubQ	Log Forms	Maintenance	Maintenance	Checked								2452		1
MMRF_1447	Third Line Therapy (following 2nd relapse)	Dexamethasone			mg	PO	Log Forms	Maintenance	Maintenance	Checked	20	Q week	Q week					2452		1
MMRF_1506	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		2.2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	77	1
MMRF_1506	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	77	1
MMRF_1506	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	77	1
MMRF_1506	First line of therapy	Melphalan		Completed regimen	mg	IVB	Log Forms	Induction	Induction		200	Q day	Q day					105	105	1
MMRF_1522	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		2.3	Other	QD (D1, D3, D6, D9)					1	105	1
MMRF_1522	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	Other	QD (D1, D3, D6, D9)					1	105	1
MMRF_1522	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	QD D1, D2, D6, D7					1	105	1
MMRF_1522	First line of therapy	Bortezomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Maintenance	Maintenance		1.3	Other	QD 1,8,15					205	1291	1
MMRF_1522	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					205	1291	1
MMRF_1522	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		20	Other	QD DAYS 1,2,8,9,15,16					205	1291	1
MMRF_1522	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Induction	Induction		200	Q day	Q day					113	113	1
MMRF_1522	Second Line Therapy (after first relapse)	Ixazomib		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		4	Other	QD(D1,D8,D15)					1322	1565	1
MMRF_1522	Second Line Therapy (after first relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					1322	1565	1
MMRF_1522	Third Line Therapy (following 2nd relapse)	Dexamethasone			mg	PO	Log Forms	Unknown	Unknown	Checked	16	Q week	Q week					1597		1
MMRF_1522	Third Line Therapy (following 2nd relapse)	Pomalidomide			mg	PO	Log Forms	Unknown	Unknown	Checked	2	QD (D1-21)	QD (D1-21)					1597		1
MMRF_1522	Third Line Therapy (following 2nd relapse)	Daratumumab			mg/kg	IV	Log Forms	Unknown	Unknown	Checked	16	Other	1X EVERY 2 WEEKS					1597		1
MMRF_1534	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		15	Other	QOD FOR 14 DAYS					1	30	1
MMRF_1534	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	QD DAYS 1,8,15					1	80	1
MMRF_1534	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		2.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	80	1
MMRF_1534	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		10	QD (D1-14)	QD (D1-14)					30	80	1
MMRF_1534	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					107	161	1
MMRF_1534	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	QD 1,8,15,21					107	161	1
MMRF_1534	First line of therapy	Melphalan		Completed regimen	mg/m^2	UNKNOWN	Log Forms	Consolidation	Consolidation		200	Other	UNKNOWN					161	163	1
MMRF_1534	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					238	947	1
MMRF_1534	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					947	1101	1
MMRF_1534	Second Line Therapy (after first relapse)	VENETOCLAX		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		800	QD (D1-21)	QD (D1-21)					1122	1290	1
MMRF_1534	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		40	Other	QD(D1,D81,D15)					1122	1290	1
MMRF_1534	Third Line Therapy (following 2nd relapse)	Daratumumab		Disease progression/Relapse	mg	SUBCUTANEOUS	Log Forms	Unknown	Unknown		1800	Other	QD(D1,D2,D3,D4,D8,D15,D22)					1331	1485	1
MMRF_1534	Fourth Line Therapy (following 3rd relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Unknown	Unknown		16	Other	WEEKLYX8WEEKS,EVERY 2WEEKSX8 WEEKS,THEN MONTHLY					1526	2149	1
MMRF_1534	Fourth Line Therapy (following 3rd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					1526	2149	1
MMRF_1534	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		40	Other	NIGHT BEFORE DARA INFUSION					1526	2149	1
MMRF_1539	Sixth Line Therapy (following 5th relapse)	CISPLATIN					Log Forms	Maintenance	Maintenance	Checked								2711		1
MMRF_1539	Sixth Line Therapy (following 5th relapse)	ETOPOSIDE					Log Forms	Maintenance	Maintenance	Checked								2711		1
MMRF_1539	Sixth Line Therapy (following 5th relapse)	Cyclophosphamide					Log Forms	Maintenance	Maintenance	Checked								2711		1
MMRF_1539	Sixth Line Therapy (following 5th relapse)	Bortezomib					Log Forms	Maintenance	Maintenance	Checked								2711		1
MMRF_1539	Fifth Line Therapy (following 4th relapse)	Cyclophosphamide		Adverse Event or co-morbidity			Log Forms	Maintenance	Maintenance									2001	2581	1
MMRF_1539	Fifth Line Therapy (following 4th relapse)	Carfilzomib		Disease progression/Relapse			Log Forms	Maintenance	Maintenance									2001	2710	1
MMRF_1539	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					45	175	1
MMRF_1539	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		1.9	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	175	1
MMRF_1539	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	QD D1,D2,D4,D5,D8,D9, D11,D12					1	175	1
MMRF_1539	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					327	1181	1
MMRF_1539	First line of therapy	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Q week	Q week					605	878	1
MMRF_1539	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Induction	Induction		140	Q day	Q day					227	227	1
MMRF_1539	Second Line Therapy (after first relapse)	Ixazomib		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		4	Other	QD(D1,8,15)					878	1181	1
MMRF_1539	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		20	Other	QD(D1,8,15)					878	1181	1
MMRF_1539	Third Line Therapy (following 2nd relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Unknown	Unknown		16	QWK	QWK					1181	1361	1
MMRF_1539	Third Line Therapy (following 2nd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					1181	1361	1
MMRF_1539	Fourth Line Therapy (following 3rd relapse)	VENETOCLAX		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		400	QD (D1-21)	QD (D1-21)					1398	1998	1
MMRF_1539	Fourth Line Therapy (following 3rd relapse)	Dexamethasone			mg	PO	Log Forms	Unknown	Unknown	Checked	20	Q week	Q week					1398		1
MMRF_1543	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	109	1
MMRF_1543	First line of therapy	Bortezomib		Completed regimen	mg	IV	Log Forms	Induction	Induction		2	Other	QD 1,8,15,22					1	109	1
MMRF_1543	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		4	Other	QD 1,8,15,22					1	109	1
MMRF_1543	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Induction	Induction		200	Q day	Q day					143	143	1
MMRF_1546	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	84	1
MMRF_1546	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg	IV SubQ	Log Forms	Induction	Induction		2.2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	84	1
MMRF_1546	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	84	1
MMRF_1546	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					140	237	1
MMRF_1546	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		10	QWK	QWK					140	596	1
MMRF_1546	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	QD (D1-21)	QD (D1-21)					238	386	1
MMRF_1546	First line of therapy	Lenalidomide			mg	PO	Log Forms	Induction	Induction	Checked	5	QD (D1-21)	QD (D1-21)					534		1
MMRF_1546	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					386	414	1
MMRF_1546	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					414	534	1
MMRF_1546	First line of therapy	Dexamethasone		TO ALLOW OPTIMAL MUSCLE STRENGTHENING	mg	PO	Log Forms	Induction	Induction		8	Q week	Q week					596	680	1
MMRF_1572	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	Q D1, D2, D4, D5, D8, D9, D11, D12					1	124	1
MMRF_1572	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		2.7	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	124	1
MMRF_1572	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	124	1
MMRF_1572	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					268	270	1
MMRF_1572	First line of therapy	Melphalan		Completed regimen	mg	IVB	Log Forms	Induction	Induction		200	Q day	Q day					149	149	1
MMRF_1572	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	Other	UNKNOWN						244	1
MMRF_1572	Third Line Therapy (following 2nd relapse)	Daratumumab					Log Forms	Maintenance	Maintenance	Checked								2479		1
MMRF_1572	Third Line Therapy (following 2nd relapse)	Pomalidomide				PO	Log Forms			Checked								2479		1
MMRF_1572	Third Line Therapy (following 2nd relapse)	Dexamethasone					Log Forms			Checked								2479		1
MMRF_1595	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		1.3	Other	QD (D1,D8,D15)					1	107	1
MMRF_1595	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					1	107	1
MMRF_1595	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	QD 1,8,15,22					1	107	1
MMRF_1595	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					107	162	1
MMRF_1595	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					179	227	1
MMRF_1602	First line of therapy	Bortezomib		Completed regimen	UNKNOWN	IV	Log Forms	Induction	Induction		2.6	QWK	QWK					1	83	1
MMRF_1602	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	83	1
MMRF_1602	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	83	1
MMRF_1602	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		200	Q day	Q day					116	116	1
MMRF_1602	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					265	704	1
MMRF_1602	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					1041		1
MMRF_1656	First line of therapy	Bortezomib		Completed regimen	mg	IV	Log Forms	Induction	Induction		2.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	79	1
MMRF_1656	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	22	1
MMRF_1656	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		4	Other	QD 1,2,4,5,8,9,11,12					1	79	1
MMRF_1656	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	Other	QOD DAYS 1-14					22	79	1
MMRF_1656	First line of therapy	Cyclophosphamide		Completed regimen	G/M2	IV	Log Forms	Other	MOBILIZATION		3	Other	UNKNOWN					99	110	1
MMRF_1656	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		140	Other	UNKNOWN					131	133	1
MMRF_1656	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					229	260	1
MMRF_1656	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					229	260	1
MMRF_1656	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		40	Other	DAYS 1,8,15,22					229	260	1
MMRF_1656	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		25	QD (D1-21)	QD (D1-21)					444	505	1
MMRF_1656	Second Line Therapy (after first relapse)	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms	Unknown	Unknown		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					444	505	1
MMRF_1656	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		40	Other	QD(D1,D8,D15,D22)					444	505	1
MMRF_1656	Third Line Therapy (following 2nd relapse)	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Unknown	Unknown		2.1	Other	QD(D1,D4)					512	515	1
MMRF_1656	Third Line Therapy (following 2nd relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Unknown	Unknown		40	QD (D1-14)	QD (D1-14)					512	515	1
MMRF_1656	Third Line Therapy (following 2nd relapse)	Cyclophosphamide		Completed regimen	mg	IVPB	Log Forms	Unknown	Unknown		660	Other	QD(D1,D4)					512	515	1
MMRF_1656	Third Line Therapy (following 2nd relapse)	ETOPOSIDE		Completed regimen	mg	IVPB	Log Forms	Unknown	Unknown		66	Other	QD(D1,D4)					512	515	1
MMRF_1656	Third Line Therapy (following 2nd relapse)	CISPLATIN		Completed regimen	mg	IVPB	Log Forms	Unknown	Unknown		16.5	Other	QD(D1,D4)					512	515	1
MMRF_1674	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		2.1	Other	QD 1,3,7,10					1	104	1
MMRF_1674	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	104	1
MMRF_1674	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	Other	QD 1,3,7,10					1	63	1
MMRF_1674	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		10	Other	QD 2,5,9,12					64	104	1
MMRF_1674	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		200	Q day	Q day					138	138	1
MMRF_1674	First line of therapy	Bortezomib		MRD NEGATIVE	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	QD 1,8,15					235	912	1
MMRF_1694	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	QD (D1-14)	QD (D1-14)					1	123	1
MMRF_1694	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	123	1
MMRF_1694	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	QD 1,2,4,5,8,9,11,12					1	123	1
MMRF_1694	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		200	Q day	Q day					168	168	1
MMRF_1694	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					394	935	1
MMRF_1694	Second Line Therapy (after first relapse)	Ixazomib		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		4	Other	QD(D1,D8,D15) EVERY 28 DAYS					935	1509	1
MMRF_1694	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		25	QD (D1-21)	QD (D1-21)					935	1509	1
MMRF_1694	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		20	QWK	QWK					935	1509	1
MMRF_1694	Third Line Therapy (following 2nd relapse)	CISPLATIN		Completed regimen	mg	IVB	Log Forms	Unknown	Unknown		24	Other	QD(D1,D2,D3,D4)					1514	1517	1
MMRF_1694	Third Line Therapy (following 2nd relapse)	Cyclophosphamide		Completed regimen	mg	IVB	Log Forms	Unknown	Unknown		970	Other	QD(D1,D2,D3,D4)					1514	1517	1
MMRF_1694	Third Line Therapy (following 2nd relapse)	ETOPOSIDE		Completed regimen	mg	IVB	Log Forms	Unknown	Unknown		97	Other	QD(D1,D2,D3,D4)					1514	1517	1
MMRF_1694	Third Line Therapy (following 2nd relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Unknown	Unknown		40	Other	QD(D1,D2,D3,D4)					1514	1517	1
MMRF_1694	Third Line Therapy (following 2nd relapse)	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Unknown	Unknown		3.1	Other	Q72HRS					1514	1517	1
MMRF_1694	Third Line Therapy (following 2nd relapse)	Daratumumab			mg/kg	IV	Log Forms	Unknown	Unknown	Checked	16	Q week	Q week					1551		1
MMRF_1694	Third Line Therapy (following 2nd relapse)	Dexamethasone			mg	PO	Log Forms	Unknown	Unknown	Checked	20	Q week	Q week					1551		1
MMRF_1694	Third Line Therapy (following 2nd relapse)	Pomalidomide			mg	PO	Log Forms	Unknown	Unknown	Checked	2	QD (D1-21)	QD (D1-21)					1642		1
MMRF_1694	Fourth Line Therapy (following 3rd relapse)	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	SALVAGE		100	Q day	Q day					2028	2029	1
MMRF_1711	Eighth Line of Therapy (following 7th relapse)	CISPLATIN		Completed regimen	mg	IV	Log Forms	Other	SALVEGE		11	Other	Q24H					1721	1724	1
MMRF_1711	Eleventh Line of Therapy (following 10th relapse)	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Other	SALVEGE		630	Other	Q24H					1721	1724	1
MMRF_1711	Eighth Line of Therapy (following 7th relapse)	ETOPOSIDE		Completed regimen	mg	IV	Log Forms	Other	SALVEGE		42	Other	Q24H					1721	1724	1
MMRF_1711	Eighth Line of Therapy (following 7th relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Other	SALVAGE		40	Other	Q24H					1721	1724	1
MMRF_1711	Twelfth Line of Therapy (following 11th relapse)	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Other	SALVAGE		840	Other	Q24H					1998	2001	1
MMRF_1711	Twelfth Line of Therapy (following 11th relapse)	CISPLATIN		Completed regimen	mg	IV	Log Forms	Other	SALVAGE		21	Other	Q24H					1998	2001	1
MMRF_1711	Twelfth Line of Therapy (following 11th relapse)	ETOPOSIDE		Completed regimen	mg	IV	Log Forms	Other	SALVAGE		84	Other	Q24H					1998	2001	1
MMRF_1711	Twelfth Line of Therapy (following 11th relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Other	SALVAE		40	Other	Q24H					1999	2001	1
MMRF_1711	Twelfth Line of Therapy (following 11th relapse)	Bortezomib		Completed regimen	mg	IV	Log Forms	Other	SALVAGE		2.7	Other	Q72H					1998	2001	1
MMRF_1711	Eleventh Line of Therapy (following 10th relapse)	TAK-573-1501	TAK-573-1501	Disease progression/Relapse	mg	IV	Log Forms	Unknown	Unknown		33	Other	QD (D1)					1976	1998	1
MMRF_1711	Tenth Line of Therapy (following 9th relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					1873	1941	1
MMRF_1711	Tenth Line of Therapy (following 9th relapse)	NIVOLUMAB		Disease progression/Relapse	mg	IV	Log Forms	Unknown	Unknown		240	Other	QD (D1 & D15)					1873	1941	1
MMRF_1711	Ninth Line of Therapy (following 8th relapse)	BB2121		Completed regimen	10^6 CELLS	IV	Log Forms	Unknown	Unknown		450	Q day	Q day					1836	1836	1
MMRF_1711	Ninth Line of Therapy (following 8th relapse)	FLUDARABINE		Completed regimen	mg	IV	Log Forms	Unknown	Unknown		50	Other	QD (D-5, D-4, D-3)					1831	1833	1
MMRF_1711	Ninth Line of Therapy (following 8th relapse)	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Unknown	Unknown		600	Other	QD (D-5, D-4, D-3)					1831	1833	1
MMRF_1711	Ninth Line of Therapy (following 8th relapse)	B2121		Completed regimen	10^6 CELLS	IV	Log Forms	Unknown	Unknown		450	Q day	Q day					1758	1758	1
MMRF_1711	Ninth Line of Therapy (following 8th relapse)	FLUDARABINE		Completed regimen	mg	IV	Log Forms	Unknown	Unknown		36.5	Other	QD (D-5, D-4, D-3)					1753	1755	1
MMRF_1711	Ninth Line of Therapy (following 8th relapse)	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Unknown	Unknown		600	Other	QD (D-5, D-4, D-3)					1753	1755	1
MMRF_1711	Eighth Line of Therapy (following 7th relapse)	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Other	SALVAGE		2.7	Other	Q72H					1721	1724	1
MMRF_1711	Eighth Line of Therapy (following 7th relapse)	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms				20	Other	QD (D1, D8, D15, D22)					1706	1718	1
MMRF_1711	Eighth Line of Therapy (following 7th relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms				16	Other	QD (D1, D8, D15, D22)					1706	1718	1
MMRF_1711	Eighth Line of Therapy (following 7th relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Unknown	Unknown		56	Other	QD (D1, D8, D15, D22)					1706	1718	1
MMRF_1711	Eighth Line of Therapy (following 7th relapse)	LEUKAPHERESIS	CART BB2121	Completed regimen			Log Forms	Unknown	Unknown									1704	1704	1
MMRF_1711	Seventh Line of Therapy (following 6th relapse)	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Unknown	Unknown		28	Other	QD (D1, D8, D15, & D22)					1640	1696	1
MMRF_1711	Seventh Line of Therapy (following 6th relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		2	QD (D1-21)	QD (D1-21)					1640	1696	1
MMRF_1711	Seventh Line of Therapy (following 6th relapse)	Elotuzumab		Disease progression/Relapse	mg	IV	Log Forms	Unknown	Unknown		812	Other	QD (D1, D8, D15, & D22)					1640	1696	1
MMRF_1711	Sixth Line Therapy (following 5th relapse)	CISPLATIN		Completed regimen	mg	IV	Log Forms	Other	SALVAGE		20	Other	ONCE					1615	1615	1
MMRF_1711	Sixth Line Therapy (following 5th relapse)	ETOPOSIDE		Completed regimen	mg	IV	Log Forms	Other	SALVAGE		80	Other	ONCE					1615	1615	1
MMRF_1711	Sixth Line Therapy (following 5th relapse)	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Other	SALVAGE		800	Other	ONCE					1615	1615	1
MMRF_1711	Sixth Line Therapy (following 5th relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Other	SALVAGE		40	Other	ONCE					1615	1615	1
MMRF_1711	Sixth Line Therapy (following 5th relapse)	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Other	SALVAGE		2.6	Other	ONCE					1615	1615	1
MMRF_1711	Fifth Line Therapy (following 4th relapse)	CISPLATIN		Completed regimen	mg	IV	Log Forms	Other	SALVAGE		20	Other	ONCE					1593	1593	1
MMRF_1711	Fifth Line Therapy (following 4th relapse)	ETOPOSIDE		Completed regimen	mg	IV	Log Forms	Other	SALVAGE		84	Other	ONCE					1593	1593	1
MMRF_1711	Fifth Line Therapy (following 4th relapse)	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Other	SALVAGE		840	Other	ONCE					1593	1593	1
MMRF_1711	Fifth Line Therapy (following 4th relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Other	SALVAGE		40	Other	ONCE					1593	1593	1
MMRF_1711	Fifth Line Therapy (following 4th relapse)	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Other	SALVAGE		2.7	Other	ONCE					1593	1593	1
MMRF_1711	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg	IV SubQ	Log Forms	Induction	Induction		2.8	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	11	1
MMRF_1711	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	Other	QD 1,2,4,5,8,9,11,12					1	11	1
MMRF_1711	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	11	1
MMRF_1711	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					29	82	1
MMRF_1711	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		15	QD (D1-14)	QD (D1-14)					29	82	1
MMRF_1711	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	QD 1,2,4,5,8,9,11,12					29	82	1
MMRF_1711	First line of therapy	Melphalan		Completed regimen	mg	UNKNOWN	Log Forms	Consolidation	Consolidation		200	Q day	Q day					122	122	1
MMRF_1711	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					240	1017	1
MMRF_1711	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		25	QD (D1-21)	QD (D1-21)					1020	1080	1
MMRF_1711	Second Line Therapy (after first relapse)	Ixazomib		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		4	Other	QD(D1,D8,D15,D22)					1020	1080	1
MMRF_1711	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		40	Q week	Q week					1020	1080	1
MMRF_1711	Third Line Therapy (following 2nd relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Unknown	Unknown		16	Other	QD(D1,D8,D15,D22)					1095	1150	1
MMRF_1711	Third Line Therapy (following 2nd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					1095	1150	1
MMRF_1711	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		20	Other	QD(D1,D8,D15,D22)					1095	1150	1
MMRF_1711	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		40	Other	D22					1157	1584	1
MMRF_1711	Fourth Line Therapy (following 3rd relapse)	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Unknown	Unknown		600	Other	QD(D1,D8,D15)					1157	1290	1
MMRF_1711	Fourth Line Therapy (following 3rd relapse)	Carfilzomib		Disease progression/Relapse	mg	IV	Log Forms	Unknown	Unknown		41	Other	QD(D1,D2)					1157	1584	1
MMRF_1711	Fourth Line Therapy (following 3rd relapse)	Carfilzomib		Disease progression/Relapse	mg	IV	Log Forms	Unknown	Unknown		56	Other	QD(D8,D9,D15,D16)					1157	1584	1
MMRF_1711	Fourth Line Therapy (following 3rd relapse)	Prednisone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		60	Other	QD(D2,D9,D16)					1304	1584	1
MMRF_1713	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	83	1
MMRF_1713	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	126	1
MMRF_1713	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		15	Other	QD 1-14 ON 21 DAY CYCLE					21	28	1
MMRF_1713	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		1.3	Other	Q WEEKLY (4 ON AND 2 OFF)					84	126	1
MMRF_1713	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					281	350	1
MMRF_1713	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Induction	Induction		200	Q day	Q day					170	170	1
MMRF_1713	First line of therapy	Lenalidomide		Patient decision	mg	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					350	448	1
MMRF_1713	Second Line Therapy (after first relapse)	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Unknown	Unknown		5	QD (D1-21)	QD (D1-21)					1053	1148	1
MMRF_1713	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		10	QD (D1-21)	QD (D1-21)					1148	1233	1
MMRF_1713	Second Line Therapy (after first relapse)	Lenalidomide			mg	PO	Log Forms	Unknown	Unknown	Checked	5	QD (D1-21)	QD (D1-21)					1233		1
MMRF_1722	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	71	1
MMRF_1722	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	71	1
MMRF_1722	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	71	1
MMRF_1722	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		140	Q day	Q day					139	139	1
MMRF_1722	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					408		1
MMRF_1736	Fourth Line Therapy (following 3rd relapse)	Dexamethasone			mg	PO	Log Forms	Maintenance	Maintenance	Checked	20	QWK	QWK					2532		1
MMRF_1736	Fourth Line Therapy (following 3rd relapse)	Carfilzomib		INTOLERANCE		IV	Log Forms	Maintenance	Maintenance	Checked		Other	DAYS 1,8,15					2532	2591	1
MMRF_1736	Third Line Therapy (following 2nd relapse)	Pomalidomide				PO	Log Forms			Checked		QD (D1-21)	QD (D1-21)					2256	2532	1
MMRF_1736	Third Line Therapy (following 2nd relapse)	Dexamethasone			mg	PO	Log Forms	Maintenance	Maintenance	Checked	4	Q day	Q day					2256	2532	1
MMRF_1736	Third Line Therapy (following 2nd relapse)	NINLARO			mg	PO	Log Forms	Maintenance	Maintenance	Checked	2.3	Other	DAYS 1,8,15					2256		1
MMRF_1736	Fourth Line Therapy (following 3rd relapse)	Pomalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	2	Q day	Q day					2602		1
MMRF_1736	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	34	1
MMRF_1736	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	Other	DAY AFTER EACH DOSE OF VELCADE					1	34	1
MMRF_1736	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		10	QD (D1-14)	QD (D1-14)					1	34	1
MMRF_1736	Second Line Therapy (after first relapse)	Daratumumab			mg/kg	IV	Log Forms	Unknown	Unknown	Checked	16	Other	QD(D1,D8,D15,D22)					1219		1
MMRF_1736	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Unknown	Unknown	Checked	4	Other	4MG TWO DAYS AFTER DARA INFUSION					1219		1
MMRF_1817	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	92	1
MMRF_1817	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	93	1
MMRF_1817	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	Other	DAYS 1,2,4,5,8,9,11,12					1	25	1
MMRF_1817	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		12	Other	QD 1,2					26	29	1
MMRF_1817	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		16	Other	QD 1,2,4,5,8,9,11,12					30	93	1
MMRF_1817	First line of therapy	Melphalan		Completed regimen	mg	IVB	Log Forms	Induction	Induction		200	Q day	Q day					169	169	1
MMRF_1817	First line of therapy	Lenalidomide		Patient decision	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					401	432	1
MMRF_1817	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					550	774	1
MMRF_1817	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					947	1251	1
MMRF_1817	Second Line Therapy (after first relapse)	VENETACLEX		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		400	Q day	Q day					1293	1404	1
MMRF_1817	Third Line Therapy (following 2nd relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Unknown	Unknown		16	Q week	Q week					1404	1551	1
MMRF_1817	Third Line Therapy (following 2nd relapse)	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					1404	1488	1
MMRF_1817	Third Line Therapy (following 2nd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		3	QD (D1-21)	QD (D1-21)					1488	1551	1
MMRF_1817	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		40	Q week	Q week					1404	1551	1
MMRF_1817	Fourth Line Therapy (following 3rd relapse)	Bortezomib		Completed regimen	mg	IVB	Log Forms	Other	SALVAGE		2.6	Other	QD(D1, D4)					1551	1554	1
MMRF_1817	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Other	SALVAGE		40	Other	QD(D1,D2,D3,D4)					1551	1554	1
MMRF_1817	Fourth Line Therapy (following 3rd relapse)	ETOPOSIDE		Completed regimen	mg	IVB	Log Forms	Other	SALVAGE		80	Other	QD(D1,D2,D3,D4)					1551	1554	1
MMRF_1817	Fourth Line Therapy (following 3rd relapse)	Cyclophosphamide		Completed regimen	mg	IVB	Log Forms	Other	SALVAGE		800	Other	QD(D1,D2,D3,D4)					1551	1554	1
MMRF_1817	Fourth Line Therapy (following 3rd relapse)	CISPLATIN		Completed regimen	mg	IVB	Log Forms	Other	SALVAGE		20	Other	QD(D1,D2,D3,D4)					1551	1554	1
MMRF_1837	First line of therapy	Bortezomib		Completed regimen	mg	IV	Log Forms	Induction	Induction		2.29	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	76	1
MMRF_1837	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	76	1
MMRF_1837	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	QD 1,2,4,5,8,9,11,12					1	76	1
MMRF_1837	First line of therapy	Melphalan		Completed regimen	mg/m^2	UNKNOWN	Log Forms	Other	CONDITIONING		200	Other	UNKNOWN					123	124	1
MMRF_1837	First line of therapy	Bortezomib		Patient decision	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	QD (D1,D8,D15)					216	700	1
MMRF_1837	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					216	1248	1
MMRF_1837	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		40	Other	QD(D1,D8,D15)					216	1248	1
MMRF_1837	First line of therapy	Ixazomib		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		4	Other	QD(D1,D8,D15)					693	776	1
MMRF_1837	First line of therapy	Ixazomib		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		3	Q week	Q week					776	1248	1
MMRF_1837	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Unknown	Unknown	Checked	20	Q week	Q week					1267		1
MMRF_1837	Second Line Therapy (after first relapse)	VENETOCLEX		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		800	Q day	Q day					1267	1323	1
MMRF_1837	Second Line Therapy (after first relapse)	VENETOCLAX			mg	PO	Log Forms	Unknown	Unknown	Checked	400	Q day	Q day					1323		1
MMRF_1854	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		2.5	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	85	1
MMRF_1854	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	85	1
MMRF_1854	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	85	1
MMRF_1854	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					211	1282	1
MMRF_1854	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	QD (D1,D8,D15)					211	1282	1
MMRF_1854	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		20	Other	QD (D1,D2,D8,D9,D15,D16)					211	1282	1
MMRF_1854	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Q day	Q day					118	118	1
MMRF_1854	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					1282		1
MMRF_1906	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					8	167	1
MMRF_1906	First line of therapy	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Induction	Induction		500	Other	QD (D1,D8)					63	206	1
MMRF_1906	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					168	206	1
MMRF_1906	First line of therapy	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Induction	Induction		500	Other	DAYS 15 AND 22 OF 28 DAY CYCLE					28	206	1
MMRF_1906	First line of therapy	Cyclophosphamide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		300	Other	QD DAYS 1,8 OF 28 DAY CYCLE					1	28	1
MMRF_1906	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	QD DAYS 1,2,4,5,8,9,11,12					8	206	1
MMRF_1906	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-14)	QD (D1-14)					238	313	1
MMRF_1906	Second Line Therapy (after first relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					344	772	1
MMRF_1906	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		40	Q week	Q week					344	772	1
MMRF_1906	Second Line Therapy (after first relapse)	Carfilzomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Unknown	Unknown		20	Other	QD(D1,D2)					421	422	1
MMRF_1906	Second Line Therapy (after first relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms	Unknown	Unknown		27	Other	QD(D8,D9,D15,D16)					421	772	1
MMRF_1906	Third Line Therapy (following 2nd relapse)	Daratumumab		Adverse Event or co-morbidity	mg/kg	IV	Log Forms	Unknown	Unknown		16	Other	QD(D1,8,15,22)					792	876	1
MMRF_1906	Third Line Therapy (following 2nd relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Unknown	Unknown		8	Other	QD(D15,22)					792	813	1
MMRF_1906	Third Line Therapy (following 2nd relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		8	Other	QD(D1,D8,D15,D22)					792	876	1
MMRF_1906	Third Line Therapy (following 2nd relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		10	QD (D1-21)	QD (D1-21)					792	876	1
MMRF_1940	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		2.7	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	81	1
MMRF_1940	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	QD 2,5,9,12					1	81	1
MMRF_1940	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	18	1
MMRF_1940	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	QD(D1,D15,D29,D43)					291	1481	1
MMRF_1940	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Induction	Induction		200	Q day	Q day					160	160	1
MMRF_1940	First line of therapy	Ixazomib			mg	PO	Log Forms	Maintenance	Maintenance	Checked	4	Q week	Q week					1481		1
MMRF_1957	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	144	1
MMRF_1957	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					1	144	1
MMRF_1957	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					324	1077	1
MMRF_1957	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Induction	Induction		270	Q day	Q day					194	194	1
MMRF_1957	Second Line Therapy (after first relapse)	VENETOCLAX			mg	PO	Log Forms	Unknown	Unknown	Checked	800	Other	QD(D1-D28)					1226		1
MMRF_1957	Third Line Therapy (following 2nd relapse)	Ixazomib		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		4	Other	DAYS 1,8,15					2353	2500	1
MMRF_1957	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		40	Other	DAYS 1,8,15,22					2353	2500	1
MMRF_1957	Fourth Line Therapy (following 3rd relapse)	Daratumumab					Log Forms			Checked								2511		1
MMRF_1957	Fourth Line Therapy (following 3rd relapse)	Pomalidomide			mg	PO	Log Forms			Checked	4							2511		1
MMRF_1957	Fourth Line Therapy (following 3rd relapse)	Dexamethasone			mg		Log Forms			Checked	20							2511		1
MMRF_2001	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	103	1
MMRF_2001	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	103	1
MMRF_2001	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	QD 1,2,4,5,8,9,11,12					1	103	1
MMRF_2001	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Q day	Q day					169	169	1
MMRF_2001	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					404	549	1
MMRF_2001	Second Line Therapy (after first relapse)	Daratumumab			mg/kg	IV	Log Forms	Unknown	Unknown	Checked	16	Other	WEEKLY X 2 MONTHS, THEN EVERY OTHER WEEK FOR MONTH 3 -6, THEN MONTHLY					1428		1
MMRF_2001	Second Line Therapy (after first relapse)	Pomalidomide			mg	PO	Log Forms	Unknown	Unknown	Checked	4	QD (D1-21)	QD (D1-21)					1428		1
MMRF_2001	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Unknown	Unknown	Checked	20	Q week	Q week					1063		1
MMRF_2090	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	95	1
MMRF_2090	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					14	95	1
MMRF_2090	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	QD 1,2,4,5,8,9,11,12					1	95	1
MMRF_2090	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Q day	Q day					139	139	1
MMRF_2090	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					263	477	1
MMRF_2090	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	5	QD (D1-21)	QD (D1-21)					513		1
MMRF_2111	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	93	1
MMRF_2111	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	93	1
MMRF_2111	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	93	1
MMRF_2111	First line of therapy	Melphalan		Completed regimen	mg	IVB	Log Forms	Induction	Induction		200	Q day	Q day					153	153	1
MMRF_2111	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					327	1564	1
MMRF_2111	Second Line Therapy (after first relapse)	Daratumumab			mg	IV	Log Forms	Maintenance	Maintenance	Checked	1300	QWK	QWK					1659		1
MMRF_2111	Second Line Therapy (after first relapse)	Pomalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	4	Q day	Q day					1659		1
MMRF_2111	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Maintenance	Maintenance	Checked	20	Q week	Q week					1659		1
MMRF_2128	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	106	1
MMRF_2128	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	Other	QD 1-14 OF 21 DAYS					1	106	1
MMRF_2128	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	QD 1,2,4,5,8,9,11,12					1	106	1
MMRF_2128	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		140	Q day	Q day					161	161	1
MMRF_2128	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					323	343	1
MMRF_2137	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		1.3	Other	QD 1,4,8,11,15,18					1	107	1
MMRF_2137	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	107	1
MMRF_2137	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	QD 1,8,15,22					1	107	1
MMRF_2137	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Q day	Q day					112	112	1
MMRF_2137	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					467		1
MMRF_2140	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					95	200	1
MMRF_2140	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					95	200	1
MMRF_2140	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	QD 1,8,15					95	200	1
MMRF_2140	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					1	451	1
MMRF_2140	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	5	QD (D1-21)	QD (D1-21)					451		1
MMRF_2140	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Other	ONCE					225	225	1
MMRF_2211	Sixth Line Therapy (following 5th relapse)	Dexamethasone			mg	PO	Log Forms	Maintenance	Maintenance	Checked	20	Other	DAYS 1,8,15					2374		1
MMRF_2211	Sixth Line Therapy (following 5th relapse)	AO-176			mg/kg	IV	Log Forms	Maintenance	Maintenance	Checked	3	Other	DAYS 1,8,15					2374		1
MMRF_2211	Fifth Line Therapy (following 4th relapse)	Dexamethasone		PER TREATMENT ORDERS	mg	IV	Log Forms	Maintenance	Maintenance		10	QWK	QWK					1990	2032	1
MMRF_2211	Fifth Line Therapy (following 4th relapse)	REGN5458-ONC-1826		Disease progression/Relapse	mg	IV	Log Forms	Maintenance	Maintenance		24	Other	QMONTH					1968	2324	1
MMRF_2211	Fifth Line Therapy (following 4th relapse)	Dexamethasone		DOSE CHANGE PER TREATMENT ORDERS	mg	IV	Log Forms	Maintenance	Maintenance		20	QWK	QWK					1969	2348	1
MMRF_2211	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms				40	Other	QD (D1, D8, & D15)					1838	1936	1
MMRF_2211	Fourth Line Therapy (following 3rd relapse)	Cyclophosphamide		Disease progression/Relapse	mg/m^2	PO	Log Forms				300	Other	QD (D1, D8, & D15)					1838	1936	1
MMRF_2211	Fourth Line Therapy (following 3rd relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Unknown	Unknown		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1838	1936	1
MMRF_2211	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		20	Q week	Q week					1722	1796	1
MMRF_2211	Third Line Therapy (following 2nd relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		25	QD (D1-21)	QD (D1-21)					1722	1796	1
MMRF_2211	Third Line Therapy (following 2nd relapse)	Ixazomib		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		4	Q week	Q week					1722	1796	1
MMRF_2211	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	74	1
MMRF_2211	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	DAYS 1,2,4,5,8,9,11,12					1	36	1
MMRF_2211	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					43	74	1
MMRF_2211	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	QD(D1,D2,D4,D5,D8,D9,D11,D12)					43	74	1
MMRF_2211	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	ASCT		200	Q day	Q day					120	120	1
MMRF_2211	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					249	396	1
MMRF_2211	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					396	1054	1
MMRF_2211	Second Line Therapy (after first relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					1075	1715	1
MMRF_2211	Second Line Therapy (after first relapse)	Prednisone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		20	Other	DAILY X 2 ON QD(D2,D9,D16,D23)					1075	1715	1
MMRF_2211	Second Line Therapy (after first relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Unknown	Unknown		16	Other	QD(D1,D8,D15,D22)					1075	1715	1
MMRF_2209	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	8	1
MMRF_2209	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	8	1
MMRF_2209	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	Other	QD 1,2,4,5,8,9,11,12					1	8	1
MMRF_2209	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		20	Other	Q WK X3 (DAYS 1,2,8,9,15,16) WITH 12 SAY REST Q 28 DAYS X					22	125	1
MMRF_2209	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	QD 1,8,15,22					22	125	1
MMRF_2209	First line of therapy	Melphalan		Completed regimen	mg/m^2	IVB	Log Forms	Induction	Induction		140	Q day	Q day					173	173	1
MMRF_2239	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	32	1
MMRF_2239	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	74	1
MMRF_2239	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	QD1 2,4,5,8,9,11,12					1	74	1
MMRF_2239	First line of therapy	Melphalan		Completed regimen	mg	IVB	Log Forms	Induction	Induction		140	Q day	Q day					126	126	1
MMRF_2239	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					236		1
MMRF_2239	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					43	74	1
MMRF_2284	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Induction	Induction		200	Q day	Q day					133	133	1
MMRF_2284	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Consolidation	Consolidation		10	QD (D1-21)	QD (D1-21)					239	771	1
MMRF_2284	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	QD 1,2,4,5,8,9,11,12					1	64	1
MMRF_2284	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	94	1
MMRF_2284	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	74	1
MMRF_2284	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		DEATH	mg	PO	Log Forms	Other	SALVAGE		20	Other	D1, 8,15, 22					1415	1487	1
MMRF_2284	Fourth Line Therapy (following 3rd relapse)	Pomalidomide		DEATH	mg	PO	Log Forms	Other	SALVAGE		2	Q day	Q day					1415	1487	1
MMRF_2284	Fourth Line Therapy (following 3rd relapse)	Daratumumab		DEATH	mg	IV	Log Forms	Other	SALVAGE		1300	Other	D1, 8,15,22					1415	1487	1
MMRF_2284	Third Line Therapy (following 2nd relapse)	ETOPOSIDE		Completed regimen	mg	IV	Log Forms	Other	SALVAGE		74	Other	Q24H					1377	1381	1
MMRF_2284	Third Line Therapy (following 2nd relapse)	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Other	SALVAGE		740	Other	Q24H					1377	1381	1
MMRF_2284	Third Line Therapy (following 2nd relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Other	SALVAGE		40	Other	Q24H					1377	1381	1
MMRF_2284	Third Line Therapy (following 2nd relapse)	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Other	SALVAGE		2.4	Other	Q72H					1377	1381	1
MMRF_2284	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		40	Other	QD D1, 8, 15, 22					1317	1400	1
MMRF_2284	Second Line Therapy (after first relapse)	MLN9708		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		4	Other	QD D1, 8, 15					1317	1400	1
MMRF_2397	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		2.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_2397	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	53	1
MMRF_2397	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	QD(1,2,4,5,8,9,11,12)					1	53	1
MMRF_2397	First line of therapy	Melphalan		Completed regimen	mg	IVB	Log Forms	Induction	Induction		400	Q day	Q day					99	99	1
MMRF_2397	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Consolidation	Consolidation		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					183	218	1
MMRF_2397	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		10	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					183	218	1
MMRF_2397	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		15	QD (D1-14)	QD (D1-14)					183	218	1
MMRF_2397	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	QD(D1,D8,D15)					284	343	1
MMRF_2397	First line of therapy	Ixazomib		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		4	Other	QD(D1,D8,D15)					343	876	1
MMRF_2397	First line of therapy	Ixazomib			mg	PO	Log Forms	Maintenance	Maintenance	Checked	3	Other	QD(D1,D8,D15)					876		1
MMRF_2383	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		2.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	74	1
MMRF_2383	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	QD(D1,D8,D15)					1	74	1
MMRF_2383	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	74	1
MMRF_2383	First line of therapy	Melphalan		Completed regimen	mg/m^2	IVB	Log Forms	Induction	Induction		200	Q day	Q day					126	126	1
MMRF_2383	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					235		1
MMRF_2388	Sixth Line Therapy (following 5th relapse)	Dexamethasone			mg	PO	Log Forms			Checked	20	Other	Q DAYS 1,8,15,22					2110		1
MMRF_2388	Sixth Line Therapy (following 5th relapse)	Pomalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	4	QD (D1-21)	QD (D1-21)					2110		1
MMRF_2388	Sixth Line Therapy (following 5th relapse)	INVESTIGATIONAL ANTI-TIGIT			mg	PO	Log Forms	Maintenance	Maintenance	Checked	240	Other	QMONTH					2083		1
MMRF_2388	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					1	85	1
MMRF_2388	First line of therapy	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Other	QD (D1,8,15)					1	616	1
MMRF_2388	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	Other	QD(D1,D8,D15)					1	1242	1
MMRF_2388	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		5	QD (D1-21)	QD (D1-21)					150	175	1
MMRF_2388	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		20	QD (D1-21)	QD (D1-21)					175	616	1
MMRF_2388	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		10	Other	QD(D1-D7),(D15-D21)					633	1088	1
MMRF_2388	Second Line Therapy (after first relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Unknown	Unknown		16	Other	QD(D1,D8,D15,D22)					633	1088	1
MMRF_2388	Third Line Therapy (following 2nd relapse)	Ixazomib		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		4	Other	QD (D1,D8,D15)					1102	1767	1
MMRF_2388	Third Line Therapy (following 2nd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					1102	1767	1
MMRF_2388	Third Line Therapy (following 2nd relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		12	Q week	Q week					1242	1557	1
MMRF_2388	Fourth Line Therapy (following 3rd relapse)	Dexamethasone			mg	PO	Log Forms	Unknown	Unknown	Checked	4	Other	QD (D1, D8, & D15)					1774		1
MMRF_2388	Fourth Line Therapy (following 3rd relapse)	Cyclophosphamide			mg/m^2	PO	Log Forms	Unknown	Unknown	Checked	300	Other	QD (D1, D8, & D15)					1774		1
MMRF_2388	Fourth Line Therapy (following 3rd relapse)	Carfilzomib			mg/m^2	IV	Log Forms	Unknown	Unknown	Checked	56	Other	QD (D1, D8, & D15)					1774		1
MMRF_2388	Fifth Line Therapy (following 4th relapse)	BELANTAMAB MAFODOTIN MONOTHERAPY		Completed regimen	mg/kg	IV	Log Forms	Maintenance	Maintenance		2.5	Other	Q21 DAYS					1999	2059	1
MMRF_2411	Fourth Line Therapy (following 3rd relapse)	CISPLATIN		Completed regimen	mg	IV	Log Forms	Other	SALVAGE		19	Other	Q24H					1578	1581	1
MMRF_2411	Fourth Line Therapy (following 3rd relapse)	ETOPOSIDE		Completed regimen	mg	IV	Log Forms	Other	SALVAGE		75	Other	Q24H					1578	1581	1
MMRF_2411	Fourth Line Therapy (following 3rd relapse)	Cyclophosphamide		Completed regimen	mg	IV	Log Forms				750	Other	Q24H					1578	1581	1
MMRF_2411	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	Other	Q24H					1578	1581	1
MMRF_2411	Fourth Line Therapy (following 3rd relapse)	CISPLATIN		Completed regimen	mg	IV	Log Forms	Other	SALVAGE		19	Other	Q24H					1599	1602	1
MMRF_2411	Fourth Line Therapy (following 3rd relapse)	ETOPOSIDE		Completed regimen	mg	IV	Log Forms				76	Other	Q24H					1599	1602	1
MMRF_2411	Fourth Line Therapy (following 3rd relapse)	Cyclophosphamide		Completed regimen	mg	IV	Log Forms				750	Other	Q24H					1599	1602	1
MMRF_2411	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	Other	Q24H					1599	1602	1
MMRF_2411	Sixth Line Therapy (following 5th relapse)	FLUDARABINE	JARC125		mg/m^2	IV	Log Forms	Unknown	Unknown	Checked	30	Other	DAYS -5, -4, & -3					1801		1
MMRF_2411	Sixth Line Therapy (following 5th relapse)	Cyclophosphamide	JCAR125		mg/m^2	IV	Log Forms	Unknown	Unknown	Checked	300	Other	DAYS -5, -4, & -3					1801		1
MMRF_2411	Fifth Line Therapy (following 4th relapse)	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Unknown	Unknown		40	Other	QD (D1, D8, D15, & D22)					1618	1737	1
MMRF_2411	Fifth Line Therapy (following 4th relapse)	Elotuzumab		Disease progression/Relapse	mg	IV	Log Forms	Unknown	Unknown		700	Other	QD (D1, D8, D15, & D22)					1618	1737	1
MMRF_2411	Fifth Line Therapy (following 4th relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		2	QD (D1-21)	QD (D1-21)					1618	1737	1
MMRF_2411	Fourth Line Therapy (following 3rd relapse)	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Other	SALVAGE		2.4	Other	Q72H					1599	1602	1
MMRF_2411	Fourth Line Therapy (following 3rd relapse)	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Other	SALVAGE		2.4	Other	Q72H					1578	1581	1
MMRF_2411	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	74	1
MMRF_2411	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		2.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	74	1
MMRF_2411	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	74	1
MMRF_2411	First line of therapy	Melphalan		Completed regimen	mg/m^2	IVB	Log Forms	Induction	Induction		200	Q day	Q day					129	129	1
MMRF_2411	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					246	914	1
MMRF_2411	Second Line Therapy (after first relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Unknown	Unknown		16	Other	QD(D1,D8,D15,D22)					926	1023	1
MMRF_2411	Second Line Therapy (after first relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					926	1023	1
MMRF_2411	Second Line Therapy (after first relapse)	Prednisone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		20	Other	DAILY X 2 DAYS BEGINNING THE DAY AFTER EACH DARA INFUSION					928	1023	1
MMRF_2411	Third Line Therapy (following 2nd relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Unknown	Unknown		56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1058	1446	1
MMRF_2411	Third Line Therapy (following 2nd relapse)	Cyclophosphamide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		600	Other	QD(D1,D8,D15)					1058	1446	1
MMRF_2411	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		20	Q week	Q week					1058	1446	1
MMRF_2459	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	82	1
MMRF_2459	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	82	1
MMRF_2459	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	QD(D1,D2,D4,D5,D8,D9,D11,D12)					1	82	1
MMRF_2459	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Q day	Q day					136	136	1
MMRF_2459	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					224	606	1
MMRF_2459	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-14)	QD (D1-14)					606		1
MMRF_2516	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					3	9	1
MMRF_2516	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1-4)	QD (D1-4)					1	4	1
MMRF_2516	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					22	74	1
MMRF_2516	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					22	77	1
MMRF_2516	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	QD 2,5,9,12					22	74	1
MMRF_2516	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		140	Q day	Q day					119	119	1
MMRF_2516	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					245	259	1
MMRF_2516	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Unknown	Unknown	Checked	40	Q week	Q week					1589		1
MMRF_2516	Second Line Therapy (after first relapse)	Daratumumab			mg/kg	IV	Log Forms	Unknown	Unknown	Checked	16	Other	QD(D1, D8, D15, D22)					1589		1
MMRF_2532	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	71	1
MMRF_2532	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		15	QD (D1-14)	QD (D1-14)					1	81	1
MMRF_2532	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	QD(D1,D2,D4,D5,D8,D9,D11,D12)					1	81	1
MMRF_2532	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		0.7	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					71	81	1
MMRF_2532	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		140	Q day	Q day					133	133	1
MMRF_2532	First line of therapy	Lenalidomide		Patient decision	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					239	605	1
MMRF_2559	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	74	1
MMRF_2559	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	74	1
MMRF_2559	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	74	1
MMRF_2559	First line of therapy	Melphalan		Completed regimen	mg/m^2	IVB	Log Forms	Induction	Induction		200	QID	QID					131	131	1
MMRF_2559	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					275	410	1
MMRF_2559	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	15	QD (D1-14)	QD (D1-14)					410		1
MMRF_1121	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	74	1
MMRF_1121	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms				2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	74	1
MMRF_1121	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				20	Other	D1,2,4,5,8,9,11,12					1	74	1
MMRF_1121	First line of therapy	Melphalan		Completed regimen	MG/M2	IV	Log Forms	Induction	Induction		200	Q day	Q day					494	494	1
MMRF_1121	First line of therapy	Lenalidomide		DOSE REDUCED DUE TO PERIPHERAL NEUROPATHY	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					345	375	1
MMRF_1121	First line of therapy	Lenalidomide		GOING ON VACATION TO CHINA	mg	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					375	464	1
MMRF_1121	First line of therapy	Lenalidomide		LOST INSURANCE FOR ONE MONTH	mg	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					541	660	1
MMRF_1121	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	5	QD (D1-21)	QD (D1-21)					660		1
MMRF_1149	First line of therapy	Dexamethasone		REFERRED FOR BONE MARROW TRANSPLANT	mg	PO	Log Forms				20	Other	D1,2,4,5,8,9,11,12					1	85	1
MMRF_1149	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg/m^2	IV	Log Forms				200	Other	TOTAL DOSE					158	204	1
MMRF_1149	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	Other	DAILY DAYS 1 - 21 OF A 28 DAY CYCLE					330	457	1
MMRF_1149	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Unknown	Unknown		4	Other	DAY 2,9,16 OF EACH 28 DAY CYCLE					458	563	1
MMRF_1149	Third Line Therapy (following 2nd relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Unknown	Unknown		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					458	564	1
MMRF_1149	Third Line Therapy (following 2nd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		2	QD (D1-21)	QD (D1-21)					458	564	1
MMRF_1149	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		20	Other	D 1,8, 15, 21					458	564	1
MMRF_1149	Third Line Therapy (following 2nd relapse)	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Unknown	Unknown		2.6	Other	QD FOR FOUR DAYS (OFF FOR 24 DAYS)					564	595	1
MMRF_1149	Third Line Therapy (following 2nd relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Unknown	Unknown		40	Other	QD FOR FOUR DAYS (OFF FOR 24 DAYS)					564	595	1
MMRF_1149	Third Line Therapy (following 2nd relapse)	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Unknown	Unknown		800	Other	QD FOR FOUR DAYS (OFF FOR 24 DAYS)					564	595	1
MMRF_1149	Third Line Therapy (following 2nd relapse)	ETOPOSIDE		Completed regimen	mg	IV	Log Forms	Unknown	Unknown		80	Other	QD FOR 4 DAYS (OFF FOR 24 DAYS)					564	595	1
MMRF_1149	Third Line Therapy (following 2nd relapse)	CISPLATIN		Completed regimen	mg	IV	Log Forms	Unknown	Unknown		20	Other	QD FOR 4 DAYS (OFF FOR 24 DAYS)					564	595	1
MMRF_1149	Third Line Therapy (following 2nd relapse)	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms	Other	SALVAGE		1.6	Other	QD 1,8,15					620	645	1
MMRF_1149	Third Line Therapy (following 2nd relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					620	645	1
MMRF_1149	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		20	Q week	Q week					620	645	1
MMRF_1149	Fourth Line Therapy (following 3rd relapse)	Bortezomib		Disease progression/Relapse	mg	IV SubQ	Log Forms	Other	SALVAGE		2.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					701	760	1
MMRF_1149	Fourth Line Therapy (following 3rd relapse)	Cyclophosphamide		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		600	Other	QD 1,8,15,22					701	760	1
MMRF_1149	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		40	Q week	Q week					701	760	1
MMRF_1149	Fourth Line Therapy (following 3rd relapse)	Thalidomide		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		50	Other	QD 1-28					701	760	1
MMRF_1149	Fourth Line Therapy (following 3rd relapse)	VORINOSTAT		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		400	QD (D1-14)	QD (D1-14)					701	730	1
MMRF_1149	Sixth Line Therapy (following 5th relapse)	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Unknown	Unknown		2.6	Other	QD 1 AND 4					772	776	1
MMRF_1149	Sixth Line Therapy (following 5th relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Unknown	Unknown		20	Other	QD 1,2,4,5					772	776	1
MMRF_1149	Sixth Line Therapy (following 5th relapse)	Thalidomide		Completed regimen	mg	PO	Log Forms	Unknown	Unknown		50	Other	QD 1,2,3,4					772	776	1
MMRF_1149	Sixth Line Therapy (following 5th relapse)	CISPLATIN		Completed regimen	mg	IV	Log Forms	Unknown	Unknown		20	Other	QD 1,2,3,4					772	776	1
MMRF_1149	Sixth Line Therapy (following 5th relapse)	Doxorubicin		Completed regimen	mg	IV	Log Forms	Unknown	Unknown		20	Other	QD 1,2,3,4					772	776	1
MMRF_1149	Sixth Line Therapy (following 5th relapse)	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Unknown	Unknown		800	Other	QD 1,2,3,4					772	776	1
MMRF_1149	Sixth Line Therapy (following 5th relapse)	ETOPOSIDE		Completed regimen	mg	IV	Log Forms	Unknown	Unknown		80	Other	QD 1,2,3,4					772	776	1
MMRF_1149	Seventh Line of Therapy (following 6th relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		28	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					809	837	1
MMRF_1149	Seventh Line of Therapy (following 6th relapse)	ELOTUZUMAB		Disease progression/Relapse	mg	IV	Log Forms	Unknown	Unknown		795	Other	QD(D1,D8,D15,D22)					809	837	1
MMRF_1149	Seventh Line of Therapy (following 6th relapse)	Bortezomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Unknown	Unknown		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					809	837	1
MMRF_1149	Seventh Line of Therapy (following 6th relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		15	QD (D1-21)	QD (D1-21)					809	837	1
MMRF_1149	Eighth Line of Therapy (following 7th relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Unknown	Unknown		40	Q day	Q day					844	845	1
MMRF_1149	Eighth Line of Therapy (following 7th relapse)	Cyclophosphamide		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Unknown	Unknown		300	Other	QD(D1,D8,D15)					844	852	1
MMRF_1149	Eighth Line of Therapy (following 7th relapse)	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Unknown	Unknown		20	Other	QD(D1,D2)					844	846	1
MMRF_1149	Eighth Line of Therapy (following 7th relapse)	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Unknown	Unknown		27	Other	QD(D8,D9,D15,D16)					851	852	1
MMRF_1149	First line of therapy	Bortezomib		REFERRED FOR BONE MARROW TRANSPLANT	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	74	1
MMRF_1149	First line of therapy	Lenalidomide		REFERRED FOR BONE MARROW TRANSPLANT	MG	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	85	1
MMRF_1080	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms				1.3	Other	D1 Q21 DAYS					1	144	1
MMRF_1080	First line of therapy	Lenalidomide		Completed regimen	mg/dL	IV	Log Forms				25	Other	D1 & D8 Q21 DAYS					1	144	1
MMRF_1080	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	QWK	QWK					1	144	1
MMRF_1080	First line of therapy	Lenalidomide			mg	PO	Log Forms			Checked	10	Q day	Q day					295		1
MMRF_1198	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	309	1
MMRF_1198	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	309	1
MMRF_1198	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg/dL	IV	Log Forms				25	Other	D1 Q21 DAYS					1	309	1
MMRF_1198	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					316	434	1
MMRF_1198	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	Other	QAD					434		1
MMRF_1255	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					4	179	1
MMRF_1255	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				20	QD (D1-14)	QD (D1-14)					1	179	1
MMRF_1255	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms				1.3	Other	Q21 DAYS					1	179	1
MMRF_1255	First line of therapy	Lenalidomide			mg	PO	Log Forms	Induction	Induction	Checked	10	Q day	Q day					179		1
MMRF_1339	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	24	1
MMRF_1339	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	24	1
MMRF_1236	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	190	1
MMRF_1236	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	190	1
MMRF_1236	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	190	1
MMRF_1236	First line of therapy	Pomalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		2	QD (D1-21)	QD (D1-21)					313	342	1
MMRF_1236	First line of therapy	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		2	QD (D1-14)	QD (D1-14)					343	1397	1
MMRF_1236	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		20	Other	DAYS 1,2,8,9,15,16 OF 21 DAY CYCLE					1028	1069	1
MMRF_1236	First line of therapy	Dexamethasone		Lack of response	mg	PO	Log Forms	Maintenance	Maintenance		20	Q week	Q week					1069	1173	1
MMRF_1236	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		20	Other	DAYS 1,4,8,11,15,19					1174	1397	1
MMRF_1236	Second Line Therapy (after first relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Induction	Induction		16	Other	WEEKLY X8, BI-WEEKLY TO 6 MONTHS,THEN MONTHLY					1407	1673	1
MMRF_1236	Second Line Therapy (after first relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		4	QD (D1-14)	QD (D1-14)					1407	1700	1
MMRF_1236	Third Line Therapy (following 2nd relapse)	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		20	Other	DAYS 1,2,8,9,15,16,22,23 OF 28 DAY CYCLE					1701	1814	1
MMRF_1236	Third Line Therapy (following 2nd relapse)	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Induction	Induction		20	Other	DAYS 1,2,8,9,15,16,22,23 OF 28 DAY CYCLE					1701	1897	1
MMRF_1236	Third Line Therapy (following 2nd relapse)	Cyclophosphamide		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Consolidation	Consolidation		300	Other	DAY 1, 8, 15					1792	1821	1
MMRF_1236	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		20	Q week	Q week					1407	1700	1
MMRF_1236	Third Line Therapy (following 2nd relapse)	Cyclophosphamide		Adverse Event or co-morbidity	mg	IV	Log Forms	Induction	Induction		500	Other	WEEKLY X3, 1 WEEK OFF					1835	1897	1
MMRF_1236	Third Line Therapy (following 2nd relapse)	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		12	Other	DAYS 1,2,8,9,15,16 OF 28 DAY CYCLE					1821	1957	1
MMRF_1236	Third Line Therapy (following 2nd relapse)	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Induction	Induction		20	Other	DAYS 1,2,15,16 OF 28 DAY CYCLE					1897	1957	1
MMRF_1236	Third Line Therapy (following 2nd relapse)	Cyclophosphamide		Adverse Event or co-morbidity	mg	IV	Log Forms	Induction	Induction		500	Other	DAYS 1,15 OF 28 DAY CYCLE					1897	2048	1
MMRF_1236	Third Line Therapy (following 2nd relapse)	Cyclophosphamide		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		500	Other	WEEK 3 OF 4 WEEK CYCLE					2048	2079	1
MMRF_1236	Third Line Therapy (following 2nd relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Induction	Induction		70	Other	WEEKS 1,3 OF 28 DAY CYCLE					1957	2086	1
MMRF_1236	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		20	Other	WEEKS 1,3 OF 28 DAY CYCLE					1957	2086	1
MMRF_1236	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		200	Other	DAYS -2, -1 PRE-TRANSPLANT					200	201	1
MMRF_1236	Fourth Line Therapy (following 3rd relapse)	Bortezomib		Completed regimen	mg	SUB-Q	Log Forms	Induction	Induction		2.3	Other	ONCE					2154	2154	1
MMRF_1236	Fourth Line Therapy (following 3rd relapse)	Bendamustine		Completed regimen	mg	IV	Log Forms	Induction	Induction		125	Other	ONCE					2154	2154	1
MMRF_1236	Fourth Line Therapy (following 3rd relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		25	Other	DAILY X 21 DAYS THEN OFF X 7 DAYS					2301	2899	1
MMRF_1236	Third Line Therapy (following 2nd relapse)	Lenalidomide	1054196	Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation			Other	DAYS -5,-4,-3,-2,-1 PRE-TRANSPLANT					2185	2190	1
MMRF_1236	Third Line Therapy (following 2nd relapse)	Melphalan	1054196	Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		100	Other	DAYS -2, -1 PRE-TRANSPLANT					2188	2188	1
MMRF_1236	Fifth Line Therapy (following 4th relapse)	BELANTAMAB			mg/m^2	IV	Log Forms	Induction	Induction	Checked	2.5	Other	EVERY 3 WEEKS					2904		1
MMRF_1918	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		25	Other	DAYS 1-21 OF 28 DAY CYCLE					456	631	1
MMRF_1918	First line of therapy	Carfilzomib		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Consolidation	Consolidation		20	Other	DAYS 1,2,8,9,15,16 OF 28 DAY CYCLE					456	471	1
MMRF_1918	First line of therapy	Carfilzomib		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Consolidation	Consolidation		27	Other	DAYS 1,2, 8,9,15,16 OF 21 DAY CYCLE					484	527	1
MMRF_1918	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		36	Other	DAYS 1,2,8,9,15,16 OF 21 DAY CYCLE					547	625	1
MMRF_1918	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		15	QD (D1-21)	QD (D1-21)					659	1627	1
MMRF_1918	First line of therapy	Ixazomib		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		4	Other	DAYS 1,8,15  OF 28 DAY CYCLE					659	1627	1
MMRF_1918	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		40	Other	DAYS 1,8,15 OF 28 DAY CYCLE					659	1627	1
MMRF_1918	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		25	QD (D1-21)	QD (D1-21)					1634	2080	1
MMRF_1918	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		28	Other	D1, D8, D22					1634	2080	1
MMRF_1918	First line of therapy	Elotuzumab		Adverse Event or co-morbidity	mg/kg	IV	Log Forms	Maintenance	Maintenance		10	Other	MONTHLY					1634	2080	1
MMRF_1918	First line of therapy	Bortezomib		REFERRED FOR AUTOLOGOUS TRANSPLANT	mg	IV SubQ	Log Forms	Induction	Induction		2.5	Other	BIW					1	270	1
MMRF_1918	First line of therapy	Dexamethasone		REFERRED FOR AUTOLOGOUS TRANSPLANT	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	270	1
MMRF_1918	First line of therapy	Lenalidomide		REFERRED FOR AUTOLOGOUS TRANSPLANT	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	273	1
MMRF_1918	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Other	STEM CELL MOBILIZATION		573	Q week	Q week					92	99	1
MMRF_1918	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Q day	Q day					286	287	1
MMRF_2329	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	176	1
MMRF_2329	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	155	1
MMRF_2329	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	176	1
MMRF_2329	First line of therapy	Lenalidomide		DOSE ESCALATION	mg	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					358	501	1
MMRF_2329	First line of therapy	Lenalidomide		WHIPPLE PROCEDURE AND COMPLICATIONS; DOSE HELD; PANCREATIC CANCER TREATMENT	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					502	724	1
MMRF_2329	Second Line Therapy (after first relapse)	Daratumumab		DIAGNOSED WITH RECURRENT METASTATIC CHOLANGIOCARCINOMA	mg/kg	IV	Log Forms	Induction	Induction		16	Other	D1, D8, D15, D22					1172	1710	1
MMRF_2329	Second Line Therapy (after first relapse)	Dexamethasone		DIAGNOSED WITH RECURRENT METASTATIC CHOLANGIOCARCINOMA	mg	IV	Log Forms	Induction	Induction		20	Other	DAY 1, DAY 8, DAY 15, DAY 22					1172	1710	1
MMRF_2329	Second Line Therapy (after first relapse)	Dexamethasone		DIAGNOSED WITH RECURRENT METASTATIC CHOLANGIOCARCINOMA	mg	PO	Log Forms	Induction	Induction		20	Other	D2, D 9, D 16, D 23					1172	1710	1
MMRF_2329	Second Line Therapy (after first relapse)	Lenalidomide		DIAGNOSED WITH RECURRENT METASTATIC CHOLANGIOCARCINOMA	mg	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					1172	1716	1
MMRF_2329	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					1016	1171	1
MMRF_1067	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	112	1
MMRF_1067	First line of therapy	Cyclophosphamide		Investigator decision for other reasons	mg/m^2	IV	Log Forms				300	Q week	Q week					1	15	1
MMRF_1067	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms				40	Other	DAYS 1, 2, 4, 5, 8, 9, 11, 12					1	12	1
MMRF_1067	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				20	Q week	Q week					53	113	1
MMRF_1067	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms				4380	Other	ONCE					148	148	1
MMRF_1067	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				12	Other	ONCE					148	148	1
MMRF_1067	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms				250	Other	ONCE					161	161	1
MMRF_1067	First line of therapy	Bortezomib		Completed regimen	mg/m^2	SUBCUTANEOUS	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					348	421	1
MMRF_1067	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				20	Other	DAYS 1,2,4,5,8,9,11,12					348	419	1
MMRF_1067	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				15	QD (D1-14)	QD (D1-14)					348	417	1
MMRF_1067	Third Line Therapy (following 2nd relapse)	Pomalidomide			mg	PO	Log Forms	Unknown	Unknown	Checked	2	QD (D1-21)	QD (D1-21)					1835		1
MMRF_1067	Third Line Therapy (following 2nd relapse)	Dexamethasone			mg	PO	Log Forms	Unknown	Unknown	Checked	20	Q week	Q week					1835		1
MMRF_1067	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		20	Q week	Q week					1595	1805	1
MMRF_1067	Third Line Therapy (following 2nd relapse)	Elotuzumab			mg/kg	IV	Log Forms	Unknown	Unknown	Checked	10	Q week	Q week					2430		1
MMRF_1067	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					718	865	1
MMRF_1067	Second Line Therapy (after first relapse)	Daratumumab		Adverse Event or co-morbidity	mg	IV	Log Forms	Induction	Induction		1216	Q week	Q week					1294	1343	1
MMRF_1067	Second Line Therapy (after first relapse)	Bortezomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Maintenance	Maintenance		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1427	1817	1
MMRF_1067	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		40	Q week	Q week					1369	1569	1
MMRF_1067	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					545	718	1
MMRF_1131	Second Line Therapy (after first relapse)	Pomalidomide		Patient decision	mg	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					312	333	1
MMRF_1131	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					22	345	1
MMRF_1131	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	SUBCUTANEOUS	Log Forms				1	Q week	Q week					100	114	1
MMRF_1131	First line of therapy	Bortezomib		Completed regimen	mg/m^2	SUBCUTANEOUS	Log Forms				1.3	Other	DQ (D1, D7, D14)					186	256	1
MMRF_1131	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					100	175	1
MMRF_1131	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				15	QD (D1-21)	QD (D1-21)					179	269	1
MMRF_1131	First line of therapy	Prednisone		Completed regimen	mg	PO	Log Forms				20	Other	1, 2, 4, 5, 8, 9, 11, 12					22	269	1
MMRF_1131	Second Line Therapy (after first relapse)	Prednisone		Patient decision	mg	PO	Log Forms	Induction	Induction		50	Q week	Q week					312	333	1
MMRF_1131	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	Other	1, 2, 4, 5					1	57	1
MMRF_1131	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms				20	Other	8, 9, 11 AND 12					8	12	1
MMRF_1131	First line of therapy	Bortezomib		Completed regimen	mg/m^2	SUBCUTANEOUSLY	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	256	1
MMRF_1245	First line of therapy	Bortezomib		Completed regimen	mg/m^2	SUBCUTANEOUS	Log Forms				1.5	Other	QD (D1, D8, D15, D22)					1	239	1
MMRF_1245	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				20	Other	QD ( D1, D8, D15, D22)					1	239	1
MMRF_1245	First line of therapy	Bortezomib		MOVED TO OHIO	mg/m^2	SUBCUTANEOUS	Log Forms	Maintenance	Maintenance		1.5	Other	ONCE EVERY 2 WEEKS					250	295	1
MMRF_1412	First line of therapy	Bortezomib		Completed regimen	mg/m^2	SUBCUTANEOUS	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	96	1
MMRF_1412	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	99	1
MMRF_1412	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	Q week	Q week					1	99	1
MMRF_1412	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		5176	Other	ONCE					134	134	1
MMRF_1412	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING REGIMEN		410	Other	ONCE					147	147	1
MMRF_1412	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	5	QD (D1-21)	QD (D1-21)					323		1
MMRF_1412	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					294	323	1
MMRF_1680	First line of therapy	Bortezomib		Completed regimen	mg/m^2	SUBCUTANEOUS	Log Forms	Induction	Induction		1.5	Other	D1, D8, D15					1	104	1
MMRF_1680	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	27	1
MMRF_1680	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	132	1
MMRF_1680	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					28	132	1
MMRF_1680	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION		6250	Other	ONCE					133	133	1
MMRF_1680	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING REGIMEN		505	Other	ONCE					145	145	1
MMRF_1680	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Other	SALVAGE		40	QD (D1-4)	QD (D1-4)					1376	1422	1
MMRF_1680	First line of therapy	CISPLATIN (PLATINOL)		Completed regimen	mg	IV	Log Forms	Other	SALVAGE		24	QD (D1-4)	QD (D1-4)					1376	1422	1
MMRF_1680	First line of therapy	Doxorubicin		Completed regimen	mg	IV	Log Forms	Other	SALVAGE		24.2	QD (D1-4)	QD (D1-4)					1376	1422	1
MMRF_1680	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Other	SALVAGE		968	QD (D1-4)	QD (D1-4)					1376	1422	1
MMRF_1680	First line of therapy	ETOPOSIDE (VERSED)		Completed regimen	mg	IV	Log Forms	Other	SALVAGE		96	QD (D1-4)	QD (D1-4)					1376	1422	1
MMRF_2119	First line of therapy	Lenalidomide		STRIGENT COMPLETE RESPONSE	mg	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					1	165	1
MMRF_2119	First line of therapy	Bortezomib		STRIGENT COMPLETE RESPONSE	mg/m^2	SUBCUTANE	Log Forms	Induction	Induction		1.5	Other	DAY 1, 8, 15					1	165	1
MMRF_2119	First line of therapy	Dexamethasone		STRIGENT COMPLETE RESPONSE	mg	PO	Log Forms	Induction	Induction		40	Other	DAY 1, 8, 15, 22					1	165	1
MMRF_2119	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Unknown	Unknown		20	Other	Q MONDAY AND TUESDAY					191	530	1
MMRF_2119	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Unknown	Unknown		10	QD (D1-21)	QD (D1-21)					191	530	1
MMRF_2119	Second Line Therapy (after first relapse)	Ixazomib		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		4	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					533	654	1
MMRF_2119	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Unknown	Unknown		1.5	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					422	530	1
MMRF_2119	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Unknown	Unknown		10	QD (D1-21)	QD (D1-21)					422	530	1
MMRF_2119	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					533	652	1
MMRF_2119	Third Line Therapy (following 2nd relapse)	Cyclophosphamide		Investigator decision for other reasons	mg	PO	Log Forms	Unknown	Unknown		50	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					653	716	1
MMRF_2119	Third Line Therapy (following 2nd relapse)	Bortezomib		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Unknown	Unknown		1.3	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					653	716	1
MMRF_2119	Third Line Therapy (following 2nd relapse)	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Unknown	Unknown		20	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					653	716	1
MMRF_2119	Third Line Therapy (following 2nd relapse)	Pomalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					736	785	1
MMRF_2119	Third Line Therapy (following 2nd relapse)	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Unknown	Unknown		20	QD (D1-21)	QD (D1-21)					736	770	1
MMRF_2119	Third Line Therapy (following 2nd relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Unknown	Unknown		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					771	925	1
MMRF_2119	Third Line Therapy (following 2nd relapse)	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Unknown	Unknown		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					771	857	1
MMRF_2213	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		300	Other	DAYS 1, 8, 15, 22					1	99	1
MMRF_2213	First line of therapy	Bortezomib		Completed regimen	mg/m^2	SUBCUTANEOUS	Log Forms	Induction	Induction		1.5	Other	DAYS 1, 8, 15, 22					1	99	1
MMRF_2213	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	99	1
MMRF_2213	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		5	Q day	Q day					312	356	1
MMRF_2213	First line of therapy	Bortezomib		Disease progression/Relapse	mg	IV	Log Forms	Maintenance	Maintenance		1.78	Other	QOW					356	1778	1
MMRF_2213	Second Line Therapy (after first relapse)	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					1785	1840	1
MMRF_2213	Second Line Therapy (after first relapse)	Carfilzomib		Adverse Event or co-morbidity	mg	IV	Log Forms	Unknown	Unknown		29.6	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1785	1840	1
MMRF_2213	Second Line Therapy (after first relapse)	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Unknown	Unknown		300	Other	QD 1,8,15					1841	1898	1
MMRF_2213	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Unknown	Unknown		20	Other	QD 1,8,15,22					1841	1898	1
MMRF_2213	Second Line Therapy (after first relapse)	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Unknown	Unknown		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1841	1898	1
MMRF_2213	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		20	Other	QD 1,8,15,22					1785	1840	1
MMRF_2213	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg	IV	Log Forms	Induction	Induction		210	Q day	Q day					1918	1918	1
MMRF_2213	Second Line Therapy (after first relapse)	Ixazomib			mg	PO	Log Forms	Maintenance	Maintenance	Checked	2.3	QD (D1-14)	QD (D1-14)					1928		1
MMRF_2476	First line of therapy	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	10	Other	Q WEDNESDAY AND THURSDAY WITH BREAKFAST					1		1
MMRF_2476	First line of therapy	Lenalidomide			mg	PO	Log Forms	Induction	Induction	Checked	10	QD (D1-21)	QD (D1-21)					29		1
MMRF_2549	First line of therapy	Dexamethasone		Lack of response	mg	PO	Log Forms	Unknown	Unknown		20	Q day	Q day					1	6	1
MMRF_2549	First line of therapy	Dexamethasone		Lack of response	mg	PO	Log Forms	Unknown	Unknown		40	Q week	Q week					7	39	1
MMRF_2549	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Unknown	Unknown		40	Other	TWICE A WEEK					39	285	1
MMRF_2549	First line of therapy	Bortezomib		Investigator decision for other reasons	mg	IV SubQ	Log Forms	Unknown	Unknown		3.08	Other	BI-WEEKLY					40	285	1
MMRF_2549	First line of therapy	Cyclophosphamide		Lack of response	mg	PO	Log Forms	Unknown	Unknown		600	Q week	Q week					292	453	1
MMRF_2549	First line of therapy	Bortezomib		Lack of response	mg	IV	Log Forms	Unknown	Unknown		3.6	Q week	Q week					292	453	1
MMRF_2549	First line of therapy	Dexamethasone		Lack of response	mg	PO	Log Forms	Unknown	Unknown		20	Q week	Q week					292	453	1
MMRF_2549	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		15	Q day	Q day					467	985	1
MMRF_2549	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		20	Other	MONDAY AND TUESDAY WEEKLY					545	985	1
MMRF_2549	Second Line Therapy (after first relapse)	Elotuzumab		Disease progression/Relapse	mg	IV	Log Forms	Unknown	Unknown		1271	Q week	Q week					880	985	1
MMRF_2549	Third Line Therapy (following 2nd relapse)	Daratumumab		Patient decision	mg/kg	IV	Log Forms	Unknown	Unknown		16	QWK	QWK					1020	1101	1
MMRF_2549	Third Line Therapy (following 2nd relapse)	Pomalidomide		Patient decision	mg	PO	Log Forms	Unknown	Unknown		4	Q day	Q day					1020	1101	1
MMRF_2549	Third Line Therapy (following 2nd relapse)	Dexamethasone		Patient decision	mg	PO	Log Forms	Unknown	Unknown		10	Q week	Q week					1020	1101	1
MMRF_1309	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms				10	Q day	Q day					1	3	1
MMRF_1309	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg	IV SubQ	Log Forms				2.6	QWK	QWK					34	97	1
MMRF_1309	Second Line Therapy (after first relapse)	Bortezomib		Adverse Event or co-morbidity	mg	IV SubQ	Log Forms	Maintenance	Maintenance		2.5	Q week	Q week					1663	1768	1
MMRF_1431	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms				25	Q day	Q day					1	1230	1
MMRF_1431	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms				40	QD (D1-4)	QD (D1-4)					1	1230	1
MMRF_1431	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg	IV SubQ	Log Forms	Maintenance	Maintenance		2.6	Q week	Q week					33	837	1
MMRF_2308	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	12	1
MMRF_2308	First line of therapy	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	20	QWK	QWK					1		1
MMRF_2308	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	Other	QOD					13	42	1
MMRF_2308	First line of therapy	Lenalidomide			mg	PO	Log Forms	Induction	Induction	Checked	5	QD (D1-21)	QD (D1-21)					94		1
MMRF_2308	First line of therapy	Bortezomib			mg	IV SubQ	Log Forms	Maintenance	Maintenance	Checked	1.8	Q week	Q week					127		1
MMRF_1077	First line of therapy	Bortezomib		CYCLE ENDED	mg/m^2	IVB	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	11	1
MMRF_1077	First line of therapy	Lenalidomide		CYCLE ENDED	MG	PO	Log Forms				10	Other	DAILY					22	31	1
MMRF_1077	First line of therapy	Dexamethasone		CYCLE ENDED	mg	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	11	1
MMRF_1077	First line of therapy	Bortezomib		CYCLE ENDED	mg/m^2	IVB	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					22	32	1
MMRF_1077	First line of therapy	Dexamethasone		CYCLE ENDED	mg	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					22	32	1
MMRF_1077	First line of therapy	Bortezomib		CYCLE ENDED	mg/m^2	IVB	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					43	71	1
MMRF_1077	First line of therapy	Dexamethasone		CYCLE ENDED	mg	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					43	71	1
MMRF_1077	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms				3510	Q day	Q day					205	205	1
MMRF_1077	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Consolidation	Consolidation		3	Q week	Q week					245	259	1
MMRF_1077	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		4	BID	BID					1429	1540	1
MMRF_1077	First line of therapy	Lenalidomide		Lack of response	MG	PO	Log Forms				10	QD (D1-14)	QD (D1-14)					43	1903	1
MMRF_1078	Second Line Therapy (after first relapse)	Prednisone		Lack of response	mg	PO	Log Forms				20	QID	QID					2290	2301	1
MMRF_1078	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms				4	Other	ONCE					2473	2473	1
MMRF_1078	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms				4	Other	ONCE					2466	2466	1
MMRF_1078	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms				4	Other	ONCE					2445	2445	1
MMRF_1078	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms				4	Other	ONCE					2438	2438	1
MMRF_1078	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms				4	Other	ONCE					2431	2431	1
MMRF_1078	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms				4	Other	ONCE					2403	2403	1
MMRF_1078	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms				4	Other	ONCE					2396	2396	1
MMRF_1078	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms				2000	Q day	Q day					142	142	1
MMRF_1078	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	Other	QD (D1-4, D8-11)					2301	2311	1
MMRF_1078	Second Line Therapy (after first relapse)	Carfilzomib		Completed regimen	mg	IV	Log Forms				60	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					2395	2396	1
MMRF_1078	Second Line Therapy (after first relapse)	Carfilzomib		Completed regimen	mg	IV	Log Forms				60	Other	RECEIVED INFUSIONS 10/3, 10/11, 10/12					2373	2382	1
MMRF_1078	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	Other	QD(D1,D8,D15)					2367	2394	1
MMRF_1078	Second Line Therapy (after first relapse)	Carfilzomib		Completed regimen	mg	IV	Log Forms				44	Q day	Q day					2367	2367	1
MMRF_1078	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	74	1
MMRF_1078	First line of therapy	Lenalidomide		Completed regimen	MG	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	77	1
MMRF_1078	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				20	Other	D1-2, D4-5, D8-9, D11-12					1	75	1
MMRF_1078	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms				406	Q day	Q day					174	174	1
MMRF_1105	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	302	1
MMRF_1105	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	Q week	Q week					1	339	1
MMRF_1105	First line of therapy	Lenalidomide		Completed regimen	MG	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	295	1
MMRF_1105	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms				875	Other	DAYS 1, 8					169	302	1
MMRF_1105	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	Other	EVERYDAY/NO BREAKS					618		1
MMRF_1136	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	85	1
MMRF_1136	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms				20	Other	D1-4, D8-11					1	23	1
MMRF_1136	First line of therapy	Lenalidomide		Completed regimen	MG	PO	Log Forms				10	QD (D1-14)	QD (D1-14)					1	77	1
MMRF_1136	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					23	64	1
MMRF_1136	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms				20	Other	D1-4, D8-11					64	85	1
MMRF_1136	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					85	95	1
MMRF_1136	First line of therapy	CISPLATIN		Completed regimen	mg	IV	Log Forms				10	QD (D1-4)	QD (D1-4)					96	100	1
MMRF_1136	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms				414	QD (D1-4)	QD (D1-4)					96	100	1
MMRF_1136	First line of therapy	ETOPOSIDE		Completed regimen	mg	IV	Log Forms				41	QD (D1-4)	QD (D1-4)					96	100	1
MMRF_1136	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	QD (D1-4)	QD (D1-4)					96	100	1
MMRF_1136	First line of therapy	CISPLATIN		Completed regimen	mg	IV	Log Forms				8	QD (D1-4)	QD (D1-4)					127	131	1
MMRF_1136	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms				610	QD (D1-4)	QD (D1-4)					127	131	1
MMRF_1136	First line of therapy	ETOPOSIDE		Completed regimen	mg	IV	Log Forms				60	QD (D1-4)	QD (D1-4)					127	131	1
MMRF_1136	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms				40	QD (D1-4)	QD (D1-4)					127	130	1
MMRF_1136	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms				6120	Q day	Q day					170	170	1
MMRF_1136	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms				284	Q day	Q day					205	205	1
MMRF_1136	First line of therapy	Carfilzomib		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Induction	Induction		15	Q week	Q week					309	309	1
MMRF_1136	Second Line Therapy (after first relapse)	Cyclophosphamide		Disease progression/Relapse	mg	PO	Log Forms				50	Q day	Q day					366	372	1
MMRF_1136	First line of therapy	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		1	Q day	Q day					342	360	1
MMRF_1136	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		40	QD (D1-7)	QD (D1-7)					342	360	1
MMRF_1148	First line of therapy	Bortezomib		PATIENT DIED	mg/m^2	IVB	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	270	1
MMRF_1148	First line of therapy	Dexamethasone		PATIENT DIED	mg	PO	Log Forms				40	Q week	Q week					6	270	1
MMRF_1148	First line of therapy	Lenalidomide		Lack of response	MG	PO	Log Forms				10	QD (D1-14)	QD (D1-14)					6	227	1
MMRF_1148	Second Line Therapy (after first relapse)	Carfilzomib		PATIENT DIED	mg/m^2	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					227	270	1
MMRF_1189	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IVB	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	11	1
MMRF_1189	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms				15	QD (D1-21)	QD (D1-21)					697	1271	1
MMRF_1189	Third Line Therapy (following 2nd relapse)	Daratumumab		Disease progression/Relapse	mg	IV	Log Forms	Consolidation	Consolidation		1500	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1600	1667	1
MMRF_1189	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms				20	Other	ONCE WEEKLY					1600	1670	1
MMRF_1189	Third Line Therapy (following 2nd relapse)	Bortezomib		Disease progression/Relapse	mg	IV SubQ	Log Forms	Consolidation	Consolidation		2.75	Other	D1, D4, D8, AND D11					1600	1670	1
MMRF_1189	First line of therapy	Melphalan		PRIOR TO TRANSPLANT	mg	IV	Log Forms	Induction	Induction		170	Other	EVERY 30MIN @1068 ML/HR OVER 30MIN					225	225	1
MMRF_1189	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		8	Other	ONCE					1675	1675	1
MMRF_1189	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	QD (D1-4)	QD (D1-4)					1	4	1
MMRF_1189	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				20	Other	QD (D8, D11)					8	11	1
MMRF_1214	First line of therapy	Bortezomib		Lack of response	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	151	1
MMRF_1214	First line of therapy	Lenalidomide		Lack of response	mg	PO	Log Forms				5	Other	QD (D1, D3, D5, D8, D10, D12)					11	18	1
MMRF_1214	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				20	Other	QD (D1-4, D9-12, D17-20)					87	162	1
MMRF_1214	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Induction	Induction		4	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					39	303	1
MMRF_1335	Second Line Therapy (after first relapse)	Cyclophosphamide		DONE IN ATTEMPT TO PROLONG PATIENT SURVIVAL	mg	IV	Log Forms	Maintenance	Maintenance		3740	Q day	Q day					1311	1311	1
MMRF_1335	Second Line Therapy (after first relapse)	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Maintenance	Maintenance		3740	Q day	Q day					781	1311	1
MMRF_1335	Second Line Therapy (after first relapse)	Doxorubicin		Completed regimen	mg	IV	Log Forms	Unknown	Unknown		100.5	Other	ONCE					1202	1202	1
MMRF_1335	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	81	1
MMRF_1335	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				20	Other	D1,2,4,5,8,9,11,12					1	355	1
MMRF_1335	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					22	71	1
MMRF_1335	Second Line Therapy (after first relapse)	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Induction	Induction		3420	Other	ONCE					354	354	1
MMRF_1402	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	Q day	Q day					1	247	1
MMRF_1402	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	Q day	Q day					1	246	1
MMRF_1402	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		2.2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					143	243	1
MMRF_1402	First line of therapy	Cyclophosphamide		Completed regimen	mg	UNKNOWN	Log Forms	Induction	Induction		2445	Other	ONCE					282	282	1
MMRF_1402	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms				318	Q day	Q day					310	310	1
MMRF_1402	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					558	1152	1
MMRF_1560	Second Line Therapy (after first relapse)	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					436		1
MMRF_1560	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg	IV	Log Forms	Induction	Induction		3.1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	25	1
MMRF_1560	First line of therapy	Lenalidomide		Patient decision	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	5	1
MMRF_1560	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	22	1
MMRF_1560	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					44	114	1
MMRF_1560	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					3	5	1
MMRF_1560	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Other	RE-INDUCTION		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					186	264	1
MMRF_1560	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	UNKNOWN	Log Forms	Other	MOBILIZATION		3000	Other	ONCE					291	291	1
MMRF_1560	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					325	325	1
MMRF_1560	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					22	114	1
MMRF_1579	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					1	112	1
MMRF_1579	First line of therapy	Dexamethasone		UNKNOWN	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					1	75	1
MMRF_1579	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		5	Other	QOD (1-21)					89	107	1
MMRF_1579	First line of therapy	Carfilzomib		Disease progression/Relapse	mg	IV	Log Forms	Consolidation	Consolidation		40	Other	DAY 1, DAY 2					981	1807	1
MMRF_1579	First line of therapy	Cyclophosphamide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		600	Other	DAY 1, DAY 15					615	1428	1
MMRF_1579	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		20	Other	DAY 1, DAY 8, DAY 15, DAY 22					973	977	1
MMRF_1579	First line of therapy	Dexamethasone			mg	PO	Log Forms	Consolidation	Consolidation	Checked	4	Other	DAY 2, DAY 9 AND DAY 16					974		1
MMRF_1613	First line of therapy	Bortezomib		RISK FOR RELAPSE.DOES NOT WANT TRANSPLANT, PURSUING MAINTENANCE- REV ONLY.	mg	IVB	Log Forms	Induction	Induction		2.86	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					4	118	1
MMRF_1613	First line of therapy	Dexamethasone		PER TREATING PHYSICIAN  GUIDANCE	mg	PO	Log Forms	Induction	Induction		20	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1	7	1
MMRF_1613	First line of therapy	Lenalidomide		Lack of response	mg	PO	Log Forms	Unknown	Unknown		5	QD (D1-21)	QD (D1-21)					396	467	1
MMRF_1613	First line of therapy	Dexamethasone		Patient decision	mg	PO	Log Forms	Unknown	Unknown		40	QWK	QWK					492	522	1
MMRF_1613	Third Line Therapy (following 2nd relapse)	Daratumumab		Patient decision	mg	IV	Log Forms	Unknown	Unknown		1500	Other	Q WK EXCEPT WHEN HELD					799	1254	1
MMRF_1613	Sixth Line Therapy (following 5th relapse)	Elotuzumab		Patient decision	mg	IV	Log Forms	Unknown	Unknown		800	Other	EVERY 2 WEEKS					1261	1282	1
MMRF_1613	First line of therapy	Dexamethasone		Patient decision	mg	PO	Log Forms	Unknown	Unknown		20	QWK	QWK					520	539	1
MMRF_1613	Second Line Therapy (after first relapse)	Dexamethasone		Patient decision	mg	PO	Log Forms	Unknown	Unknown		10	Q week	Q week					684	695	1
MMRF_1613	Second Line Therapy (after first relapse)	Dexamethasone		Patient decision	mg	PO	Log Forms	Unknown	Unknown		20	QWK	QWK					695	799	1
MMRF_1613	Third Line Therapy (following 2nd relapse)	Dexamethasone		Patient decision	mg	PO	Log Forms	Unknown	Unknown		4	Other	TWICE WEEKLY					800	1008	1
MMRF_1613	Third Line Therapy (following 2nd relapse)	Dexamethasone		Patient decision	mg	PO	Log Forms	Unknown	Unknown		40	Q day	Q day					878	882	1
MMRF_1613	Third Line Therapy (following 2nd relapse)	Dexamethasone		Patient decision	mg	PO	Log Forms	Unknown	Unknown		20	QWK	QWK					883	1004	1
MMRF_1613	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Patient decision	mg	PO	Log Forms	Unknown	Unknown		12	QWK	QWK					1008	1129	1
MMRF_1613	Fifth Line Therapy (following 4th relapse)	Dexamethasone		Patient decision	mg	PO	Log Forms	Unknown	Unknown		28	QWK	QWK					1226	1283	1
MMRF_1613	First line of therapy	Lenalidomide		Lack of response	mg	PO	Log Forms	Consolidation	Consolidation		10	QD (D1-21)	QD (D1-21)					468	694	1
MMRF_1613	Second Line Therapy (after first relapse)	Lenalidomide		Lack of response	mg	PO	Log Forms	Consolidation	Consolidation		15	QD (D1-21)	QD (D1-21)					695	799	1
MMRF_1613	First line of therapy	Dexamethasone		PER TREATING PHYSICIAN GUIDANCE	mg	PO	Log Forms	Induction	Induction		40	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					8	43	1
MMRF_1613	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	TWICE WEEKLY					44	118	1
MMRF_1761	First line of therapy	Bortezomib		Investigator decision for other reasons	mg	IV SubQ	Log Forms	Induction	Induction		2.9	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	990	1
MMRF_1761	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Unknown	Unknown		15	QID	QID					231	568	1
MMRF_1761	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	IV	Log Forms	Maintenance	Maintenance		20	BID	BID					231	260	1
MMRF_1761	Second Line Therapy (after first relapse)	Lenalidomide		Patient decision	mg	PO	Log Forms	Unknown	Unknown		5	Other	THREE TIMES WEEKLY					1822	1840	1
MMRF_1761	Second Line Therapy (after first relapse)	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Unknown	Unknown		20	Q week	Q week					1450	1822	1
MMRF_1761	Second Line Therapy (after first relapse)	Lenalidomide		Completed regimen	mg	PO	Log Forms	Unknown	Unknown		15	Q day	Q day					1184	1205	1
MMRF_1761	Second Line Therapy (after first relapse)	Ixazomib			mg	PO	Log Forms	Unknown	Unknown	Checked	4	Q week	Q week					1155		1
MMRF_1890	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg	IV	Log Forms	Induction	Induction		2.4	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	100	1
MMRF_1890	Second Line Therapy (after first relapse)	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Unknown	Unknown		5880	Other	ONCE					121	121	1
MMRF_1890	Second Line Therapy (after first relapse)	MESNA		Completed regimen	mg	IV	Log Forms	Unknown	Unknown		1176	BID	BID					121	122	1
MMRF_1890	Second Line Therapy (after first relapse)	Dexamethasone		Lack of response	mg	PO	Log Forms	Unknown	Unknown		40	Other	EVERY DAY EXCEPT FOR A BREAK FROM 8.24-8.27.2014					119	133	1
MMRF_2183	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg	IV	Log Forms	Induction	Induction		1.3	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					2	103	1
MMRF_2183	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	Q day	Q day					1	103	1
MMRF_2183	First line of therapy	Lenalidomide		Patient decision	mg	PO	Log Forms	Induction	Induction		5	Other	21/28D					121	336	1
MMRF_2246	First line of therapy	Lenalidomide		UNKNOWN	mg	PO	Log Forms	Induction	Induction		25	Q day	Q day					23	219	1
MMRF_2246	First line of therapy	Dexamethasone		UNKNOWN	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	158	1
MMRF_2246		Dexamethasone		Completed regimen	mg	PO	Log Forms				8	Other	ONCE					1900	1900	1
MMRF_2246	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				8	Other	ONCE					1866	1866	1
MMRF_2246	First line of therapy	Prednisone		Patient decision	mg	PO	Log Forms	Unknown	Unknown		20	Q day	Q day					345	478	1
MMRF_2246	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				15	Q day	Q day					183	231	1
MMRF_2246	First line of therapy	Dexamethasone		Patient decision	mg	PO	Log Forms				4	Q week	Q week					141	262	1
MMRF_2246		Bortezomib					Log Forms			Checked								1866		1
MMRF_2246		Daratumumab					Log Forms			Checked								2006		1
MMRF_2477	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	Q day	Q day					1	71	1
MMRF_2477	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg	IV SubQ	Log Forms	Induction	Induction		2.4	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					8	71	1
MMRF_2477	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		25	Q day	Q day					40	57	1
MMRF_2477	Second Line Therapy (after first relapse)	Ixazomib		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		3	Other	D1, 8, 15 OF 28 D CYCLE					382	483	1
MMRF_1163	First line of therapy	Bortezomib		Disease progression/Relapse	mg	IV SubQ	Log Forms				2.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					3	136	1
MMRF_1163	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms				40	QWK	QWK					3	136	1
MMRF_1163	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms				25	Other	QD X 14 DAYS EVERY 21 DAYS					1	136	1
MMRF_1163	Second Line Therapy (after first relapse)	Carfilzomib			mg	IV	Log Forms			Checked	40	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					150		1
MMRF_1182	First line of therapy	Bortezomib		CHANGE IN DOSAGE	mg	IV	Log Forms	Induction	Induction		2.4	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	11	1
MMRF_1182	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	234	1
MMRF_1182	First line of therapy	Bortezomib		Completed regimen	mg	IV	Log Forms	Induction	Induction		2.5	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					25	234	1
MMRF_1182	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	QD (D1,D2, D4, D5, D8, D9, D11, D12					1	234	1
MMRF_1182	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					264	433	1
MMRF_1182	First line of therapy	Lenalidomide		Patient decision	mg	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					433	644	1
MMRF_1182	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Other	ONCE					131	131	1
MMRF_1186	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	234	1
MMRF_1186	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	Other	QD (D1-4, 9-12, 17-20)					1	215	1
MMRF_1186	Second Line Therapy (after first relapse)	Lenalidomide		PATIENT DEATH	mg	PO	Log Forms	Unknown	Unknown		10	Q day	Q day					1264	1850	1
MMRF_1186	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					312	979	1
MMRF_1201	Sixth Line Therapy (following 5th relapse)	Dexamethasone		AWAITING CLINICAL TRIAL SLOT	mg	PO	Log Forms	Other	BRIDGING		16	Other	QD X3-4 (PATIENT TOOK AT HOME, UNSURE IF TOOK FOR 3 OR 4 DAYS TOTAL)					2128	2131	1
MMRF_1201	Sixth Line Therapy (following 5th relapse)	Daratumumab		Completed regimen	mg/kg	IV	Log Forms	Other	BRIDGING		16	QWK	QWK					2233	2252	1
MMRF_1201	Sixth Line Therapy (following 5th relapse)	Pomalidomide		Completed regimen	mg	PO	Log Forms	Other	BRIDGING		4	QD (D1-21)	QD (D1-21)					2233	2252	1
MMRF_1201	Sixth Line Therapy (following 5th relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Other	BRIDGING		20	Q week	Q week					2233	2252	1
MMRF_1201	Sixth Line Therapy (following 5th relapse)	FLUDARABINE		Completed regimen	mg/m^2	IV	Log Forms	Other	CAR-T		24	Other	QD X3					2275	2277	1
MMRF_1201	Seventh Line of Therapy (following 6th relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Other	SALVAGE		16	QWK	QWK					2410	2472	1
MMRF_1201	Seventh Line of Therapy (following 6th relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		4	QD (D1-21)	QD (D1-21)					2410	2472	1
MMRF_1201	Seventh Line of Therapy (following 6th relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		4	Other	ON DAY 2 AND 3 AFTER EACH DARA					2410	2472	1
MMRF_1201	Eighth Line of Therapy (following 7th relapse)	Cyclophosphamide		STARTING CLINICAL TRIAL	mg	PO	Log Forms	Other	BRIDGING		300	Other	Q WEEK					2486	2500	1
MMRF_1201	Eighth Line of Therapy (following 7th relapse)	Carfilzomib		STARTING CLINICAL TRIAL	mg/m^2	IV	Log Forms	Other	BRIDGING		20	Q week	Q week					2486	2500	1
MMRF_1201	Eighth Line of Therapy (following 7th relapse)	Dexamethasone		STARTING CLINICAL TRIAL	mg	PO	Log Forms	Other	BRIDGING		20	Q week	Q week					2486	2500	1
MMRF_1201	Eighth Line of Therapy (following 7th relapse)	CYCLOPHOSPHAMIDE		Completed regimen	mg/m^2	IV	Log Forms	Other	CAR-T		300	Other	QD X3					2549	2551	1
MMRF_1201	Fifth Line Therapy (following 4th relapse)	Bendamustine		Disease progression/Relapse	mg/m^2	IV	Log Forms	Other	SALVAGE		80	Other	DAY 1, 2					1848	2128	1
MMRF_1201	Fifth Line Therapy (following 4th relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		2	QD (D1-21)	QD (D1-21)					1848	2128	1
MMRF_1201	Fifth Line Therapy (following 4th relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		20	Other	DAY 1, 8, 15, 22					1848	2128	1
MMRF_1201	Eighth Line of Therapy (following 7th relapse)	FLUDARABINE		Completed regimen	mg/m^2	IV	Log Forms	Other	CAR-T		75	Other	QD X3					2549	2551	1
MMRF_1201	Sixth Line Therapy (following 5th relapse)	Bendamustine		AWAITING CLINICAL TRIAL SLOT	mg/m^2	IV	Log Forms	Other	BRIDGING		80	Other	QD X2					2128	2129	1
MMRF_1201	Sixth Line Therapy (following 5th relapse)	CYTOXAN		Completed regimen	mg/m^2	IV	Log Forms	Other	CAR-T		300	Other	QD X3					2275	2277	1
MMRF_1201	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Other	ONCE					195	197	1
MMRF_1201	Second Line Therapy (after first relapse)	Dexamethasone		Lack of response	mg	PO	Log Forms	Other	SALVAGE		40	Q week	Q week					790	923	1
MMRF_1201	Second Line Therapy (after first relapse)	Cyclophosphamide		Lack of response	mg	PO	Log Forms	Other	SALVAGE		450	Q week	Q week					790	923	1
MMRF_1201	Third Line Therapy (following 2nd relapse)	CB-5083		Lack of response	mg	PO	Log Forms	Other	SALVAGE		200	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1007	1034	1
MMRF_1201	Third Line Therapy (following 2nd relapse)	Panobinostat		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		20	Other	DAYS 1, 3, 5, 8, 10, 12, 15, 17, 19					1034	1356	1
MMRF_1201	Third Line Therapy (following 2nd relapse)	Carfilzomib		Disease progression/Relapse	mg	IV	Log Forms	Other	SALVAGE		59	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1034	1356	1
MMRF_1201	Fourth Line Therapy (following 3rd relapse)	CC-90002		Lack of response	mg	IV	Log Forms	Other	SALVAGE		116	Other	D 1, 15					1392	1422	1
MMRF_1201	Fourth Line Therapy (following 3rd relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Other	SALVAGE		16	Q week	Q week					1430	1728	1
MMRF_1201	Fourth Line Therapy (following 3rd relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		15	QD (D1-21)	QD (D1-21)					1430	1729	1
MMRF_1201	Fifth Line Therapy (following 4th relapse)	Bortezomib		Lack of response	mg/m^2	IV SubQ	Log Forms	Other	SALVAGE		1.3	Q week	Q week					1731	1773	1
MMRF_1201	Fifth Line Therapy (following 4th relapse)	Dexamethasone		Lack of response	mg	PO	Log Forms	Other	SALVAGE		20	Q week	Q week					1731	1773	1
MMRF_1201	Fifth Line Therapy (following 4th relapse)	VENETOCLAX		Lack of response	mg	PO	Log Forms	Other	SALVAGE		600	Q day	Q day					1731	1773	1
MMRF_1201	Fifth Line Therapy (following 4th relapse)	Pomalidomide		Lack of response	mg	PO	Log Forms	Other	SALVAGE		2	QD (D1-21)	QD (D1-21)					1783	1835	1
MMRF_1201	Fifth Line Therapy (following 4th relapse)	Cyclophosphamide		Lack of response	mg	PO	Log Forms	Other	SALVAGE		400	Other	D 1-2					1783	1835	1
MMRF_1201	Fifth Line Therapy (following 4th relapse)	Dexamethasone		Lack of response	mg	PO	Log Forms	Other	SALVAGE		20	Other	D 1, 8, 15, 22					1783	1835	1
MMRF_1201	First line of therapy	Bortezomib		INVESTIGATOR CHANGE IN FREQUENCY	mg/m^2	IV SubQ	Log Forms	Induction	Induction		2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	63	1
MMRF_1201	First line of therapy	Lenalidomide		INVESTIGATOR CHANGE IN FREQUENCY	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	63	1
MMRF_1201	First line of therapy	Dexamethasone		INVESTIGATOR CHANGED DOSAGE	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	31	1
MMRF_1201	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		2	Q week	Q week					71	148	1
MMRF_1201	First line of therapy	Dexamethasone		INVESTIGATOR CHANGE IN FREQUENCY	mg	PO	Log Forms	Induction	Induction		20	QD (D1-4)	QD (D1-4)					50	54	1
MMRF_1201	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					71	196	1
MMRF_1201	First line of therapy	Lenalidomide		DOSAGE CHANGED, SUBJECT ON MAINTENANCE REV	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					71	148	1
MMRF_1201	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					436	513	1
MMRF_1201	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					643	789	1
MMRF_1201	Second Line Therapy (after first relapse)	Bortezomib		Lack of response	mg	IV SubQ	Log Forms	Other	SALVAGE		2.1	Q week	Q week					790	923	1
MMRF_1202	Second Line Therapy (after first relapse)	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					697	810	1
MMRF_1202	Second Line Therapy (after first relapse)	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		20	Other	TWICE WEEKLY					697	810	1
MMRF_1202	First line of therapy	Melphalan		Completed regimen	UNK	UNK	Log Forms	Other	ASCT		0	Other	UNK					312	312	1
MMRF_1202	Third Line Therapy (following 2nd relapse)	Carfilzomib		Lack of response	mg	IV	Log Forms	Consolidation	Consolidation		60	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					872	890	1
MMRF_1202	Third Line Therapy (following 2nd relapse)	Dexamethasone		Lack of response	mg	PO	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					872	890	1
MMRF_1202	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	227	1
MMRF_1202	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	227	1
MMRF_1202	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					152	227	1
MMRF_1202	Second Line Therapy (after first relapse)	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					697	810	1
MMRF_1210	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		2.9	Q week	Q week					1	156	1
MMRF_1210	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	123	1
MMRF_1210	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1	156	1
MMRF_1210	First line of therapy	Bortezomib		Completed regimen	mg	IV	Log Forms	Induction	Induction		2.9	QWK	QWK					171	292	1
MMRF_1210	Second Line Therapy (after first relapse)	Lenalidomide		STARTING ASCT	mg	PO	Log Forms	Other	SALVAGE		10	QD (D1-21)	QD (D1-21)					1503	1681	1
MMRF_1210	Second Line Therapy (after first relapse)	Carfilzomib		STARTING ASCT	mg/m^2	IV	Log Forms	Other	SALVAGE		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1503	1681	1
MMRF_1210	First line of therapy	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	EVERY OTHER WEEK					503	1495	1
MMRF_1210	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					503	1495	1
MMRF_1210	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		12	Q week	Q week					1055	1495	1
MMRF_1210	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					171	292	1
MMRF_1210	Second Line Therapy (after first relapse)	Carfilzomib			mg/m^2	IV	Log Forms	Maintenance	Maintenance	Checked	27	Other	DAYS 1, 2, 15, 16					1819		1
MMRF_1210	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	Other	DAYS 1, 2, 15, 16					1819		1
MMRF_1210	Second Line Therapy (after first relapse)	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					1819		1
MMRF_1210	Second Line Therapy (after first relapse)	Dexamethasone		STARTING ASCT	mg	PO	Log Forms	Other	SALVAGE		10	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1503	1681	1
MMRF_1210	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Other	ONCE					1679	1679	1
MMRF_1293	Fourth Line Therapy (following 3rd relapse)	FLUDARABINE	NCT03601078	Completed regimen	mg	IV	Log Forms	Other	CAR-T		60	Q day	Q day					2527	2529	1
MMRF_1293	Fourth Line Therapy (following 3rd relapse)	CYTOXAN	NCT03601078	Completed regimen	mg	IV	Log Forms	Other	CAR-T		600	Q day	Q day					2527	2529	1
MMRF_1293	Second Line Therapy (after first relapse)	BIAXIN		Lack of response	mg	PO	Log Forms	Other	SALVAGE		250	Q day	Q day					1100	1163	1
MMRF_1293	Second Line Therapy (after first relapse)	Carfilzomib		Lack of response	mg/m^2	IV	Log Forms	Other	SALVAGE		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1184	1226	1
MMRF_1293	Second Line Therapy (after first relapse)	Dexamethasone		Lack of response	mg	PO	Log Forms	Other	SALVAGE		8	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1184	1226	1
MMRF_1293	Second Line Therapy (after first relapse)	Cyclophosphamide		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		400	Other	WEEKLY, 3/4 WEEKS					1245	2383	1
MMRF_1293	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		8	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1245	1288	1
MMRF_1293	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		12	Q week	Q week					1100	1163	1
MMRF_1293	Third Line Therapy (following 2nd relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Other	SALVAGE		16	QWK	QWK					1450	2451	1
MMRF_1293	Third Line Therapy (following 2nd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		2	QD (D1-21)	QD (D1-21)					1450	2451	1
MMRF_1293	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		3	Q week	Q week					1	432	1
MMRF_1293	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	432	1
MMRF_1293	First line of therapy	Lenalidomide		INVESTIGATOR CHANGED DOSAGE	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	21	1
MMRF_1293	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					32	432	1
MMRF_1293	Second Line Therapy (after first relapse)	Lenalidomide		Lack of response	mg	PO	Log Forms	Other	SALVAGE		10	QID	QID					916	1163	1
MMRF_1293	Second Line Therapy (after first relapse)	Dexamethasone		Lack of response	mg	PO	Log Forms	Other	SALVAGE		12	Q week	Q week					916	1163	1
MMRF_1293	Third Line Therapy (following 2nd relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		25	QD (D1-14)	QD (D1-14)					1320	1398	1
MMRF_1293	Third Line Therapy (following 2nd relapse)	ATEZOLIZUMAB		Disease progression/Relapse	mg	IV	Log Forms	Other	SALVAGE		1200	Other	ONCE EVERY 3 WEEKS					1320	1398	1
MMRF_1293	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Other	ONCE					258	258	1
MMRF_1320	First line of therapy	Bortezomib		Completed regimen	mg	IV	Log Forms	Induction	Induction		2.6	Q week	Q week					2	46	1
MMRF_1320	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	D1-3, 8-11, 15-18					1	46	1
MMRF_1320	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Induction	Induction		700	QD (D1-4)	QD (D1-4)					2	46	1
MMRF_1320	First line of therapy	Bortezomib		Disease progression/Relapse	mg	IV	Log Forms	Maintenance	Maintenance		3	Other	EVERY OTHER WEEK					337	1073	1
MMRF_1320	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					337	1073	1
MMRF_1320	Second Line Therapy (after first relapse)	Carfilzomib		Disease progression/Relapse	mg	IV	Log Forms	Other	SALVAGE		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1149	2123	1
MMRF_1320	Second Line Therapy (after first relapse)	Cyclophosphamide		Disease progression/Relapse	mg/m^2	IV	Log Forms	Other	SALVAGE		300	Other	WEEKLY, 3 OUT OF  4 WEEKS					1149	2123	1
MMRF_1320	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Other	SALVAGE		10	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1149	2123	1
MMRF_1320	Third Line Therapy (following 2nd relapse)	Daratumumab		Disease progression/Relapse	mg	IV	Log Forms	Other	SALVAGE		1000	Other	EVERY OTHER WEEK					2123	2675	1
MMRF_1320	Third Line Therapy (following 2nd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		3	QD (D1-21)	QD (D1-21)					2123	2698	1
MMRF_1320	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		2	Other	EVERY OTHER WEEK (AS DARA PRE-MED)					2123	2724	1
MMRF_1320	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					46	337	1
MMRF_1320	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.5	Other	WEEKLY, 3/4 WEEKS					46	337	1
MMRF_1320	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	WEEKLY, 3/4 WEEKS					46	337	1
MMRF_1320	Fourth Line Therapy (following 3rd relapse)	FOR46	NCT03650491		mg/kg	IV	Log Forms	Other	SALVAGE	Checked	2.2	Other	EVERY 21 DAYS					2724		1
MMRF_1320	Fourth Line Therapy (following 3rd relapse)	Dexamethasone			mg	PO	Log Forms	Other	SALVAGE	Checked	10	Other	EVERY 21 DAYS AS PREMED TO FOR46					2724		1
MMRF_1300	Fifth Line Therapy (following 4th relapse)	Bortezomib		Disease progression/Relapse	mg	IV SubQ	Log Forms	Other	SALVAGE		3.5	Other	ONCE EVERY OTHER WEEK					1484	1801	1
MMRF_1300	Sixth Line Therapy (following 5th relapse)	Cyclophosphamide		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		400	Other	DAY 1, 8, 15					1801	2386	1
MMRF_1300	Sixth Line Therapy (following 5th relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		2	QD (D1-21)	QD (D1-21)					1801	2386	1
MMRF_1300	Sixth Line Therapy (following 5th relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		20	Other	DAYS 1, 8, 15					1801	2386	1
MMRF_1300	Seventh Line of Therapy (following 6th relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Other	SALVAGE		20	Other	DAYS 1, 8, 15					2386	2569	1
MMRF_1300	Seventh Line of Therapy (following 6th relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		10	Other	DAYS 1, 8, 15					2386	2569	1
MMRF_1300	Eighth Line of Therapy (following 7th relapse)	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		350	Other	Q12H ON DAYS 1-3 X 2 CYCLES					2582	2612	1
MMRF_1300	Eighth Line of Therapy (following 7th relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	DAYS 1-4, 8-11, AND 15-18 FOR CYCLE 1; DAYS 1-4 AND 8-11 FOR CYCLE 2					2582	2620	1
MMRF_1300	Eighth Line of Therapy (following 7th relapse)	Melphalan		Completed regimen	mg	IV	Log Forms	Consolidation	Consolidation		294	Q day	Q day					2647	2647	1
MMRF_1300	Fifth Line Therapy (following 4th relapse)	Daratumumab		Disease progression/Relapse	mg	IV	Log Forms	Other	SALVAGE		800	Other	EVERY OTHER WEEK					1484	1801	1
MMRF_1300	Second Line Therapy (after first relapse)	BIAXIN		Completed regimen	mg	PO	Log Forms	Other	SALVAGE		500	Other	Q12H					490	727	1
MMRF_1300	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		20	QWK	QWK					1141	1484	1
MMRF_1300	Fourth Line Therapy (following 3rd relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		15	QD (D1-21)	QD (D1-21)					1141	1484	1
MMRF_1300	Fourth Line Therapy (following 3rd relapse)	BIAXIN		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		500	BID	BID					1141	1484	1
MMRF_1300	Fourth Line Therapy (following 3rd relapse)	Bortezomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Other	SALVAGE		1.3	Other	QD (DAYS 1, 8, AND 15)					1141	1484	1
MMRF_1300	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Other	SALVAGE		20	QWK	QWK					1063	1097	1
MMRF_1300	Fourth Line Therapy (following 3rd relapse)	Cyclophosphamide		Investigator decision for other reasons	mg	IV	Log Forms	Other	SALVAGE		200	QWK	QWK					1063	1097	1
MMRF_1300	Fourth Line Therapy (following 3rd relapse)	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms	Other	SALVAGE		1.3	QWK	QWK					1063	1097	1
MMRF_1300	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					1	154	1
MMRF_1300	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	QD (D1-21)	QD (D1-21)					1	154	1
MMRF_1300	First line of therapy	BIAXIN (BIRD REGIMEN FOR A FEW MONTHS THEN RVD ONLY)		Completed regimen	mg	PO	Log Forms	Induction	Induction		500	QID	QID					1	154	1
MMRF_1300	First line of therapy	Bortezomib		Lack of response	mg/m^2	IV	Log Forms	Induction	Induction		1.3	Other	SQ WK					154	207	1
MMRF_1300	First line of therapy	Bortezomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Maintenance	Maintenance		1.3	Other	SQ WK					207	490	1
MMRF_1300	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		20	Other	SQ WK					207	490	1
MMRF_1300	Second Line Therapy (after first relapse)	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Other	SALVAGE		1.3	Other	EVERY 7 (SEVEN) DAYS. 3 OUT OF 4 WEEKS					490	727	1
MMRF_1300	Second Line Therapy (after first relapse)	Lenalidomide		Completed regimen	mg	PO	Log Forms	Other	SALVAGE		25	QD (D1-21)	QD (D1-21)					490	727	1
MMRF_1300	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Other	SALVAGE		20	Other	EVERY 7 (SEVEN) DAYS. 3 OUT OF 4 WEEKS					490	727	1
MMRF_1300	Third Line Therapy (following 2nd relapse)	Lenalidomide		Lack of response	mg	PO	Log Forms	Other	SALVAGE		15	QD (D1-21)	QD (D1-21)					910	1479	1
MMRF_1300	Third Line Therapy (following 2nd relapse)	Bortezomib		Lack of response	mg/m^2	IV SubQ	Log Forms	Other	SALVAGE		1.3	Other	QD (D1, 8 & 15)					910	1479	1
MMRF_1300	Third Line Therapy (following 2nd relapse)	Dexamethasone		Lack of response	mg	PO	Log Forms	Other	SALVAGE		20	Other	QD (D1, 8 & 15)					910	1479	1
MMRF_1300	Eighth Line of Therapy (following 7th relapse)	Ixazomib			mg	PO	Log Forms	Maintenance	Maintenance	Checked	3	Other	WEEKLY FOR 3/4 WEEKS					2839		1
MMRF_1338	First line of therapy	Dexamethasone		MD ORDER	mg	PO	Log Forms				40	Q day	Q day					1	4	1
MMRF_1338	First line of therapy	Dexamethasone		MD ORDER	mg	PO	Log Forms				40	Q day	Q day					9	12	1
MMRF_1338	First line of therapy	Lenalidomide		ALLERGIC REACTION, RASH CHANGED TO QOD INSTEAD	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					15	22	1
MMRF_1338	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms				25	Other	QOD NO BREAK 14/28 DAYS					22	852	1
MMRF_1338	First line of therapy	Bortezomib		Disease progression/Relapse	mg	IV SubQ	Log Forms				1.3	Q week	Q week					15	852	1
MMRF_1338	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms				40	Q week	Q week					15	852	1
MMRF_1375	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		2.8	Q week	Q week					21	181	1
MMRF_1375	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	BID	BID					1	181	1
MMRF_1375	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	Q day	Q day					41	181	1
MMRF_1375	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					360	1218	1
MMRF_1375	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					181	181	1
MMRF_1490	Third Line Therapy (following 2nd relapse)	Carfilzomib		MARROW WITHOUT MYELOMA; TREATMENT NOT NEEDED PER PRIMARY ONCOLOGIST	mg/m^2	IV	Log Forms	Other	SALVAGE		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					2675	2717	1
MMRF_1490	Second Line Therapy (after first relapse)	Dexamethasone		PRESUMED PROGRESSION, (PATIENT DID NOT END UP HAVING PD)	mg	PO	Log Forms	Other	SALVAGE		20	QWK	QWK					2003	2652	1
MMRF_1490	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	483	1
MMRF_1490	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.6	QWK	QWK					1	325	1
MMRF_1490	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	7	1
MMRF_1490	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					15	1331	1
MMRF_1490	Second Line Therapy (after first relapse)	Pomalidomide		PRESUMED PROGRESSION, (PATIENT DID NOT END UP HAVING PD)	mg	PO	Log Forms	Other	SALVAGE		4	QD (D1-21)	QD (D1-21)					514	2652	1
MMRF_1518	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	74	1
MMRF_1518	First line of therapy	Bortezomib			mg/m^2	IV SubQ	Log Forms	Induction	Induction	Checked	2.7	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_1518	First line of therapy	Dexamethasone		DOSE CHANGE	mg	PO	Log Forms	Induction	Induction		20	Other	D1,2, 4,5, 8,9, 11,12					1	98	1
MMRF_1518	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Induction	Induction		730	Q day	Q day					98	135	1
MMRF_1518	First line of therapy	Doxorubicin		Completed regimen	mg	IV	Log Forms	Induction	Induction		20	Q day	Q day					98	135	1
MMRF_1518	First line of therapy	Dexamethasone		CHANGE IN DOSE	mg	PO	Log Forms	Induction	Induction		40	Q day	Q day					98	135	1
MMRF_1518	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Consolidation	Consolidation		340	Q day	Q day					155	155	1
MMRF_1518	Second Line Therapy (after first relapse)	Pomalidomide		PATIENT DEATH	mg	PO	Log Forms	Consolidation	Consolidation		4	QD (D1-21)	QD (D1-21)					221	240	1
MMRF_1518	Second Line Therapy (after first relapse)	Carfilzomib		PATIENT DEATH	mg	IV SubQ	Log Forms	Consolidation	Consolidation		20	Other	QD 1 AND 2 AND THEN 27MG /M2					221	240	1
MMRF_1518	Second Line Therapy (after first relapse)	Dexamethasone		PATIENT DEATH	mg	PO	Log Forms	Induction	Induction		20	Other	ON DAYS OF CARFILZOMIB					221	240	1
MMRF_1772	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		25	Q day	Q day					1	65	1
MMRF_1772	First line of therapy	Bortezomib		Disease progression/Relapse	mg	IV SubQ	Log Forms	Induction	Induction		2.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	65	1
MMRF_1772	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	1157	1
MMRF_1772	First line of therapy	Carfilzomib		Disease progression/Relapse	mg	IV	Log Forms	Maintenance	Maintenance		43	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					73	1157	1
MMRF_1772	First line of therapy	Cyclophosphamide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		650	Q day	Q day					73	1157	1
MMRF_1772	Second Line Therapy (after first relapse)	Ixazomib			mg	PO	Log Forms	Other	SALVAGE	Checked	4	Q week	Q week					1256		1
MMRF_1772	Second Line Therapy (after first relapse)	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	SALVAGE		2	QD (D1-21)	QD (D1-21)					1256	1312	1
MMRF_1772	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Other	SALVAGE	Checked	20	Q week	Q week					1256		1
MMRF_1772	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					208	208	1
MMRF_1772	Second Line Therapy (after first relapse)	Lenalidomide			mg	PO	Log Forms	Other	SALVAGE	Checked	2	QD (D1-21)	QD (D1-21)					1312		1
MMRF_1952	First line of therapy	Bortezomib		Patient decision	mg/m^2	IV SubQ	Log Forms	Induction	Induction		2.7	Q week	Q week					1	309	1
MMRF_1952	First line of therapy	Cyclophosphamide		Patient decision	mg	IV SubQ	Log Forms	Induction	Induction		540	Q week	Q week					1	309	1
MMRF_1952	First line of therapy	Dexamethasone		Patient decision	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	309	1
MMRF_1952	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		25	Other	EVERY OTHER DAY					320	1580	1
MMRF_1952	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		8	Other	D 1, 7, 14					320	1600	1
MMRF_1952	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Other	SALVAGE	Checked	4	Other	TWICE A WEEK					1600		1
MMRF_1952	Second Line Therapy (after first relapse)	Pomalidomide			mg	PO	Log Forms	Other	SALVAGE	Checked	3	QD (D1-21)	QD (D1-21)					1600		1
MMRF_1952	Second Line Therapy (after first relapse)	Daratumumab			mg/kg	IV	Log Forms	Other	SALVAGE	Checked	16	Q week	Q week					1593		1
MMRF_1952	First line of therapy	BIAXIN		Lack of response	mg	PO	Log Forms	Induction	Induction		250	Q day	Q day					1188	1244	1
MMRF_1983	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	316	1
MMRF_1983	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	316	1
MMRF_1983	Second Line Therapy (after first relapse)	Daratumumab			mg/kg	IV	Log Forms	Unknown	Unknown	Checked	16	Other	WEEKLY X8, THEN Q 2 WEEKS X8, THEN Q 4 WEEKS					1230		1
MMRF_1983	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Unknown	Unknown	Checked	20	Q week	Q week					1230		1
MMRF_1983	Second Line Therapy (after first relapse)	Lenalidomide			mg	PO	Log Forms	Unknown	Unknown	Checked	25	Other	DAILY, DAYS 1-21/28					1230		1
MMRF_1991	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		25	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	20	1
MMRF_1991	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		2.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	9	1
MMRF_1991	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1-21)	QD (D1-21)					1	9	1
MMRF_1991	Second Line Therapy (after first relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms	Other	SALVAGE		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					516	822	1
MMRF_1991	Second Line Therapy (after first relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		2	QD (D1-21)	QD (D1-21)					516	822	1
MMRF_1991	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	SALVAGE		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					516	822	1
MMRF_1991	Third Line Therapy (following 2nd relapse)	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Other	SALVAGE		350	Other	D 1-4					828	871	1
MMRF_1991	Third Line Therapy (following 2nd relapse)	MESNA		Disease progression/Relapse	mg/m^2	IV	Log Forms	Other	SALVAGE		700	QD (D1-4)	QD (D1-4)					828	871	1
MMRF_1991	Third Line Therapy (following 2nd relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Other	SALVAGE		40	Other	D 1-4, 15-18					828	871	1
MMRF_1991	Third Line Therapy (following 2nd relapse)	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Other	SALVAGE		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					828	871	1
MMRF_1991	Third Line Therapy (following 2nd relapse)	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	SALVAGE		4	Q day	Q day					876	1457	1
MMRF_1991	Third Line Therapy (following 2nd relapse)	Daratumumab			mg/kg	IV	Log Forms	Other	SALVAGE	Checked	16	Q week	Q week					876		1
MMRF_1991	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO/IV	Log Forms	Maintenance	Maintenance			Other	WEEKLY, 3/4 WEEKS (ON DAYS OF VELCADE)					260	507	1
MMRF_1991	First line of therapy	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	WEEKLY FOR 3/4 WEEKS					260	507	1
MMRF_1991	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					119	119	1
MMRF_2097	First line of therapy	Cyclophosphamide		Lack of response	mg	PO	Log Forms	Induction	Induction		600	Q week	Q week					1	162	1
MMRF_2097	First line of therapy	Bortezomib		Investigator decision for other reasons	mg	IV SubQ	Log Forms	Induction	Induction		2.6	Q week	Q week					7	311	1
MMRF_2097	First line of therapy	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					7		1
MMRF_2097	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					162	1373	1
MMRF_2097	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					1360	1360	1
MMRF_2367	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		3	Other	WEEKLY 3 OUT OF 4 WEEKS					1	612	1
MMRF_2367	First line of therapy	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Induction	Induction		800	Other	WEEKLY 3 OUT OF 4 WEEKS					1	246	1
MMRF_2367	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	WEEKLY 3 OUT OF 4 WEEKS					1	581	1
MMRF_2367	Second Line Therapy (after first relapse)	Daratumumab			mg/kg	IV	Log Forms	Other	SALVAGE	Checked	8	Q week	Q week					1109		1
MMRF_2367	Second Line Therapy (after first relapse)	Carfilzomib			mg/m^2	IV	Log Forms	Other	SALVAGE	Checked	20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1109		1
MMRF_2367	Second Line Therapy (after first relapse)	Dexamethasone					Log Forms	Other	SALVAGE	Checked								1109		1
MMRF_2412	First line of therapy	Bortezomib		Patient decision	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Other	TWICE PER WEEK					1	130	1
MMRF_2412	First line of therapy	Cyclophosphamide		Patient decision	mg	PO	Log Forms	Induction	Induction		400	Q week	Q week					1	130	1
MMRF_2412	First line of therapy	Dexamethasone		Patient decision	mg	PO	Log Forms	Induction	Induction		40	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1	130	1
MMRF_2412	Second Line Therapy (after first relapse)	TURMERIC		Patient decision	GMS	PO	Log Forms	Unknown	Unknown		8	QID	QID					164	1004	1
MMRF_2412	Second Line Therapy (after first relapse)	Daratumumab		Patient decision	mg/kg	IV	Log Forms	Other	SALVAGE		16	Q week	Q week					727	1261	1
MMRF_2433	First line of therapy	Bortezomib		STARTING SCT	mg	IV SubQ	Log Forms	Induction	Induction		2.9	Q week	Q week					1	209	1
MMRF_2433	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Induction	Induction		760	Q week	Q week					1	153	1
MMRF_2433	First line of therapy	Dexamethasone		STARTING SCT	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	215	1
MMRF_2433	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	AUTOLOGOUS HCT		200	Other	ONCE					246	246	1
MMRF_2433	First line of therapy	Lenalidomide		STARTING SCT	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					167	215	1
MMRF_2433	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	Q day	Q day					342		1
MMRF_2458	Second Line Therapy (after first relapse)	Daratumumab			mg	IV SubQ	Log Forms	Other	SALVAGE	Checked	1800	Other	QWEEK X1 MONTH, THEN QOW FOR 8 DOSES, THEN EVERY 4 WEEKS ONGOING.					1968		1
MMRF_2458	Second Line Therapy (after first relapse)	Lenalidomide			mg	PO	Log Forms	Other	SALVAGE	Checked	15	QD (D1-21)	QD (D1-21)					1968		1
MMRF_2458	First line of therapy	Lenalidomide		Patient decision	mg	PO	Log Forms	Maintenance	Maintenance		15	Q day	Q day					436	1793	1
MMRF_2458	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		20	QWK	QWK					351	436	1
MMRF_2458	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					351	436	1
MMRF_2458	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		27	Other	TWICE A WEEK EVERY OTHER WEEK					351	436	1
MMRF_2458	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		12	Other	TAKEN ON DAYS OF AND AFTER VELCADE					138	169	1
MMRF_2458	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					141	169	1
MMRF_2458	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					141	169	1
MMRF_2458	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Other	SALVAGE	Checked	20	Other	20 MG WEEK 1, THEN 4 MG ON DAYS 2 + 3 WEEK 2-3					1968		1
MMRF_2458	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	120	1
MMRF_2458	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.5	Other	D 1, 8, 15					1	120	1
MMRF_2458	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	120	1
MMRF_1112	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				15	QD (D1-21)	QD (D1-21)					2	190	1
MMRF_1112	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.3	Q week	Q week					1	190	1
MMRF_1112	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	Q week	Q week					1	190	1
MMRF_1112	First line of therapy	Dexamethasone			mg	PO	Log Forms	Maintenance	Maintenance	Checked	20	Q week	Q week					489		1
MMRF_1112	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					489	685	1
MMRF_1112	Second Line Therapy (after first relapse)	ACP-196		Disease progression/Relapse	mg	PO	Log Forms	Other	REL/REFR		100	BID	BID					1316	1379	1
MMRF_1112	Second Line Therapy (after first relapse)	PEMBROLIZUMAB		Disease progression/Relapse	mg/kg	IV	Log Forms	Other	REL/REFR		2	Other	Q3WK					1316	1358	1
MMRF_1112	Third Line Therapy (following 2nd relapse)	Carfilzomib		Investigator decision for other reasons	mg	IV	Log Forms	Other	REL/REFR		92	Q week	Q week					1385	1695	1
MMRF_1152	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.3	Other	DAY 1, 8, 15					1	192	1
MMRF_1152	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	Other	DAY 1, 8, 15, 22					1	192	1
MMRF_1152	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				15	QD (D1-21)	QD (D1-21)					108	192	1
MMRF_1152	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-14)	QD (D1-14)					304	2685	1
MMRF_1283	First line of therapy	Lenalidomide			mg	PO	Log Forms			Checked	10	QD (D1-21)	QD (D1-21)					1		1
MMRF_1283	First line of therapy	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	4	Q day	Q day					1		1
MMRF_1360	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				15	QD (D1-21)	QD (D1-21)					1	389	1
MMRF_1360	First line of therapy	Bortezomib		COMPLETED THIS PIECE, ON MAINTENANCE DEX/LENOLIDAMIDE	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					1	176	1
MMRF_1360	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	399	1
MMRF_1484	First line of therapy	Bortezomib			mg	IV	Log Forms	Induction	Induction	Checked	1.3	Q week	Q week					1		1
MMRF_1484	First line of therapy	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	40	Q week	Q week					1		1
MMRF_1601	First line of therapy	Bortezomib		Investigator decision for other reasons	mg	IV SubQ	Log Forms	Induction	Induction		1.9	Q week	Q week					1	16	1
MMRF_1601	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	16	1
MMRF_1641	First line of therapy	Bortezomib		Disease progression/Relapse	mg	IV SubQ	Log Forms	Induction	Induction		2.2	Other	D1, D8, D15 Q28D					1	146	1
MMRF_1641	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Unknown	Unknown		500	Other	D1 D8 Q4WK CYCLE					34	145	1
MMRF_1641	Third Line Therapy (following 2nd relapse)	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Unknown	Unknown		70	Other	D1,8,15 Q28D					211	470	1
MMRF_1641	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Unknown	Unknown		40	Other	D1,8, 15 Q28D					20	506	1
MMRF_2083	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					1	321	1
MMRF_2083	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					1	321	1
MMRF_2083	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	321	1
MMRF_2083	First line of therapy	Carfilzomib		Disease progression/Relapse	mg	IV	Log Forms	Other	REL/REF		105	Other	D1, D8, D15 - Q4W					476	630	1
MMRF_2083	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	REL/REFR		40	Other	D1, D8, D15, D22 - Q4WK					476	630	1
MMRF_2083	Third Line Therapy (following 2nd relapse)	Daratumumab		Adverse Event or co-morbidity	mg	IV	Log Forms	Other	REL/REF		1600	Other	EVERY 2 WEEKS					659	667	1
MMRF_2083	Third Line Therapy (following 2nd relapse)	METHYLPREDNISOLONE		Adverse Event or co-morbidity	mg	IV	Log Forms	Other	REL/REF		100	Other	EVERY OTHER WEEK					659	667	1
MMRF_2083	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	REL/REF		40	QD (D1-4)	QD (D1-4)					682	683	1
MMRF_2083	Fourth Line Therapy (following 3rd relapse)	Cyclophosphamide		Disease progression/Relapse	mg	IV	Log Forms	Other	REL/REF		820	QD (D1-4)	QD (D1-4)					682	722	1
MMRF_2083	Fourth Line Therapy (following 3rd relapse)	ETOPOSIDE		Disease progression/Relapse	mg	IV	Log Forms	Other	REL/REF		82	QD (D1-4)	QD (D1-4)					682	722	1
MMRF_2083	Fourth Line Therapy (following 3rd relapse)	CISPLATIN		Disease progression/Relapse	mg	IV	Log Forms	Other	REL/REF		20	QD (D1-4)	QD (D1-4)					682	722	1
MMRF_2083	Fourth Line Therapy (following 3rd relapse)	Doxorubicin		Disease progression/Relapse	mg	IV	Log Forms	Other	REL/REF		82	QD (D1-4)	QD (D1-4)					682	722	1
MMRF_2083	Fifth Line Therapy (following 4th relapse)	Dexamethasone		Patient decision	mg	PO	Log Forms	Other	REL/REF		20	Q week	Q week					804	869	1
MMRF_2083	Fifth Line Therapy (following 4th relapse)	Elotuzumab		Patient decision	mg	IV	Log Forms	Other	REL/REF		900	Other	QD (D1, D8, D15, D22)					804	869	1
MMRF_2400	First line of therapy	Lenalidomide			mg	PO	Log Forms	Induction	Induction	Checked	25	QD (D1-21)	QD (D1-21)					1		1
MMRF_2400	First line of therapy	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	10	QWK	QWK					1		1
MMRF_2400	First line of therapy	Bortezomib		NOT SPECIFIED IF CONTINUING AS PART OF REGIMEN AT THIS TIME	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Q day	Q day					14	14	1
MMRF_2473	First line of therapy	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	10	Q day	Q day					1		1
MMRF_2473	First line of therapy	Lenalidomide			mg	PO	Log Forms	Induction	Induction	Checked	15	QD (D1-21)	QD (D1-21)					1		1
MMRF_1310	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms				300	QWK	QWK					1	148	1
MMRF_1310	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms				1.5	QWK	QWK					1	148	1
MMRF_1310	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms				20	QWK	QWK					1	148	1
MMRF_1310	First line of therapy	Lenalidomide		DECREASED DOSE	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	182	1
MMRF_1310	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					183	211	1
MMRF_1310	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					225	1751	1
MMRF_1407	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	78	1
MMRF_1407	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				20	Other	D1-2, 4-5, 8-9 AND 11-12					1	78	1
MMRF_1407	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					7	78	1
MMRF_1407	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Consolidation	Consolidation		2.8	QWK	QWK					201	271	1
MMRF_1407	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		20	QWK	QWK					201	271	1
MMRF_1407	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		10	QD (D1-21)	QD (D1-21)					201	277	1
MMRF_1407	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					286	1021	1
MMRF_1407	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		200	Q day	Q day					118	119	1
MMRF_1424	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	95	1
MMRF_1424	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	95	1
MMRF_1424	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	109	1
MMRF_1424	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		1.5	Q week	Q week					150	192	1
MMRF_1424	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		20	Q week	Q week					150	192	1
MMRF_1424	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Other	MOBILIZATION		3000	Q day	Q day					214	214	1
MMRF_1424	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONIDITIONING		100	Q day	Q day					247	248	1
MMRF_1424	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					361	473	1
MMRF_1424	First line of therapy	Lenalidomide		DOSE CHANGED FROM 10MG QOD TO 5MG QD	mg	PO	Log Forms	Maintenance	Maintenance		10	Other	EVERY OTHER DAY					586	676	1
MMRF_1424	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					677	926	1
MMRF_1424	First line of therapy	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Q week	Q week					981	1278	1
MMRF_1424	Second Line Therapy (after first relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		3	QD (D1-21)	QD (D1-21)					1376	1495	1
MMRF_1424	Second Line Therapy (after first relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Consolidation	Consolidation		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1376	1377	1
MMRF_1424	Second Line Therapy (after first relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Consolidation	Consolidation		56	Q week	Q week					1383	1495	1
MMRF_1424	Third Line Therapy (following 2nd relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IVPB	Log Forms	Unknown	Unknown		16	Other	D1, D8, D15 & D22 Q 28 DAYS X 7 CYCLES					1516	1600	1
MMRF_1424	Third Line Therapy (following 2nd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		3	QD (D1-21)	QD (D1-21)					1516	1600	1
MMRF_1424	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		20	Other	D1, D8, D15 & D22 Q 28 DAYS					1516	1600	1
MMRF_1424	Third Line Therapy (following 2nd relapse)	Dexamethasone		ADDITIONAL STEROID TO PREVENT INFUSION REACTION. NO LONGER REQUIRED.	mg	IV	Log Forms	Unknown	Unknown		20	Other	D1, D8, D15 & D22 Q CYCLE					1516	1517	1
MMRF_1424	Fourth Line Therapy (following 3rd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Other	TREATMENT UNTIL DISEASE PROGRESSION		3	QD (D1-21)	QD (D1-21)					1614	1719	1
MMRF_1424	Fourth Line Therapy (following 3rd relapse)	Elotuzumab		Disease progression/Relapse	mg	IVB	Log Forms	Other	TREATMENT UNTIL DISEASE PROGRESSION		800	QWK	QWK					1614	1712	1
MMRF_1424	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	TREATMENT UNTIL DISEASE PROGRESSION		28	QWK	QWK					1614	1719	1
MMRF_1424	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Disease progression/Relapse	mg	IVB	Log Forms	Other	TREATMENT UNTIL DISEASE PROGRESSION		8	QWK	QWK					1614	1712	1
MMRF_1424	Fifth Line Therapy (following 4th relapse)	BUSULFAN		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		204	Q day	Q day					1759	1760	1
MMRF_1424	Fifth Line Therapy (following 4th relapse)	Melphalan		Completed regimen	mg/dL	IV	Log Forms	Other	CONDITIONING		130	Q day	Q day					1760	1761	1
MMRF_1424	Fifth Line Therapy (following 4th relapse)	Ixazomib		DOSE REDUCED	mg	PO	Log Forms	Maintenance	Maintenance		4	QWK	QWK					1919	1941	1
MMRF_1424	Fifth Line Therapy (following 4th relapse)	Ixazomib		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		3	QWK	QWK					1955	2032	1
MMRF_1424	Fifth Line Therapy (following 4th relapse)	Pomalidomide		DOSE REDUCTION	mg	PO	Log Forms	Maintenance	Maintenance		3	QD (D1-21)	QD (D1-21)					1919	1941	1
MMRF_1424	Fifth Line Therapy (following 4th relapse)	Pomalidomide		INSURANCE TERMED	mg	PO	Log Forms	Maintenance	Maintenance		2	QD (D1-21)	QD (D1-21)					1955	2102	1
MMRF_1424	Fifth Line Therapy (following 4th relapse)	Dexamethasone		DEATH	mg	PO	Log Forms	Maintenance	Maintenance		20	Q week	Q week					1919	2144	1
MMRF_1556	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		1.5	Q week	Q week					1	113	1
MMRF_1556	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Induction	Induction		300	Q week	Q week					1	113	1
MMRF_1556	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Induction	Induction		20	Q week	Q week					1	113	1
MMRF_1556	Second Line Therapy (after first relapse)	Bortezomib		Lack of response	mg/m^2	IV SubQ	Log Forms	Consolidation	Consolidation		1.5	Q week	Q week					1212	1337	1
MMRF_1556	Second Line Therapy (after first relapse)	Cyclophosphamide		Lack of response	mg/m^2	IVB	Log Forms	Consolidation	Consolidation		300	Other	D1, D8 & D15 Q28					1212	1335	1
MMRF_1556	Second Line Therapy (after first relapse)	Dexamethasone		Lack of response	mg	IV	Log Forms	Consolidation	Consolidation		20	Other	WKLY					1212	1335	1
MMRF_1617	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					1	101	1
MMRF_1617	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					2	108	1
MMRF_1617	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					2	101	1
MMRF_1617	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		120	Q day	Q day					146	147	1
MMRF_1617	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					251	2672	1
MMRF_1617	Third Line Therapy (following 2nd relapse)	Pomalidomide			mg	PO	Log Forms	Other	TREATMENT FOR RELAPSE	Checked	4	Q day	Q day					2743		1
MMRF_1617	Third Line Therapy (following 2nd relapse)	Daratumumab			mg	IV	Log Forms	Other	TREATMENT FOR RELAPSE	Checked	1860	Other	D1 & D15 Q28D					2743		1
MMRF_1617	Second Line Therapy (after first relapse)	Dexamethasone		Lack of response	mg	IV	Log Forms	Other	TREATMENT FOR RELAPSE		20	Q week	Q week					2673	2725	1
MMRF_1617	Second Line Therapy (after first relapse)	Daratumumab		Lack of response	mg	IV	Log Forms	Other	TREATMENT FOR RELAPSE		1880	Q week	Q week					2673	2718	1
MMRF_1617	Second Line Therapy (after first relapse)	Bortezomib		Lack of response	mg	IV SubQ	Log Forms	Other	TREATMENT FOR RELAPSE		3.1	Q week	Q week					2673	2725	1
MMRF_1723	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					1	267	1
MMRF_1723	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					1	267	1
MMRF_1723	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	121	1
MMRF_1723	First line of therapy	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Induction	Induction		500	QWK	QWK					128	267	1
MMRF_1723	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					272	2673	1
MMRF_1723	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		20	Other	D1, 8, 15 Q28DAYS					272	1609	1
MMRF_1723	Fifth Line Therapy (following 4th relapse)	SELINEXOR		Lack of response	mg	PO	Log Forms	Unknown	Unknown		80	Other	TWICE WEEKLY					2725	2864	1
MMRF_1723	Fourth Line Therapy (following 3rd relapse)	BELANTAMAB MAFODOTIN-BLMF		Lack of response	mg	IV	Log Forms	Other	TREATMENT FOR RELAPSE		195	Other	Q21D					2673	2694	1
MMRF_1723	Third Line Therapy (following 2nd relapse)	Dexamethasone		Lack of response	mg	PO	Log Forms	Other	TREATMENT FOR RELAPSE		20	Q week	Q week					2547	2659	1
MMRF_1723	Third Line Therapy (following 2nd relapse)	Lenalidomide		Lack of response	mg	PO	Log Forms	Other	TREATMENT FOR RELAPSE		25	QD (D1-21)	QD (D1-21)					2547	2659	1
MMRF_1723	Third Line Therapy (following 2nd relapse)	Ixazomib		Lack of response	mg	PO	Log Forms	Other	TREATMENT FOR RELAPSE		4	Q week	Q week					2547	2659	1
MMRF_1723	Third Line Therapy (following 2nd relapse)	Dexamethasone		Lack of response	mg	IV	Log Forms	Other	TREATMENT FOR RELAPSE		20	Other	D1 & D15 Q28D					2316	2485	1
MMRF_1723	Third Line Therapy (following 2nd relapse)	Daratumumab		Lack of response	mg/kg	IV	Log Forms	Other	TREATMENT FOR RELAPSE		16	Other	D1 & D15 Q28D					2316	2485	1
MMRF_1723	Second Line Therapy (after first relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		4	Q day	Q day					1990	2290	1
MMRF_1723	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Other	TREATMENT FOR RELAPSE		20	Q week	Q week					1610	1899	1
MMRF_1723	Second Line Therapy (after first relapse)	Carfilzomib		Completed regimen	mg	IV	Log Forms	Other	TREATMENT FOR RELAPSE		75	Other	D1, D8, D15 Q28D					1610	1899	1
MMRF_1984	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.5	QWK	QWK					1	84	1
MMRF_1984	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	84	1
MMRF_1984	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	84	1
MMRF_1984	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	Q day	Q day					257		1
MMRF_1107	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	IV	Log Forms				12	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	94	1
MMRF_1107	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms				1.3	Q week	Q week					1	15	1
MMRF_1107	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms				1	Q week	Q week					15	93	1
MMRF_1227	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV	Log Forms				1.3	Q week	Q week					1	127	1
MMRF_1227	First line of therapy	Dexamethasone		CHANGE IN FREQUENCY	mg	IV	Log Forms				12	Q week	Q week					1	64	1
MMRF_1227	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms				12	Other	TWICE A WEEK					65	206	1
MMRF_1227	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms				25	Other	3 WEEKS ON, 1 WEEK OFF					73	206	1
MMRF_1227	First line of therapy	Pomalidomide		Investigator decision for other reasons	mg	PO	Log Forms				4	Q day	Q day					207	257	1
MMRF_1227	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms				20	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)					207	413	1
MMRF_1227	First line of therapy	Pomalidomide		Patient decision	mg	PO	Log Forms	Unknown	Unknown		2	Q day	Q day					258	413	1
MMRF_1271	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	269	1
MMRF_1271	First line of therapy	Melphalan		Adverse Event or co-morbidity	mg	PO	Log Forms				18	Q day	Q day					1	22	1
MMRF_1271	First line of therapy	Cyclophosphamide		Investigator decision for other reasons	mg	IV	Log Forms	Maintenance	Maintenance		500	Other	Q3 WKS					383	450	1
MMRF_1271	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Induction	Induction		500	QWK	QWK					39	269	1
MMRF_1271	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	QWK	QWK					12	306	1
MMRF_1271	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		5	Other	QOD					292	354	1
MMRF_1271	First line of therapy	Bortezomib		Completed regimen	mg	IV	Log Forms	Maintenance	Maintenance		2.5	Other	Q 3 WEKS					383	1058	1
MMRF_1271	First line of therapy	Cyclophosphamide		Investigator decision for other reasons	mg	IV	Log Forms	Maintenance	Maintenance		1450	Other	Q3 WKS					471	542	1
MMRF_1271	First line of therapy	Cyclophosphamide		LOWERING DOSE TO AVOID LONG TERM PROBLEMS W BONE MARROW ON ALKALATING AGENT	mg	IV	Log Forms	Maintenance	Maintenance		1200	Other	Q3 WKS					569	980	1
MMRF_1271	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Maintenance	Maintenance		500	Other	Q 6WEEKS					981	1058	1
MMRF_1271	First line of therapy	Melphalan		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		8	QD (D1-4)	QD (D1-4)					1142	1206	1
MMRF_1271	First line of therapy	Prednisone		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		50	Other	DAYS 1-2					1142	1204	1
MMRF_1271	First line of therapy	Daratumumab		Completed regimen	mg	IV	Log Forms	Induction	Induction		1270	QWK	QWK					1262	1320	1
MMRF_1271	First line of therapy	Prednisone		BLOOD SUGAR BECOME QUITE HIGH (SIDE EFFECT)	mg	PO	Log Forms				100	Q day	Q day					1	12	1
MMRF_1440	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		12	Q week	Q week					708	1226	1
MMRF_1440	Second Line Therapy (after first relapse)	Bortezomib		Completed regimen	mg	IVB	Log Forms	Maintenance	Maintenance		2.2	Q week	Q week					568	799	1
MMRF_1440	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	IVB	Log Forms	Induction	Induction		10	Q week	Q week					568	680	1
MMRF_1440	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	Other	Q21DAYS  -OFF 7DAYS Q28DAYS					192		1
MMRF_1440	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms				2.2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	149	1
MMRF_1440	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	149	1
MMRF_1687	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		15	Q day	Q day					1	114	1
MMRF_1687	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	QWK	QWK					1	114	1
MMRF_1687	First line of therapy	Bortezomib		PT BECAME TO ILL	mg	IV	Log Forms	Induction	Induction		2.1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					146	177	1
MMRF_1929	First line of therapy	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Induction	Induction		450	Other	DAY 1, 8, 15 AND 22					1	85	1
MMRF_1929	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		2.2	Other	DAYS 1,8,15 AND 22					1	85	1
MMRF_1929	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	DAYS 1-4, 9-12 AND 17-20					1	85	1
MMRF_1929	First line of therapy	Lenalidomide		DOES REDUCTION	mg	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					238	1005	1
MMRF_1929	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		140	Other	ONCE					111	111	1
MMRF_1929	Second Line Therapy (after first relapse)	Ixazomib			mg	PO	Log Forms	Maintenance	Maintenance	Checked	3	Other	D1, D5, D15					1329		1
MMRF_1929	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	2.5	QD (D1-21)	QD (D1-21)					1006		1
MMRF_1929	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Maintenance	Maintenance	Checked	20	Other	D1, D8, D15					1329		1
MMRF_2132	First line of therapy	Bortezomib		PT IN REHAB	mg	IV SubQ	Log Forms	Induction	Induction		2.7	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	134	1
MMRF_2132	First line of therapy	Dexamethasone		PT IN REHAB	mg	PO	Log Forms	Induction	Induction		40	Other	1-4,9-12					1	134	1
MMRF_2455	First line of therapy	Bortezomib		DEATH	mg	IV SubQ	Log Forms	Induction	Induction		2.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	257	1
MMRF_2455	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	255	1
MMRF_2455	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	255	1
MMRF_1388	First line of therapy	Bortezomib		Patient decision	mg	SUB - Q	Log Forms				2.1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	383	1
MMRF_2598	First line of therapy	Dexamethasone		DEATH	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	1690	1
MMRF_2598	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					10	42	1
MMRF_2598	First line of therapy	Lenalidomide		Patient decision	mg	PO	Log Forms	Induction	Induction		5	QD (D1-21)	QD (D1-21)					100	1304	1
MMRF_1170	First line of therapy	Bortezomib		Patient decision	mg	IV	Log Forms				2.6	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	169	1
MMRF_1170	First line of therapy	Dexamethasone		Patient decision	mg	PO	Log Forms				40	BID	BID					1	161	1
MMRF_1346	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg	IV SubQ	Log Forms				1.9	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	62	1
MMRF_1439	First line of therapy	Bortezomib		PATIENT DID NOT SHOW TO THE CLINIC. LOST TO FOLLOW UP	mg	IV	Log Forms				2.6	QD (D1-21)	QD (D1-21)					1	51	1
MMRF_1108	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	MG	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					4	40	1
MMRF_1108	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms				40	Other	D1,D8,D15,D22					1	44	1
MMRF_1108	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms				10	QD (D1-21)	QD (D1-21)					4	40	1
MMRF_1108	First line of therapy	Dexamethasone		PARTIAL RESPONSE	mg	IV	Log Forms				10	Other	DAY 1, AND D 15					4	40	1
MMRF_1108	First line of therapy	Bortezomib		PARTIAL RESPONSE	mg	IV SubQ	Log Forms				1.6	Other	D1, AND D8					40	194	1
MMRF_1108	Second Line Therapy (after first relapse)	Bortezomib		SWITCHED TO A HIGHER DOSE	mg	SUB-Q	Log Forms	Other	POST INDUCTION		1.6	Other	C1, D8					306	1034	1
MMRF_1108	Second Line Therapy (after first relapse)	Bortezomib		BIOCHEMICAL PROGRESSION	mg	SUB Q	Log Forms	Other	POST INDUCTION		2.2	Other	D1, D8 AND D21					1048	1174	1
MMRF_1108	Second Line Therapy (after first relapse)	Dexamethasone		SWITCHED TO A HIGHER DOSE	mg	IV	Log Forms	Other	POST INDUCTION		10	Other	D1, D15 EVERY 21 DAYS					306	1034	1
MMRF_1108	Second Line Therapy (after first relapse)	Dexamethasone		BIOCHEMICAL PROGRESSION	mg	IV	Log Forms	Other	POST INDUCTION		20	Other	D1, D8 EVERY 21 DAYS					1048	1174	1
MMRF_1108	Second Line Therapy (after first relapse)	Bortezomib		Adverse Event or co-morbidity	mg	SUB-Q	Log Forms	Other	POST INDUCTION		2.2	Other	EVERY 21 DAYS C1, D15					1188	1314	1
MMRF_1108	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	IV	Log Forms	Other	POST INDUCTION		20	Other	EVERY 21 DAYS D1 , D15					1188	1314	1
MMRF_1108	Second Line Therapy (after first relapse)	Pomalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Other	POST INDUCTION		2	Other	DAYS 21 AND 28					1083	1230	1
MMRF_1108	Third Line Therapy (following 2nd relapse)	Ixazomib		UNTIL NEXT TREATMENT	mg	PO	Log Forms	Other	PROGRESSIVE DISEASE		3	Other	EVERY ONE PO EVERY WEDNESDAY FOR 3 WEEKS					1433	1433	1
MMRF_1108	Third Line Therapy (following 2nd relapse)	Dexamethasone		UNTIL NEXT TREATMENT	mg	PO	Log Forms	Other	POST INDUCTION		12	Other	ONCE A WEEK WITH ORAL CHEMO					1433	1433	1
MMRF_1113	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	48	1
MMRF_1113	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms				20	Q week	Q week					8	101	1
MMRF_1113	First line of therapy	Bortezomib		Disease progression/Relapse	MG	IV SubQ	Log Forms				2.3	Other	D1 AND D8 ONOF 21 D CYCLE					8	101	1
MMRF_1113	First line of therapy	Bortezomib		Investigator decision for other reasons	mg	IV SubQ	Log Forms	Maintenance	Maintenance		2.2	Other	DAYS 1 AND 15					444	598	1
MMRF_1113	First line of therapy	Carfilzomib		Investigator decision for other reasons	mg	IV	Log Forms	Unknown	Unknown		35	Other	WEEKLY 2 DAYS A WEEK					114	121	1
MMRF_1113	Second Line Therapy (after first relapse)	Bortezomib		Lack of response	mg	IV SubQ	Log Forms	Maintenance	Maintenance		1.4	QD (D1-14)	QD (D1-14)					997	1137	1
MMRF_1113	First line of therapy	Thalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		100	Q day	Q day					66	111	1
MMRF_1113	First line of therapy	Thalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		200	BID	BID					126	174	1
MMRF_1113	First line of therapy	Thalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		200	Other	EVERY OTHER DAY					174	197	1
MMRF_1113	First line of therapy	Thalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		100	Q day	Q day					412	441	1
MMRF_1113	First line of therapy	Thalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		50	Q day	Q day					441	604	1
MMRF_1113	First line of therapy	Thalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		50	Q day	Q day					678	926	1
MMRF_1113	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					55	62	1
MMRF_1113	First line of therapy	Melphalan		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		200	Other	ONCE					225	225	1
MMRF_1164	First line of therapy	Lenalidomide		Lack of response	mg	PO	Log Forms				25	Q day	Q day					1	280	1
MMRF_1164	First line of therapy	Dexamethasone		DEATH	mg	PO	Log Forms				40	Q week	Q week					1	372	1
MMRF_1164	First line of therapy	Bortezomib		DEATH	mg	IV	Log Forms	Maintenance	Maintenance		24	QWK	QWK					280	372	1
MMRF_1169	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	121	1
MMRF_1169	First line of therapy	Dexamethasone		DISEASE PROGRESSION	mg	PO	Log Forms				40	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1	139	1
MMRF_1169	First line of therapy	Bortezomib		DISEASE PROGRESSION	mg	IV SubQ	Log Forms				2.1	Other	EVERY 21 DAYS					121	139	1
MMRF_1312	Second Line Therapy (after first relapse)	Melphalan		Investigator decision for other reasons	mg	IV SubQ	Log Forms	Induction	Induction		140	Other	2 DAYS					200	200	1
MMRF_1312	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	Q day	Q day					1569	1844	1
MMRF_1312	Second Line Therapy (after first relapse)	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IVB	Log Forms	Induction	Induction		20	QWK	QWK					1579	1586	1
MMRF_1312	Second Line Therapy (after first relapse)	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IVB	Log Forms	Induction	Induction		27	Q week	Q week					1586	2178	1
MMRF_1312	Second Line Therapy (after first relapse)	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		4	Q day	Q day					1870	2794	1
MMRF_1312	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Consolidation	Consolidation		10	Other	D1,2,8,9,15,16,22,23,28					1870	2794	1
MMRF_1312	First line of therapy	Bortezomib		PREPARATION FOR TRANSPLANT	mg	IV SubQ	Log Forms	Consolidation	Consolidation		2.8	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	150	1
MMRF_1312	First line of therapy	Lenalidomide		PREPARATION FOR TRANSPLANT	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-14)	QD (D1-14)					1	150	1
MMRF_1312	First line of therapy	Dexamethasone		PREPERATION FOR TRANSPLANT	mg	PO	Log Forms	Consolidation	Consolidation		40	Other	DAY 1, 8, 15, AND 22					1	150	1
MMRF_1312	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					341	739	1
MMRF_1796	First line of therapy	Lenalidomide		NOT TOLERATING TREATMENT OF VELCADE + DEX	mg	PO	Log Forms	Induction	Induction		25	Q day	Q day					1	63	1
MMRF_1796	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		10	QWK	QWK					1	63	1
MMRF_1796	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					66	177	1
MMRF_1796	First line of therapy	Dexamethasone		CHEMOTHERAPY HELD UNTIL PATIENT RECOVERED FROM AUTOLOGOUS TRANSPLANT.	mg	PO	Log Forms	Unknown	Unknown		40	Q week	Q week					66	231	1
MMRF_1796	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					317	1192	1
MMRF_1796	First line of therapy	Bortezomib			mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance	Checked	1	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1206		1
MMRF_2186	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					37	1694	1
MMRF_2186	Second Line Therapy (after first relapse)	Bortezomib		Adverse Event or co-morbidity	mg	IV SubQ	Log Forms	Consolidation	Consolidation		2.9	QWK	QWK					1560	1679	1
MMRF_2186							Log Forms													1
MMRF_2186							Log Forms													1
MMRF_2186							Log Forms													1
MMRF_2186	First line of therapy	Bortezomib		TREATMENT ON HOLD FOR HIP SURGERY	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	244	1
MMRF_2186	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					2	37	1
MMRF_2186	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		10	QID	QID					41	447	1
MMRF_2545	First line of therapy	Dexamethasone		PATIENT EXPIRED 23DEC2019.	mg	IV	Log Forms	Induction	Induction		10	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	1681	1
MMRF_2545	First line of therapy	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	74	1
MMRF_2545	Third Line Therapy (following 2nd relapse)	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IVB	Log Forms	Induction	Induction		55	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1122	1402	1
MMRF_2545	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					213	241	1
MMRF_2545	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					255	1088	1
MMRF_2545	Fourth Line Therapy (following 3rd relapse)	Daratumumab		PATIENT EXPIRED 23DEC2019	mg/kg	IVB	Log Forms	Induction	Induction		16	QD (D1-7)	QD (D1-7)					1572	1671	1
MMRF_2545	Fourth Line Therapy (following 3rd relapse)	Pomalidomide		PATIENT EXPIRED 23DEC2019.	mg	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					1572	1681	1
MMRF_2545	Third Line Therapy (following 2nd relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IVB	Log Forms	Induction	Induction		45	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1402	1508	1
MMRF_1239	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	742	1
MMRF_1239	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms				40	QWK	QWK					12	176	1
MMRF_1436	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms				25	Q day	Q day					1	323	1
MMRF_1436	First line of therapy	Dexamethasone			mg	PO	Log Forms			Checked	40	Q day	Q day					1		1
MMRF_1436	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					323		1
MMRF_2595	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	75	1
MMRF_2595	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	20 MG BY MOUTH ON DAY OF AND DAY AFTER VELCADE THERAPY					1	92	1
MMRF_2595	First line of therapy	Bortezomib		Disease progression/Relapse	mg/m^2	SQ	Log Forms	Maintenance	Maintenance		1.3	Other	EVERY OTHER WEEK					260	344	1
MMRF_2595	Second Line Therapy (after first relapse)	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		4	QD (D1-21)	QD (D1-21)					360	451	1
MMRF_2595	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					498	1072	1
MMRF_2595	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					505	1072	1
MMRF_2595	Second Line Therapy (after first relapse)	Daratumumab		Adverse Event or co-morbidity	mg/kg	IV	Log Forms	Induction	Induction		16	Other	QW(FOR WEEKS 1-8); Q2W(FOR WEEKS 9-24); Q4W(THERE AFTER UNTIL PROGRESSION)					501	788	1
MMRF_2595	Second Line Therapy (after first relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Induction	Induction		16	Q week	Q week					1009	1072	1
MMRF_2595	Third Line Therapy (following 2nd relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1079	1151	1
MMRF_2595	Third Line Therapy (following 2nd relapse)	Cyclophosphamide		Disease progression/Relapse	mg/m^2	PO	Log Forms	Induction	Induction		300	Q week	Q week					1079	1151	1
MMRF_2595	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1079	1151	1
MMRF_2595	Fourth Line Therapy (following 3rd relapse)	Bendamustine		DEATH	mg	IV	Log Forms	Maintenance	Maintenance		163	Other	Q 4 WEEKS					1169	1169	1
MMRF_2595	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	BONE MARROW TRANSPLANT		200	Other	ONCE					114	114	1
MMRF_2595	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	92	1
MMRF_1273	First line of therapy	Bortezomib		DEATH	mg	SQ	Log Forms				2.9	Q week	Q week					1	113	1
MMRF_1273	First line of therapy	Cyclophosphamide		DEATH	mg	PO	Log Forms				600	Q week	Q week					1	113	1
MMRF_1109	First line of therapy	Dexamethasone		DEATH	mg	PO	Log Forms				8	Other	8MG PO, ONCE A WEEK ON MONDAY, BEFORE TREATMENT					1	117	1
MMRF_1109	First line of therapy	Bortezomib		DEATH	mg	IV	Log Forms				2.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	117	1
MMRF_1117	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	74	1
MMRF_1117	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	Other	DAY 1,2,4,5,8,9,11,12					1	106	1
MMRF_1117	First line of therapy	Lenalidomide		Lack of response	mg	PO	Log Forms				5	QD (D1-14)	QD (D1-14)					321	340	1
MMRF_1117	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					395	736	1
MMRF_1117	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					85	95	1
MMRF_1117	Second Line Therapy (after first relapse)	Lenalidomide		PER MD KAPPA LIGHT CHAINS CONTINUE TO SHOW INCREASE SLOWLY	mg	PO	Log Forms	Induction	Induction		10	QD (D1-14)	QD (D1-14)					341	394	1
MMRF_1117	Third Line Therapy (following 2nd relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-4)	QD (D1-4)					737	924	1
MMRF_1117	Fourth Line Therapy (following 3rd relapse)	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					925	1193	1
MMRF_1117	Fifth Line Therapy (following 4th relapse)	Pomalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		4	Other	21 DAYS ON 7 DAYS OFF					1062	1312	1
MMRF_1146	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	167	1
MMRF_1146	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms				4	Other	10 TABS A WEEK					9	184	1
MMRF_1146	First line of therapy	Melphalan		PREPARATIVE REGIMEN FOR TRANSPLANT	mg	IV	Log Forms				214	Q day	Q day					198	199	1
MMRF_1146	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					319	1194	1
MMRF_1146	Second Line Therapy (after first relapse)	Bortezomib			mg	IV SubQ	Log Forms	Induction	Induction	Checked	3.3	Q week	Q week					1201		1
MMRF_1184	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	161	1
MMRF_1184	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	Other	DAYS 1,8,15,22					1	199	1
MMRF_1184	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					295	546	1
MMRF_1184	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	5	Q day	Q day					547		1
MMRF_1250	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	33	1
MMRF_1250	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	Other	DAYS 1,8,15 & 22					1	298	1
MMRF_1250	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				15	QD (D1-21)	QD (D1-21)					33	298	1
MMRF_1250	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	Q day	Q day					337		1
MMRF_1261	First line of therapy	Cyclophosphamide		Completed regimen	mg	PO	Log Forms				300	Q week	Q week					1	106	1
MMRF_1261	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.5	Q week	Q week					1	232	1
MMRF_1261	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1	202	1
MMRF_1261	First line of therapy	Bortezomib		Disease progression/Relapse	mg	IV SubQ	Log Forms	Maintenance	Maintenance		2.5	Other	Q14DAYS					364	615	1
MMRF_1261	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					351	615	1
MMRF_1261	Second Line Therapy (after first relapse)	Carfilzomib		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		33	Other	DAYS 1, 8, 15					638	757	1
MMRF_1261	Third Line Therapy (following 2nd relapse)	INVESTIGATIONAL PRODUCT		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		45	BID	BID					793	909	1
MMRF_1261	Fourth Line Therapy (following 3rd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		4	Q day	Q day					932	1060	1
MMRF_1261	Fourth Line Therapy (following 3rd relapse)	INVESTIGATIONAL PRODUCT		Disease progression/Relapse	TABLET	PO	Log Forms	Induction	Induction		1	Other	DAYS 1-2, 8-9, 15-16, 22-23					932	1060	1
MMRF_1261	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		20	Other	DAYS 1-2, 8-9, 15-16, 22-23					932	1060	1
MMRF_1261	Fifth Line Therapy (following 4th relapse)	INVESTIGATIONAL PRODUCT		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		110	Other	Q21D					1077	1098	1
MMRF_1261	Fifth Line Therapy (following 4th relapse)	INVESTIGATIONAL PRODUCT		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		100	BID	BID					1077	1098	1
MMRF_1260	First line of therapy	Bortezomib		Completed regimen	mg	IV	Log Forms				2.5	Q week	Q week					1	106	1
MMRF_1260	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO	Log Forms				300	Other	DAYS 1,8,15,22					1	106	1
MMRF_1260	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	Other	DAYS 1-4,9-12,17-20 ON CYCLES 1 &2					1	106	1
MMRF_1260	First line of therapy	Bortezomib		Disease progression/Relapse	mg	SUB-Q	Log Forms	Maintenance	Maintenance		2.5	Other	Q2WEEKS					142	1038	1
MMRF_1260	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		40	Other	DAYS 1, 8, 15, 22					142	226	1
MMRF_1295	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms				1.3	Q week	Q week					2	381	1
MMRF_1295	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms				20	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1	282	1
MMRF_1295	First line of therapy	Cyclophosphamide		Investigator decision for other reasons	mg	PO	Log Forms				500	Other	DAY 1, DAY 8, DAY 15 AND DAY 22					37	282	1
MMRF_1295	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.5	QWK	QWK					23	262	1
MMRF_1295	First line of therapy	Lenalidomide		UNKNOWN AT THIS TIME	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					418	1376	1
MMRF_1295	First line of therapy	Dexamethasone			mg	PO	Log Forms	Maintenance	Maintenance	Checked	20	Other	EVERY MONDAY					418		1
MMRF_1344	First line of therapy	Bortezomib		DOSE CHANGED DUE TO GRADE 1 NEUROPATHY	mg/m^2	IV SubQ	Log Forms				1.5	QWK	QWK					1	100	1
MMRF_1344	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO	Log Forms				300	QWK	QWK					1	106	1
MMRF_1344	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	QWK	QWK					1	106	1
MMRF_1344	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1	QWK	QWK					106	106	1
MMRF_1344	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	MOBILIZATION FOR STEM CELL TRANSPLANT		200	Other	ONCE					169	169	1
MMRF_1344	First line of therapy	Dexamethasone			mg	PO	Log Forms	Maintenance	Maintenance	Checked	20	QWK	QWK					361		1
MMRF_1344	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	Q day	Q day					361		1
MMRF_1453	First line of therapy	Cyclophosphamide		Completed regimen	mg	PO	Log Forms				700	Other	DAYS 1,8,15,22					1	106	1
MMRF_1453	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.5	Q week	Q week					1	106	1
MMRF_1453	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	Other	DAYS 1-4, 9-12, 17-20					1	106	1
MMRF_1453	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	Q day	Q day					236		1
MMRF_1538	First line of therapy	Bortezomib		REVIEW OF BONE MARROW BIOPSY SHOWED NO EVIDENCE OF DISEASE	mg	IV SubQ	Log Forms	Induction	Induction		3.1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	944	1
MMRF_1538	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	134	1
MMRF_1538	First line of therapy	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	20	Other	QD (D1, D2, D4, D5, D8, D9, D11, D12)					1		1
MMRF_1588	First line of therapy	Cyclophosphamide		PREP FOR BONE MARROW TRANSPLANT	mg	PO	Log Forms	Induction	Induction		700	Other	QD (D1, D8, D15, D22)					1	161	1
MMRF_1588	First line of therapy	Bortezomib		PREP FOR BONE MARROW TRANSPLANT	mg	IV SubQ	Log Forms	Induction	Induction		3.5	Q week	Q week					1	161	1
MMRF_1588	First line of therapy	Dexamethasone		PREP FOR BONE MARROW TRANSPLANT	mg	PO	Log Forms	Induction	Induction		40	Other	QD (D1-4, D9-12, D17-20)					1	161	1
MMRF_1588	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	TRANSPLANT		200	Other	ONCE					205	205	1
MMRF_1588	Second Line Therapy (after first relapse)	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	25	QD (D1-21)	QD (D1-21)					1458		1
MMRF_1588	Second Line Therapy (after first relapse)	Elotuzumab			mg	IV	Log Forms	Maintenance	Maintenance	Checked	1100	Other	Q4W					1463		1
MMRF_1596	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	186	1
MMRF_1596	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.5	QWK	QWK					1	8	1
MMRF_1596	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	186	1
MMRF_1596	First line of therapy	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QWK	QWK					15	186	1
MMRF_1596	Second Line Therapy (after first relapse)	Cyclophosphamide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		400	QWK	QWK					200	249	1
MMRF_1596	Third Line Therapy (following 2nd relapse)	ETOPOSIDE		Lack of response	mg/m^2	IV	Log Forms	Induction	Induction		40	QD (D1-4)	QD (D1-4)					284	310	1
MMRF_1596	Second Line Therapy (after first relapse)	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.5	QWK	QWK					200	249	1
MMRF_1596	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		40	QWK	QWK					200	249	1
MMRF_1596	Third Line Therapy (following 2nd relapse)	CISPLATIN		Lack of response	mg/m^2	IV	Log Forms	Induction	Induction		10	QD (D1-14)	QD (D1-14)					284	310	1
MMRF_1596	Third Line Therapy (following 2nd relapse)	Cyclophosphamide		Lack of response	mg	IV	Log Forms	Induction	Induction		1000	QD (D1-4)	QD (D1-4)					284	310	1
MMRF_1596	Third Line Therapy (following 2nd relapse)	Doxorubicin		Lack of response	mg/m^2	IV	Log Forms	Induction	Induction		9	QD (D1-4)	QD (D1-4)					284	310	1
MMRF_1596	Third Line Therapy (following 2nd relapse)	Dexamethasone		Lack of response	mg	PO	Log Forms	Induction	Induction		40	QD (D1-4)	QD (D1-4)					284	310	1
MMRF_1596	Fourth Line Therapy (following 3rd relapse)	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					327	343	1
MMRF_1596	Fourth Line Therapy (following 3rd relapse)	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Induction	Induction		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					356	364	1
MMRF_1596	Fourth Line Therapy (following 3rd relapse)	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					327	364	1
MMRF_1596	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					327	364	1
MMRF_1740	First line of therapy	Lenalidomide			mg	PO	Log Forms	Induction	Induction	Checked	25	Q day	Q day					1		1
MMRF_1740	First line of therapy	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	12	QWK	QWK					9		1
MMRF_1740	Second Line Therapy (after first relapse)	Bortezomib			mg/m^2	IV SubQ	Log Forms	Unknown	Unknown	Checked	1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					715		1
MMRF_1794	First line of therapy	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Induction	Induction		240	QWK	QWK					1	239	1
MMRF_1794	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	239	1
MMRF_1794	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.5	QWK	QWK					1	239	1
MMRF_1794	Third Line Therapy (following 2nd relapse)	Dexamethasone		DEATH	mg	PO	Log Forms	Maintenance	Maintenance		20	Other	D1, 8, 15, 22					1379	1707	1
MMRF_1794	Third Line Therapy (following 2nd relapse)	Lenalidomide		DEATH	mg	PO	Log Forms	Maintenance	Maintenance		20	QD (D1-21)	QD (D1-21)					1379	1707	1
MMRF_1794	Third Line Therapy (following 2nd relapse)	Elotuzumab		PATIENT DEATH	mg	IV	Log Forms	Maintenance	Maintenance		1100	Other	Q2W					1378	1707	1
MMRF_1794	Second Line Therapy (after first relapse)	Daratumumab		Completed regimen	mg	IV	Log Forms	Maintenance	Maintenance		960	Other	Q4W					1059	1640	1
MMRF_1932	First line of therapy	Lenalidomide		PREP FOR BONE MARROW TRANSPLANT	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	164	1
MMRF_1932	First line of therapy	Dexamethasone		PREP FOR BONE MARROW TRANSPLANT	mg	PO	Log Forms	Induction	Induction		10	Other	DAYS 1,8,15 AND 22					1	164	1
MMRF_1932	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	Q day	Q day					325		1
MMRF_1932	First line of therapy	Melphalan		STEM CELL	mg/m^2	IV	Log Forms	Other	PREPARATION		200	Other	ONCE					184	184	1
MMRF_1980	First line of therapy	Lenalidomide		INCREASE IN KAPPA LIGHT CHAIN	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	742	1
MMRF_1980	First line of therapy	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	10	Other	D1, 8, 15, 22					1		1
MMRF_1980	Second Line Therapy (after first relapse)	Bortezomib			mg	IV SubQ	Log Forms	Maintenance	Maintenance	Checked	2.2	Q week	Q week					1020		1
MMRF_1980	Second Line Therapy (after first relapse)	Daratumumab			mg	IV	Log Forms	Maintenance	Maintenance	Checked	1030	Other	Q4W					1195		1
MMRF_2173	Second Line Therapy (after first relapse)	Lenalidomide		PATIENT DIED	mg	PO	Log Forms	Maintenance	Maintenance		25	Q day	Q day					42	1986	1
MMRF_2173	First line of therapy	Dexamethasone		UNKNOWN	mg	PO	Log Forms	Induction	Induction		40	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1	355	1
MMRF_2173	First line of therapy	Bortezomib		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		2	Other	D1, 8, 15 , 22					15	1645	1
MMRF_2173	First line of therapy	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Induction	Induction		400	Other	DAYS 1, 8, 15, 22					15	380	1
MMRF_2220	First line of therapy	Bortezomib		Patient decision	mg	SUBQ	Log Forms	Induction	Induction		2.8	Other	D1, 8, 15, 22					1	1614	1
MMRF_2220	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO	Log Forms	Induction	Induction		300	Q week	Q week					1	106	1
MMRF_2220	First line of therapy	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	40	Other	D1-4, 9-12, 17-20					1		1
MMRF_2220	Second Line Therapy (after first relapse)	Carfilzomib			mg	IV	Log Forms	Maintenance	Maintenance	Checked	32	Other	D1, 8, 15					1668		1
MMRF_2587	First line of therapy	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Induction	Induction		500	Other	DAYS 1, 8, 15, 22					1	104	1
MMRF_2587	First line of therapy	Bortezomib			mg	SUB Q	Log Forms	Induction	Induction	Checked	2.5	Other	DAYS 1, 8, 15, 22					1		1
MMRF_2587	First line of therapy	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	40	Other	1-4, 9-12, 17-20					1		1
MMRF_2587	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	HIGH DOSE FOLLOWED BY STEM CELL TRANSPLANT		200	Q day	Q day					134	138	1
MMRF_1216	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms				1.7	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	116	1
MMRF_1216	First line of therapy	Dexamethasone		DIFFERENT FREQUENCY	mg	PO	Log Forms				40	Other	DAY 1-4 THEN DAYS 9-12					1	33	1
MMRF_1216	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	QD (D1-4)	QD (D1-4)					43	1023	1
MMRF_1216	First line of therapy	Bortezomib		Disease progression/Relapse	mg	IV SubQ	Log Forms				2.3	Other	D1,8,15 AND 22 Q42DAYS					141	1023	1
MMRF_1216	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	Q day	Q day					1024	1108	1
MMRF_1216	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		4	Q day	Q day					1024	1108	1
MMRF_1216	Third Line Therapy (following 2nd relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1207	1345	1
MMRF_1216	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		4	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1207	1345	1
MMRF_1228	First line of therapy	Bortezomib		Disease progression/Relapse	mg	IV	Log Forms				3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	1366	1
MMRF_1228	First line of therapy	Doxorubicin		Disease progression/Relapse	mg	IV	Log Forms				70	Other	Q3 WEEKS					1	1366	1
MMRF_1228	Second Line Therapy (after first relapse)	Daratumumab		Disease progression/Relapse	mg/m^2	IV	Log Forms	Induction	Induction		16	Q week	Q week					1218	1366	1
MMRF_1228	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					103	1366	1
MMRF_1228	First line of therapy	Cyclophosphamide		Lack of response	mg/m^2	IV	Log Forms	Induction	Induction		300	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)					916	1098	1
MMRF_1296	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	197	1
MMRF_1296	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms				40	Q week	Q week					1	256	1
MMRF_1296	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					198	256	1
MMRF_1364	First line of therapy	Lenalidomide		Lack of response	mg	PO	Log Forms				25	Q day	Q day					1	83	1
MMRF_1364	First line of therapy	Dexamethasone			mg	PO	Log Forms	Unknown	Unknown	Checked	40	Q week	Q week					1		1
MMRF_1364	First line of therapy	Cyclophosphamide			G/M^2	IV	Log Forms	Other	MOBILIZATION FOR TRANSPLANT	Checked	4	Q week	Q week					172		1
MMRF_1364	First line of therapy	Bortezomib			mg	IV	Log Forms	Induction	Induction	Checked	2.8	Q week	Q week					1		1
MMRF_1531	First line of therapy	Bortezomib		DEATH	mg/m^2	IV SubQ	Log Forms	Unknown	Unknown		1.5	QWK	QWK					1	520	1
MMRF_1531	First line of therapy	Dexamethasone		DEATH	mg	PO	Log Forms	Unknown	Unknown		40	Q week	Q week					1	520	1
MMRF_1531	First line of therapy	Cyclophosphamide		DEATH	mg/m^2	PO	Log Forms	Unknown	Unknown		300	Q week	Q week					1	520	1
MMRF_1659	First line of therapy	Bortezomib		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		2.6	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)					21	323	1
MMRF_1659	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	589	1
MMRF_1659	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		25	Q day	Q day					22	329	1
MMRF_1659	Second Line Therapy (after first relapse)	Carfilzomib		Completed regimen	mg	IV	Log Forms	Induction	Induction		41	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					331	346	1
MMRF_1659	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		4	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					331	346	1
MMRF_1659	Second Line Therapy (after first relapse)	Carfilzomib		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Maintenance	Maintenance		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					359	403	1
MMRF_1659	Second Line Therapy (after first relapse)	Dexamethasone		Investigator decision for other reasons	mg	IV	Log Forms	Maintenance	Maintenance		4	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					359	403	1
MMRF_1659	Second Line Therapy (after first relapse)	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Unknown	Unknown		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					420	463	1
MMRF_1659	Second Line Therapy (after first relapse)	Doxorubicin		Completed regimen	mg/m^2	IV	Log Forms	Unknown	Unknown		10	QD (D1-4)	QD (D1-4)					420	463	1
MMRF_1659	Second Line Therapy (after first relapse)	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Unknown	Unknown		400	QD (D1-4)	QD (D1-4)					420	463	1
MMRF_1659	Second Line Therapy (after first relapse)	ETOPOSIDE		Completed regimen	mg/m^2	IV	Log Forms	Unknown	Unknown		40	QD (D1-4)	QD (D1-4)					420	463	1
MMRF_1659	Second Line Therapy (after first relapse)	CISPLATIN		Completed regimen	mg/m^2	IV	Log Forms	Unknown	Unknown		10	QD (D1-4)	QD (D1-4)					420	463	1
MMRF_1659	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	IV	Log Forms	Unknown	Unknown		40	QD (D1-4)	QD (D1-4)					420	463	1
MMRF_1659	Second Line Therapy (after first relapse)	Lenalidomide		Completed regimen	mg	PO	Log Forms	Unknown	Unknown		10	Q day	Q day					413	589	1
MMRF_1659	Third Line Therapy (following 2nd relapse)	Melphalan		Completed regimen	mg	IV	Log Forms	Consolidation	Consolidation		200	Q day	Q day					498	498	1
MMRF_1659	Fourth Line Therapy (following 3rd relapse)	Melphalan		Completed regimen	mg	IV	Log Forms	Consolidation	Consolidation		200	Q day	Q day					679	679	1
MMRF_1659	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Completed regimen	mg	IV	Log Forms	Consolidation	Consolidation		10	Q day	Q day					679	679	1
MMRF_1659	Fifth Line Therapy (following 4th relapse)	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					756	1773	1
MMRF_1659	Fifth Line Therapy (following 4th relapse)	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		4	Q day	Q day					756	1772	1
MMRF_1659	Fifth Line Therapy (following 4th relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	IV	Log Forms	Induction	Induction		4	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					756	1772	1
MMRF_1659	Fifth Line Therapy (following 4th relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	Other	QD (D1, 8, 15, 22)					756	1772	1
MMRF_1659	Fifth Line Therapy (following 4th relapse)	Pomalidomide		DEATH	mg	PO	Log Forms	Unknown	Unknown		3	Other	21 DAYS-7DAYS OFF					1773	1785	1
MMRF_1659	Fifth Line Therapy (following 4th relapse)	Dexamethasone		DEATH	mg	PO	Log Forms	Unknown	Unknown		4	Q day	Q day					1773	1785	1
MMRF_1691	Third Line Therapy (following 2nd relapse)	Dexamethasone		DEATH	mg	PO	Log Forms	Unknown	Unknown		20	Q day	Q day					2442	2487	1
MMRF_1691	Third Line Therapy (following 2nd relapse)	Bortezomib		DEATH	mg/m^2	IV	Log Forms	Unknown	Unknown		1.3	QD (D1, D4, D8, D11, D28, D35, D38)	QD (D1, D4, D8, D11, D28, D35, D38)					2443	2487	1
MMRF_1691	Third Line Therapy (following 2nd relapse)	Daratumumab		DEATH	mg/kg	IV	Log Forms	Unknown	Unknown		16	QWK	QWK					2443	2487	1
MMRF_1691	First line of therapy	Bortezomib		Completed regimen	mg	IV	Log Forms	Induction	Induction		3.3	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	78	1
MMRF_1691	First line of therapy	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Induction	Induction		300	Q week	Q week					1	147	1
MMRF_1691	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	113	1
MMRF_1691	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					118	372	1
MMRF_1691	First line of therapy	Carfilzomib		Completed regimen	mg	IV	Log Forms	Maintenance	Maintenance		60	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					125	356	1
MMRF_1691	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg	IV	Log Forms	Other	HIGH DOSE CHEMO PRE TRANSPLANT		300	Q day	Q day					597	597	1
MMRF_1691	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		25	Q day	Q day					734	2440	1
MMRF_1691	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	PRE STEM CELL TRANSPLANT		200	QD (D1-3)	QD (D1-3)					382	385	1
MMRF_1803	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Q day	Q day					140	141	1
MMRF_1803	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		3	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1	99	1
MMRF_1803	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	182	1
MMRF_1803	First line of therapy	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Induction	Induction		600	Q day	Q day					1	182	1
MMRF_1810	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		25	Q day	Q day					1	149	1
MMRF_1810	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		40	Q day	Q day					1	8	1
MMRF_1810	First line of therapy	Bortezomib		Investigator decision for other reasons	mg	IV SubQ	Log Forms	Induction	Induction		2.7	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					23	149	1
MMRF_1810	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Induction	Induction		191	Q day	Q day					159	160	1
MMRF_1810	Third Line Therapy (following 2nd relapse)	Elotuzumab		Completed regimen	mg/kg	IV	Log Forms	Induction	Induction		10	QWK	QWK					1090	1132	1
MMRF_1810	Third Line Therapy (following 2nd relapse)	Melphalan		Completed regimen	mg	IV	Log Forms	Consolidation	Consolidation		200	Q day	Q day					1154	1155	1
MMRF_1810	Second Line Therapy (after first relapse)	Bortezomib		Investigator decision for other reasons	mg	IV SubQ	Log Forms	Maintenance	Maintenance		0.9	QWK	QWK					901	999	1
MMRF_1810	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		4	Other	ONCE EVERY OTHER WEEK					261	642	1
MMRF_1810	Second Line Therapy (after first relapse)	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		4	Q week	Q week					936	1055	1
MMRF_1810	Third Line Therapy (following 2nd relapse)	Dexamethasone		Completed regimen	mg	IV	Log Forms	Induction	Induction		8	QWK	QWK					1090	1132	1
MMRF_1810	Third Line Therapy (following 2nd relapse)	Bortezomib		Lack of response	mg	IV SubQ	Log Forms	Maintenance	Maintenance		2.6	Other	D1, D15					1258	1693	1
MMRF_1810	Third Line Therapy (following 2nd relapse)	Daratumumab			mg/kg	IV	Log Forms	Induction	Induction	Checked	16	Q week	Q week					1707		1
MMRF_1810	Third Line Therapy (following 2nd relapse)	Dexamethasone			mg	IV	Log Forms	Induction	Induction	Checked	20	Q week	Q week					1707		1
MMRF_1810	Third Line Therapy (following 2nd relapse)	Pomalidomide			mg	PO	Log Forms	Induction	Induction	Checked	3	Q day	Q day					1707		1
MMRF_1831	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg	IV	Log Forms	Induction	Induction		2.8	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	80	1
MMRF_1831	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	IV	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	80	1
MMRF_1831	First line of therapy	Liposomal doxorubicin		Adverse Event or co-morbidity	mg	IV	Log Forms	Induction	Induction		64	Other	EVERY 3 WEEKS					2	80	1
MMRF_1831	First line of therapy	Dexamethasone		Lack of response	mg	IV	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					114	1738	1
MMRF_1831	First line of therapy	Bortezomib		Lack of response	mg	IV SubQ	Log Forms	Induction	Induction		2.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					204	1738	1
MMRF_1917	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	Q day	Q day					1	315	1
MMRF_1917	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q day	Q day					1	315	1
MMRF_1917	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		20	Other	D1,2,8,9,15,16					16	303	1
MMRF_1917	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		15	Q day	Q day					329	389	1
MMRF_1917	Second Line Therapy (after first relapse)	Lenalidomide			mg	PO	Log Forms	Induction	Induction	Checked	25	Q day	Q day					715		1
MMRF_1917	First line of therapy	Carfilzomib		Completed regimen	mg	IV	Log Forms	Induction	Induction		93	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					44	142	1
MMRF_2290	First line of therapy	Dexamethasone		DEATH	mg	PO	Log Forms	Induction	Induction		20	Q day	Q day					1	139	1
MMRF_2290	First line of therapy	Lenalidomide		DEATH	mg	PO	Log Forms	Induction	Induction		25	Q day	Q day					14	139	1
MMRF_2461	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		4	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	504	1
MMRF_2461	Second Line Therapy (after first relapse)	Ixazomib		Patient decision	mg	PO	Log Forms	Induction	Induction		3	Q week	Q week					505	767	1
MMRF_2461	Second Line Therapy (after first relapse)	Lenalidomide		Patient decision	mg	PO	Log Forms	Induction	Induction		10	Q day	Q day					505	767	1
MMRF_2461	Second Line Therapy (after first relapse)	Dexamethasone		Patient decision	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					505	767	1
MMRF_2461	First line of therapy	Bortezomib		Disease progression/Relapse	mg	IV SubQ	Log Forms	Induction	Induction		1.7	Q week	Q week					1	491	1
MMRF_1254	First line of therapy	Bortezomib		Disease progression/Relapse	mg	IV	Log Forms				2.4	Other	D1, 8, 15, 22					1	267	1
MMRF_1254	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	QD (D1-4)	QD (D1-4)					1	211	1
MMRF_1254	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Consolidation	Consolidation		15	QD (D1-21)	QD (D1-21)					283	967	1
MMRF_1254	Third Line Therapy (following 2nd relapse)	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		3	Q day	Q day					1386	1451	1
MMRF_1254	Third Line Therapy (following 2nd relapse)	Pomalidomide		Patient decision	mg	PO	Log Forms	Maintenance	Maintenance		2	Q day	Q day					1451	1719	1
MMRF_1348	First line of therapy	Bortezomib			mg	IV SubQ	Log Forms			Checked	3.4	Other	DAYS 1,8, 15 & 22					1		1
MMRF_1348	First line of therapy	Dexamethasone			mg	PO	Log Forms			Checked	40	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1		1
MMRF_1371	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	PRE TRASNSPLANT TREATMENT		100	Q day	Q day					292	293	1
MMRF_1371	Third Line Therapy (following 2nd relapse)	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Q day	Q day					2497	2498	1
MMRF_1371	First line of therapy	Bortezomib		Lack of response	mg/m^2	IV	Log Forms				1.3	QWK	QWK					1	57	1
MMRF_1371	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QWK	QWK					71	250	1
MMRF_1371	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Consolidation	Consolidation		1500	Other	ONCE					264	264	1
MMRF_1371	First line of therapy	Lenalidomide		CHANGED DOSE	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					404	819	1
MMRF_1371	First line of therapy	Lenalidomide		CHANGE DOSE	mg	PO	Log Forms	Maintenance	Maintenance		10	Other	QD (D1-5)					819	911	1
MMRF_1371	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-4)	QD (D1-4)					911	2290	1
MMRF_1371	First line of therapy	Dexamethasone		Completed regimen	mg	IVB	Log Forms	Induction	Induction		20	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1	264	1
MMRF_1371	Second Line Therapy (after first relapse)	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation			QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					2308	2469	1
MMRF_1371	Second Line Therapy (after first relapse)	Pomalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		4	QD (D1-21)	QD (D1-21)					2308	2469	1
MMRF_1371	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	IV	Log Forms	Consolidation	Consolidation		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					2310	2469	1
MMRF_1371	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	PRE-TRANSPLANT		100	Q day	Q day					2497	2498	1
MMRF_1371	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	IV	Log Forms	Consolidation	Consolidation		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					2337	2464	1
MMRF_1371	Second Line Therapy (after first relapse)	Pomalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		4	QD (D1-21)	QD (D1-21)					2308	2469	1
MMRF_1371	Second Line Therapy (after first relapse)	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction			QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					2308	2469	1
MMRF_1371	Second Line Therapy (after first relapse)	Bortezomib			mg	SUBQ	Log Forms	Maintenance	Maintenance	Checked	2.8	Other	EVERY OTHER WEEK					2597		1
MMRF_1371	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Q day	Q day					209	210	1
MMRF_1377	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING PRIOR TO BM TRANSPLANT		200	Q day	Q day					288	289	1
MMRF_1377	Third Line Therapy (following 2nd relapse)	Bendamustine			mg/m^2	IV	Log Forms	Unknown	Unknown	Checked	100	Other	D 1-2 Q 4 WEEK					2705		1
MMRF_1377	First line of therapy	Cyclophosphamide		Completed regimen	mg	PO	Log Forms				500	QWK	QWK					1	143	1
MMRF_1377	First line of therapy	Bortezomib		Completed regimen	mg	SQ	Log Forms				3.5	QWK	QWK					1	134	1
MMRF_1377	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	QWK	QWK					1	143	1
MMRF_1377	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Other	AUTOLOGOUS BLOOD STEM CELL MOBILIZATION		3000	Other	ONCE					165	165	1
MMRF_1377	Second Line Therapy (after first relapse)	Lenalidomide		CHANGING DOSE	mg	PO	Log Forms	Induction	Induction		10	Q day	Q day					753	984	1
MMRF_1377	Second Line Therapy (after first relapse)	Dexamethasone		CHANGED DOSE	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					753	1026	1
MMRF_1377	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		15	Other	QOD DAYS 1-21					984	1257	1
MMRF_1377	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					1267	1799	1
MMRF_1377	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	SUB-Q	Log Forms	Maintenance	Maintenance		1.3	Other	Q2WK					1813	2061	1
MMRF_1703	First line of therapy	Cyclophosphamide		Lack of response	mg	PO	Log Forms	Induction	Induction		500	Q week	Q week					1	164	1
MMRF_1703	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg	IV SubQ	Log Forms	Induction	Induction		3.1	Q week	Q week					1	164	1
MMRF_1703	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	563	1
MMRF_1703	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	QD (D1-14)	QD (D1-14)					164	1318	1
MMRF_1703	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		4	Other	TAKE 10 TABLETS PER WEEK (40MG PER WK)					606	1318	1
MMRF_1703	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg	IV SubQ	Log Forms	Induction	Induction		2.7	Q week	Q week					164	185	1
MMRF_1703	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg	IV SubQ	Log Forms	Induction	Induction		2.1	Q week	Q week					185	598	1
MMRF_1703	Second Line Therapy (after first relapse)	Bortezomib		Adverse Event or co-morbidity	mg	IV SubQ	Log Forms	Induction	Induction		1.7	Q week	Q week					612	773	1
MMRF_2166	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		4	TID	TID					1	12	1
MMRF_2166	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					17	28	1
MMRF_2324	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					1	98	1
MMRF_2324	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	QD (D1-21)	QD (D1-21)					1	126	1
MMRF_2324	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	126	1
MMRF_2324	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-7)	QD (D1-7)					275		1
MMRF_2324	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	PRE MB TRASPLANT CONDITIONING		200	Q day	Q day					153	154	1
MMRF_2326	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	PRE BM TRANSPLANT CONDITIONING		200	Q day	Q day					161	162	1
MMRF_2326	Second Line Therapy (after first relapse)	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Unknown	Unknown		1.3	Other	QWK WEEKS 1-3.  WEEK 4 REST					1763	1872	1
MMRF_2326	Second Line Therapy (after first relapse)	Pomalidomide		DEATH	mg	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					1763	1933	1
MMRF_2326	Second Line Therapy (after first relapse)	Dexamethasone		DEATH	mg	FEEDING TUBE	Log Forms	Unknown	Unknown		40	QWK	QWK					1763	1933	1
MMRF_2326	Second Line Therapy (after first relapse)	Ixazomib		PT UNDERWENT SURGERY FOR RECONSTRUCTION OF MANDIBLE	mg	PO	Log Forms	Maintenance	Maintenance		4	Other	DAYS 1,8,15					1549	1655	1
MMRF_2326	Second Line Therapy (after first relapse)	Dexamethasone		UNDERGOING RECONSTRUCTIVE SURGERY	mg	PO	Log Forms	Maintenance	Maintenance		4	Q week	Q week					1549	1655	1
MMRF_2326	Second Line Therapy (after first relapse)	Pomalidomide		UNDERGOING RECONSTRUCTIVE SURGERY OF MANDIBLE	mg	PO	Log Forms	Maintenance	Maintenance		4	QD (D1-21)	QD (D1-21)					1549	1653	1
MMRF_2326	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					1	99	1
MMRF_2326	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					2	106	1
MMRF_2326	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					2	203	1
MMRF_2326	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-7)	QD (D1-7)					281	1543	1
MMRF_1090	First line of therapy	Bortezomib		Adverse Event or co-morbidity	MG	IV SubQ	Log Forms				2.4	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1	94	1
MMRF_1090	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms				40	QWK	QWK					134	432	1
MMRF_1090	First line of therapy	Cyclophosphamide		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms				250	Other	DAY 1 AND DAY 8 Q 35 DAYS					1	73	1
MMRF_1090	First line of therapy	Thalidomide		Investigator decision for other reasons	MG	PO	Log Forms				100	Q day	Q day					1	127	1
MMRF_1090	First line of therapy	Bortezomib		Disease progression/Relapse	mg	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	QWK	QWK					134	432	1
MMRF_1090	Second Line Therapy (after first relapse)	Bendamustine		PATIENT DECEASED	mg	IV	Log Forms	Maintenance	Maintenance		90	Other	(D1& 2 Q 28 D)					435	681	1
MMRF_1090	Second Line Therapy (after first relapse)	RITUXAN		PATIENT DECEASED	mg	IV	Log Forms	Maintenance	Maintenance		375	Other	D1					435	681	1
MMRF_1122	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms				2.63	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)					1	123	1
MMRF_1122	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	Other	D1-14 Q 21 D					64	123	1
MMRF_1122	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		4	TID	TID					1	123	1
MMRF_1122	Second Line Therapy (after first relapse)	Lenalidomide		PATIENT TO RECEIVE TRANSPLANT	mg	PO	Log Forms	Maintenance	Maintenance		25	Q day	Q day					176	229	1
MMRF_1122	Third Line Therapy (following 2nd relapse)	Bortezomib		PATIENT DIED	mg	IV SubQ	Log Forms	Other	NEW TREATMENT FOR DISEASE PROGRESSION		2.67	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					666	697	1
MMRF_1122	Third Line Therapy (following 2nd relapse)	Dexamethasone		PATIENT DIED	mg	PO	Log Forms	Other	NEW TREATMENT FOR DISEASE PROGRESSION		20	Q week	Q week					666	697	1
MMRF_1386	First line of therapy	Carfilzomib		PER PROTOCOL, 20 MG/M^2 ONLY FOR C1D1 AND C1D2	mg/m^2	IV	Log Forms				20	Other	QD (C1D1, C1D2)					1	2	1
MMRF_1386	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		45	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					8	156	1
MMRF_1386	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	QD (D1-2, D8-9, D15-16, D22-23)					1	162	1
MMRF_1386	First line of therapy	Dexamethasone		PROTOCOL PROCEDURES	mg	PO	Log Forms	Consolidation	Consolidation		40	Other	QD (D1, 8, 15, 22)					178	217	1
MMRF_1386	First line of therapy	Lenalidomide		PER PROTOFCOL PROCEDURES	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					178	216	1
MMRF_1386	First line of therapy	CLARITHROMYCIN		Adverse Event or co-morbidity	mg	PO	Log Forms	Consolidation	Consolidation		500	BID	BID					178	193	1
MMRF_1386	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					234		1
MMRF_1403	First line of therapy	Carfilzomib		PER PROTOCOL, 20 MG/M^2 ONLY FOR C1D1 AND C1D2	mg/m^2	IV	Log Forms	Induction	Induction		20	Other	QD (C1D1, C1D2)					1	2	1
MMRF_1403	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		45	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					8	156	1
MMRF_1403	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	QD (D1-2, D8-9, D15-16, D22-23)					1	163	1
MMRF_1403	First line of therapy	Lenalidomide		PROTOCOL PROCEDURES	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					178	226	1
MMRF_1403	First line of therapy	Dexamethasone		PROTOCOL PROCEDURES	mg	PO	Log Forms	Consolidation	Consolidation		40	Other	QD (D1, 8, 15, 22)					178	227	1
MMRF_1403	First line of therapy	CLARITHROMYCIN		PROTOCOL PROCEDURES	mg	PO	Log Forms	Consolidation	Consolidation		500	BID	BID					178	233	1
MMRF_1403	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					234	926	1
MMRF_1403	Second Line Therapy (after first relapse)	Lenalidomide		Completed regimen	mg	PO	Log Forms	Other	TRANSPLANT PHASE (CONDITIONING)		350	Other	150MG QAM AND 200MG QPM ON DAYS 1-5					940	944	1
MMRF_1403	Second Line Therapy (after first relapse)	Ixazomib		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		4	QD (D1-21)	QD (D1-21)					1535	2213	1
MMRF_1403	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	TRANSPLANT PHASE (CONDITIONING)		200	Other	DAYS 4 AND 5					943	944	1
MMRF_1403	Third Line Therapy (following 2nd relapse)	Thalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		100	QD (D1-21)	QD (D1-21)					2507	2759	1
MMRF_1403	Third Line Therapy (following 2nd relapse)	Daratumumab		Investigator decision for other reasons	mg/kg	IV	Log Forms	Maintenance	Maintenance		16	Other	MONTHLY					2415	2717	1
MMRF_1403	Third Line Therapy (following 2nd relapse)	Bortezomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Maintenance	Maintenance		1.3	Other	EVERY OTHER WEEK					2451	2759	1
MMRF_1403	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO OR IV	Log Forms	Consolidation	Consolidation		12	Other	QD (D1, D15)					2241	2759	1
MMRF_1403	Third Line Therapy (following 2nd relapse)	Daratumumab		Completed regimen	mg/kg	IV	Log Forms	Consolidation	Consolidation		16	Other	QD (D1, D15)					2290	2388	1
MMRF_1403	Third Line Therapy (following 2nd relapse)	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		1.3	Other	D1, 8, 15					2318	2437	1
MMRF_1403	Third Line Therapy (following 2nd relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		4	Q day	Q day					2234	2235	1
MMRF_1403	Third Line Therapy (following 2nd relapse)	Daratumumab		Completed regimen	mg/kg	IV	Log Forms	Induction	Induction		16	QWK	QWK					2234	2283	1
MMRF_1403	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		2.5	QD (D1-21)	QD (D1-21)					1402	1491	1
MMRF_1403	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					1318	1394	1
MMRF_1403	Second Line Therapy (after first relapse)	Lenalidomide		ORDERED THE CORRECT DOSAGE FOR THE FOLLOWING CYCLE	mg	PO	Log Forms	Maintenance	Maintenance		10	Other	EVERY OTHER DAY X 21 DAYS					1290	1310	1
MMRF_1403	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					1226	1275	1
MMRF_1403	Second Line Therapy (after first relapse)	Lenalidomide		ORDERED THE CORRECT DOSAGE THE FOLLOWING CYCLE	mg	PO	Log Forms	Maintenance	Maintenance		15	Other	EVERY OTHER DAY X 21 DAYS					1192	1212	1
MMRF_1403	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					1129	1184	1
MMRF_1403	Second Line Therapy (after first relapse)	Lenalidomide		ORDERED THE CORRECT DOSAGE THE FOLLOWING CYCLE	mg	PO	Log Forms	Maintenance	Maintenance		25	Other	EVERY OTHER DAY X 21 DAYS					1101	1121	1
MMRF_1403	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		25	QD (D1-21)	QD (D1-21)					1045	1093	1
MMRF_1403	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		4	Other	DAYS 1, 8, 15					1535	2213	1
MMRF_1403	Third Line Therapy (following 2nd relapse)	Cyclophosphamide		Investigator decision for other reasons	mg	IV	Log Forms	Maintenance	Maintenance		500	Other	EVERY OTHER WEEK					2605	2731	1
MMRF_1403	Third Line Therapy (following 2nd relapse)	Daratumumab		Disease progression/Relapse	mg	SC	Log Forms	Maintenance	Maintenance		1800	Other	DAY 1					2745	2745	1
MMRF_1403	Fourth Line Therapy (following 3rd relapse)	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Other	SALVAGE		20	Other	ONCE					2816	2816	1
MMRF_1403	Fourth Line Therapy (following 3rd relapse)	CISPLATIN		Completed regimen	mg/m^2	IVBP	Log Forms	Other	SALVAGE		10	Q day	Q day					2816	2819	1
MMRF_1403	Fourth Line Therapy (following 3rd relapse)	ETOPOSIDE		Completed regimen	mg/m^2	IVBP	Log Forms	Other	SALVAGE		40	Q day	Q day					2816	2819	1
MMRF_1403	Fourth Line Therapy (following 3rd relapse)	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Other	SALVAGE		27	Other	ONCE					2817	2817	1
MMRF_1403	Fourth Line Therapy (following 3rd relapse)	Cyclophosphamide		Completed regimen	mg/m^2	IVBP	Log Forms	Other	SALVAGE		400	Other	ONCE					2816	2819	1
MMRF_1403	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Other	SALVAGE		40	Q day	Q day					2815	2818	1
MMRF_1403	Fifth Line Therapy (following 4th relapse)	TRASTUZUMAB			mg/kg	IV	Log Forms	Unknown	Unknown	Checked	2.5	Other	Q3W					2842		1
MMRF_1403	Fifth Line Therapy (following 4th relapse)	SELINEXOR			mg	PO	Log Forms	Unknown	Unknown	Checked	60	QWK	QWK					2879		1
MMRF_1458	First line of therapy	Carfilzomib		PER PROTOCOL, 20 MG/M^2 ONLY FOR C1D1 AND C1D2	mg/m^2	IV	Log Forms	Induction	Induction		20	Other	QD (C1D1, C1D2)					1	2	1
MMRF_1458	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		45	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					8	128	1
MMRF_1458	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	QD (D1-2, D8-9, D15-16, D22-23)					1	135	1
MMRF_1458	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		15	QD (D1-21)	QD (D1-21)					233	540	1
MMRF_1458	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Unknown	Unknown		20	Q week	Q week					233	540	1
MMRF_1458	Second Line Therapy (after first relapse)	Ixazomib		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					1342	1459	1
MMRF_1458	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		5	QD (D1-21)	QD (D1-21)					1342	1837	1
MMRF_1462	First line of therapy	Carfilzomib		PER PROTOCOL, 20 MG/M^2 ONLY FOR C1D1 AND C1D2	mg/m^2	IV	Log Forms	Induction	Induction		20	Other	QD (C1D1, C1D2)					1	2	1
MMRF_1462	First line of therapy	Carfilzomib		PROTOCOL PROCEDURES	mg/m^2	IV	Log Forms	Induction	Induction		45	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					8	100	1
MMRF_1462	First line of therapy	Dexamethasone		PROTOCOL PROCEDURES	mg	PO	Log Forms	Induction	Induction		20	Other	QD (D1-2, D8-9, D15-16, D22-23)					1	107	1
MMRF_1462	First line of therapy	CLARITHROMYCIN		PROTOCOL PROCEDURES	mg	PO	Log Forms	Consolidation	Consolidation		500	BID	BID					122	177	1
MMRF_1462	First line of therapy	Lenalidomide		PROTOCOL PROCEDURES	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					122	170	1
MMRF_1462	First line of therapy	Dexamethasone		PROTOCOL PROCEDURES	mg	PO	Log Forms	Consolidation	Consolidation		40	Other	QD (D1, D8, D15, D22)					122	171	1
MMRF_1462	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					178	627	1
MMRF_1462	Second Line Therapy (after first relapse)	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					646	712	1
MMRF_1462	Fifth Line Therapy (following 4th relapse)	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		100	Q day	Q day					1128	1129	1
MMRF_1462	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	Other	QD (D1-2, D4-5, D8-9, D11-12)					646	677	1
MMRF_1462	Third Line Therapy (following 2nd relapse)	ACY-241		Investigator decision for other reasons	mg	PO	Log Forms	Unknown	Unknown		180	QD (D1-21)	QD (D1-21)					890	910	1
MMRF_1462	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		40	Other	DAYS 1, 8, 15, 22					890	912	1
MMRF_1462	Third Line Therapy (following 2nd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					900	912	1
MMRF_1462	Fourth Line Therapy (following 3rd relapse)	Carfilzomib		Completed regimen	mg	IV	Log Forms	Unknown	Unknown		46	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					912	913	1
MMRF_1462	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		20	Q day	Q day					912	1123	1
MMRF_1462	Fourth Line Therapy (following 3rd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					912	1123	1
MMRF_1462	Fifth Line Therapy (following 4th relapse)	Daratumumab			mg	SC	Log Forms	Maintenance	Maintenance	Checked	1800	Other	MONTHLY					2606		1
MMRF_1462	Fifth Line Therapy (following 4th relapse)	Dexamethasone			mg	PO	Log Forms	Maintenance	Maintenance	Checked	12	Other	MONTHLY					1376		1
MMRF_1462	Fifth Line Therapy (following 4th relapse)	Daratumumab		Investigator decision for other reasons	mg/kg	IV	Log Forms	Maintenance	Maintenance		16	Other	MONTHLY					1376	2579	1
MMRF_1462	Fifth Line Therapy (following 4th relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		20	Other	D1, 15					1285	1354	1
MMRF_1462	Fifth Line Therapy (following 4th relapse)	Daratumumab		Completed regimen	mg	IV	Log Forms	Maintenance	Maintenance		20	Other	D1, 15					1285	1354	1
MMRF_1462	Fifth Line Therapy (following 4th relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		20	QWK	QWK					1195	1271	1
MMRF_1462	Fifth Line Therapy (following 4th relapse)	Daratumumab		Completed regimen	mg/kg	IV	Log Forms	Maintenance	Maintenance		16	QWK	QWK					1195	1271	1
MMRF_1462	Fourth Line Therapy (following 3rd relapse)	Carfilzomib		Disease progression/Relapse	mg	IV	Log Forms	Unknown	Unknown		60	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					919	1123	1
MMRF_1462	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		10	Other	D1-2, 4-5, 8-9, 11-12					698	842	1
MMRF_1462	Second Line Therapy (after first relapse)	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					716	719	1
MMRF_1493	First line of therapy	Carfilzomib		THIS DOSE IS ONLY FOR C1D1 AND C1D2	mg/m^2	IV	Log Forms	Induction	Induction		20	Other	QD (C1D1, C1D2)					1	2	1
MMRF_1493	First line of therapy	Dexamethasone		Patient decision	mg	PO	Log Forms	Induction	Induction		20	Other	QD (D1-2, D8-9, D15-16, D22-23)					1	37	1
MMRF_1493	First line of therapy	Carfilzomib		Patient decision	mg/m^2	IV	Log Forms	Induction	Induction		56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					8	37	1
MMRF_1493	First line of therapy	Cyclophosphamide		Investigator decision for other reasons	mg	IV	Log Forms	Induction	Induction		500	Q week	Q week					50	162	1
MMRF_1493	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					50	162	1
MMRF_1493	First line of therapy	Bortezomib		Investigator decision for other reasons	mg	IV SubQ	Log Forms	Induction	Induction		2.6	Q week	Q week					50	162	1
MMRF_1493	First line of therapy	Lenalidomide			mg	PO	Log Forms	Induction	Induction	Checked	10	QD (D1-21)	QD (D1-21)					163		1
MMRF_1608	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		20	Other	QD (D1, D2)					1	2	1
MMRF_1608	First line of therapy	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Induction	Induction		56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					8	29	1
MMRF_1608	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	QD (D1-2, D8-9, D15-16, D22-23)					1	386	1
MMRF_1608	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		45	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					56	386	1
MMRF_1608	First line of therapy	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		500	BID	BID					399	539	1
MMRF_1608	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		40	Q week	Q week					399	533	1
MMRF_1608	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					399	532	1
MMRF_1608	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					540	1772	1
MMRF_1608	Second Line Therapy (after first relapse)	Daratumumab			mg	SC	Log Forms	Maintenance	Maintenance	Checked	1800	Other	MONTHLY					2535		1
MMRF_1608	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Maintenance	Maintenance	Checked	12	Other	MONTHLY					1961		1
MMRF_1608	Second Line Therapy (after first relapse)	Pomalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	2	QD (D1-21)	QD (D1-21)					1988		1
MMRF_1608	Second Line Therapy (after first relapse)	Daratumumab		Investigator decision for other reasons	mg/kg	IV	Log Forms	Maintenance	Maintenance		16	Other	MONTHLY					1961	2326	1
MMRF_1608	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		12	Other	D1, 15					1835	1932	1
MMRF_1608	Second Line Therapy (after first relapse)	Pomalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Consolidation	Consolidation		3	QD (D1-21)	QD (D1-21)					1835	1973	1
MMRF_1608	Second Line Therapy (after first relapse)	Daratumumab		Completed regimen	mg/kg	IV	Log Forms	Consolidation	Consolidation		16	Other	D1, 15					1835	1932	1
MMRF_1608	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		12	QWK	QWK					1772	1828	1
MMRF_1608	Second Line Therapy (after first relapse)	Pomalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					1772	1888	1
MMRF_1608	Second Line Therapy (after first relapse)	Daratumumab		Completed regimen	mg/kg	IV	Log Forms	Induction	Induction		16	QWK	QWK					1772	1828	1
MMRF_1662	First line of therapy	CLARITHROMYCIN		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		500	BID	BID					1	98	1
MMRF_1662	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	356	1
MMRF_1662	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	98	1
MMRF_1662	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					99	192	1
MMRF_1662	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	15	QD (D1-21)	QD (D1-21)					722		1
MMRF_1689	First line of therapy	Bortezomib		Investigator decision for other reasons	mg	IV	Log Forms	Induction	Induction		2.6	QWK	QWK					1	31	1
MMRF_1689	First line of therapy	Cyclophosphamide		Investigator decision for other reasons	mg	IV	Log Forms	Induction	Induction		500	Q day	Q day					1	1	1
MMRF_1689	First line of therapy	Cyclophosphamide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		300	QWK	QWK					7	28	1
MMRF_1689	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		20	QWK	QWK					1	31	1
MMRF_1689	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg	SC	Log Forms	Maintenance	Maintenance		2.7	Q week	Q week					45	129	1
MMRF_1689	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		4	QWK	QWK					188	498	1
MMRF_1689	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					188	230	1
MMRF_1689	Second Line Therapy (after first relapse)	Daratumumab		Completed regimen	mg/kg	IV	Log Forms	Induction	Induction		16	Q week	Q week					1213	1311	1
MMRF_1689	Second Line Therapy (after first relapse)	Daratumumab			mg	SC	Log Forms	Maintenance	Maintenance	Checked	1800	Other	MONTHLY					2458		1
MMRF_1689	Second Line Therapy (after first relapse)	Daratumumab		Investigator decision for other reasons	mg/kg	IV	Log Forms	Maintenance	Maintenance		16	Other	MONTHLY					1449	2381	1
MMRF_1689	Second Line Therapy (after first relapse)	Daratumumab		Completed regimen	mg/kg	IV	Log Forms	Consolidation	Consolidation		16	Other	D1,15					1325	1423	1
MMRF_1718	First line of therapy	Carfilzomib		CHANGE OF DOSE AS PART OF REGIMEN	mg/m^2	IV	Log Forms	Induction	Induction		20	Q day	Q day					1	2	1
MMRF_1718	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					3	183	1
MMRF_1718	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	QD (D1-2, D8-9, D15-16, D22-23)					1	183	1
MMRF_1718	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					205	288	1
MMRF_1718	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		40	Other	QD (D1, D8, D15, D22)					205	288	1
MMRF_1718	First line of therapy	CLARITHROMYCIN		Adverse Event or co-morbidity	mg	PO	Log Forms	Consolidation	Consolidation		500	BID	BID					205	260	1
MMRF_1718	First line of therapy	CLARITHROMYCIN		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		250	BID	BID					261	288	1
MMRF_1718	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					289	410	1
MMRF_1718	Second Line Therapy (after first relapse)	Cyclophosphamide		PATIENT WENT TO TRANSPLANT	mg	PO	Log Forms	Induction	Induction		500	Other	QD (D1, D8)					418	449	1
MMRF_1718	Second Line Therapy (after first relapse)	Bortezomib		PATIENT WENT TO TRANSPLANT	mg	IV SubQ	Log Forms	Induction	Induction		2.7	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					418	449	1
MMRF_1718	Second Line Therapy (after first relapse)	Dexamethasone		PATIENT WENT TO TRANSPLANT	mg	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					418	449	1
MMRF_1718	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg	IV	Log Forms	Consolidation	Consolidation		195	Q day	Q day					468	469	1
MMRF_1733	First line of therapy	Carfilzomib		CHANGE OF DOSE AS PART OF REGIMEN	mg/m^2	IV	Log Forms	Induction	Induction		20	Q day	Q day					1	2	1
MMRF_1733	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	Other	QD (D1-2, D8-9, D15-16, D22-23)					1	19	1
MMRF_1733	First line of therapy	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Induction	Induction		56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					3	8	1
MMRF_1733	First line of therapy	CLARITHROMYCIN		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		250	BID	BID					37	274	1
MMRF_1733	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					37	119	1
MMRF_1733	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Consolidation	Consolidation		40	Q week	Q week					37	274	1
MMRF_1733	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		15	QD (D1-21)	QD (D1-21)					120	336	1
MMRF_1733	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					337	420	1
MMRF_1733	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		12	QWK	QWK					302	337	1
MMRF_1733	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Consolidation	Consolidation		20	QWK	QWK					274	302	1
MMRF_1733	First line of therapy	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Induction	Induction		45	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					15	15	1
MMRF_1775	First line of therapy	Carfilzomib		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Induction	Induction		20	Q day	Q day					1	2	1
MMRF_1775	First line of therapy	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Induction	Induction		56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					3	28	1
MMRF_1775	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	Other	QD (D1-2, D8-9, D15-16, D22-23)					1	84	1
MMRF_1775	First line of therapy	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Induction	Induction		45	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					29	56	1
MMRF_1775	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					57	168	1
MMRF_1775	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		12	Other	QD (D1-2, D8-9, D15-16, D22-23)					85	168	1
MMRF_1775	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		24	Other	QD (D1, D8, D15, D22)					184	267	1
MMRF_1775	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					184	267	1
MMRF_1775	First line of therapy	CLARITHROMYCIN		Adverse Event or co-morbidity	mg	PO	Log Forms	Consolidation	Consolidation		500	BID	BID					184	231	1
MMRF_1775	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					268		1
MMRF_1795	First line of therapy	Melphalan		Adverse Event or co-morbidity	mg/m^2	PO	Log Forms	Induction	Induction		7	QD (D1-4)	QD (D1-4)					1	1	1
MMRF_1795	First line of therapy	Melphalan		Completed regimen	mg/m^2	PO	Log Forms	Induction	Induction		5	QD (D1-4)	QD (D1-4)					2	392	1
MMRF_1795	First line of therapy	Prednisone		Completed regimen	mg	PO	Log Forms	Induction	Induction		100	QD (D1-4)	QD (D1-4)					1	390	1
MMRF_1795	Second Line Therapy (after first relapse)	Elotuzumab		Adverse Event or co-morbidity	mg	IV	Log Forms	Induction	Induction		689	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1307	1335	1
MMRF_1795	First line of therapy	Carfilzomib		CHANGE OF DOSE AS PART OF REGIMEN	mg/m^2	IV	Log Forms	Induction	Induction		20	Q day	Q day					1	2	1
MMRF_1795	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		36	Other	QD (D1-2, D8-9, D22-23, D29-30)					9	390	1
MMRF_1795	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		4	Other	QD (D8-9, D22-23, D29-30)					9	390	1
MMRF_1795	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1307	1335	1
MMRF_1795	Second Line Therapy (after first relapse)	Prednisone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	Other	WITH ELOTUZUMAB					1307	1335	1
MMRF_1795	Third Line Therapy (following 2nd relapse)	Carfilzomib		INCREASED DOSE	mg/m^2	IV	Log Forms	Induction	Induction		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1342	1376	1
MMRF_1795	Third Line Therapy (following 2nd relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					1342	1350	1
MMRF_1795	Third Line Therapy (following 2nd relapse)	Prednisone		SWITCHED DOSING SCHEDULE	mg	PO	Log Forms	Induction	Induction		20	Other	D1,8,15					1342	1600	1
MMRF_1795	Third Line Therapy (following 2nd relapse)	Carfilzomib		START MAINTENANCE	mg/m^2	IV	Log Forms	Induction	Induction		56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1390	1433	1
MMRF_1795	Third Line Therapy (following 2nd relapse)	Prednisone		PATIENT PREFERENCE	mg	PO	Log Forms	Maintenance	Maintenance		20	Other	D1,15					1614	2042	1
MMRF_1795	Third Line Therapy (following 2nd relapse)	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Maintenance	Maintenance		56	Other	D1,15					1446	2070	1
MMRF_1795	Third Line Therapy (following 2nd relapse)	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Maintenance	Maintenance		36	Other	D1,15					2084	2167	1
MMRF_1825	Third Line Therapy (following 2nd relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					2089	2830	1
MMRF_1825	Third Line Therapy (following 2nd relapse)	Lenalidomide		CORRECT DOSE ORDERED	mg	PO	Log Forms	Maintenance	Maintenance		25	Other	EVERY OTHER DAY FROM D1-21					2061	2088	1
MMRF_1825	Third Line Therapy (following 2nd relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		25	QD (D1-21)	QD (D1-21)					1215	2053	1
MMRF_1825	Third Line Therapy (following 2nd relapse)	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		100	Other	DAY -2 AND -1					1114	1115	1
MMRF_1825	Third Line Therapy (following 2nd relapse)	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		350	Other	150MG QAM, 200MG QPM					1111	1115	1
MMRF_1825	First line of therapy	Carfilzomib		CHANGE OF DOSE AS PART OF REGIMEN	mg/m^2	IV	Log Forms	Induction	Induction		20	Q day	Q day					1	2	1
MMRF_1825	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		45	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					8	196	1
MMRF_1825	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	QD (D1-2, D8-9, D15-16, D22-23)					1	196	1
MMRF_1825	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		40	Q week	Q week					197	287	1
MMRF_1825	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					197	257	1
MMRF_1825	First line of therapy	CLARITHROMYCIN		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		500	BID	BID					197	287	1
MMRF_1825	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					1	927	1
MMRF_1825	Second Line Therapy (after first relapse)	Elotuzumab		Patient decision	mg/kg	IV	Log Forms	Consolidation	Consolidation		10	QWK	QWK					889	1088	1
MMRF_1825	Second Line Therapy (after first relapse)	Lenalidomide		Patient decision	mg	PO	Log Forms	Consolidation	Consolidation		25	Q day	Q day					889	1081	1
MMRF_1825	Second Line Therapy (after first relapse)	Dexamethasone		Patient decision	mg	PO	Log Forms	Consolidation	Consolidation		4	Other	7TABS 3-24 HOURS PRIOR D1,8,15,22 & IN C1&C2 & D1 & D1&D15 IN C3 AND BEYOND					889	1088	1
MMRF_1825	Fourth Line Therapy (following 3rd relapse)	SELINEXOR			mg	PO	Log Forms	Induction	Induction	Checked	60	Other	D1,8,15					2851		1
MMRF_1825	Fourth Line Therapy (following 3rd relapse)	Pomalidomide			mg	PO	Log Forms	Induction	Induction	Checked	4	QD (D1-21)	QD (D1-21)					2851		1
MMRF_1825	Fourth Line Therapy (following 3rd relapse)	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	40	QWK	QWK					2851		1
MMRF_1835	First line of therapy	Carfilzomib		CHANGE OF DOSE AS PART OF REGIMEN	mg/m^2	IV	Log Forms	Induction	Induction		20	Q day	Q day					1	2	1
MMRF_1835	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	Other	QD (D1-2, D8-9, D15-16, D22-23)					1	204	1
MMRF_1835	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					9	282	1
MMRF_1835	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		12	Other	QD (D1-2, D8-9, D15-16, D22-23)					205	282	1
MMRF_1835	First line of therapy	Cyclophosphamide		Adverse Event or co-morbidity	mg	PO	Log Forms	Consolidation	Consolidation		500	BID	BID					289	305	1
MMRF_1835	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					289	372	1
MMRF_1835	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Consolidation	Consolidation		24	Q week	Q week					289	305	1
MMRF_1835	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					373	1934	1
MMRF_1835	Second Line Therapy (after first relapse)	Daratumumab		Investigator decision for other reasons	mg/kg	IV	Log Forms	Induction	Induction		16	QWK	QWK					1984	2047	1
MMRF_1835	Second Line Therapy (after first relapse)	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					1984	2004	1
MMRF_1835	Second Line Therapy (after first relapse)	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Induction	Induction		1.3	QWK	QWK					1984	1991	1
MMRF_1835	Second Line Therapy (after first relapse)	Daratumumab			mg/kg	IV	Log Forms	Induction	Induction	Checked	16	Other	D1,15					2054		1
MMRF_1835	Second Line Therapy (after first relapse)	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Induction	Induction		1	QWK	QWK					1997	2026	1
MMRF_1835	Second Line Therapy (after first relapse)	Carfilzomib		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Induction	Induction		20	Other	ONCE					2033	2033	1
MMRF_1835	Second Line Therapy (after first relapse)	Carfilzomib		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Induction	Induction		27	Other	ONCE					2040	2040	1
MMRF_1835	Second Line Therapy (after first relapse)	Carfilzomib			mg/m^2	IV	Log Forms	Induction	Induction	Checked	56	Other	3/4 WEEKS					2047		1
MMRF_1855	First line of therapy	Carfilzomib		CHANGE OF DOSE AS PART OF REGIMEN	mg/m^2	IV	Log Forms	Induction	Induction		20	Q day	Q day					1	2	1
MMRF_1855	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	QD (D1-2, D8-9, D15-16, D22-23)					1	183	1
MMRF_1855	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					8	183	1
MMRF_1855	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					184	239	1
MMRF_1855	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		40	Other	QD (D1-2, D8-9, D15-16, D22-23)					184	239	1
MMRF_1855	First line of therapy	CLARITHROMYCIN		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		500	BID	BID					184	239	1
MMRF_1855	First line of therapy	Lenalidomide		PATIENT MOVING AWAY	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					240	882	1
MMRF_1935	Fourth Line Therapy (following 3rd relapse)	JNJ-64407564		Disease progression/Relapse	MCG/KG	IV	Log Forms	Unknown	Unknown		3.38	QWK	QWK					1715	1812	1
MMRF_1935	Fifth Line Therapy (following 4th relapse)	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Unknown	Unknown		681	QD (D1-3)	QD (D1-3)					1865	1867	1
MMRF_1935	Fifth Line Therapy (following 4th relapse)	FLUDARABINE		Completed regimen	mg	IV	Log Forms	Unknown	Unknown		68	QD (D1-3)	QD (D1-3)					1865	1867	1
MMRF_1935	Fifth Line Therapy (following 4th relapse)	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Unknown	Unknown		40	Other	ONCE					1829	1829	1
MMRF_1935	Fifth Line Therapy (following 4th relapse)	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Unknown	Unknown		1.3	Other	EVERY 3 DAYS					1829	1838	1
MMRF_1935	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg	IV	Log Forms	Consolidation	Consolidation		452	Other	ONCE					285	285	1
MMRF_1935	First line of therapy	Carfilzomib		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	611	1
MMRF_1935	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	611	1
MMRF_1935	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	611	1
MMRF_1935	Second Line Therapy (after first relapse)	Elotuzumab		Completed regimen	mg/kg	IV	Log Forms	Induction	Induction		10	Other	WEEKLY X 3 WEEKS ON/1 WEEK OFF					632	1343	1
MMRF_1935	Second Line Therapy (after first relapse)	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					632	1630	1
MMRF_1935	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		8	Other	WEEKLY X 3 WEEKS ON/1 WEEK OFF					632	1630	1
MMRF_1935	Second Line Therapy (after first relapse)	Bortezomib		Lack of response	mg/m^2	IV	Log Forms	Consolidation	Consolidation		1.3	Q week	Q week					804	1343	1
MMRF_1935	Third Line Therapy (following 2nd relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Unknown	Unknown		16	Q week	Q week					1378	1602	1
MMRF_1935	Third Line Therapy (following 2nd relapse)	ATEZOLIZUMAB		Disease progression/Relapse	mg/dL	IV	Log Forms	Unknown	Unknown		840	Other	Q2WEEKS					1378	1616	1
MMRF_1935	Third Line Therapy (following 2nd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					1378	1630	1
MMRF_1985	First line of therapy	Carfilzomib		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Induction	Induction		20	Q day	Q day					1	2	1
MMRF_1985	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					3	175	1
MMRF_1985	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	QD (D1-2, D8-9, D15-16, D22-23)					1	175	1
MMRF_1985	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		40	Q week	Q week					198	252	1
MMRF_1985	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					198	252	1
MMRF_1985	First line of therapy	CLARITHROMYCIN		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		500	BID	BID					198	252	1
MMRF_1985	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					253		1
MMRF_2072	First line of therapy	Carfilzomib		PER PROTOCOL	mg/m^2	IV	Log Forms	Induction	Induction		20	Q day	Q day					1	2	1
MMRF_2072	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	D1-2, 8-9, 15-16, 22-23					1	135	1
MMRF_2072	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		45	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					15	128	1
MMRF_2072	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		24	Q week	Q week					141	191	1
MMRF_2072	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					50	190	1
MMRF_2072	First line of therapy	CLARITHROMYCIN		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		500	BID	BID					50	197	1
MMRF_2072	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					198	1019	1
MMRF_2072	Second Line Therapy (after first relapse)	Daratumumab		DOSING FREQUENCY CHANGED	mg/kg	IV	Log Forms	Induction	Induction		16	Q week	Q week					1073	1124	1
MMRF_2072	Second Line Therapy (after first relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Unknown	Unknown		16	Other	EVERY OTHER WEEK					1131	2143	1
MMRF_2072	Third Line Therapy (following 2nd relapse)	Pomalidomide			mg	PO	Log Forms	Unknown	Unknown	Checked	4	QD (D1-21)	QD (D1-21)					2144		1
MMRF_2072	Third Line Therapy (following 2nd relapse)	Dexamethasone			mg	PO	Log Forms	Unknown	Unknown	Checked	4	QWK	QWK					2144		1
MMRF_2072	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					601	964	1
MMRF_2072	Second Line Therapy (after first relapse)	Pomalidomide		DOSE CHANGED	mg	PO	Log Forms	Unknown	Unknown		2	QD (D1-21)	QD (D1-21)					1529	1955	1
MMRF_2072	Third Line Therapy (following 2nd relapse)	Ixazomib			mg	PO	Log Forms	Unknown	Unknown	Checked	4	Other	D1,8,15					2144		1
MMRF_2072	Second Line Therapy (after first relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		3	QD (D1-21)	QD (D1-21)					1963	2143	1
MMRF_2095	Third Line Therapy (following 2nd relapse)	Bortezomib		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Induction	Induction		1.3	Other	QOW					1534	1646	1
MMRF_2095	Third Line Therapy (following 2nd relapse)	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		12	Other	ONCE					1534	1534	1
MMRF_2095	Third Line Therapy (following 2nd relapse)	Daratumumab		Adverse Event or co-morbidity	mg/kg	IV	Log Forms	Induction	Induction		16	QWK	QWK					1543	1856	1
MMRF_2095	First line of therapy	Bortezomib		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		2.2	Other	D1, 4, 8, 11, 22, 25, 29, 32					1	519	1
MMRF_2095	First line of therapy	Melphalan		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		12	QD (D1-4)	QD (D1-4)					1	519	1
MMRF_2095	First line of therapy	Prednisone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		100	QD (D1-4)	QD (D1-4)					1	519	1
MMRF_2095	Second Line Therapy (after first relapse)	Ixazomib		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		3	QID	QID					877	1079	1
MMRF_2095	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					877	1079	1
MMRF_2095	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		16	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					877	1079	1
MMRF_2159	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	72	1
MMRF_2159	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	D1-2, 8-9, 15-16, 22-23					1	90	1
MMRF_2159	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	2	1
MMRF_2159	First line of therapy	Lenalidomide		Patient decision	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					91	455	1
MMRF_2159	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Consolidation	Consolidation		40	Q week	Q week					91	120	1
MMRF_2159	First line of therapy	CLARITHROMYCIN		Patient decision	mg	PO	Log Forms	Consolidation	Consolidation		500	BID	BID					91	455	1
MMRF_2159	First line of therapy	Dexamethasone		Patient decision	mg	PO	Log Forms	Consolidation	Consolidation		20	Q week	Q week					121	455	1
MMRF_2159	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	MG/M2	IV	Log Forms	Other	CONDITIONING		100	BID	BID					1149	1150	1
MMRF_2159	Second Line Therapy (after first relapse)	Lenalidomide		Patient decision	mg	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					1311	1690	1
MMRF_2159	Second Line Therapy (after first relapse)	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	5	QD (D1-21)	QD (D1-21)					1800		1
MMRF_2237	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		20	Other	D1,2					1	2	1
MMRF_2237	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					120	208	1
MMRF_2237	First line of therapy	CLARITHROMYCIN		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		500	BID	BID					120	208	1
MMRF_2237	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		40	QWK	QWK					120	208	1
MMRF_2237	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					8	120	1
MMRF_2237	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	QD (D1-2, D8-9, D15-16, D22-23)					1	100	1
MMRF_2237	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					233		1
MMRF_2236	First line of therapy	Carfilzomib			mg/m^2	IV	Log Forms	Induction	Induction	Checked	56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1		1
MMRF_2236	First line of therapy	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	20	Other	QD (D1-2, D8-9, D15-16, D22-23)					1		1
MMRF_2244	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					8	100	1
MMRF_2244	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		20	Other	QD (D1-2, D8-9, D15-16, D22-23)					1	715	1
MMRF_2244	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					220	712	1
MMRF_2244	Second Line Therapy (after first relapse)	Dexamethasone		DOSE REDUCED	mg	PO	Log Forms	Induction	Induction		40	QWK	QWK					786	1818	1
MMRF_2244	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		20	Other	D1,2					1	2	1
MMRF_2244	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					120	212	1
MMRF_2244	First line of therapy	CLARITHROMYCIN		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		500	BID	BID					120	219	1
MMRF_2244	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		40	QWK	QWK					120	213	1
MMRF_2244	Second Line Therapy (after first relapse)	CLARITHROMYCIN		IGA INCREASE	mg	PO	Log Forms	Induction	Induction		500	BID	BID					786	1863	1
MMRF_2244	Second Line Therapy (after first relapse)	Lenalidomide		IGA INCREASE	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					786	1863	1
MMRF_2244	Second Line Therapy (after first relapse)	Dexamethasone		IGA INCREASE	mg	PO	Log Forms	Induction	Induction		12	QWK	QWK					1818	1863	1
MMRF_2244	Second Line Therapy (after first relapse)	Pomalidomide			mg	PO	Log Forms	Unknown	Unknown	Checked	4	QD (D1-21)	QD (D1-21)					1895		1
MMRF_2244	Second Line Therapy (after first relapse)	CLARITHROMYCIN			mg	PO	Log Forms	Unknown	Unknown	Checked	500	BID	BID					1895		1
MMRF_2244	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Unknown	Unknown	Checked	12	QWK	QWK					1895		1
MMRF_2281	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					262	864	1
MMRF_2281	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					880	1052	1
MMRF_2281	Second Line Therapy (after first relapse)	CLARITHROMYCIN		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		500	BID	BID					880	1052	1
MMRF_2281	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		20	QWK	QWK					880	1052	1
MMRF_2281	Third Line Therapy (following 2nd relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Induction	Induction		16	QWK	QWK					1054	1129	1
MMRF_2281	Third Line Therapy (following 2nd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					1054	1129	1
MMRF_2281	Third Line Therapy (following 2nd relapse)	Dexamethasone		DOSE CHANGE	mg	PO	Log Forms	Induction	Induction		20	Other	ONCE					1054	1054	1
MMRF_2281	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		12	QWK	QWK					1060	1129	1
MMRF_2281	Fourth Line Therapy (following 3rd relapse)	Carfilzomib		DOSE CHANGE	mg	IV	Log Forms	Induction	Induction		57	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1144	1263	1
MMRF_2281	Fourth Line Therapy (following 3rd relapse)	Pomalidomide		ASCT	mg	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					1144	1382	1
MMRF_2281	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		SCHEDULE CHANGE	mg	PO	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1144	1242	1
MMRF_2281	Fourth Line Therapy (following 3rd relapse)	Carfilzomib		ASCT	mg/m^2	IV	Log Forms	Induction	Induction		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1269	1382	1
MMRF_2281	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		ASCT	mg	PO	Log Forms	Induction	Induction		20	Other	D1,8,15					1256	1382	1
MMRF_2281	Fifth Line Therapy (following 4th relapse)	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		100	Other	DAY -2 AND -1					1399	1400	1
MMRF_2281	Fifth Line Therapy (following 4th relapse)	Lenalidomide		Completed regimen	mg	PO	Log Forms	Other	CONDITIONING		350	Other	D-5 TO -1 (150MG QAM AND 200MG QPM)					1396	1400	1
MMRF_2281							Log Forms													1
MMRF_2281	Fifth Line Therapy (following 4th relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		25	QD (D1-21)	QD (D1-21)					1502	1605	1
MMRF_2281	Sixth Line Therapy (following 5th relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		20	QWK	QWK					1613	1655	1
MMRF_2281	Sixth Line Therapy (following 5th relapse)	Bortezomib		Disease progression/Relapse	mg/m^2	SC	Log Forms	Induction	Induction		1.3	QWK	QWK					1613	1655	1
MMRF_2281	Sixth Line Therapy (following 5th relapse)	Bendamustine		Disease progression/Relapse	mg/m^2	IV	Log Forms	Induction	Induction		90	Other	D1,8					1613	1655	1
MMRF_2281	Seventh Line of Therapy (following 6th relapse)	Dexamethasone		Completed regimen	N/A	N/A	Log Forms	Unknown	Unknown			Other	N/A					1689	1694	1
MMRF_2281	Seventh Line of Therapy (following 6th relapse)	Cyclophosphamide		Completed regimen	N/A	N/A	Log Forms	Unknown	Unknown			Other	N/A					1689	1694	1
MMRF_2281	Seventh Line of Therapy (following 6th relapse)	ETOPOSIDE		Completed regimen	N/A	N/A	Log Forms	Unknown	Unknown			Other	N/A					1689	1694	1
MMRF_2281	Seventh Line of Therapy (following 6th relapse)	CISPLATIN		Completed regimen	N/A	N/A	Log Forms	Unknown	Unknown			Other	N/A					1689	1694	1
MMRF_2281	Seventh Line of Therapy (following 6th relapse)	Carfilzomib		Completed regimen	N/A	N/A	Log Forms	Unknown	Unknown			Other	N/A					1689	1694	1
MMRF_2281	Seventh Line of Therapy (following 6th relapse)	Doxorubicin		Completed regimen	N/A	N/A	Log Forms	Unknown	Unknown			Other	N/A					1689	1694	1
MMRF_2281	Eighth Line of Therapy (following 7th relapse)	CAR-T CELL INFUSION		Completed regimen	N/A	N/A	Log Forms	Unknown	Unknown			Other	ONCE					1731	1731	1
MMRF_2281	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	2	1
MMRF_2281	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	QD (D1-2, D8-9, D15-16, D22-23)					1	162	1
MMRF_2281	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					8	156	1
MMRF_2281	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		40	QWK	QWK					178	254	1
MMRF_2281	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					178	254	1
MMRF_2281	First line of therapy	CLARITHROMYCIN		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		500	BID	BID					178	255	1
MMRF_2292	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	127	1
MMRF_2292	First line of therapy	Cyclophosphamide		Adverse Event or co-morbidity	mg	IV	Log Forms	Induction	Induction		500	Other	D1,8					1	9	1
MMRF_2292	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	241	1
MMRF_2292	Second Line Therapy (after first relapse)	Daratumumab		Investigator decision for other reasons	mg	IV	Log Forms	Induction	Induction		800	QWK	QWK					857	865	1
MMRF_2292	First line of therapy	Ixazomib		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		4	Other	3 OUT OF 4 WEEKS					429	836	1
MMRF_2292	Second Line Therapy (after first relapse)	Daratumumab		Investigator decision for other reasons	mg/kg	IV	Log Forms	Induction	Induction		16	QWK	QWK					871	879	1
MMRF_2292	Second Line Therapy (after first relapse)	Bortezomib		Adverse Event or co-morbidity	mg/m^2	SC	Log Forms	Induction	Induction		1.3	Other	D1,15					955	969	1
MMRF_2292	First line of therapy	Cyclophosphamide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		500	QWK	QWK					127	241	1
MMRF_2292	First line of therapy	Cyclophosphamide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		500	QWK	QWK					241	484	1
MMRF_2292	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		20	QWK	QWK					241	484	1
MMRF_2292	Second Line Therapy (after first relapse)	Daratumumab		Investigator decision for other reasons	mg	IV	Log Forms	Induction	Induction		800	QWK	QWK					886	886	1
MMRF_2292	Second Line Therapy (after first relapse)	Daratumumab		Investigator decision for other reasons	mg/kg	IV	Log Forms	Induction	Induction		16	QWK	QWK					892	906	1
MMRF_2292	Second Line Therapy (after first relapse)	Daratumumab		Investigator decision for other reasons	mg/kg	IV	Log Forms	Induction	Induction		16	Other	D1,15					913	983	1
MMRF_2292	Second Line Therapy (after first relapse)	Daratumumab		Investigator decision for other reasons	mg/kg	IV	Log Forms	Maintenance	Maintenance		16	Other	MONTHLY					997	1019	1
MMRF_2292	Second Line Therapy (after first relapse)	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	15	QD (D1-21)	QD (D1-21)					1013		1
MMRF_2292	Second Line Therapy (after first relapse)	Daratumumab		Investigator decision for other reasons	mg/kg	IV	Log Forms	Maintenance	Maintenance		16	Other	D1,8,22					1026	1081	1
MMRF_2292	Second Line Therapy (after first relapse)	Daratumumab		Investigator decision for other reasons	mg/kg	IV	Log Forms	Maintenance	Maintenance		16	Other	D1,15					1095	1207	1
MMRF_2292	Second Line Therapy (after first relapse)	Daratumumab			mg/kg	IV	Log Forms	Maintenance	Maintenance	Checked	16	Other	MONTHLY					1235		1
MMRF_2292	First line of therapy	Cyclophosphamide		Investigator decision for other reasons	mg	IV	Log Forms	Induction	Induction		500	Other	D1,8					30	127	1
MMRF_2325	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					8	212	1
MMRF_2325	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					234	393	1
MMRF_2325	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		40	QWK	QWK					234	394	1
MMRF_2325	First line of therapy	CLARITHROMYCIN		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		500	BID	BID					234	400	1
MMRF_2325	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					401	2290	1
MMRF_2325	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		20	Other	D1,2					1	2	1
MMRF_2325	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	QD (D1-2, 8-9, 15-16, 22-23)					1	212	1
MMRF_2325	Second Line Therapy (after first relapse)	Daratumumab		SWITCHED DOSE AND ROUTE	mg/kg	IV	Log Forms	Induction	Induction		16	QWK	QWK					2297	2304	1
MMRF_2325	Second Line Therapy (after first relapse)	Daratumumab		CHANGED FREQUENCY	mg	SC	Log Forms	Induction	Induction		1800	QWK	QWK					2311	2346	1
MMRF_2325	Second Line Therapy (after first relapse)	Daratumumab		CHANGED FREQUENCY	mg	SC	Log Forms	Induction	Induction		1800	QWK	QWK					2353	2451	1
MMRF_2325	Second Line Therapy (after first relapse)	Daratumumab			mg	SC	Log Forms	Induction	Induction	Checked	1800	QWK	QWK					2465		1
MMRF_2325	Second Line Therapy (after first relapse)	Bortezomib			mg/m^2	SC	Log Forms	Induction	Induction	Checked	1.3	QWK	QWK					2297		1
MMRF_2325	Second Line Therapy (after first relapse)	Pomalidomide			mg	PO	Log Forms	Induction	Induction	Checked	4	QD (D1-21)	QD (D1-21)					2297		1
MMRF_2363	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	2	1
MMRF_2363	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		45	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					7	127	1
MMRF_2363	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	QD (D1-2, D8-9, D15-16, D22-23)					1	127	1
MMRF_2363	Second Line Therapy (after first relapse)	Ixazomib		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		4	Q week	Q week					619	829	1
MMRF_2363	Second Line Therapy (after first relapse)	Cyclophosphamide		Investigator decision for other reasons	mg	IV	Log Forms	Induction	Induction		500	Q week	Q week					231	364	1
MMRF_2363	Second Line Therapy (after first relapse)	Bortezomib		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					231	364	1
MMRF_2363	Second Line Therapy (after first relapse)	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					231	364	1
MMRF_2363	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		100	Other	DAY -2 AND -1					384	385	1
MMRF_2363	Third Line Therapy (following 2nd relapse)	Daratumumab		Investigator decision for other reasons	mg/kg	IV	Log Forms	Induction	Induction		16	Other	QOW					883	1066	1
MMRF_2363	Third Line Therapy (following 2nd relapse)	Carfilzomib		SCHEDULE CHANGE	mg	IV	Log Forms	Induction	Induction		47	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					883	961	1
MMRF_2363	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					148	216	1
MMRF_2363	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Consolidation	Consolidation		40	QWK	QWK					148	216	1
MMRF_2363	First line of therapy	CLARITHROMYCIN		Adverse Event or co-morbidity	mg	PO	Log Forms	Consolidation	Consolidation		500	BID	BID					148	216	1
MMRF_2363	Second Line Therapy (after first relapse)	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		50	Other	BID DAYS -5 TO -1					381	385	1
MMRF_2363	Third Line Therapy (following 2nd relapse)	Daratumumab			mg	IV	Log Forms	Unknown	Unknown	Checked	1045	Other	MONTHLY					728		1
MMRF_2363	Third Line Therapy (following 2nd relapse)	Carfilzomib		DOSE CHANGE	mg	IV	Log Forms	Unknown	Unknown		47	Other	QOW					974	1267	1
MMRF_2363	Third Line Therapy (following 2nd relapse)	Carfilzomib		DOSE CHANGE	mg/m^2	IV	Log Forms	Unknown	Unknown		45	Other	QOW					1275	1351	1
MMRF_2363	Third Line Therapy (following 2nd relapse)	METHYLPREDNISOLONE			mg	IV	Log Forms	Unknown	Unknown	Checked		Other	QOW					1267		1
MMRF_2363	Third Line Therapy (following 2nd relapse)	Carfilzomib			mg/m^2	IV	Log Forms	Unknown	Unknown	Checked	56	Other	QOW					1393		1
MMRF_2363	Third Line Therapy (following 2nd relapse)	Pomalidomide			mg	PO	Log Forms	Unknown	Unknown	Checked	3	QD (D1-21)	QD (D1-21)					1051		1
MMRF_2363	Third Line Therapy (following 2nd relapse)	Pomalidomide		UNKNOWN	mg	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					891	1051	1
MMRF_2394	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					118	166	1
MMRF_2394	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		40	QWK	QWK					118	167	1
MMRF_2394	First line of therapy	CLARITHROMYCIN		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		500	BID	BID					118	173	1
MMRF_2394	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					174	425	1
MMRF_2394	Second Line Therapy (after first relapse)	ELOTUZUMAB		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		720	QWK	QWK					454	559	1
MMRF_2394	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					454	559	1
MMRF_2394	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		20	QWK	QWK					454	559	1
MMRF_2394	Third Line Therapy (following 2nd relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Induction	Induction		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					587	839	1
MMRF_2394	Fifth Line Therapy (following 4th relapse)	Daratumumab		DOSING SCHEDULE CHANGE	mg	IV	Log Forms	Induction	Induction		1175	QWK	QWK					905	968	1
MMRF_2394	Fifth Line Therapy (following 4th relapse)	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction			QWK	QWK					905	1023	1
MMRF_2394	Fifth Line Therapy (following 4th relapse)	Bortezomib		Disease progression/Relapse	mg	SC	Log Forms	Induction	Induction		2.4	Other	QOW					951	1015	1
MMRF_2394	Fifth Line Therapy (following 4th relapse)	Daratumumab		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		1175	Other	QOW					975	1023	1
MMRF_2394	Fifth Line Therapy (following 4th relapse)	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		100	Other	QD					1028	1029	1
MMRF_2394	Fifth Line Therapy (following 4th relapse)	Bortezomib		Adverse Event or co-morbidity	mg/m^2	SC	Log Forms	Maintenance	Maintenance		1.3	Other	D1,8,15					1148	1259	1
MMRF_2394	Fifth Line Therapy (following 4th relapse)	Bortezomib		Adverse Event or co-morbidity	mg/m^2	SC	Log Forms	Maintenance	Maintenance		1	Other	D1,8,15					1266	1315	1
MMRF_2394	Fifth Line Therapy (following 4th relapse)	Bortezomib		Adverse Event or co-morbidity	mg/m^2	SC	Log Forms	Maintenance	Maintenance		0.7	Other	D1,8,15					1364	1426	1
MMRF_2394	Fifth Line Therapy (following 4th relapse)	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance			QD (D1-21)	QD (D1-21)					1224	1610	1
MMRF_2394	Fifth Line Therapy (following 4th relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		20	Other	D1,8,15					1259	1707	1
MMRF_2394	Fifth Line Therapy (following 4th relapse)	VENETOCLAX		DOSE CHANGE	mg	PO	Log Forms	Maintenance	Maintenance		100	QID	QID					1253	1497	1
MMRF_2394	Fifth Line Therapy (following 4th relapse)	VENETOCLAX		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		100	Other	5 TIMES/DAY					1498	1707	1
MMRF_2394	Fifth Line Therapy (following 4th relapse)	Carfilzomib		DOSE INCREASED	mg/m^2	IV	Log Forms	Maintenance	Maintenance		27	Other	ONCE					1434	1434	1
MMRF_2394	Fifth Line Therapy (following 4th relapse)	Carfilzomib		DOSE INCREASED	mg/m^2	IV	Log Forms	Maintenance	Maintenance		36	Other	ONCE					1441	1441	1
MMRF_2394	Fifth Line Therapy (following 4th relapse)	Carfilzomib		UNKNOWN	mg/m^2	IV	Log Forms	Maintenance	Maintenance		56	Other	ONCE					1447	1447	1
MMRF_2394	Fifth Line Therapy (following 4th relapse)	Carfilzomib		DOSE INCREASED	mg/m^2	IV	Log Forms	Maintenance	Maintenance		36	Other	ONCE					1463	1463	1
MMRF_2394	Fifth Line Therapy (following 4th relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Maintenance	Maintenance		56	Other	D1,8,15					1469	1707	1
MMRF_2394	Sixth Line Therapy (following 5th relapse)	SEA-BCMA		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		1600	Other	D1,15					1728	1756	1
MMRF_2394	Seventh Line of Therapy (following 6th relapse)	SELINEXOR		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		80	QWK	QWK					1777	1784	1
MMRF_2394	Seventh Line of Therapy (following 6th relapse)	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Induction	Induction		27	QWK	QWK					1777	1784	1
MMRF_2394	Seventh Line of Therapy (following 6th relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction			QWK	QWK					1777	1784	1
MMRF_2394	Eighth Line of Therapy (following 7th relapse)	Bendamustine			mg/m^2	IV	Log Forms	Induction	Induction	Checked	90	Other	D1,8					1791		1
MMRF_2394	Eighth Line of Therapy (following 7th relapse)	Bortezomib			mg/m^2	SC	Log Forms	Induction	Induction	Checked	1.3	Other	D1,8,15					1791		1
MMRF_2394	Eighth Line of Therapy (following 7th relapse)	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	20	Other	D1,8,15					1791		1
MMRF_2394	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	2	1
MMRF_2394	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	QD (D1-2, D8-9, D15-16, D22-23)					1	104	1
MMRF_2394	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					6	97	1
MMRF_2394	Third Line Therapy (following 2nd relapse)	Carfilzomib		DOSE INCREASE	mg	IV	Log Forms	Induction	Induction		40	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					582	582	1
MMRF_2394	Third Line Therapy (following 2nd relapse)	Melphalan		UNKNOWN	mg	IV	Log Forms	Induction	Induction		20	Other	MONTHLY					582	722	1
MMRF_2394	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction			QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					582	839	1
MMRF_2394	Fourth Line Therapy (following 3rd relapse)	NIVOLUMAB		Adverse Event or co-morbidity	mg	IV	Log Forms	Induction	Induction		240	Other	D1,15					860	860	1
MMRF_2394	Fourth Line Therapy (following 3rd relapse)	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					860	872	1
MMRF_2394	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	QWK	QWK					860	873	1
MMRF_2399	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	2	1
MMRF_2399	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					8	184	1
MMRF_2399	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	QD (D1-2, D8-9, D15-16, D22-23)					1	192	1
MMRF_2399	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					212	372	1
MMRF_2399	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		40	QWK	QWK					212	373	1
MMRF_2399	First line of therapy	CLARITHROMYCIN		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		500	BID	BID					212	379	1
MMRF_2399	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					380	709	1
MMRF_2399	Second Line Therapy (after first relapse)	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					711	848	1
MMRF_2399	Second Line Therapy (after first relapse)	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		20	QWK	QWK					711	848	1
MMRF_2399	Third Line Therapy (following 2nd relapse)	Ixazomib		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		4	QWK	QWK					856	1289	1
MMRF_2399	Third Line Therapy (following 2nd relapse)	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		20	QWK	QWK					856	1289	1
MMRF_2399	Third Line Therapy (following 2nd relapse)	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					856	1289	1
MMRF_2399	Third Line Therapy (following 2nd relapse)	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		100	Other	DAY -2 AND -1					1325	1326	1
MMRF_2399	Third Line Therapy (following 2nd relapse)	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		350	Other	DAY -5 TO -1 (150MG QAM AND 200MG QPM)					1322	1326	1
MMRF_2399							Log Forms													1
MMRF_2399	Third Line Therapy (following 2nd relapse)	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	25	QD (D1-21)	QD (D1-21)					1435		1
MMRF_2453	First line of therapy	Cyclophosphamide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		500	Other	QD (D1, D8)					1	273	1
MMRF_2453	First line of therapy	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	301	1
MMRF_2453	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	301	1
MMRF_2453	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		200	Other	DAY -2 AND DAY-1					310	312	1
MMRF_2453	Second Line Therapy (after first relapse)	Ixazomib			mg	PO	Log Forms	Maintenance	Maintenance	Checked	4	Other	QD D1, 8, 15 AND 28					481		1
MMRF_2503	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		20	Other	C1 D1-2					1	2	1
MMRF_2503	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					8	156	1
MMRF_2503	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	QD (D1-2, D8-9, D15-16, D22-23)					1	163	1
MMRF_2503	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	Other	QD (D1-21)					261	868	1
MMRF_2503	Second Line Therapy (after first relapse)	CC-122 (PLEIOTROPIC PATHWAY MODIFIER ML-122)		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		4	Other	D1-5, 8-12, 15-19, AND 22-26					883	995	1
MMRF_2503	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	QWK	QWK					883	904	1
MMRF_2503	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					176	252	1
MMRF_2503	First line of therapy	CLARITHROMYCIN		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		500	BID	BID					176	259	1
MMRF_2503	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		40	QWK	QWK					176	253	1
MMRF_2503	Second Line Therapy (after first relapse)	CC-122		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		3	Other	D1-5, 8-12, 15-19, AND 22-26					1002	1506	1
MMRF_2503	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	QWK	QWK					911	911	1
MMRF_2503	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		10	QWK	QWK					918	1506	1
MMRF_2503	Third Line Therapy (following 2nd relapse)	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		100	Other	DAY -2 AND -1					1548	1549	1
MMRF_2503							Log Forms													1
MMRF_2503	Third Line Therapy (following 2nd relapse)	Daratumumab		SCHEDULE CHANGE	mg/kg	IV	Log Forms	Maintenance	Maintenance		16	QWK	QWK					1646	1704	1
MMRF_2503	Third Line Therapy (following 2nd relapse)	Carfilzomib		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Maintenance	Maintenance		27	Other	D1,8,15					1646	1653	1
MMRF_2503	Third Line Therapy (following 2nd relapse)	Dexamethasone		UNKNOWN	mg	IV	Log Forms	Maintenance	Maintenance		20	Other	ONCE					1646	1646	1
MMRF_2503	Third Line Therapy (following 2nd relapse)	Dexamethasone		UNKNOWN	mg	IV	Log Forms	Maintenance	Maintenance		12	Other	ONCE					1653	1653	1
MMRF_2503	Third Line Therapy (following 2nd relapse)	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Maintenance	Maintenance		56	Other	D1,8,15					1660	1732	1
MMRF_2503	Third Line Therapy (following 2nd relapse)	Daratumumab		SCHEDULE CHANGE	mg/kg	IV	Log Forms	Maintenance	Maintenance		16	Other	D1,15					1709	1744	1
MMRF_2503	Third Line Therapy (following 2nd relapse)	Daratumumab			mg/kg	IV	Log Forms	Maintenance	Maintenance	Checked	16	Other	MONTHLY					1772		1
MMRF_2522	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	2	1
MMRF_2522	First line of therapy	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	20	Other	QD (D1,2,8,9,15,16,22,23)					1		1
MMRF_2522	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					3	92	1
MMRF_2522	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	25	QD (D1-21)	QD (D1-21)					92		1
MMRF_2524	First line of therapy	Carfilzomib			mg/m^2	IV	Log Forms	Induction	Induction	Checked	56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					3		1
MMRF_2524	First line of therapy	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	20	Other	QD (D1,2,8,9,15,16,22,23)					1		1
MMRF_2524	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	2	1
MMRF_2599	First line of therapy	Carfilzomib		Completed regimen	mg	IV	Log Forms	Other	CAR/DEX TO PLATEAU FOLLOWD BY BIOXIN/REV/DEX TO PLATEAU FOLLOWED BY REV MAINTENANCE		31	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	85	1
MMRF_2599	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	CAR/DEX TO PLATEAU FOLLOWD BY BIOXIN/REV/DEX TO PLATEAU FOLLOWED BY REV MAINTENANCE		20	Other	1, 8, 15, 22					1	100	1
MMRF_2599	First line of therapy	BIAXIN		Disease progression/Relapse	mg	PO	Log Forms	Other	CAR/DEX TO PLATEAU FOLLOWD BY BIOXIN/REV/DEX TO PLATEAU FOLLOWED BY REV MAINTENANCE		500	BID	BID					114	793	1
MMRF_2599	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Other	CAR/DEX TO PLATEAU FOLLOWD BY BIOXIN/REV/DEX TO PLATEAU FOLLOWED BY REV MAINTENANCE		25	QD (D1-21)	QD (D1-21)					114	814	1
MMRF_2599	Second Line Therapy (after first relapse)	CELGENE CC-122 -PLEIOTROPIC PATHWAY			mg	PO	Log Forms	Induction	Induction	Checked	4	Other	Q D1-5, 8-12, 15-19, AND 22-26					828		1
MMRF_2599	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	40	Other	Q D1 D8 D15 D22					828		1
MMRF_1120	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms				1.6	Q week	Q week					1	21	1
MMRF_1120	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.6	Q week	Q week					35	203	1
MMRF_1120	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				20	Other	DAY OF AND DAY AFTER EACH DOSE OF VELCADE. DAY 1,2,8,9,15,16, 22, 23					1	237	1
MMRF_1120	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	Q day	Q day					16	237	1
MMRF_1120	First line of therapy	Lenalidomide		Patient decision	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					473	2421	1
MMRF_1120	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING REGIMEN		100	Other	DAILY ON DAYS -2 AND -1 FROM ASCT					237	238	1
MMRF_1120	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING REGIMEN		100	Other	DAILY ON DAYS -2 AND -1 FROM ASCT					356	357	1
MMRF_1120	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	15	Q day	Q day					2831		1
MMRF_1140	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	ASCT CONDITIONING		200	Q day	Q day					329	330	1
MMRF_1140	Second Line Therapy (after first relapse)	Daratumumab		Investigator decision for other reasons	mg/kg	IV	Log Forms	Induction	Induction		16	Q week	Q week					1988	2144	1
MMRF_1140	Second Line Therapy (after first relapse)	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		20	QWK	QWK					1988	2144	1
MMRF_1140	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		10	Q day	Q day					1988	2002	1
MMRF_1140	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg	IV	Log Forms	Other	ASCT CONDITIONING		200	Q day	Q day					2164	2165	1
MMRF_1140	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				2.5	Q week	Q week					169	204	1
MMRF_1140	First line of therapy	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	EVERY OTHER WEEK					451	1955	1
MMRF_1140	First line of therapy	Lenalidomide		Completed regimen	MG	PO	Log Forms				25	Q day	Q day					2	23	1
MMRF_1140	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				20	Other	TAKEN DAY OF AND DAY AFTER EACH DOSE OF VELCADE. DAY 1, 2, 8, 9, 15, 16, 22					1	330	1
MMRF_1140	First line of therapy	Bortezomib		LOCAL VELCADE REACTION, <GRADE 3 RXN	mg/m^2	IV SubQ	Log Forms				1.6	Q week	Q week					1	8	1
MMRF_1140	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				3	Q week	Q week					15	162	1
MMRF_1167	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	Other	ONCE					1	2	1
MMRF_1167	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				10	Q day	Q day					2	5	1
MMRF_1167	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				10	Q day	Q day					9	10	1
MMRF_1167	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				10	Q day	Q day					12	13	1
MMRF_1167	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms				1.3	Q week	Q week					12	22	1
MMRF_1167	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				10	Q day	Q day					15	16	1
MMRF_1167	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms				10	Other	Q WEEK FOR THREE WEEKS THEN HOLD FOR TWO WEEKS					43	630	1
MMRF_1167	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms				2.75	Other	Q WEEK FOR THREE WEEKS THEN HOLD FOR TWO WEEKS					43	293	1
MMRF_1167	First line of therapy	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms				1.5	Other	Q2WEEKS					293	630	1
MMRF_1167	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		15	Q day	Q day					630	819	1
MMRF_1167	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		20	Q week	Q week					630	834	1
MMRF_1167	Second Line Therapy (after first relapse)	Lenalidomide		HIGH RISK COMPLICATIONS OF WARFARIN ON TERMINAL, SECOND MALIGNANCY	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					834	946	1
MMRF_1336	First line of therapy	Melphalan		Investigator decision for other reasons	mg	PO	Log Forms				15	QD (D1-4)	QD (D1-4)					1	30	1
MMRF_1336	First line of therapy	Prednisone		Investigator decision for other reasons	mg	PO	Log Forms				100	QD (D1-4)	QD (D1-4)					1	30	1
MMRF_1336	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms				1.3	Other	D1, 8, 15, 22					6	30	1
MMRF_1336	First line of therapy	Dexamethasone		Lack of response	mg	PO	Log Forms				40	Other	DAY 1, 8, 15 AND 22					30	275	1
MMRF_1336	First line of therapy	Cyclophosphamide		Lack of response	mg/m^2	PO	Log Forms				300	Other	DAYS 1, 8, 15, AND 22					37	268	1
MMRF_1336	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					275	359	1
MMRF_1336	First line of therapy	Bortezomib		Lack of response	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Other	D1, 8, 15, 22					44	268	1
MMRF_1336	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.5	Other	D1, 8, 15					275	359	1
MMRF_1336	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					289	360	1
MMRF_1336	First line of therapy	Bortezomib		PATIENT COULD NO LONGER AFFORD TREATMENT	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	EVERY OTHER WEEK					616	933	1
MMRF_1587	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		2.75	Other	D1, D4, D8, D11					1	167	1
MMRF_1587	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	D1-4 AND D8-11					1	167	1
MMRF_1587	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		300	Other	D1, D8, D15					1	167	1
MMRF_1587	First line of therapy	Bortezomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Maintenance	Maintenance		1.5	Other	D1, D8, D15, D22					190	234	1
MMRF_1587	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		20	Other	D1, D2					190	234	1
MMRF_1587	Second Line Therapy (after first relapse)	Cyclophosphamide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		600	Q week	Q week					234	298	1
MMRF_1587	Second Line Therapy (after first relapse)	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		40	Other	D1-4, D8-11					234	298	1
MMRF_1587	Second Line Therapy (after first relapse)	Bortezomib		Investigator decision for other reasons	mg	IV SubQ	Log Forms	Induction	Induction		2.8	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					238	298	1
MMRF_1587	Second Line Therapy (after first relapse)	Bortezomib		Lack of response	mg	IV SubQ	Log Forms	Maintenance	Maintenance		1.5	Q week	Q week					309	629	1
MMRF_1587	Second Line Therapy (after first relapse)	Lenalidomide		Lack of response	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					309	550	1
MMRF_1587	Second Line Therapy (after first relapse)	Dexamethasone		Lack of response	mg	PO	Log Forms	Maintenance	Maintenance		40	Q week	Q week					309	550	1
MMRF_1857	First line of therapy	Cyclophosphamide		Lack of response	mg	PO	Log Forms	Induction	Induction		450	Q week	Q week					1	114	1
MMRF_1857	First line of therapy	Bortezomib		Lack of response	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					2	114	1
MMRF_1857	First line of therapy	Dexamethasone		Lack of response	mg	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	114	1
MMRF_1857	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	Q day	Q day					377		1
MMRF_1857	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		2	Other	PER EMR, FREQUENCY NOT KNOWN; PATIENT NOT SEEN AT OHSU					124	219	1
MMRF_1857	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					124	206	1
MMRF_1857	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		15	Q day	Q day					124	206	1
MMRF_2297	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	24	1
MMRF_2297	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	26	1
MMRF_2297	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	Other	D1-2, 4-5, 8-9, 11-12					1	24	1
MMRF_2297	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING REGIMEN		100	Other	DAYS -2 AND -1					274	275	1
MMRF_2297	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.5	Other	D1, 8, 15, 22					105	210	1
MMRF_2297	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					105	198	1
MMRF_2297	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	D1, D15					406	686	1
MMRF_2297	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					138	198	1
MMRF_2297	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg	IV	Log Forms	Maintenance	Maintenance		2	Other	D1 AND D15					728	1234	1
MMRF_2297	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					1248	2148	1
MMRF_2297	Second Line Therapy (after first relapse)	Daratumumab			mg	IV SubQ	Log Forms	Induction	Induction	Checked	1800	QWK	QWK					2191		1
MMRF_2297	Second Line Therapy (after first relapse)	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					2191	2205	1
MMRF_2297	Second Line Therapy (after first relapse)	Dexamethasone			mg		Log Forms	Induction	Induction	Checked	20	Q week	Q week					2191		1
MMRF_2297	Second Line Therapy (after first relapse)	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		2	QD (D1-21)	QD (D1-21)					2222	2278	1
MMRF_2297	Second Line Therapy (after first relapse)	Pomalidomide			mg	PO	Log Forms	Induction	Induction	Checked	2	Other	QOD					2303		1
MMRF_2302	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	20	Q week	Q week					2404		1
MMRF_2302	Second Line Therapy (after first relapse)	Daratumumab			mg	IV SubQ	Log Forms	Induction	Induction	Checked	1800	Q week	Q week					2404		1
MMRF_2302	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					1	264	1
MMRF_2302	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	264	1
MMRF_2302	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms	Unknown	Unknown		1.3	Other	D1, 8, 15, 22					283	325	1
MMRF_2302	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Unknown	Unknown		20	Other	D1, 8,15, 22					283	325	1
MMRF_2302	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Unknown	Unknown		15	QD (D1-21)	QD (D1-21)					283	325	1
MMRF_2302	First line of therapy	Lenalidomide		Patient decision	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					376	1056	1
MMRF_2352	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	139	1
MMRF_2352	First line of therapy	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Induction	Induction		600	QWK	QWK					1	139	1
MMRF_2352	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	DAYS 1, 2, 4, 5, 8, 9, 11, 12, 15, 16					3	139	1
MMRF_2352	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					307	882	1
MMRF_2352	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING REGIMEN		190	Other	DAY -2 AND -1 TO ASCT					149	150	1
MMRF_2352	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	5	Other	D1-D28 OF A 28 DAY CYCLE					883		1
MMRF_2464	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_2464	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	56	1
MMRF_2464	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	DAYS 1-2, 4-5, 8-9, 11-12					1	54	1
MMRF_2464	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING REGIMEN		100	Other	DAY -2 AND -1					119	120	1
MMRF_2464	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					252	1129	1
MMRF_2464	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Unknown	Unknown		1900	Other	Q 3HRS X3					95	96	1
MMRF_2464	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Consolidation	Consolidation		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					210	241	1
MMRF_2464	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		10	Other	D1, 2, 4, 5, 8, 9, 11 AND 12					210	242	1
MMRF_2464	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-14)	QD (D1-14)					210	244	1
MMRF_2464	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	5	Q day	Q day					1157		1
MMRF_2217	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		2.7	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	11	1
MMRF_2217	First line of therapy	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Induction	Induction		500	Other	DAY 1 AND 8					1	8	1
MMRF_2217	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	DAYS 1-4, DAY 8 AND DAY 11					1	11	1
MMRF_2217	First line of therapy	Cyclophosphamide		DOSE INCREASED	mg	PO	Log Forms	Induction	Induction		600	QWK	QWK					21	254	1
MMRF_2217	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QWK	QWK					21	373	1
MMRF_2217	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		2.7	Q week	Q week					21	373	1
MMRF_2217	First line of therapy	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Induction	Induction		650	Q week	Q week					254	373	1
MMRF_2217	First line of therapy	Bortezomib		Lack of response	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	DAY 1 AND DAY 15					373	718	1
MMRF_2217	First line of therapy	Dexamethasone		Lack of response	mg	PO	Log Forms	Maintenance	Maintenance		4	Other	4 MG ON DAYS 1, 2, 15, 16 OF 28-DAY CYCLE					373	736	1
MMRF_2217	Second Line Therapy (after first relapse)	NIVOLUMAB		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		240	Other	C1D15, C2-6 D1, D15					997	1164	1
MMRF_2217	Second Line Therapy (after first relapse)	Daratumumab		Lack of response	mg/kg	IV	Log Forms	Induction	Induction		16	Other	C1 D1,15,22. C2 D1,16,22. C3-6 D1,15					1182	1203	1
MMRF_2217	Second Line Therapy (after first relapse)	Dexamethasone		Lack of response	mg	PO	Log Forms	Induction	Induction		4	Other	C1,C2 D2,3,9,10,16,17,23,24					1182	1203	1
MMRF_2217	Third Line Therapy (following 2nd relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Unknown	Unknown		20	Other	D1,2,8,9,15,16					1204	1487	1
MMRF_2217	Third Line Therapy (following 2nd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					1204	1487	1
MMRF_2217	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		40	Other	QD (D1,8,15,22)					1204	1487	1
MMRF_2217	Fourth Line Therapy (following 3rd relapse)	BCMA AB	NCT03489525	Disease progression/Relapse	mg/kg		Log Forms	Induction	Induction		0.2							1542	1619	1
MMRF_2217	Fifth Line Therapy (following 4th relapse)	Ixazomib	NCT02633059	Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		4							1633	1667	1
MMRF_2217	Fifth Line Therapy (following 4th relapse)	IDASANUTLIN		Disease progression/Relapse	mg		Log Forms	Unknown	Unknown		200							1633	1667	1
MMRF_1629	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		190	Q day	Q day					203	204	1
MMRF_1629	First line of therapy	Bortezomib		Disease progression/Relapse	mg	IV SubQ	Log Forms	Maintenance	Maintenance		2.8	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					350	1707	1
MMRF_1629	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					350	1707	1
MMRF_1629	Second Line Therapy (after first relapse)	Daratumumab			mg/kg	IV	Log Forms	Other	SALVAGE	Checked	16	Q week	Q week					1721		1
MMRF_1629	Second Line Therapy (after first relapse)	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	SALVAGE		2	QD (D1-21)	QD (D1-21)					1721	2085	1
MMRF_1629	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Other	SALVAGE	Checked	40	Q week	Q week					1721		1
MMRF_1629	First line of therapy	Bortezomib		MOVED TO SCT	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					1	189	1
MMRF_1629	First line of therapy	Cyclophosphamide		MOVED TO SCT	mg/m^2	PO	Log Forms	Induction	Induction		300	Q week	Q week					1	189	1
MMRF_1629	First line of therapy	Dexamethasone		MOVED TO SCT	mg	PO	Log Forms	Induction	Induction		50	Q week	Q week					1	189	1
MMRF_1380	First line of therapy	Pomalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	2	QD (D1-21)	QD (D1-21)					1252		1
MMRF_1380	First line of therapy	Bortezomib		Disease progression/Relapse	mg	IV SubQ	Log Forms				2.6	QWK	QWK					1	166	1
MMRF_1380	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	166	1
MMRF_1380	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				20	QWK	QWK					1	386	1
MMRF_1380	First line of therapy	Cyclophosphamide		Disease progression/Relapse	mg	IV	Log Forms	Other	INTENSIFICATION OF  INDUCTION THERAPY		950	Q week	Q week					106	166	1
MMRF_1380	First line of therapy	Carfilzomib		Completed regimen	mg	IV	Log Forms	Consolidation	Consolidation		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					166	387	1
MMRF_1380	First line of therapy	Pomalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Consolidation	Consolidation		4	QD (D1-21)	QD (D1-21)					178	1251	1
MMRF_1432	First line of therapy	Dexamethasone		PATIENT DIED	mg	PO	Log Forms				20	Q week	Q week					1	400	1
MMRF_1432	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg	IV SubQ	Log Forms				2.3	QWK	QWK					1	48	1
MMRF_1432	First line of therapy	Lenalidomide		Lack of response	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	337	1
MMRF_1432	First line of therapy	Cyclophosphamide		Investigator decision for other reasons	mg	IV	Log Forms	Other	REPLACEMENT OF VELCADE		1200	Other	QMONTH					89	194	1
MMRF_1432	Second Line Therapy (after first relapse)	Pomalidomide		Patient decision	mg	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					337	393	1
MMRF_1432	Second Line Therapy (after first relapse)	Melphalan		Patient decision	mg	PO	Log Forms	Unknown	Unknown		8	QD (D1-3)	QD (D1-3)					348	393	1
MMRF_1460	First line of therapy	Bortezomib		TREATMENT DISCONTINUED DUE TO PROGRESSION OF DEMENTIA	mg	IV SubQ	Log Forms	Induction	Induction		2.7	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	258	1
MMRF_1460	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					1	166	1
MMRF_1542	First line of therapy	Lenalidomide		Patient decision	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					1	128	1
MMRF_1542	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					5	43	1
MMRF_1542	First line of therapy	Dexamethasone		Patient decision	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					5	101	1
MMRF_1542	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					262	437	1
MMRF_1542	Second Line Therapy (after first relapse)	Pomalidomide		DEATH	mg	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					803	1137	1
MMRF_1542	Second Line Therapy (after first relapse)	Cyclophosphamide		DEATH	GRAM	IV	Log Forms	Induction	Induction		1	Other	Q EVERY 4 WEEKS					520	1137	1
MMRF_1542	First line of therapy	Bortezomib		DEATH	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Other	QEVERY 4 WEEKS					155	1137	1
MMRF_1646	First line of therapy	Bortezomib		Patient decision	mg	IV SubQ	Log Forms	Induction	Induction		2.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	15	1
MMRF_1646	First line of therapy	Dexamethasone		Patient decision	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					1	23	1
MMRF_1647	First line of therapy	Bortezomib		Investigator decision for other reasons	mg	IV SubQ	Log Forms	Induction	Induction		2.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	204	1
MMRF_1647	First line of therapy	Dexamethasone		Patient decision	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					1	36	1
MMRF_1647	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					206	239	1
MMRF_1647	First line of therapy	Bortezomib		Patient decision	mg	IV SubQ	Log Forms	Maintenance	Maintenance		2.3	QD (D1-14)	QD (D1-14)					344	766	1
MMRF_1647	First line of therapy	Dexamethasone		Patient decision	mg	PO	Log Forms	Maintenance	Maintenance		20	QD (D1-14)	QD (D1-14)					344	766	1
MMRF_1778	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					1	1	1
MMRF_1778	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg	IV SubQ	Log Forms	Induction	Induction		2.5	Q week	Q week					1	1	1
MMRF_2058	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	15	QD (D1-21)	QD (D1-21)					704		1
MMRF_2058	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		25	QD (D1-21)	QD (D1-21)					371	703	1
MMRF_2058	First line of therapy	Lenalidomide		Lack of response	mg	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					307	370	1
MMRF_2058	First line of therapy	Lenalidomide		DOSE REDUCED FOR MAINTENANCE	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	191	1
MMRF_2058	First line of therapy	Dexamethasone		PATIENT REACHED VGPR	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	191	1
MMRF_2058	First line of therapy	Lenalidomide		INCREASE IN M-SPIKE	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					191	306	1
MMRF_2079	First line of therapy	Bortezomib			mg	IV SubQ	Log Forms	Induction	Induction	Checked	2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_2079	First line of therapy	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	40	Q week	Q week					1		1
MMRF_2079	First line of therapy	Lenalidomide		RASH	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					2	26	1
MMRF_2079	First line of therapy	Cyclophosphamide			mg	PO	Log Forms	Induction	Induction	Checked	500	Q week	Q week					65		1
MMRF_2143	First line of therapy	Dexamethasone		HOSPITAL ADMISSION	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					1	1	1
MMRF_2143	First line of therapy	Lenalidomide		DEATH	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					42	841	1
MMRF_2143	First line of therapy	Dexamethasone		DISCONTINUED BY PHARMACIST	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					42	118	1
MMRF_2204	First line of therapy	Dexamethasone		Patient decision	mg	PO	Log Forms	Induction	Induction		20	QWK	QWK					1	109	1
MMRF_2204	First line of therapy	Lenalidomide		Patient decision	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	147	1
MMRF_2204	Second Line Therapy (after first relapse)	Bortezomib		Adverse Event or co-morbidity	mg	IV SubQ	Log Forms	Induction	Induction		2.6	Q week	Q week					232	359	1
MMRF_2204	Second Line Therapy (after first relapse)	Cyclophosphamide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		300	Q week	Q week					375	394	1
MMRF_2204	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					235	394	1
MMRF_2362	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg	IV SubQ	Log Forms	Induction	Induction		2.5	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	246	1
MMRF_2362	First line of therapy	Dexamethasone		Patient decision	mg	PO	Log Forms	Induction	Induction		20	QD (D1-4)	QD (D1-4)					1	527	1
MMRF_2362	First line of therapy	Dexamethasone			mg	PO	Log Forms	Maintenance	Maintenance	Checked	20	Q week	Q week					631		1
MMRF_2362	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					36	527	1
MMRF_2362	Second Line Therapy (after first relapse)	Carfilzomib		Investigator decision for other reasons	mg	IV	Log Forms	Maintenance	Maintenance		100	Other	3 WEEKS ON, 1 WEEK OFF					1585	1649	1
MMRF_2362	Second Line Therapy (after first relapse)	Carfilzomib			mg	IV	Log Forms	Maintenance	Maintenance	Checked	100	Other	EVERY 4 WEEKS					1677		1
MMRF_2487	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		20	Q week	Q week					1283	1465	1
MMRF_2487	First line of therapy	Bortezomib		Investigator decision for other reasons	mg	SUBQ	Log Forms	Maintenance	Maintenance		3	Q week	Q week					1283	1465	1
MMRF_2487	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		20	Other	EVERY 2 WEEKS					898	1268	1
MMRF_2487	First line of therapy	Bortezomib		Investigator decision for other reasons	mg	SUBQ	Log Forms	Maintenance	Maintenance		2.1	Other	EVERY 2 WEEKS					435	1268	1
MMRF_2487	First line of therapy	Dexamethasone		BONE MARROW TRANSPLANTATION	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					79	226	1
MMRF_2487	First line of therapy	Bortezomib		BONE MARROW TRANSPLANTATION	mg	SUBQ	Log Forms	Induction	Induction		2.7	Q week	Q week					79	226	1
MMRF_2487	First line of therapy	Bortezomib		Disease progression/Relapse	mg/m^2	SUBQ	Log Forms	Maintenance	Maintenance		1.3	Other	QWEEK, 3 WEEKS ON, 1 WEEK OFF.					1899	2095	1
MMRF_2487	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		20	Other	QWEEK, 3 WEEKS ON, 1 WEEK OFF.					1899	2095	1
MMRF_2487	First line of therapy	Bortezomib		RADIATION THERAPY	mg	SUBQ	Log Forms	Induction	Induction		2.7	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	52	1
MMRF_2487	First line of therapy	Dexamethasone		RADIATION THERAPY	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					1	52	1
MMRF_2487	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		100	Other	QD 1-2					258	259	1
MMRF_2487	Second Line Therapy (after first relapse)	Carfilzomib			mg	IV	Log Forms	Unknown	Unknown	Checked	60	Other	QD (D1, D8, D15, D22)					2102		1
MMRF_2487	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Unknown	Unknown	Checked	20	Other	QD (D1, D8, D15, D22)					2102		1
MMRF_2487	Second Line Therapy (after first relapse)	DARATUMUMAB + HYALURONIDASE			mg	SQ	Log Forms	Unknown	Unknown	Checked	1800	Other	QD (D1, D8, D15, D22)					2102		1
MMRF_2581	First line of therapy	Bortezomib		Investigator decision for other reasons	mg	IV SubQ	Log Forms	Induction	Induction		2.1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	83	1
MMRF_2581	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	83	1
MMRF_1504	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		40	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	84	1
MMRF_1504	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg	IV SubQ	Log Forms	Induction	Induction		2.4	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	84	1
MMRF_1504	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					11	158	1
MMRF_1504	First line of therapy	Bortezomib		Completed regimen	mg	SUBQ	Log Forms	Maintenance	Maintenance		2.4	Other	DAY 1 AND DAY 8 OF EACH CYCLE					84	152	1
MMRF_1504	First line of therapy	Dexamethasone		Patient decision	mg	PO	Log Forms	Maintenance	Maintenance		20	Other	DAYS 1, 8 AND 15					84	309	1
MMRF_1504	First line of therapy	Lenalidomide		Patient decision	mg	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					179	262	1
MMRF_1504	First line of therapy	Lenalidomide		Patient decision	mg	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					309	675	1
MMRF_1504	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					1082	1345	1
MMRF_1504	Second Line Therapy (after first relapse)	Dexamethasone		Lack of response	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					1082	2345	1
MMRF_1504	Third Line Therapy (following 2nd relapse)	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Other	DAY 1, 8 AND 15					1345	2043	1
MMRF_1504	Fifth Line Therapy (following 4th relapse)	Elotuzumab		Disease progression/Relapse	mg	IV	Log Forms	Unknown	Unknown		800	Other	WEEKLY FIRST 2 CYCLES, THEN EVERY 4 WK AFTER C3					2358	2380	1
MMRF_1504	Fifth Line Therapy (following 4th relapse)	Pomalidomide		DEATH	mg	PO	Log Forms	Unknown	Unknown		4	Other	QD (1-21 OF 28 DAY CYCLE)					2353	2424	1
MMRF_1504	Fifth Line Therapy (following 4th relapse)	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Unknown	Unknown		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					2387	2415	1
MMRF_1504	Fourth Line Therapy (following 3rd relapse)	Daratumumab		Disease progression/Relapse	mg	IV	Log Forms	Unknown	Unknown		700	Other	EVERY WEEK FOR 8 WEEKS, THEN EVERY 2 WEEKS					2058	2316	1
MMRF_1504	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		4	Other	D2-3, D8-9, D14-15, D21-22					2058	2424	1
MMRF_1504	Fourth Line Therapy (following 3rd relapse)	Lenalidomide		Completed regimen	mg	PO	Log Forms	Unknown	Unknown		10	QD (D1-21)	QD (D1-21)					2065	2346	1
MMRF_2055	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		15	Other	EVERY OTHER DAY					1	283	1
MMRF_2055	First line of therapy	Dexamethasone		HYPERGLYCEMIA	mg	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	178	1
MMRF_2055	Second Line Therapy (after first relapse)	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		15	Other	EVERY OTHER DAY; TAKE EVERY OTHER DAY FOR 21 DAYS EVERY 28 DAY CYCLE					811	1177	1
MMRF_2055	Second Line Therapy (after first relapse)	Bortezomib		Completed regimen	mg/dL	IV SubQ	Log Forms	Induction	Induction		1.3	Other	DAY 1, 8, 15 AND 22					906	1655	1
MMRF_2055	Second Line Therapy (after first relapse)	Dexamethasone		DEATH	mg	PO	Log Forms	Induction	Induction		28	Other	DAY 1, 8, 15 AND 22					906	1662	1
MMRF_2253	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		2.6	Other	DAYS 1, 5 , 8 & 11					1	157	1
MMRF_2253	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	157	1
MMRF_2253	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	DAYS 1, 8 AND 15					1	157	1
MMRF_2253	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	STEM CELL TRANSPLANT		401	Other	DAILY X 1, DAY (-2)					164	164	1
MMRF_2253	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Other	STEM CALL TRANSPLANT		12	Other	DAY (-2)					164	164	1
MMRF_2253	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Other	STEM CELL TRANSPLANT		8	Other	DAILY DAYS (-1, 0)					165	166	1
MMRF_2253	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					260	495	1
MMRF_2253	First line of therapy	Bortezomib		Disease progression/Relapse	mg	IV SubQ	Log Forms	Induction	Induction		2.7	Q week	Q week					514	710	1
MMRF_2253	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					514	716	1
MMRF_2253	Second Line Therapy (after first relapse)	Carfilzomib		DEATH	mg	IV	Log Forms	Induction	Induction		42	Other	X1 ON DAY 1 TO 2					716	744	1
MMRF_2253	Second Line Therapy (after first relapse)	Pomalidomide		DEATH	mg	PO	Log Forms	Induction	Induction		4	Q day	Q day					719	744	1
MMRF_1349	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)					1	508	1
MMRF_1349	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms				40	Q week	Q week					1	512	1
MMRF_1332	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms				2.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	167	1
MMRF_1332	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms				40	Q week	Q week					1	167	1
MMRF_1332	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms				25	Q day	Q day					10	167	1
MMRF_1332	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					310		1
MMRF_1365	First line of therapy	Bortezomib		DOSE CHANGE	mg	IV SubQ	Log Forms				2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	1	1
MMRF_1365	First line of therapy	Dexamethasone		DOSE PRESCRIBED CHANGED TRANSFER TO NEW PROVIDER	mg	PO	Log Forms				40	Q week	Q week					1	30	1
MMRF_1365	First line of therapy	Cyclophosphamide		DOSE CHANGED	mg	IV	Log Forms				460	Q week	Q week					8	20	1
MMRF_1365	First line of therapy	Bortezomib		DOSE CHANGE	mg	IV SubQ	Log Forms	Induction	Induction		2.3	Other	ONCE					8	8	1
MMRF_1365	First line of therapy	Bortezomib		DOSE CHANGE	mg	IV SubQ	Log Forms	Induction	Induction		2.45	Other	ONCE					22	22	1
MMRF_1365	First line of therapy	Bortezomib		DOSE CHANGE	mg	IV SubQ	Log Forms	Induction	Induction		1	Other	ONCE					30	30	1
MMRF_1365	First line of therapy	Bortezomib			mg/m^2	IV SubQ	Log Forms	Induction	Induction	Checked	1	QWK	QWK					60		1
MMRF_1365	First line of therapy	Cyclophosphamide		DOSE CHANGED	mg	IV	Log Forms	Induction	Induction		470	QWK	QWK					22	30	1
MMRF_1365	First line of therapy	Cyclophosphamide			mg/m^2	IV	Log Forms	Induction	Induction	Checked	300	QWK	QWK					67		1
MMRF_1425	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms				40	QWK	QWK					1	22	1
MMRF_1425	First line of therapy	Bortezomib		Investigator decision for other reasons	mg	IV SubQ	Log Forms				2.7	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	11	1
MMRF_1425	First line of therapy	Bortezomib		Investigator decision for other reasons	mg	IV SubQ	Log Forms	Induction	Induction		2.6	Q week	Q week					22	108	1
MMRF_1425	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					115	227	1
MMRF_1425	First line of therapy	Bortezomib		PERIPHERAL NEUROPATHY	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	EVERY 2 WEEK					227	1107	1
MMRF_1425	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					22	227	1
MMRF_1425	First line of therapy	Dexamethasone		DEATH	mg	PO	Log Forms	Maintenance	Maintenance		20	Other	EVERY 2 WEEKS					237	1260	1
MMRF_1451	First line of therapy	Bortezomib		DEATH	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	154	1
MMRF_1451	First line of therapy	Dexamethasone		DEATH	mg	PO	Log Forms				20	QWK	QWK					1	154	1
MMRF_1451	First line of therapy	Lenalidomide		DEATH	mg	PO	Log Forms	Induction	Induction		10	Q day	Q day					147	154	1
MMRF_1501	First line of therapy	Bortezomib		Lack of response	mg	IV SubQ	Log Forms	Induction	Induction		2.5	Q week	Q week					1	375	1
MMRF_1501	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Induction	Induction		40	Q week	Q week					1	314	1
MMRF_1501	Second Line Therapy (after first relapse)	Pomalidomide		Lack of response	mg	PO	Log Forms	Unknown	Unknown		4	Q day	Q day					375	504	1
MMRF_1501	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		10	QWK	QWK					84	224	1
MMRF_1501	Third Line Therapy (following 2nd relapse)	Carfilzomib		Lack of response	mg	IV	Log Forms	Induction	Induction		42	QWK	QWK					504	734	1
MMRF_1501	First line of therapy	Lenalidomide		Lack of response	mg	PO	Log Forms	Induction	Induction		25	Q day	Q day					224	671	1
MMRF_1501	Third Line Therapy (following 2nd relapse)	Dexamethasone		Lack of response	mg	PO	Log Forms	Induction	Induction		4	BID	BID					448	606	1
MMRF_1501	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		4	Other	TAKE 1 TAB BY MOUTH EVERY 6 HOURS. 2 DAILY FOR 4 DAYS, THEN 1 DAILY X 4 DA					606	622	1
MMRF_1501	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Lack of response	mg	PO	Log Forms	Maintenance	Maintenance		4	Other	TAKE 40 MG PER WEEK					622	874	1
MMRF_1525	Third Line Therapy (following 2nd relapse)	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		4	QD (D1-21)	QD (D1-21)					1840	2598	1
MMRF_1525	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Other	D1, D8, D15					1	237	1
MMRF_1525	First line of therapy	Dexamethasone		Lack of response	mg	PO	Log Forms	Induction	Induction		20	Other	D1, 8, 15					1	1568	1
MMRF_1525	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					27	208	1
MMRF_1525	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					208	273	1
MMRF_1525	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					889	1421	1
MMRF_1525	Second Line Therapy (after first relapse)	Lenalidomide		Lack of response	mg	PO	Log Forms	Induction	Induction		25	QD (D1-7)	QD (D1-7)					1421	1568	1
MMRF_1525	Second Line Therapy (after first relapse)	Ixazomib		Lack of response	mg	PO	Log Forms	Induction	Induction		4	QWK	QWK					1421	1568	1
MMRF_1525	Third Line Therapy (following 2nd relapse)	Carfilzomib		Lack of response	mg	IV	Log Forms	Other	NEW THERAPY AFTER A LACK OF RESPOSE TO SECOND LINE THERAPY		35.4	Other	D1 - D2					1589	1773	1
MMRF_1519	First line of therapy	Bortezomib		CHANGE FROM ONE TIME DOSING TO WEEKLY DOSING AND TO WEIGHT BASED DOSE	mg	IV SubQ	Log Forms	Induction	Induction		3.1	Other	ONE TIME ORDER AUG 10 AND 15					1	6	1
MMRF_1519	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	QWK	QWK					1	195	1
MMRF_1519	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					81	391	1
MMRF_1519	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					13	195	1
MMRF_1519	Second Line Therapy (after first relapse)	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	EVERY 2 WEEKS					265	307	1
MMRF_1519	Second Line Therapy (after first relapse)	Dexamethasone		PATIENT DEATH	mg	PO	Log Forms	Maintenance	Maintenance		20	Q week	Q week					269	647	1
MMRF_1627	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	13	1
MMRF_1627	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	13	1
MMRF_1627	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					103	165	1
MMRF_1627	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					172	251	1
MMRF_1627	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					27	90	1
MMRF_1627	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					27	97	1
MMRF_1627	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					131	160	1
MMRF_1627	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		5	Q day	Q day					644	742	1
MMRF_1627	Third Line Therapy (following 2nd relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					1325	1472	1
MMRF_1627	Fourth Line Therapy (following 3rd relapse)	Bortezomib		PATIENT DECEASED AFTER THIS LAST DATE OF TREATMENT	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	ONCE VERY OTHER WEEK					1526	1568	1
MMRF_1633	First line of therapy	Bortezomib			mg/m^2	IV SubQ	Log Forms	Induction	Induction	Checked	1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_1633	First line of therapy	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_1639	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	105	1
MMRF_1639	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	105	1
MMRF_1639	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					140	575	1
MMRF_1639	Second Line Therapy (after first relapse)	Pomalidomide		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		1	Q day	Q day					520	679	1
MMRF_1639	First line of therapy	Lenalidomide		Lack of response	mg	PO	Log Forms	Induction	Induction		5	Q day	Q day					210	521	1
MMRF_1639	Second Line Therapy (after first relapse)	Carfilzomib		Lack of response	mg	IV	Log Forms	Induction	Induction		34.2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					657	679	1
MMRF_1639	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	IV	Log Forms	Induction	Induction		4	Other	ONCE					657	657	1
MMRF_1645	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.5	Other	EVERY OTHER WEEK					1	117	1
MMRF_1645	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		40	Other	EVERY OTHER WEEK					1	117	1
MMRF_1645	First line of therapy	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Induction	Induction		600	Other	EVERY OTHER WEEK					1	117	1
MMRF_1645	First line of therapy	Lenalidomide		STEM CELL TRANSPLANT	mg	PO	Log Forms	Consolidation	Consolidation		5	Other	M-W-F FOR 3 WEEKS AND ONE WEEK OFF					180	439	1
MMRF_1645	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					180	370	1
MMRF_1645	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	MG/M2	IV	Log Forms	Other	SCT		140	Q day	Q day					440	440	1
MMRF_1645	Second Line Therapy (after first relapse)	Lenalidomide		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		2.5	Q day	Q day					943	1639	1
MMRF_1645	Second Line Therapy (after first relapse)	Lenalidomide		STEM CELL TRANSPLANT SURGEON WANTED TO INCREASE DOSE	mg	PO	Log Forms	Maintenance	Maintenance		5	Other	3 TIMES PER WEEK - MONDAY, WEDNESDAY, AND FRIDAY					540	943	1
MMRF_1651	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.6	Other	DAY 1, 8, 15, 22					1	120	1
MMRF_1651	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		300	Other	DAY 8, 15, 22					8	120	1
MMRF_1651	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	DAY 1, 8, 15, 22					1	120	1
MMRF_1651	First line of therapy	Lenalidomide		PATIENT RESPONDING TO TREATMENT	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					120	358	1
MMRF_1651	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		20	QWK	QWK					120	633	1
MMRF_1651	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		15	Q day	Q day					358	379	1
MMRF_1650	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					1	32	1
MMRF_1650	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	36	1
MMRF_1650	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					106	316	1
MMRF_1650	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		5	Other	BY MOUTH EVERY MON, WED, AND FRIDAY THEN ONE WEEK OFF.					316	486	1
MMRF_1650	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-14)	QD (D1-14)					486	659	1
MMRF_1650	Second Line Therapy (after first relapse)	Pomalidomide		HOSPICE	mg	PO	Log Forms	Induction	Induction		2	Q day	Q day					652	997	1
MMRF_1650	Second Line Therapy (after first relapse)	Dexamethasone		HOSPICE	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					666	997	1
MMRF_1672	First line of therapy	Bortezomib		Investigator decision for other reasons	mg	IV SubQ	Log Forms	Induction	Induction		2.5	QWK	QWK					1	99	1
MMRF_1672	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	120	1
MMRF_1672	First line of therapy	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Induction	Induction		500	Q week	Q week					1	120	1
MMRF_1672	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		1.7	Q week	Q week					106	120	1
MMRF_1672	First line of therapy	Lenalidomide		DUE TO THROMBOCYTOPENIA	mg	PO	Log Forms	Maintenance	Maintenance		25	Q day	Q day					154	536	1
MMRF_1672	First line of therapy	Lenalidomide			mg	PO	Log Forms	Induction	Induction	Checked	10	Q day	Q day					536		1
MMRF_1693	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					2	166	1
MMRF_1693	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	166	1
MMRF_1693	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					145	166	1
MMRF_1693	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					532	2360	1
MMRF_1693	Second Line Therapy (after first relapse)	Elotuzumab		Completed regimen	mg/kg	IV	Log Forms	Unknown	Unknown		10	Q week	Q week					2182	2324	1
MMRF_1693	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	TRANSPLANT CONDITIONING		200	Other	ONCE					257	257	1
MMRF_1693	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Other	ONCE					2513	2513	1
MMRF_1780	First line of therapy	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	182	1
MMRF_1780	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	259	1
MMRF_1780	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					182	259	1
MMRF_1780	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					259	287	1
MMRF_1780	Second Line Therapy (after first relapse)	Bortezomib		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		3.26	Q week	Q week					559	615	1
MMRF_1780	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		5	Q day	Q day					287	629	1
MMRF_1780	Second Line Therapy (after first relapse)	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		15	Q day	Q day					552	629	1
MMRF_1780	Third Line Therapy (following 2nd relapse)	Carfilzomib		Completed regimen	mg	IV	Log Forms	Consolidation	Consolidation		41	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					629	644	1
MMRF_1780	Third Line Therapy (following 2nd relapse)	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Consolidation	Consolidation		3.42	Q week	Q week					673	680	1
MMRF_1780	Third Line Therapy (following 2nd relapse)	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		700	Q week	Q week					673	687	1
MMRF_1897	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	26	1
MMRF_1897	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					25	61	1
MMRF_1922	First line of therapy	Pomalidomide			mg	PO	Log Forms	Induction	Induction	Checked	4	QD (D1-21)	QD (D1-21)					2078		1
MMRF_1922	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	169	1
MMRF_1922	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	148	1
MMRF_1922	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					341	1323	1
MMRF_1922	First line of therapy	Daratumumab			mg	IV	Log Forms	Induction	Induction	Checked	1634	Other	EVERY OTHER WEEK					1468		1
MMRF_1922	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1482	1791	1
MMRF_1922	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	BONE MARROW TRANSPLANT		200	Other	ONCE					235	235	1
MMRF_1922	First line of therapy	Dexamethasone			mg	PO	Log Forms	Unknown	Unknown	Checked	20	Q week	Q week					2455		1
MMRF_1945	First line of therapy	Bortezomib			mg/m^2	IV SubQ	Log Forms	Induction	Induction	Checked	1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_1945	First line of therapy	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_1994	First line of therapy	Bortezomib		LACK OF RESPONSE AND HOSPICE	mg	IV SubQ	Log Forms	Induction	Induction		1.96	Other	QD (D1, D8, D15, D22)					1	272	1
MMRF_1994	First line of therapy	Dexamethasone		LACK OF RESPONSE AND HOSPICE	mg	PO	Log Forms	Induction	Induction		4	Q week	Q week					1	249	1
MMRF_1994	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					148	207	1
MMRF_2160	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Induction	Induction		2.72	Q week	Q week					1	11	1
MMRF_2160	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					1	79	1
MMRF_2160	First line of therapy	Lenalidomide		Patient decision	mg	PO	Log Forms	Induction	Induction		5	QD (D1-3)	QD (D1-3)					60	71	1
MMRF_2478	First line of therapy	Bortezomib		Completed regimen	mg	IV	Log Forms	Induction	Induction		2.81	QWK	QWK					6	167	1
MMRF_2478	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	167	1
MMRF_2478	First line of therapy	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Induction	Induction		550	Q week	Q week					1	601	1
MMRF_2478	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		40	Q week	Q week					174	855	1
MMRF_2478	Second Line Therapy (after first relapse)	Bortezomib		Adverse Event or co-morbidity	mg	IV	Log Forms	Maintenance	Maintenance		2.81	Q week	Q week					174	319	1
MMRF_2478	Third Line Therapy (following 2nd relapse)	Daratumumab		Patient decision	mg	IV	Log Forms	Induction	Induction		1324	Q day	Q day					848	848	1
MMRF_2478	Third Line Therapy (following 2nd relapse)	Pomalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		1	Other	TUESDAYS, THURSDAY, AND SATURDAY DAYS 1 - 21					847	910	1
MMRF_2478	Third Line Therapy (following 2nd relapse)	Pomalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		2	Other	TUESDAYS, THURSDAY, AND SATURDAY DAYS 1 - 21					910	938	1
MMRF_2478	Third Line Therapy (following 2nd relapse)	ELOTUZUMAB		Adverse Event or co-morbidity	mg/kg	IV	Log Forms	Induction	Induction		10	Q week	Q week					1035	2197	1
MMRF_2478	Third Line Therapy (following 2nd relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1035	2577	1
MMRF_2505	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		15	Q week	Q week					2	22	1
MMRF_2505	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					1	443	1
MMRF_2505	First line of therapy	Bortezomib		Disease progression/Relapse	mg	IV SubQ	Log Forms	Induction	Induction		2.6	Other	EVERY 21 DAYS					74	808	1
MMRF_2505	Second Line Therapy (after first relapse)	Carfilzomib		Adverse Event or co-morbidity	mg	IV	Log Forms	Induction	Induction		41	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					850	865	1
MMRF_2505	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					850	857	1
MMRF_2504	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		2.17	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)					3	164	1
MMRF_2504	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		4	Q week	Q week					23	185	1
MMRF_2504	First line of therapy	Lenalidomide		DID NOT TOLERATE DUE TO PRURITUS OF THE SCALP	mg	PO	Log Forms	Induction	Induction		15	Q day	Q day					1	80	1
MMRF_2504	First line of therapy	Cyclophosphamide		Adverse Event or co-morbidity	mg	IV	Log Forms	Induction	Induction		516	Q week	Q week					54	68	1
MMRF_2504	First line of therapy	Cyclophosphamide		Adverse Event or co-morbidity	mg	IV	Log Forms	Induction	Induction		525	QWK	QWK					102	118	1
MMRF_2504	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING FOR AUTOLOGOUS TRANSPLANT		200	Other	ONCE					200	200	1
MMRF_2523	First line of therapy	Bortezomib		Completed regimen	mg	IV	Log Forms	Induction	Induction		2.5	QWK	QWK					1	297	1
MMRF_2523	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		40	Q week	Q week					1	661	1
MMRF_2523	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		5	Q day	Q day					24	641	1
MMRF_2589	First line of therapy	Bortezomib		Completed regimen	mg	IV	Log Forms	Induction	Induction		2.65	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)					1	131	1
MMRF_2589	First line of therapy	Dexamethasone		PREPARE FOR BLOODESS TRANSPLANT	mg	PO	Log Forms	Induction	Induction		4	Q day	Q day					2	327	1
MMRF_2589	First line of therapy	Lenalidomide		PREPARE FOR TRANSPLANT	mg	PO	Log Forms	Induction	Induction		25	Q day	Q day					8	327	1
MMRF_2589	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	HIGH DOSE CHEMOTHERAPY FOR BLOODLESS TRANSPLANT		140	Other	ONCE					374	374	1
MMRF_2589	First line of therapy	Lenalidomide		PNEUMONIA	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					519	712	1
MMRF_2589	Second Line Therapy (after first relapse)	Lenalidomide		PATIENT DECEASED	mg	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					766	911	1
MMRF_1607	First line of therapy	Bortezomib		Completed regimen	mg	IV	Log Forms	Induction	Induction		2.58	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	203	1
MMRF_1607	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		15	QD (D1-14)	QD (D1-14)					1	203	1
MMRF_1607	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	113	1
MMRF_1607	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		2.2	Other	DAYS 1, 8, 15					141	190	1
MMRF_1607	First line of therapy	Dexamethasone		PREPARING FOR STEM CELL TRANSPLANT	mg	PO	Log Forms	Induction	Induction		8	Q week	Q week					113	190	1
MMRF_1605	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Other	DAYS 1, 8, 15					1	176	1
MMRF_1605	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	176	1
MMRF_1605	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	Other	DAYS 1-4 AND DAYS 9-11					1	113	1
MMRF_1605	First line of therapy	Bortezomib		Lack of response	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					383	453	1
MMRF_1605	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		25	Other	DAYS 1-14 FOLLOWED BY DAYS 15-27 REST					383	525	1
MMRF_1605	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		20	Other	DAYS 1, 8, 15 FOLLOWED BY 14 DAYS REST					114	176	1
MMRF_1605	First line of therapy	Carfilzomib		DECISION BY ONCOLOGY PHARMACIST	mg/m^2	IV	Log Forms	Consolidation	Consolidation		20	Other	DAYS 1, 8, 15 FOLLOWED BY 14 DAYS REST					523	1636	1
MMRF_1605	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		20	Q week	Q week					383	494	1
MMRF_1605	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	25	Other	25 MG PO DAILY X 21 DAY FOLLOWED BY 7 DAYS OFF					579		1
MMRF_1605	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		12	Q day	Q day					495	525	1
MMRF_1605	First line of therapy	Dexamethasone			mg	PO	Log Forms	Maintenance	Maintenance	Checked	20	Q week	Q week					579		1
MMRF_1939	First line of therapy	Lenalidomide		Patient decision	mg	PO	Log Forms	Induction	Induction		15	QD (D1-14)	QD (D1-14)					1	295	1
MMRF_1939	First line of therapy	Dexamethasone		Patient decision	mg	PO	Log Forms	Induction	Induction		40	Other	WEEKLY X 3 WEEKS WHEN RECEIVING VELCADE					1	295	1
MMRF_1939	First line of therapy	Bortezomib		Patient decision	mg/m^2	IV	Log Forms	Induction	Induction		1.3	Other	WEEKLY X 3 WEEKS					1	295	1
MMRF_2035	First line of therapy	Bortezomib			mg	IV SubQ	Log Forms	Induction	Induction	Checked	2.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_2035	First line of therapy	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_2493	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					6	16	1
MMRF_2493	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	16	1
MMRF_2493	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Other	WEEKLY X 3 FOLLOWED BY 1 WEEK REST					36	258	1
MMRF_2493	First line of therapy	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	40	Q week	Q week					36		1
MMRF_2493	First line of therapy	Ixazomib		Lack of response	mg	PO	Log Forms	Maintenance	Maintenance		4	Q week	Q week					482	573	1
MMRF_2493	First line of therapy	Daratumumab		Completed regimen	mg/kg	IV	Log Forms	Maintenance	Maintenance		16	Other	Q 4 WEEKS					587	982	1
MMRF_1470	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					5	59	1
MMRF_1470	First line of therapy	Dexamethasone		Patient decision	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	27	1
MMRF_1470	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					200	611	1
MMRF_1470	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		40	Q week	Q week					185	213	1
MMRF_1470	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		40	Q week	Q week					291	607	1
MMRF_1470	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					60	199	1
MMRF_1820	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		10	QD (D1-14)	QD (D1-14)					22	29	1
MMRF_1820	First line of therapy	Bortezomib		Completed regimen	mg	SQ	Log Forms	Induction	Induction		2.2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	106	1
MMRF_1820	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	D 1,2,4,5,8,9,11,12 Q 21 DAYS					1	106	1
MMRF_1820	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		10	QD (D1-14)	QD (D1-14)					43	57	1
MMRF_1820	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		15	QD (D1-14)	QD (D1-14)					64	77	1
MMRF_1820	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					85	106	1
MMRF_1820	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Other	STEM CELL MOBILIZATION		5160	Other	ONCE					138	138	1
MMRF_1820	First line of therapy	Carfilzomib		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING REGIMEN FOR TRANSPLANT		34.4	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					164	209	1
MMRF_1820	First line of therapy	Melphalan		Completed regimen			Log Forms	Other	CONDITIONING REGIMEN FOR TRANSPLANT			Other	TRANSPLANT  DAY -2 AND -1					191	192	1
MMRF_1820	First line of therapy	Bendamustine		Completed regimen		IV	Log Forms	Other	CONDITIONING FOR TRANSPLANT			Other	DAY -2 AND DAY -1					191	192	1
MMRF_2115	First line of therapy	Bortezomib		PATIENT DIED OF NON DISEASE RELATED CAUSES	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					1	21	1
MMRF_2115	First line of therapy	Dexamethasone		PATIENT DIED OF NON DISEASE RELATED CAUSES	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	21	1
MMRF_2115	First line of therapy	Cyclophosphamide		PATIENT DIED OF NON DISEASE RELATED CAUSES	mg	PO	Log Forms	Induction	Induction		650	Q week	Q week					1	21	1
MMRF_2269	Sixth Line Therapy (following 5th relapse)	Carfilzomib			mg/m^2	IV	Log Forms	Unknown	Unknown	Checked	27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					2495		1
MMRF_2269	Sixth Line Therapy (following 5th relapse)	Lenalidomide			mg	PO	Log Forms	Unknown	Unknown	Checked	15	QD (D1-21)	QD (D1-21)					2495		1
MMRF_2269	Fifth Line Therapy (following 4th relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		10	QD (D1-21)	QD (D1-21)					2355	2495	1
MMRF_2269	Fifth Line Therapy (following 4th relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		15	QD (D1-21)	QD (D1-21)					2243	2355	1
MMRF_2269	Fifth Line Therapy (following 4th relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		25	QD (D1-21)	QD (D1-21)					2159	2243	1
MMRF_2269	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Unknown	Unknown		20	Other	WITH EVERY DOSE OF DARATUMUMAB					1858	2138	1
MMRF_2269	Fourth Line Therapy (following 3rd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					1858	2138	1
MMRF_2269	Fourth Line Therapy (following 3rd relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Unknown	Unknown		16	Other	Q 4 WEEKS					1998	2138	1
MMRF_2269	Fourth Line Therapy (following 3rd relapse)	Daratumumab		Completed regimen	mg/kg	IV	Log Forms	Unknown	Unknown		16	Other	EVERY TWO WEEKS					1858	1970	1
MMRF_2269	Third Line Therapy (following 2nd relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Unknown	Unknown		16	Other	EVERY TWO WEEKS					1830	1844	1
MMRF_2269	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	119	1
MMRF_2269	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	116	1
MMRF_2269	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	D1,2,4,5,8,9,11,12 Q 21 DAYS					1	117	1
MMRF_2269	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	Other	DAY 1-21 EVERY 28 DAYS					134	1355	1
MMRF_2269	Second Line Therapy (after first relapse)	Ixazomib		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		4	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1379	1754	1
MMRF_2269	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		25	QD (D1-21)	QD (D1-21)					1369	1691	1
MMRF_2269	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1369	1691	1
MMRF_2269	Third Line Therapy (following 2nd relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Unknown	Unknown		16	Q week	Q week					1760	1817	1
MMRF_2269	Fifth Line Therapy (following 4th relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Unknown	Unknown		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					2159	2495	1
MMRF_2269	Fifth Line Therapy (following 4th relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		40	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					2159	2495	1
MMRF_2269	Sixth Line Therapy (following 5th relapse)	Dexamethasone			mg	PO	Log Forms	Unknown	Unknown	Checked	20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					2495		1
MMRF_2026	First line of therapy	Bortezomib		PATIENT'S NEUROPATHY- GRADE 2	mg/m^2	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	147	1
MMRF_2026	First line of therapy	Cyclophosphamide		PATIENT'S NEUROPATHY	mg	PO	Log Forms	Induction	Induction		750	QWK	QWK					1	147	1
MMRF_2026	First line of therapy	Dexamethasone		Patient decision	mg	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	938	1
MMRF_2026	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		25	QD (D1-21)	QD (D1-21)					155	917	1
MMRF_2026	Second Line Therapy (after first relapse)	Pomalidomide		Patient decision	mg	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					918	938	1
MMRF_2436	First line of therapy	Bortezomib		DOSE CHANGE TO 1.5 MG/M^2	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					1	27	1
MMRF_2436	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					34	215	1
MMRF_2436	First line of therapy	Cyclophosphamide		DOSE CHANGE FROM 500 TO 550 MG D1, D8, D15 AND D22	mg	PO	Log Forms	Induction	Induction		500	Q week	Q week					27	54	1
MMRF_2436	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	215	1
MMRF_2436	First line of therapy	Cyclophosphamide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		550	Other	D1, D8, D15, D22					54	215	1
MMRF_2436	First line of therapy	Lenalidomide			mg	PO	Log Forms	Other	PT VERY FRAIL, TRAVEL DIFFICULTY, NEED TO HAVE HIM ON A REGIMEN THAT HE WOULD HAVE A RESTORED QOL	Checked	5	QD (D1-21)	QD (D1-21)					259		1
MMRF_1486	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Other	D1, D8, D15, OFF DAY 22					1	316	1
MMRF_1486	First line of therapy	Dexamethasone		PATIENT DECEASED	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					1	437	1
MMRF_1486	First line of therapy	Cyclophosphamide		Investigator decision for other reasons	mg	IV	Log Forms	Induction	Induction		600	Q week	Q week					113	316	1
MMRF_1486	First line of therapy	Bortezomib		PATIENT DECEASED	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Other	Q WEEK (D1, D8, D15, OFF DAY 22)					317	437	1
MMRF_1486	First line of therapy	Cyclophosphamide		PATIENT DECEASED	mg	IV	Log Forms	Induction	Induction		600	Other	Q WEEK (D1, D8, D15, OFF DAY 22)					317	437	1
MMRF_1671	First line of therapy	Bortezomib		Investigator decision for other reasons	mg	IV SubQ	Log Forms	Induction	Induction		2.4	Q week	Q week					1	394	1
MMRF_1671	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					1	394	1
MMRF_1671	First line of therapy	Cyclophosphamide		Investigator decision for other reasons	mg	IV	Log Forms	Induction	Induction		550	Q week	Q week					1	394	1
MMRF_1671	Second Line Therapy (after first relapse)	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		15	Q day	Q day					141	407	1
MMRF_1671	Third Line Therapy (following 2nd relapse)	Bortezomib		Investigator decision for other reasons	mg	IV SubQ	Log Forms	Induction	Induction		2.3	Other	D1, D8. D15					449	547	1
MMRF_1671	Third Line Therapy (following 2nd relapse)	Cyclophosphamide		Investigator decision for other reasons	mg	IV	Log Forms	Induction	Induction		530	Other	D1, D8, D15					449	547	1
MMRF_1671	Third Line Therapy (following 2nd relapse)	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					449	547	1
MMRF_1671	Third Line Therapy (following 2nd relapse)	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		15	Q day	Q day					449	547	1
MMRF_1671	Third Line Therapy (following 2nd relapse)	Lenalidomide		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		15	Q day	Q day					548	903	1
MMRF_1671	Fourth Line Therapy (following 3rd relapse)	Carfilzomib		DOSE OF CARFILZOMIB INCREASED AT BEGINNING OF NEXT CYCLE	mg/m^2	IV	Log Forms	Maintenance	Maintenance		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					877	903	1
MMRF_1671	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Consolidation	Consolidation		40	QWK	QWK					877	1227	1
MMRF_1671	Fourth Line Therapy (following 3rd relapse)	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Consolidation	Consolidation		2	Q day	Q day					904	1227	1
MMRF_1671	Fourth Line Therapy (following 3rd relapse)	Carfilzomib		DOSE OF CARFILZOMIB INCREASED AT BEGINNING OF NEXT CYCLE	mg/m^2	IV	Log Forms	Consolidation	Consolidation		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					904	1050	1
MMRF_1671	Fifth Line Therapy (following 4th relapse)	Carfilzomib		DOSE OF CARFILZOMIB INCREASED AT BEGINNING OF NEXT CYCLE	mg/m^2	IV	Log Forms	Consolidation	Consolidation		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1072	1128	1
MMRF_1671	Fifth Line Therapy (following 4th relapse)	Carfilzomib		DOSE OF CARFILZOMIB INCREASED AT BEGINNING OF NEXT CYCLE	mg/m^2	IV	Log Forms	Consolidation	Consolidation		30	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1051	1071	1
MMRF_1671	Fifth Line Therapy (following 4th relapse)	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Consolidation	Consolidation		52	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1128	1227	1
MMRF_1671	Fifth Line Therapy (following 4th relapse)	Cyclophosphamide		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Consolidation	Consolidation		300	Other	QD (D1, D8, D15)					1156	1227	1
MMRF_1671	Fifth Line Therapy (following 4th relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Consolidation	Consolidation		56	Other	QD (D1, D8, D15)					1303	1507	1
MMRF_1671	Fifth Line Therapy (following 4th relapse)	Cyclophosphamide		Disease progression/Relapse	mg/m^2	IV	Log Forms	Consolidation	Consolidation		100	Other	QD (D1, D8, D15)					1303	1507	1
MMRF_1671	Fifth Line Therapy (following 4th relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		40	Q week	Q week					1303	1507	1
MMRF_1671	Fifth Line Therapy (following 4th relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		2	QD (D1-21)	QD (D1-21)					1303	1507	1
MMRF_1671	Sixth Line Therapy (following 5th relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Unknown	Unknown		16	Q week	Q week					1527	1835	1
MMRF_1671	Sixth Line Therapy (following 5th relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					1527	1835	1
MMRF_1671	Sixth Line Therapy (following 5th relapse)	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Unknown	Unknown		40	Q week	Q week					1527	1835	1
MMRF_1671	Seventh Line of Therapy (following 6th relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		4	Other	DAYS 1-21 OF 28 DAY CYCLE					2161	2224	1
MMRF_1671	Seventh Line of Therapy (following 6th relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		40	Q week	Q week					2161	2224	1
MMRF_1671	Sixth Line Therapy (following 5th relapse)	CAR-T	NCT03288493	Completed regimen			Log Forms	Other	CLINICAL TRIAL									1977	1978	1
MMRF_1671	Seventh Line of Therapy (following 6th relapse)	Elotuzumab		Disease progression/Relapse	mg	IV	Log Forms	Unknown	Unknown		700	QWK	QWK					2161	2224	1
MMRF_1671	Eighth Line of Therapy (following 7th relapse)	SELINEXOR		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		80	Other	QD DAY 1 AND DAY 4					2320	2335	1
MMRF_1671	Eighth Line of Therapy (following 7th relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		20	Other	QD DAY 1 AND DAY 4					2320	2335	1
MMRF_1671	Ninth Line of Therapy (following 8th relapse)	Melphalan		Patient decision	mg/kg	PO	Log Forms	Unknown	Unknown		0.25	Other	DAY 1-4 OF 42 DAY CYCLE					2351	2452	1
MMRF_1671	Ninth Line of Therapy (following 8th relapse)	Prednisone			mg/m^2	PO	Log Forms	Unknown	Unknown	Checked	60	Other	D1-4 OF 42 DAY CYCLE					2351		1
MMRF_1671	Eighth Line of Therapy (following 7th relapse)	Lenalidomide		Lack of response	mg	PO	Log Forms	Unknown	Unknown		15	Other	DAYS 1-14 OF 21 DAY CYCLE					2266	2314	1
MMRF_1671	Eighth Line of Therapy (following 7th relapse)	Dexamethasone		Lack of response	mg	PO	Log Forms	Unknown	Unknown		40	Other	QD (D1, D8, D15)					2252	2314	1
MMRF_1671	Eighth Line of Therapy (following 7th relapse)	Bortezomib		Lack of response	mg	IV SubQ	Log Forms	Unknown	Unknown		2.4	Other	ONCE EVERY 21 DAY CYCLE					2252	2314	1
MMRF_1720	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg	IV SubQ	Log Forms	Induction	Induction		1.9	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	38	1
MMRF_1720	First line of therapy	Dexamethasone		GIVEN AS ONE TIME DOSE SINCE PATIENT DID NOT HAVE ORAL AVAILABLE	mg	IV	Log Forms	Induction	Induction		8	Other	IV ONE TIME ONLY					1	1	1
MMRF_1720	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		8	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					4	38	1
MMRF_1912	First line of therapy	Bortezomib		Investigator decision for other reasons	mg	IV SubQ	Log Forms	Induction	Induction		2.8	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	127	1
MMRF_1912	First line of therapy	Cyclophosphamide		Investigator decision for other reasons	mg	IV	Log Forms	Induction	Induction		610	Q week	Q week					1	127	1
MMRF_1912	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	IV	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	127	1
MMRF_1912	Second Line Therapy (after first relapse)	Carfilzomib		Disease progression/Relapse	mg	IV	Log Forms	Consolidation	Consolidation		60	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					211	341	1
MMRF_1912	First line of therapy	Bortezomib		Disease progression/Relapse	mg	IV SubQ	Log Forms	Induction	Induction		2.7	Other	D1, D8, D15					128	204	1
MMRF_1912	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		40	QWK	QWK					128	204	1
MMRF_1912	First line of therapy	Cyclophosphamide		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		630	Other	D1, D8, D15					128	204	1
MMRF_1912	Second Line Therapy (after first relapse)	Cyclophosphamide		Disease progression/Relapse	mg	IV	Log Forms	Consolidation	Consolidation		640	Other	D1, D8, D15					211	341	1
MMRF_1912	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		40	Other	D1, D8, D15					211	341	1
MMRF_1505	First line of therapy	Bortezomib			mg/dL	IV SubQ	Log Forms	Induction	Induction	Checked	3.6	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1		1
MMRF_1505	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Induction	Induction		1204	Other	DAY 8 STARTING CYCLE 2 ONWARDS					36	127	1
MMRF_1505	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	Q day	Q day					1	15	1
MMRF_1782	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		2.4	Other	WEEKLY X3 WEEKS/MONTH					1	113	1
MMRF_1782	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	113	1
MMRF_1782	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	WEEKLY X3 WEEKS/MONTH WITH VELCADE					1	113	1
MMRF_1782	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		25	Q week	Q week					574	727	1
MMRF_1782	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		20	Q week	Q week					727	835	1
MMRF_1944	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg	IV	Log Forms	Induction	Induction		1.4	Q week	Q week					4	84	1
MMRF_1944	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Induction	Induction		300	Q week	Q week					4	19	1
MMRF_1944	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					1	49	1
MMRF_1944	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Consolidation	Consolidation		695	Other	ONE DOSE					33	40	1
MMRF_1944	First line of therapy	Dexamethasone		DEATH	mg	PO	Log Forms	Other	DOSE REDUCED		4	TID	TID					67	84	1
MMRF_2203	First line of therapy	Bortezomib			mg/m^2	IV SubQ	Log Forms	Induction	Induction	Checked	1.5	Q week	Q week					1		1
MMRF_2203	First line of therapy	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	20	Q week	Q week					1		1
MMRF_2203	First line of therapy	Cyclophosphamide			mg/m^2	IV SubQ	Log Forms	Induction	Induction	Checked	500	QWK	QWK					1		1
MMRF_1533	First line of therapy	METHYLPREDNISOLONE			mg	PO	Log Forms	Induction	Induction	Checked	8	Other	EVERY OTHER DAY					1		1
MMRF_1533	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg	SUBCUTANEOUS	Log Forms	Induction	Induction		3.7	Q week	Q week					1	398	1
MMRF_1533	First line of therapy	Bortezomib		Disease progression/Relapse	mg	SUBCUTANEOUS	Log Forms	Induction	Induction		3	Other	EVERY 2 WEEKS					399	567	1
MMRF_1533	Second Line Therapy (after first relapse)	Pomalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	4	Q day	Q day					581		1
MMRF_1580	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg	SUBCUTANEOUS	Log Forms	Induction	Induction		3.3	QWK	QWK					1	70	1
MMRF_1580	First line of therapy	Prednisone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	Other	EVERY 48 HOURS					1	8	1
MMRF_1580	First line of therapy	Bortezomib			mg	SUBCUTANEOUS	Log Forms	Maintenance	Maintenance	Checked	3.3	Q week	Q week					81		1
MMRF_2113	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		10	Q day	Q day					1	116	1
MMRF_2113	First line of therapy	METHYLPREDNISOLONE			mg	PO	Log Forms	Induction	Induction	Checked	40	Other	EVERY OTHER DAY					1		1
MMRF_2113	First line of therapy	Bortezomib			mg	SUBCUTANEOUS	Log Forms	Induction	Induction	Checked	31	Q week	Q week					123		1
MMRF_1499	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	25	1
MMRF_1499	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		28	Other	D1, D15					1	363	1
MMRF_1499	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		40	Other	IT IS TAKEN ON D8, D22 NON-ELOTUZUMAB TREATMENT DAYS					56	363	1
MMRF_1499	First line of therapy	Elotuzumab		Investigator decision for other reasons	mg/kg	IV	Log Forms	Induction	Induction		10	Other	IT IS TAKEN ON D1, D8, D15, D22					1	507	1
MMRF_1499	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		25	Other	IT IS TAKEN FROM D1 TO D21					85	624	1
MMRF_1499	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		15	Other	Q2 DAYS FOR 21 DAYS.					624	1232	1
MMRF_1499	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		12	Other	TAKE IT ON DAY 1 AND DAY 15					364	447	1
MMRF_1499	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		20	Other	TAKE ON DAY 8 AND DAY 22 ON NON-ELOTUZUMAB DAYS.					364	447	1
MMRF_1499	First line of therapy	Elotuzumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Induction	Induction		20	Other	DAILY FOR 1 DAY					516	1232	1
MMRF_1499	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		12	Other	TAKE ON DAY 8, 15 AND 22.					448	1232	1
MMRF_1499	Second Line Therapy (after first relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Induction	Induction		16	Other	DAY 1 OF EACH CYCLE					1254	1308	1
MMRF_1499	Second Line Therapy (after first relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		4	Other	DAILY FOR 21 DAYS EVERY CYCLE.					1254	1308	1
MMRF_1499	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		40	Other	Q1 WEEK FOR 4 WEEKS IN EACH CYCLE					1254	1308	1
MMRF_1499	Third Line Therapy (following 2nd relapse)	Cyclophosphamide		DOSE CHANGE	mg/m^2	PO	Log Forms	Induction	Induction		300	Other	Q1 WEEK FOR 3 WEEKS.					1309	1309	1
MMRF_1499	Third Line Therapy (following 2nd relapse)	Bortezomib			mg/m^2	IV	Log Forms	Induction	Induction	Checked	1.5	Other	1 DAY PER WEEK, EVERY 3 WEEKS ( ONE CYCLE)					1309		1
MMRF_1499	Third Line Therapy (following 2nd relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	Q 1 WEEK FOR 4 WEEKS					1309	1336	1
MMRF_1499	Third Line Therapy (following 2nd relapse)	Cyclophosphamide			mg/m^2	PO	Log Forms	Induction	Induction	Checked	263.15	Other	Q1 WEEK FOR 3 WEEKS					1393		1
MMRF_1499	Third Line Therapy (following 2nd relapse)	Dexamethasone			mg	PO	Log Forms	Maintenance	Maintenance	Checked	20	Other	Q 1 WEEK FOR 3 WEEKS					1337		1
MMRF_1512	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO	Log Forms	Induction	Induction		425	Q week	Q week					1	84	1
MMRF_1512	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		1.5	QWK	QWK					1	84	1
MMRF_1512	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	22	1
MMRF_1512	First line of therapy	Bortezomib		Completed regimen	mg	IV	Log Forms	Induction	Induction		2.2	Other	THIS IS 4TH CYCLE, IT IS GIVEN ON D1, D8, D15, D22					85	158	1
MMRF_1512	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Induction	Induction		3680	Other	AT 2500MG/M^2 FOR 1 DAY					119	119	1
MMRF_1512	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		12	Other	THIS IS 4TH CYCLE, IT IS TAKEN ONCE A WEEK FOR FOUR WEEKS.					119	125	1
MMRF_1512	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		10	Other	DAILY FOR 21 DAYS					344	943	1
MMRF_1512	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		1.3	Other	ON DAY 1 AND 7 FOR 1 WEEK.					155	162	1
MMRF_1512	Second Line Therapy (after first relapse)	Cyclophosphamide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		425	Other	Q1 WEEK FOR 4 WEEKS					1541	1988	1
MMRF_1512	Second Line Therapy (after first relapse)	Bortezomib		Patient decision	mg	IV SubQ	Log Forms	Maintenance	Maintenance		2.2	Q day	Q day					1546	1777	1
MMRF_1512	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Maintenance	Maintenance	Checked	20	Other	Q1 WEEK FOR 4 WEEKS EACH CYCLE					1541		1
MMRF_1512	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING FOR BONE MARROW TRANSPLANT		200	Q day	Q day					160	160	1
MMRF_1512	Second Line Therapy (after first relapse)	Bortezomib		Disease progression/Relapse	mg	IV SubQ	Log Forms	Maintenance	Maintenance		2.2	Other	Q2WEEKS					1874	1988	1
MMRF_1512	Third Line Therapy (following 2nd relapse)	Daratumumab			mg	IV	Log Forms	Maintenance	Maintenance	Checked	720	Q day	Q day					1989		1
MMRF_1512	Third Line Therapy (following 2nd relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					1989		1
MMRF_1577	Third Line Therapy (following 2nd relapse)	Cyclophosphamide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance	Checked	200	Other	DAYS 1,8 AND 15					1998		1
MMRF_1577	Third Line Therapy (following 2nd relapse)	Cyclophosphamide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		300	Other	DAYS 1,8 AND 15					1969	1998	1
MMRF_1577	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING FOR BONE MARROW TRANSPLANT		200	Q day	Q day					248	248	1
MMRF_1577	Second Line Therapy (after first relapse)	Bortezomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Induction	Induction		1.3	Other	Q1 WEEK FOR 4 WEEKS					1081	1494	1
MMRF_1577	Second Line Therapy (after first relapse)	SELINEXOR (KPT-330)		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		100	Other	Q 1 WEEK FOR 5 WEEKS					1081	1227	1
MMRF_1577	Second Line Therapy (after first relapse)	Dexamethasone		POOR TOLERANCE	mg	PO	Log Forms	Induction	Induction		40	Other	Q 1 WEEK FOR 5 WEEKS					1081	1473	1
MMRF_1577	Second Line Therapy (after first relapse)	SELINEXOR (KPT-330)		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		80	Other	Q 1 WEEK FOR 5 WEEKS					1228	1332	1
MMRF_1577	Second Line Therapy (after first relapse)	SELINEXOR (KPT-330)		Patient decision	mg	PO	Log Forms	Induction	Induction		60	Other	Q 1 WEEK FOR 5 WEEKS					1333	1473	1
MMRF_1577	Third Line Therapy (following 2nd relapse)	Daratumumab			mg/kg	IV	Log Forms	Induction	Induction	Checked	16	Q day	Q day					1572		1
MMRF_1577	Third Line Therapy (following 2nd relapse)	Pomalidomide			mg	PO	Log Forms	Induction	Induction	Checked	4	QD (D1-21)	QD (D1-21)					1572		1
MMRF_1577	Third Line Therapy (following 2nd relapse)	Cyclophosphamide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		400	Other	DAYS 1, 8, 15					1572	1998	1
MMRF_1577	Third Line Therapy (following 2nd relapse)	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	20	Q day	Q day					1572		1
MMRF_1577	First line of therapy	Bortezomib		Investigator decision for other reasons	mg	IV SubQ	Log Forms	Induction	Induction		3	Other	TWICE A WEEK FOR 14 DAYS					1	128	1
MMRF_1577	First line of therapy	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Induction	Induction		700	Other	ONCE A WEEK FOR 3 WEEKS					1	149	1
MMRF_1577	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	ONCE A WEEK FOR 4 WEEKS					1	233	1
MMRF_1577	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	Other	DAILY FOR 14 DAYS					86	233	1
MMRF_1577	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Induction	Induction		4640	Other	DAILY FOR 1 DAY					172	172	1
MMRF_1577	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		1.5	Other	ONCE A WEEK FOR 14 DAYS					128	152	1
MMRF_1577	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		15	Other	DAILY FOR 21 DAYS					340	382	1
MMRF_1577	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		1.5	Other	DAILY FOR 21 DAYS					340	382	1
MMRF_1577	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Consolidation	Consolidation		20	Other	Q 1 WEEK FOR 3 WEEKS					340	539	1
MMRF_1577	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		15	Other	DAILY FOR 21 DAYS					396	1061	1
MMRF_1577	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		16	Q day	Q day					535	562	1
MMRF_1577	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		8	Other	Q 1 WEEK FOR 4 WEEKS					563	589	1
MMRF_1589	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		2500	Other	DAILY FOR 1 DAY					167	196	1
MMRF_1589	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		10	Other	DAILY FOR 21 DAYS					273	480	1
MMRF_1589	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		12	Other	DAILY FOR 1 DAY					162	196	1
MMRF_1589	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		10	Other	DAILY FOR 21 DAYS.					610	1211	1
MMRF_1589	First line of therapy	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Induction	Induction		600	Other	(AT 263.2MG/M2) TWICE A DAY  FOR 14 DAYS					1	128	1
MMRF_1589	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		3.4	Other	(AT 1.5MG/M2) DAILY FOR 1DAY FOR 14 DAYS					1	128	1
MMRF_1589	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	FOR 1 DAY					1	134	1
MMRF_1589	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		2500	Other	DAILY FOR 1 DAY					162	162	1
MMRF_1589	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					197	197	1
MMRF_1715	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING FOR BONE MARROW TRANSPLANT		200	Q day	Q day					161	161	1
MMRF_1715	First line of therapy	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Induction	Induction		525	Other	Q 1 WEEK FOR 4 WEEKS					1	126	1
MMRF_1715	First line of therapy	Bortezomib		Completed regimen	mg	IV	Log Forms	Induction	Induction		2.3	Other	DAILY FOR 1 DAY					64	64	1
MMRF_1715	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	12 MG PRIOR TO CHEMO,4MG FOR FOUR DOSES STARTING ON DAY 1 OF EACH CYCLE.					1	126	1
MMRF_1715	First line of therapy	Bortezomib		Completed regimen	mg	IV	Log Forms	Induction	Induction		2.6	Other	DAILY FOR 1 DAY WEEKLY					15	43	1
MMRF_1715	First line of therapy	Bortezomib		Completed regimen	mg	IV	Log Forms	Induction	Induction		2.6	Other	DAILY FOR 1 DAY EVERY TWO WEEKS					50	63	1
MMRF_1867	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING FOR BONE MARROW TRANSPLANT		200	Q day	Q day					126	126	1
MMRF_1867	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO	Log Forms	Induction	Induction		300	Other	Q 1 WEEK FOR 4 WEEKS					1	91	1
MMRF_1867	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		1.5	Other	ONCE A WEEK FOR THREE WEEKS					1	71	1
MMRF_1867	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	Q 1 WEEK FOR FOUR WEEKS					1	91	1
MMRF_1867	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Other	PART OF BONE MARROW TRANSPLANT PROCEDURE.		2500	Other	FOR 1 DAY.					92	92	1
MMRF_1867	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	Other	DAILY FOR 21 DAYS.					233		1
MMRF_1867	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		12	Other	DAILY FOR 1 DAY					92	93	1
MMRF_1867	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Other	BOTEZOMIB PRE-TREATMENT FOR AUTOLOGOUS BONE MARROW TRANSPLANT		1.3	Other	FOR 1 DAY					121	124	1
MMRF_1873	First line of therapy	Cyclophosphamide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		300	Other	ONCE A WEEK FOR 4 WEEKS					1	127	1
MMRF_1873	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Induction	Induction		1.3	Other	ON DAYS 1, 8, AND 16.					1	127	1
MMRF_1873	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		20	Other	ONCE A WEEK FOR 4 WEEKS					1	127	1
MMRF_1910	First line of therapy	Prednisone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		5	Other	DAILY					1	62	1
MMRF_1910	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO	Log Forms	Induction	Induction		300	Other	ORAL Q 1 WEEK FOR 4 WEEKS					52	93	1
MMRF_1910	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Induction	Induction		1.3	Other	ONCE A WEEK FOR 4 WEEKS					52	94	1
MMRF_1910	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	ONCE A WEEK FOR 4 WEEKS					52	220	1
MMRF_1910	Second Line Therapy (after first relapse)	Bortezomib		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Induction	Induction		1.5	Other	DAILY FOR 1 DAY					95	193	1
MMRF_1910	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		25	Other	DAILY FOR 21 DAYS					123	415	1
MMRF_1910	Second Line Therapy (after first relapse)	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		2500	Other	DAILY FOR 1 DAY					220	220	1
MMRF_1910	Second Line Therapy (after first relapse)	Bortezomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Induction	Induction		1.5	Other	Q 1 WEEK FOR 3 WEEKS					333	415	1
MMRF_1910	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		40	Other	ONCE A WEEK					333	415	1
MMRF_1910	Third Line Therapy (following 2nd relapse)	Bortezomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Induction	Induction		1.5	Other	Q 1 WEEK FOR 3 WEEKS					417	487	1
MMRF_1910	Third Line Therapy (following 2nd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		4	Other	DAILY FOR 21 DAYS.					417	487	1
MMRF_1910	Fourth Line Therapy (following 3rd relapse)	KPT-330		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		40	Other	DAILY ON MONDAY AND WEDNESDAY FOR 7 DAYS.					491	507	1
MMRF_1910	Fifth Line Therapy (following 4th relapse)	KPT-330		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		60	Other	DAILY ON TU AND THUR FOR 7 DAYS.					512	533	1
MMRF_1910	Fifth Line Therapy (following 4th relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		40	Other	20MG DAILY ON TU TH FOR 7 DAYS, 8MG EVERY 8 HOURS FOR 4 WEEKS.					512	514	1
MMRF_1910	Fourth Line Therapy (following 3rd relapse)	Prednisone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		5	QID	QID					526	535	1
MMRF_1910	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING FOR BONE MARROW TRANSPLANT		200	Q day	Q day					254	254	1
MMRF_1927	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING FOR BONE MARROW TRANSPLANT		200	Q day	Q day					279	279	1
MMRF_1927	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		1.5	Other	ONCE A WEEK					1	274	1
MMRF_1927	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO	Log Forms	Induction	Induction		300	Other	ONCE A WEEK FOR 4 WEEKS					1	134	1
MMRF_1927	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		8	Other	DAILY FOR 12 DAYS					3	148	1
MMRF_1927	First line of therapy	Cyclophosphamide		Investigator decision for other reasons	mg	IV	Log Forms	Induction	Induction		5200	Other	ONCE FOR ONE DAY					175	175	1
MMRF_1927	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	Q 1 WEEK FOR 4 WEEKS					175	204	1
MMRF_1927	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		10	Other	DAILY FOR 21 DAYS.					389	472	1
MMRF_1927	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		5	Other	DAILY FOR 21 DAYS.					473	788	1
MMRF_1927	Second Line Therapy (after first relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Induction	Induction		16	Other	Q1 WEEK FOR 4 WEEKS IN EACH CYCLE.					1072	1121	1
MMRF_1927	Third Line Therapy (following 2nd relapse)	Pomalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		4	Other	DAILY FOR 14 DAYS.					1128	1260	1
MMRF_1927	Second Line Therapy (after first relapse)	Dexamethasone		DOSE CHANGE	mg	PO	Log Forms	Induction	Induction		40	Other	Q 1 WEEK FOR 4 WEEKS					1072	1525	1
MMRF_1927	Third Line Therapy (following 2nd relapse)	Bortezomib		Adverse Event or co-morbidity	mg	IV SubQ	Log Forms	Induction	Induction		1.9	Other	DAILY M,F FOR 2 WEEKS					1128	1238	1
MMRF_1927	Third Line Therapy (following 2nd relapse)	Carfilzomib		DOSE CHANGE	mg	IV	Log Forms	Consolidation	Consolidation		40	Other	DAILY FOR 2 DAYS					1260	1261	1
MMRF_1927	Third Line Therapy (following 2nd relapse)	Carfilzomib		DOSE CHANGE	mg	IV	Log Forms	Consolidation	Consolidation		113	Other	DAILY FOR 2 DAYS					1271	1279	1
MMRF_1927	Third Line Therapy (following 2nd relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Consolidation	Consolidation		27	Other	DAILY FOR 2 DAYS					1292	1590	1
MMRF_1927	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		20	QD (D1-7)	QD (D1-7)					1525	1590	1
MMRF_2265	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO	Log Forms	Induction	Induction		276.2	Other	Q 1 WEEK FOR 4 WEEKS					1	124	1
MMRF_2265	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		1.5	Other	DAILY FOR 1 DAY					1	124	1
MMRF_2265	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	DAYS 1TO 4, AND 17 TO 20.					1	124	1
MMRF_2265	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		2500	Other	FOR 1 DAY					126	127	1
MMRF_2265	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		12	Other	FOR 1 DAY					126	127	1
MMRF_2265	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		1	Other	FOR 1 DAY					153	153	1
MMRF_2265	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		1	Other	FOR DAY 1 AND DAY 3.					155	158	1
MMRF_2265	First line of therapy	Lenalidomide		STARTING MAINTENANCE	mg	PO	Log Forms	Consolidation	Consolidation		10	Other	DAILY FOR 21 DAYS.					260	315	1
MMRF_2265	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		40	Other	ONCE A WEEK FOR 4 WEEKS.					260	316	1
MMRF_2265	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	Other	DAYS 1-21					316	1548	1
MMRF_2265	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING FOR BONE MARROW TRANSPLANT		200	Q day	Q day					159	159	1
MMRF_2563	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING FOR BONE MARROW TRANSPLANT		200	Q day	Q day					175	175	1
MMRF_2563	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		1.5	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1	98	1
MMRF_2563	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		40	Other	Q 1 WEEK FOR 4 WEEKS					1	299	1
MMRF_2563	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO	Log Forms	Induction	Induction		300	Other	Q1 WEEK FOR 4 WEEKS					1	113	1
MMRF_2563	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		2500	Other	FOR 1 DAY.					134	135	1
MMRF_2563	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		10	Other	10 MG PER DAY FOR 21 DAYS, THEN 7 DAYS OFF.					238	293	1
MMRF_2563	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		1.3	Other	FOR 1 DAY.					167	171	1
MMRF_2563	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		1.5	Other	Q1 WEEK FOR 4 WEEKS					240	300	1
MMRF_2563	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	Other	DAILY FOR 21 DAYS.					342	707	1
MMRF_2563	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		1.5	Other	Q 2 WEEKS FOR 2 DOSES.					342	650	1
MMRF_2563	First line of therapy	Bortezomib			mg/m^2	IV	Log Forms	Maintenance	Maintenance	Checked	1.3	Other	Q 2 WEEKS FOR 4 DOSES.					651		1
MMRF_2563	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	5	Other	DAILY FOR 21 TRO 42 DAYS					775		1
MMRF_1597	First line of therapy	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Induction	Induction		600	Other	D1, 8, 15					2	16	1
MMRF_1597	First line of therapy	Dexamethasone		MAINTENANCE THERAPY STARTED	mg	PO	Log Forms	Induction	Induction		40	Other	DAY 1, 8, 15					2	16	1
MMRF_1597	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Maintenance	Maintenance		3	Other	DAY 1, D7, D14					27	100	1
MMRF_1597	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		2.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					2	12	1
MMRF_1597	First line of therapy	Dexamethasone		Patient decision	mg	PO	Log Forms	Maintenance	Maintenance		40	Other	ONE DOSE					27	27	1
MMRF_1597	First line of therapy	Dexamethasone		Patient decision	mg	PO	Log Forms	Induction	Induction		40	Other	SINGLE DOSE					1	1	1
MMRF_1597	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Induction	Induction		5100	Q day	Q day					117	117	1
MMRF_1597	First line of therapy	BUSULPHAN		Completed regimen	mg	IV	Log Forms	Induction	Induction		225	Other	DAY -5, -4, -3					147	149	1
MMRF_1597	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Induction	Induction		280	Other	SINGLE DOSE					150	150	1
MMRF_1597	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					251	501	1
MMRF_1597	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	15	QD (D1-21)	QD (D1-21)					502		1
MMRF_1610	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		3.4	Other	DAY 1, 8, 15					1	15	1
MMRF_1610	First line of therapy	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Induction	Induction		700	Other	DAY 1, 8, 15, 22					1	22	1
MMRF_1610	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	DAY 1, 8, 15, 22					1	22	1
MMRF_1610	First line of therapy	BUSULPHAN		Completed regimen	mg	IV	Log Forms	Induction	Induction		274.6	Other	DAY -5, -4, -3					150	152	1
MMRF_1610	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Induction	Induction		330.4	Other	SINGLE DOSE					153	153	1
MMRF_1610	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	Q day	Q day					260		1
MMRF_1614	First line of therapy	Lenalidomide			mg	PO	Log Forms	Induction	Induction	Checked	25	QD (D1-21)	QD (D1-21)					1		1
MMRF_1614	First line of therapy	Dexamethasone		EXCELLANT RESPONSE SO DISCONTINUED	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	394	1
MMRF_1638	First line of therapy	Bortezomib		DOSE TITRATED	mg	IV SubQ	Log Forms	Induction	Induction		3.2	Other	D1, 8, 15					1	15	1
MMRF_1638	First line of therapy	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Induction	Induction		500	Other	D1, 8, 15, 22					1	128	1
MMRF_1638	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	D1, 8, 15, 22					1	128	1
MMRF_1638	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		3.3	QWK	QWK					29	135	1
MMRF_1638	First line of therapy	Melphalan		Completed regimen	MCG	IV	Log Forms	Other	TRANSPLANT INDUCTION		440	Other	SINGLE DOSE					184	184	1
MMRF_1638	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					319	683	1
MMRF_1638	Second Line Therapy (after first relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					683	767	1
MMRF_1638	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		40	QWK	QWK					683	767	1
MMRF_1655	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		2.5	Q week	Q week					1	162	1
MMRF_1655	First line of therapy	Cyclophosphamide		TITRATED	mg	PO	Log Forms	Induction	Induction		300	QWK	QWK					1	77	1
MMRF_1655	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	162	1
MMRF_1655	First line of therapy	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Induction	Induction		500	QWK	QWK					84	162	1
MMRF_1655	First line of therapy	Melphalan		Completed regimen	MCG	IV	Log Forms	Induction	Induction		350	Other	ONE DOSE					225	225	1
MMRF_1655	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					318	1851	1
MMRF_1655	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms			Checked	40	Q week	Q week					2002		1
MMRF_1655	Second Line Therapy (after first relapse)	Cyclophosphamide			mg	PO	Log Forms			Checked	300	Q week	Q week					2171		1
MMRF_1655	Second Line Therapy (after first relapse)	Daratumumab			mg/kg	IV	Log Forms			Checked	16	Other	ONCE EVERY 4 WEEKS					2030		1
MMRF_1655	Second Line Therapy (after first relapse)	Lenalidomide			mg	PO	Log Forms			Checked	25	QD (D1-21)	QD (D1-21)					1853		1
MMRF_1655	Second Line Therapy (after first relapse)	Daratumumab		Disease progression/Relapse	mg	IV	Log Forms				922	QWK	QWK					1858	2492	1
MMRF_1856	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					736	2007	1
MMRF_1856	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	ASCT CONDITIONING		400	Q day	Q day					187	187	1
MMRF_1856	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		3.1	Q week	Q week					1	138	1
MMRF_1856	First line of therapy	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Induction	Induction		500	Q week	Q week					1	138	1
MMRF_1856	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	138	1
MMRF_1856	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					253	335	1
MMRF_1856	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		20	Q week	Q week					253	335	1
MMRF_1856	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					340	735	1
MMRF_2170	First line of therapy	Bortezomib		DOSE ADJUSTED FOR WEIGHT LOSS	mg	IV SubQ	Log Forms	Induction	Induction		2.2	Q week	Q week					2	10	1
MMRF_2170	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		40	Other	D1, 8, 15					1	14	1
MMRF_2170	First line of therapy	Cyclophosphamide		DRUG SENSITIVITY	mg	PO	Log Forms	Induction	Induction		441	Other	D1,8,15, 22					1	65	1
MMRF_2170	First line of therapy	Bortezomib		Investigator decision for other reasons	mg	IV SubQ	Log Forms	Induction	Induction		1.9	Q week	Q week					15	71	1
MMRF_2170	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	Other	DAY 1, 8,15 & 22					15	429	1
MMRF_2170	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					72	107	1
MMRF_2170	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					86	429	1
MMRF_2170	Second Line Therapy (after first relapse)	Cyclophosphamide			mg	PO	Log Forms	Induction	Induction	Checked	400	Other	D1,D8,D15					1291		1
MMRF_2170	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	20	Other	D1,D2D8,D9,D15,D16,D22,D23					1291		1
MMRF_2170	Second Line Therapy (after first relapse)	Daratumumab			mg	IV	Log Forms	Induction	Induction	Checked	1008	Other	C1-2 (D1,8,15,22) C3-6 (D1,15) C6+ (D1)					1291		1
MMRF_2279	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					2068		1
MMRF_2279	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		2.8	Other	D1, 8, 15, 22					1	101	1
MMRF_2279	First line of therapy	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Induction	Induction		550	Other	D1, 8, 15, 22					1	116	1
MMRF_2279	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	D1, 8, 15, 22					1	116	1
MMRF_2279	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	ASCT CONDITIONING		330	Q day	Q day					148	148	1
MMRF_2279	First line of therapy	Bortezomib		Completed regimen	mg	IV	Log Forms	Other	ASCT CONDITIONING		2.1	Other	D1, D4					151	154	1
MMRF_2279	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					260	1913	1
MMRF_2288	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		2.9	Q week	Q week					1	333	1
MMRF_2288	First line of therapy	Cyclophosphamide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		500	Q week	Q week					1	22	1
MMRF_2288	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	333	1
MMRF_2288	First line of therapy	Cyclophosphamide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		300	Q week	Q week					32	332	1
MMRF_2288	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Maintenance	Maintenance		2.5	QD (D1-14)	QD (D1-14)					416	466	1
MMRF_1676	First line of therapy	Bortezomib		STEM CELL MOBILIZATON AND COLLECTION	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					1	112	1
MMRF_1676	First line of therapy	Cyclophosphamide		STEM CELL MOBILIZATON AND COLLECTION	mg	PO	Log Forms	Induction	Induction		550	Q week	Q week					1	112	1
MMRF_1676	First line of therapy	Dexamethasone		STEM CELL MOBILIZATON AND COLLECTION	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	112	1
MMRF_1676	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Other	STEM CELL MOBILIZATION		4700	Q day	Q day					123	123	1
MMRF_1676	First line of therapy	BUSULFAN		Completed regimen	mg/kg	IV	Log Forms	Other	ASCT CONDITIONING		3.2	Q day	Q day					176	178	1
MMRF_1676	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	ASCT CONDITIONING		140	Q day	Q day					179	179	1
MMRF_1676	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					140	175	1
MMRF_1676	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					140	175	1
MMRF_1676	First line of therapy	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Induction	Induction		550	Q week	Q week					140	175	1
MMRF_1676	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					271	326	1
MMRF_1676	First line of therapy	Lenalidomide		DOSE INCREASE	mg	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					327	354	1
MMRF_1676	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					355	1426	1
MMRF_1676	First line of therapy	Lenalidomide		Investigator decision for other reasons	ALTERNATE BETWEEN 5 AND 10MG DAILY	PO	Log Forms	Maintenance	Maintenance			Other	ALTERNATE BETWEEN 5 AND 10MG DAILY					1426	1650	1
MMRF_1676	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	Q day	Q day					1650		1
MMRF_1725	First line of therapy	Bortezomib		STEM CELL MOBILIZATION AND COLLECTION	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					1	112	1
MMRF_1725	First line of therapy	Cyclophosphamide		STEM CELL MOBILIZATION AND COLLECTION	mg	PO	Log Forms	Induction	Induction		575	Q week	Q week					1	112	1
MMRF_1725	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		40	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1	56	1
MMRF_1725	First line of therapy	Dexamethasone		STEM CELL MOBILIZATION AND COLLECTION	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					57	112	1
MMRF_1725	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Other	STEM CELL MOBILIZATION		4750	Q day	Q day					119	119	1
MMRF_1725	First line of therapy	BUSULFAN		Completed regimen	mg/kg	IV	Log Forms	Other	ASCT CONDITIONING		3.2	Q day	Q day					192	194	1
MMRF_1725	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	ASCT CONDITIONING		140	Q day	Q day					195	195	1
MMRF_1725	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					148	196	1
MMRF_1725	First line of therapy	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Induction	Induction		575	Q week	Q week					148	196	1
MMRF_1725	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					148	196	1
MMRF_1725	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					271	452	1
MMRF_1725	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					513	627	1
MMRF_1725	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					638	932	1
MMRF_1725	First line of therapy	Lenalidomide		ANTIBIOTICS PROPHYLAXIS DUE TO ROOT CANAL	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					452	504	1
MMRF_1725	First line of therapy	Lenalidomide		DOSE REDUCE	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					932	1107	1
MMRF_1725	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					1107	1380	1
MMRF_1725	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					1380	1828	1
MMRF_1725	First line of therapy	Lenalidomide		COLONOSCOPY	mg	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					1836	1871	1
MMRF_1725	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					1880		1
MMRF_1725	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day						2192	1
MMRF_1725	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					2220	2218	1
MMRF_1725	First line of therapy	Lenalidomide		DOSE REDUCTION	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					2249	2162	1
MMRF_1725	First line of therapy	Lenalidomide		SKIN GRAFT SURGERY	mg	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					2314	2520	1
MMRF_1771	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					1	48	1
MMRF_1771	First line of therapy	Cyclophosphamide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		550	Q week	Q week					1	48	1
MMRF_1771	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	48	1
MMRF_1771	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Other	STEM CELL MOBILIZATION		4550	Q day	Q day					118	118	1
MMRF_1771	First line of therapy	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Induction	Induction		550	Q week	Q week					189	201	1
MMRF_1771	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					189	201	1
MMRF_1771	First line of therapy	Bortezomib		STEM CELL MOBILIZATION AND COLLECTION	mg	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					56	111	1
MMRF_1771	First line of therapy	Cyclophosphamide		STEM CELL MOBILIZATION AND COLLECTION	mg	PO	Log Forms	Induction	Induction		550	Q week	Q week					56	111	1
MMRF_1771	First line of therapy	Dexamethasone		STEM CELL MOBILIZATION AND COLLECTION	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					56	111	1
MMRF_1771	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					133	160	1
MMRF_1771	First line of therapy	Cyclophosphamide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		550	Q week	Q week					133	160	1
MMRF_1771	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					133	160	1
MMRF_1771	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	STEM CELL TRANSPLANT CONDITIONING		200	Q day	Q day					203	203	1
MMRF_1771	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					310	346	1
MMRF_1771	First line of therapy	Lenalidomide		DOSE INCREASE	mg	PO	Log Forms	Maintenance	Maintenance		5	Other	MONDAY, WEDNESDAY AND FRIDAY (3 DAYS PER WEEK)					364	426	1
MMRF_1771	First line of therapy	Lenalidomide		ELEVATED LIVER FUNCTION TESTS. TREAT HELD DUE TO SUSPECTED VIRAL HEPATITIS	mg	PO	Log Forms	Maintenance	Maintenance		5	Other	MONDAY TO FRIDAY (5 DAYS PER WEEK)					427	455	1
MMRF_1771	Second Line Therapy (after first relapse)	CYTARABINE		LOST TO FOLLOW-UP	mg	INTRATHECAL	Log Forms	Other	TREATMENT OF CEREBROSPINAL FLUID INVOLVEMENT		40	Other	TWICE WEEKLY					491	507	1
MMRF_1771	Second Line Therapy (after first relapse)	METHOTREXATE		LOST TO FOLLOW-UP	mg	INTRATHECAL	Log Forms	Other	TREATMENT OF CEREBROSPINAL FLUID INVOLVEMENT		12	Other	TWICE WEEKLY					491	507	1
MMRF_1771	Second Line Therapy (after first relapse)	HYDROCORTISONE		LOST TO FOLLOW-UP	mg	INTRATHECAL	Log Forms	Other	TREATMENT OF CEREBROSPINAL FLUID INVOLVEMENT		15	Other	TWICE WEEKLY					491	507	1
MMRF_1777	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					1	97	1
MMRF_1777	First line of therapy	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Induction	Induction		525	Q week	Q week					1	405	1
MMRF_1777	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1	29	1
MMRF_1777	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					30	92	1
MMRF_1777	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					112	405	1
MMRF_1777	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					163	405	1
MMRF_1777	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		2.5	Other	ONCE EVERY 2 WEEKS					441	2241	1
MMRF_1777	First line of therapy	Bortezomib			mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance	Checked	2.4	Other	Q MONTH					2241		1
MMRF_1785	Second Line Therapy (after first relapse)	Ixazomib		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		3	Other	QD (D1, D8, AND D22 OF 28 DAY CYCLE)					1618	2684	1
MMRF_1785	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					1	11	1
MMRF_1785	First line of therapy	Cyclophosphamide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		550	Q week	Q week					1	11	1
MMRF_1785	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	11	1
MMRF_1785	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					49	217	1
MMRF_1785	First line of therapy	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Induction	Induction		550	Q week	Q week					49	217	1
MMRF_1785	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					49	217	1
MMRF_1785	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Other	STEM CELL MOBILIZATION		4550	Q day	Q day					223	223	1
MMRF_1785	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	STEM CELL TRANSPLANT CONDITIONING		200	Q day	Q day					258	258	1
MMRF_1785	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	STEM CELL TRANSPLANT CONDITIONING		200	Q day	Q day					417	417	1
MMRF_1785	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	Other	DAY 1 TO 21 OF A 28 DAY CYCLE					461	553	1
MMRF_1785	First line of therapy	Lenalidomide		RECURRING COUGH	mg	PO	Log Forms	Maintenance	Maintenance		10	Other	DAY 1 TO 21 OF A 28 DAY CYCLE					639	687	1
MMRF_1785	Second Line Therapy (after first relapse)	Carfilzomib		Completed regimen	UNKNOWN	IV	Log Forms	Other	RELAPSE			Other	UNKNOWN					796	1352	1
MMRF_1785	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		15	Other	QD (D1-21 OF 28)					796	1010	1
MMRF_1785	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					796	884	1
MMRF_1785	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					884	888	1
MMRF_1785	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		8	Q week	Q week					888	940	1
MMRF_1785	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					1010	1248	1
MMRF_1785	Second Line Therapy (after first relapse)	Lenalidomide		Completed regimen	mg	PO	Log Forms	Other	RELAPSE		5	QD (D1-21)	QD (D1-21)					1248	1366	1
MMRF_1785	Second Line Therapy (after first relapse)	Ixazomib		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		4	Other	WEEKLY (3 WEEK ON 1 WEEK OFF)					1366	1618	1
MMRF_1785	Third Line Therapy (following 2nd relapse)	Pomalidomide			mg	PO	Log Forms	Other	RELAPSE	Checked	4	QD (D1-21)	QD (D1-21)					2909		1
MMRF_1785	Third Line Therapy (following 2nd relapse)	Dexamethasone			mg	PO	Log Forms	Other	RELAPSE	Checked	20	Q week	Q week					2909		1
MMRF_1785	Third Line Therapy (following 2nd relapse)	ISATUXIMAB			mg/kg		Log Forms	Other	RELAPSE	Checked	10	Other	Q EVERY OTHER WEEK					2909		1
MMRF_1785	Third Line Therapy (following 2nd relapse)	ISATUXIMAB		Adverse Event or co-morbidity	mg/kg		Log Forms	Other	RELAPSE		10	Other	Q WEEK FOR 4 WEEKS. THEN Q EVERY OTHER WEEK					2817	2885	1
MMRF_1785	Third Line Therapy (following 2nd relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	RELAPSE		20	Q week	Q week					2775	2885	1
MMRF_1785	Third Line Therapy (following 2nd relapse)	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	RELAPSE		4	QD (D1-21)	QD (D1-21)					3140	2885	1
MMRF_1785	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse			Log Forms	Other	RELAPSE									2747	3140	1
MMRF_1785	Second Line Therapy (after first relapse)	Ixazomib		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		4	Other	QD (D1, D8, D22)					2684	2775	1
MMRF_1792	First line of therapy	Bortezomib		STEM CELL MOBILIZATION AND COLLECTION	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					1	113	1
MMRF_1792	First line of therapy	Cyclophosphamide		STEM CELL MOBILIZATION AND COLLECTION	mg	PO	Log Forms	Induction	Induction		550	Q week	Q week					1	113	1
MMRF_1792	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1	57	1
MMRF_1792	First line of therapy	Dexamethasone		STEM CELL MOBILIZATION AND COLLECTION	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					58	113	1
MMRF_1792	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1	Q week	Q week					163	197	1
MMRF_1792	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Other	STEM CELL MOBILIZATION		4600	Q day	Q day					118	118	1
MMRF_1792	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					149	162	1
MMRF_1792	First line of therapy	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Induction	Induction		550	Q week	Q week					149	197	1
MMRF_1792	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					149	197	1
MMRF_1792	First line of therapy	BUSULFAN		Completed regimen	mg/kg	IV	Log Forms	Other	STEM CELL TRANSPLANT CONDITIONING		3.2	Q day	Q day					203	205	1
MMRF_1792	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	STEM CELL TRANSPLANT CONDITIONING		140	Q day	Q day					206	206	1
MMRF_1792	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					301	482	1
MMRF_1792	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					484	1131	1
MMRF_1792	Second Line Therapy (after first relapse)	Bortezomib		Patient decision	mg	IV SubQ	Log Forms	Induction	Induction		2.91	Q week	Q week					1154	1181	1
MMRF_1792	Second Line Therapy (after first relapse)	Bortezomib		Disease progression/Relapse	mg	IV SubQ	Log Forms	Induction	Induction		2.91	Q week	Q week					1189	1229	1
MMRF_1792	Third Line Therapy (following 2nd relapse)	Bortezomib		Disease progression/Relapse	mg	IV SubQ	Log Forms	Induction	Induction		2.91	Q week	Q week					1252	1279	1
MMRF_1792	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1154	1228	1
MMRF_1792	Second Line Therapy (after first relapse)	Cyclophosphamide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		500	Q week	Q week					1154	1228	1
MMRF_1792	Second Line Therapy (after first relapse)	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		40	Other	4 DAYS ON 4 DAYS OFF					1143	1153	1
MMRF_1792	Third Line Therapy (following 2nd relapse)	Bortezomib		Disease progression/Relapse	mg	IV SubQ	Log Forms	Induction	Induction		2.91	Q week	Q week					1229	1244	1
MMRF_1792	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1229	1274	1
MMRF_1792	Third Line Therapy (following 2nd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		4	Other	QD (D1-21)					1229	1274	1
MMRF_1792	Fourth Line Therapy (following 3rd relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Other	RELAPSE		16	Other	QWEEK (WEEK 1 TO 8), Q2WEEK (WEEK 9 TO 24), Q4WEEK (WEEK 25+)					1276	1465	1
MMRF_1792	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	RELAPSE		40	QWK	QWK					1276	1437	1
MMRF_1792	Fourth Line Therapy (following 3rd relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Other	RELAPSE		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1309	1465	1
MMRF_1792	Fifth Line Therapy (following 4th relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Other	RELAPSE		4	QD (D1-21)	QD (D1-21)					1406	1465	1
MMRF_1792	Fourth Line Therapy (following 3rd relapse)	Carfilzomib		LOWER DOSE FOR FIRST AND 2ND INFUSION OF CARFILZOMIB	mg/m^2	IV	Log Forms	Other	RELAPSE		20	Other	DAY 1 AND 2 OF FIRST CYCLE					1302	1303	1
MMRF_1792	Sixth Line Therapy (following 5th relapse)	Cyclophosphamide		Disease progression/Relapse	mg	IV	Log Forms	Other	RELAPSE		708	QD (D1-4)	QD (D1-4)					1497	1500	1
MMRF_1792	Sixth Line Therapy (following 5th relapse)	Doxorubicin		Disease progression/Relapse	mg	IV	Log Forms	Other	RELAPSE		17.7	QD (D1-4)	QD (D1-4)					1497	1500	1
MMRF_1792	Sixth Line Therapy (following 5th relapse)	CISPLATIN		Disease progression/Relapse	mg	IV	Log Forms	Other	RELAPSE		17.7	QD (D1-4)	QD (D1-4)					1497	1500	1
MMRF_1792	Sixth Line Therapy (following 5th relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	RELAPSE		40	QD (D1-4)	QD (D1-4)					1497	1500	1
MMRF_1792	Sixth Line Therapy (following 5th relapse)	ETOPOSIDE		Disease progression/Relapse	mg	IV	Log Forms	Other	RELAPSE		70.8	QD (D1-4)	QD (D1-4)					1497	1500	1
MMRF_1792	Fifth Line Therapy (following 4th relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	RELAPSE		40	Other	DAY 1,2,3,4,8,15, AND 22					1437	1465	1
MMRF_1805	First line of therapy	Bortezomib		STEM CELL MOBILIZATION AND COLLECTION	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					1	168	1
MMRF_1805	First line of therapy	Cyclophosphamide		STEM CELL MOBILIZATION AND COLLECTION	mg	PO	Log Forms	Induction	Induction		525	Q week	Q week					1	175	1
MMRF_1805	First line of therapy	Bortezomib		STEM CELL MOBILIZATION AND COLLECTION	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.5	Other	QD (D1, D8, D15, D22) OF 35 DAY CYCLE					190	259	1
MMRF_1805	First line of therapy	Cyclophosphamide		DOSE INCREASE	mg	PO	Log Forms	Induction	Induction		500	Q week	Q week					190	224	1
MMRF_1805	First line of therapy	Cyclophosphamide		STEM CELL MOBILIZATION AND COLLECTION	mg	PO	Log Forms	Induction	Induction		550	Q week	Q week					225	259	1
MMRF_1805	First line of therapy	Cyclophosphamide		AUTOLOGOUS STEM CELL TRANSPLANT	mg	PO	Log Forms	Induction	Induction		500	Q week	Q week					281	313	1
MMRF_1805	First line of therapy	Dexamethasone		AUTOLOGOUS STEM CELL TRANSPLANT	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					281	313	1
MMRF_1805	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING FOR AUTOLOGOUS STEM CELL TRANSPLANT		200	Q day	Q day					314	314	1
MMRF_1805	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					415	467	1
MMRF_1805	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	Other	EVERY OTHER DAY					467	498	1
MMRF_1805	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		5	Other	EVERY OTHER DAY					532	589	1
MMRF_1805	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		5	Other	3 TIMES PER WEEK					701	889	1
MMRF_1805	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		5	Other	EVERY OTHER DAY					889	973	1
MMRF_1805	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					973	1631	1
MMRF_1805	Third Line Therapy (following 2nd relapse)	IXAZOMIB		Disease progression/Relapse			Log Forms	Other	RELAPSE									2221	2417	1
MMRF_1805	Third Line Therapy (following 2nd relapse)	Pomalidomide		Disease progression/Relapse		PO	Log Forms	Other	RELAPSE									2221	2417	1
MMRF_1805	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse			Log Forms	Other	RELAPSE									2221	2417	1
MMRF_1805	Fourth Line Therapy (following 3rd relapse)	Pomalidomide		Disease progression/Relapse		PO	Log Forms	Other	RELAPSE									2417	2598	1
MMRF_1805	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Disease progression/Relapse			Log Forms	Other	RELAPSE									2417	2598	1
MMRF_1805	Fourth Line Therapy (following 3rd relapse)	ISATUXIMAB		Disease progression/Relapse			Log Forms	Other	RELAPSE									2417	2598	1
MMRF_1805	Fifth Line Therapy (following 4th relapse)	CC-92480 (CC-92480-MM-001 STUDY)		Adverse Event or co-morbidity			Log Forms	Other	RELAPSE									2614	2717	1
MMRF_1805	Fifth Line Therapy (following 4th relapse)	Dexamethasone		Adverse Event or co-morbidity			Log Forms	Other	RELAPSE									2614	2717	1
MMRF_1805	Second Line Therapy (after first relapse)	Ixazomib		Adverse Event or co-morbidity	mg	PO	Log Forms				4	Other	QD (D1, D8, D15 OF 28D CYCLE)					2060	2086	1
MMRF_1805	Second Line Therapy (after first relapse)	Cyclophosphamide		Adverse Event or co-morbidity	mg	PO	Log Forms				550	Q week	Q week					2060	2086	1
MMRF_1805	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms				40	Q week	Q week					2060	2086	1
MMRF_1805	Second Line Therapy (after first relapse)	Ixazomib			mg	PO	Log Forms			Checked	4	Other	QD (D1, D8, D15 OF 28D CYCLE)					2130		1
MMRF_1805	Second Line Therapy (after first relapse)	Cyclophosphamide		Disease progression/Relapse	mg	PO	Log Forms				550	Q week	Q week					2130	2221	1
MMRF_1805	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms				40	Q week	Q week					2130	2221	1
MMRF_1805	Second Line Therapy (after first relapse)	Ixazomib		Adverse Event or co-morbidity	mg	PO	Log Forms				4	Other	QD (D1, D8, D15 OF 28)					1694	1716	1
MMRF_1805	Second Line Therapy (after first relapse)	Cyclophosphamide		Adverse Event or co-morbidity	mg	PO	Log Forms				550	Q week	Q week					1694	1716	1
MMRF_1805	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms				40	Q week	Q week					1694	1716	1
MMRF_1805	Second Line Therapy (after first relapse)	Ixazomib		Adverse Event or co-morbidity	mg	PO	Log Forms				4	Other	QD (D1, D8, AND D15 OF 28)					1716	1850	1
MMRF_1805	Second Line Therapy (after first relapse)	Cyclophosphamide		Adverse Event or co-morbidity	mg	PO	Log Forms				550	Q week	Q week					1716	1850	1
MMRF_1805	Second Line Therapy (after first relapse)	Ixazomib		Adverse Event or co-morbidity	mg	PO	Log Forms				4	Other	QD (D1, D8, AND D15 OF 28)					1941	2053	1
MMRF_1805	Second Line Therapy (after first relapse)	Cyclophosphamide		Adverse Event or co-morbidity	mg	PO	Log Forms				550	Q week	Q week					1948	2419	1
MMRF_1805	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms				40	Q week	Q week					1948	2419	1
MMRF_1805	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms				40	Q week	Q week					1716	1850	1
MMRF_1846	Second Line Therapy (after first relapse)	Ixazomib		Lack of response	mg	PO	Log Forms	Other	RELAPSE		4	Other	QD (D1, D8, AND D15)					2268	2310	1
MMRF_1846	Second Line Therapy (after first relapse)	Cyclophosphamide		Lack of response	mg	PO	Log Forms	Other	RELAPSE		600	Q week	Q week					2268	2317	1
MMRF_1846	Second Line Therapy (after first relapse)	Dexamethasone		Lack of response	mg	PO	Log Forms	Other	RELAPSE		40	Q week	Q week					2268	2317	1
MMRF_1846	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Other	RELAPSE		40	Q day	Q day					2333	2335	1
MMRF_1846	Second Line Therapy (after first relapse)	Ixazomib		Completed regimen	mg	PO	Log Forms	Other	RELAPSE		4	Other	QD (D1, D8, D15)					2335	2437	1
MMRF_1846	Second Line Therapy (after first relapse)	Lenalidomide			mg	PO	Log Forms	Other	RELAPSE		15	QD (D1-21)	QD (D1-21)					2335	2346	1
MMRF_1846	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Other	RELAPSE		40	Q week	Q week					2333	2437	1
MMRF_1846	Second Line Therapy (after first relapse)	Lenalidomide		Completed regimen	mg	PO	Log Forms	Other	RELAPSE		25	QD (D1-21)	QD (D1-21)					2346	2437	1
MMRF_1846	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					2044	2247	1
MMRF_1846	First line of therapy	Bortezomib		STEM CELL MOBILIZATION AND COLLECTION	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					1	116	1
MMRF_1846	First line of therapy	Cyclophosphamide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		600	Q week	Q week					1	28	1
MMRF_1846	First line of therapy	Dexamethasone		STEM CELL MOBILIZATION AND COLLECTION	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	116	1
MMRF_1846	First line of therapy	Cyclophosphamide		STEM CELL MOBILIZATION AND COLLECTION	mg	PO	Log Forms	Induction	Induction		500	Q week	Q week					28	116	1
MMRF_1846	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Other	STEM CELL MOBILIZATION		4950	Q day	Q day					119	119	1
MMRF_1846	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					145	186	1
MMRF_1846	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					145	186	1
MMRF_1846	First line of therapy	Cyclophosphamide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		500	Q week	Q week					145	168	1
MMRF_1846	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	ASCT CONDITIONING		200	Q day	Q day					190	190	1
MMRF_1846	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					317	561	1
MMRF_1846	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					575	833	1
MMRF_1846	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		10	Other	EVERY OTHER DAY					834	885	1
MMRF_1846	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					885	1093	1
MMRF_1846	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					1097	2010	1
MMRF_1846	Fourth Line Therapy (following 3rd relapse)	ISATUXIMAB		Adverse Event or co-morbidity			Log Forms	Other	RELEAPSE		0							2879	2879	1
MMRF_1846	Fourth Line Therapy (following 3rd relapse)	Pomalidomide		Adverse Event or co-morbidity		PO	Log Forms	Other	RELAPSE									2864	2864	1
MMRF_1846	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Adverse Event or co-morbidity		PO	Log Forms	Other	RELAPSE									2864	2864	1
MMRF_1845	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					1	56	1
MMRF_1845	First line of therapy	Cyclophosphamide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		475	Q week	Q week					1	56	1
MMRF_1845	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1	56	1
MMRF_1845	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					171	198	1
MMRF_1845	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					145	198	1
MMRF_1845	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					145	170	1
MMRF_1845	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	STEM CELL TRANSPLANT CONDITIONING		200	Q day	Q day					200	200	1
MMRF_1845	Second Line Therapy (after first relapse)	Carfilzomib		Completed regimen	mg	IV	Log Forms	Induction	Induction		40	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1147	1278	1
MMRF_1845	Second Line Therapy (after first relapse)	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	Other	QD 1-21 OF 28 DAY CYCLE					1147	1278	1
MMRF_1845	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1147	1166	1
MMRF_1845	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					1167	1278	1
MMRF_1845	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	STEM CELL TRANSPLANT CONDITIONING		200	Q day	Q day					1297	1297	1
MMRF_1845	Second Line Therapy (after first relapse)	Carfilzomib		Adverse Event or co-morbidity	mg	IV	Log Forms	Consolidation	Consolidation			QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1399	1490	1
MMRF_1845	Second Line Therapy (after first relapse)	Lenalidomide			mg	PO	Log Forms	Consolidation	Consolidation	Checked	25	Other	DAYS 1 TO 21 OF 28 DAY CYCLE					1399		1
MMRF_1845	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Consolidation	Consolidation	Checked	20	Q week	Q week					1399		1
MMRF_1845	Second Line Therapy (after first relapse)	Carfilzomib		Adverse Event or co-morbidity	mg	IV	Log Forms	Maintenance	Maintenance		40	Other	QD (D1-2, D15-16)					1513	1541	1
MMRF_1845	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					2015	2134	1
MMRF_1845	Second Line Therapy (after first relapse)	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	Q day	Q day					2142		1
MMRF_1845	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		25	Other	QD (D1-21 OF 28)					1513	1542	1
MMRF_1845	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		20	Q week	Q week					1513	1554	1
MMRF_1845	Second Line Therapy (after first relapse)	Carfilzomib		Adverse Event or co-morbidity	mg	IV	Log Forms	Maintenance	Maintenance			Other	QD (D1-2, D15-16)					1541	1554	1
MMRF_1845	Second Line Therapy (after first relapse)	Carfilzomib		Adverse Event or co-morbidity	mg	IV	Log Forms	Maintenance	Maintenance			Other	QD (D1-2, D15-16)					1613	1744	1
MMRF_1845	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		20	Other	QD (D1-21 OF 28)					1613	1653	1
MMRF_1845	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		20	Q week	Q week					1613	1884	1
MMRF_1845	Second Line Therapy (after first relapse)	Carfilzomib		Completed regimen	mg	IV	Log Forms	Maintenance	Maintenance		43	Other	QD (D1-2, 15-16)					1762	1884	1
MMRF_1845	Second Line Therapy (after first relapse)	Lenalidomide		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		20	Other	QD (D1-21 OF 28)					1653	1884	1
MMRF_1845	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		15	Q day	Q day					1884	1945	1
MMRF_1845	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		15	Q day	Q day					1959	2381	1
MMRF_1928	Second Line Therapy (after first relapse)	Daratumumab		Adverse Event or co-morbidity	mg/kg	IV	Log Forms				16	Other	Q MONTH					1330	1944	1
MMRF_1928	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms				10	Q week	Q week					1386	1944	1
MMRF_1928	Second Line Therapy (after first relapse)	Daratumumab		Investigator decision for other reasons	mg/kg	IV	Log Forms				16	Other	Q MONTH					1974	2113	1
MMRF_1928	Second Line Therapy (after first relapse)	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms				4	QD (D1-21)	QD (D1-21)					1974	2289	1
MMRF_1928	Second Line Therapy (after first relapse)	Daratumumab			mg/kg	IV	Log Forms	Other	RELAPSE	Checked	16	Other	Q MONTH					2177		1
MMRF_1928	Second Line Therapy (after first relapse)	Pomalidomide			mg	PO	Log Forms	Other	RELAPSE	Checked	3	QD (D1-21)	QD (D1-21)					2289		1
MMRF_1928	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					1	119	1
MMRF_1928	First line of therapy	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Induction	Induction		500	Q week	Q week					1	119	1
MMRF_1928	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	119	1
MMRF_1928	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Other	STEM CELL MOBILIZATION		5150	Q day	Q day					123	123	1
MMRF_1928	First line of therapy	Cyclophosphamide		ADMITTED FOR ASCT	mg	PO	Log Forms	Induction	Induction		600	Q week	Q week					138	169	1
MMRF_1928	First line of therapy	Dexamethasone		ADMITTED FOR ASCT	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					138	169	1
MMRF_1928	First line of therapy	Bortezomib		ADMITTED FOR ASCT	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					148	169	1
MMRF_1928	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		200	Q day	Q day					170	170	1
MMRF_1928	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					276	1140	1
MMRF_1928	Second Line Therapy (after first relapse)	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms				4	QD (D1-21)	QD (D1-21)					1162	1944	1
MMRF_1928	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms				40	Q week	Q week					1162	1300	1
MMRF_1928	Second Line Therapy (after first relapse)	Daratumumab		Completed regimen	mg/kg	IV	Log Forms				16	Q week	Q week					1162	1330	1
MMRF_1928	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	RELAPSE		20	Q week	Q week					1301	1386	1
MMRF_1960	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Other	QD (D1, D8, D15, D22) OF 35 DAY CYCLE					1	315	1
MMRF_1960	First line of therapy	Melphalan		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		14	QD (D1-4)	QD (D1-4)					1	35	1
MMRF_1960	First line of therapy	Prednisone		Completed regimen	mg	PO	Log Forms	Induction	Induction		95	QD (D1-4)	QD (D1-4)					1	315	1
MMRF_1960	First line of therapy	Melphalan		Completed regimen	mg	PO	Log Forms	Induction	Induction		10	QD (D1-4)	QD (D1-4)					36	315	1
MMRF_1960	First line of therapy	Lenalidomide		PALLIATIVE	mg	PO	Log Forms	Other	SUSPECTED AMYLOID INVOLVEMENT		5	Other	EVERY OTHER DAY					525	565	1
MMRF_1960	First line of therapy	Dexamethasone		PALLIATIVE	mg	PO	Log Forms	Other	SUSPECTED AMYLOID INVOLVEMENT		20	Q week	Q week					525	565	1
MMRF_2174	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Q day	Q day					1	4	1
MMRF_2174	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Other	1, 8, 15, 22 OF A 35 DAY CYCLE					6	250	1
MMRF_2174	First line of therapy	Melphalan		CONCERNS ON NONCOMPLIANCE AND LACK OF RESPONSE	mg	PO	Log Forms	Induction	Induction		4	QD (D1-4)	QD (D1-4)					6	145	1
MMRF_2174	First line of therapy	Prednisone		CONCERNS ON NONCOMPLIANCE AND LACK OF RESPONSE	mg	PO	Log Forms	Induction	Induction		120	QD (D1-4)	QD (D1-4)					6	145	1
MMRF_2174	Second Line Therapy (after first relapse)	Cyclophosphamide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		400	Other	1, 8, 15, 22 OF 35 DAY CYCLE					146	250	1
MMRF_2174	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	Other	1, 8, 15, 22 OF A 35 DAY CYCLE					146	201	1
MMRF_2174	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		10	Other	1, 8, 15, 22 OF A 35 DAY CYCLE					202	250	1
MMRF_2251	First line of therapy	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					8	99	1
MMRF_2251	First line of therapy	Cyclophosphamide		DOSE INCREASE	mg	PO	Log Forms	Induction	Induction		400	Q week	Q week					8	21	1
MMRF_2251	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		40	Other	QD (D1-4, D9-12, D17-20)					8	99	1
MMRF_2251	First line of therapy	Cyclophosphamide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		500	Q week	Q week					22	99	1
MMRF_2251	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Induction	Induction		40	Q day	Q day					1	4	1
MMRF_2428	First line of therapy	Bortezomib		START CLINICAL TRIAL	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					15	28	1
MMRF_2428	First line of therapy	Cyclophosphamide		START CLINICAL TRIAL	mg/m^2	PO	Log Forms	Induction	Induction		300	Q week	Q week					1	28	1
MMRF_2428	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	147	1
MMRF_2428	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		36	Other	QD (D1-2, D8-9, D15-16). FIRST CYCLE ONLY 20MG/M^2 FOR D1-2.					29	147	1
MMRF_2428	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	Other	DAYS 1 TO 21 OF A 28 DAY CYCLE					29	147	1
MMRF_2428	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	ASCT CONDITIONING		200	Q day	Q day					261	261	1
MMRF_2428	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		36	Other	DAY 1,2,8,9,15 AND 16 OF A 28 DAY CYCLE					197	224	1
MMRF_2428	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	Other	DAYS 1 TO 21 OF A 28 DAY CYCLE					197	224	1
MMRF_2428	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					197	224	1
MMRF_2428	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	4 DAYS ON THEN 4 DAYS OFF					176	191	1
MMRF_2428	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					1	8	1
MMRF_2428	First line of therapy	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Consolidation	Consolidation		36	Other	QD (D1-2, D8-9, D15-16) OF A 28 DAY CYCLE					351	357	1
MMRF_2428	First line of therapy	Lenalidomide		DOSE INCREASE	mg	PO	Log Forms	Consolidation	Consolidation		15	QD (D1-21)	QD (D1-21)					351	378	1
MMRF_2428	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Consolidation	Consolidation		20	Q week	Q week					351	385	1
MMRF_2428	First line of therapy	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Consolidation	Consolidation		36	Other	QD (D1-2, D8-9, D15-16) OF A 28 DAY CYCLE					365	385	1
MMRF_2428	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					407	434	1
MMRF_2428	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Maintenance	Maintenance		36	Other	QD (D1-2, D15-16)					435	715	1
MMRF_2428	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		20	Q week	Q week					407	434	1
MMRF_2428	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		20	Q week	Q week					435	715	1
MMRF_2428	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					407	434	1
MMRF_2428	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		25	QD (D1-21)	QD (D1-21)					435	715	1
MMRF_2428	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					379	385	1
MMRF_2428	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					715	1135	1
MMRF_2428	First line of therapy	Lenalidomide		DOSE INCREASE	mg	PO	Log Forms	Maintenance	Maintenance		10	Other	EVERY OTHER DAY, 21 DAYS OF 28					1268		1
MMRF_2428	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					2072	2303	1
MMRF_2428	Second Line Therapy (after first relapse)	Pomalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					2312	2423	1
MMRF_2428	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					2312	2423	1
MMRF_2428	Second Line Therapy (after first relapse)	ISATUXIMAB		EXPECTED DOSE SCHEDULE CHANGE	mg	IV	Log Forms	Induction	Induction		900	Q week	Q week					2312	2347	1
MMRF_2428	Second Line Therapy (after first relapse)	ISATUXIMAB		Completed regimen	mg	IV	Log Forms	Induction	Induction		950	Other	Q 2 WEEKS					2347	2417	1
MMRF_2428	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					1887	2072	1
MMRF_2428	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	Other	QD (D1-21 OF 28)						1730	1
MMRF_2428	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	ASCT CONDITIONING		200	Q day	Q day					2432	2432	1
MMRF_1555	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Other	Q D1 & D8 Q21DAYS					1	79	1
MMRF_1555	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		15	QD (D1-14)	QD (D1-14)					1	47	1
MMRF_1555	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		20	Other	D1 AND D8					1	79	1
MMRF_1555	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		10	QD (D1-14)	QD (D1-14)					47	79	1
MMRF_1555	Second Line Therapy (after first relapse)	Carfilzomib		Disease progression/Relapse	mg	IV SubQ	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					130	230	1
MMRF_1555	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					130	230	1
MMRF_1555	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					130	230	1
MMRF_1555	Third Line Therapy (following 2nd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		2	Other	QD D1-21					248	340	1
MMRF_1555	Third Line Therapy (following 2nd relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Induction	Induction		20	Other	TWICE WEEKLY					248	340	1
MMRF_1555	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		4	Other	TWICE WEEKLY BEFORE CARFILZOMIB					248	340	1
MMRF_1564	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		4	Other	THREE TIMES A WEEK					137	193	1
MMRF_1564	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		4	Other	0900 EVERY OTHER DAY, DAYS 1-21 OF 28 DAY CYCLE					193	216	1
MMRF_1564	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		2	Q week	Q week					216	528	1
MMRF_1564	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		1	Other	TAKE 1 MG FOR 2 DAYS THEN 1 DAY OFF, REPEAT CYCLE					528	603	1
MMRF_1564	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		0.5	Q day	Q day					603	884	1
MMRF_1564	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		5	QD (D1-21)	QD (D1-21)					193	1215	1
MMRF_1564	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		1	Other	QD EVERY SATURDAY AND SUNDAY					884	1215	1
MMRF_1564	Second Line Therapy (after first relapse)	Lenalidomide		Lack of response	mg	PO	Log Forms	Unknown	Unknown		5	QD (D1-21)	QD (D1-21)					1215	1290	1
MMRF_1564	Second Line Therapy (after first relapse)	Bortezomib		Lack of response	mg	IV	Log Forms	Unknown	Unknown		2.75	Q week	Q week					1215	1290	1
MMRF_1564	Second Line Therapy (after first relapse)	Dexamethasone		Lack of response	mg	PO	Log Forms	Unknown	Unknown		8	Other	8MG PRIOR TO BORTEZOMIB  INFUSION AND 1MG Q DAY FOR ADRENAL SUPPORT					1215	1290	1
MMRF_1564	Second Line Therapy (after first relapse)	Daratumumab		Adverse Event or co-morbidity	mg	IV	Log Forms	Induction	Induction		1640	Other	WEEKLY INFUSIONS FOR 8 WEEKS, THEN EVERY TWO WEEKS FOR 16 WEEKS, FOLLOWED B					1304	1355	1
MMRF_1564	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	IV ON DARA DOSING DAYS PO X2 DAYS FOLLOWING	Log Forms	Induction	Induction		8	Other	PRIOR TO DARA INFUSION AND 4MG X2 DAYS FOLLOWING EACH DARATUMUMAB INFUSION					1304	1355	1
MMRF_1564	Second Line Therapy (after first relapse)	Daratumumab		Completed regimen	mg	IV	Log Forms	Unknown	Unknown		1640	Other	EVERY 2 WEEKS					1397	1493	1
MMRF_1564	Second Line Therapy (after first relapse)	Pomalidomide		Completed regimen	mg	PO	Log Forms	Unknown	Unknown		2	Other	EVERY OTHER DAY					1397	1493	1
MMRF_1564	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					1	193	1
MMRF_1564	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					1	72	1
MMRF_1564	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		12	Q week	Q week					72	137	1
MMRF_1569	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					1	1202	1
MMRF_1569	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					1	429	1
MMRF_1569	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		8	Q week	Q week					616	1104	1
MMRF_1569	Second Line Therapy (after first relapse)	Ixazomib		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		4	Other	DAYS 1,8,15					1222	1361	1
MMRF_1569	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		20	Other	DAYS 1,8,15					1222	1361	1
MMRF_1569	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					1222	1361	1
MMRF_1569	Third Line Therapy (following 2nd relapse)	DURVALUMAB		Adverse Event or co-morbidity	mg	IV	Log Forms	Unknown	Unknown		1500	Other	ONCE EVERY 4 WEEKS					1407	1557	1
MMRF_1569	Third Line Therapy (following 2nd relapse)	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		4	Other	DAYS 1-21 OF CYCLE					1407	1557	1
MMRF_1569	Third Line Therapy (following 2nd relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		4	Other	DAYS 1, 8, 15, 22 OF CYCLE					1407	1557	1
MMRF_1569	Fourth Line Therapy (following 3rd relapse)	Daratumumab			mg/kg	IV	Log Forms	Unknown	Unknown	Checked	16	Q week	Q week					1556		1
MMRF_1569	Fourth Line Therapy (following 3rd relapse)	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Unknown	Unknown		1.5	Q week	Q week					1556	1674	1
MMRF_1569	Fourth Line Therapy (following 3rd relapse)	Dexamethasone			mg	IV	Log Forms	Unknown	Unknown	Checked	20	Q week	Q week					1556		1
MMRF_1574	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	32	1
MMRF_1574	First line of therapy	Dexamethasone		TRANSPLANT	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	221	1
MMRF_1574	First line of therapy	Lenalidomide		TRANSPLANT	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					32	221	1
MMRF_1574	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Induction	Induction		455	Other	ONCE					246	246	1
MMRF_1574							Log Forms													1
MMRF_1574	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		10	Other	EVERY OTHER DAY					569	1577	1
MMRF_1593	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Induction	Induction		1.3	Other	TWICE A WEEK					1	73	1
MMRF_1593	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	Other	TWICE A WEEK, PRIOR TO VELCADE DOSE					1	73	1
MMRF_1593	Second Line Therapy (after first relapse)	Carfilzomib		DOSE CHANGE	mg/m^2	IVB	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					105	133	1
MMRF_1593	Second Line Therapy (after first relapse)	Lenalidomide		TRANSPLANT	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					105	189	1
MMRF_1593	Second Line Therapy (after first relapse)	Carfilzomib		TRANSPLANT	mg/m^2	IVB	Log Forms	Induction	Induction		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					133	189	1
MMRF_1593	Second Line Therapy (after first relapse)	Dexamethasone		TRANSPLANT	mg	IVB	Log Forms	Induction	Induction		8	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					133	217	1
MMRF_1593	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Q day	Q day					216	216	1
MMRF_1593	First line of therapy	Lenalidomide		DOSE CHANGE	mg	PO	Log Forms	Maintenance	Maintenance		10	Other	2 WEEKS ON, 1 WEEK OFF					343	492	1
MMRF_1593	First line of therapy	Lenalidomide		DOSE CHANGE SECONDARY TO DIARRHEA AT DAILY DOSING LEVEL S/P 28 DAYS	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					312	343	1
MMRF_1593	First line of therapy	Lenalidomide		DOSE CHANGE	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					492	606	1
MMRF_1593	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					606		1
MMRF_1618	First line of therapy	Bortezomib		TRANSPLANT	mg	IV SubQ	Log Forms	Induction	Induction		2.44	Other	TWICE A WEEK, MONDAYS AND THURSDAYS					1	86	1
MMRF_1618	First line of therapy	Lenalidomide		TRANSPLANT	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	86	1
MMRF_1618	First line of therapy	Dexamethasone		TRANSPLANT	mg	PO	Log Forms	Induction	Induction		4	Other	TWICE WEEKLY, MONDAYS AND THURSDAYS					1	86	1
MMRF_1618	First line of therapy	Lenalidomide		DECREASE OF DOSE DUE TO NEUTROPENIA (NOT DEEMED GRADE 3)	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					338	1479	1
MMRF_1618	Second Line Therapy (after first relapse)	Pomalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					1479	1630	1
MMRF_1618	Second Line Therapy (after first relapse)	Daratumumab		Completed regimen	mg/kg	IV	Log Forms	Induction	Induction		16	Other	EVERY 2 WEEKS					1479	1630	1
MMRF_1618	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	IV	Log Forms	Induction	Induction		40	Q week	Q week					1479	1630	1
MMRF_1618	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg	IV	Log Forms	Other	TRANSPLANT		325	Other	ONCE					1679	1679	1
MMRF_1618	Second Line Therapy (after first relapse)	Daratumumab		Disease progression/Relapse		IV	Log Forms	Maintenance	Maintenance									1753	2198	1
MMRF_1618	Second Line Therapy (after first relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		4	QD (D1-21)	QD (D1-21)					1753	2198	1
MMRF_1618	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse		PO	Log Forms	Maintenance	Maintenance									1753	2564	1
MMRF_1618	Third Line Therapy (following 2nd relapse)	CB-839HCL		INSURANCE	mg	PO	Log Forms	Maintenance	Maintenance		600	BID	BID					2226	2252	1
MMRF_1618	Third Line Therapy (following 2nd relapse)	Carfilzomib		INSURANCE	mg/m^2	IV	Log Forms	Maintenance	Maintenance		56	Other	DAYS 1, 8, AND 15					2226	2252	1
MMRF_1618	Third Line Therapy (following 2nd relapse)	Dexamethasone		INSURANCE	mg	PO	Log Forms	Maintenance	Maintenance		40	Other	DAYS 1, 8, 15, AND 22					2226	2252	1
MMRF_1618	Fourth Line Therapy (following 3rd relapse)	Carfilzomib			mg/m^2	IV	Log Forms	Maintenance	Maintenance	Checked	70	Other	DAYS 1, 8, AND 15					2252		1
MMRF_1618	Fourth Line Therapy (following 3rd relapse)	Cyclophosphamide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	50	Other	DAYS 1,8, AND 15					2252		1
MMRF_1618	Fourth Line Therapy (following 3rd relapse)	Dexamethasone			mg	IV	Log Forms	Maintenance	Maintenance	Checked	20	Other	DAYS 1, 8, AND 15					2252		1
MMRF_1618	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	TRANSPLANT		200	Other	ONCE					117	117	1
MMRF_1717	First line of therapy	Lenalidomide		TRANSPLANT	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					1	104	1
MMRF_1717	First line of therapy	Dexamethasone		TRANSPLANT	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					1	104	1
MMRF_1717	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Other	ONCE					160	162	1
MMRF_1717	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		5	Other	REVLIMID RESTARTED 25-MAR-2015 TIW X 1 WEEK, THEN QOD X 1 WEEK, THEN DAILY.					334	391	1
MMRF_1717	First line of therapy	Lenalidomide		DOSE MODIFICATION	mg	PO	Log Forms	Induction	Induction		5	Other	TIW X 1 WEEK, THEN QOD X 1 WEEK, THEN DAILY					419	454	1
MMRF_1717	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		5	Q day	Q day					454	1464	1
MMRF_1717	Second Line Therapy (after first relapse)	Pomalidomide		DEATH	mg	PO	Log Forms	Induction	Induction		2	QD (D1-21)	QD (D1-21)					1499	2086	1
MMRF_1717	Second Line Therapy (after first relapse)	Dexamethasone		DEATH	mg	PO OR IV DEPENDING ON CHEMO DAYS	Log Forms	Induction	Induction		20	Other	DAYS 1, 8, AND 15 OF 28 DAY CYCLES					1499	2086	1
MMRF_1717	Second Line Therapy (after first relapse)	Carfilzomib		DEATH	mg/m^2	IV	Log Forms	Induction	Induction		20	Q week	Q week					1499	2086	1
MMRF_1726	First line of therapy	Dexamethasone		Lack of response	mg	PO	Log Forms	Induction	Induction		20	QWK	QWK					1	119	1
MMRF_1726	First line of therapy	Lenalidomide		Lack of response	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					99	176	1
MMRF_1726	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					176	564	1
MMRF_1726	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					135	564	1
MMRF_1726	Third Line Therapy (following 2nd relapse)	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1	Other	DAYS 1, 8, 15					566	635	1
MMRF_1726	Third Line Therapy (following 2nd relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					564	635	1
MMRF_1726	Third Line Therapy (following 2nd relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					564	635	1
MMRF_1726	Third Line Therapy (following 2nd relapse)	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1	Other	DAYS 1,8,15					664	678	1
MMRF_1726	Third Line Therapy (following 2nd relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					664	678	1
MMRF_1726	Third Line Therapy (following 2nd relapse)	Lenalidomide		Adverse Event or co-morbidity	mg/dL	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					664	693	1
MMRF_1726	First line of therapy	Bortezomib		Completed regimen	mg	SUBQ	Log Forms	Induction	Induction		2.75	Q week	Q week					1	99	1
MMRF_1763	Third Line Therapy (following 2nd relapse)	Cyclophosphamide					Log Forms	Unknown	Unknown	Checked								2352		1
MMRF_1763	Third Line Therapy (following 2nd relapse)	Daratumumab					Log Forms	Unknown	Unknown	Checked								2352		1
MMRF_1763	Third Line Therapy (following 2nd relapse)	Dexamethasone					Log Forms	Unknown	Unknown	Checked								2352		1
MMRF_1763	First line of therapy	Dexamethasone		TRANSPLANT	mg	PO	Log Forms	Unknown	Unknown		40	Q week	Q week					1	133	1
MMRF_1763	First line of therapy	Lenalidomide		HIGH COPAY	mg	PO	Log Forms	Unknown	Unknown		25	Q day	Q day					2	38	1
MMRF_1763	First line of therapy	Lenalidomide		DOSE CHANGE	mg	PO	Log Forms	Unknown	Unknown		21	Q day	Q day					1	2	1
MMRF_1763	First line of therapy	Bortezomib		TRANSPLANT	mg/m^2	IV	Log Forms	Unknown	Unknown		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					54	106	1
MMRF_1763	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Other	ONCE					131	131	1
MMRF_1763	First line of therapy	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	Q 2WKS					194	764	1
MMRF_1763	Second Line Therapy (after first relapse)	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Unknown	Unknown		1.32	Other	DAYS 1, 8, 15					769	937	1
MMRF_1763	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		20	Q week	Q week					769	937	1
MMRF_1763	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		25	QD (D1-21)	QD (D1-21)					769	937	1
MMRF_1763	Second Line Therapy (after first relapse)	Lenalidomide		ALLOGENIC SCT 1/17/2017	mg	PO	Log Forms	Unknown	Unknown		25	Other	DAYS 1-21					939	1072	1
MMRF_1763	Second Line Therapy (after first relapse)	Dexamethasone		ALLOGENIC SCT 1/17/2017	mg	PO	Log Forms	Unknown	Unknown		12	Other	WEEKLY					939	1072	1
MMRF_1763	Second Line Therapy (after first relapse)	Ixazomib		DOSE INCREASE DUE TO A STUDY PROTOCOL	mg	PO	Log Forms	Maintenance	Maintenance		3	Other	DAYS 1, 8, 15					1192	1275	1
MMRF_1763	Third Line Therapy (following 2nd relapse)	Ixazomib		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		7	Other	DAYS 1, 8, 15					1276	1400	1
MMRF_1763	Third Line Therapy (following 2nd relapse)	Ixazomib		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		2.3	Other	DAYS 1, 8, 15					1405	1606	1
MMRF_1763	Third Line Therapy (following 2nd relapse)	Prednisone			mg	PO	Log Forms	Maintenance	Maintenance	Checked	20	Q day	Q day					1496		1
MMRF_1847	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	Other	DAY 1,4,8&11					1	44	1
MMRF_1847	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Other	DAYS 1,4,8 &11					1	44	1
MMRF_1847	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	IN ADDITTION		15	QD (D1-21)	QD (D1-21)					20	44	1
MMRF_1847	First line of therapy	Bortezomib		TRANSPLANT	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Other	DAY 1,8					44	128	1
MMRF_1847	First line of therapy	Dexamethasone		TRANSPLANT	mg	PO	Log Forms	Induction	Induction		20	Other	DAY 1,8					44	128	1
MMRF_1847	First line of therapy	Lenalidomide		TRANSPLANT	mg	PO	Log Forms	Induction	Induction		10	QD (D1-14)	QD (D1-14)					44	128	1
MMRF_1847	First line of therapy	Lenalidomide		FOR PT. CONVENIENCE	mg	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					380	672	1
MMRF_1847	First line of therapy	Bortezomib		FOR PT. CONVENIENCE	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Other	QD D1 AND D15					380	672	1
MMRF_1847	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		12	Other	QD D1 AND D15					380	455	1
MMRF_1847	First line of therapy	Dexamethasone		FOR PT. CONVENIENCE	mg	PO	Log Forms	Induction	Induction		8	Other	TAKE ON DAYS 1 AND 15					455	672	1
MMRF_1847	First line of therapy	Ixazomib			mg	PO	Log Forms	Maintenance	Maintenance	Checked	4	Other	DAYS 1,8,15 OF 28 DAY CYCLE					692		1
MMRF_1847	First line of therapy	Dexamethasone			mg	PO	Log Forms	Maintenance	Maintenance	Checked	8	Other	DAYS 1,8,15 OF 28 DAY CYCLE					692		1
MMRF_1847	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					692		1
MMRF_1847	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	TRANSPLANT		200	Other	ONCE					159	159	1
MMRF_1888	First line of therapy	Bortezomib		Lack of response	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QWK	QWK					1	29	1
MMRF_1888	First line of therapy	Dexamethasone		Lack of response	mg	PO	Log Forms	Induction	Induction		20	QWK	QWK					1	29	1
MMRF_1888	First line of therapy	Bortezomib		TRANSPLANT	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Other	DAY 1,8&15					29	85	1
MMRF_1888	First line of therapy	Lenalidomide		TRANSPLANT	mg	PO	Log Forms	Induction	Induction		15	QD (D1-14)	QD (D1-14)					29	85	1
MMRF_1888	First line of therapy	Dexamethasone		TRANSPLANT	mg	PO	Log Forms	Induction	Induction		20	Other	BIW ( MONDAY AND THURSDAY)					29	85	1
MMRF_1888	First line of therapy	Lenalidomide			mg	PO	Log Forms	Induction	Induction	Checked	10	Other	DAYS 1-21					388		1
MMRF_1888	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Q day	Q day					143	143	1
MMRF_1915	First line of therapy	Bortezomib		DECREASED DOES D/T PREPHERAL NEUROPATHY	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Other	BIW					1	53	1
MMRF_1915	First line of therapy	Dexamethasone		TRANSPLANT	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					1	82	1
MMRF_1915	First line of therapy	Bortezomib		TRANSPLANT	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1	Other	BIW					53	82	1
MMRF_1915	First line of therapy	Lenalidomide		TRANSPLANT	mg	PO	Log Forms	Induction	Induction		10	QD (D1-14)	QD (D1-14)					25	82	1
MMRF_1915	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Induction	Induction		360	Other	ONCE W AUTO-HSCT					113	113	1
MMRF_1915	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					358	365	1
MMRF_1915	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		10	Other	TIW X 1 WEEK, THEN EVERY OTHER DAY X1 WEEK THEN DAILY					358	850	1
MMRF_2041	First line of therapy	Dexamethasone		TRANSPLANT	mg	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	29	1
MMRF_2041	First line of therapy	Bortezomib		TRANSPLANT	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	29	1
MMRF_2041	First line of therapy	Cyclophosphamide		TRANSPLANT	mg	PO	Log Forms	Induction	Induction		400	Other	ON D1 AND 8 EVERY 21DAYS					1	29	1
MMRF_2041	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	Other	QD DAYS 1-21 EACH 28 DAY CYCLE					199	497	1
MMRF_2041	First line of therapy	Lenalidomide			mg	PO	Log Forms	Induction	Induction	Checked	5	QD (D1-21)	QD (D1-21)					497		1
MMRF_2041	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Q day	Q day					106	106	1
MMRF_2064	First line of therapy	Bortezomib		TRANSPLANT	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	102	1
MMRF_2064	First line of therapy	Dexamethasone		TRANSPLANT	mg	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	102	1
MMRF_2064	Second Line Therapy (after first relapse)	Carfilzomib		Patient decision	mg/m^2	IV	Log Forms	Induction	Induction		20	Q week	Q week					1221	1338	1
MMRF_2064	Second Line Therapy (after first relapse)	Dexamethasone		Patient decision	mg	IV	Log Forms	Induction	Induction		20	Q week	Q week					1221	1338	1
MMRF_2064	Second Line Therapy (after first relapse)	Lenalidomide			mg	PO	Log Forms	Induction	Induction	Checked	10	QD (D1-21)	QD (D1-21)					1341		1
MMRF_2064	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		12	Q week	Q week					1341	1430	1
MMRF_2064	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	8	Q week	Q week					1430		1
MMRF_2064	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Q day	Q day					116	116	1
MMRF_2409	First line of therapy	Bortezomib		TRANSPLANT	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Other	BIW					1	135	1
MMRF_2409	First line of therapy	Dexamethasone		STEM CELL TRANSPLANT	mg	PO	Log Forms	Induction	Induction		20	Other	PRE MED					1	135	1
MMRF_2409	First line of therapy	Melphalan		AUTO-HSCT	mg/dL	IV	Log Forms	Induction	Induction		410	Other	ONCE					176	176	1
MMRF_2409	First line of therapy	Lenalidomide			mg	PO	Log Forms	Induction	Induction	Checked	10	Q day	Q day					345		1
MMRF_2585	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					1	8	1
MMRF_2585	First line of therapy	Dexamethasone		TRANSPLANT AUTO HSCT	mg	PO	Log Forms	Induction	Induction		20	QWK	QWK					1	413	1
MMRF_2585	First line of therapy	Lenalidomide		CHANGED DOSE FREQUENCY	mg	PO	Log Forms	Induction	Induction		15	Other	TIW					19	44	1
MMRF_2585	First line of therapy	Lenalidomide		CHANGED DRUG FREQUENCY	mg	PO	Log Forms	Induction	Induction		15	Q day	Q day					45	59	1
MMRF_2585	First line of therapy	Lenalidomide		TRANSPLANT AUTO HSCT	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					59	413	1
MMRF_2585	First line of therapy	Lenalidomide			mg	PO	Log Forms	Consolidation	Consolidation	Checked	10	QD (D1-21)	QD (D1-21)					635		1
MMRF_2585	First line of therapy	Dexamethasone			mg	PO	Log Forms	Consolidation	Consolidation	Checked	8	Other	DAYS 1, 8, 15					635		1
MMRF_1750	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg	IV SubQ	Log Forms	Induction	Induction		3	Q week	Q week					1	51	1
MMRF_1750	First line of therapy	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Induction	Induction		50	Q week	Q week					1	79	1
MMRF_1750	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		4	Q week	Q week					1	79	1
MMRF_1750	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		2.6	Q week	Q week					51	79	1
MMRF_1750	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING REGIMEN		200	Other	ONCE					126	126	1
MMRF_1750	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		15	Q day	Q day					212	316	1
MMRF_1750	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					317	961	1
MMRF_1750	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	5	Q day	Q day					962		1
MMRF_2019	First line of therapy	Melphalan		TRANSPLANT			Log Forms	Other	HIGH-DOSE FOR TRANSPLANT										142	1
MMRF_2019	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	115	1
MMRF_2019	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	140	1
MMRF_2019	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					251	303	1
MMRF_2019	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	DAYS 1&15 Q 28 DAYS					399	771	1
MMRF_2377	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_2377	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	DAYS 1, 2, 4, 5, 8,9,11, AND 12					1	53	1
MMRF_2377	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	53	1
MMRF_2377	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Other	MOBILIZATION FOR TRANSPLANT		3000	Other	ONCE					85	85	1
MMRF_2377	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					113	207	1
MMRF_2377	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		10	QD (D1-14)	QD (D1-14)					113	207	1
MMRF_2377	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		10	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					113	207	1
MMRF_2377	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	15	Q day	Q day					211		1
MMRF_2380	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	170	1
MMRF_2380	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		20	Other	DAY OF AND VELCADE AND DAY AFTER VELCADE					4	177	1
MMRF_2380	Second Line Therapy (after first relapse)	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		1.5	Q week	Q week					547	631	1
MMRF_2380	Second Line Therapy (after first relapse)	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		10	QD (D1-14)	QD (D1-14)					547	631	1
MMRF_2380	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					547	631	1
MMRF_2380	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING REGIMEN FOR SCT		200	Other	ONCE					659	659	1
MMRF_2402	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	414	1
MMRF_2402	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	414	1
MMRF_2402	Second Line Therapy (after first relapse)	Lenalidomide		DEATH	mg	PO	Log Forms	Induction	Induction		20	Other	QD DAYS 1-21/28					414	1368	1
MMRF_2402	Second Line Therapy (after first relapse)	Ixazomib		DEATH	mg	PO	Log Forms	Induction	Induction		4	Other	DAYS 1, 8, 15 / 28					414	1368	1
MMRF_2402	Second Line Therapy (after first relapse)	Dexamethasone		DEATH	mg	PO	Log Forms	Induction	Induction		40	QWK	QWK					414	1368	1
MMRF_1930	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	59	1
MMRF_1930	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	D1, D2, D4, D5, D8, D9, D11, D12					1	59	1
MMRF_1930	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	59	1
MMRF_1930	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		10	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					224	273	1
MMRF_1930	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Other	MOBILIZATION		3000	Q day	Q day					87	87	1
MMRF_1930	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Q day	Q day					113	113	1
MMRF_1930	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					224	256	1
MMRF_1930	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-14)	QD (D1-14)					224	259	1
MMRF_1930	First line of therapy	Lenalidomide		ALL DIAGNOSIS	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					274	2297	1
MMRF_2167	First line of therapy	Bortezomib		Lack of response	mg	IV	Log Forms	Induction	Induction		3.07	QWK	QWK					1	185	1
MMRF_2167	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Induction	Induction		40	Q day	Q day					1	4	1
MMRF_2167	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Induction	Induction		10	QWK	QWK					10	194	1
MMRF_2167	Second Line Therapy (after first relapse)	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					201	299	1
MMRF_2167	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	IV	Log Forms	Induction	Induction		10	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					201	299	1
MMRF_2167	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Q day	Q day					333	333	1
MMRF_2167	Second Line Therapy (after first relapse)	Dexamethasone		DEATH	mg	IV	Log Forms	Induction	Induction		20	Q week	Q week					460	839	1
MMRF_2167	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		5	Q day	Q day					454	496	1
MMRF_2167	Second Line Therapy (after first relapse)	ELOTUZUMAB		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		1202	Q week	Q week					460	517	1
MMRF_2167	Third Line Therapy (following 2nd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		2	QD (D1-21)	QD (D1-21)					517	833	1
MMRF_2167	Third Line Therapy (following 2nd relapse)	Daratumumab		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		1886.4	Other	QWK C1-2, C3-6 D 1&15, THEN D1 EVERY CYCLE (1 CYCLE=28 DAYS)					524	622	1
MMRF_2167	Fourth Line Therapy (following 3rd relapse)	Carfilzomib		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		66	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					636	824	1
MMRF_2167	Fourth Line Therapy (following 3rd relapse)	Cyclophosphamide		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		660	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					678	823	1
MMRF_2167	Fifth Line Therapy (following 4th relapse)	PEMBROLIZUMAB (KEYTRUDA)		SUBJECT ON HOSPICE 1-5-17 AND EXPIRED SAME DAY	mg	IV	Log Forms	Induction	Induction		200	Other	ONCE					825	825	1
MMRF_2167	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					201	307	1
MMRF_1456	First line of therapy	Bortezomib		Patient decision	mg/m^2	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)					1	43	1
MMRF_1456	First line of therapy	Dexamethasone		Patient decision	mg	PO	Log Forms				40	Q week	Q week					1	43	1
MMRF_1456	First line of therapy	Lenalidomide		Patient decision	mg	PO	Log Forms	Unknown	Unknown		15	Q day	Q day					22	43	1
MMRF_1535	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	154	1
MMRF_1535	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	154	1
MMRF_1535	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		5	Other	MONDAY, WEDNESDAY, FRIDAY					366	394	1
MMRF_2112	First line of therapy	Lenalidomide		PATIENT DECEASED	mg	PO	Log Forms	Induction	Induction		25	Q day	Q day					1	201	1
MMRF_2112	First line of therapy	Bortezomib		PATIENT DECEASED	mg	IV SubQ	Log Forms	Induction	Induction		2.3	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)					5	201	1
MMRF_2112	First line of therapy	Dexamethasone		DEATH	mg	PO	Log Forms	Induction	Induction		4	TID	TID					1	201	1
MMRF_2151	First line of therapy	Bortezomib		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		2.5	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	13	1
MMRF_2151	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		15	QD (D1-14)	QD (D1-14)					9	13	1
MMRF_2151	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	13	1
MMRF_2379	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					1	83	1
MMRF_1882	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		3.3	QWK	QWK					1	86	1
MMRF_1882	First line of therapy	Dexamethasone		Patient decision	mg	PO	Log Forms	Induction	Induction		40	QWK	QWK					30	562	1
MMRF_1882	First line of therapy	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Induction	Induction		450	QWK	QWK					37	268	1
MMRF_1882	First line of therapy	Bortezomib		Completed regimen	mg	SUBCUTANEOUSLY	Log Forms	Consolidation	Consolidation		3.5	Q week	Q week					93	121	1
MMRF_1882	First line of therapy	Bortezomib		Completed regimen	mg	SUBCUTANEOUSLY	Log Forms	Maintenance	Maintenance		3.3	Q week	Q week					134	268	1
MMRF_1882	First line of therapy	Bortezomib		Patient decision	mg	SUBQ	Log Forms	Maintenance	Maintenance		3.6	Q week	Q week					280	562	1
MMRF_2015	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg	IV SubQ	Log Forms	Induction	Induction		2.8	QWK	QWK					33	138	1
MMRF_2015	First line of therapy	Cyclophosphamide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		50	QD (D1-14)	QD (D1-14)					8	23	1
MMRF_2015	First line of therapy	Dexamethasone		DEATH	mg	PO	Log Forms	Induction	Induction		40	Q day	Q day					1	520	1
MMRF_2187	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg	IV SubQ	Log Forms	Induction	Induction		3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	11	1
MMRF_2187	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	11	1
MMRF_2187	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		10	Other	ONCE					1	11	1
MMRF_2386	First line of therapy	Bortezomib		Completed regimen	mg/m^2	SUB-Q	Log Forms	Induction	Induction		3.17	Q week	Q week					1	179	1
MMRF_2386	First line of therapy	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Induction	Induction		600	Q week	Q week					1	179	1
MMRF_2386	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	179	1
MMRF_2386	Second Line Therapy (after first relapse)	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms	Unknown	Unknown		2.9	Q week	Q week					197	316	1
MMRF_2386	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		25	QD (D1-21)	QD (D1-21)					197	316	1
MMRF_2386	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		40	Q week	Q week					197	316	1
MMRF_2386	Third Line Therapy (following 2nd relapse)	Carfilzomib		Lack of response	mg	IV	Log Forms	Unknown	Unknown		60	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					341	867	1
MMRF_2386	Third Line Therapy (following 2nd relapse)	Dexamethasone			mg	PO	Log Forms	Unknown	Unknown	Checked	4	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					341		1
MMRF_2386	Third Line Therapy (following 2nd relapse)	Lenalidomide		Lack of response	mg	PO	Log Forms	Unknown	Unknown		25	QD (D1-21)	QD (D1-21)					341	454	1
MMRF_2386	Third Line Therapy (following 2nd relapse)	Pomalidomide			mg	PO	Log Forms	Unknown	Unknown	Checked	4	QD (D1-21)	QD (D1-21)					467		1
MMRF_2386	Fourth Line Therapy (following 3rd relapse)	Daratumumab			mg	IV	Log Forms	Unknown	Unknown	Checked	1600	Q week	Q week					867		1
MMRF_2078	First line of therapy	Bortezomib			mg	SUB Q	Log Forms	Induction	Induction	Checked	1.8	QWK	QWK					1		1
MMRF_1644	First line of therapy	Bortezomib			mg	IV SubQ	Log Forms	Induction	Induction	Checked	2.1	Q week	Q week					1		1
MMRF_2118	First line of therapy	Bortezomib		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		2.4	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	705	1
MMRF_2118	First line of therapy	Dexamethasone			mg	FIRST IV AND THEN PO	Log Forms	Induction	Induction	Checked	40	Q day	Q day					1		1
MMRF_2118	Second Line Therapy (after first relapse)	Elotuzumab		Disease progression/Relapse	mg	IV	Log Forms	Maintenance	Maintenance		667	Q week	Q week					624	1016	1
MMRF_2118	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					624	1044	1
MMRF_2118	Third Line Therapy (following 2nd relapse)	Daratumumab			mg	IV	Log Forms	Maintenance	Maintenance	Checked	1110	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1056		1
MMRF_2118	Third Line Therapy (following 2nd relapse)	Bortezomib			mg/m^2	IV	Log Forms	Maintenance	Maintenance	Checked	1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1056		1
MMRF_2118	Third Line Therapy (following 2nd relapse)	METHOTREXATE		Completed regimen	mg	INTRATHECAL	Log Forms	Consolidation	Consolidation		12	Q week	Q week					1037	1058	1
MMRF_2138	First line of therapy	Bortezomib		Lack of response	mg	IV SubQ	Log Forms	Induction	Induction		2.2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	119	1
MMRF_2138	First line of therapy	Dexamethasone		Lack of response	mg	FIRST IV THEN PO	Log Forms	Induction	Induction		40	Q day	Q day					1	119	1
MMRF_2138	First line of therapy	Carfilzomib		Disease progression/Relapse	mg	IV	Log Forms	Maintenance	Maintenance		34	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					165	567	1
MMRF_2138	Second Line Therapy (after first relapse)	Elotuzumab		Disease progression/Relapse	mg	IV	Log Forms	Unknown	Unknown		667	QWK	QWK					609	1873	1
MMRF_2138	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		25	QD (D1-21)	QD (D1-21)					609	1873	1
MMRF_2138	Third Line Therapy (following 2nd relapse)	Daratumumab			mg/kg	IV	Log Forms	Unknown	Unknown	Checked	16	Other	DAYS 1, 8, AND 15 OF CYCLES 1, 2, AND 3; THEN DAY 1 ONLY					1887		1
MMRF_2138	Third Line Therapy (following 2nd relapse)	Bortezomib			mg/m^2	IV SubQ	Log Forms	Unknown	Unknown	Checked	1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1887		1
MMRF_2138	Third Line Therapy (following 2nd relapse)	Dexamethasone			mg	IV	Log Forms	Unknown	Unknown	Checked	20	Other	DAYS 1, 8, 11, 15					1887		1
MMRF_1706	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					1	105	1
MMRF_1706	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	105	1
MMRF_1706	First line of therapy	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Induction	Induction		700	Q week	Q week					1	105	1
MMRF_1706	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Other	STEM CELL MOBILIZATION		5650	Other	ONCE (SINGLE TREATMENT)					116	116	1
MMRF_1706	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	STEM CELL TRANSPLANT CONDITIONING		310	Other	ONCE (SINGLE TREATMENT)					163	163	1
MMRF_1706	First line of therapy	BUSULFAN		Completed regimen	mg	IV	Log Forms	Other	STEM CELL TRANSPLANT CONDITIONING		280	Q day	Q day					160	162	1
MMRF_1706	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					265	455	1
MMRF_1881	Second Line Therapy (after first relapse)	METHOTREXATE		Completed regimen	mg/m^2	IV PUSH	Log Forms	Unknown	Unknown		5	Other	ONCE					1257	1258	1
MMRF_1881	Second Line Therapy (after first relapse)	METHOTREXATE		Completed regimen	mg/m^2	IV PUSH	Log Forms	Unknown	Unknown		10	Other	ONCE					1256	1256	1
MMRF_1881	Second Line Therapy (after first relapse)	ALEMTUZUMAB		Completed regimen	mg	SC	Log Forms	Induction	Induction		330	Other	ONCE					1250	1250	1
MMRF_1881	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		70	Other	ONCE					1252	1252	1
MMRF_1881	Second Line Therapy (after first relapse)	FLUDRABINE		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		30	Q day	Q day					1249	1253	1
MMRF_1881	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					1	171	1
MMRF_1881	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO	Log Forms	Induction	Induction		300	Q week	Q week					1	171	1
MMRF_1881	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	171	1
MMRF_1881	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Other	STEM CELL MOBILIZATION		4400	Other	ONCE (SINGLE ADMINISTRATION)					196	196	1
MMRF_1881	First line of therapy	BUSULFAN		Completed regimen	mg	IV	Log Forms	Other	STEM CELL TRANSPLANT CONDITIONING		216	Q day	Q day					249	251	1
MMRF_1881	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	STEM CELL TRANSPLANT CONDITIONING		250	Other	ONCE (SINGLE ADMINISTRATION)					252	252	1
MMRF_1881	First line of therapy	Lenalidomide		PER MCRN-001 PROTOCOL (MAINTENANCE REV DOSE TO BE INCREASED TO 15 MG)	mg	PO	Log Forms	Maintenance	Maintenance		10	Other	QDAY (D1-28 OF 28 DAY CYCLE)					358	446	1
MMRF_1881	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		15	Other	Q DAY (D1-28 OF 28 DAY CYCLE)					448	751	1
MMRF_1972	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					1	88	1
MMRF_1972	First line of therapy	Cyclophosphamide		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Induction	Induction		300	Q week	Q week					1	88	1
MMRF_1972	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					1	88	1
MMRF_1972	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.5	Other	DAY 1, 7, 15 OF 28 DAY CYCLE (3WEEKS ON, 1 WEEK REST)					95	368	1
MMRF_1972	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		300	Other	DAY 1, 7, 15 OF 28 DAY CYCLE (3WEEKS ON, 1 WEEK REST)					95	368	1
MMRF_1972	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	DAY 1, 7, 15 OF 28 DAY CYCLE (3WEEKS ON, 1 WEEK REST)					95	368	1
MMRF_1972	Second Line Therapy (after first relapse)	Lenalidomide		PHYSICIAN INCREASED DOSE TO 15 MG	mg	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					1054	1183	1
MMRF_1972	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	RELAPSED DISEASE		20	Other	D1, D8, D15, D22 OF 28 DAY CYCLE					1054	1915	1
MMRF_1972	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					1184	1235	1
MMRF_1972	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Other	REALPSED DISEASE TREATMENT		10	QD (D1-21)	QD (D1-21)					1236	1915	1
MMRF_1972	Third Line Therapy (following 2nd relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Other	RELAPSED DISEASE TREATMENT		16	Q week	Q week					1933	2108	1
MMRF_1972	Third Line Therapy (following 2nd relapse)	Bortezomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Other	RELAPSED DISEASE TREATMENT		1.3	Q week	Q week					1933	2122	1
MMRF_1972	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	RELAPSED DISEASE TREATMENT		40	Q week	Q week					1933	2129	1
MMRF_2007	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Other	RELAPSED DISEASE TREATMENT	Checked	40	Q week	Q week					1704		1
MMRF_2007	Second Line Therapy (after first relapse)	Daratumumab			mg/kg	IV	Log Forms	Other	RELAPSED DISEASE TREATMENT	Checked	16	Other	D1-15					1704		1
MMRF_2007	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					1	101	1
MMRF_2007	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		300	Q week	Q week					1	101	1
MMRF_2007	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	101	1
MMRF_2007	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Other	STEM CELL MOBILIZATION		2500	Other	ONCE					112	112	1
MMRF_2007	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	MELPHALAN CONDITIONING FOR ASCT		210	Other	QDAY FOR 2 DAYS					151	152	1
MMRF_2007	First line of therapy	Lenalidomide		Patient decision	mg	PO	Log Forms	Other	CONSOLIDATION AND MAINTENANCE		10	Other	QDAY (D1-28 OF 28 DAY CYCLE)					436	1005	1
MMRF_1829	First line of therapy	Bortezomib		I DIDN'T SEE THE REASON FOR DISCONTINUED DOCUMENTED. THE NURSE AND MD ARE NO LONGER HERE.	mg	IV	Log Forms	Induction	Induction		2.7	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	93	1
MMRF_1829	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					104	245	1
MMRF_1829	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg	IV	Log Forms	Consolidation	Consolidation		2.6	Other	D1, D4, D8					94	104	1
MMRF_1829	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	IV	Log Forms	Consolidation	Consolidation		10	Other	D1, D4, D8					94	167	1
MMRF_1829	First line of therapy	Lenalidomide		UTI	mg	PO	Log Forms	Consolidation	Consolidation		5	QD (D1-14)	QD (D1-14)					49	248	1
MMRF_1829	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg	IV SubQ	Log Forms	Consolidation	Consolidation		2.4	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					160	216	1
MMRF_1829	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg	IV	Log Forms	Consolidation	Consolidation		2.5	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					104	167	1
MMRF_1829	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		2.5	QD (D1-21)	QD (D1-21)					230	455	1
MMRF_1829	Second Line Therapy (after first relapse)	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					938	939	1
MMRF_1977	First line of therapy	Bortezomib			mg	IV	Log Forms	Induction	Induction	Checked	2.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_1977	First line of therapy	Lenalidomide			mg	PO	Log Forms	Induction	Induction	Checked	15	Other	Q 48 HOURS X 14 DAYS					1		1
MMRF_1977	First line of therapy	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	40	Q week	Q week					1		1
MMRF_2012	First line of therapy	Lenalidomide		CHANGE TO MAINTENANCE DOSE FOR CR	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					1	351	1
MMRF_2012	First line of therapy	Dexamethasone		DOSE ADJUSTMENT BASED ON IMPROVED SPEP AND IFE	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					1	93	1
MMRF_2012	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		8	Q week	Q week					94	390	1
MMRF_2012	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					597	1236	1
MMRF_2012	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					597	1236	1
MMRF_2012	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					358	418	1
MMRF_2106	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	225	1
MMRF_2106	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	225	1
MMRF_2106	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	D1-5, 8-9, 11-12					1	225	1
MMRF_2106	Second Line Therapy (after first relapse)	Carfilzomib		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					271	272	1
MMRF_2106	Second Line Therapy (after first relapse)	ETOPOSIDE		Completed regimen	mg	IV	Log Forms	Consolidation	Consolidation		68	Q day	Q day					272	277	1
MMRF_2106	Second Line Therapy (after first relapse)	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		1	Other	ONE DOSE					276	276	1
MMRF_2106	Second Line Therapy (after first relapse)	Doxorubicin		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		30	Other	ONE DOSE					276	276	1
MMRF_2106	Second Line Therapy (after first relapse)	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Consolidation	Consolidation		2	Q day	Q day					271	337	1
MMRF_2106	Second Line Therapy (after first relapse)	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Induction	Induction		475	Other	ONE DOSE					337	337	1
MMRF_2106	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	ONE DOSE					337	337	1
MMRF_2106	Second Line Therapy (after first relapse)	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		20	Other	ONE DOSE					337	337	1
MMRF_2125	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	294	1
MMRF_2125	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	442	1
MMRF_2125	First line of therapy	Dexamethasone		DOSE ADJUSTMENT	mg	PO	Log Forms	Induction	Induction		20	Other	D1, 2, 4, 5, 8-9 AND 11-12					1	116	1
MMRF_2125	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		10	Other	D1, D2, D4, D5, D8, D9, D11, D12					116	294	1
MMRF_2125	Second Line Therapy (after first relapse)	Elotuzumab		ELOTUZUMAB WAS APPROVED BY THE FDA.	mg/kg	IV	Log Forms	Induction	Induction		10	Other	D1, D8, D15, D22					455	512	1
MMRF_2125	Second Line Therapy (after first relapse)	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					455	512	1
MMRF_2125	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		28	Other	3-24 HOURS PRIOR TO ELO ON D1, D8, D15, D22					455	512	1
MMRF_2125	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	IV	Log Forms	Induction	Induction		8	Other	45-90 MINUTES PRIOR TO ELO INFUSION ON D1, D8, D15, D22					455	512	1
MMRF_2125	Second Line Therapy (after first relapse)	Elotuzumab		CHANGED DUE TO STABLE PROTEINS	mg/kg	IV	Log Forms	Consolidation	Consolidation		10	Other	EVERY TWO WEEKS					518	609	1
MMRF_2125	Second Line Therapy (after first relapse)	Dexamethasone		STABLE PROTEINS	mg	IV	Log Forms	Consolidation	Consolidation		8	Other	EVERY TWO WEEKS					518	609	1
MMRF_2125	Second Line Therapy (after first relapse)	Carfilzomib			mg/m^2	IV	Log Forms	Consolidation	Consolidation	Checked	20	Other	EVERY TWO WEEKS					609		1
MMRF_2125	Second Line Therapy (after first relapse)	Dexamethasone			mg	IV	Log Forms	Consolidation	Consolidation	Checked	10	Other	EVERY TWO WEEKS					609		1
MMRF_2256	First line of therapy	Bortezomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Induction	Induction		1.3	Other	D1, D4, D7, D10					1	309	1
MMRF_2256	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		10	Other	D1, D4, D7, D10					1	196	1
MMRF_2259	First line of therapy	Bortezomib		DEATH	mg/m^2	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	123	1
MMRF_2259	First line of therapy	Lenalidomide		DEATH	mg	PO	Log Forms	Induction	Induction		25	Other	EVERY DAY X 14 DAYS					1	123	1
MMRF_2259	First line of therapy	Dexamethasone		DEATH	mg	PO	Log Forms	Induction	Induction		20	Other	D1, D2, D4, D5, D8, D9					1	123	1
MMRF_2525	First line of therapy	Lenalidomide		Lack of response	mg	PO	Log Forms	Induction	Induction		25	Q day	Q day					1	148	1
MMRF_2525	First line of therapy	Dexamethasone		DOSE OR FREQUENCY CHANGE	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	505	1
MMRF_2525	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	WEEKLY ON 2 DAYS BEFORE AND DAY OF [BORTEZOMIB]					148	519	1
MMRF_2525	Second Line Therapy (after first relapse)	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		1.6	Q week	Q week					148	519	1
MMRF_2525	First line of therapy	Dexamethasone		Lack of response	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					121	148	1
MMRF_2525	First line of therapy	Dexamethasone		DOSE OR FREQUENCY CHANGE	mg	PO	Log Forms	Induction	Induction		40	Other	Q 4 WEEK					65	120	1
MMRF_1753	First line of therapy	Bortezomib		DEATH	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	101	1
MMRF_1753	First line of therapy	Cyclophosphamide		DEATH	mg/m^2	PO	Log Forms	Induction	Induction		300	QWK	QWK					1	101	1
MMRF_1753	First line of therapy	Dexamethasone		DEATH	mg	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	101	1
MMRF_1786	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	109	1
MMRF_1786	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO	Log Forms	Induction	Induction		300	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					8	120	1
MMRF_1786	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					8	120	1
MMRF_1786	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		15	Other	DAILY 1-21 (28 DAY CYCLE)					207	360	1
MMRF_1786	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					360	1290	1
MMRF_1786	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		28	Other	DAY 1					1444	1549	1
MMRF_1786	Second Line Therapy (after first relapse)	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Maintenance	Maintenance		20	Other	DAYS 1, 2					1444	1543	1
MMRF_1786	Second Line Therapy (after first relapse)	Dexamethasone			mg	IV	Log Forms	Maintenance	Maintenance	Checked	8	Other	DAY 1					1444		1
MMRF_1786	Second Line Therapy (after first relapse)	Elotuzumab			mg/kg	IV	Log Forms	Maintenance	Maintenance	Checked	10	Other	DAY 1					1444		1
MMRF_1786	Second Line Therapy (after first relapse)	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	25	QD (D1-21)	QD (D1-21)					1444		1
MMRF_1786	Third Line Therapy (following 2nd relapse)	Dexamethasone			mg	PO	Log Forms	Maintenance	Maintenance	Checked	40	Other	C1-2 D1,15  C3 D1,8,15,22					2060		1
MMRF_1786	Third Line Therapy (following 2nd relapse)	Pomalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	3	QD (D1-21)	QD (D1-21)					2060		1
MMRF_1786	Third Line Therapy (following 2nd relapse)	Daratumumab			mg/kg	IV	Log Forms	Maintenance	Maintenance	Checked	16	Other	D1					2060		1
MMRF_1793	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	42	1
MMRF_1793	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	42	1
MMRF_1793	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	105	1
MMRF_1793	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					64	105	1
MMRF_1793	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					64	105	1
MMRF_1793	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					196		1
MMRF_1816	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	96	1
MMRF_1816	First line of therapy	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Induction	Induction		450	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	100	1
MMRF_1816	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	100	1
MMRF_1816	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					140	140	1
MMRF_1816	First line of therapy	Carfilzomib		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Maintenance	Maintenance		20	Q day	Q day					232	233	1
MMRF_1816	First line of therapy	Carfilzomib		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Maintenance	Maintenance		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					239	352	1
MMRF_1816	First line of therapy	Carfilzomib		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Maintenance	Maintenance		56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					359	1235	1
MMRF_1816	First line of therapy	Pomalidomide		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		2	QD (D1-21)	QD (D1-21)					232	1978	1
MMRF_1816	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		40	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					232	562	1
MMRF_1816	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					576	1235	1
MMRF_1842	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		2.7	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	123	1
MMRF_1842	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	103	1
MMRF_1842	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	106	1
MMRF_1842	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Consolidation	Consolidation		400	Other	ONCE					159	159	1
MMRF_1842	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					227	689	1
MMRF_1842	Second Line Therapy (after first relapse)	Lenalidomide		M-SPIKE AND FLC CONTINUE TO RISE	mg	PO	Log Forms	Maintenance	Maintenance		25	QD (D1-21)	QD (D1-21)					732	897	1
MMRF_1842	Second Line Therapy (after first relapse)	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Unknown	Unknown		20	Other	DAYS 1, 8, 15, 22					732	1289	1
MMRF_1842	Second Line Therapy (after first relapse)	Elotuzumab		M-SPIKE AND FLC CONTINUE TO RISE	mg/kg	IV	Log Forms	Maintenance	Maintenance		10	Other	DAYS 1, 15					732	884	1
MMRF_1842	Third Line Therapy (following 2nd relapse)	Daratumumab		Investigator decision for other reasons	mg/kg	IV	Log Forms	Maintenance	Maintenance		16	Other	DAYS 1, 8, 15, 22					898	1122	1
MMRF_1842	Third Line Therapy (following 2nd relapse)	Pomalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		2	QD (D1-21)	QD (D1-21)					898	1072	1
MMRF_1842	Third Line Therapy (following 2nd relapse)	Pomalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		4	QD (D1-21)	QD (D1-21)					1094	1142	1
MMRF_1842	Third Line Therapy (following 2nd relapse)	Carfilzomib		Completed regimen	mg	IV	Log Forms	Maintenance	Maintenance		42	Other	DAYS 1, 2					1157	1158	1
MMRF_1842	Third Line Therapy (following 2nd relapse)	Carfilzomib		Investigator decision for other reasons	mg	IV	Log Forms	Maintenance	Maintenance		60	Other	DAYS 8, 9, 15, 16					1157	1290	1
MMRF_1842	Third Line Therapy (following 2nd relapse)	VENETOCLAX		PATIENT DID NOT TAKE C1D1 CORRECTLY	mg	PO	Log Forms	Maintenance	Maintenance		200	Other	DAYS 1-7					1157	1163	1
MMRF_1842	Third Line Therapy (following 2nd relapse)	VENETOCLAX		PATIENT DID NOT TAKE C1D1 CORRECTLY	mg	PO	Log Forms	Maintenance	Maintenance		400	Other	DAYS 8-14					1164	1170	1
MMRF_1842	Third Line Therapy (following 2nd relapse)	VENETOCLAX		PATIENT DID NOT TAKE C1D1 CORRECTLY	mg	PO	Log Forms	Maintenance	Maintenance		800	Other	DAYS 15-21					1171	1177	1
MMRF_1842	Third Line Therapy (following 2nd relapse)	VENETOCLAX		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		800	QD (D1-21)	QD (D1-21)					1191	1211	1
MMRF_1842	Third Line Therapy (following 2nd relapse)	VENETOCLAX		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		700	QD (D1-21)	QD (D1-21)					1219	1267	1
MMRF_1842	Third Line Therapy (following 2nd relapse)	VENETOCLAX		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		200	QD (D1-21)	QD (D1-21)					1275	1295	1
MMRF_1842	Third Line Therapy (following 2nd relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		40	Other	DAYS 1, 2, 3, 4					1297	1300	1
MMRF_1842	Third Line Therapy (following 2nd relapse)	Carfilzomib		Completed regimen	mg	IV	Log Forms	Maintenance	Maintenance		43	Other	DAY 1, 2					1297	1298	1
MMRF_1842	Third Line Therapy (following 2nd relapse)	CISPLATIN		Completed regimen	mg	IV	Log Forms	Maintenance	Maintenance		22	Other	DAYS 1, 2, 3, 4					1297	1327	1
MMRF_1842	Third Line Therapy (following 2nd relapse)	ETOPOSIDE		Completed regimen	mg	IV	Log Forms	Maintenance	Maintenance		64	Other	DAYS 1, 2, 3, 4					1297	1327	1
MMRF_1842	Third Line Therapy (following 2nd relapse)	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Maintenance	Maintenance		860	Other	DAYS 1, 2, 3, 4					1297	1300	1
MMRF_1842	Third Line Therapy (following 2nd relapse)	Doxorubicin		Completed regimen	mg	IV	Log Forms	Maintenance	Maintenance		16	Other	DAYS 1, 2, 3, 4					1297	1300	1
MMRF_1842	Third Line Therapy (following 2nd relapse)	Carfilzomib		Investigator decision for other reasons	mg	IV	Log Forms	Maintenance	Maintenance		120	Other	DAYS 1, 8, 15, 22					1325	1375	1
MMRF_1842	Third Line Therapy (following 2nd relapse)	Panobinostat		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		10	Other	DAYS 1, 3, 5, 15, 17, 18					1325	1372	1
MMRF_1842	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		40	Other	DAYS 1, 8, 15, 22					1325	1522	1
MMRF_1842	Fourth Line Therapy (following 3rd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		4	QD (D1-21)	QD (D1-21)					1409	1522	1
MMRF_1842	Fourth Line Therapy (following 3rd relapse)	Cyclophosphamide		Disease progression/Relapse	mg	IV	Log Forms	Maintenance	Maintenance		500	Other	DAYS 1, 8, 15, 22					1409	1522	1
MMRF_1858	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg	IV SubQ	Log Forms	Induction	Induction		2.2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	25	1
MMRF_1858	First line of therapy	Cyclophosphamide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		500	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	25	1
MMRF_1858	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	25	1
MMRF_1858	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					76	327	1
MMRF_1858	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					76	153	1
MMRF_1858	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		12	Q week	Q week					153	327	1
MMRF_1858	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					744	1033	1
MMRF_1858	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		12	Q week	Q week					744	909	1
MMRF_1858	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		8	Q week	Q week					910	1033	1
MMRF_1858	Third Line Therapy (following 2nd relapse)	Dexamethasone		DEATH	mg	PO	Log Forms	Maintenance	Maintenance		20	Other	DAYS 1, 8, 15, 22					1037	1278	1
MMRF_1858	Third Line Therapy (following 2nd relapse)	Carfilzomib		DEATH	mg/m^2	IV	Log Forms	Maintenance	Maintenance		20	Other	DAY 1					1037	1278	1
MMRF_1858	Third Line Therapy (following 2nd relapse)	Carfilzomib		DEATH	mg/m^2	IV	Log Forms	Maintenance	Maintenance		56	Other	DAYS 8, 15					1037	1278	1
MMRF_1858	Third Line Therapy (following 2nd relapse)	Cyclophosphamide		DEATH	mg/m^2	IV	Log Forms	Maintenance	Maintenance		300	Other	DAYS 1, 8, 15					1037	1278	1
MMRF_1886	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	99	1
MMRF_1886	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	43	1
MMRF_1886	First line of therapy	Cyclophosphamide		Adverse Event or co-morbidity	mg/m^2	PO	Log Forms	Induction	Induction		500	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	43	1
MMRF_1886	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					99	143	1
MMRF_1886	First line of therapy	Cyclophosphamide		Adverse Event or co-morbidity	mg/m^2	PO	Log Forms	Induction	Induction		300	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					43	99	1
MMRF_1886	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO	Log Forms	Induction	Induction		200	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					99	143	1
MMRF_1886	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					43	143	1
MMRF_1886	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		1	Other	DAYS 1  AND DAY15					155	477	1
MMRF_1886	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		12	Other	DAYS 1 AND DAY 15					155	477	1
MMRF_1886	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		0.8	Other	DAYS 1 AND 15					547	561	1
MMRF_1886	Second Line Therapy (after first relapse)	Elotuzumab		Completed regimen	mg/kg	IV	Log Forms	Induction	Induction		10	Q week	Q week					1514	1563	1
MMRF_1886	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	IV	Log Forms	Induction	Induction		20	Q week	Q week					1514	1535	1
MMRF_1886	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	IV	Log Forms	Induction	Induction		30	Q week	Q week					1542	1563	1
MMRF_1886	Second Line Therapy (after first relapse)	Lenalidomide			mg	PO	Log Forms	Induction	Induction	Checked	10	QD (D1-21)	QD (D1-21)					1514		1
MMRF_1886	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	40	Q week	Q week					1570		1
MMRF_1886	Second Line Therapy (after first relapse)	Elotuzumab			mg/kg	IV	Log Forms	Induction	Induction	Checked	10	Other	QD (D1, D15)					1570		1
MMRF_2074	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	67	1
MMRF_2074	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	67	1
MMRF_2074	First line of therapy	Thalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		100	QD (D1-21)	QD (D1-21)					1	50	1
MMRF_2074	First line of therapy	Thalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		50	QD (D1-21)	QD (D1-21)					57	127	1
MMRF_2074	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		12	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					85	116	1
MMRF_2074	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					85	116	1
MMRF_2074	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		200	Q day	Q day					169	169	1
MMRF_2074	First line of therapy	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		1	Other	DAYS 1 AND 15					302	1198	1
MMRF_2074	Second Line Therapy (after first relapse)	Dexamethasone		AMGEN-20160275 TRIAL; C2+ CYCLES ARE DIFFERENT	mg	IV	Log Forms	Maintenance	Maintenance		20	Other	DAYS 1, 2					1268	1269	1
MMRF_2074	Second Line Therapy (after first relapse)	Carfilzomib		AMGEN-20160275 TRIAL; C2+ CYCLES ARE DIFFERENT	mg/m^2	IV	Log Forms	Maintenance	Maintenance		20	Other	DAYS 1, 2					1268	1269	1
MMRF_2074	Second Line Therapy (after first relapse)	Dexamethasone			mg	IV	Log Forms	Maintenance	Maintenance	Checked	20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1296		1
MMRF_2074	Second Line Therapy (after first relapse)	Carfilzomib			mg/m^2	IV	Log Forms	Maintenance	Maintenance	Checked	56	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1296		1
MMRF_2074	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Maintenance	Maintenance	Checked	40	Other	DAYS 22, 23					1296		1
MMRF_2093	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	57	1
MMRF_2093	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	43	1
MMRF_2093	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO	Log Forms	Induction	Induction		300	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	127	1
MMRF_2093	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					57	123	1
MMRF_2093	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO	Log Forms	Induction	Induction		300	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					57	127	1
MMRF_2093	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		200	Q day	Q day					177	177	1
MMRF_2093	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					253	531	1
MMRF_2093	Second Line Therapy (after first relapse)	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		20	Other	DAYS 1, 8, 15, 22 (MISSED C2 D8, 15, 22)					827	1158	1
MMRF_2093	Second Line Therapy (after first relapse)	Carfilzomib		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Maintenance	Maintenance		20	Other	DAYS 1, 2					827	829	1
MMRF_2093	Second Line Therapy (after first relapse)	Carfilzomib		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Maintenance	Maintenance		27	Other	DAYS 8, 9, 15, 16 (MISSED C2 D8, 9, 15, 16)					827	843	1
MMRF_2093	Second Line Therapy (after first relapse)	Cyclophosphamide		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Maintenance	Maintenance		300	Other	DAYS 1, 8, 15 (MISSED C2 D8, 15)					827	1158	1
MMRF_2093	Second Line Therapy (after first relapse)	Carfilzomib		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Maintenance	Maintenance		27	Other	DAYS 1, 2, 8, 9, 15, 16					855	1158	1
MMRF_2093	Third Line Therapy (following 2nd relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Maintenance	Maintenance		16	Other	DAY 1					1172	1811	1
MMRF_2093	Third Line Therapy (following 2nd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		2	QD (D1-21)	QD (D1-21)					1172	1811	1
MMRF_2093	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Maintenance	Maintenance		20	Other	DAY 1					1172	1811	1
MMRF_2093	Sixth Line Therapy (following 5th relapse)	Panobinostat		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		20	Other	QD (1,3,5,8,10,12,15,17,19)					2028	2043	1
MMRF_2093	Sixth Line Therapy (following 5th relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Maintenance	Maintenance		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					2028	2043	1
MMRF_2093	Fifth Line Therapy (following 4th relapse)	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Maintenance	Maintenance		20	Q week	Q week					1979	2022	1
MMRF_2093	Fifth Line Therapy (following 4th relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Maintenance	Maintenance		56	Q week	Q week					1979	2022	1
MMRF_2093	Fifth Line Therapy (following 4th relapse)	SELINEXOR		Disease progression/Relapse	mg	IV	Log Forms	Maintenance	Maintenance		60	Q week	Q week					2007	2022	1
MMRF_2093	Fifth Line Therapy (following 4th relapse)	SELINEXOR		Disease progression/Relapse	mg	IV	Log Forms	Maintenance	Maintenance		80	Q week	Q week					1979	2006	1
MMRF_2093	Fourth Line Therapy (following 3rd relapse)	MEDI2228		Disease progression/Relapse	mg	IV	Log Forms	Maintenance	Maintenance		13.6	Q week	Q week					1837	1888	1
MMRF_2266	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Other	DAY 1, DAY 7, DAY 14					1	68	1
MMRF_2266	First line of therapy	Cyclophosphamide		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Induction	Induction		300	Other	DAY 1, DAY 7, DAY 14					1	68	1
MMRF_2266	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	IV	Log Forms	Induction	Induction		40	Other	DAY 1, DAY 7, DAY 14					1	68	1
MMRF_2266	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1	Other	DAYS 1 AND 15 EVERY 28 DAYS					68	369	1
MMRF_2266	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	IV	Log Forms	Induction	Induction		8	Other	DAYS 1 AND 15 OF EVERY 28 DAYS					68	369	1
MMRF_2306	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.5	Other	DAY 1, 7, 14					1	14	1
MMRF_2306	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	DAY 1, 7, 14					1	14	1
MMRF_2306	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		500	Other	DAY 1, 7, 14					1	14	1
MMRF_2306	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.5	Other	DAY 1, 8, 15					21	98	1
MMRF_2306	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	Other	DAY 1, 8, 15					21	119	1
MMRF_2306	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		500	Other	DAY 1, 8, 15					21	168	1
MMRF_2306	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	DAY 1, 8, 15					126	168	1
MMRF_2306	First line of therapy	Bortezomib		Disease progression/Relapse	mg	IV SubQ	Log Forms	Induction	Induction		1	Other	DAY 1, 15					126	245	1
MMRF_2306	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1	Other	DAY 1, 8, 15					105	168	1
MMRF_2306	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	Other	DAYS 1, 8, 15, 22					266	287	1
MMRF_2306	Second Line Therapy (after first relapse)	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		20	Other	DAYS 1 AND 2					266	267	1
MMRF_2306	Second Line Therapy (after first relapse)	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		27	Other	DAYS 8, 9, 15, AND 16					273	281	1
MMRF_2306	Second Line Therapy (after first relapse)	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		500	Other	DAYS 1, 8, 15					266	364	1
MMRF_2306	Second Line Therapy (after first relapse)	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					294	365	1
MMRF_2306	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		12	Other	DAYS 1, 8, 15, 22					294	371	1
MMRF_2306	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE ON DAY -2					425	425	1
MMRF_2306	Second Line Therapy (after first relapse)	Carfilzomib		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Maintenance	Maintenance		27	Other	Q 2 WEEKS					502	961	1
MMRF_2306	Second Line Therapy (after first relapse)	Dexamethasone		Investigator decision for other reasons	mg	IV	Log Forms	Maintenance	Maintenance		8	Other	DAYS 1, 15					516	852	1
MMRF_2306	Second Line Therapy (after first relapse)	Dexamethasone		Investigator decision for other reasons	mg	IV	Log Forms	Maintenance	Maintenance		4	Other	DAYS 1, 15					866	961	1
MMRF_2306	Third Line Therapy (following 2nd relapse)	Carfilzomib			mg/m^2	IV	Log Forms	Maintenance	Maintenance	Checked	27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1006		1
MMRF_2306	Third Line Therapy (following 2nd relapse)	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	25	QD (D1-21)	QD (D1-21)					1006		1
MMRF_2306	Third Line Therapy (following 2nd relapse)	Dexamethasone			mg	PO	Log Forms	Maintenance	Maintenance	Checked	20	Other	DAYS 1, 8, 15					1006		1
MMRF_2486	First line of therapy	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Induction	Induction		800	Other	DAYS 1, 8, 15, 22					1	176	1
MMRF_2486	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Other	DAYS 1, 8, 15, 22					1	176	1
MMRF_2486	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	DAYS 1, 8, 15, 22					1	176	1
MMRF_2486	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		40	Other	DAYS 1, 8, 15, 22					288	337	1
MMRF_2486	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Maintenance	Maintenance		20	Other	DAY 1 (PATIENT MISSED DAY 2)					288	288	1
MMRF_2486	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Maintenance	Maintenance		27	Other	DAYS 8, 9, 15, 16					295	303	1
MMRF_2486	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		25	QD (D1-21)	QD (D1-21)					288	552	1
MMRF_2486	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Maintenance	Maintenance		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					316	331	1
MMRF_2486	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE ON DAY -2					217	217	1
MMRF_2486	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Maintenance	Maintenance		56	Other	DAYS 1 (MISSED DAY 15)					344	344	1
MMRF_2486	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	DAYS 1, 8, 15, 22					383	553	1
MMRF_2486	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		27	Other	DAYS 1-2,8-9,15-16					383	547	1
MMRF_2486	First line of therapy	Carfilzomib			mg/m^2	IV	Log Forms	Consolidation	Consolidation	Checked	27	Other	DAYS 1, 15					560		1
MMRF_2486	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Consolidation	Consolidation		15	QD (D1-21)	QD (D1-21)					560	629	1
MMRF_2486	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	5	QD (D1-21)	QD (D1-21)					714		1
MMRF_2497	First line of therapy	Lenalidomide		DECREASED TO 10MG FOR CYCLE 1 FOR CREATENINE CLEARENCE < 60	mg	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					1	22	1
MMRF_2497	First line of therapy	Dexamethasone		Patient decision	mg	PO	Log Forms	Induction	Induction		20	Other	D1, D8, D15, D22					1	1043	1
MMRF_2497	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					30	223	1
MMRF_2497	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					240	490	1
MMRF_2497	First line of therapy	Lenalidomide			mg	PO	Log Forms	Induction	Induction	Checked	10	QD (D1-21)	QD (D1-21)					511		1
MMRF_2497	First line of therapy	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	10	Other	DAYS 1, 8, 15, 22					1050		1
MMRF_2501	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Other	D1, D8, D15, D22					1	113	1
MMRF_2501	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO	Log Forms	Induction	Induction		300	Other	D1, D8, D15, D22					1	113	1
MMRF_2501	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	D1, D8, D15, D22					1	113	1
MMRF_2501	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Other	IV OVER 20 MINUTES					170	170	1
MMRF_2501	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					276	984	1
MMRF_2501	Second Line Therapy (after first relapse)	Daratumumab		Adverse Event or co-morbidity	mg/kg	IV	Log Forms	Maintenance	Maintenance		16	Other	DAYS 1, 8, 15 (CYCLE 1: DAY 1 ONLY)					1012	1121	1
MMRF_2501	Second Line Therapy (after first relapse)	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	DAYS 1, 8, 15 (CYCLE 1: DAY 1 ONLY)					1012	1121	1
MMRF_2501	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		40	Other	DAYS 1, 8, 15 (CYCLE 2+)					1029	1121	1
MMRF_2501	Second Line Therapy (after first relapse)	Daratumumab			mg/kg	IV	Log Forms	Unknown	Unknown	Checked	16	Other	DAYS 1, 8, 15 (CYCLE 1: DAY 1 ONLY)					1205		1
MMRF_2501	Second Line Therapy (after first relapse)	Bortezomib			mg/m^2	IV SubQ	Log Forms	Unknown	Unknown	Checked	1.3	Other	DAYS 1, 8, 15 (CYCLE 1: DAY 1 ONLY)					1205		1
MMRF_2501	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Unknown	Unknown		12	Other	DAYS 1, 8, 15					1205	1898	1
MMRF_2557	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.01	Other	DAYS 1, 8, 15					5	117	1
MMRF_2557	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		20	Other	DAYS 1, 8, AND 15					1	264	1
MMRF_2557	First line of therapy	Cyclophosphamide		Disease progression/Relapse	mg/m^2	IV	Log Forms	Induction	Induction		300	Other	DAYS 1, 8, 15					131	222	1
MMRF_2557	First line of therapy	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1	Other	DAYS 1, 8, 15					131	222	1
MMRF_2557	Second Line Therapy (after first relapse)	Lenalidomide		Patient decision	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					232	257	1
MMRF_2557	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		10	Other	OVER 3 MINUTES FOR 1 DAY					131	222	1
MMRF_2557	Second Line Therapy (after first relapse)	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Induction	Induction		20	Other	DAYS 1, 8, 15					251	264	1
MMRF_2087	First line of therapy	Lenalidomide		MEDICATION IS ON HOLD DUE TO PATIENT'S NAUSEA	mg	PO	Log Forms	Induction	Induction		10	Other	3 WEEKS ON 1 WEEK OFF					1	26	1
MMRF_2087	First line of therapy	Dexamethasone		INCREASED DOSAGE	mg	PO	Log Forms	Induction	Induction		20	QWK	QWK					1	165	1
MMRF_2087	First line of therapy	Lenalidomide		MEDICATION HOLD/CHEMO INDUCED NEUTROPENIA	mg	PO	Log Forms	Induction	Induction		10	Q day	Q day					58	86	1
MMRF_2087	First line of therapy	Lenalidomide		REDUCED DOSE/ 5 MG EVERY OTHER DAY	mg	PO	Log Forms	Induction	Induction		5	Q day	Q day					103	130	1
MMRF_2087	First line of therapy	Lenalidomide		HELD BY PHYSICIAN FOR PT DEVELOPING SHINGLES; PLAN RESTART AFTER RECOVERY	mg	PO	Log Forms	Induction	Induction		5	Other	EVERY OTHER DAY					131	198	1
MMRF_2087	First line of therapy	Dexamethasone		HELD BY PHYSICIAN FOR PT DEVELOPING SHINGLES; PLAN RESTART AFTER RECOVERY	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					166	198	1
MMRF_2087	First line of therapy	Bortezomib		HELD BY PHYSICIAN FOR PT DEVELOPING SHINGLES; PLAN RESTART AFTER RECOVERY	mg	SUBQ	Log Forms	Induction	Induction		2.34	Other	QD (1, 4, 8, 15)					165	198	1
MMRF_2087	Second Line Therapy (after first relapse)	Lenalidomide		COVERING DOCTOR HELD MEDICATION	mg	PO	Log Forms	Induction	Induction		5	Other	EVERY OTHER DAY					208	229	1
MMRF_2087	Second Line Therapy (after first relapse)	Bortezomib		Lack of response	mg	SUBQ	Log Forms	Induction	Induction		2.2	Q week	Q week					208	249	1
MMRF_2087	Second Line Therapy (after first relapse)	Dexamethasone		DOCTOR COVERING: REDUCED DOSE TO 20 MG QWK	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					208	229	1
MMRF_2087	Second Line Therapy (after first relapse)	Dexamethasone		BEGAN HOSPICE CARE STRICT PALLIATIVE CARE ONLY WITHOUT CHEMOTHERAPY	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					230	261	1
MMRF_2087	Second Line Therapy (after first relapse)	Carfilzomib		COVERING DOCTOR INCREASED DOSAGE TO 45 MG	mg	IV	Log Forms	Induction	Induction		35	Other	DAY 1, DAY 2 OF EVERY WEEK, 3 WEEKS ON, 1 WEEK OFF					249	256	1
MMRF_2087	Second Line Therapy (after first relapse)	Carfilzomib		BEGAN HOSPICE CARE STRICT PALLIATIVE CARE ONLY WITHOUT CHEMOTHERAPY	mg	IV	Log Forms	Induction	Induction		45	Other	DAY 1, DAY 2 OF EVERY WEEK, 3 WEEKS ON, 1 WEEK OFF					256	261	1
MMRF_2141	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		100	Q day	Q day					268	299	1
MMRF_2141	First line of therapy	Bortezomib		HOLD VELCADE: EVAL FOR AUTOLOGOUS TRANSPLANT	mg	SUBQ	Log Forms	Induction	Induction		2.67	Q week	Q week					3	175	1
MMRF_2141	First line of therapy	Dexamethasone		DECREASE DOSE TO 20 MG TO MINIMIZE SIDE EFFECTS	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	175	1
MMRF_2141	First line of therapy	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	20	Q week	Q week					176		1
MMRF_2141	Second Line Therapy (after first relapse)	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	25	Other	DAILY FOR 14 DAYS WITH 7 DAY REST PERIOD					1837		1
MMRF_2141	Second Line Therapy (after first relapse)	Bortezomib			mg	SC	Log Forms	Maintenance	Maintenance	Checked	2.7	Q week	Q week					1837		1
MMRF_2141	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		40	Q week	Q week					1837	1864	1
MMRF_2141	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Maintenance	Maintenance	Checked	20	Q week	Q week					1865		1
MMRF_2149	First line of therapy	Bortezomib		Patient decision	mg	SUBQ	Log Forms	Induction	Induction		2.27	Q week	Q week					1	163	1
MMRF_2149	First line of therapy	Dexamethasone		Patient decision	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	163	1
MMRF_2153	First line of therapy	Bortezomib		Disease progression/Relapse	mg	SUBQ	Log Forms	Induction	Induction		2	Q week	Q week					3	382	1
MMRF_2153	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					1	382	1
MMRF_2153	Second Line Therapy (after first relapse)	Lenalidomide		PATIENT LOST TO FOLLOW-UP AFTER THIS CYCLE, MOVED TO DIFFERENT CITY	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					393	584	1
MMRF_2191	Seventh Line of Therapy (following 6th relapse)	Dexamethasone			mg	PO	Log Forms	Maintenance	Maintenance	Checked	20	Q week	Q week					2170		1
MMRF_2191	Seventh Line of Therapy (following 6th relapse)	Bortezomib			mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance	Checked	1.3	Q week	Q week					2170		1
MMRF_2191	Seventh Line of Therapy (following 6th relapse)	Panobinostat			mg	PO	Log Forms	Maintenance	Maintenance	Checked	20	Other	DAYS 1, 3, 5, 8, 10, AND 12					2151		1
MMRF_2191	Fifth Line Therapy (following 4th relapse)	Elotuzumab		Adverse Event or co-morbidity	mg	IV	Log Forms	Maintenance	Maintenance		1200	Q week	Q week					1856	1877	1
MMRF_2191	Fifth Line Therapy (following 4th relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		28	Q week	Q week					1855	1876	1
MMRF_2191	Fifth Line Therapy (following 4th relapse)	Pomalidomide		Lack of response	mg	PO	Log Forms	Maintenance	Maintenance		4	QD (D1-21)	QD (D1-21)					1856	1939	1
MMRF_2191	Fifth Line Therapy (following 4th relapse)	Dexamethasone		Lack of response	mg	PO	Log Forms	Maintenance	Maintenance		20	Q week	Q week					1891	1939	1
MMRF_2191	Sixth Line Therapy (following 5th relapse)	SELINEXOR		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		80	Other	TWICE WEEKLY					1968	2129	1
MMRF_2191	Sixth Line Therapy (following 5th relapse)	Dexamethasone			mg	PO	Log Forms	Maintenance	Maintenance	Checked	20	Other	TWICE WEEKLY WITH SELINEXOR					1968		1
MMRF_2191	First line of therapy	Bortezomib		Investigator decision for other reasons	mg	SUBQ	Log Forms	Induction	Induction		3	QWK	QWK					1	135	1
MMRF_2191	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	379	1
MMRF_2191	First line of therapy	Bortezomib		Investigator decision for other reasons	mg	SUBQ	Log Forms	Maintenance	Maintenance		2.6	Q week	Q week					141	268	1
MMRF_2191	First line of therapy	Bortezomib		Disease progression/Relapse	mg	SUBQ	Log Forms	Maintenance	Maintenance		2.6	Q week	Q week					287	352	1
MMRF_2191	Second Line Therapy (after first relapse)	Carfilzomib		Investigator decision for other reasons	mg	IV	Log Forms	Maintenance	Maintenance		96	QWK	QWK					581	689	1
MMRF_2191	Second Line Therapy (after first relapse)	Lenalidomide		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		25	QD (D1-21)	QD (D1-21)					568	694	1
MMRF_2191	Third Line Therapy (following 2nd relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Maintenance	Maintenance		8	Other	D1-2 Q28D					868	1211	1
MMRF_2191	Third Line Therapy (following 2nd relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		20	QD (D1-21)	QD (D1-21)					868	1291	1
MMRF_2191	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Maintenance	Maintenance		20	Other	DAY 2, Q28D CYCLE					869	1291	1
MMRF_2191	Fourth Line Therapy (following 3rd relapse)	MELFLUFEN (OP-103)	NCT03151811	Adverse Event or co-morbidity	mg	IV	Log Forms	Maintenance	Maintenance		40	Other	Q4W					1353	1780	1
MMRF_2191	Fourth Line Therapy (following 3rd relapse)	Dexamethasone	NCT03151811	Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		40	Q week	Q week					1353	1780	1
MMRF_2228	First line of therapy	Bortezomib		Completed regimen	mg	SUBQ	Log Forms	Induction	Induction		3.5	Q week	Q week					1	406	1
MMRF_2228	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	392	1
MMRF_2301	First line of therapy	Bortezomib		Completed regimen	mg	SUBQ	Log Forms	Induction	Induction		2.9	Q week	Q week					1	157	1
MMRF_2301	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	WITH BORTEZOMIB					1	157	1
MMRF_2301	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		20	QD (D1-21)	QD (D1-21)					1122	1284	1
MMRF_2301	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		20	Q week	Q week					1122	1284	1
MMRF_1766	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					1	155	1
MMRF_1766	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO	Log Forms	Induction	Induction		300	Q week	Q week					1	155	1
MMRF_1766	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	22	1
MMRF_1766	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					22	155	1
MMRF_1766	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Other	PRIMING CHEMOTHERAPY		8440	Other	ONCE					185	185	1
MMRF_1766	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	PREP REGIMEN		410	Other	ONCE					217	217	1
MMRF_1766	First line of therapy	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	Q2W					339	989	1
MMRF_1766	Second Line Therapy (after first relapse)	SELINEXOR			mg	PO	Log Forms	Induction	Induction	Checked	60	Q week	Q week					1066		1
MMRF_1766	Second Line Therapy (after first relapse)	Lenalidomide			mg	PO	Log Forms	Induction	Induction	Checked	25	QD (D1-21)	QD (D1-21)					1066		1
MMRF_1766	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	20	Q week	Q week					1066		1
MMRF_1824	First line of therapy	Carfilzomib		Completed regimen	mg	IV	Log Forms	Induction	Induction		42	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	163	1
MMRF_1824	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO	Log Forms	Induction	Induction		300	Other	QD (D1, D8, D15)					1	162	1
MMRF_1824	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	162	1
MMRF_1824	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	PREP REGIMEN		255	Other	ONCE					220	220	1
MMRF_1824	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					325	430	1
MMRF_1824	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	5	Q day	Q day					430		1
MMRF_1879	First line of therapy	Bortezomib		PATIENT INABLE TO COMPLY WITH TREATMENT	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Other	QD (D1, D8, D15)					1	225	1
MMRF_1879	First line of therapy	Cyclophosphamide		PATIENT INABLE TO COMPLY WITH TREATMENT	mg/m^2	PO	Log Forms	Induction	Induction		300	Other	QD (D1, D8, D15)					1	225	1
MMRF_1879	First line of therapy	Dexamethasone		PATIENT INABLE TO COMPLY WITH TREATMENT	mg	PO	Log Forms	Induction	Induction		40	Other	QD (D1, D8, D15)					1	225	1
MMRF_2006	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	102	1
MMRF_2006	First line of therapy	PLERIXAFOR		Completed regimen	mg	IV SubQ	Log Forms	Other	PRIMING CHEMOTHERAPY		27	Other	ONCE					121	121	1
MMRF_2006	First line of therapy	PLERIXAFOR		Completed regimen	mg	IV SubQ	Log Forms	Other	PRIMING CHEMOTHERAPY		24	Q day	Q day					122	123	1
MMRF_2006	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	PRIMING CHEMOTHERAPY		440	Other	ONCE					127	127	1
MMRF_2006	First line of therapy	Bortezomib			mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance	Checked	1.3	Other	EVERY OTHER WEEK					232		1
MMRF_2006	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Other	QD (D1, D8, D15)					7	102	1
MMRF_2006	First line of therapy	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Induction	Induction		700	Q week	Q week					1	102	1
MMRF_2047	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	162	1
MMRF_2047	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO	Log Forms	Induction	Induction		300	Other	QD (D1, D8, D15)					1	162	1
MMRF_2047	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	QD (D1, D8, D15, D22)					1	162	1
MMRF_2047	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Other	ONCE					185	185	1
MMRF_2047	First line of therapy	Bortezomib			mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance	Checked	1.3	Other	EVERY OTHER WEEK					288		1
MMRF_2116	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	99	1
MMRF_2116	First line of therapy	Cyclophosphamide		Adverse Event or co-morbidity	mg/m^2	PO	Log Forms	Induction	Induction		300	Other	D1, D8, D15					1	99	1
MMRF_2116	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	Other	D1, D8, D15, D21					1	99	1
MMRF_2116	First line of therapy	Dexamethasone		WENT TO TRANSPLANT	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					107	190	1
MMRF_2116	First line of therapy	Lenalidomide		WENT TO TRANSPLANT	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					107	190	1
MMRF_2116	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		420	Other	ONCE					226	226	1
MMRF_2116	First line of therapy	Lenalidomide		Patient decision	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					303	487	1
MMRF_2116	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					631	639	1
MMRF_2116	First line of therapy	Bortezomib			mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance	Checked	1.3	Other	EVERY OTHER WEEK					729		1
MMRF_2201	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Other	QD (D1, D8, D15)					1	8	1
MMRF_2201	First line of therapy	Cyclophosphamide		Adverse Event or co-morbidity	mg/m^2	PO	Log Forms	Induction	Induction		300	Other	QD (D1, D8, D15)					1	8	1
MMRF_2201	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	Other	QD (D1, D8, D15)					1	8	1
MMRF_2232	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	57	1
MMRF_2232	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	50	1
MMRF_2232	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	QD (D1, D2, D4, D5, D8, D9, D11, D12)					1	53	1
MMRF_2232	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Other	PRIMING CHEMOTHERAPY		3000	Other	ONCE					80	80	1
MMRF_2232	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	PREP REGIMEN		200	Other	ONCE					99	99	1
MMRF_2232	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					176	207	1
MMRF_2232	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-14)	QD (D1-14)					176	207	1
MMRF_2232	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		10	Other	QD (D1, D2, D4, D5, D8, D9, D11, D12)					176	207	1
MMRF_2232	First line of therapy	Lenalidomide		PER PROTOCOL DOSE INCREASED	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					227	310	1
MMRF_2232	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		15	Q day	Q day					311	380	1
MMRF_2232	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	Q day	Q day					381		1
MMRF_2425	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					1	225	1
MMRF_2425	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO	Log Forms	Induction	Induction		300	Q week	Q week					1	225	1
MMRF_2425	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	225	1
MMRF_2425	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Other	ONCE					232	232	1
MMRF_2425	First line of therapy	Lenalidomide		INCREASED DOSE	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					344	521	1
MMRF_2425	First line of therapy	Lenalidomide		PT WAS ON LEANALIDOMIDE MAINTENANCE UP TO HOSPITAL ADMIT ON 5/22	mg	PO	Log Forms	Maintenance	Maintenance		15	Q day	Q day					521	812	1
MMRF_2440	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	84	1
MMRF_2440	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	QD (D1, D2, D4, D5, D8, D9, D11, D12)					1	84	1
MMRF_2440	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	84	1
MMRF_2440	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Other	PRIMING CHEMOTHERAPY		3000	Other	ONCE					88	88	1
MMRF_2440	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Other	ONCE					113	113	1
MMRF_2440	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Consolidation	Consolidation		1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					210	253	1
MMRF_2440	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		10	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					210	253	1
MMRF_2440	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-14)	QD (D1-14)					210	253	1
MMRF_2440	First line of therapy	Lenalidomide		INCREASED DOSE	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					259	349	1
MMRF_2440	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		15	Q day	Q day					350	462	1
MMRF_2440	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	Q day	Q day					463		1
MMRF_2485	First line of therapy	Bortezomib		WENT TO TRANSPLANT	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					1	238	1
MMRF_2485	First line of therapy	Cyclophosphamide		WENT TO TRANSPLANT	mg/m^2	IV	Log Forms	Induction	Induction		300	Q week	Q week					1	238	1
MMRF_2485	First line of therapy	Dexamethasone		WENT TO TRANSPLANT	mg	IV	Log Forms	Induction	Induction		40	Q week	Q week					1	238	1
MMRF_2485	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Other	ONCE					291	291	1
MMRF_2485	First line of therapy	Bortezomib			mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance	Checked	1.3	Other	EVERY OTHER WEEK					434		1
MMRF_2566	First line of therapy	Bortezomib		STOPPED FOR STEM CELL COLLECTION	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_2566	First line of therapy	Dexamethasone		STOPPED FOR STEM CELL COLLECTION	mg	PO	Log Forms	Induction	Induction		20	Other	QD (D1, D2, D4, D5, D8, D9, D11, D12)					1	74	1
MMRF_2566	First line of therapy	Lenalidomide		STOPPED FOR STEM CELL COLLECTION	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	57	1
MMRF_2566	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Other	PRIMING CHEMOTHERAPY		3000	Other	ONCE					74	74	1
MMRF_2566	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					123	221	1
MMRF_2566	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		10	Other	QD (D1, D2, D4, D5, D8, D9, D11, D12)					123	221	1
MMRF_2566	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					123	221	1
MMRF_2566	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	Q day	Q day					241		1
MMRF_2590	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	8	1
MMRF_2590	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	8	1
MMRF_2590	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	8	1
MMRF_2590	First line of therapy	Bortezomib		TOLERATED WELL, INCREASED DOSE	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					50	60	1
MMRF_2590	First line of therapy	Bortezomib		Patient decision	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					71	113	1
MMRF_2590	First line of therapy	Dexamethasone		Patient decision	mg	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					71	113	1
MMRF_2590	First line of therapy	Prednisone		Patient decision	mg	PO	Log Forms	Induction	Induction		60	Q week	Q week					113	120	1
MMRF_2590	First line of therapy	Prednisone		Adverse Event or co-morbidity	mg	INTRAMUSCULAR	Log Forms	Induction	Induction		62.5	Q week	Q week					113	127	1
MMRF_2590	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					113	127	1
MMRF_2590	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					192	199	1
MMRF_2590	First line of therapy	Prednisone		Lack of response	mg	INTRAMUSCULAR	Log Forms	Induction	Induction		62.5	Q week	Q week					192	253	1
MMRF_2590	First line of therapy	Bortezomib			mg/m^2	IV SubQ	Log Forms	Induction	Induction	Checked	1	Q week	Q week					199		1
MMRF_2622	First line of therapy	Bortezomib		STEM CELL COLLECTION	mg/m^2	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_2622	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	QD (D1, D2, D4, D5, D8, D9, D11, D12)					1	205	1
MMRF_2622	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	197	1
MMRF_2622	First line of therapy	Lenalidomide		DOSE CHANGED	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					205	288	1
MMRF_2622	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		15	Q day	Q day					288	316	1
MMRF_2622	First line of therapy	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	10	Q day	Q day					337		1
MMRF_2147	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	Q WEEK D1, D8 D15, D22					1	22	1
MMRF_2147	First line of therapy	Carfilzomib		Completed regimen	mg	IV	Log Forms	Induction	Induction		45	Other	D1 AND D2					1	2	1
MMRF_2147	First line of therapy	Carfilzomib		Completed regimen	mg	IV	Log Forms	Induction	Induction		36	Other	D 8, D9, D15, D16					12	16	1
MMRF_2147	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	21	1
MMRF_2147	First line of therapy	Carfilzomib		Completed regimen	mg	IV	Log Forms	Induction	Induction		78	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					29	274	1
MMRF_2147	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					29	280	1
MMRF_2147	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	D1, D8, D15, D22					29	281	1
MMRF_2147	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		15	Other	DAILY 3 WEEKS OUT OF 4					309	392	1
MMRF_2419	First line of therapy	Bortezomib		Lack of response	mg	IV	Log Forms	Induction	Induction		3.3	Other	WEEKLY D1,D8,D15,D21,D28					1	162	1
MMRF_2419	First line of therapy	Dexamethasone		PBSCT	mg	PO	Log Forms	Induction	Induction		40	Other	WEEKLY D1, D8,D15,D21,D28					1	274	1
MMRF_2419	First line of therapy	Cyclophosphamide		PBSCT	mg	PO	Log Forms	Induction	Induction		600	Other	WEEKLY D1, D8, D15, D21, D28					1	274	1
MMRF_2419	First line of therapy	Lenalidomide		PBSCT	mg	PO	Log Forms	Induction	Induction		25	Q day	Q day					162	274	1
MMRF_2419	Second Line Therapy (after first relapse)	Dexamethasone		PBSCT	mg	PO	Log Forms	Induction	Induction		40	QWK	QWK					162	274	1
MMRF_2419	Second Line Therapy (after first relapse)	Carfilzomib		PBSCT	mg	IV	Log Forms	Induction	Induction		43.6	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					162	274	1
MMRF_2419	Second Line Therapy (after first relapse)	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	5	QD (D1-21)	QD (D1-21)					519		1
MMRF_2438	Fifth Line Therapy (following 4th relapse)	Bortezomib		Investigator decision for other reasons		IV	Log Forms	Other	PALLIATIVE			Other	ONCE					1157	1160	1
MMRF_2438	First line of therapy	Bortezomib		Completed regimen	mg	SUBCUTANEOUSLY	Log Forms	Induction	Induction		2.93	Other	D1, D8, D15, AND D22					1	106	1
MMRF_2438	First line of therapy	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Induction	Induction		500	Other	D1,D8, D15, AND D22					1	106	1
MMRF_2438	First line of therapy	Bortezomib		Disease progression/Relapse	MG/ML	IV SubQ	Log Forms	Maintenance	Maintenance		2.5	Q week	Q week					288	383	1
MMRF_2438	Second Line Therapy (after first relapse)	Carfilzomib		Patient decision	mg	IV	Log Forms	Induction	Induction		52	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					458	606	1
MMRF_2438	Second Line Therapy (after first relapse)	Lenalidomide		Patient decision	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					458	606	1
MMRF_2438	Second Line Therapy (after first relapse)	Dexamethasone		Patient decision	mg	IV	Log Forms	Induction	Induction		4	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					458	606	1
MMRF_2438	Third Line Therapy (following 2nd relapse)	Dexamethasone		Investigator decision for other reasons	mg	IV SubQ	Log Forms	Unknown	Unknown		4	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					656	671	1
MMRF_2438	Third Line Therapy (following 2nd relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Unknown	Unknown		40	QD (D1-4)	QD (D1-4)					684	694	1
MMRF_2438	Third Line Therapy (following 2nd relapse)	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Unknown	Unknown		1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					684	694	1
MMRF_2438	Third Line Therapy (following 2nd relapse)	CISPLATIN		Completed regimen	mg/m^2	IV	Log Forms	Unknown	Unknown		10	QD (D1-4)	QD (D1-4)					684	694	1
MMRF_2438	Third Line Therapy (following 2nd relapse)	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Unknown	Unknown		400	QD (D1-4)	QD (D1-4)					684	694	1
MMRF_2438	Third Line Therapy (following 2nd relapse)	ETOPOSIDE		Completed regimen	mg/m^2	IV	Log Forms	Unknown	Unknown		40	QD (D1-4)	QD (D1-4)					684	694	1
MMRF_2438	Third Line Therapy (following 2nd relapse)	Doxorubicin		Completed regimen	mg/m^2	IV	Log Forms	Unknown	Unknown		10	QD (D1-4)	QD (D1-4)					684	694	1
MMRF_2438	Third Line Therapy (following 2nd relapse)	Daratumumab		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		1300	Other	QWEEK (W1-8) Q2WEEKS (W9-24)					739	866	1
MMRF_2438	Third Line Therapy (following 2nd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		4	Other	QD (D1-28)					739	866	1
MMRF_2438	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		4	Other	QAM (D2, D3, FOLLOWING DARA INFUSION)					739	866	1
MMRF_2438	Fourth Line Therapy (following 3rd relapse)	Cyclophosphamide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		300	Other	QD (D1, D8, D15; EVERY 28 DAY CYCLE)					929	1072	1
MMRF_2438	Fourth Line Therapy (following 3rd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		2	QD (D1-21)	QD (D1-21)					929	1072	1
MMRF_2438	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		40	Q week	Q week					929	1072	1
MMRF_2438	Fifth Line Therapy (following 4th relapse)	CISPLATIN		Investigator decision for other reasons			Log Forms	Other	PALLIATIVE			Other	ONCE					1157	1160	1
MMRF_2438	Fifth Line Therapy (following 4th relapse)	Cyclophosphamide		Investigator decision for other reasons			Log Forms	Other	PALLIATIVE			Other	ONCE					1157	1160	1
MMRF_2438	Fifth Line Therapy (following 4th relapse)	ETOPOSIDE		Investigator decision for other reasons			Log Forms	Other	PALLIATIVE			Other	ONCE					1157	1160	1
MMRF_2438	Fifth Line Therapy (following 4th relapse)	Doxorubicin		Investigator decision for other reasons			Log Forms	Other	PALLIATIVE			Other	ONCE					1157	1160	1
MMRF_2517	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Other	ONCE					170	170	1
MMRF_2517	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	EVERY 7 DAYS					1	120	1
MMRF_2517	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		3.2	Other	Q D1, D8, D15, AND D22					1	106	1
MMRF_2517	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	Q day	Q day					1	120	1
MMRF_2517	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					260	673	1
MMRF_2573	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					1	268	1
MMRF_2573	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		4	Other	QD DAY 2, DAY 9, AND DAY16					2	268	1
MMRF_2573	First line of therapy	Carfilzomib		Completed regimen	mg	IV	Log Forms	Induction	Induction		40	Other	QD DAY 1 AND DAY 2					1	2	1
MMRF_2573	First line of therapy	Carfilzomib		Completed regimen	mg	IV	Log Forms	Induction	Induction		27	Other	QD DAY 8 , DAY 9, DAY 15, AND DAY 16					8	268	1
MMRF_2573	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	268	1
MMRF_2573	First line of therapy	Lenalidomide		Patient decision	mg	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					284	979	1
MMRF_2573	First line of therapy	Daratumumab			mg	IV	Log Forms	Unknown	Unknown	Checked	1300	Q week	Q week					981		1
MMRF_2573	First line of therapy	Dexamethasone			mg	PO	Log Forms	Unknown	Unknown	Checked	8	Other	Q WEEK (D2, D3; WITH DARA BEING INFUSED ON D1)					982		1
MMRF_2597	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	QD DAYS 1,8,15,AND 22					1	106	1
MMRF_2597	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		2.85	Other	QD DAYS 1,8,15, AND 22					1	106	1
MMRF_2597	First line of therapy	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Induction	Induction		600	Other	QD DAYS 1,8, 15, AND 22					1	106	1
MMRF_2597	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		40	Q day	Q day					261	288	1
MMRF_2597	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					261	288	1
MMRF_2597	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					290	988	1
MMRF_2597	First line of therapy	Melphalan		Completed regimen	mg		Log Forms				350							147	513	1
MMRF_2608	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg	IV	Log Forms	Induction	Induction		2.9	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					4	105	1
MMRF_2608	First line of therapy	Cyclophosphamide		DOES REDUCED	mg	PO	Log Forms	Induction	Induction		500	Other	QD D1, D4, D8, D11					4	105	1
MMRF_2608	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		40	Other	QD (D1-4, D9-13, D17-21)					1	33	1
MMRF_2608	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					44	326	1
MMRF_2608	First line of therapy	Cyclophosphamide		CONCERNS WORSENING HEART FAILURE	mg	PO	Log Forms	Induction	Induction		400	Q week	Q week					168	326	1
MMRF_2608	Second Line Therapy (after first relapse)	Lenalidomide			mg	PO	Log Forms	Unknown	Unknown	Checked	15	QD (D1-21)	QD (D1-21)					986		1
MMRF_2608	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		8	Other	D1, D8, D15					986	1064	1
MMRF_2608							Log Forms													1
MMRF_2223	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	158	1
MMRF_2223	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	22	1
MMRF_2223	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					22	176	1
MMRF_2223	First line of therapy	Bortezomib		BORTEZOMIB CONTINUED, BUT DOSAGE WAS HANGED	mg/m^2	IV	Log Forms	Maintenance	Maintenance		1.3	Other	DAY 1 AND DAY 15					447	603	1
MMRF_2223	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	20	Other	Q2W					1757		1
MMRF_2223	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		10	Other	Q2W					1462	1757	1
MMRF_2223	First line of therapy	Dexamethasone		INCREASING DOSAGE	mg	PO	Log Forms	Induction	Induction		4	QD (D1-14)	QD (D1-14)					433	1462	1
MMRF_2223	First line of therapy	Bortezomib		REDUCING DOSAGE	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Other	DAY 1 AND DAY 15					629	1757	1
MMRF_2223	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1-21)	QD (D1-21)					433	629	1
MMRF_2223	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		5	QD (D1-21)	QD (D1-21)					176	237	1
MMRF_2223	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					43	176	1
MMRF_2568	Second Line Therapy (after first relapse)	Bortezomib		Completed regimen	mg	IV	Log Forms	Induction	Induction		2.5	QD (D1-14)	QD (D1-14)					1481	1634	1
MMRF_2568	Second Line Therapy (after first relapse)	Daratumumab		Completed regimen	mg	IV	Log Forms	Induction	Induction		1200	QD (D1-14)	QD (D1-14)					1481	1634	1
MMRF_2568	First line of therapy	Lenalidomide		PATIENT DEVELOPED MDS AND COULD NOT CONTINUE ON REVLIMID.	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	757	1
MMRF_2568	First line of therapy	Dexamethasone		D/C AFTER TRANSPLANT	mg	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	159	1
MMRF_2568	First line of therapy	Melphalan		Completed regimen	mg	IVB	Log Forms	Unknown	Unknown		270	Other	ONCE					169	169	1
MMRF_1833	Third Line Therapy (following 2nd relapse)	Daratumumab			mg	IV	Log Forms	Maintenance	Maintenance	Checked	1224	Other	Q28 DAY					2209		1
MMRF_1833	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg	IV	Log Forms	Induction	Induction		2.85	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					8	162	1
MMRF_1833	First line of therapy	Carfilzomib		Completed regimen	mg	IV	Log Forms	Consolidation	Consolidation		43	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					176	360	1
MMRF_1833	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	QD (D1-7)	QD (D1-7)					1	44	1
MMRF_1833	Second Line Therapy (after first relapse)	Pomalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		4	QD (D1-21)	QD (D1-21)					1009	2551	1
MMRF_1833	First line of therapy	Dexamethasone			mg	PO	Log Forms	Maintenance	Maintenance	Checked	20	QWK	QWK					8		1
MMRF_2196	First line of therapy	Bortezomib		Completed regimen	mg	IV	Log Forms	Induction	Induction		3.08	Other	D1, D8, D15, D22					1	134	1
MMRF_2196	First line of therapy	Cyclophosphamide		Investigator decision for other reasons	mg	PO	Log Forms	Unknown	Unknown		50	Other	DAY 1, 8, 15, 22					1	126	1
MMRF_2196	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Unknown	Unknown		40	Q week	Q week					1	126	1
MMRF_2196	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					406	1050	1
MMRF_2196	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					196	198	1
MMRF_2196	Second Line Therapy (after first relapse)	Pomalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Unknown	Unknown		4	Other	QD FOR 21 DAYS					1073	1121	1
MMRF_2196	Second Line Therapy (after first relapse)	Daratumumab		Disease progression/Relapse	mg	IV	Log Forms	Unknown	Unknown		1500	Q week	Q week					1086	1319	1
MMRF_2196	Second Line Therapy (after first relapse)	Pomalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Unknown	Unknown		3	Other	QD FOR 21 DAYS					1122	1242	1
MMRF_2196	Second Line Therapy (after first relapse)	Dexamethasone		PATIENT PASSED	mg	IV	Log Forms	Unknown	Unknown		40	Other	PRN					1086	1412	1
MMRF_2196	Second Line Therapy (after first relapse)	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Unknown	Unknown		40	Q week	Q week					1086	1383	1
MMRF_2196	Third Line Therapy (following 2nd relapse)	Pomalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		2	QD (D1-21)	QD (D1-21)					1243	1270	1
MMRF_2196	Third Line Therapy (following 2nd relapse)	Pomalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		1	QD (D1-21)	QD (D1-21)					1278	1399	1
MMRF_2196	Fourth Line Therapy (following 3rd relapse)	Carfilzomib		DOSE CHANGE	mg	IV	Log Forms	Maintenance	Maintenance		36.6	Q day	Q day					1347	1361	1
MMRF_2196	Fourth Line Therapy (following 3rd relapse)	Carfilzomib		Investigator decision for other reasons	mg	IV	Log Forms	Maintenance	Maintenance		53.46	Q day	Q day					1361	1383	1
MMRF_2054	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Other	DAYS # 1,8,15,+ 22					1	227	1
MMRF_2054	First line of therapy	Cyclophosphamide		Lack of response	mg/m^2	IVB	Log Forms	Induction	Induction		750	Other	Q DAY #1 ONLY					1	85	1
MMRF_2054	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	DAYS 1,8,15 + 22					1	576	1
MMRF_2054	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					85	227	1
MMRF_2054	Second Line Therapy (after first relapse)	Carfilzomib		Completed regimen	mg	IV	Log Forms	Unknown	Unknown		40	Other	D 1, 2, 8 & 15					401	576	1
MMRF_2054	Second Line Therapy (after first relapse)	Pomalidomide		Completed regimen	mg	PO	Log Forms	Other	REFRACTORY DISEASE		4	QD (D1-21)	QD (D1-21)					401	576	1
MMRF_2054	Second Line Therapy (after first relapse)	Ixazomib		Investigator decision for other reasons	mg	PO	Log Forms	Other	SALVAGE		4	Other	Q D1, D8, D15					730	933	1
MMRF_2054	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Other	SALVAGE		4	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					730	1291	1
MMRF_2054	Second Line Therapy (after first relapse)	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Other	SALVAGE		25	QD (D1-21)	QD (D1-21)					730	933	1
MMRF_2054	Second Line Therapy (after first relapse)	Lenalidomide		CHANGE TO 15MG DOSE	mg	PO	Log Forms	Maintenance	Maintenance		20	QD (D1-21)	QD (D1-21)					934	1059	1
MMRF_2054	Second Line Therapy (after first relapse)	Ixazomib		CHANGE DOSE TO 2.3	mg	PO	Log Forms	Maintenance	Maintenance		3	Other	Q D1, D8, D15					934	1059	1
MMRF_2054	Second Line Therapy (after first relapse)	Ixazomib		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		2.3	Other	Q D1, D8, D15 OF 28 DAY CYCLE					1059	1800	1
MMRF_2054	Second Line Therapy (after first relapse)	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	15	QD (D1-21)	QD (D1-21)					1059		1
MMRF_2054	Second Line Therapy (after first relapse)	Ixazomib			mg	PO	Log Forms	Maintenance	Maintenance	Checked	2.3	Other	Q1, 8, 15					1800		1
MMRF_2054	First line of therapy	Melphalan		MEPHALAN AND STEM CELL REINFUSION	mg	IV	Log Forms	Unknown	Unknown		380	Other	ONCE					288	288	1
MMRF_2062	First line of therapy	Dexamethasone		PATIENT DID NOT KEEP APPOINTMENTS	mg	IV	Log Forms	Induction	Induction		40	Other	DAYS 1,8,15, AND 22					1	472	1
MMRF_2062	First line of therapy	Bortezomib		PATIENT FAILED TO COME FOR APPOINTMENTS	mg	IV SubQ	Log Forms	Induction	Induction		2.9	Other	DAYS # 1,8,15, + 22					1	472	1
MMRF_2171	First line of therapy	Bortezomib		Completed regimen	mg/m^2	SUBQ	Log Forms	Induction	Induction		1.5	QWK	QWK					1	120	1
MMRF_2171	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		750	Other	DAY 1 OF EACH CYCLE					1	95	1
MMRF_2171	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	95	1
MMRF_2171	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		5	Other	DAILY FOR 21 DAYS, THEN NONE FOR 1 WEEK					287	1997	1
MMRF_2171	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	PRE-TRANSPLANT		200	Other	ONCE					169	169	1
MMRF_2181	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	SUBQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	304	1
MMRF_2181	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	IV	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	304	1
MMRF_2181	First line of therapy	Cyclophosphamide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		500	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					42	155	1
MMRF_2181	First line of therapy	Lenalidomide			mg	PO	Log Forms	Induction	Induction	Checked	5	QD (D1-21)	QD (D1-21)					318		1
MMRF_2222	Third Line Therapy (following 2nd relapse)	Daratumumab			mg	IV	Log Forms	Maintenance	Maintenance	Checked	1800	QD (D1-14)	QD (D1-14)					2235		1
MMRF_2222	Third Line Therapy (following 2nd relapse)	Daratumumab		Adverse Event or co-morbidity	mg	IV	Log Forms	Maintenance	Maintenance		1800	Other	Q28 DAY					2116	2144	1
MMRF_2222	Third Line Therapy (following 2nd relapse)	Lenalidomide			mg	PO	Log Forms	Maintenance	Maintenance	Checked	5	QD (D1-21)	QD (D1-21)					2105		1
MMRF_2222	Second Line Therapy (after first relapse)	Daratumumab		Adverse Event or co-morbidity	mg	IV	Log Forms	Maintenance	Maintenance		1800	Other	EVERY 4 WEEKS					1878	1906	1
MMRF_2222	First line of therapy	CARMUSTINE		Completed regimen	mg/m^2	IV	Log Forms	Other	PRE BONE MARROW TRANSPLANT		500	Other	ONCE					1958	1958	1
MMRF_2222	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	PRE-BONE MARROW TRANSPLANT		200	Other	ONCE					1960	1960	1
MMRF_2222	First line of therapy	Cyclophosphamide		Investigator decision for other reasons	mg	IV	Log Forms	Induction	Induction		1665	Other	ONE TIME					1	1	1
MMRF_2222	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Induction	Induction		4	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1	106	1
MMRF_2222	First line of therapy	Bortezomib		Completed regimen	mg	SUBCU	Log Forms	Induction	Induction		3.33	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1	106	1
MMRF_2222	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Unknown	Unknown		400	Other	ONE TIME					153	153	1
MMRF_2222	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					258	915	1
MMRF_2222	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					915	1666	1
MMRF_2222	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		25	QD (D1-21)	QD (D1-21)					1666	1724	1
MMRF_2222	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		20	Q week	Q week					1688	1990	1
MMRF_2222	Second Line Therapy (after first relapse)	Daratumumab		Completed regimen	mg	IV	Log Forms	Maintenance	Maintenance		1800	Other	EVERY OTHER WEEK					1689	1878	1
MMRF_2222	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					1766	2070	1
MMRF_2286	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		3	Other	DAYS 1, 8, 15, 22					1	110	1
MMRF_2286	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Induction	Induction		1507	Other	DAYS 1, 8, 15, 22					1	110	1
MMRF_2286	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	DAYS 1, 8, 15, 22					1	110	1
MMRF_2286	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	PRIOR TO STEM CELL TRANSPLANT		200	Q day	Q day					342	342	1
MMRF_2286	First line of therapy	Lenalidomide		UNKNOWN, OCCURRED DURING HOSPITAL STAY	mg	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					473	920	1
MMRF_2286	First line of therapy	Lenalidomide		DEATH	mg	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					985	1069	1
MMRF_2507	First line of therapy	Bortezomib		CARE TRANSFERRED TO ANOTHER FACILITY	mg	IV SubQ	Log Forms	Induction	Induction		2.2	Other	EVERY 3RD DAY					1	162	1
MMRF_2507	First line of therapy	Prednisone		MOVED TREATMENT TO ANOTHER FACILITY	mg	IV	Log Forms	Induction	Induction		40	Other	EVERY THIRD DAY					1	162	1
MMRF_2507	First line of therapy	Cyclophosphamide		PT BEING FOLLOWED AT ANOTHER FACILITY	mg	IV	Log Forms	Induction	Induction		1257	Other	EVERY 3 WEEKS					28	162	1
MMRF_2507	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					171	324	1
MMRF_2507	First line of therapy	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	40	Q week	Q week					171		1
MMRF_2507	First line of therapy	Bortezomib			mg/m^2	IV SubQ	Log Forms	Induction	Induction	Checked	2.2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					328		1
MMRF_2126	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg	IV SubQ	Log Forms	Induction	Induction		3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	36	1
MMRF_2126	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	249	1
MMRF_2126	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	36	1
MMRF_2126	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg	IV SubQ	Log Forms	Induction	Induction		2.8	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					92	117	1
MMRF_2126	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg	IV SubQ	Log Forms	Induction	Induction		2.2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					134	246	1
MMRF_2126	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		20	Other	Q WEEK 3 WEEKS ON 1 WEEK OFF					330	543	1
MMRF_2126	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					330	551	1
MMRF_2339	First line of therapy	Bortezomib		CHANGE IN DOSE	mg	IV SubQ	Log Forms	Induction	Induction		2.2	Q week	Q week					1	50	1
MMRF_2339	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	162	1
MMRF_2339	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	162	1
MMRF_2339	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Unknown	Unknown		200	Other	ONCE FOR STEM CELL TRANSPLANT					214	214	1
MMRF_2339	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Unknown	Unknown	Checked	20	Q week	Q week					2308		1
MMRF_2339	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		2.3	Q week	Q week					57	162	1
MMRF_2339	Second Line Therapy (after first relapse)	Lenalidomide			mg	PO	Log Forms	Unknown	Unknown	Checked	15	Q day	Q day					2308		1
MMRF_2339	Second Line Therapy (after first relapse)	Bortezomib			mg	IV SubQ	Log Forms	Unknown	Unknown	Checked	2.4	QWK	QWK					2308		1
MMRF_2114	First line of therapy	Bortezomib		TX D'CED BECAUSE PT IS GOING FOR STEM CELL HARVEST ON 1/13 -1/14/15	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					1	134	1
MMRF_2114	First line of therapy	Dexamethasone		TX D'CED BECAUSE PT IS GOING FOR STEM CELL HARVEST ON 1/13 -1/14/15	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	134	1
MMRF_2114	First line of therapy	Lenalidomide		DOSE REDUCED DUE TO NEUTROPENIA	mg	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	36	1
MMRF_2114	First line of therapy	Cyclophosphamide		CYTOXAN WAS REPLACED WITH REVLIMID WHILE WAITING TO SCHEDULE FOR TRANSPLANT	mg/m^2	IV	Log Forms	Induction	Induction		300	Other	WEEKLY 3/4 WEEKS					109	134	1
MMRF_2114	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					235	235	1
MMRF_2114	First line of therapy	Lenalidomide		TX DCED IN PREP FOR POSSIBLE TRANSPLANT	mg	PO	Log Forms	Unknown	Unknown		15	QD (D1-14)	QD (D1-14)					37	85	1
MMRF_2114	First line of therapy	Carfilzomib		TREATMENT WAS INTERRUPTED DUE TO RIGHT BREAST MASTITIS.	mg/m^2	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					169	177	1
MMRF_2114	First line of therapy	Carfilzomib		TX WAS HELD BECAUSE PT GOING FOR ASCTX ON 4/7/15	mg/m^2	IV	Log Forms	Induction	Induction		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					189	218	1
MMRF_2114	First line of therapy	Lenalidomide		TREATMENT WAS INTERRUPTED DUE TO RIGHT BREAST MASTITIS & DUE TO CYTOPENIAS	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					169	179	1
MMRF_2114	First line of therapy	Dexamethasone		TREATMENT WAS INTERRUPTED DUE TO RIGHT BREAST MASTITIS.	mg	PO	Log Forms	Induction	Induction		20	QWK	QWK					169	177	1
MMRF_2114	First line of therapy	Bortezomib		D'CED DUE TO WORSENING OF NEUROPATHY	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	QWK	QWK					351	383	1
MMRF_2114	First line of therapy	Lenalidomide		MS MD DECIDED TO DOSE REDUCED DUE TO DIARRHEA & INCREASE IN NEUROPATHY	mg	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					351	635	1
MMRF_2114	First line of therapy	Dexamethasone		DOSE REDUCED WITH THE NEW REGIMEN	mg	PO	Log Forms	Maintenance	Maintenance		40	QWK	QWK					351	383	1
MMRF_2114	First line of therapy	Dexamethasone		TX WAS HELD BECAUSE PT GOING FOR ASCTX ON 4/7/15	mg	PO	Log Forms	Induction	Induction		20	QWK	QWK					189	211	1
MMRF_2114	First line of therapy	Lenalidomide		TX WAS HELD BECAUSE PT GOING FOR ASCTX ON 4/7/15	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					204	224	1
MMRF_2114	First line of therapy	Dexamethasone		DOSE INCREASED DUE TO ADDITION OF MORE MEDS	mg	PO	Log Forms	Maintenance	Maintenance		20	QWK	QWK					393	1041	1
MMRF_2114	First line of therapy	Carfilzomib		DOSE INCREASED TO ACCOMODATE PATIENTS TRAVEL PLANS	mg/m^2	IV	Log Forms	Maintenance	Maintenance		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					393	475	1
MMRF_2114	First line of therapy	Carfilzomib		MD CHANGED REGIMEN TO 2 CONSECUTIVE DAYS EOW	mg/m^2	IV	Log Forms	Maintenance	Maintenance		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					481	796	1
MMRF_2114	First line of therapy	Lenalidomide		STOPPED DUE TO CHRONIC DIARRHEA	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					642	725	1
MMRF_2114	First line of therapy	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Maintenance	Maintenance		27	Other	2 CONSECUTIVE DAYS EOW FOR A 28 DAY CYCLE					817	887	1
MMRF_2114	Second Line Therapy (after first relapse)	Carfilzomib		CHANGED DUE TO URI & RIGHT BREST MASTITIS	mg/m^2	IV	Log Forms	Maintenance	Maintenance		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					908	1222	1
MMRF_2114	Second Line Therapy (after first relapse)	Elotuzumab		AFTER THIS DOSE, PT WILL BE SWITCHING OVER TO EOW	mg/kg	IV	Log Forms	Maintenance	Maintenance		10	QWK	QWK					1054	1111	1
MMRF_2114	Second Line Therapy (after first relapse)	Dexamethasone		CHANGED DUE TO URI & RIGHT BREST MASTITIS	mg	PO	Log Forms	Maintenance	Maintenance		40	QWK	QWK					1054	1222	1
MMRF_2114	Second Line Therapy (after first relapse)	Lenalidomide		DOSE REDUCED DUE TO DIARRHEA	mg	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					1062	1082	1
MMRF_2114	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					1083	1266	1
MMRF_2114	Second Line Therapy (after first relapse)	Elotuzumab		CHANGED DUE TO URI & RIGHT BREST MASTITIS	mg/kg	IV	Log Forms	Maintenance	Maintenance		10	Other	EOW					1111	1222	1
MMRF_2114	Second Line Therapy (after first relapse)	Elotuzumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Maintenance	Maintenance		10	Other	EOW					1237	1266	1
MMRF_2114	Second Line Therapy (after first relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Maintenance	Maintenance		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1237	1266	1
MMRF_2114	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		40	Other	WEEKLY FOR 3 OUT OF 4 WEEKS					1237	1266	1
MMRF_2114	Third Line Therapy (following 2nd relapse)	Daratumumab		Completed regimen	mg/kg	IV	Log Forms	Maintenance	Maintenance		16	QWK	QWK					1279	1328	1
MMRF_2114	Third Line Therapy (following 2nd relapse)	Dexamethasone		PATIENT TRANSFERRED HER CARE TO AN OUTSIDE INSTITUTION	mg	PO	Log Forms	Maintenance	Maintenance		20	Other	ONLY DAY AFTER TX					1280	1461	1
MMRF_2114	Third Line Therapy (following 2nd relapse)	Daratumumab		PATIENT TRANSFERRED HER CARE TO AN OUTSIDE INSTITUTION	mg/kg	IV	Log Forms	Maintenance	Maintenance		16	QWK	QWK					1335	1461	1
MMRF_2114	Second Line Therapy (after first relapse)	Elotuzumab		Adverse Event or co-morbidity	mg/kg	IV	Log Forms	Maintenance	Maintenance		10	Other	QOW					1125	1210	1
MMRF_2150	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		40	Other	EVERY FRI ON THE OFF WEEK					2131	2214	1
MMRF_2150	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Unknown	Unknown		40	Other	WEEKLY					2157	2214	1
MMRF_2150	Fourth Line Therapy (following 3rd relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Unknown	Unknown		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					2100	2214	1
MMRF_2150	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Unknown	Unknown		20	Other	EVERY FRI ON THE OFF WEEK					2094	2124	1
MMRF_2150	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Completed regimen	mg	IV	Log Forms	Unknown	Unknown		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					2072	2143	1
MMRF_2150	Fourth Line Therapy (following 3rd relapse)	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Unknown	Unknown		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					2072	2087	1
MMRF_2150	Fifth Line Therapy (following 4th relapse)	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Unknown	Unknown		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					2220	2276	1
MMRF_2150	Fifth Line Therapy (following 4th relapse)	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Unknown	Unknown		40	Other	WEEKLY					2220	2381	1
MMRF_2150	Fifth Line Therapy (following 4th relapse)	Daratumumab		Completed regimen	mg/kg	IV	Log Forms	Unknown	Unknown		8	Other	DAY 1 & 2 FOR WEEK 1					2227	2228	1
MMRF_2150	Fifth Line Therapy (following 4th relapse)	Daratumumab		Completed regimen	mg/kg	IV	Log Forms	Unknown	Unknown		16	Other	WEEKLY X 7					2234	2276	1
MMRF_2150	Fifth Line Therapy (following 4th relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Unknown	Unknown		16	Other	BI-WEEKLY X 8					2283	2381	1
MMRF_2150	Fifth Line Therapy (following 4th relapse)	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Unknown	Unknown		50	Other	DAY 1, 8, 15 EVERY 28 DAYS					2283	2297	1
MMRF_2150	Fifth Line Therapy (following 4th relapse)	Dexamethasone		STOPPED AS PER DR. JAGANNATHS ADVICE @ MT. SINAI	mg	PO	Log Forms	Unknown	Unknown		40	Other	EVERY FRI ON THE OFF WEEK					2222	2427	1
MMRF_2150	Fifth Line Therapy (following 4th relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Unknown	Unknown		70	Other	DAY 1, 8, 15 EVERY 28 DAYS					2305	2381	1
MMRF_2150	Sixth Line Therapy (following 5th relapse)	REGN5458	NCT03761108	Completed regimen	mg/kg	IV	Log Forms	Unknown	Unknown		5	Other	WEEKLY WITH DOSE ESCALATION					2447	2447	1
MMRF_2150	Sixth Line Therapy (following 5th relapse)	REGN5458	NCT03761108	Completed regimen	mg/kg	IV	Log Forms	Unknown	Unknown		25	Other	WEEKLY WITH DOSE ESCALATION					2454	2454	1
MMRF_2150	Sixth Line Therapy (following 5th relapse)	REGN5458	NCT03761108	Completed regimen	mg/kg	IV	Log Forms	Unknown	Unknown		200	Other	WEEKLY (SPLIT INFUSION)					2454	2455	1
MMRF_2150	Sixth Line Therapy (following 5th relapse)	REGN5458	NCT03761108	Completed regimen	mg/kg	IV	Log Forms	Unknown	Unknown		400	Other	WEEKLY UNTIL WEEK 16					2461	2552	1
MMRF_2150	Sixth Line Therapy (following 5th relapse)	REGN5458	NCT03761108		mg/kg	IV	Log Forms	Unknown	Unknown	Checked	400	Other	BI-WEEKLY					2566		1
MMRF_2150	First line of therapy	Bortezomib		TX WAS HELD IN THE ANTICIPATION OF STEM CELL HARVEST	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QWK	QWK					1	212	1
MMRF_2150	First line of therapy	Dexamethasone		TX WAS HELD IN THE ANTICIPATION OF STEM CELL HARVEST	mg	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	212	1
MMRF_2150	First line of therapy	Lenalidomide		TX WAS HELD IN THE ANTICIPATION OF STEM CELL HARVEST	mg	PO	Log Forms	Unknown	Unknown		15	QD (D1-21)	QD (D1-21)					120	212	1
MMRF_2150	First line of therapy	Cyclophosphamide		PROGRESSIVE INCREASE IN IGA	mg/m^2	IV	Log Forms	Unknown	Unknown		300	QWK	QWK					225	267	1
MMRF_2150	First line of therapy	Lenalidomide		PROGRESSIVE DECREASE IN MONOCLONAL PROTEIN, THEREFORE, TX REG WAS CHANGED.	mg	PO	Log Forms	Unknown	Unknown		15	QD (D1-21)	QD (D1-21)					288	470	1
MMRF_2150	First line of therapy	Bortezomib		PROGRESSIVE INCREASE IN IGA	mg/m^2	IV SubQ	Log Forms	Unknown	Unknown		1.3	QWK	QWK					225	267	1
MMRF_2150	First line of therapy	Dexamethasone		PROGRESSIVE INCREASE IN IGA	mg	PO	Log Forms	Unknown	Unknown		40	QWK	QWK					225	267	1
MMRF_2150	First line of therapy	Bortezomib		PROGRESSIVE DECREASE IN MONOCLONAL PROTEIN, THEREFORE, TX REG WAS CHANGED.	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QWK	QWK					288	470	1
MMRF_2150	First line of therapy	Dexamethasone		PROGRESSIVE DECREASE IN MONOCLONAL PROTEIN, THEREFORE, TX REG WAS CHANGED.	mg	PO	Log Forms	Induction	Induction		40	QWK	QWK					288	470	1
MMRF_2150	First line of therapy	Bortezomib		SWITCHED FROM 1ST LINE TO 2ND LINE THERAPY	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Other	EVERY OTHER WEEK					491	1129	1
MMRF_2150	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					491	1135	1
MMRF_2150	First line of therapy	Dexamethasone		POD CONFIRMED BY INCREASE IN MONOCLONAL PROTEIN + PROGRESSIVE ANEMIA	mg	PO	Log Forms	Maintenance	Maintenance		40	QWK	QWK					491	1135	1
MMRF_2150	Second Line Therapy (after first relapse)	Pomalidomide		SWITCHED LINES OF THERAPY, DUE TO POD	mg	PO	Log Forms	Unknown	Unknown		2	QD (D1-21)	QD (D1-21)					1143	1219	1
MMRF_2150	Third Line Therapy (following 2nd relapse)	Daratumumab		Completed regimen	mg/kg	IV	Log Forms	Unknown	Unknown		16	QWK	QWK					1226	1282	1
MMRF_2150	Third Line Therapy (following 2nd relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Unknown	Unknown		16	Other	EVERY OTHER WEEK FOR 16 WEEKS					1289	2003	1
MMRF_2150	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		40	QWK	QWK					1143	1213	1
MMRF_2150	Second Line Therapy (after first relapse)	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms	Unknown	Unknown		1.3	Other	EVERY OTHER WEEK					1143	1213	1
MMRF_2150	Third Line Therapy (following 2nd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		2	QD (D1-21)	QD (D1-21)					1227	2003	1
MMRF_2150	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		40	QWK	QWK					1226	2003	1
MMRF_1642	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg	IV SubQ	Log Forms	Induction	Induction		2.2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	8	1
MMRF_1642	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		10	Q day	Q day					1	8	1
MMRF_1661	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg	IV SubQ	Log Forms	Induction	Induction		2.5	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	250	1
MMRF_1661	First line of therapy	Melphalan		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		14	QD (D1-4)	QD (D1-4)					18	36	1
MMRF_1661	First line of therapy	Cyclophosphamide		Adverse Event or co-morbidity	mg	IV	Log Forms	Induction	Induction		1200	QD (D1-21)	QD (D1-21)					86	250	1
MMRF_1661	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					18	250	1
MMRF_1682	First line of therapy	Bortezomib		Disease progression/Relapse	mg	IV SubQ	Log Forms	Induction	Induction		2.2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	295	1
MMRF_1682	First line of therapy	Melphalan		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		14	QD (D1-4)	QD (D1-4)					1	295	1
MMRF_1682	First line of therapy	Prednisone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		100	QD (D1-14)	QD (D1-14)					1	295	1
MMRF_1682	Second Line Therapy (after first relapse)	Bortezomib		Investigator decision for other reasons	mg	IV SubQ	Log Forms	Maintenance	Maintenance		2.2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					338	447	1
MMRF_1682	Second Line Therapy (after first relapse)	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		25	QD (D1-21)	QD (D1-21)					338	447	1
MMRF_1682	Second Line Therapy (after first relapse)	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					338	447	1
MMRF_1682	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		20	QD (D1-4)	QD (D1-4)					448	577	1
MMRF_1682	Third Line Therapy (following 2nd relapse)	Bortezomib		Disease progression/Relapse	mg	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					448	577	1
MMRF_1682	Third Line Therapy (following 2nd relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					448	577	1
MMRF_1682	Fourth Line Therapy (following 3rd relapse)	Bortezomib		Investigator decision for other reasons	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					578	617	1
MMRF_1682	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		40	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					578	617	1
MMRF_1682	Fourth Line Therapy (following 3rd relapse)	Doxorubicin		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Maintenance	Maintenance		36	Q day	Q day					612	612	1
MMRF_1682	Fourth Line Therapy (following 3rd relapse)	Cyclophosphamide		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Maintenance	Maintenance		30	Q day	Q day					578	580	1
MMRF_1705	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	610	1
MMRF_1705	First line of therapy	Melphalan		Completed regimen	mg	PO	Log Forms	Induction	Induction		14	QD (D1-4)	QD (D1-4)					1	610	1
MMRF_1705	First line of therapy	Prednisone		Completed regimen	mg	PO	Log Forms	Induction	Induction		100	QD (D1-4)	QD (D1-4)					1	610	1
MMRF_1862	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		2.4	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	198	1
MMRF_1862	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		10	Q day	Q day					1	198	1
MMRF_1862	First line of therapy	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					728	1059	1
MMRF_1862	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Maintenance	Maintenance		20	QD (D1-4)	QD (D1-4)					728	1059	1
MMRF_1862	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Consolidation	Consolidation	Checked	20	QD (D1, D4, D8, D11, D28, D35, D38)	QD (D1, D4, D8, D11, D28, D35, D38)					1913		1
MMRF_1862	Second Line Therapy (after first relapse)	Carfilzomib			mg	IV	Log Forms	Consolidation	Consolidation	Checked	20	QD (D1, D4, D8, D11, D28, D35, D38)	QD (D1, D4, D8, D11, D28, D35, D38)					1913		1
MMRF_1969	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					2	279	1
MMRF_1969	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Induction	Induction		40	Q day	Q day					1	279	1
MMRF_1969	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Consolidation	Consolidation		2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					538	600	1
MMRF_1969	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		5	Q day	Q day					538	600	1
MMRF_1969	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		20	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					538	600	1
MMRF_1969	First line of therapy	Lenalidomide		DEATH	mg	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					600	945	1
MMRF_1969	First line of therapy	Dexamethasone		DEATH	mg	PO	Log Forms	Maintenance	Maintenance		20	QD (D1-4)	QD (D1-4)					628	945	1
MMRF_2024	Third Line Therapy (following 2nd relapse)	Dexamethasone	20	TASPE	mg	PO	Log Forms	Consolidation	Consolidation		20	QD (D1, D4, D8, D11, D28, D35, D38)	QD (D1, D4, D8, D11, D28, D35, D38)					1654	1773	1
MMRF_2024	Third Line Therapy (following 2nd relapse)	Carfilzomib		TASPE	mg	IV	Log Forms	Consolidation	Consolidation		20	QD (D1, D4, D8, D11, D28, D35, D38)	QD (D1, D4, D8, D11, D28, D35, D38)					1654	1773	1
MMRF_2024	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					3	200	1
MMRF_2024	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		10	QD (D1-4)	QD (D1-4)					1	200	1
MMRF_2024	First line of therapy	Lenalidomide		DOSE CHANGED	mg	PO	Log Forms	Consolidation	Consolidation		15	QD (D1-3)	QD (D1-3)					88	95	1
MMRF_2024	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		5	Q day	Q day					96	200	1
MMRF_2024	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Consolidation	Consolidation		1.2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					374	420	1
MMRF_2024	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		40	Q day	Q day					374	420	1
MMRF_2024	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		10	QD (D1-21)	QD (D1-21)					374	420	1
MMRF_2024	First line of therapy	Lenalidomide		Lack of response	mg	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					452	732	1
MMRF_2024	Second Line Therapy (after first relapse)	Lenalidomide		Lack of response	mg	PO	Log Forms	Induction	Induction		5	QD (D1-21)	QD (D1-21)					1313	1481	1
MMRF_2039	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	197	1
MMRF_2039	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Induction	Induction		40	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1	197	1
MMRF_2039	First line of therapy	Thalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		100	BID	BID					154	280	1
MMRF_2039	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					386	473	1
MMRF_2039	Second Line Therapy (after first relapse)	Bortezomib		Adverse Event or co-morbidity	mg	IV SubQ	Log Forms	Maintenance	Maintenance		2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					312	473	1
MMRF_2039	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		40	QD (D1-4)	QD (D1-4)					312	475	1
MMRF_2515	First line of therapy	Melphalan		Completed regimen	mg	PO	Log Forms	Induction	Induction		12	QD (D1-4)	QD (D1-4)					1	441	1
MMRF_2515	First line of therapy	Prednisone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	QD (D1-4)	QD (D1-4)					1	469	1
MMRF_2515	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		1.8	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					33	469	1
MMRF_2543	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		2.4	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	161	1
MMRF_2543	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Induction	Induction		1900	QD (D1-21)	QD (D1-21)					1	161	1
MMRF_2543	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1	161	1
MMRF_2543	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		20	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					800	1100	1
MMRF_2543	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					800	1100	1
MMRF_2543	Third Line Therapy (following 2nd relapse)	Daratumumab		DEATH	mg/kg	IV	Log Forms	Induction	Induction		16	Q week	Q week					1113	1400	1
MMRF_2543	Third Line Therapy (following 2nd relapse)	Bortezomib		DEATH	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1113	1400	1
MMRF_2543	Third Line Therapy (following 2nd relapse)	Dexamethasone		DEATH	mg	PO	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1113	1400	1
MMRF_2586	First line of therapy	Bortezomib		Disease progression/Relapse	mg	IV SubQ	Log Forms	Induction	Induction		2.3	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1	707	1
MMRF_2586	First line of therapy	Melphalan		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		16	QD (D1-4)	QD (D1-4)					1	707	1
MMRF_2586	First line of therapy	Prednisone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		100	QD (D1-4)	QD (D1-4)					1	707	1
MMRF_1908	First line of therapy	Bortezomib		Investigator decision for other reasons	mg	IV SubQ	Log Forms	Induction	Induction		1.99	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	123	1
MMRF_1908	First line of therapy	Thalidomide		PARESTHESIA	mg	PO	Log Forms	Induction	Induction		100	Q day	Q day					1	179	1
MMRF_1908	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	123	1
MMRF_1908	First line of therapy	Thalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		100	Q day	Q day					387	718	1
MMRF_1908	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING REGIMEN FOR AUTOLOGOUS TRANSPLANT		200	Q day	Q day					187	188	1
MMRF_1908	Second Line Therapy (after first relapse)	Bendamustine		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		100	QD (D1-4)	QD (D1-4)					983	1734	1
MMRF_1908	Second Line Therapy (after first relapse)	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					983	2057	1
MMRF_1908	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		4	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					983	2057	1
MMRF_2013	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	165	1
MMRF_2013	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	Other	QD DAYS 1-21					1	176	1
MMRF_2013	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	QD DAYS 1,2,3,4,9,10,11,12					1	166	1
MMRF_2013	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	BMT CONDITIONING		100	Q day	Q day					224	225	1
MMRF_2013	First line of therapy	Dexamethasone	NCT02406144	Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		20	Other	QD (1-4, 9-12)					491	1311	1
MMRF_2013	First line of therapy	Lenalidomide	NCT02406144	Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					491	1311	1
MMRF_2185	Third Line Therapy (following 2nd relapse)	Daratumumab		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		1200	Q week	Q week					897	946	1
MMRF_2185	Second Line Therapy (after first relapse)	Daratumumab		Lack of response	mg	IV	Log Forms	Induction	Induction		1200	Q week	Q week					949	1002	1
MMRF_2185	Second Line Therapy (after first relapse)	Bortezomib		Disease progression/Relapse	mg	SUBCUTANEOUS	Log Forms	Induction	Induction		2.35	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					949	1002	1
MMRF_2185	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		20	QD (D1-14)	QD (D1-14)					949	1002	1
MMRF_2185	First line of therapy	Bortezomib		Completed regimen	mg	SC	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	165	1
MMRF_2185	First line of therapy	Thalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		100	Q day	Q day					1	183	1
MMRF_2185	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	QD DAYS 1 TO 11					1	165	1
MMRF_2185	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	BMT CONDITIONING		100	Q day	Q day					219	220	1
MMRF_2185	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					533	718	1
MMRF_2185	Second Line Therapy (after first relapse)	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Induction	Induction		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					774	861	1
MMRF_2185	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					774	861	1
MMRF_2185	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					774	861	1
MMRF_1790	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	SUBCUTANEOUS	Log Forms	Induction	Induction		1.88	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)					1	113	1
MMRF_1790	First line of therapy	Melphalan		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		10	QD (D1-4)	QD (D1-4)					1	123	1
MMRF_1790	First line of therapy	Prednisone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		90	QD (D1-4)	QD (D1-4)					1	123	1
MMRF_1790	Second Line Therapy (after first relapse)	Bortezomib		Adverse Event or co-morbidity	mg	SUBCUTANEOUS	Log Forms	Unknown	Unknown		1.88	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					359	554	1
MMRF_1790	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	IV	Log Forms	Unknown	Unknown		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					359	554	1
MMRF_1790	Second Line Therapy (after first relapse)	Bendamustine		Adverse Event or co-morbidity	mg	IV	Log Forms	Unknown	Unknown		100	QD (D1-4)	QD (D1-4)					359	547	1
MMRF_1790	Third Line Therapy (following 2nd relapse)	Lenalidomide		Lack of response	mg	PO	Log Forms	Unknown	Unknown		15	QD (D1-21)	QD (D1-21)					614	660	1
MMRF_1790	Third Line Therapy (following 2nd relapse)	Dexamethasone		Lack of response	mg	PO	Log Forms	Unknown	Unknown		20	QWK	QWK					614	663	1
MMRF_1790	Fourth Line Therapy (following 3rd relapse)	Cyclophosphamide		Lack of response	mg	IV	Log Forms	Unknown	Unknown		400	QD (D1-4)	QD (D1-4)					677	739	1
MMRF_1790	Fourth Line Therapy (following 3rd relapse)	ETOPOSIDE		Lack of response	mg	IV	Log Forms	Unknown	Unknown		40	QD (D1-4)	QD (D1-4)					677	739	1
MMRF_1790	Fourth Line Therapy (following 3rd relapse)	CISPLATIN		Lack of response	mg	IV	Log Forms	Unknown	Unknown		20	QD (D1-4)	QD (D1-4)					677	739	1
MMRF_1790	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Lack of response	mg	IV	Log Forms	Unknown	Unknown		40	QD (D1-4)	QD (D1-4)					677	740	1
MMRF_1790	Fourth Line Therapy (following 3rd relapse)	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Unknown	Unknown		15	QD (D1-21)	QD (D1-21)					780	813	1
MMRF_1790	Fourth Line Therapy (following 3rd relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		10	QD (D1-21)	QD (D1-21)					828	897	1
MMRF_1790	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		20	Q week	Q week					780	897	1
MMRF_1790	Fifth Line Therapy (following 4th relapse)	Carfilzomib		Lack of response	mg/m^2	IV	Log Forms	Unknown	Unknown		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					926	962	1
MMRF_1790	Fifth Line Therapy (following 4th relapse)	Dexamethasone		Lack of response	mg	PO	Log Forms	Unknown	Unknown		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					926	962	1
MMRF_2225	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	168	1
MMRF_2225	First line of therapy	Bortezomib		Completed regimen	mg	SUBCUTANEOUS	Log Forms	Induction	Induction		2.11	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)					2	165	1
MMRF_2225	First line of therapy	Doxorubicin		Completed regimen	mg	IV	Log Forms	Induction	Induction		32	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)					2	165	1
MMRF_2225	First line of therapy	Bortezomib		Completed regimen	mg/m^2	SUBCUTANEOUS	Log Forms	Consolidation	Consolidation		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					239	270	1
MMRF_2225	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					239	270	1
MMRF_2225	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	HIGH DOSE CHEMOTHERAPY GIVEN FOR BMT		160	Other	D1,D2					180	181	1
MMRF_2225	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		40	Q week	Q week					353	527	1
MMRF_2225	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					353	527	1
MMRF_2225	Second Line Therapy (after first relapse)	Dexamethasone		Lack of response	mg	IV	Log Forms	Unknown	Unknown		40	QD (D1-4)	QD (D1-4)					552	555	1
MMRF_2225	Second Line Therapy (after first relapse)	ETOPOSIDE		Lack of response	mg	IV	Log Forms	Unknown	Unknown		60	QD (D1-4)	QD (D1-4)					552	555	1
MMRF_2225	Second Line Therapy (after first relapse)	CISPLATIN		Lack of response	mg	IV	Log Forms	Unknown	Unknown		10	QD (D1-4)	QD (D1-4)					552	555	1
MMRF_2225	Second Line Therapy (after first relapse)	Cyclophosphamide		Lack of response	mg	IV	Log Forms	Unknown	Unknown		630	QD (D1-4)	QD (D1-4)					552	555	1
MMRF_2225	Third Line Therapy (following 2nd relapse)	Carfilzomib		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Unknown	Unknown		20	Other	D1-D2					591	592	1
MMRF_2225	Third Line Therapy (following 2nd relapse)	Dexamethasone		Lack of response	mg	IV	Log Forms	Unknown	Unknown		40	Q week	Q week					591	635	1
MMRF_2225	Third Line Therapy (following 2nd relapse)	Lenalidomide		Lack of response	mg	PO	Log Forms	Unknown	Unknown		25	QD (D1-21)	QD (D1-21)					591	639	1
MMRF_2225	Third Line Therapy (following 2nd relapse)	Carfilzomib		Lack of response	mg/m^2	IV	Log Forms	Unknown	Unknown		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					598	635	1
MMRF_2225	Fourth Line Therapy (following 3rd relapse)	Pomalidomide		CHANGED DOSE	mg	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					648	675	1
MMRF_2225	Fourth Line Therapy (following 3rd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		3	QD (D1-21)	QD (D1-21)					684	765	1
MMRF_2225	Fourth Line Therapy (following 3rd relapse)	Cyclophosphamide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		50	QD (D1-21)	QD (D1-21)					648	765	1
MMRF_2225	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		40	Other	D1-D4 EVERY WEEK					648	765	1
MMRF_2225	Fourth Line Therapy (following 3rd relapse)	CLARITHOMYCIN		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		500	BID	BID					648	765	1
MMRF_2307	First line of therapy	Bortezomib			mg	SUBCUTANEOUS	Log Forms	Induction	Induction	Checked	2.26	Other	D1,D2,D3,D4					1		1
MMRF_2307	First line of therapy	Doxorubicin			mg	IV	Log Forms	Induction	Induction	Checked	34	QD (D1-4)	QD (D1-4)					1		1
MMRF_2307	First line of therapy	Prednisone			mg	PO	Log Forms	Induction	Induction	Checked	40	QD (D1-4)	QD (D1-4)					1		1
MMRF_2465	First line of therapy	Doxorubicin		Completed regimen	mg	IV	Log Forms	Induction	Induction		26	QD (D1-4)	QD (D1-4)					4	138	1
MMRF_2465	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Induction	Induction		40	Other	0.666666667					1	145	1
MMRF_2465	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Consolidation	Consolidation		200	Q day	Q day					177	178	1
MMRF_2465	First line of therapy	Bortezomib		Completed regimen	mg	IV	Log Forms	Induction	Induction		1.92	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					4	145	1
MMRF_2465	Second Line Therapy (after first relapse)	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Unknown	Unknown		20	Other	D1					1660	1660	1
MMRF_2465	Second Line Therapy (after first relapse)	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Unknown	Unknown		56	Other	QD (D1, D8, D15)					1667	1828	1
MMRF_2465	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		40	Other	QD (D1, D8, D15, D22)					1660	1828	1
MMRF_2465	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		25	QD (D1-21)	QD (D1-21)					1660	1828	1
MMRF_2556	First line of therapy	Bortezomib		Completed regimen	mg/m^2	SC	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	180	1
MMRF_2556	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	QD 1-4 / 9-12					1	181	1
MMRF_2556	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	190	1
MMRF_2556	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Induction	Induction		180	Q day	Q day					207	208	1
MMRF_2556	First line of therapy	Bortezomib		Completed regimen	mg	IV	Log Forms	Consolidation	Consolidation		2.4	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					310	348	1
MMRF_2556	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					310	358	1
MMRF_2556	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		40	Other	QD (D1-D4) (D9-D12)					310	349	1
MMRF_2556	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					408	1767	1
MMRF_2556	First line of therapy	Dexamethasone		DOSE REDUCTION	mg	PO	Log Forms	Maintenance	Maintenance		20	Other	D1D4, D9-D12					408	447	1
MMRF_2556	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		10	Other	D1-D4/D9-D12					466	1750	1
MMRF_2556	Third Line Therapy (following 2nd relapse)	Dexamethasone			mg	PO	Log Forms	Unknown	Unknown	Checked	20	Q week	Q week					2243		1
MMRF_2556	Third Line Therapy (following 2nd relapse)	Cyclophosphamide			mg	PO	Log Forms	Unknown	Unknown	Checked	50	QD (D1-21)	QD (D1-21)					2243		1
MMRF_2556	Third Line Therapy (following 2nd relapse)	Pomalidomide			mg	PO	Log Forms	Unknown	Unknown	Checked	4	QD (D1-21)	QD (D1-21)					2243		1
MMRF_2556	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Unknown	Unknown		20	Other	D1-D2 / D4-D5 / D8-D9 / D11-D12					2004	2165	1
MMRF_2556	Second Line Therapy (after first relapse)			Completed regimen	mg/kg	SC	Log Forms	Unknown	Unknown		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					2004	2164	1
MMRF_2556	Second Line Therapy (after first relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV/SC	Log Forms	Unknown	Unknown		16	Other	C1-C3 Q1W / C1-C8 Q3W / C9+ Q4W					2004	2234	1
MMRF_2567	First line of therapy	Dexamethasone		COLON CANCER	mg	PO	Log Forms	Maintenance	Maintenance		20	Other	QD D1-4/D9-12					407	438	1
MMRF_2567	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	SUBCUTANEOUS	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	105	1
MMRF_2567	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	189	1
MMRF_2567	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	D1-4 / D9-12					1	180	1
MMRF_2567	First line of therapy	Bortezomib		Completed regimen	mg/m^2	SUBCUTANEOUS	Log Forms	Induction	Induction		1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					106	179	1
MMRF_2567	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Induction	Induction		210	Q day	Q day					211	212	1
MMRF_2567	First line of therapy	Bortezomib		Completed regimen	mg/m^2	SC	Log Forms	Consolidation	Consolidation		0.7	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					295	343	1
MMRF_2567	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		40	Other	D1-4/D9-12					295	344	1
MMRF_2567	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					295	352	1
MMRF_2567	First line of therapy	Lenalidomide		COLON CANCER	mg	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					407	443	1
MMRF_1727	First line of therapy	Melphalan		Completed regimen	mg/m^2	PO	Log Forms	Induction	Induction		9	QD (D1-4)	QD (D1-4)					1	344	1
MMRF_1727	First line of therapy	Prednisone		Completed regimen	mg/m^2	PO	Log Forms	Induction	Induction		60	QD (D1-4)	QD (D1-4)					1	344	1
MMRF_1727	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		4	Other	DAYS: 8,9,22,23,29,30					9	29	1
MMRF_1727	Second Line Therapy (after first relapse)	Ixazomib		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		4	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					831	1924	1
MMRF_1727	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					831	1924	1
MMRF_1727	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					831	1924	1
MMRF_1727	Third Line Therapy (following 2nd relapse)	MELFLUFEN		Adverse Event or co-morbidity	mg	IV	Log Forms	Induction	Induction		40	Other	Q4W					1970	2092	1
MMRF_1727	Third Line Therapy (following 2nd relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					1970	2092	1
MMRF_1727	Fourth Line Therapy (following 3rd relapse)	Pomalidomide		PATIEND DIED	mg	PO	Log Forms	Induction	Induction		4	QD (D1-14)	QD (D1-14)					2190	2256	1
MMRF_1727	Fourth Line Therapy (following 3rd relapse)	Bortezomib		PATIEND DIED	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					2190	2256	1
MMRF_1727	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		PATIEND DIED	mg	PO	Log Forms	Induction	Induction		10	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					2190	2256	1
MMRF_1727	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		36	Other	DAYS: 1,2,8.9,22,23,29,30					1	372	1
MMRF_1916	First line of therapy	Melphalan		Completed regimen	mg/m^2	PO	Log Forms	Induction	Induction		9	QD (D1-4)	QD (D1-4)					1	346	1
MMRF_1916	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1	370	1
MMRF_1916	First line of therapy	Prednisone		Completed regimen	mg/m^2	D1: IV AND D2-4: PO	Log Forms	Induction	Induction		60	QD (D1-4)	QD (D1-4)					1	345	1
MMRF_1916	First line of therapy	Daratumumab		Completed regimen	mg/kg	IV	Log Forms	Induction	Induction		16	Other	DAYS, 1, 8,15,22					1	363	1
MMRF_1916	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1266	1598	1
MMRF_1916	Second Line Therapy (after first relapse)	Ixazomib		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		4	Q week	Q week					1266	1598	1
MMRF_1916	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					1266	1598	1
MMRF_1971	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	DAYS 1,2,4,5,8,9,15,16					1	357	1
MMRF_1971	First line of therapy	Daratumumab		Completed regimen	mg/kg	IV	Log Forms	Induction	Induction		16	Other	DAYS: 1,8,15,22					1	357	1
MMRF_1971	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					865	1239	1
MMRF_1971	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		20	QWK	QWK					865	1239	1
MMRF_1971	Second Line Therapy (after first relapse)	Ixazomib		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		4	QWK	QWK					865	1239	1
MMRF_1971	Third Line Therapy (following 2nd relapse)	FILANESIB		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Induction	Induction		1.4	Other	DAYS 1,2,15,16 EACH 28					1246	1391	1
MMRF_1971	Third Line Therapy (following 2nd relapse)	Pomalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					1246	1391	1
MMRF_1971	Third Line Therapy (following 2nd relapse)	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1246	1391	1
MMRF_1971	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	364	1
MMRF_2017	First line of therapy	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	188	1
MMRF_2017	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		20	Other	DAYS 1,2,4,5,8,9,11,12					1	188	1
MMRF_2017	First line of therapy	DARATUMUMAB		Disease progression/Relapse	mg/kg	IV	Log Forms	Induction	Induction		16	Q week	Q week					1	188	1
MMRF_2017	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		15	QD (D1-21)	QD (D1-21)					258	366	1
MMRF_2017	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		20	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					258	366	1
MMRF_2017	Third Line Therapy (following 2nd relapse)	Pomalidomide		DEATH	mg	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					372	410	1
MMRF_2017	Third Line Therapy (following 2nd relapse)	Dexamethasone		DEATH	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					366	400	1
MMRF_2068	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		2.1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	397	1
MMRF_2068	First line of therapy	Dexamethasone		Completed regimen	mg	DAYS 1,8,15 IV  ..... REST DAYS  PO	Log Forms	Induction	Induction		20	Other	DAYS: 1,2,4,5,8,9,11,12,15,16 (21 DAYS EACH CYCLE)					1	397	1
MMRF_2068	First line of therapy	Daratumumab		Completed regimen	mg/kg	IV	Log Forms	Induction	Induction		16	Q week	Q week					1	391	1
MMRF_2089	First line of therapy	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Other	DAYS 1,4,8,11,22,25,29,32					1	274	1
MMRF_2089	First line of therapy	Melphalan		Disease progression/Relapse	mg/m^2	PO	Log Forms	Induction	Induction		9	Other	DAYS 1,2,3,4					1	253	1
MMRF_2089	First line of therapy	Prednisone		Disease progression/Relapse	mg/m^2	PO	Log Forms	Induction	Induction		60	Other	DAYS 1,2,3,4					1	253	1
MMRF_2089	Second Line Therapy (after first relapse)	Lenalidomide		EXITUS	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					295	449	1
MMRF_2089	Second Line Therapy (after first relapse)	Dexamethasone		EXITUS	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					295	449	1
MMRF_2102	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		10	Other	QD(1-21)					711	1166	1
MMRF_2102	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		40	Other	QD(D1,D8,D15)					711	1166	1
MMRF_2102	Second Line Therapy (after first relapse)	Carfilzomib		Disease progression/Relapse	mg/m^2	IV	Log Forms	Induction	Induction		36	Other	QD(D1,D2,D8,D9,D15,D16)					717	1166	1
MMRF_2102	Third Line Therapy (following 2nd relapse)	FILANESIB		Disease progression/Relapse	mg/m^2	IV	Log Forms	Induction	Induction		1.4	Other	DAYS 1,2,15,16 EACH 28					1173	1389	1
MMRF_2102	Third Line Therapy (following 2nd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					1173	1389	1
MMRF_2102	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1173	1389	1
MMRF_2102	Fourth Line Therapy (following 3rd relapse)	DARATUMUMAB			mg	IV	Log Forms	Induction	Induction	Checked	896	Q week	Q week					1394		1
MMRF_2102	Fourth Line Therapy (following 3rd relapse)	Dexamethasone			mg	IV	Log Forms	Induction	Induction	Checked	20	Q week	Q week					1394		1
MMRF_2102	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.2	Other	DAYS 1,4,8,11,22,25,29,32					1	379	1
MMRF_2102	First line of therapy	Melphalan		Completed regimen	mg/m^2	PO	Log Forms	Induction	Induction		9	Other	DAYS 1,2,3,4					1	379	1
MMRF_2102	First line of therapy	Prednisone		Completed regimen	mg/m^2	PO	Log Forms	Induction	Induction		60	Other	DAYS 1,2,3,4					1	379	1
MMRF_2142	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	274	1
MMRF_2142	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Induction	Induction		14	QD (D1-4)	QD (D1-4)					1	274	1
MMRF_2142	First line of therapy	Prednisone		Completed regimen	mg	IV	Log Forms	Induction	Induction		100	QD (D1-4)	QD (D1-4)					1	274	1
MMRF_2335	First line of therapy	Bortezomib		DEATH	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	264	1
MMRF_2335	First line of therapy	Lenalidomide		DEATH	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	264	1
MMRF_2335	First line of therapy	Dexamethasone		DEATH	mg	PO	Log Forms	Induction	Induction		40	Other	QD (1-4) QD (9-12)					1	264	1
MMRF_2468	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	189	1
MMRF_2468	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	189	1
MMRF_2468	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	QD (D1-D4) Y (D9-12)					1	189	1
MMRF_2468	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	BONE MARROW TRASPLANT		200	Other	DAYS -2, AND -1 RESPECT AT BONE MARROW TRASPLANT					220	221	1
MMRF_2468	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		20	Other	(QD (D1-D4) Y (D9-12))					418	1082	1
MMRF_2468	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					418	1082	1
MMRF_2468	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		40	Other	(QD (D1-D4) Y (D9-12))					351	404	1
MMRF_2468	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					351	404	1
MMRF_2468	First line of therapy	Bortezomib		Completed regimen	mg	IV	Log Forms	Consolidation	Consolidation		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					351	404	1
MMRF_1654	First line of therapy	Bortezomib		DEATH	mg	IV SubQ	Log Forms	Induction	Induction		2.21	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	81	1
MMRF_1654	First line of therapy	Dexamethasone		DEATH	mg	IV	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	50	1
MMRF_1678	First line of therapy	Thalidomide		DEATH	mg	PO	Log Forms	Induction	Induction		100	BID	BID					1	231	1
MMRF_1678	First line of therapy	Melphalan		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		100	BID	BID					1	212	1
MMRF_1678	First line of therapy	Prednisone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		100	BID	BID					1	212	1
MMRF_1738	Third Line Therapy (following 2nd relapse)	Dexamethasone		DEATH	mg	PO	Log Forms	Unknown	Unknown		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					554	689	1
MMRF_1738	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	71	1
MMRF_1738	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	71	1
MMRF_1738	Second Line Therapy (after first relapse)	Cyclophosphamide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		50	Q day	Q day					93	526	1
MMRF_1738	Third Line Therapy (following 2nd relapse)	Lenalidomide		DEATH	mg	PO	Log Forms	Unknown	Unknown		15	QD (D1-21)	QD (D1-21)					554	689	1
MMRF_2224	First line of therapy	Bortezomib		Completed regimen	mg	SC	Log Forms	Induction	Induction		2.63	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	400	1
MMRF_2224	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Unknown	Unknown		25	QD (D1-21)	QD (D1-21)					1	45	1
MMRF_2224	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Unknown	Unknown		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	401	1
MMRF_2224	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					477	1222	1
MMRF_2224	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		20	Other	QD (1-4, 9-12)					477	1222	1
MMRF_2224	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	CONDITIONING		294	Q day	Q day					240	240	1
MMRF_2368	First line of therapy	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	106	1
MMRF_2368	First line of therapy	Melphalan		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		13.32	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	106	1
MMRF_2368	First line of therapy	Prednisone		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		88.8	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	106	1
MMRF_2050	First line of therapy	Bortezomib			mg/m^2	IV	Log Forms	Induction	Induction	Checked	1.3	Other	EVERY 42 DAYS					1		1
MMRF_2050	First line of therapy	Melphalan			mg/m^2	PO	Log Forms	Induction	Induction	Checked	9	Other	EVERY 42 DAYS					1		1
MMRF_2050	First line of therapy	Prednisone			mg/m^2	IV SubQ	Log Forms	Induction	Induction	Checked	60	Other	EVERY042 DAYS					1		1
MMRF_2197	First line of therapy	Bortezomib			mg	SUBCUTANEOUS	Log Forms	Induction	Induction	Checked	2.4	Other	FOUR DAYS PER MONTH					1		1
MMRF_2197	First line of therapy	Melphalan			mg	PO	Log Forms	Induction	Induction	Checked	16	Other	FOUR TIMES PER MONTH					1		1
MMRF_2197	First line of therapy	Prednisone			mg	PO	Log Forms	Induction	Induction	Checked	110	Other	FOUR DAYS PER MONTH					1		1
MMRF_2200	First line of therapy	Bortezomib		Disease progression/Relapse	mg	SUBCUTANEOUS	Log Forms	Induction	Induction		2.6	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)					1	147	1
MMRF_2200	First line of therapy	Doxorubicin		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		79.6	Other	ONCE A MONTH					20	147	1
MMRF_2200	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		40	QD (D1-4)	QD (D1-4)					1	147	1
MMRF_2200	Second Line Therapy (after first relapse)	Thalidomide		COMPLETE RESPONSE, PATIENT IS ADMITTED FOR AUTOLOGOUS STEM CELL TCPH	mg	PO	Log Forms	Induction	Induction		200	Other	ONCE A DAY					147	208	1
MMRF_2200	Second Line Therapy (after first relapse)	Cyclophosphamide		COMPLETE RESPONSE, PATIENT IS ADMITTED FOR AUTOLOGOUS STEM CELL TCPH	mg	PO	Log Forms	Induction	Induction		50	Other	ONCE A DAY					147	208	1
MMRF_2200	Second Line Therapy (after first relapse)	Dexamethasone		COMPLETE RESPONSE, PATIENT IS ADMITTED FOR AUTOLOGOUS STEM CELL TCPH	mg	PO	Log Forms	Induction	Induction		40	Other	ONCE A DAY, ONLY THE FIRST 4DAYS OF EACH CICLE					147	208	1
MMRF_2200	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg	IV	Log Forms	Consolidation	Consolidation		260	Q day	Q day					209	940	1
MMRF_2273	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Consolidation	Consolidation		300	Other	ONCE					253	253	1
MMRF_2273	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		2.2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	266	1
MMRF_2273	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Induction	Induction		500	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	266	1
MMRF_2273	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1-4)	QD (D1-4)					1	266	1
MMRF_2273	Second Line Therapy (after first relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Induction	Induction		16	Other	ONCE A WEEK					1075	1348	1
MMRF_2273	Second Line Therapy (after first relapse)	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	Q day	Q day					1076	1340	1
MMRF_2273	Second Line Therapy (after first relapse)	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		20	Other	ONCE A WEEK					1075	1341	1
MMRF_2336	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		2.4	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	132	1
MMRF_2336	First line of therapy	Thalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		100	Other	100MG A DAY FOR 21DAYS. TOTAL 2100MG					1	122	1
MMRF_2336	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1-4)	QD (D1-4)					1	125	1
MMRF_2336	Second Line Therapy (after first relapse)	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					670	801	1
MMRF_2336	Second Line Therapy (after first relapse)	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		40	Other	EVERY WEEK					670	900	1
MMRF_2336	Second Line Therapy (after first relapse)	Carfilzomib		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Induction	Induction		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					729	900	1
MMRF_2336	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Other	TRANSPLANT CONDITIONING		370	Other	ONCE					163	163	1
MMRF_2365	First line of therapy	Bortezomib			mg	IV SubQ	Log Forms	Induction	Induction	Checked	1.87	Other	D1,D8					1		1
MMRF_2365	First line of therapy	Prednisone			mg	PO	Log Forms	Induction	Induction	Checked	80	QD (D1-4)	QD (D1-4)					1		1
MMRF_2365	First line of therapy	Melphalan			mg	PO	Log Forms	Induction	Induction	Checked	12	QD (D1-14)	QD (D1-14)					1		1
MMRF_2519	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		2.9	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	156	1
MMRF_2519	First line of therapy	Thalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		100	Other	ONCE A DAY					1	876	1
MMRF_2519	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	ONCE A DAY ON DAY 1,2,3,4.					1	148	1
MMRF_2519	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Consolidation	Consolidation		450	Other	ONCE					185	185	1
MMRF_2578	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	Other	D1, D8, D15, D21					126	760	1
MMRF_2578	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	Q day	Q day					126	760	1
MMRF_2578	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg	IV SubQ	Log Forms	Induction	Induction		2.28	Other	ONCE A DAY, DAYS 1,4,8,11,22,25,29,32					1	109	1
MMRF_2578	First line of therapy	Melphalan		Adverse Event or co-morbidity	mg	IV	Log Forms	Induction	Induction		16	QD (D1-4)	QD (D1-4)					1	81	1
MMRF_2578	First line of therapy	Prednisone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		100	QD (D1-4)	QD (D1-4)					1	81	1
MMRF_2602	First line of therapy	Bortezomib			mg/m^2	IV SubQ	Log Forms	Induction	Induction	Checked	1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_2602	First line of therapy	Dexamethasone			mg	IV	Log Forms	Induction	Induction	Checked	40	QD (D1-4)	QD (D1-4)					1		1
MMRF_2606	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		1.98	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	200	1
MMRF_2606	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Induction	Induction		460	Other	ONCE A DAY ON DAYS 1, 8, 15 AND 22					1	211	1
MMRF_2606	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1	209	1
MMRF_2606	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Consolidation	Consolidation		310	Other	ONCE					220	220	1
MMRF_2606	Second Line Therapy (after first relapse)	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					625	1118	1
MMRF_2606	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					592	1571	1
MMRF_2606	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					592	1515	1
MMRF_2606	Third Line Therapy (following 2nd relapse)	Daratumumab		Disease progression/Relapse	mg/m^2	IV	Log Forms	Induction	Induction		16	Other	DAY 1					1678	1794	1
MMRF_2606	Third Line Therapy (following 2nd relapse)	Bortezomib			mg/m^2	IV SubQ	Log Forms	Induction	Induction	Checked	1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1678		1
MMRF_2606	Third Line Therapy (following 2nd relapse)	Dexamethasone			mg	PO	Log Forms	Maintenance	Maintenance	Checked	20	Q week	Q week					1678		1
MMRF_1923	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	162	1
MMRF_1923	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	D1-2, D8-9					1	152	1
MMRF_1923	First line of therapy	Thalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		10	Other	D1-21					1	152	1
MMRF_1923	First line of therapy	Daratumumab		Completed regimen	mg/kg	IV	Log Forms	Induction	Induction		16	Other	D1, D8, D15					1	152	1
MMRF_1923	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Consolidation	Consolidation		360	Q day	Q day					171	171	1
MMRF_1923	First line of therapy	IXAZOMIB VS PLACEBO		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		2.3	Other	DAYS 1, 8, 15					318	990	1
MMRF_1716	First line of therapy	Bortezomib		DEATH	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	76	1
MMRF_1716	First line of therapy	Prednisone		DEATH	mg	PO	Log Forms	Induction	Induction		60	QD (D1-4)	QD (D1-4)					1	76	1
MMRF_1716	First line of therapy	Melphalan		DEATH	mg	PO	Log Forms	Induction	Induction		9	QD (D1-4)	QD (D1-4)					1	76	1
MMRF_1931	First line of therapy	Bortezomib		Completed regimen	mg/m^2	SC	Log Forms	Induction	Induction		1.3	Other	QD(D1,D4,D8,D11,D22,D25,D29,D32					1	310	1
MMRF_1931	First line of therapy	Melphalan		Completed regimen	mg/m^2	PO	Log Forms	Induction	Induction		9	QD (D1-4)	QD (D1-4)					1	310	1
MMRF_1931	First line of therapy	Prednisone		Completed regimen	mg/m^2	PO	Log Forms	Induction	Induction		60	QD (D1-4)	QD (D1-4)					1	310	1
MMRF_1931	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					796	1768	1
MMRF_1931	Second Line Therapy (after first relapse)	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					796	936	1
MMRF_1931	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		20	Q week	Q week					936	1768	1
MMRF_1931	Third Line Therapy (following 2nd relapse)	Carfilzomib	KYCYDEX	Patient decision	mg/m^2	IV	Log Forms	Induction	Induction		56	Other	QD (D1, D8, D15)					1895	2084	1
MMRF_1931	Third Line Therapy (following 2nd relapse)	Cyclophosphamide	KYCYDEX	Patient decision	mg/m^2	IV	Log Forms	Induction	Induction		300	Other	QD (D1, D8, D15)					1895	2084	1
MMRF_1931	Third Line Therapy (following 2nd relapse)	Dexamethasone	KYCYDEX	Patient decision	mg	PO	Log Forms	Induction	Induction		10	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1895	2084	1
MMRF_2194	First line of therapy	Bortezomib		Completed regimen	mg/m^2	SUBCUTANEOUS	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	289	1
MMRF_2194	First line of therapy	Melphalan		Completed regimen	mg/m^2	PO	Log Forms	Induction	Induction		9	QD (D1-4)	QD (D1-4)					1	289	1
MMRF_2194	First line of therapy	Prednisone		Completed regimen	mg/m^2	PO	Log Forms	Induction	Induction		60	QD (D1-4)	QD (D1-4)					1	289	1
MMRF_2194	Second Line Therapy (after first relapse)	Lenalidomide		Lack of response	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					449	591	1
MMRF_2194	Second Line Therapy (after first relapse)	Dexamethasone		Lack of response	mg	IV	Log Forms	Induction	Induction		40	Q week	Q week					449	591	1
MMRF_2194	Second Line Therapy (after first relapse)	Cyclophosphamide		Lack of response	mg	PO	Log Forms	Induction	Induction		50	Q day	Q day					542	591	1
MMRF_2194	Third Line Therapy (following 2nd relapse)	Vincristine		Lack of response	mg	IV	Log Forms	Induction	Induction		0.4	QD (D1-4)	QD (D1-4)					592	648	1
MMRF_2194	Third Line Therapy (following 2nd relapse)	ADRIAMYCIN		Lack of response	mg/m^2	IV	Log Forms	Induction	Induction		9	QD (D1-4)	QD (D1-4)					592	648	1
MMRF_2194	Third Line Therapy (following 2nd relapse)	Dexamethasone		Lack of response	mg	IV	Log Forms	Induction	Induction		40	QD (D1-4)	QD (D1-4)					592	648	1
MMRF_2194	Fourth Line Therapy (following 3rd relapse)	Carfilzomib		Lack of response	mg/m^2	IV	Log Forms	Induction	Induction		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					670	787	1
MMRF_2194	Fourth Line Therapy (following 3rd relapse)	Lenalidomide		Lack of response	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					670	787	1
MMRF_2194	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Lack of response	mg	PO	Log Forms	Induction	Induction		40	Other	QD (D 1-4, D9-12)					670	787	1
MMRF_2194	Fifth Line Therapy (following 4th relapse)	Daratumumab		Disease progression/Relapse	mg/kg	IV	Log Forms	Induction	Induction		16	Q week	Q week					850	1061	1
MMRF_2245	First line of therapy	Bortezomib			mg/m^2	SUBCUTANEOUS	Log Forms	Induction	Induction	Checked	1.3	Q week	Q week					1		1
MMRF_2245	First line of therapy	Melphalan			mg/m^2	PO	Log Forms	Induction	Induction	Checked	9	QD (D1-4)	QD (D1-4)					1		1
MMRF_2245	First line of therapy	Prednisone			mg/m^2	PO	Log Forms	Induction	Induction	Checked	60	QD (D1-4)	QD (D1-4)					1		1
MMRF_2257	First line of therapy	Bortezomib		Completed regimen	mg/m^2	SUBCUTANEOUS	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	103	1
MMRF_2257	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1	103	1
MMRF_2257	Second Line Therapy (after first relapse)	Bortezomib		Completed regimen	mg/m^2	SUBCUTANEOUS	Log Forms	Induction	Induction		1.3	Q week	Q week					1154	1293	1
MMRF_2257	Second Line Therapy (after first relapse)	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Induction	Induction		400	Q week	Q week					1154	1293	1
MMRF_2257	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					1154	1293	1
MMRF_2526	First line of therapy	Bortezomib		Completed regimen	mg	SUBCUTANEOUS	Log Forms	Induction	Induction		2.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	260	1
MMRF_2526	First line of therapy	Melphalan		Completed regimen	mg	PO	Log Forms	Induction	Induction		8	QD (D1-4)	QD (D1-4)					1	260	1
MMRF_2526	First line of therapy	Prednisone		Completed regimen	mg	PO	Log Forms	Induction	Induction		90	QD (D1-4)	QD (D1-4)					1	260	1
MMRF_1913	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	369	1
MMRF_1913	First line of therapy	Melphalan		Completed regimen	mg/m^2	PO	Log Forms	Induction	Induction		9	QD (D1-4)	QD (D1-4)					1	369	1
MMRF_1913	First line of therapy	Prednisone		Completed regimen	mg/m^2	PO	Log Forms	Induction	Induction		60	QD (D1-4)	QD (D1-4)					1	369	1
MMRF_1913	Second Line Therapy (after first relapse)	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		15	Other	ALTERNATE DAYS					651	676	1
MMRF_1913	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		15	Q day	Q day					677	733	1
MMRF_1913	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	Other	QD (D1-4, 9-12)					651	662	1
MMRF_1913	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		4	Q week	Q week					684	704	1
MMRF_1913	Second Line Therapy (after first relapse)	Prednisone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		50	Q week	Q week					705	733	1
MMRF_1913	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					677	683	1
MMRF_1913	Third Line Therapy (following 2nd relapse)	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Induction	Induction		70	Other	QD (D1, D8, D15)					804	936	1
MMRF_1913	Third Line Therapy (following 2nd relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					804	936	1
MMRF_1913	Fourth Line Therapy (following 3rd relapse)	Daratumumab		Disease progression/Relapse	mg	SUBCUTANEOUS	Log Forms	Induction	Induction		1800	Other	C1-2: D1, 8, 15, 22; C3-6: D1, 15; FROM C7: D1.					1104	1265	1
MMRF_1978	First line of therapy	Melphalan		Completed regimen	mg	PO	Log Forms	Induction	Induction		18	QD (D1-4)	QD (D1-4)					1	263	1
MMRF_1978	First line of therapy	Prednisone		Completed regimen	mg	PO	Log Forms	Induction	Induction		120	QD (D1-4)	QD (D1-4)					1	263	1
MMRF_1978	First line of therapy	Bortezomib		Completed regimen	mg	IV	Log Forms	Induction	Induction		2.5	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)					1	281	1
MMRF_1978	Second Line Therapy (after first relapse)	Lenalidomide			mg	PO	Log Forms	Unknown	Unknown	Checked	15	QD (D1-21)	QD (D1-21)					646		1
MMRF_1978	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Unknown	Unknown	Checked	40	Q week	Q week					646		1
MMRF_1989	First line of therapy	Bortezomib		Completed regimen	mg	IV	Log Forms	Induction	Induction		2.7	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	190	1
MMRF_1989	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	200	1
MMRF_1989	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	QD (D1-4, D9-12)					1	191	1
MMRF_1989	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING TREATMENT PRETRASPLANT		100	Q day	Q day					232	233	1
MMRF_1989	First line of therapy	Bortezomib		Completed regimen	mg	IV	Log Forms	Maintenance	Maintenance		2.7	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					333	1205	1
MMRF_1989	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		25	QD (D1-21)	QD (D1-21)					333	1205	1
MMRF_1989	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		40	Other	QD (D1-4, D9-12)					333	1205	1
MMRF_2049	Second Line Therapy (after first relapse)	Bortezomib		DOSE CHANGE	mg/m^2	IV SubQ	Log Forms	Unknown	Unknown		1	QWK	QWK					1730	1759	1
MMRF_2049	Second Line Therapy (after first relapse)	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Unknown	Unknown		300	QWK	QWK					1730	1946	1
MMRF_2049	Second Line Therapy (after first relapse)	Prednisone		Completed regimen	mg	PO	Log Forms	Unknown	Unknown		15	Q day	Q day					1730	1946	1
MMRF_2049	Second Line Therapy (after first relapse)	Bortezomib		DOSE CHANGE	mg/m^2	IV SubQ	Log Forms	Unknown	Unknown		1.3	QWK	QWK					1760	1790	1
MMRF_2049	Second Line Therapy (after first relapse)	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Unknown	Unknown		1	QWK	QWK					1836	1946	1
MMRF_2049	Second Line Therapy (after first relapse)	Cyclophosphamide		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Consolidation	Consolidation		650							1947	2041	1
MMRF_2049	Second Line Therapy (after first relapse)	Prednisone		Investigator decision for other reasons	mg	PO	Log Forms	Consolidation	Consolidation		7.5	Q day	Q day					1947	2041	1
MMRF_2049	Third Line Therapy (following 2nd relapse)	Lenalidomide			mg	PO	Log Forms	Other	SALVAGE	Checked	15	Other	EVERY 48 HOURS					2711		1
MMRF_2049	Third Line Therapy (following 2nd relapse)	Prednisone			mg	PO	Log Forms	Other	SALVAGE	Checked	15	Other	EVERY 48 HOURS					2711		1
MMRF_2049	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	Q day	Q day					1	157	1
MMRF_2049	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	147	1
MMRF_2049	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	Other	QD (D 1-4, D9-12)					1	147	1
MMRF_2384	First line of therapy	Bortezomib	NCT01916252	Completed regimen	mg	IV	Log Forms	Induction	Induction		1.9	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	185	1
MMRF_2384	First line of therapy	Lenalidomide	NCT01916252	Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	185	1
MMRF_2384	First line of therapy	Dexamethasone	NCT01916252	Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	QD (D1-4, D9-12)					1	185	1
MMRF_2384	First line of therapy	BISULFAN	NCT01916252	Completed regimen	mg	IV	Log Forms	Induction	Induction		180	Q day	Q day					226	228	1
MMRF_2384	First line of therapy	Melphalan	NCT01916252	Completed regimen	mg	IV	Log Forms	Induction	Induction		225	Q day	Q day					229	229	1
MMRF_2384	First line of therapy	Bortezomib	NCT01916252	Completed regimen	mg	IV SubQ	Log Forms	Consolidation	Consolidation		2.1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					386	449	1
MMRF_2384	First line of therapy	Lenalidomide	NCT01916252	Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					386	449	1
MMRF_2384	First line of therapy	Dexamethasone	NCT01916252	Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		40	QWK	QWK					386	449	1
MMRF_2384	First line of therapy	Lenalidomide	NCT02406144	Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					492	1270	1
MMRF_2384	First line of therapy	Dexamethasone	NCT02406144	Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		20	Other	QD (D1-4, 9-12)					492	1270	1
MMRF_2384	First line of therapy	MLN9708	NCT02406144	Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		4	Other	QD (D1, 8, 15)					492	1270	1
MMRF_2385	First line of therapy	Melphalan		Completed regimen	mg	IV	Log Forms	Induction	Induction		200	Q day	Q day					136	137	1
MMRF_2385	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	77	1
MMRF_2385	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Induction	Induction		1600	Other	MONTHLY					1	77	1
MMRF_2385	First line of therapy	METHYLPREDNISOLONE		Completed regimen	mg	IV	Log Forms	Induction	Induction		125	Other	MONTHLY					1	77	1
MMRF_2385	Second Line Therapy (after first relapse)	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Other	RESCUE		2.8	QWK	QWK					619	701	1
MMRF_2385	Second Line Therapy (after first relapse)	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Other	RESCUE		1080	Other	MONTHLY					619	701	1
MMRF_2385	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Other	RESCUE		40	QWK	QWK					619	701	1
MMRF_2385	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		25	QD (D1-21)	QD (D1-21)					738	1027	1
MMRF_2385	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		40	Q week	Q week					738	1027	1
MMRF_2385	Third Line Therapy (following 2nd relapse)	Daratumumab		DEATH	mg	IV	Log Forms	Unknown	Unknown		1550	Q week	Q week					1137	1816	1
MMRF_2385	Third Line Therapy (following 2nd relapse)	Bortezomib		DEATH	mg	IV SubQ	Log Forms	Unknown	Unknown		2.8	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1137	1816	1
MMRF_2385	Third Line Therapy (following 2nd relapse)	Dexamethasone		DEATH	mg	IV	Log Forms	Unknown	Unknown		20	Q week	Q week					1137	1816	1
MMRF_2413	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg	IV	Log Forms	Induction	Induction		2.9	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	11	1
MMRF_2413	First line of therapy	Melphalan		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		16	QD (D1-4)	QD (D1-4)					1	4	1
MMRF_2413	First line of therapy	Prednisone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		125	QD (D1-14)	QD (D1-14)					1	4	1
MMRF_2413	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Induction	Induction		1200	Other	EACH 4 WEEKS					48	400	1
MMRF_2413	First line of therapy	Prednisone		Completed regimen	mg	PO	Log Forms	Induction	Induction		15	Q day	Q day					48	400	1
MMRF_2413	Second Line Therapy (after first relapse)	Cyclophosphamide		Lack of response	mg	IV	Log Forms	Unknown	Unknown		1200	Q week	Q week					851	935	1
MMRF_2413	Second Line Therapy (after first relapse)	Prednisone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		15	Q day	Q day					857	913	1
MMRF_2413	Second Line Therapy (after first relapse)	Lenalidomide		DEATH	mg	PO	Log Forms	Unknown	Unknown		15	QD (D1-21)	QD (D1-21)					935	1442	1
MMRF_2413	Second Line Therapy (after first relapse)	Dexamethasone		DEATH	mg	PO	Log Forms	Unknown	Unknown		20	Q week	Q week					935	1442	1
MMRF_2580	First line of therapy	Bortezomib			mg	IV	Log Forms	Induction	Induction	Checked	2.1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_2580	First line of therapy	Melphalan			mg	PO	Log Forms	Induction	Induction	Checked	14	QD (D1-4)	QD (D1-4)					1		1
MMRF_2580	First line of therapy	Prednisone			mg	PO	Log Forms	Induction	Induction	Checked	96	QD (D1-4)	QD (D1-4)					1		1
MMRF_1861	First line of therapy	Melphalan		Completed regimen	mg	PO	Log Forms	Induction	Induction		10	QD (D1-4)	QD (D1-4)					102	252	1
MMRF_1861	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1040	1067	1
MMRF_1861	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1040	1067	1
MMRF_1861	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					1068	1305	1
MMRF_1861	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1068	1305	1
MMRF_1861	Second Line Therapy (after first relapse)	Ixazomib		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		4	Q week	Q week					1237	1255	1
MMRF_1861	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	SUBCUTANEOUS	Log Forms	Induction	Induction		1.3	Other	D1, D4, D8, D11, D22, D25, D29, D32 (CYCLE 1) AND Q WEEK STARTING CYCLE 2					1	123	1
MMRF_1861	First line of therapy	Melphalan		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		12	QD (D1-4)	QD (D1-4)					1	77	1
MMRF_1861	First line of therapy	Prednisone		Completed regimen	mg	PO	Log Forms	Induction	Induction		90	QD (D1-4)	QD (D1-4)					1	252	1
MMRF_1861	First line of therapy	Bortezomib		Completed regimen	mg/m^2	SUBCUTANEOS	Log Forms	Induction	Induction		1	Q week	Q week					130	270	1
MMRF_1933	Second Line Therapy (after first relapse)	Melphalan			mg	PO	Log Forms	Induction	Induction	Checked	12	QD (D1-4)	QD (D1-4)					944		1
MMRF_1933	Second Line Therapy (after first relapse)	Prednisone			mg	PO	Log Forms	Induction	Induction	Checked	120	QD (D1-4)	QD (D1-4)					944		1
MMRF_1933	First line of therapy	Melphalan		BY MISSUNDERSTANDING OF THE PROPER ADMINISTRATION	mg	PO	Log Forms	Induction	Induction		2	Q day	Q day					1	38	1
MMRF_1933	First line of therapy	Prednisone		Completed regimen	mg	PO	Log Forms	Induction	Induction		120	QD (D1-4)	QD (D1-4)					1	242	1
MMRF_1933	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	SUBCUTANEOUS	Log Forms	Induction	Induction		1.3	Q week	Q week					39	95	1
MMRF_1933	First line of therapy	Bortezomib		Completed regimen	mg/m^2	SUBCUTANEOS	Log Forms	Induction	Induction		1.3	Q week	Q week					109	260	1
MMRF_1933	First line of therapy	Melphalan		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		16	QD (D1-4)	QD (D1-4)					39	126	1
MMRF_1933	First line of therapy	Melphalan		Completed regimen	mg	PO	Log Forms	Induction	Induction		12	QD (D1-4)	QD (D1-4)					151	242	1
MMRF_1933	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	SUBCUTANEOUS	Log Forms	Induction	Induction		1.3	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1	29	1
MMRF_1995	First line of therapy	Bortezomib		WE DECIDED ONLY ONE CYCLE OF VELCADE+DEXA AND THEN ANOTHER TREATMENT	mg/m^2	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	22	1
MMRF_1995	First line of therapy	Dexamethasone		WE DECIDED ONLY ONE CYCLE OF VELCADE+DEXA AND THEN ANOTHER TREATMENT	mg	PO	Log Forms	Induction	Induction		40	QD (D1-4)	QD (D1-4)					1	22	1
MMRF_1995	First line of therapy	Bortezomib		CHANGE OF FRECUENCY	mg/m^2	IV	Log Forms	Induction	Induction		1.3	Other	DAY 1,4,8,11,22,25,29,32 (CYCLES OF 42 DAYS)					41	75	1
MMRF_1995	First line of therapy	Melphalan		CHANGE OF DOSE	mg	PO	Log Forms	Induction	Induction		18	QD (D1-4)	QD (D1-4)					41	145	1
MMRF_1995	First line of therapy	Prednisone		Completed regimen	mg	PO	Log Forms	Induction	Induction		120	QD (D1-4)	QD (D1-4)					41	275	1
MMRF_1995	First line of therapy	Bortezomib		CHANGE OF DOSE	mg/m^2	IV	Log Forms	Induction	Induction		1.3	Q week	Q week					76	208	1
MMRF_1995	First line of therapy	Melphalan		Completed regimen	mg	PO	Log Forms	Induction	Induction		14	QD (D1-4)	QD (D1-4)					146	275	1
MMRF_1995	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		0.7	Q week	Q week					209	293	1
MMRF_1995	Second Line Therapy (after first relapse)	Lenalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					460	980	1
MMRF_1995	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		40	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					460	1159	1
MMRF_1995	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					981	1147	1
MMRF_1995	Third Line Therapy (following 2nd relapse)	Daratumumab		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		1184	Q week	Q week					1198	1218	1
MMRF_1995	Third Line Therapy (following 2nd relapse)	Bortezomib		Disease progression/Relapse	mg/m^2	SUBQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1198	1218	1
MMRF_1995	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		40	Q week	Q week					1198	1218	1
MMRF_1995	Fourth Line Therapy (following 3rd relapse)	Carfilzomib		DAYS 1,2 DIFFERENT DOSE	mg	IV	Log Forms	Induction	Induction		37	Q day	Q day					1232	1233	1
MMRF_1995	Fourth Line Therapy (following 3rd relapse)	Carfilzomib		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		128	Other	DAYS 1,8,15					1234	1362	1
MMRF_1995	Fourth Line Therapy (following 3rd relapse)	Cyclophosphamide		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		550	Other	DAYS1,8,15					1232	1362	1
MMRF_1995	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		40	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1232	1363	1
MMRF_1995	Fifth Line Therapy (following 4th relapse)	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					1367	1461	1
MMRF_1995	Fifth Line Therapy (following 4th relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1367	1461	1
MMRF_2008	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					6	426	1
MMRF_2008	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	1-4 AND 9-12 DAYS					1	12	1
MMRF_2008	First line of therapy	Melphalan		DOSIS REDUCED DUE TO RENAL INSUFICENCE	mg/m^2	PO	Log Forms	Induction	Induction		9	QD (D1-4)	QD (D1-4)					34	61	1
MMRF_2008	First line of therapy	Prednisone		DOSIS REDUCED DUE TO ADVERSE EVENT	mg/m^2	PO	Log Forms	Induction	Induction		60	QD (D1-4)	QD (D1-4)					34	61	1
MMRF_2008	First line of therapy	Melphalan		INCREASE OF DOSE	mg	PO	Log Forms	Induction	Induction		12	QD (D1-4)	QD (D1-4)					62	208	1
MMRF_2008	First line of therapy	Prednisone		Completed regimen	mg	PO	Log Forms	Induction	Induction		90	QD (D1-14)	QD (D1-14)					62	426	1
MMRF_2008	First line of therapy	Melphalan		INCREASE OF DOSE DUE TO CREATININE IS BETTER	mg	PO	Log Forms	Induction	Induction		14	QD (D1-4)	QD (D1-4)					209	236	1
MMRF_2008	First line of therapy	Melphalan		Completed regimen	mg	PO	Log Forms	Induction	Induction		18	QD (D1-4)	QD (D1-4)					237	426	1
MMRF_2008	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					427	568	1
MMRF_2008	First line of therapy	Dexamethasone		Lack of response	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					427	925	1
MMRF_2008	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					569	1063	1
MMRF_2008	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		30	Other	2 DAYS PER WEEK					926	1065	1
MMRF_2008	Second Line Therapy (after first relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					1101	1210	1
MMRF_2008	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					1101	1210	1
MMRF_2008	Third Line Therapy (following 2nd relapse)	Daratumumab		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		1600	Q week	Q week					1263	1324	1
MMRF_2008	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		20	Q week	Q week					1263	1324	1
MMRF_2008	Fourth Line Therapy (following 3rd relapse)	Carfilzomib		DECEASED PATIENT	mg/m^2	IV	Log Forms	Induction	Induction		70	Other	DAY 1,8,15					1325	1380	1
MMRF_2008	Fourth Line Therapy (following 3rd relapse)	Cyclophosphamide		DECEASED PATIENT	mg	IV	Log Forms	Induction	Induction		650	Other	DAYS 1,8,15					1325	1380	1
MMRF_2008	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		DECEASED PATIENT	mg	PO	Log Forms	Induction	Induction		40	Other	DAYS 1,8,15,22					1325	1380	1
MMRF_2011	First line of therapy	Bortezomib		ADVERSE EVENT + DISEASE PROGRESION	mg/m^2	SC	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)					281	302	1
MMRF_2011	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					316	399	1
MMRF_2011	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		15	Other	EVERY 48 HOURS D1-D21					400	429	1
MMRF_2011	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	Other	D1-2, D8-9, D15-16, D22-23					316	429	1
MMRF_2011	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		15	Other	EVERY 48 HOURS D1-D21					444	464	1
MMRF_2011	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		20	Other	QD (D1-2, D8-9, D14-15, D21-22)					444	466	1
MMRF_2011	Third Line Therapy (following 2nd relapse)	Carfilzomib		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					661	688	1
MMRF_2011	Third Line Therapy (following 2nd relapse)	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		40	QWK	QWK					661	1207	1
MMRF_2011	Third Line Therapy (following 2nd relapse)	Carfilzomib		Adverse Event or co-morbidity	mg	IV	Log Forms	Induction	Induction		120	QWK	QWK					689	1193	1
MMRF_2011	Fourth Line Therapy (following 3rd relapse)	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					1768	1816	1
MMRF_2011	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					1768	1816	1
MMRF_2011	Fourth Line Therapy (following 3rd relapse)	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					1838	1885	1
MMRF_2011	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	QWK	QWK					1838	1885	1
MMRF_2011	Fourth Line Therapy (following 3rd relapse)	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					1348	1737	1
MMRF_2011	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					1348	1737	1
MMRF_2011	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	SC	Log Forms	Induction	Induction		1.3	Other	D1, D8, D22 AND D29					1	42	1
MMRF_2011	First line of therapy	Melphalan		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		10	QD (D1-4)	QD (D1-4)					1	98	1
MMRF_2011	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		40	Q day	Q day					1	4	1
MMRF_2011	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	SC	Log Forms	Induction	Induction		1.3	Q week	Q week					43	98	1
MMRF_2011	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	SC	Log Forms	Induction	Induction		1.3	Other	D1, D4, D8, D11, D22, D25, D29, D32					113	133	1
MMRF_2011	First line of therapy	Melphalan		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		20	QD (D1-4)	QD (D1-4)					113	315	1
MMRF_2011	First line of therapy	Prednisone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		60	QD (D1-4)	QD (D1-4)					5	98	1
MMRF_2011	First line of therapy	Prednisone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		60	QD (D1-4)	QD (D1-4)					113	315	1
MMRF_2011	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	SC	Log Forms	Induction	Induction		1	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)					137	227	1
MMRF_2011	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	SC	Log Forms	Induction	Induction		1	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)					239	259	1
MMRF_2011	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	SC	Log Forms	Induction	Induction		1	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)					267	280	1
MMRF_2085	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	SC	Log Forms	Induction	Induction		1.3	Other	DAY 1,4,8,11,22,25,29,32 (CYCLES OF 42 DAYS)					1	9	1
MMRF_2085	First line of therapy	Melphalan		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	QD (D1-4)	QD (D1-4)					1	4	1
MMRF_2085	First line of therapy	Prednisone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		120	QD (D1-4)	QD (D1-4)					1	4	1
MMRF_2085	Second Line Therapy (after first relapse)	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Induction	Induction		1000	Other	ONLY 1 DAY					96	96	1
MMRF_2085	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	IV	Log Forms	Induction	Induction		40	QD (D1-4)	QD (D1-4)					96	99	1
MMRF_2085	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					122	141	1
MMRF_2085	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					122	141	1
MMRF_2085	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					418	435	1
MMRF_2085	Second Line Therapy (after first relapse)	Melphalan		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		20	QD (D1-4)	QD (D1-4)					234	417	1
MMRF_2085	Second Line Therapy (after first relapse)	Prednisone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		120	QD (D1-4)	QD (D1-4)					234	417	1
MMRF_2229	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					1	239	1
MMRF_2229	First line of therapy	Cyclophosphamide		Completed regimen	mg	PO	Log Forms	Induction	Induction		250	Other	DAYS 2,9,16					1	28	1
MMRF_2229	First line of therapy	Prednisone		Completed regimen	mg	PO	Log Forms	Induction	Induction		100	Other	3 TIMES PER WEEK (MONDAY, WEDNESDAY AND FRIDAY)					1	250	1
MMRF_2229	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Induction	Induction		1000	Other	DAY 1 OF EACH CYCLE					29	225	1
MMRF_2229	First line of therapy	Bortezomib		TOXICITY	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	DAY 1 AND 8 OF CYCLES OF 28 DAYS					337	966	1
MMRF_2229	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					533	1002	1
MMRF_2229	First line of therapy	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms	Maintenance	Maintenance		1	Other	DAY 1 AND 8 OF CYCLES OF 28 DAYS					967	1002	1
MMRF_2229	Second Line Therapy (after first relapse)	Daratumumab		Adverse Event or co-morbidity	mg	IV	Log Forms	Induction	Induction		1056	Q week	Q week					1248	1342	1
MMRF_2229	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1248	1347	1
MMRF_2229	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	IV	Log Forms	Induction	Induction		40	Q week	Q week					1248	1347	1
MMRF_2328	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Other	D1, D4, D8, D11, D21, D24, D28, D31					5	35	1
MMRF_2328	First line of therapy	Cyclophosphamide		INTERRUPTED DUE TO MOBILIZATION PREVIOUS TPH	mg	IV	Log Forms	Induction	Induction		1000	Other	D1, D21					5	272	1
MMRF_2328	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		40	Other	D1-4, D25-28					1	28	1
MMRF_2328	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	SUBCUTANEOS	Log Forms	Induction	Induction		1	Other	D1, D4, D8, D11, D21, D24, D28, D31					53	56	1
MMRF_2328	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	SUBCUTANEOS	Log Forms	Induction	Induction		0.7	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					137	165	1
MMRF_2328	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	SUBCUTANEOS	Log Forms	Induction	Induction		1	Other	D1, D4, D8, D11, D21, D24, D28, D31					63	77	1
MMRF_2328	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	SUBCUTANEOS	Log Forms	Induction	Induction		1	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					179	207	1
MMRF_2328	First line of therapy	Bortezomib		INTERRUPTED DUE TO MOBILIZATION PREVIOUS TPH	mg/m^2	SUBCUTANEOS	Log Forms	Induction	Induction		1.3	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					221	272	1
MMRF_2328	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		40	Other	D25-28					74	161	1
MMRF_2328	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		40	Other	D1-4, D25-28					179	357	1
MMRF_2328	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION OF PERIPHERAL BLOOD HEMATOPOIETIC PROGENITORS		2870	Q day	Q day					273	273	1
MMRF_2328	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	SUBCUTANEOUS	Log Forms	Induction	Induction		1.3	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					312	354	1
MMRF_2328	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	IN ORDER TO OBTAIN A BETTER RESPONSE PREVIOUS TO TPH, THERE WAS NO RELAPSE/PROGRESSION		25	QD (D1-21)	QD (D1-21)					426	572	1
MMRF_2328	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	IN ODER TO OBTAIN A BETTER RESPONSE PREVIOUS TO TPH, THERE WAS NO RELAPSE/PROGRESSION		40	Other	D1-4, D9-12, D17-20					426	572	1
MMRF_2328	First line of therapy	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Other	MOBILIZATION OF PERIPHERAL BLOOD HEMATOPOIETIC PROGENITORS		2870	Q day	Q day					385	385	1
MMRF_2328	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		40	Other	D 1-4, D8-11					813	823	1
MMRF_2328	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					690	774	1
MMRF_2328	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					690	774	1
MMRF_2328	Third Line Therapy (following 2nd relapse)	Carfilzomib		Adverse Event or co-morbidity	mg	IV	Log Forms	Induction	Induction		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					824	858	1
MMRF_2328	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	IV+PO	Log Forms	Induction	Induction		40	Q week	Q week					824	879	1
MMRF_2328	Third Line Therapy (following 2nd relapse)	Cyclophosphamide		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		545	Q week	Q week					824	879	1
MMRF_2328	Third Line Therapy (following 2nd relapse)	Carfilzomib		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		66	QID	QID					866	867	1
MMRF_2328	Third Line Therapy (following 2nd relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		40	Q day	Q day					880	883	1
MMRF_2328	Fourth Line Therapy (following 3rd relapse)	Daratumumab		Adverse Event or co-morbidity	mg	IV	Log Forms	Induction	Induction		1176	Q week	Q week					908	919	1
MMRF_2328	Fourth Line Therapy (following 3rd relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					908	919	1
MMRF_2328	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	IV	Log Forms	Induction	Induction		40	Q week	Q week					908	919	1
MMRF_2328	Fourth Line Therapy (following 3rd relapse)	Pomalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		4	Q day	Q day					939	941	1
MMRF_2328	Fourth Line Therapy (following 3rd relapse)	CLARITROMICINE		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		500	BID	BID					939	941	1
MMRF_2328	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					939	941	1
MMRF_2328	Fourth Line Therapy (following 3rd relapse)	Daratumumab		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		1100	Q week	Q week					945	970	1
MMRF_2328	Fourth Line Therapy (following 3rd relapse)	Bortezomib		Disease progression/Relapse	mg	SC	Log Forms	Induction	Induction		2.3	Other	D1, D7					945	970	1
MMRF_2328	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Disease progression/Relapse	mg	IV	Log Forms	Induction	Induction		40	Q week	Q week					945	970	1
MMRF_2401	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		40	QD (D1-4)	QD (D1-4)					251	270	1
MMRF_2401	Third Line Therapy (following 2nd relapse)	CLARITHROMYCIN		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		500	Other	12 HOURS					251	270	1
MMRF_2401	Third Line Therapy (following 2nd relapse)	CISPLATINE		Disease progression/Relapse	mg/m^2	IV	Log Forms	Unknown	Unknown		10	QD (D1-4)	QD (D1-4)					251	270	1
MMRF_2401	Third Line Therapy (following 2nd relapse)	ETOPOSIDE (VP16)		Disease progression/Relapse	mg/m^2	IV	Log Forms	Unknown	Unknown		40	QD (D1-4)	QD (D1-4)					251	270	1
MMRF_2401	Third Line Therapy (following 2nd relapse)	Doxorubicin		Disease progression/Relapse	mg/m^2	IV	Log Forms	Unknown	Unknown		10	QD (D1-4)	QD (D1-4)					251	270	1
MMRF_2401	Third Line Therapy (following 2nd relapse)	Melphalan		Disease progression/Relapse	mg	IV	Log Forms	Unknown	Unknown		16	QD (D1-4)	QD (D1-4)					251	270	1
MMRF_2401	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	PO	Log Forms	Maintenance	Maintenance		20	QD (D1-4)	QD (D1-4)					295	298	1
MMRF_2401	First line of therapy	Thalidomide		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		50	Q day	Q day					1	14	1
MMRF_2401	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	IV AND PO	Log Forms	Induction	Induction		40	Other	DAY 1-4, DAY 8-11					1	98	1
MMRF_2401	Second Line Therapy (after first relapse)	Bortezomib		EVOLUTION TO PLASMA CELL LEUKEMIA	mg/m^2	SUBCUTANEOS	Log Forms	Induction	Induction		1.3	Other	QD (D1, 5, 8, 12,22, 26, 29, 33)					123	249	1
MMRF_2401	Second Line Therapy (after first relapse)	Cyclophosphamide		EVOLUTION TO PLASMA CELL LEUKEMIA	mg/m^2	IV	Log Forms	Induction	Induction		1000	Other	QD (D1, D22)					123	249	1
MMRF_2401	Second Line Therapy (after first relapse)	Dexamethasone		EVOLUTION TO PLASMA CELL LEUKEMIA	mg	IV + PO	Log Forms	Induction	Induction		40	Other	QD (D1-4, D22-25)					123	249	1
MMRF_2401	First line of therapy	Thalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		100	Q day	Q day					15	115	1
MMRF_2401	Third Line Therapy (following 2nd relapse)	Melphalan		Disease progression/Relapse	mg	IV	Log Forms	Other	CONDITIONING FOR AUTO-TRASPLANT		167	Q day	Q day					271	272	1
MMRF_2401	Third Line Therapy (following 2nd relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		20	Other	EVERY 2 DAYS /WEEK					305	364	1
MMRF_2401	Third Line Therapy (following 2nd relapse)	Bortezomib		Adverse Event or co-morbidity	mg/m^2	SUBCUTANEOS	Log Forms	Maintenance	Maintenance		1	Q week	Q week					305	364	1
MMRF_2401	Third Line Therapy (following 2nd relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					305	350	1
MMRF_2401	First line of therapy	Bortezomib		Disease progression/Relapse	mg/m^2	SUBCUTANEOS	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	99	1
MMRF_2427	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	235	1
MMRF_2427	First line of therapy	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		40	Other	1-4 AND 9-12 DAYS					1	306	1
MMRF_2427	First line of therapy	Thalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		100	Q day	Q day					1	246	1
MMRF_2427	First line of therapy	CLARITROMICINA		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		500	BID	BID					180	250	1
MMRF_2427	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					246	250	1
MMRF_2427	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					344	370	1
MMRF_2427	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					344	398	1
MMRF_2427	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					371	398	1
MMRF_2427	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		10	Other	DAY1-21					446	554	1
MMRF_2427	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					446	554	1
MMRF_2435	First line of therapy	Bortezomib		Investigator decision for other reasons	mg/m^2	SUBCUTANEOS	Log Forms	Induction	Induction		1.3	Other	D 1, 4, 8, 11, 22, 25, 29, 32					1	32	1
MMRF_2435	First line of therapy	Melphalan		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		14	QD (D1-4)	QD (D1-4)					1	102	1
MMRF_2435	First line of therapy	Prednisone		Completed regimen	mg	PO	Log Forms	Induction	Induction		105	QD (D1-4)	QD (D1-4)					1	221	1
MMRF_2435	First line of therapy	Bortezomib		Completed regimen	mg/m^2	SUBCUTANEOS	Log Forms	Induction	Induction		1.3	Q week	Q week					43	218	1
MMRF_2435	First line of therapy	Melphalan		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		12	QD (D1-4)	QD (D1-4)					127	130	1
MMRF_2435	First line of therapy	Melphalan		Completed regimen	mg	PO	Log Forms	Induction	Induction		12	Q day	Q day					218	221	1
MMRF_2435	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		20	Q week	Q week					260	705	1
MMRF_2488	Second Line Therapy (after first relapse)	Carfilzomib	GEM-KYCYDEX		mg/m^2	IV	Log Forms	Induction	Induction	Checked	56	Other	D1, 8, 15 EVERY 28 DAYS					1585		1
MMRF_2488	Second Line Therapy (after first relapse)	Cyclophosphamide	GEM-KYCYDEX		mg/m^2	IV	Log Forms	Induction	Induction	Checked	300	Other	D1, 8, 15 EVERY 28 DAYS					1585		1
MMRF_2488	Second Line Therapy (after first relapse)	Dexamethasone	GEM-KYCYDEX		mg	PO	Log Forms	Induction	Induction	Checked	20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1585		1
MMRF_2488	First line of therapy	Bortezomib		EXTRACTION PROGENITORS FOR AUTO-TPH	mg/m^2	SUBCUTANEOS	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	90	1
MMRF_2488	First line of therapy	Lenalidomide		EXTRACTION PROGENITORS FOR AUTO-TPH	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	90	1
MMRF_2488	First line of therapy	Dexamethasone		EXTRACTION PROGENITORS FOR AUTO-TPH	mg	PO	Log Forms	Induction	Induction		40	Other	D1-4, D9-12					1	90	1
MMRF_2488	First line of therapy	Bortezomib		Completed regimen	mg/m^2	SUBCUTANEOS	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					105	188	1
MMRF_2488	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					105	188	1
MMRF_2488	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	D1-4, D8-11					105	188	1
MMRF_2488	First line of therapy	BUSULFAN		Completed regimen	mg/kg	IV	Log Forms	Other	CONDITIONING FOR AUTO-TPH		3.2	Q day	Q day					243	245	1
MMRF_2488	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Other	CONDITIONING FOR AUTO-TPH		140	Q day	Q day					246	246	1
MMRF_2488	First line of therapy	Bortezomib		Completed regimen	mg/m^2	SUBCUTANEOS	Log Forms	Consolidation	Consolidation		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					346	402	1
MMRF_2488	First line of therapy	Lenalidomide		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					346	402	1
MMRF_2488	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Consolidation	Consolidation		40	Other	D1-4, D8-11					346	402	1
MMRF_2488	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					430	609	1
MMRF_2488	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Maintenance	Maintenance		20	Other	DAYS 1-4 AND 9-12					430	609	1
MMRF_2488	First line of therapy	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					700	1520	1
MMRF_2488	First line of therapy	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Maintenance	Maintenance		20	Other	D1-4, 8-11					700	1520	1
MMRF_2490	First line of therapy	Bortezomib		DOSE CHANGED	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_2490	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		20	Other	DAYS 1-4 AND 8-11					1	53	1
MMRF_2490	First line of therapy	Bortezomib		Disease progression/Relapse	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1	Q week	Q week					54	82	1
MMRF_2490	First line of therapy	Melphalan		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		8	QD (D1-4)	QD (D1-4)					54	82	1
MMRF_2490	First line of therapy	Prednisone		Disease progression/Relapse	mg/m^2	PO	Log Forms	Induction	Induction		60	Q week	Q week					54	82	1
MMRF_2490	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					91	146	1
MMRF_2490	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Induction	Induction		20	Q week	Q week					91	146	1
MMRF_2490	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					161	343	1
MMRF_2490	Second Line Therapy (after first relapse)	Cyclophosphamide		Adverse Event or co-morbidity	mg	IV	Log Forms	Induction	Induction		1000	Other	DAY 1 OF EACH CYCLE					161	343	1
MMRF_2490	Second Line Therapy (after first relapse)	CLARITROMICINA		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		500	Other	BID DURING 21 DAYS					161	343	1
MMRF_2490	Second Line Therapy (after first relapse)	Thalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		50	Q day	Q day					161	223	1
MMRF_2518	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)					1	42	1
MMRF_2518	First line of therapy	Melphalan		Patient decision	mg	PO	Log Forms	Induction	Induction		16	QD (D1-4)	QD (D1-4)					1	171	1
MMRF_2518	First line of therapy	Prednisone		Patient decision	mg	PO	Log Forms	Induction	Induction		105	QD (D1-4)	QD (D1-4)					1	171	1
MMRF_2518	First line of therapy	Daratumumab		Completed regimen	mg	IV	Log Forms	Induction	Induction		1168	QWK	QWK					1	42	1
MMRF_2518	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					43	125	1
MMRF_2518	First line of therapy	Daratumumab		Patient decision	mg/kg	IV	Log Forms	Induction	Induction		16	QD (D1-21)	QD (D1-21)					43	188	1
MMRF_2518	First line of therapy	Bortezomib		Patient decision	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1	Q week	Q week					126	237	1
MMRF_2293	First line of therapy	Bortezomib			mg/m^2	IV SubQ	Log Forms	Induction	Induction	Checked	1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_2293	First line of therapy	Thalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		200	Q day	Q day					1	399	1
MMRF_2293	First line of therapy	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	40	Other	QD (D1-4, D 9-13)					1		1
MMRF_2293	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Other	ONE DOSE					297	297	1
MMRF_2300	First line of therapy	Bortezomib		EXITUS	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					3	66	1
MMRF_2300	First line of therapy	Dexamethasone		Completed regimen	mg	IV	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	14	1
MMRF_2300	First line of therapy	Prednisone		EXITUS	mg	PO	Log Forms	Induction	Induction		100	QD (D1-4)	QD (D1-4)					24	66	1
MMRF_2300	First line of therapy	Cyclophosphamide		EXITUS	mg	IV	Log Forms	Induction	Induction		1000	Other	Q 3WK					42	66	1
MMRF_2313	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Other	ONE DOSE					267	267	1
MMRF_2313	Fourth Line Therapy (following 3rd relapse)	Cyclophosphamide		Disease progression/Relapse	mg	IV	Log Forms	Unknown	Unknown		1000	Other	EVERY TWO WEEKS					1610	1893	1
MMRF_2313	Fourth Line Therapy (following 3rd relapse)	Pomalidomide		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					1624	1933	1
MMRF_2313	Fourth Line Therapy (following 3rd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Unknown	Unknown		40	QD (D1-21)	QD (D1-21)					1624	1933	1
MMRF_2313	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	235	1
MMRF_2313	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	QD (D1-4, D 9-13)					1	235	1
MMRF_2313	First line of therapy	Thalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		200	Q day	Q day					8	235	1
MMRF_2313	Second Line Therapy (after first relapse)	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Other	TREATMENT AT RELAPSE WHILE WAITING FOR A DEFINITIVE REGIMEN		2.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					749	759	1
MMRF_2313	Second Line Therapy (after first relapse)	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Other	TREATMENT AT RELAPSE WHILE WAITING FOR A DEFINITIVE REGIMEN		500	Other	SINGLE DOSE					743	743	1
MMRF_2313	Second Line Therapy (after first relapse)	Dexamethasone		Completed regimen	mg	IV	Log Forms	Other	TREATMENT AT RELAPSE WHILE WAITING FOR A DEFINITIVE REGIMEN		40	Q day	Q day					743	746	1
MMRF_2313	Second Line Therapy (after first relapse)	Carfilzomib		Disease progression/Relapse	mg	IV	Log Forms	Other	TREATMENT AT RELAPSE		60	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					773	1282	1
MMRF_2313	Second Line Therapy (after first relapse)	Lenalidomide		Disease progression/Relapse	mg	PO	Log Forms	Other	TREATMENT AT RELAPSE		25	QD (D1-21)	QD (D1-21)					773	1610	1
MMRF_2313	Second Line Therapy (after first relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	TREATMENT AT RELAPSE		40	Other	D1, D8, CD15, D22					773	1282	1
MMRF_2313	Third Line Therapy (following 2nd relapse)	Daratumumab		Disease progression/Relapse	mg	IV	Log Forms	Other	TREATMENT AT RELAPSE		1878	QWK	QWK					1295	1610	1
MMRF_2313	Third Line Therapy (following 2nd relapse)	Dexamethasone		Disease progression/Relapse	mg	PO	Log Forms	Other	TREATMENT AT RELAPSE		20	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1295	1610	1
MMRF_2314	First line of therapy	Bortezomib		EXITUS	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					2	90	1
MMRF_2314	First line of therapy	Dexamethasone		EXITUS	mg	IV	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	90	1
MMRF_2314	First line of therapy	Thalidomide		EXITUS	mg	PO	Log Forms	Induction	Induction		50	Q day	Q day					5	90	1
MMRF_2327	First line of therapy	Bortezomib		Lack of response	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	Other	QD (D1, D4, D8, D11, D22, D25, D29, D32)					1	204	1
MMRF_2327	First line of therapy	Melphalan		Lack of response	mg	PO	Log Forms	Induction	Induction		16	QD (D1-4)	QD (D1-4)					2	204	1
MMRF_2327	First line of therapy	Prednisone		Lack of response	mg	PO	Log Forms	Induction	Induction		100	QD (D1-4)	QD (D1-4)					2	204	1
MMRF_2327	First line of therapy	Cyclophosphamide		Investigator decision for other reasons	mg	IV	Log Forms	Unknown	Unknown		1000	Q day	Q day					225	225	1
MMRF_2327	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		25	QD (D1-21)	QD (D1-21)					263	1108	1
MMRF_2327	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		40	QD (D1-4)	QD (D1-4)					263	1108	1
MMRF_2327	Second Line Therapy (after first relapse)	Lenalidomide		Lack of response	mg	PO	Log Forms	Unknown	Unknown		10	QD (D1-21)	QD (D1-21)					1140	1196	1
MMRF_2327	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		20	Q week	Q week					1140	1507	1
MMRF_2327	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		25	QD (D1-21)	QD (D1-21)					1196	1507	1
MMRF_2364	First line of therapy	Bortezomib		EXITUS	mg	IV SubQ	Log Forms	Induction	Induction		2.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	156	1
MMRF_2364	First line of therapy	Dexamethasone		EXITUS	mg	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	156	1
MMRF_2364	First line of therapy	Thalidomide		EXITUS	mg	PO	Log Forms	Induction	Induction		200	Q day	Q day					1	156	1
MMRF_2452	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		2.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	168	1
MMRF_2452	First line of therapy	Thalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		200	Q day	Q day					1	294	1
MMRF_2452	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	QD (D1-4, D9-13)					1	170	1
MMRF_2452	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Other	ONE DOSE					192	192	1
MMRF_2535	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					3	200	1
MMRF_2535	First line of therapy	Thalidomide		Completed regimen	mg	PO	Log Forms	Induction	Induction		200	Q day	Q day					17	200	1
MMRF_2535	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	D 1-4, D 5-9 Q 28D					1	200	1
MMRF_2535	Second Line Therapy (after first relapse)	Vincristine		Completed regimen	mg	IV	Log Forms	Other	SECOND LINE THERAPY AFTER FIRST RELAPSE		2	Other	Q10WEEK					342	358	1
MMRF_2535	Second Line Therapy (after first relapse)	CARMUSTINE		Completed regimen	mg	IV	Log Forms	Other	SECOND LINE THERAPY AFTER FIRST RELAPSE		37	Other	Q10 SEMANAS					342	358	1
MMRF_2535	Second Line Therapy (after first relapse)	Cyclophosphamide		Completed regimen	mg	IV	Log Forms	Other	SECOND LINE THERAPY AFTER FIRST RELAPSE		749	Other	Q10WEEK					342	358	1
MMRF_2535	Second Line Therapy (after first relapse)	Melphalan		Completed regimen	mg	PO	Log Forms	Other	SECOND LINE THERAPY AFTER FIRST RELAPSE		20	QD (D1-4)	QD (D1-4)					341	358	1
MMRF_2535	Second Line Therapy (after first relapse)	Prednisone		Completed regimen	mg	PO	Log Forms	Other	SECOND LINE THERAPY AFTER FIRST RELAPSE		75	QD (D1-4)	QD (D1-4)					341	358	1
MMRF_2535	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		200	Other	SINGLE DOSE					212	212	1
MMRF_2572	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		2.3	Other	QD (D1, D4, D8, D11, D22, D25, D29, D32)					1	376	1
MMRF_2572	First line of therapy	Melphalan		Completed regimen	mg	PO	Log Forms	Induction	Induction		16	QD (D1-4)	QD (D1-4)					1	376	1
MMRF_2572	First line of therapy	Prednisone		Completed regimen	mg	PO	Log Forms	Induction	Induction		100	QD (D1-4)	QD (D1-4)					1	376	1
MMRF_2572	Second Line Therapy (after first relapse)	Cyclophosphamide		Lack of response	mg	IV	Log Forms	Other	SECOND LINE AFTER FIRST PROGRESSION		750	Other	EVERY 2 MONTHS					813	876	1
MMRF_2572	Second Line Therapy (after first relapse)	Bortezomib		Lack of response	mg	IV SubQ	Log Forms	Other	SECOND LINE AFTER FIRST PROGRESSSION		2	Other	DAYS 1 AND 8					652	729	1
MMRF_2572	Second Line Therapy (after first relapse)	Cyclophosphamide		Lack of response	mg	PO	Log Forms	Other	SECOND LINE AFTER FIRST PROGRESSION		50	Q day	Q day					652	715	1
MMRF_2572	Third Line Therapy (following 2nd relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Other	SECOND LINE AFTER FIRST PROGRESSION		10	QD (D1-21)	QD (D1-21)					887	1103	1
MMRF_2572	Third Line Therapy (following 2nd relapse)	Dexamethasone		Lack of response	mg	PO	Log Forms	Other	SECOND LINE AFTER FIRST PROGRESSION		16	QWK	QWK					887	1103	1
MMRF_2601	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		2.47	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	366	1
MMRF_2601	First line of therapy	Melphalan		Completed regimen	mg	PO	Log Forms	Induction	Induction		16	QD (D1-4)	QD (D1-4)					1	341	1
MMRF_2601	First line of therapy	Prednisone		Completed regimen	mg	PO	Log Forms	Induction	Induction		100	QD (D1-4)	QD (D1-4)					1	341	1
MMRF_2601	Second Line Therapy (after first relapse)	Lenalidomide			mg	PO	Log Forms	Other	TREATMENE AT FIRST RELAPSE	Checked	25	QD (D1-21)	QD (D1-21)					575		1
MMRF_2601	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Other	TREATMENE AT FIRST RELAPSE	Checked	40	Other	D1, D8, D15, D22					575		1
MMRF_2613	First line of therapy	Bortezomib		Completed regimen	mg	IV SubQ	Log Forms	Induction	Induction		2.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	326	1
MMRF_2613	First line of therapy	Melphalan		DEATH	mg	PO	Log Forms	Induction	Induction		14	QD (D1-4)	QD (D1-4)					4	621	1
MMRF_2613	First line of therapy	Prednisone		Completed regimen	mg	PO	Log Forms	Induction	Induction		100	QD (D1-4)	QD (D1-4)					4	326	1
MMRF_2613	Second Line Therapy (after first relapse)	Lenalidomide		Lack of response	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					344	534	1
MMRF_2613	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	QD (D1-4)	QD (D1-4)					344	348	1
MMRF_2613	Third Line Therapy (following 2nd relapse)	Cyclophosphamide		Lack of response	mg	IV	Log Forms	Other	TREATMENE AT SECOND RELAPSE		1000	Other	D1 EVERY 28 DAYS					536	575	1
MMRF_2613	Third Line Therapy (following 2nd relapse)	Carfilzomib		DEATH	mg	IV	Log Forms	Other	TREATMENT AT RELAPSE		44	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					582	621	1
MMRF_2613	Third Line Therapy (following 2nd relapse)	Lenalidomide		DEATH	mg	PO	Log Forms	Other	TREATMENT AT RELAPSE		25	QD (D1-21)	QD (D1-21)					582	621	1
MMRF_2613	Third Line Therapy (following 2nd relapse)	Dexamethasone		DEATH	mg	PO	Log Forms	Other	TREATMENT AT RELAPSE		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					582	621	1
MMRF_2016	First line of therapy	Bortezomib		Adverse Event or co-morbidity	mg/m^2	SC	Log Forms	Unknown	Unknown		1.3	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)					1	107	1
MMRF_2016	First line of therapy	Melphalan		Adverse Event or co-morbidity	mg/m^2	PO	Log Forms	Unknown	Unknown		9	QD (D1-4)	QD (D1-4)					1	107	1
MMRF_2016	First line of therapy	Prednisone		Adverse Event or co-morbidity	mg	PO	Log Forms	Unknown	Unknown		120	QD (D1-4)	QD (D1-4)					1	107	1
MMRF_2016	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					124	1520	1
MMRF_2016	First line of therapy	Prednisone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		10	Q day	Q day					124	1520	1
MMRF_2268	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)					1	85	1
MMRF_2268	First line of therapy	Prednisone		Completed regimen	mg/m^2	PO	Log Forms	Induction	Induction		60	QD (D1-4)	QD (D1-4)					1	405	1
MMRF_2268	First line of therapy	Melphalan		Completed regimen	mg/m^2	PO	Log Forms	Induction	Induction		9	QD (D1-4)	QD (D1-4)					1	405	1
MMRF_2268	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					92	405	1
MMRF_2268	Second Line Therapy (after first relapse)	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Induction	Induction		27	Other	DAYS 1,2, 8,9, 15,16					907	1184	1
MMRF_2268	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	Q day	Q day					907	1548	1
MMRF_2268	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		20	QWK	QWK					907	1548	1
MMRF_2305	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	131	1
MMRF_2305	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		900	Other	EVERY THREE WEEKS					1	131	1
MMRF_2305	First line of therapy	Prednisone		Lack of response	mg	PO	Log Forms	Induction	Induction		15	Q day	Q day					1	131	1
MMRF_2305	Second Line Therapy (after first relapse)	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IV	Log Forms	Induction	Induction		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					873	889	1
MMRF_2305	Second Line Therapy (after first relapse)	Lenalidomide			mg	PO	Log Forms	Induction	Induction	Checked	25	QD (D1-21)	QD (D1-21)					862		1
MMRF_2305	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	40	Q week	Q week					862		1
MMRF_2421	First line of therapy	Bortezomib		Completed regimen	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	98	1
MMRF_2421	First line of therapy	Dexamethasone		Completed regimen	mg	PO	Log Forms	Induction	Induction		40	Other	QD1,2,4,5,8,9,11,12					1	98	1
MMRF_2421	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	IV	Log Forms	Induction	Induction		900	Other	EVERY 3 WEEKS					1	98	1
MMRF_2444	First line of therapy	Bortezomib		PAIENT DIED 23.05.15 AT 00:05H	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)					1	75	1
MMRF_2444	First line of therapy	Melphalan		Adverse Event or co-morbidity	mg/m^2	PO	Log Forms	Induction	Induction		9	QD (D1-4)	QD (D1-4)					1	75	1
MMRF_2444	First line of therapy	Prednisone		Adverse Event or co-morbidity	mg/m^2	PO	Log Forms	Induction	Induction		60	QD (D1-4)	QD (D1-4)					1	75	1
MMRF_2558	First line of therapy	Bortezomib		Patient decision	mg/m^2	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)					1	113	1
MMRF_2558	First line of therapy	Melphalan		Patient decision	mg/m^2	PO	Log Forms	Induction	Induction		9	Other	D1,D9					1	113	1
MMRF_2558	First line of therapy	Prednisone		Patient decision	mg/m^2	PO	Log Forms	Induction	Induction		60	Other	D1, D9					1	113	1
MMRF_2195	First line of therapy	Bortezomib		Completed regimen	mg	SUBCUTANEOUS	Log Forms	Induction	Induction		2.4	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	405	1
MMRF_2195	First line of therapy	Melphalan		Completed regimen	mg	PO	Log Forms	Induction	Induction		16	QD (D1-4)	QD (D1-4)					1	380	1
MMRF_2195	First line of therapy	Prednisone		Completed regimen	mg	PO	Log Forms	Induction	Induction		75	QD (D1-4)	QD (D1-4)					1	380	1
MMRF_2195	Second Line Therapy (after first relapse)	Lenalidomide		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					741	1149	1
MMRF_2195	Second Line Therapy (after first relapse)	Dexamethasone		Adverse Event or co-morbidity	mg	PO	Log Forms	Induction	Induction		40	Q week	Q week					741	784	1
MMRF_2195	Second Line Therapy (after first relapse)	Carfilzomib		Investigator decision for other reasons	mg/m^2	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1294	1362	1
MMRF_2195	Second Line Therapy (after first relapse)	Dexamethasone		Investigator decision for other reasons	mg	PO	Log Forms	Induction	Induction		40	QWK	QWK					1294	1362	1
MMRF_2195	Third Line Therapy (following 2nd relapse)	Cyclophosphamide		INSUFFICIENT RESPONSE	mg	IV	Log Forms	Other	PALLIATIVE CARE		750	Other	MONTHLY					1362	1490	1
MMRF_2195	Third Line Therapy (following 2nd relapse)	Daratumumab		Adverse Event or co-morbidity	mg	IV	Log Forms	Induction	Induction		1000	Other	WEEKLY FIRST 2 CYCLES. BIWEEKLY AFTERWARDS					1552	1678	1
MMRF_2317	First line of therapy	Bortezomib		Completed regimen	mg	SUBCUTANEOUS	Log Forms	Induction	Induction		1.8	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	338	1
MMRF_2317	First line of therapy	Melphalan		Completed regimen	mg	PO	Log Forms	Induction	Induction		16	QD (D1-4)	QD (D1-4)					1	288	1
MMRF_2317	First line of therapy	Prednisone		Completed regimen	mg	PO	Log Forms	Induction	Induction		75	QD (D1-4)	QD (D1-4)					1	319	1
MMRF_2317	Second Line Therapy (after first relapse)	Lenalidomide			mg	PO	Log Forms	Induction	Induction	Checked	15	QD (D1-21)	QD (D1-21)					610		1
MMRF_2317	Second Line Therapy (after first relapse)	Dexamethasone			mg	PO	Log Forms	Induction	Induction	Checked	20	Q week	Q week					610		1
MMRF_2426	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle		Fatigue			1	64	1
MMRF_2426	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	125	1
MMRF_2426	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	125	1
MMRF_2426	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			10	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					64	125	1
MMRF_2426	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					125	135	1
MMRF_2426	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		344	Oth	prior to stem cell infusion					169	169	1
MMRF_2426	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					262	443	1
MMRF_2426	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Consolidation			25	Oth	Days 1-21 per cycle					262	443	1
MMRF_2426	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Consolidation			10	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					262	443	1
MMRF_2426	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Maintenance			10	Oth	Days 1-21 per cycle					443	583	1
MMRF_2583	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	116	1
MMRF_2583	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	116	1
MMRF_2583	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	116	1
MMRF_2583	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					116	128	1
MMRF_2583	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		292	Oth	prior to stem cell infusion					157	157	1
MMRF_2583	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					267	414	1
MMRF_2583	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Consolidation			25	Oth	Days 1-21 per cycle					267	414	1
MMRF_2583	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					267	414	1
MMRF_2583	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Maintenance			10	Oth	Days 1-21 per cycle					414	526	1
MMRF_2584	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	118	1
MMRF_2584	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle					1	118	1
MMRF_2584	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	118	1
MMRF_2584	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					118	129	1
MMRF_2584	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		284	Oth	prior to stem cell infusion					153	153	1
MMRF_2584	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO		Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle		Respiratory tox			267	267	1
MMRF_2584	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					267	422	1
MMRF_2584	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Consolidation			300	Oth	Days 1, 8, 15 per cycle					267	422	1
MMRF_2584	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Consolidation			10	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					267	422	1
MMRF_2584	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Maintenance			10	Oth	Days 1-21 per cycle					422	534	1
MMRF_2604	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	133	1
MMRF_2604	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle					1	133	1
MMRF_2604	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	133	1
MMRF_2604	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					133	143	1
MMRF_2604	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		390	Oth	prior to stem cell infusion					203	203	1
MMRF_2604	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					311	437	1
MMRF_2604	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Consolidation			300	Oth	Days 1, 8, 15 per cycle					311	437	1
MMRF_2604	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					311	437	1
MMRF_2604	First line of therapy	Carfilzomib			mg/m^2	IV		Maintenance		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					437		1
MMRF_2604	First line of therapy	Lenalidomide			mg	PO		Maintenance		Checked	10	Oth	Days 1-21 per cycle					437		1
MMRF_2609	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	114	1
MMRF_2609	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	114	1
MMRF_2609	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	114	1
MMRF_2609	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					114	125	1
MMRF_2609	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					169	407	1
MMRF_2609	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Consolidation			25	Oth	Days 1-21 per cycle					169	407	1
MMRF_2609	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					169	407	1
MMRF_2609	First line of therapy	Lenalidomide			mg	PO		Maintenance		Checked	10	Oth	Days 1-21 per cycle					407		1
MMRF_2624	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	114	1
MMRF_2624	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle					1	114	1
MMRF_2624	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	114	1
MMRF_2624	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					114	125	1
MMRF_2624	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		320	Oth	prior to stem cell infusion					161	161	1
MMRF_2624	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					274	405	1
MMRF_2624	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Consolidation			300	Oth	Days 1, 8, 15 per cycle					274	405	1
MMRF_2624	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					274	405	1
MMRF_2624	First line of therapy	Carfilzomib			mg/m^2	IV		Maintenance		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					405		1
MMRF_2624	First line of therapy	Lenalidomide			mg	PO		Maintenance		Checked	10	Oth	Days 1-21 per cycle					405		1
MMRF_2626	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	130	1
MMRF_2626	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	130	1
MMRF_2626	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	130	1
MMRF_2626	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					130	142	1
MMRF_2626	First line of therapy	Carfilzomib			mg/m^2	IV		Consolidation		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					218		1
MMRF_2626	First line of therapy	Lenalidomide			mg	PO		Consolidation		Checked	25	Oth	Days 1-21 per cycle					218		1
MMRF_2626	First line of therapy	Dexamethasone			mg	PO		Consolidation		Checked	20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					218		1
MMRF_2628	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	114	1
MMRF_2628	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	114	1
MMRF_2628	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	114	1
MMRF_2628	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					114	127	1
MMRF_2628	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		390	Oth	prior to stem cell infusion					157	157	1
MMRF_2628	First line of therapy	Carfilzomib			mg/m^2	IV		Consolidation		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					253		1
MMRF_2628	First line of therapy	Lenalidomide			mg	PO		Consolidation		Checked	25	Oth	Days 1-21 per cycle					253		1
MMRF_2628	First line of therapy	Dexamethasone			mg	PO		Consolidation		Checked	20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					253		1
MMRF_2630	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	139	1
MMRF_2630	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	139	1
MMRF_2630	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	139	1
MMRF_2630	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					139	151	1
MMRF_2630	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		380	Oth	prior to stem cell infusion					198	198	1
MMRF_2630	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					296	429	1
MMRF_2630	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Consolidation			25	Oth	Days 1-21 per cycle					296	429	1
MMRF_2630	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					296	429	1
MMRF_2630	First line of therapy	Carfilzomib			mg/m^2	IV		Maintenance		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					429		1
MMRF_2630	First line of therapy	Lenalidomide			mg	PO		Maintenance		Checked	10	Oth	Days 1-21 per cycle					429		1
MMRF_2631	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	121	1
MMRF_2631	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle					1	121	1
MMRF_2631	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	121	1
MMRF_2631	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					121	132	1
MMRF_2631	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		390	Oth	prior to stem cell infusion					157	157	1
MMRF_2631	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					274	393	1
MMRF_2631	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Consolidation			300	Oth	Days 1, 8, 15 per cycle					274	393	1
MMRF_2631	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					274	393	1
MMRF_2631	First line of therapy	Carfilzomib			mg/m^2	IV		Maintenance		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					393		1
MMRF_2631	First line of therapy	Lenalidomide			mg	PO		Maintenance		Checked	10	Oth	Days 1-21 per cycle					393		1
MMRF_2634	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	117	1
MMRF_2634	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	117	1
MMRF_2634	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	117	1
MMRF_2634	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					117	129	1
MMRF_2634	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		386	Oth	prior to stem cell infusion					170	170	1
MMRF_2634	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					263	382	1
MMRF_2634	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Consolidation			25	Oth	Days 1-21 per cycle					263	382	1
MMRF_2634	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					263	382	1
MMRF_2634	First line of therapy	Lenalidomide			mg	PO		Maintenance		Checked	10	Oth	Days 1-21 per cycle					382		1
MMRF_2635	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	123	1
MMRF_2635	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	123	1
MMRF_2635	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	123	1
MMRF_2635	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					123	134	1
MMRF_2635	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		366	Oth	prior to stem cell infusion					163	163	1
MMRF_2635	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					275	385	1
MMRF_2635	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Consolidation			25	Oth	Days 1-21 per cycle					275	385	1
MMRF_2635	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					275	385	1
MMRF_2635	First line of therapy	Lenalidomide			mg	PO		Maintenance		Checked	10	Oth	Days 1-21 per cycle					385		1
MMRF_2636	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	113	1
MMRF_2636	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle					1	113	1
MMRF_2636	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	113	1
MMRF_2636	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					113	125	1
MMRF_2636	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		400	Oth	prior to stem cell infusion					158	158	1
MMRF_2636	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					259	371	1
MMRF_2636	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Consolidation			300	Oth	Days 1, 8, 15 per cycle					259	371	1
MMRF_2636	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					259	371	1
MMRF_2637	First line of therapy	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle		Hepatic tox			1	30	1
MMRF_2637	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO		Induction			25	Oth	Days 1-21 per cycle		Hepatic tox			1	30	1
MMRF_2637	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle		Hepatic tox			1	30	1
MMRF_2637	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO		Induction			15	Oth	Days 1-21 per cycle		Hepatic tox			30	71	1
MMRF_2637	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			20	Oth	Days 1-2, 8-9, 15-16 per cycle					30	144	1
MMRF_2637	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			4	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					30	144	1
MMRF_2637	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO		Induction			10	Oth	Days 1-21 per cycle		Hepatic tox			71	106	1
MMRF_2637	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			5	Oth	Days 1-21 per cycle					106	144	1
MMRF_2637	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					144	154	1
MMRF_2637	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		334	Oth	prior to stem cell infusion					185	185	1
MMRF_2637	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					281	393	1
MMRF_2637	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Consolidation			5	Oth	Days 1-21 per cycle					281	393	1
MMRF_2637	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Consolidation			4	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					281	393	1
MMRF_2638	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	120	1
MMRF_2638	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle					1	120	1
MMRF_2638	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	120	1
MMRF_2638	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					120	132	1
MMRF_2638	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		300	Oth	prior to stem cell infusion					163	163	1
MMRF_2638	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					260	386	1
MMRF_2638	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Consolidation			300	Oth	Days 1, 8, 15 per cycle					260	386	1
MMRF_2638	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					260	386	1
MMRF_2638	First line of therapy	Lenalidomide			mg	PO		Maintenance		Checked	10	Oth	Days 1-21 per cycle					386		1
MMRF_2639	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	146	1
MMRF_2639	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	146	1
MMRF_2639	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	146	1
MMRF_2639	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					146	155	1
MMRF_2639	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					203	441	1
MMRF_2639	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Consolidation			25	Oth	Days 1-21 per cycle					203	441	1
MMRF_2639	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					203	441	1
MMRF_2640	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	157	1
MMRF_2640	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle					1	157	1
MMRF_2640	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	157	1
MMRF_2640	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					157	170	1
MMRF_2640	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		370	Oth	prior to stem cell infusion					201	201	1
MMRF_2640	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					302	421	1
MMRF_2640	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Consolidation			300	Oth	Days 1, 8, 15 per cycle					302	421	1
MMRF_2640	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					302	421	1
MMRF_2640	First line of therapy	Carfilzomib			mg/m^2	IV		Maintenance		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					421		1
MMRF_2640	First line of therapy	Lenalidomide			mg	PO		Maintenance		Checked	10	Oth	Days 1-21 per cycle					421		1
MMRF_2641	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	128	1
MMRF_2641	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	128	1
MMRF_2641	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	128	1
MMRF_2641	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					128	140	1
MMRF_2641	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					232	428	1
MMRF_2641	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Consolidation			25	Oth	Days 1-21 per cycle					232	428	1
MMRF_2641	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					232	428	1
MMRF_2642	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	122	1
MMRF_2642	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	122	1
MMRF_2642	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	122	1
MMRF_2642	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					122	171	1
MMRF_2642	First line of therapy	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IV		Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle		asthenia			196	315	1
MMRF_2642	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Consolidation			25	Oth	Days 1-21 per cycle					196	427	1
MMRF_2642	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					196	427	1
MMRF_2642	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Consolidation			27	Oth	Days 1-2, 8-9, 15-16 per cycle					315	427	1
MMRF_2643	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	117	1
MMRF_2643	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle					1	117	1
MMRF_2643	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	117	1
MMRF_2643	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					117	128	1
MMRF_2643	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		380	Oth	prior to stem cell infusion					156	156	1
MMRF_2643	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					253	365	1
MMRF_2643	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Consolidation			300	Oth	Days 1, 8, 15 per cycle					253	365	1
MMRF_2643	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					253	365	1
MMRF_2647	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	138	1
MMRF_2647	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	138	1
MMRF_2647	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	138	1
MMRF_2647	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					138	150	1
MMRF_2647	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		370	Oth	prior to stem cell infusion					198	198	1
MMRF_2647	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					309	421	1
MMRF_2647	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Consolidation			25	Oth	Days 1-21 per cycle					309	421	1
MMRF_2647	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					309	421	1
MMRF_2644	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	130	1
MMRF_2644	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle					1	130	1
MMRF_2644	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	130	1
MMRF_2644	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					130	140	1
MMRF_2644	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		350	Oth	prior to stem cell infusion					162	162	1
MMRF_2644	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					260	384	1
MMRF_2644	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Consolidation			300	Oth	Days 1, 8, 15 per cycle					260	384	1
MMRF_2644	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					260	384	1
MMRF_2644	First line of therapy	Lenalidomide			mg	PO		Maintenance		Checked	10	Oth	Days 1-21 per cycle					384		1
MMRF_2646	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle		Hyperglicemia			1	42	1
MMRF_2646	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	127	1
MMRF_2646	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	127	1
MMRF_2646	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			15	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					42	127	1
MMRF_2646	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					127	138	1
MMRF_2646	First line of therapy	Carfilzomib			mg/m^2	IV		Consolidation		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					154		1
MMRF_2646	First line of therapy	Lenalidomide			mg	PO		Consolidation		Checked	25	Oth	Days 1-21 per cycle					154		1
MMRF_2646	First line of therapy	Dexamethasone			mg	PO		Consolidation		Checked	10	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					154		1
MMRF_2646	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO		Consolidation			15	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle		Investigations and metabolism disorders			154	154	1
MMRF_2648	First line of therapy	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle		GGT increased			1	50	1
MMRF_2648	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO		Induction			25	Oth	Days 1-21 per cycle		GGT increased			1	78	1
MMRF_2648	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	144	1
MMRF_2648	First line of therapy	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IV		Induction			27	Oth	Days 1-2, 8-9, 15-16 per cycle		GGT increased			50	78	1
MMRF_2648	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			20	Oth	Days 1-2, 8-9, 15-16 per cycle					78	144	1
MMRF_2648	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			15	Oth	Days 1-21 per cycle					78	144	1
MMRF_2648	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					144	155	1
MMRF_2648	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Consolidation			20	Oth	Days 1-2, 8-9, 15-16 per cycle					183	423	1
MMRF_2648	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Consolidation			15	Oth	Days 1-21 per cycle					183	423	1
MMRF_2648	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					183	423	1
MMRF_2648	First line of therapy	Carfilzomib			mg/m^2	IV		Maintenance		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					423		1
MMRF_2648	First line of therapy	Lenalidomide			mg	PO		Maintenance		Checked	10	Oth	Days 1-21 per cycle					423		1
MMRF_2650	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	149	1
MMRF_2650	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	149	1
MMRF_2650	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	149	1
MMRF_2650	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					149	163	1
MMRF_2650	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		340	Oth	prior to stem cell infusion					188	188	1
MMRF_2651	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	123	1
MMRF_2651	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle					1	123	1
MMRF_2651	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	123	1
MMRF_2651	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					123	136	1
MMRF_2651	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		368	Oth	prior to stem cell infusion					169	169	1
MMRF_2651	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					267	414	1
MMRF_2651	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Consolidation			300	Oth	Days 1, 8, 15 per cycle					267	414	1
MMRF_2651	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					267	414	1
MMRF_2651	First line of therapy	Carfilzomib			mg/m^2	IV		Maintenance		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					414		1
MMRF_2651	First line of therapy	Lenalidomide			mg	PO		Maintenance		Checked	10	Oth	Days 1-21 per cycle					414		1
MMRF_2652	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	117	1
MMRF_2652	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	117	1
MMRF_2652	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	117	1
MMRF_2652	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					117	150	1
MMRF_2652	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					157	415	1
MMRF_2652	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Consolidation			25	Oth	Days 1-21 per cycle					157	415	1
MMRF_2652	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					157	415	1
MMRF_2652	First line of therapy	Carfilzomib			mg/m^2	IV		Maintenance		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					415		1
MMRF_2652	First line of therapy	Lenalidomide			mg	PO		Maintenance		Checked	10	Oth	Days 1-21 per cycle					415		1
MMRF_2653	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	130	1
MMRF_2653	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	130	1
MMRF_2653	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	130	1
MMRF_2653	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					130	141	1
MMRF_2653	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					183	456	1
MMRF_2653	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Consolidation			25	Oth	Days 1-21 per cycle					183	456	1
MMRF_2653	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					183	456	1
MMRF_2654	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	116	1
MMRF_2654	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle					1	116	1
MMRF_2654	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	116	1
MMRF_2654	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					116	126	1
MMRF_2654	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		320	Oth	prior to stem cell infusion					175	175	1
MMRF_2655	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	150	1
MMRF_2655	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle					1	150	1
MMRF_2655	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	150	1
MMRF_2655	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					150	162	1
MMRF_2655	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		315	Oth	prior to stem cell infusion					183	183	1
MMRF_2655	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					300	447	1
MMRF_2655	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Consolidation			300	Oth	Days 1, 8, 15 per cycle					300	447	1
MMRF_2655	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					300	447	1
MMRF_2659	First line of therapy	Carfilzomib			mg/m^2	IV		Induction		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					1		1
MMRF_2659	First line of therapy	Lenalidomide			mg	PO		Induction		Checked	25	Oth	Days 1-21 per cycle					1		1
MMRF_2659	First line of therapy	Dexamethasone			mg	PO		Induction		Checked	20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1		1
MMRF_2660	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	123	1
MMRF_2660	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	123	1
MMRF_2660	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	123	1
MMRF_2660	First line of therapy	Carfilzomib			mg/m^2	IV		Consolidation		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					30		1
MMRF_2660	First line of therapy	Lenalidomide			mg	PO		Consolidation		Checked	25	Oth	Days 1-21 per cycle					30		1
MMRF_2660	First line of therapy	Dexamethasone			mg	PO		Consolidation		Checked	20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					30		1
MMRF_2660	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					123	134	1
MMRF_2660	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		400	Oth	prior to stem cell infusion					162	162	1
MMRF_2664	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	138	1
MMRF_2664	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	138	1
MMRF_2664	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	138	1
MMRF_2664	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					138	152	1
MMRF_2664	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		360	Oth	prior to stem cell infusion					183	183	1
MMRF_2664	First line of therapy	Carfilzomib			mg/m^2	IV		Consolidation		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					276		1
MMRF_2664	First line of therapy	Lenalidomide			mg	PO		Consolidation		Checked	25	Oth	Days 1-21 per cycle					276		1
MMRF_2664	First line of therapy	Dexamethasone			mg	PO		Consolidation		Checked	20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					276		1
MMRF_2665	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	115	1
MMRF_2665	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle					1	115	1
MMRF_2665	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	115	1
MMRF_2665	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					115	126	1
MMRF_2665	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		400	Oth	prior to stem cell infusion					168	168	1
MMRF_2665	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					223	344	1
MMRF_2665	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Consolidation			300	Oth	Days 1, 8, 15 per cycle					223	344	1
MMRF_2665	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					223	344	1
MMRF_2665	First line of therapy	Lenalidomide			mg	PO		Maintenance		Checked	10	Oth	Days 1-21 per cycle					344		1
MMRF_2667	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle		Costitutional Symptoms (Insomnia - Medical History			1	1	1
MMRF_2667	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	122	1
MMRF_2667	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	122	1
MMRF_2667	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			10	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	122	1
MMRF_2667	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					122	131	1
MMRF_2667	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		320	Oth	prior to stem cell infusion					162	162	1
MMRF_2667	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO		Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle		Gastrintestinal tox			247	275	1
MMRF_2667	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					247	366	1
MMRF_2667	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Consolidation			25	Oth	Days 1-21 per cycle					247	366	1
MMRF_2667	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Consolidation			10	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					275	366	1
MMRF_2667	First line of therapy	Lenalidomide			mg	PO		Maintenance		Checked	10	Oth	Days 1-21 per cycle					366		1
MMRF_2666	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	117	1
MMRF_2666	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle					1	117	1
MMRF_2666	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	117	1
MMRF_2666	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					117	128	1
MMRF_2666	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		388	Oth	prior to stem cell infusion					156	156	1
MMRF_2669	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO		Induction			25	Oth	Days 1-21 per cycle		Rash maculo-papular			1	62	1
MMRF_2669	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	128	1
MMRF_2669	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	128	1
MMRF_2669	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			15	Oth	Days 1-21 per cycle					62	128	1
MMRF_2669	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					128	140	1
MMRF_2669	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					230	342	1
MMRF_2669	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Consolidation			25	Oth	Days 1-21 per cycle					230	342	1
MMRF_2669	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					230	342	1
MMRF_2670	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	124	1
MMRF_2670	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	124	1
MMRF_2670	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	124	1
MMRF_2670	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					124	134	1
MMRF_2670	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					169	386	1
MMRF_2670	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Consolidation			25	Oth	Days 1-21 per cycle					169	386	1
MMRF_2670	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					169	386	1
MMRF_2671	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	160	1
MMRF_2671	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	160	1
MMRF_2671	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	160	1
MMRF_2671	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					160	173	1
MMRF_2671	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		200	Oth	prior to stem cell infusion					197	197	1
MMRF_2671	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					310	436	1
MMRF_2671	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Consolidation			25	Oth	Days 1-21 per cycle					310	436	1
MMRF_2671	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					310	436	1
MMRF_2675	First line of therapy	Carfilzomib			mg/m^2	IV		Induction		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					1		1
MMRF_2675	First line of therapy	Dexamethasone			mg	PO		Induction		Checked	20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1		1
MMRF_2675	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO		Induction			25	Oth	Days 1-21 per cycle		Atrial fibrillation			1	29	1
MMRF_2675	First line of therapy	Lenalidomide			mg	PO		Induction		Checked	15	Oth	Days 1-21 per cycle					29		1
MMRF_2676	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	131	1
MMRF_2676	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle					1	131	1
MMRF_2676	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	131	1
MMRF_2676	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					131	142	1
MMRF_2676	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		360	Oth	prior to stem cell infusion					178	178	1
MMRF_2676	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					269	451	1
MMRF_2676	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Consolidation			300	Oth	Days 1, 8, 15 per cycle					269	451	1
MMRF_2676	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					269	451	1
MMRF_2677	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO		Induction			25	Oth	Days 1-21 per cycle		Creatinine increase			1	34	1
MMRF_2677	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	123	1
MMRF_2677	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	123	1
MMRF_2677	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			10	Oth	Days 1-21 per cycle					34	123	1
MMRF_2677	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					123	135	1
MMRF_2677	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					170	447	1
MMRF_2677	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Consolidation			10	Oth	Days 1-21 per cycle					170	447	1
MMRF_2677	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					170	447	1
MMRF_2678	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	117	1
MMRF_2678	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle					1	117	1
MMRF_2678	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	117	1
MMRF_2678	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					117	127	1
MMRF_2678	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		292	Oth	prior to stem cell infusion					151	151	1
MMRF_2678	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					262	381	1
MMRF_2678	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Consolidation			300	Oth	Days 1, 8, 15 per cycle					262	381	1
MMRF_2678	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					262	381	1
MMRF_2679	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	116	1
MMRF_2679	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	116	1
MMRF_2679	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	116	1
MMRF_2679	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					116	127	1
MMRF_2679	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		350	Oth	prior to stem cell infusion					149	149	1
MMRF_2679	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					246	372	1
MMRF_2679	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Consolidation			25	Oth	Days 1-21 per cycle					246	372	1
MMRF_2679	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					246	372	1
MMRF_2680	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	144	1
MMRF_2680	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	144	1
MMRF_2680	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	144	1
MMRF_2680	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					144	154	1
MMRF_2680	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					184	429	1
MMRF_2680	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Consolidation			25	Oth	Days 1-21 per cycle					184	429	1
MMRF_2680	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					184	429	1
MMRF_2681	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	121	1
MMRF_2681	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle					1	121	1
MMRF_2681	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	121	1
MMRF_2681	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					121	133	1
MMRF_2681	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		400	Oth	prior to stem cell infusion					160	160	1
MMRF_2681	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO		Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle		Gastrintestinal tox			253	288	1
MMRF_2681	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					253	377	1
MMRF_2681	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Consolidation			300	Oth	Days 1, 8, 15 per cycle					253	377	1
MMRF_2681	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Consolidation			10	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					288	377	1
MMRF_2682	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	139	1
MMRF_2682	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	139	1
MMRF_2682	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	139	1
MMRF_2682	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					139	152	1
MMRF_2682	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		372	Oth	prior to stem cell infusion					196	196	1
MMRF_2682	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					295	427	1
MMRF_2682	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Consolidation			25	Oth	Days 1-21 per cycle					295	427	1
MMRF_2682	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					295	427	1
MMRF_2683	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	130	1
MMRF_2683	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	130	1
MMRF_2683	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	130	1
MMRF_2683	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					130	142	1
MMRF_2683	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		320	Oth	prior to stem cell infusion					222	222	1
MMRF_2685	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	145	1
MMRF_2685	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	145	1
MMRF_2685	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	145	1
MMRF_2685	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					145	157	1
MMRF_2685	First line of therapy	Carfilzomib			mg/m^2	IV		Consolidation		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					268		1
MMRF_2685	First line of therapy	Lenalidomide			mg	PO		Consolidation		Checked	25	Oth	Days 1-21 per cycle					268		1
MMRF_2685	First line of therapy	Dexamethasone			mg	PO		Consolidation		Checked	20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					268		1
MMRF_2688	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	123	1
MMRF_2688	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle					1	123	1
MMRF_2688	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	123	1
MMRF_2688	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					123	137	1
MMRF_2688	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		340	Oth	prior to stem cell infusion					155	155	1
MMRF_2690	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	117	1
MMRF_2690	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	117	1
MMRF_2690	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	117	1
MMRF_2690	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					117	128	1
MMRF_2690	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					183	411	1
MMRF_2690	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Consolidation			25	Oth	Days 1-21 per cycle					183	411	1
MMRF_2690	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					183	411	1
MMRF_2689	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	141	1
MMRF_2689	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	141	1
MMRF_2689	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	141	1
MMRF_2689	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					141	152	1
MMRF_2689	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					170	403	1
MMRF_2689	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Consolidation			25	Oth	Days 1-21 per cycle					170	403	1
MMRF_2689	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					170	403	1
MMRF_2691	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	113	1
MMRF_2691	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	113	1
MMRF_2691	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	113	1
MMRF_2691	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					113	124	1
MMRF_2691	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		350	Oth	prior to stem cell infusion					152	152	1
MMRF_2691	First line of therapy	Carfilzomib			mg/m^2	IV		Consolidation		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					251		1
MMRF_2691	First line of therapy	Lenalidomide			mg	PO		Consolidation		Checked	25	Oth	Days 1-21 per cycle					251		1
MMRF_2691	First line of therapy	Dexamethasone			mg	PO		Consolidation		Checked	20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					251		1
MMRF_2692	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO		Induction			25	Oth	Days 1-21 per cycle		Creatinine increase			1	29	1
MMRF_2692	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	125	1
MMRF_2692	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	125	1
MMRF_2692	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			10	Oth	Days 1-21 per cycle					29	125	1
MMRF_2692	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					125	136	1
MMRF_2694	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	125	1
MMRF_2694	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle					1	125	1
MMRF_2694	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	125	1
MMRF_2694	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					125	136	1
MMRF_2694	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		350	Oth	prior to stem cell infusion					171	171	1
MMRF_2694	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					263	410	1
MMRF_2694	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Consolidation			300	Oth	Days 1, 8, 15 per cycle					263	410	1
MMRF_2694	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					263	410	1
MMRF_2695	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	145	1
MMRF_2695	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle					1	145	1
MMRF_2695	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	145	1
MMRF_2695	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					145	156	1
MMRF_2695	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		200	Oth	prior to stem cell infusion					191	191	1
MMRF_2695	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					268	450	1
MMRF_2695	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Consolidation			300	Oth	Days 1, 8, 15 per cycle					268	450	1
MMRF_2695	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					268	450	1
MMRF_2696	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	111	1
MMRF_2696	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle					1	111	1
MMRF_2696	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	111	1
MMRF_2696	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					111	133	1
MMRF_2696	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		200	Oth	prior to stem cell infusion					162	162	1
MMRF_2696	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					274	386	1
MMRF_2696	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Consolidation			300	Oth	Days 1, 8, 15 per cycle					274	386	1
MMRF_2696	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					274	386	1
MMRF_2697	First line of therapy	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle		Hepatic tox			1	71	1
MMRF_2697	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO		Induction			25	Oth	Days 1-21 per cycle		Hepatic tox			1	71	1
MMRF_2697	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	113	1
MMRF_2697	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			27	Oth	Days 1-2, 8-9, 15-16 per cycle					71	183	1
MMRF_2697	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			15	Oth	Days 1-21 per cycle					71	183	1
MMRF_2698	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	121	1
MMRF_2698	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	121	1
MMRF_2698	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	121	1
MMRF_2698	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					121	131	1
MMRF_2698	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					196	420	1
MMRF_2698	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Consolidation			25	Oth	Days 1-21 per cycle					196	420	1
MMRF_2698	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					196	420	1
MMRF_2702	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	124	1
MMRF_2702	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	124	1
MMRF_2702	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	124	1
MMRF_2702	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					124	135	1
MMRF_2702	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					183	428	1
MMRF_2702	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Consolidation			25	Oth	Days 1-21 per cycle					183	428	1
MMRF_2702	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					183	428	1
MMRF_2699	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	135	1
MMRF_2699	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	135	1
MMRF_2699	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	135	1
MMRF_2699	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					135	146	1
MMRF_2699	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					181	456	1
MMRF_2699	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Consolidation			25	Oth	Days 1-21 per cycle					181	456	1
MMRF_2699	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					181	456	1
MMRF_2700	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	150	1
MMRF_2700	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	150	1
MMRF_2700	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	150	1
MMRF_2700	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					150	162	1
MMRF_2700	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					191	428	1
MMRF_2700	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Consolidation			25	Oth	Days 1-21 per cycle					191	428	1
MMRF_2700	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					191	428	1
MMRF_2701	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	153	1
MMRF_2701	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	153	1
MMRF_2701	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	153	1
MMRF_2701	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					153	165	1
MMRF_2701	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		140	Oth	prior to stem cell infusion					195	195	1
MMRF_2703	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	165	1
MMRF_2703	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	165	1
MMRF_2703	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	165	1
MMRF_2703	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					165	178	1
MMRF_2703	First line of therapy	Carfilzomib			mg/m^2	IV		Consolidation		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					206		1
MMRF_2703	First line of therapy	Lenalidomide			mg	PO		Consolidation		Checked	25	Oth	Days 1-21 per cycle					206		1
MMRF_2703	First line of therapy	Dexamethasone			mg	PO		Consolidation		Checked	20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					206		1
MMRF_2704	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	123	1
MMRF_2704	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	123	1
MMRF_2704	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	123	1
MMRF_2704	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					123	137	1
MMRF_2704	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					155	295	1
MMRF_2704	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Consolidation			25	Oth	Days 1-21 per cycle					155	295	1
MMRF_2704	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					155	295	1
MMRF_2705	First line of therapy	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle		Hepatic tox			1	37	1
MMRF_2705	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO		Induction			25	Oth	Days 1-21 per cycle		Hepatic tox			1	37	1
MMRF_2705	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	124	1
MMRF_2705	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			27	Oth	Days 1-2, 8-9, 15-16 per cycle					37	124	1
MMRF_2705	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			15	Oth	Days 1-21 per cycle					37	124	1
MMRF_2705	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					124	164	1
MMRF_2705	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		320	Oth	prior to stem cell infusion					194	194	1
MMRF_2706	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	116	1
MMRF_2706	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle					1	116	1
MMRF_2706	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	116	1
MMRF_2706	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					116	128	1
MMRF_2706	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		320	Oth	prior to stem cell infusion					156	156	1
MMRF_2707	First line of therapy	Carfilzomib			mg/m^2	IV		Induction		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					1		1
MMRF_2707	First line of therapy	Lenalidomide			mg	PO		Induction		Checked	25	Oth	Days 1-21 per cycle					1		1
MMRF_2707	First line of therapy	Dexamethasone			mg	PO		Induction		Checked	20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1		1
MMRF_2708	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	131	1
MMRF_2708	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle					1	131	1
MMRF_2708	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	131	1
MMRF_2708	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					131	142	1
MMRF_2709	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	120	1
MMRF_2709	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	120	1
MMRF_2709	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	120	1
MMRF_2709	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					120	132	1
MMRF_2709	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		300	Oth	prior to stem cell infusion					166	166	1
MMRF_2716	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	118	1
MMRF_2716	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle					1	118	1
MMRF_2716	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	118	1
MMRF_2716	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					118	128	1
MMRF_2716	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		328	Oth	prior to stem cell infusion					162	162	1
MMRF_2716	First line of therapy	Carfilzomib			mg/m^2	IV		Consolidation		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					260		1
MMRF_2716	First line of therapy	Cyclophosphamide			mg/m^2	PO		Consolidation		Checked	300	Oth	Days 1, 8, 15 per cycle					260		1
MMRF_2716	First line of therapy	Dexamethasone			mg	PO		Consolidation		Checked	20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					260		1
MMRF_2711	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	137	1
MMRF_2711	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	137	1
MMRF_2711	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	137	1
MMRF_2711	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					137	151	1
MMRF_2711	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		332	Oth	prior to stem cell infusion					200	200	1
MMRF_2715	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	124	1
MMRF_2715	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle					1	124	1
MMRF_2715	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	124	1
MMRF_2715	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					124	135	1
MMRF_2715	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		400	Oth	prior to stem cell infusion					159	159	1
MMRF_2717	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	117	1
MMRF_2717	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	117	1
MMRF_2717	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	117	1
MMRF_2717	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					117	131	1
MMRF_2717	First line of therapy	Carfilzomib			mg/m^2	IV		Consolidation		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					158		1
MMRF_2717	First line of therapy	Lenalidomide			mg	PO		Consolidation		Checked	25	Oth	Days 1-21 per cycle					158		1
MMRF_2717	First line of therapy	Dexamethasone			mg	PO		Consolidation		Checked	20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					158		1
MMRF_2714	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	139	1
MMRF_2714	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	139	1
MMRF_2714	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	139	1
MMRF_2714	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					139	150	1
MMRF_2714	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		388.4	Oth	prior to stem cell infusion					177	177	1
MMRF_2714	First line of therapy	Carfilzomib			mg/m^2	IV		Consolidation		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					274		1
MMRF_2714	First line of therapy	Lenalidomide			mg	PO		Consolidation		Checked	25	Oth	Days 1-21 per cycle					274		1
MMRF_2714	First line of therapy	Dexamethasone			mg	PO		Consolidation		Checked	20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					274		1
MMRF_2718	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	109	1
MMRF_2718	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	109	1
MMRF_2718	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	109	1
MMRF_2718	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					109	119	1
MMRF_2718	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					148	260	1
MMRF_2718	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Consolidation			25	Oth	Days 1-21 per cycle					148	260	1
MMRF_2718	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					148	260	1
MMRF_2719	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	152	1
MMRF_2719	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	152	1
MMRF_2719	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	152	1
MMRF_2719	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					152	205	1
MMRF_2719	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		380	Oth	prior to stem cell infusion					231	231	1
MMRF_2720	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	115	1
MMRF_2720	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle					1	115	1
MMRF_2720	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	115	1
MMRF_2720	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					115	129	1
MMRF_2721	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	125	1
MMRF_2721	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle					1	125	1
MMRF_2721	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	125	1
MMRF_2721	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					125	135	1
MMRF_2727	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	145	1
MMRF_2727	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	145	1
MMRF_2727	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	145	1
MMRF_2727	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					145	156	1
MMRF_2722	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	130	1
MMRF_2722	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle					1	130	1
MMRF_2722	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	130	1
MMRF_2722	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					130	141	1
MMRF_2723	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	125	1
MMRF_2723	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle					1	125	1
MMRF_2723	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	125	1
MMRF_2723	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					125	134	1
MMRF_2723	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		404	Oth	prior to stem cell infusion					158	158	1
MMRF_2728	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	118	1
MMRF_2728	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	118	1
MMRF_2728	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	118	1
MMRF_2728	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					118	129	1
MMRF_2728	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					154	266	1
MMRF_2728	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Consolidation			25	Oth	Days 1-21 per cycle					154	266	1
MMRF_2728	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					154	266	1
MMRF_2729	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	115	1
MMRF_2729	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	115	1
MMRF_2729	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	115	1
MMRF_2729	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					115	126	1
MMRF_2729	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		200	Oth	prior to stem cell infusion					154	154	1
MMRF_2730	First line of therapy	Carfilzomib			mg/m^2	IV		Induction		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					1		1
MMRF_2730	First line of therapy	Lenalidomide			mg	PO		Induction		Checked	25	Oth	Days 1-21 per cycle					1		1
MMRF_2730	First line of therapy	Dexamethasone			mg	PO		Induction		Checked	20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1		1
MMRF_2731	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	120	1
MMRF_2731	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle					1	120	1
MMRF_2731	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	120	1
MMRF_2731	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					120	129	1
MMRF_2731	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		408	Oth	prior to stem cell infusion					165	165	1
MMRF_2732	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	131	1
MMRF_2732	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	131	1
MMRF_2732	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	131	1
MMRF_2732	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					131	142	1
MMRF_2732	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		394	Oth	prior to stem cell infusion					184	184	1
MMRF_2733	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	160	1
MMRF_2733	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	160	1
MMRF_2733	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	160	1
MMRF_2733	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					160	171	1
MMRF_2733	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		360	Oth	prior to stem cell infusion					223	223	1
MMRF_2734	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	113	1
MMRF_2734	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle					1	113	1
MMRF_2734	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	113	1
MMRF_2734	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					113	125	1
MMRF_2734	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		350	Oth	prior to stem cell infusion					154	154	1
MMRF_2736	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	120	1
MMRF_2736	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle					1	120	1
MMRF_2736	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	120	1
MMRF_2736	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					120	131	1
MMRF_2736	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		310	Oth	prior to stem cell infusion					150	150	1
MMRF_2737	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	116	1
MMRF_2737	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle					1	116	1
MMRF_2737	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	116	1
MMRF_2737	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					116	125	1
MMRF_2737	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		320	Oth	prior to stem cell infusion					160	160	1
MMRF_2738	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	124	1
MMRF_2738	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	124	1
MMRF_2738	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	124	1
MMRF_2738	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					124	137	1
MMRF_2738	First line of therapy	Carfilzomib			mg/m^2	IV		Consolidation		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					172		1
MMRF_2738	First line of therapy	Lenalidomide			mg	PO		Consolidation		Checked	25	Oth	Days 1-21 per cycle					172		1
MMRF_2738	First line of therapy	Dexamethasone			mg	PO		Consolidation		Checked	20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					172		1
MMRF_2739	First line of therapy	Carfilzomib			mg/m^2	IV		Induction		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					1		1
MMRF_2739	First line of therapy	Cyclophosphamide			mg/m^2	PO		Induction		Checked	300	Oth	Days 1, 8, 15 per cycle					1		1
MMRF_2739	First line of therapy	Dexamethasone			mg	PO		Induction		Checked	20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1		1
MMRF_2742	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	121	1
MMRF_2742	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	121	1
MMRF_2742	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	121	1
MMRF_2742	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					121	134	1
MMRF_2740	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	122	1
MMRF_2740	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	122	1
MMRF_2740	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	122	1
MMRF_2740	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					122	133	1
MMRF_2740	First line of therapy	Carfilzomib			mg/m^2	IV		Consolidation		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					162		1
MMRF_2740	First line of therapy	Lenalidomide			mg	PO		Consolidation		Checked	25	Oth	Days 1-21 per cycle					162		1
MMRF_2740	First line of therapy	Dexamethasone			mg	PO		Consolidation		Checked	20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					162		1
MMRF_2743	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO		Induction			25	Oth	Days 1-21 per cycle		Rash maculo-papular			1	29	1
MMRF_2743	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	122	1
MMRF_2743	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	122	1
MMRF_2743	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			15	Oth	Days 1-21 per cycle					29	122	1
MMRF_2743	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					122	132	1
MMRF_2743	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		330	Oth	prior to stem cell infusion					164	164	1
MMRF_2745	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	119	1
MMRF_2745	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	119	1
MMRF_2745	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	119	1
MMRF_2745	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					119	133	1
MMRF_2745	First line of therapy	Carfilzomib			mg/m^2	IV		Consolidation		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					162		1
MMRF_2745	First line of therapy	Lenalidomide			mg	PO		Consolidation		Checked	25	Oth	Days 1-21 per cycle					162		1
MMRF_2745	First line of therapy	Dexamethasone			mg	PO		Consolidation		Checked	20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					162		1
MMRF_2746	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	136	1
MMRF_2746	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle					1	136	1
MMRF_2746	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	136	1
MMRF_2746	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					136	146	1
MMRF_2746	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		200	Oth	prior to stem cell infusion					171	171	1
MMRF_2749	First line of therapy	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle		Hepatic tox			1	32	1
MMRF_2749	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO		Induction			25	Oth	Days 1-21 per cycle		Hepatic tox			1	88	1
MMRF_2749	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	124	1
MMRF_2749	First line of therapy	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IV		Induction			27	Oth	Days 1-2, 8-9, 15-16 per cycle		Hepatic tox			32	88	1
MMRF_2749	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			20	Oth	Days 1-2, 8-9, 15-16 per cycle					88	124	1
MMRF_2749	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			15	Oth	Days 1-21 per cycle					88	124	1
MMRF_2749	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					124	136	1
MMRF_2749	First line of therapy	Carfilzomib			mg/m^2	IV		Consolidation		Checked	20	Oth	Days 1-2, 8-9, 15-16 per cycle					190		1
MMRF_2749	First line of therapy	Lenalidomide			mg	PO		Consolidation		Checked	15	Oth	Days 1-21 per cycle					190		1
MMRF_2749	First line of therapy	Dexamethasone			mg	PO		Consolidation		Checked	20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					190		1
MMRF_2750	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	123	1
MMRF_2750	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	123	1
MMRF_2750	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	123	1
MMRF_2750	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					123	133	1
MMRF_2750	First line of therapy	Carfilzomib			mg/m^2	IV		Consolidation		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					183		1
MMRF_2750	First line of therapy	Lenalidomide			mg	PO		Consolidation		Checked	25	Oth	Days 1-21 per cycle					183		1
MMRF_2750	First line of therapy	Dexamethasone			mg	PO		Consolidation		Checked	20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					183		1
MMRF_2751	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	128	1
MMRF_2751	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	128	1
MMRF_2751	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	128	1
MMRF_2751	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					128	142	1
MMRF_2752	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	140	1
MMRF_2752	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	140	1
MMRF_2752	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	140	1
MMRF_2752	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					140	151	1
MMRF_2754	First line of therapy	Carfilzomib			mg/m^2	IV		Induction		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					1		1
MMRF_2754	First line of therapy	Lenalidomide			mg	PO		Induction		Checked	25	Oth	Days 1-21 per cycle					1		1
MMRF_2754	First line of therapy	Dexamethasone			mg	PO		Induction		Checked	20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1		1
MMRF_2753	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	136	1
MMRF_2753	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle					1	136	1
MMRF_2753	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	136	1
MMRF_2753	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					136	148	1
MMRF_2753	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		400	Oth	prior to stem cell infusion					174	174	1
MMRF_2755	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	117	1
MMRF_2755	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle					1	117	1
MMRF_2755	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	117	1
MMRF_2755	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					117	128	1
MMRF_2755	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		370	Oth	prior to stem cell infusion					152	152	1
MMRF_2756	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	143	1
MMRF_2756	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	143	1
MMRF_2756	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	143	1
MMRF_2756	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					143	154	1
MMRF_2757	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	131	1
MMRF_2757	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	131	1
MMRF_2757	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	131	1
MMRF_2757	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					131	142	1
MMRF_2757	First line of therapy	Carfilzomib			mg/m^2	IV		Consolidation		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					191		1
MMRF_2757	First line of therapy	Lenalidomide			mg	PO		Consolidation		Checked	25	Oth	Days 1-21 per cycle					191		1
MMRF_2757	First line of therapy	Dexamethasone			mg	PO		Consolidation		Checked	20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					191		1
MMRF_2758	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	135	1
MMRF_2758	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle					1	135	1
MMRF_2758	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	135	1
MMRF_2758	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					135	146	1
MMRF_2758	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		400	Oth	prior to stem cell infusion					197	197	1
MMRF_2760	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	117	1
MMRF_2760	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle					1	117	1
MMRF_2760	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	117	1
MMRF_2760	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					117	129	1
MMRF_2760	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		286	Oth	prior to stem cell infusion					161	161	1
MMRF_2761	First line of therapy	Carfilzomib			mg/m^2	IV		Induction		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					1		1
MMRF_2761	First line of therapy	Lenalidomide			mg	PO		Induction		Checked	25	Oth	Days 1-21 per cycle					1		1
MMRF_2761	First line of therapy	Dexamethasone			mg	PO		Induction		Checked	20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1		1
MMRF_2762	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	126	1
MMRF_2762	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	126	1
MMRF_2762	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	126	1
MMRF_2762	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					126	135	1
MMRF_2762	First line of therapy	Carfilzomib			mg/m^2	IV		Consolidation		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					155		1
MMRF_2762	First line of therapy	Lenalidomide			mg	PO		Consolidation		Checked	25	Oth	Days 1-21 per cycle					155		1
MMRF_2762	First line of therapy	Dexamethasone			mg	PO		Consolidation		Checked	20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					155		1
MMRF_2763	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	127	1
MMRF_2763	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	127	1
MMRF_2763	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	127	1
MMRF_2763	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					127	137	1
MMRF_2763	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		300	Oth	prior to stem cell infusion					160	160	1
MMRF_2764	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	130	1
MMRF_2764	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	130	1
MMRF_2764	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	130	1
MMRF_2764	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					130	150	1
MMRF_2764	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		400	Oth	prior to stem cell infusion					214	214	1
MMRF_2765	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	138	1
MMRF_2765	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle					1	138	1
MMRF_2765	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	138	1
MMRF_2765	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					138	149	1
MMRF_2767	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	143	1
MMRF_2767	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	143	1
MMRF_2767	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	143	1
MMRF_2767	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					143	155	1
MMRF_2767	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		280	Oth	prior to stem cell infusion					179	179	1
MMRF_2768	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO		Induction			25	Oth	Days 1-21 per cycle		Erythroderma			1	94	1
MMRF_2768	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	154	1
MMRF_2768	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	154	1
MMRF_2768	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			15	Oth	Days 1-21 per cycle					94	154	1
MMRF_2768	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					154	165	1
MMRF_2769	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	122	1
MMRF_2769	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	122	1
MMRF_2769	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	122	1
MMRF_2769	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					122	133	1
MMRF_2769	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		400	Oth	prior to stem cell infusion					156	156	1
MMRF_2770	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	123	1
MMRF_2770	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle					1	123	1
MMRF_2770	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	123	1
MMRF_2770	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					123	133	1
MMRF_2770	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		200	Oth	prior to stem cell infusion					160	160	1
MMRF_2772	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	147	1
MMRF_2772	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	147	1
MMRF_2772	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	147	1
MMRF_2772	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					147	158	1
MMRF_2774	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	122	1
MMRF_2774	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle					1	122	1
MMRF_2774	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	122	1
MMRF_2774	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					122	134	1
MMRF_2774	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		303	Oth	prior to stem cell infusion					174	174	1
MMRF_2775	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	132	1
MMRF_2775	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	132	1
MMRF_2775	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	132	1
MMRF_2775	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					132	178	1
MMRF_2775	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		300	Oth	prior to stem cell infusion					198	198	1
MMRF_2776	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	133	1
MMRF_2776	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle					1	133	1
MMRF_2776	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	133	1
MMRF_2776	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					133	145	1
MMRF_2776	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		180	Oth	prior to stem cell infusion					203	203	1
MMRF_2778	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	113	1
MMRF_2778	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	113	1
MMRF_2778	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	113	1
MMRF_2778	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					113	124	1
MMRF_2778	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		335	Oth	prior to stem cell infusion					151	151	1
MMRF_2779	First line of therapy	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle		Rash maculo-papular			1	44	1
MMRF_2779	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO		Induction			25	Oth	Days 1-21 per cycle		Rash maculo-papular			1	44	1
MMRF_2779	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	133	1
MMRF_2779	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			20	Oth	Days 1-2, 8-9, 15-16 per cycle					44	133	1
MMRF_2779	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			15	Oth	Days 1-21 per cycle					44	133	1
MMRF_2779	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					133	143	1
MMRF_2781	First line of therapy	Carfilzomib			mg/m^2	IV		Induction		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					1		1
MMRF_2781	First line of therapy	Cyclophosphamide			mg/m^2	PO		Induction		Checked	300	Oth	Days 1, 8, 15 per cycle					1		1
MMRF_2781	First line of therapy	Dexamethasone			mg	PO		Induction		Checked	10	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1		1
MMRF_2781	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle		Hyperglycemia			1	1	1
MMRF_2782	First line of therapy	Dexamethasone		Adverse Event or co-morbidity	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle		Hyperglycemia			1	92	1
MMRF_2782	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	127	1
MMRF_2782	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle					1	127	1
MMRF_2782	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			15	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					92	127	1
MMRF_2782	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					127	139	1
MMRF_2782	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		358	Oth	prior to stem cell infusion					213	213	1
MMRF_2787	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	123	1
MMRF_2787	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	123	1
MMRF_2787	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	123	1
MMRF_2787	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					123	132	1
MMRF_2788	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	138	1
MMRF_2788	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle					1	138	1
MMRF_2788	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	138	1
MMRF_2788	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					138	148	1
MMRF_2788	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		400	Oth	prior to stem cell infusion					198	198	1
MMRF_2789	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	117	1
MMRF_2789	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	117	1
MMRF_2789	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	117	1
MMRF_2789	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					117	128	1
MMRF_2792	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	134	1
MMRF_2792	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	134	1
MMRF_2792	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	134	1
MMRF_2792	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					134	148	1
MMRF_2793	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	137	1
MMRF_2793	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle					1	137	1
MMRF_2793	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	137	1
MMRF_2793	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					137	148	1
MMRF_2793	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		300	Oth	prior to stem cell infusion					179	179	1
MMRF_2794	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	131	1
MMRF_2794	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	131	1
MMRF_2794	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	131	1
MMRF_2794	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					131	143	1
MMRF_2795	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	119	1
MMRF_2795	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	119	1
MMRF_2795	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	119	1
MMRF_2795	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					119	130	1
MMRF_2795	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		346	Oth	prior to stem cell infusion					162	162	1
MMRF_2801	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	127	1
MMRF_2801	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	127	1
MMRF_2801	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	127	1
MMRF_2801	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					127	165	1
MMRF_2801	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		294	Oth	prior to stem cell infusion					203	203	1
MMRF_2796	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	121	1
MMRF_2796	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	121	1
MMRF_2796	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	121	1
MMRF_2796	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					121	132	1
MMRF_2796	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		330	Oth	prior to stem cell infusion					159	159	1
MMRF_2799	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	128	1
MMRF_2799	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle					1	128	1
MMRF_2799	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	128	1
MMRF_2799	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					128	138	1
MMRF_2805	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	118	1
MMRF_2805	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	118	1
MMRF_2805	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	118	1
MMRF_2805	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					118	128	1
MMRF_2805	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		200	Oth	prior to stem cell infusion					163	163	1
MMRF_2807	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	124	1
MMRF_2807	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle					1	124	1
MMRF_2807	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	124	1
MMRF_2807	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					124	137	1
MMRF_2807	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		400	Oth	prior to stem cell infusion					194	194	1
MMRF_2808	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	131	1
MMRF_2808	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	131	1
MMRF_2808	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	131	1
MMRF_2808	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					131	177	1
MMRF_2809	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	127	1
MMRF_2809	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	127	1
MMRF_2809	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	127	1
MMRF_2809	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					127	138	1
MMRF_2809	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		370	Oth	prior to stem cell infusion					223	223	1
MMRF_2810	First line of therapy	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle		ischemic heart disease			1	29	1
MMRF_2810	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle					1	130	1
MMRF_2810	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	130	1
MMRF_2810	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			27	Oth	Days 1-2, 8-9, 15-16 per cycle					29	130	1
MMRF_2810	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					130	140	1
MMRF_2810	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		200	Oth	prior to stem cell infusion					175	175	1
MMRF_2813	First line of therapy	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle		Infusion-related reaction (acute episode of intens			1	30	1
MMRF_2813	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	116	1
MMRF_2813	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	116	1
MMRF_2813	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			27	Oth	Days 1-2, 8-9, 15-16 per cycle					30	116	1
MMRF_2813	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					116	128	1
MMRF_2814	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	128	1
MMRF_2814	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	128	1
MMRF_2814	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	128	1
MMRF_2814	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					128	140	1
MMRF_2814	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		400	Oth	prior to stem cell infusion					198	198	1
MMRF_2815	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	141	1
MMRF_2815	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	141	1
MMRF_2815	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	141	1
MMRF_2815	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					141	150	1
MMRF_2816	First line of therapy	Cyclophosphamide		Adverse Event or co-morbidity	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle		Hematological tox			1	65	1
MMRF_2816	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	130	1
MMRF_2816	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	130	1
MMRF_2816	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			200	Oth	Days 1, 8, 15 per cycle					65	130	1
MMRF_2816	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					130	141	1
MMRF_2816	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		366	Oth	prior to stem cell infusion					169	169	1
MMRF_2817	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	118	1
MMRF_2817	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle					1	118	1
MMRF_2817	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	118	1
MMRF_2817	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					118	160	1
MMRF_2818	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	140	1
MMRF_2818	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	140	1
MMRF_2818	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	140	1
MMRF_2818	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					140	152	1
MMRF_2819	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	127	1
MMRF_2819	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	127	1
MMRF_2819	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	127	1
MMRF_2819	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					127	139	1
MMRF_2819	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		271.6000061	Oth	prior to stem cell infusion					245	245	1
MMRF_2820	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	129	1
MMRF_2820	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle					1	129	1
MMRF_2820	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	129	1
MMRF_2820	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					129	139	1
MMRF_2820	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		330	Oth	prior to stem cell infusion					175	175	1
MMRF_2821	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	124	1
MMRF_2821	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	124	1
MMRF_2821	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	124	1
MMRF_2821	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					124	135	1
MMRF_2822	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	123	1
MMRF_2822	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	123	1
MMRF_2822	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	123	1
MMRF_2822	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					123	134	1
MMRF_2822	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		280	Oth	prior to stem cell infusion					173	173	1
MMRF_2823	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	183	1
MMRF_2823	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle					1	183	1
MMRF_2823	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	183	1
MMRF_2823	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		340	Oth	prior to stem cell infusion					223	223	1
MMRF_2826	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	119	1
MMRF_2826	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	119	1
MMRF_2826	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	119	1
MMRF_2826	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					119	130	1
MMRF_2827	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	133	1
MMRF_2827	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			15	Oth	Days 1-21 per cycle					1	133	1
MMRF_2827	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	133	1
MMRF_2827	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					133	143	1
MMRF_2827	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		360	Oth	prior to stem cell infusion					189	189	1
MMRF_2828	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	145	1
MMRF_2828	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	145	1
MMRF_2828	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	145	1
MMRF_2828	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					145	157	1
MMRF_2829	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	144	1
MMRF_2829	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	144	1
MMRF_2829	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	144	1
MMRF_2829	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					144	155	1
MMRF_2830	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO		Induction			25	Oth	Days 1-21 per cycle		Rash maculo-papular			1	58	1
MMRF_2830	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	113	1
MMRF_2830	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	113	1
MMRF_2830	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			15	Oth	Days 1-21 per cycle					58	113	1
MMRF_2830	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					113	124	1
MMRF_2831	First line of therapy	Carfilzomib		Adverse Event or co-morbidity	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle		Cardiac ischemia			1	85	1
MMRF_2831	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	166	1
MMRF_2831	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	166	1
MMRF_2831	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			27	Oth	Days 1-2, 8-9, 15-16 per cycle					85	166	1
MMRF_2831	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					166	177	1
MMRF_2831	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		374	Oth	prior to stem cell infusion					203	203	1
MMRF_2832	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	124	1
MMRF_2832	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle					1	124	1
MMRF_2832	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	124	1
MMRF_2832	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					124	134	1
MMRF_2832	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		360	Oth	prior to stem cell infusion					173	173	1
MMRF_2833	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	113	1
MMRF_2833	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	113	1
MMRF_2833	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	113	1
MMRF_2834	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	126	1
MMRF_2834	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle					1	126	1
MMRF_2834	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	126	1
MMRF_2834	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					126	140	1
MMRF_2835	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	136	1
MMRF_2835	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	136	1
MMRF_2835	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	136	1
MMRF_2835	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					136	147	1
MMRF_2835	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		400	Oth	prior to stem cell infusion					167	167	1
MMRF_2836	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	126	1
MMRF_2836	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	126	1
MMRF_2836	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	126	1
MMRF_2836	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					126	135	1
MMRF_2836	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		340	Oth	prior to stem cell infusion					161	161	1
MMRF_2838	First line of therapy	Lenalidomide		Adverse Event or co-morbidity	mg	PO		Induction			25	Oth	Days 1-21 per cycle		Rash maculo-papular			1	65	1
MMRF_2838	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	145	1
MMRF_2838	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	145	1
MMRF_2838	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			15	Oth	Days 1-21 per cycle					65	145	1
MMRF_2838	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					145	159	1
MMRF_2839	First line of therapy	Carfilzomib			mg/m^2	IV		Induction		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					1		1
MMRF_2839	First line of therapy	Cyclophosphamide			mg/m^2	PO		Induction		Checked	300	Oth	Days 1, 8, 15 per cycle					1		1
MMRF_2839	First line of therapy	Dexamethasone			mg	PO		Induction		Checked	20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1		1
MMRF_2840	First line of therapy	Carfilzomib			mg/m^2	IV		Induction		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					1		1
MMRF_2840	First line of therapy	Cyclophosphamide			mg/m^2	PO		Induction		Checked	300	Oth	Days 1, 8, 15 per cycle					1		1
MMRF_2840	First line of therapy	Dexamethasone			mg	PO		Induction		Checked	20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1		1
MMRF_2843	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	177	1
MMRF_2843	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	177	1
MMRF_2843	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	177	1
MMRF_2843	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					177	190	1
MMRF_2846	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	121	1
MMRF_2846	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle					1	121	1
MMRF_2846	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	121	1
MMRF_2846	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					121	131	1
MMRF_2846	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		200	Oth	prior to stem cell infusion					199	199	1
MMRF_2847	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	131	1
MMRF_2847	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	131	1
MMRF_2847	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	131	1
MMRF_2847	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					131	144	1
MMRF_2848	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	154	1
MMRF_2848	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	154	1
MMRF_2848	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	154	1
MMRF_2848	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					154	166	1
MMRF_2848	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		340	Oth	prior to stem cell infusion					198	198	1
MMRF_2851	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	122	1
MMRF_2851	First line of therapy	Cyclophosphamide		Completed regimen	mg/m^2	PO		Induction			300	Oth	Days 1, 8, 15 per cycle					1	122	1
MMRF_2851	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	122	1
MMRF_2851	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					122	133	1
MMRF_2851	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		360	Oth	prior to stem cell infusion					189	189	1
MMRF_2853	First line of therapy	Carfilzomib		Completed regimen	mg/m^2	IV		Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	129	1
MMRF_2853	First line of therapy	Lenalidomide		Completed regimen	mg	PO		Induction			25	Oth	Days 1-21 per cycle					1	129	1
MMRF_2853	First line of therapy	Dexamethasone		Completed regimen	mg	PO		Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	129	1
MMRF_2853	First line of therapy	Cyclophosphamide		Completed regimen	g/m^2	IV		Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					129	139	1
MMRF_2853	First line of therapy	Melphalan		Completed regimen	mg/m^2	IV		Other	In preparation for stem cell infusion		200	Oth	prior to stem cell infusion					170	170	1
